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Circulating tumor DNA (ctDNA) analysis has become a valuable tool for the investigation of 
cancer biomarkers in both early- and late-stage scenarios.  To evaluate the utility of ctDNA as a 
biomarker of response in patients with advanced lung cancer, we have developed an ultrasensitive 
measure of cell-free tumor load using targeted and whole genome sequencing approaches to assess 
responses to tyrosine kinase inhibitors.  Analyses of patients treated with anti-EGFR or HER2 
therapies revealed a bimodal distribution of ctDNA after therapy initiation, with molecular 
responders having nearly complete elimination of ctDNA (>98%).  Molecular non-responders 
displayed limited changes in ctDNA levels post-treatment and experienced significantly shorter 
progression-free survival (median 1.6 vs. 13.7 months, P < 0.0001) which was detected on average 
four weeks earlier than CT imaging.  To further explore the role of ctDNA as a biomarker for 
minimal residual disease, we have developed an approach to identify ctDNA alterations through 
ultrasensitive targeted sequencing analyses of matched cell-free DNA (cfDNA) and white blood 
cells from the same patient.  Liquid biopsy analyses of 50 patients with resectable gastric cancer 
with available blood samples from multiple time points revealed that 52% of alterations in cfDNA 
were derived from the matched white blood cells.  After filtering blood cell alterations from cfDNA, 
we found that the presence of ctDNA can predict recurrence when analyzed within nine weeks after 
preoperative treatment (median 18.4 months vs. median not reached, P = 0.012) and after surgery 
(median 18.7 months vs. median not reached, P < 0.001) in patients with gastric cancer eligible for 
multimodal treatment.  We further developed a novel approach to evaluate genome-wide 
fragmentation patterns of cfDNA in patients with early-stage cancers.  We applied this method to 
analyze fragmentation profiles of 236 patients with breast, colorectal, lung, ovarian, pancreatic, 
gastric, or bile duct cancers and 245 healthy individuals.  A machine learning model incorporating 
genome-wide fragmentation features had sensitivities of detection ranging from 57% to >99% 
among the seven cancer types at 98% specificity.  Fragmentation profiles could be used to identify 
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the tissue of origin of the cancers to a limited number of sites in 75% of cases.  These observations 
highlight the utility of ctDNA as a broadly applicable approach for treatment monitoring, screening, 
and, early detection of human cancer. 
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Worldwide, over nine million cancer deaths were expected in 2018 alone (1).  In the same global 
report, the International Agency for Research on Cancer from the World Health Organization states 
that the total number of individuals who were alive within five years of a cancer diagnosis was 
estimated to be 44 million.  In parallel to these alarming cancer burden statistics, efforts on cancer 
genome characterization are transforming our understanding of tumor biology at an unprecedented 
level (2, 3), opening new venues for early detection and more efficient disease monitoring 
strategies.  From that perspective, a variety of genomic approaches applied to tumor specimens 
have leveraged the development of biomarkers for cancer detection and prediction of treatment 
response (4).  However, tumor tissue availability for molecular profiling usually requires invasive 
procedures that are prone to iatrogenic complications and inconvenient for serial assessment of 
tumor evolution.  In the past few years, the development of noninvasive liquid biopsy approaches 
based on the ctDNA analysis has helped to circumvent some of the downsides associated with 
tissue processing and analysis (5), but there is still a long way to go in order to fully validate ctDNA 
assessment in the clinical setting. 
The earliest evidence of increased cfDNA amounts in patients with cancer as well as the effect of 
therapy on its levels was demonstrated over 40 years ago (6).  More recently, next-generation 
sequencing-based technologies, in combination with computational methods, has allowed the 
interrogation of cancer-specific genomic abnormalities at a broader set of applications than 
previously possible (7-15).  Interestingly, these seminal ctDNA analyses have also enabled further 
assessment of intratumor heterogeneity along with the detection of subclonal alterations and the 
characterization of distinct genomic signatures (15-18).  Either through direct detection of ctDNA 
or through analyses guided by tumor tissue sequencing, these approaches can be applied to response 
assessment in patients with late-stage cancers receiving systemic therapies, detection of minimal 
residual disease after curative surgery, and even noninvasive direct detection of solid tumors at 
very early stages.  
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We first assessed the utility of liquid biopsy approaches to evaluate early noninvasive detection of 
response to targeted therapy in patients with advanced non-small cell lung cancer (19).  Overall, 
therapeutic efficacy of targeted therapies has been limited by incomplete pharmacological 
suppression of tumors or through the selection of resistance mutations in subclonal populations of 
tumor cells.  Disease monitoring using computed tomography (CT) imaging is the current clinical 
practice for assessing response to targeted therapy, yet this approach does not fully represent the 
molecular and pathologic changes occurring in tumors during therapy.  Repeat tissue biopsies of 
accessible cancer lesions have been used to provide insights into therapeutic decision-making but 
rarely capture the complexity of intra- and inter-tumoral heterogeneity and are invasive procedures 
with potential complications.  Theoretically, the ability to noninvasively track specific clonal 
populations of tumor cells over time has the potential to rapidly and dynamically inform therapy 
sequence and combinatorial strategies.  However, there are currently no approved or clinically 
recognized noninvasive molecularly defined strategies to assess early drug responsiveness or 
adaptive resistance in cancer patients before radiographic progression.  A variety of studies have 
focused on changes in ctDNA during the course of therapy, but have largely focused on the analysis 
of specific or limited number of alterations that may only represent specific subclones of the tumor 
(9, 20-28).  More recent studies have used panels of commonly mutated driver genes to allow 
detection of multiple driver clones, typically at the time of diagnosis (8, 14, 15, 18, 29).  However, 
no study has yet assessed the clinical value of a comprehensive genome-wide analysis of ctDNA 
alterations to evaluate tumor burden at very early timepoints following commencement of targeted 
therapy. 
We hypothesized that kinetic changes in the amount of DNA released from tumor cells may occur 
within hours to days of treatment administration.  In this study, we used an ultrasensitive liquid 
biopsy approach to evaluate patients with advanced non-small cell lung cancer who had tumor 
responses or progression on tyrosine kinase inhibitors, including erlotinib, a first-generation 
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inhibitor of the epidermal growth factor receptor (EGFR), afatinib, a second-generation inhibitor 
of EGFR and erb-b2 receptor tyrosine kinase 2 (ERBB2) (30-32), as well as osimertinib and 
mavelertinib, third-generation tyrosine kinase inhibitors targeting EGFR with activating and 
resistance (T790M) mutations (33, 34).  These analyses investigated whether rapid changes and the 
overall levels in the amounts of ctDNA can serve as real-time and predictive biomarkers of patient 
outcome to a targeted cancer therapy.   
Through our analyses of liquid biopsies for treatment response assessment in patients with 
advanced lung cancer, we speculated that ctDNA dynamics could be a useful approach to predict 
treatment benefit in patients with resectable cancer receiving preoperative chemotherapy followed 
by surgery.  However, blood-based deep sequencing approaches of multiples genes have raised 
concerns about detection and misclassification of white blood cell (WBC) derived variants in 
cfDNA associated with clonal hematopoiesis of indeterminate potential (CHIP) (15, 35-37).  We 
then assessed the value of matched white blood cell and cell-free DNA analyses for detection 
response and minimal residual disease in patients with resectable gastric cancer (38).  A major 
challenge after multimodal curative treatment for resectable gastric cancer is identifying patients 
with microscopic residual disease at high risk of recurrence after surgery (39-42).  Currently 
available imaging techniques and traditional blood biomarkers to capture minimal residual disease 
(MRD) state after surgery have poor sensitivity and do not play a role in clinical practice (43).    
Histopathological assessment of the effects of neoadjuvant chemotherapy on resection specimens 
has become an important tool to provide prognostic information (44-46).  However, microscopic 
residual tumor, lymph node infiltration, and poor histopathological response do not measure the 
real-time presence of residual disease.  More recent approaches such as detection of ctDNA through 
liquid biopsies may provide new opportunities for identifying patients that would benefit from 
adjuvant treatment options and further follow-up (47). 
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Theoretically, the ability to non-invasively detect tumor-specific alterations in the circulation after 
neoadjuvant chemotherapy and surgery has the potential to rapidly and dynamically inform the 
presence of minimal residual disease.  Cell-free ctDNA is released from tumor cells into the 
circulation and has been detected in patients with early and late stage cancers (13-15, 48-50).  A 
key challenge of liquid biopsy approaches has been developing methods to detect and characterize 
small amounts of ctDNA in large populations of cfDNA.  A variety of studies have focused on 
changes in ctDNA during the course of therapy, but mostly in the setting of metastatic disease and 
largely centered on the analysis of a limited number of genomic positions that may only represent 
a subset of clones of the tumor (9, 20-25, 51, 52).  More recent studies have used panels of 
commonly mutated driver genes to allow detection of multiple driver clones, typically at the time 
of diagnosis, after surgery, or at disease progression (8, 12, 14, 15, 18, 19, 29, 51, 53).  To date, no 
study has longitudinally assessed the value of deep sequencing matched white blood cells and 
cfDNA from the same patient to filter WBC alterations and identify high-probability tumor-specific 
cfDNA variants. 
In this second study, we applied a matched cfDNA and WBC sequencing approach to accurately 
detect ctDNA alterations after preoperative chemotherapy and after surgery in patients with 
resectable gastric cancer.  We hypothesized that ctDNA detection after completion of preoperative 
treatment as well as minimal residual disease detection after surgery can predict recurrence and 
survival in patients with resectable gastric cancer treated with multimodal therapeutic regimens.  
Overall, these analyses evaluated a new strategy to distinguish ctDNA alterations from cfDNA 
variants related to clonal hematopoiesis and investigated whether ctDNA elimination before or after 
surgery can serve as a predictive biomarker of patient outcome to perioperative treatment. 
We finally extended our liquid biopsy analyses to explore patterns of genome-wide cfDNA 
fragmentation in healthy individuals and patients with early- and late-stage cancers.  Analyses of 
alterations in cfDNA have largely focused on targeted sequencing of specific genes.  Such studies 
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permit detection of a small number of tumor-specific alterations in patients with cancer but not all 
patients, especially those with early stage disease, have detectable changes (13, 15, 54).  Whole 
genome sequencing of cfDNA can identify chromosomal abnormalities in cancer patients but 
detecting such alterations may be challenging due to the difficulty in distinguishing a small number 
of abnormal from normal chromosomal changes (9, 24, 55-57).  Analyses of the size of cfDNA 
fragments have suggested that patients with cancer may have abnormal cfDNA, but these 
observations have been contradictory, indicating both increases (58-63) as well as decreases in the 
overall distribution of cfDNA (57, 64-66).  Recent studies have suggested that size selection of 
small cfDNA can increase enrichment of mutations and somatic copy number alterations in late-
stage cancer patients (64).  Nucleosome positions (65, 67), cfDNA patterns near transcription start 
sites (67, 68), and the end positions of cfDNA molecules (69) may differ between cancer and 
normal tissues but the sequencing needed for nucleosome footprint evaluation of cfDNA is 
impractical for routine analyses.  Conceptually, the sensitivity of any cfDNA approach depends on 
the number of alterations examined as well as the technical and biologic limitations of detecting 
such changes.  As a typical blood sample contains ~2000 genome equivalents of cfDNA per 
milliliter of plasma (15), the theoretical limit of detection of a single alteration can be no better than 
one in a few thousand mutant to wild-type molecules.   
In this third study, we hypothesized that an approach to detect a larger number of alterations in the 
same number of genome equivalents may be more sensitive for detecting cancer in the circulation.  
We developed an approach based on low coverage whole genome sequencing called DELFI (DNA 
Evaluation of Fragments for early Interception), that allows simultaneous evaluation of a large 
number of abnormalities in cfDNA through genome-wide analysis of fragmentation patterns.  The 
results of DELFI analyses highlight important properties of cfDNA and provide a facile approach 





EARLY NONINVASIVE DETECTION OF RESPONSE TO TARGETED 






In this proof-of-principle retrospective study, we assessed serial blood draws from 28 advanced 
NSCLC patients undergoing treatment with targeted TKIs to directly detect somatic sequence and 
structural alterations in cfDNA, monitor ctDNA dynamics during therapy, determine cell-free 
tumor burden, and predict clinical outcome (Figure 2.1).  Liquid biopsies were obtained 
immediately prior to treatment (baseline) and at serial timepoints until disease progression.  This 
cohort included 12 patients with RECIST 1.1 partial response, 8 with stable disease, 5 with 
progressive disease, and 3 with unmeasurable disease but who derived clinical benefit.  We used 
the ultrasensitive targeted error correction sequencing (TEC-Seq) approach (15) as well as whole 
genome sequencing to identify tumor-derived sequence alterations and chromosomal copy number 
changes in cfDNA.  We evaluated the dynamics of alterations identified and developed a 
noninvasive measure of cfTL to evaluate real-time response to treatment.  We analyzed changes in 
cfTL within hours to days after treatment compared to baseline and assessed whether cfTL could 
serve as a marker of patient outcome. 
Patient and sample characteristics 
Twenty-eight patients with metastatic non-small cell lung cancer undergoing treatment with TKIs 
at University of California San Diego or Johns Hopkins University were included in our study.  
Clinical and pathological characteristics for all patients are summarized in Tables 2.1 and 2.2, and 
tumor load dynamics are shown in Figure 2.2 and 2.3.  Patient enrollment and genomic studies 
were conducted in accordance with the Declaration of Helsinki, were approved by the Institutional 




The response evaluation criteria in solid tumors (RECIST) version 1.1 (70) were used for 
assessment of response.  Of these 28 patients, twenty eventually experienced disease progression 
while eight continue to derive clinical benefit from targeted inhibition (Table 2.1).   
For all patients, serial blood draws were collected over the course of treatment with targeted 
inhibition for isolation of plasma and extraction of cfDNA for genomic analyses.  Timepoints were 
analyzed immediately prior to treatment for baseline assessment as well as at serial intervals until 
disease progression (Table 2.2).   
Sample preparation and next-generation sequencing of cfDNA 
Whole blood was collected in K2 EDTA tubes or Streck tubes and processed immediately or within 
2 hours after storage at 4°C for EDTA tubes or room temperature for Streck tubes, respectively.  
Plasma and cellular components were separated by centrifugation at 800g for 10 minutes at 4°C.  
Plasma was centrifuged a second time at 18,000g at room temperature to remove any remaining 
cellular debris and stored at -80°C until the time of DNA extraction.  DNA was isolated from 
plasma using the Qiagen Circulating Nucleic Acids Kit (Qiagen GmbH) and eluted in LoBind tubes 
(Eppendorf AG).  Concentration and quality of cfDNA was assessed using the Bioanalyzer 2100 
(Agilent Technologies).   
TEC-Seq next-generation sequencing cell-free DNA libraries were prepared from 11 to 350 ng of 
cfDNA.  Genomic libraries were prepared as previously described (15).  Briefly, the NEBNext 
DNA Library Prep Kit for Illumina [New England Biolabs (NEB)] was used with four main 
modifications to the manufacturer’s guidelines: i) The library purification steps utilized the on-bead 
Ampure XP approach, ii) reagent volumes were adjusted accordingly to accommodate the on-bead 
strategy, iii) a pool of 8 unique Illumina dual index adapters with 8 bp barcodes were used in the 
ligation reaction, and iv) cfDNA libraries were amplified with Hotstart Phusion Polymerase.  
Genomic library preparation was performed as previously described (15).  Concentration and 
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quality of cfDNA genomic libraries were assessed using the Bioanalyzer 2100 (Agilent 
Technologies).   
Targeted capture was performed using the Agilent SureSelect reagents and a custom set of 
hybridization probes targeting 58 genes (Table 2.3) per the manufacturer’s guidelines.  The 
captured library was amplified with HotStart Phusion Polymerase (NEB).  The concentration and 
quality of captured cfDNA libraries was assessed on the Bioanalyzer (Agilent Technologies).  TEC-
seq libraries were sequenced using 100-bp paired end runs on the Illumina HiSeq 2500 (Illumina). 
Primary processing of next-generation sequencing data and identification of putative somatic 
mutations 
Primary processing of next-generation sequence data for analyses of sequence alterations in cfDNA 
samples was performed as previously described (15). Briefly, Illumina CASAVA (Consensus 
Assessment of Sequence and Variation) software (version 1.8) was used for demultiplexing and 
masking of dual index adapter sequences. Sequence reads were aligned against the human reference 
genome (hg19) using NovoAlign with additional realignment of select regions using the 
Needleman-Wunsch method (Table 2.4) (71).   
Candidate somatic mutations, consisting of point mutations, small insertions, and deletions were 
identified using VariantDx (71) across the targeted regions of interest as previously described 
(Table 2.5) (15).  Briefly, an alteration was considered a candidate somatic mutation only when: (i) 
Three distinct paired reads contained the mutation in the plasma and the number of distinct paired 
reads containing a particular mutation in the plasma was at least 0.1% of the total distinct read 
pairs; or (ii) Four distinct paired reads contained the mutation in the plasma and the number of 
distinct paired reads containing a particular mutation in the plasma was at least 0.05% and less than 
0.1% of the total distinct read pairs; (iii) the mismatched base was not present in >1% of the reads 
in a panel of unmatched normal samples as well as not present in a custom database of common 
11 
 
germline variants derived from dbSNP; (iv) the altered base did not arise from misplaced genome 
alignments including paralogous sequences; and (v) the mutation fell within a protein coding region 
and was classified as a missense, nonsense, frameshift, or splice site alteration. 
Candidate alterations were defined as somatic hotspots if the nucleotide change and amino acid 
change were identical to an alteration observed in ≥ 20 cancer cases reported in the COSMIC 
database.  Alterations that were not hotspots were retained only if either (i) seven or more distinct 
paired reads contained the mutation in the plasma and the number of distinct paired reads containing 
a particular mutation in the plasma was at least 0.1% and less than 0.2%, of the total distinct read 
pairs, or (ii) six or more distinct paired reads contained the mutation in the plasma and the number 
of distinct paired reads containing a particular mutation in the plasma was at least 0.2% of the total 
distinct read pairs.  In order to track clonal changes over time, any alteration identified in at least 
one blood draw was assessed in the remaining timepoints.  
Common germline variants were identified and removed if present in ≥ 25% of reads or < 25% of 
reads if the variant was recurrent and the majority of alterations at that position had a mutant allele 
fraction ≥ 25%.  Variants known to be at a somatic hotspot position or producing a truncating 
mutation in a tumor suppressor gene were not excluded as germline changes.  Because of the high 
frequency of mutations in specific genes and the possible confounding between somatic and 
germline changes, we limited analyses in the APC gene to frameshift or nonsense mutations, and 
in KRAS, HRAS and NRAS to positions to 12, 13, 61, and 146.  Finally, we excluded 
hematopoietic expansion related variants that have been previously described (35-37, 72, 73), 
including those in DNMT3A, IDH1, and IDH2 and specific alterations within ATM, GNAS, JAK2, 
or TP53 (Table 2.6). 
Primary processing of next-generation sequence data for analyses of copy number alterations in 
cfDNA samples was performed as follows: Bam files were preprocessed by successively running 
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CleanSam and MarkDuplicates from Picard Tools version 2.9.0. 
(http://broadinstitute.github.io/picard).  Sequence reads were aligned against the human reference 
genome (hg19) using NovoAlign.    
Candidate somatic structural variants were identified through analyses of low-coverage whole-
genome sequencing data obtained from off-target reads mapping outside of the targeted capture of 
58 cancer driver genes (Table 2.3) in areas of the genome farther than 1000 base pairs from the 
start or end of a targeted region.  Off-target reads were divided into 100kb bins with the exception 
of filtered bins i) with less than 10kb due to spacing of target regions, ii) having GC content less 
than 30% or greater than 70%, iii) where 25% fell within the ENCODE Duke Excluded Regions 
Track (http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncode Mapability).  The total 
number of unique reads mapping to each bin were counted to exclude filtered regions: 
sb =   𝑙𝑜𝑔2 (
100000
𝑥𝑏 − 𝑓𝑏
 ∙  𝑟𝑏) 
where rb is the number of unique reads mapped to bin b,  xb is the length of bin b, and fb is the 
number of filtered base pairs within bin b, and the normalized score, sb, was assigned to each bin.  
To remove GC-bias and normalize for sequencing depth we used LOESS smoothing to predict a 
bin’s normalized score from the bin-specific GC content. The GC-corrected score for each bin, 𝑠?̃?, 
is defined for bin b by subtracting the predicted score from sb and exponentiating this using base 2.  
We summed the GC-corrected scores for each chromosome arm.  The summed score for a given 
chromosome arm was divided by the summed score using all bins to calculate the percentage of 
genomic representation. 
Z scores were calculated as previously described (9) for each chromosome arm for each timepoint 
and patient assessed to determine areas of genome over or under representation.  PA scores were 
calculated as previously described (9) for each timepoint for each patient assessed in order to 
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concisely represent the aneuploidy observed in each sample by using the five chromosomes arms 
with the largest absolute z scores (Table 2.7).  PA scores higher than the threshold score of 2.4 
provide a specificity greater than 90% (Student t distribution, three degrees of freedom) for the 
presence of aneuploid circulating tumor DNA. 
Cell-free tumor load 
We directly detected sequence and copy number alterations in cfDNA for each patient at each 
timepoint analyzed and used a tiered approach to evaluate tumor burden.  For patients with 
detectable sequence alterations, the mutant allele fraction of the most abundant alteration in a clone 
targeted by the TKI was used as readout of cfTL.  In patients without detectable sequence 
alterations, we evaluated the PA score as a binary readout of cfTL where a score above 2.4 indicated 
aneuploidy and evidence of tumor burden and a score below 2.4 indicated normal ploidy and the 
absence of detectable tumor burden in plasma.   
Changes in cfTL were evaluated to compare tumor burden at baseline and at other timepoints during 
treatment using quantitative assessment of cfTL mutant allele fractions for patients with detectable 
sequence clones and qualitative assessment of change from aneuploidy to normal ploidy 
representing a complete response for patients without detectable sequence clones.   
Statistical analysis 
Significance was determined using a variety of methods.  To assess the significance of reduction 
in cfTL, in the number of sequence mutations detected, and reduction in PA scores in patients with 
radiographic response or stable disease versus patients with no radiographic response post 
treatment we used the Wilcoxon signed rank test.  The significance of newly emerging mutations 
in six of eight patients within the same day after initiation of therapy were evaluated by comparison 
to emerging alterations in two patients detected at earlier timepoints within 188 days prior to 
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therapy.  The rates of emerging mutations in the presence (within 4-12 hours) and absence of 
selective pressure of therapy were compared using a Gamma-Poisson Bayesian model.  A Gamma 
(1, 100) prior was used for both mutation rates.  Reported rates were based on the posterior mean 
and 99% posterior credible intervals (CI).  We compared progression-free survival in ctDNA 
responders versus ctDNA non-responders as well as in RECIST subgroups (partial response, stable 
disease, and progressive disease) using the Mantel-Cox log-rank test.  Paired t test was used to 







As a proof of concept, we evaluated cell-free DNA (cfDNA) from 28 patients with advanced non-
small cell lung cancer.  Of the twenty-eight patients, nine were initially diagnosed with stage IA, 
IIA, or IIIA disease, and the remaining presented with metastatic disease at initial diagnosis (Table 
2.1).  Prior to these analyses, patients received treatment with anti-EGFR agents (n=20), platinum-
based chemotherapy (n=11), or immune checkpoint inhibitors (n=1) (Table 2.1).  Nine patients 
initially treated with first- or second-generation EGFR TKIs developed the EGFR T790M 
resistance mutation and were subsequently treated with third generation EGFR TKIs (Table 2.1).  
We performed liquid biopsy analyses during treatment with targeted therapies, including 
osimertinib (n=15), afatinib (n=5), mavelertinib (n=5), or erlotinib (n=3) (Supplementary Table 
S1).   
Tumor response for these patients was determined using response evaluation criteria in solid tumors 
(RECIST) version 1.1 (70). Of the 28 patients analyzed, 12 achieved a partial response based on 
their initial CT assessment after treatment initiation, while eight patients exhibited stable disease, 
and five developed progressive disease (Table 2.1). One patient with limited miliary metastases in 
the lungs and two with exclusive bone lesions were classified as having unmeasurable disease 
(Table 2.1).   
For each patient, ~5 ml of plasma were collected immediately prior to therapy (baseline), at a 
median time of 19 days after therapy initiation, and at additional serial timepoints until disease 
progression was confirmed by radiographic assessment (Tables 2.1 and 2.2).   To analyze changes 
in cfDNA in these patients and capture the clonal heterogeneity of metastatic disease, we developed 
a combined comprehensive approach for analysis of both sequence and chromosomal changes.   For 
sequence analyses, we used our recently developed targeted error correction sequencing (TEC-Seq) 
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approach to evaluate 58 well-known cancer driver genes (Figure 2.1 and Tables 2.3, 2.4, and 2.5) 
(15).  This method is based on targeted capture and deep sequencing (>30,000x) of DNA fragments 
to provide a high degree of specificity across 80,930 bp of coding gene regions and enables 
identification of tumor-specific alterations in ctDNA while distinguishing these from amplification 
and sequencing artifacts, germline changes, or alterations related to blood cell proliferation that 
may be present in cfDNA (15).   To evaluate chromosomal changes that may be present in ctDNA, 
we used whole genome sequences obtained from off-target fragments that were not captured during 
analysis of targeted regions in manner similar to other genome wide copy number analyses, 
including Digital Karyotyping and related NGS approaches (9, 11, 74).  The most aberrant 
alterations in the genome representation of individual chromosome arms were used to construct a 
plasma aneuploidy score (PA-Score) that was evaluated to detect changes in ctDNA during therapy 
(Table 2.7).   
Dynamics of cell-free tumor load  
We evaluated ctDNA in all patients at baseline (pre-treatment) and after the initiation of therapy.  
In the blood draws that were analyzed, we detected sequence alterations in 24 of 28 cases.  At the 
baseline timepoint, patients had an average of 3.2 tumor-specific somatic mutations, affecting 16 
driver genes, ranging from one to 14 alterations per case (Table 2.5). Of 24 patients with detectable 
sequence alterations, 23 had at least one targetable mutation in either EGFR or ERBB2, with ctDNA 
mutant allele fractions ranging from 0.10% to 53.71% (Table 2.5).  Nine out of the 15 patients 
treated with osimertinib had EGFR T790M acquired resistance mutations in the circulation at 
baseline, with ctDNA mutant allele fractions ranging from 0.13% to 10.09% (Table 2.5), consistent 
with their previous treatment with EGFR TKIs (Table 2.1).  Previously described alterations in 
genes involved in blood cell proliferation (35-37, 72, 73) were observed in 18 patients across all 
timepoints analyzed, and were removed from further analyses (Table 2.6).   For a subset of patients, 
we analyzed chromosomal changes, and detected abnormalities in 13 of 15 cases analyzed.  In most 
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patients, multiple chromosomal arms were aberrant (Figures 2.2 and 2.3 and Table 2.7), resulting 
in PA-Scores ranging from 1.3 to 14.9 at the baseline blood sample.  Through our combined 
analyses we identified either a tumor-derived sequence or chromosomal change or both types of 
alterations in 25 of 28 cases.    
Based on the alterations observed in cfDNA through analyses of multiple genes, we developed a 
new metric, termed cell-free tumor load (cfTL), which is defined as the contribution of the most 
abundant alterations in cfDNA at any particular timepoint during the course of tumor evolution 
(Figure 2.1 and Tables 2.5 and 2.7).  In this study, the most abundant alterations were typically in 
driver genes targeted by the TKIs utilized (e.g., EGFR and ERBB2).  We used a tiered approach to 
evaluate ctDNA levels, first using cfTL levels based on sequence changes, and then PA-Scores 
based on chromosomal changes if sequence alterations were not present.  This approach has the 
benefit of providing a comprehensive assessment of tumor-derived alterations that would represent 
overall tumor burden during the course of disease and selective pressure of therapeutic 
interventions.   
All patients with an initial objective radiographic response to targeted therapy displayed dramatic 
reduction of cfTL with mutant allele concentrations reduced from an average of 10.80% at baseline 
to 0.18% at a median time of 19 days after treatment initiation (>95% decrease, P<0.001, Wilcoxon 
signed rank test) (Figures 2.2, 2.3, and 2.4, and Table 2.1).  Fig. 2 depicts a representative patient 
with metastatic disease (CGPLLU12) who had a rapid decline of cfTL from baseline to day 10 after 
initiation of osimertinib. This patient exhibited a progression-free survival of 7.0 months, then 
subsequently developed resistance in the primary lung lesion.  In patients with radiographic stable 
disease, mutant allele concentrations were reduced from an average of 2.24% at baseline to 1.04% 
after treatment initiation (Figure 2.4 A, Table 2.5) (P = 0.03, Wilcoxon signed rank test).  Likewise, 
PA-Scores decreased in responders (average decrease of 92%, P = 0.002, Wilcoxon signed rank 
test), including in patient CGPLLU97 who had no sequence alterations detected in the plasma 
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(Figure 2.5).  In contrast, all five patients with radiographic progressive disease experienced limited 
variation in cfTL, as measured through both sequence and chromosomal alterations, ranging from 
an average mutant allele fraction of 14.23% at baseline to 11.84% after initiation of therapy 
(Figures 2.2, 2.3, 2.4 A, and 2.5) (P = 0.6, Wilcoxon signed rank test).  
In addition to changes in cfTL, the average number of observed alterations also decreased in 
responders from 3.6 to 1.1 mutations per patient (P < 0.01, Wilcoxon signed rank test), while 
patients with stable or progressive disease had no significant change in the number of mutations 
observed during therapy (Figure 2.4 B).  Clinical NGS testing performed to identify alterations in 
tumor tissue or plasma during the care of these patients independently confirmed 79.2% of the 
changes detected in our study (Figure 2.6).  These observations suggest that both ctDNA levels and 
clonal heterogeneity are dramatically reduced at early timepoints in responding patients due to 
therapeutic selective pressure, and in non-responding patients the emergence and growth of tumor 
subclones can be detected earlier than radiographic progression. 
Analysis of cfDNA within hours of therapy 
For a subset of patients, we evaluated multiple follow-up blood draws at extremely early timepoints 
in therapy.  An immediate timepoint within the same day at 4-12 hours after the initiation of the 
first dose of treatment was available for five patients who experienced a radiographic partial 
response on the first or second scan (CGPLLU12, CGPLLU14, CGPLLU86, CGPLLU99, and 
CGLU344), two clinical responders classified with non-measurable disease (CGLU315 and 
CGLU373), and one patient with progressive disease (CGLU294).  In six of the eight patients for 
whom immediate timepoints were evaluated, increasing ctDNA levels allowed for the identification 
of eight tumor-derived alterations not previously detected at baseline including the targetable 
EGFR 746ELREATS>D clone in patient CGPLLU86 and an EGFR-resistance mutation T790M in 
patient CGLU344 (Figure 2.7 A).  Mutant allele fractions of the newly detected clones ranged from 
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0.15% to 1.70% with an average of 0.57% and suggested that these alterations were likely below 
the limit of detection at baseline and were detected due to an increase in ctDNA levels.  Evaluating 
the relative rate of emerging mutations in a Bayesian statistical model, we estimated a 110-fold 
increase in the rate of emerging mutations comparing post-treatment to pre-treatment levels (99% 
CI: 13 – 732).  Overall cfDNA amounts remained relatively constant between baseline and 
timepoints 4-12 hours after treatment indicating that changes in ctDNA levels occurred due to 
changes in the relative abundance of mutated clones within cfDNA (Figure 2.7 B).  These 
observations suggest that the emergence of novel ctDNA variants may be related to early effects of 
therapy and are consistent with studies showing BIM-mediated apoptosis in responsive tumors 6-
48 hours after exposure to EGFR inhibitors (75, 76).   
Cell-free tumor load and clinical outcome 
We evaluated whether the dynamic cfTL changes observed at early timepoints after treatment 
initiation were associated with differences in clinical outcome.  cfTL levels at these early time 
points were bimodal, with the lower group clustering at an average reduction in cfTL of 99.8% and 
the higher group having an average increase in cfTL of 0.06% (Figure 2.8 A).  We defined ctDNA 
responders as those with reduction in cfTL levels within three standard deviations of average 
reduction of the lower group (greater than 98.4%) while non-responders were below this threshold.  
Eight of twelve patients who developed a complete ctDNA response (cfTL reduction of 100%) 
experienced progression-free survival longer than one year (Figures 2.8 B and 2.9).  Of the six 
patients with radiographic stable disease, ctDNA analyses identified four patients with a molecular 
response (average PFS of 11.3 months) and two molecular non-responders (average PFS of 2.6 
months).  One patient who was a radiographic partial responder, but a molecular non-responder 
had a PFS of 3.9 months.  Importantly, two patients with non-measurable disease by RECIST were 
clearly identified as molecular responders with an average PFS of 13.7 months.  Overall, we 
observed a significantly shorter median progression-free survival for ctDNA non-responders 
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compared to ctDNA responders (1.6 months vs. 13.7 months, P < 0.0001, HR = 66.6, 95% CI: 13.0 
to 341.7, Log-rank test) (Figure 2.8 C).  Importantly, cfTL reduction at a median of 19 days 
appeared to be a more accurate predictor of clinical outcome compared to initial CT imaging 
performed an average of 47 days after initiation of therapy (P < 0.0001, Wilcoxon signed rank test) 
(Figures 2.8 C, D, E, and 2.9). 
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Figure 2.1. Schematic of cfTL determination and prediction of therapeutic response.  Liquid biopsies 
from metastatic non-small-cell lung cancer (mNSCLC) patients undergoing treatment with tyrosine kinase 
inhibition (TKI) were analyzed at baseline and at serial time points after treatment.  The TEC-Seq approach 
was used to directly identify sequence alterations across 58 genes encompassing 80,930 bases sequenced to 
>30,000X coverage, and whole-genome approaches were used to identify copy number changes in cfDNA.  
Cell-free tumor load (cfTL) was determined as the mutant allele fraction of the most abundant alteration in 
a clone targeted by TKI for patients with detected sequence alterations, or as the presence or absence of 
aneuploidy based on PA score in patients without detectable sequence alterations.  Prediction of therapeutic 
response to targeted therapy based on ctDNA dynamics was assessed through changes in cfTL from 
baseline to subsequent time points treatment whereas response assessment through CT imaging was 
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Figure 2.2. Dynamic changes of ctDNA during therapy.  Characteristic patterns of ctDNA changes during therapy are shown for a responder 
(CGPLLU12) (A) and a non-responder (CGPLLU244) (B), both treated with osimertinib.  Mutant allele fractions of clones identified in cfDNA 
through the TEC-Seq approach are shown for each timepoint analyzed with the ctDNA clone representing cfTL shown in bright green and 
treatment initiation highlighted with a red arrow (top).  Copy number changes identified in cfDNA from analyses of whole-genome data are shown 
at each timepoint analyzed as Z scores (burgundy dots) for each chromosome arm and PA scores (orange diamonds) (middle).  RECIST 1.1 sum of 
longest diameters (SLD, gray boxes) were measured from CT scans at intervals during therapy (top) and CT images show representative tumor 







Figure 2.3. Dynamic changes of ctDNA during therapy. Patterns of ctDNA changes during therapy are 
shown for patients with initial radiographic partial response (A, B, E-I, M, N, R), non-measureable disease 
(C, X), stable disease (D, J-L, S-V), or progressive disease (O-Q, W) after treatment with targeted therapy. 
Mutant allele fractions of clones identified in cfDNA through the TEC-Seq approach are shown for each 
timepoint analyzed with treatment initiation highlighted with a red arrow. Copy number changes identified 
in cfDNA from analyses of whole-genome data are shown at timepoints analyzed as Z scores (burgundy 
dots) for each chromosome arm and PA scores (orange diamonds). RECIST 1.1 sum of longest diameters 
(SLD, gray boxes) were measured from CT scans at intervals during therapy.  
P < 0.001
P = 0.03
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Figure 2.6. Concordance between alterations observed with TEC-Seq in the plasma and clinical NGS analyses in the tumor tissue or plasma. Mutant 
allele fractions of alterations directly detected in plasma through analyses with TEC-Seq are indicated. The presence of each alteration in matched tumor tissue or 
plasma specimen evaluated with clinical NGS tests are indicated with dark blue and light blue dots respectively whereas non-concordant mutations are indicated 

















































Figure 2.8. Changes in ctDNA and prediction of response to therapy.  Changes in cfTL from baseline to the time of ctDNA assessment revealed a bimodal 
distribution (A).  Patients with reduction of cfTL >98% and ≤98% were categorized as ctDNA responders and ctDNA non-responders, respectively.  cfTL at the 
time of ctDNA assessment (blue) and PFS (orange) are depicted for patients analyzed (B).  Radiographic assessment is indicated in the right column as partial 
response (PR), stable disease (SD), non-measurable disease (NM), or progressive disease (PD). Patient CGPLLU244 had cfTL levels >100% at the time of 
ctDNA assessment (*).  Progression-free survival for ctDNA responders and non-responders (P < 0.0001, Mantel-Cox log rank test) (C). Progression-free 
survival based on initial radiographic assessment (P = 0.0002, Mantel-Cox log rank test) (D) Time to response assessment as determined by CT scans (blue) or 
analyses of ctDNA (orange) are indicated with median time to assessment shown in dotted lines (P < 0.0001, Wilcoxon signed rank test) (E). 
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Table 2.1.  Summary of clinical characteristics of patients analyzed. 
Patient ID Age Gender Smoking Status 
Histopathological 





Overall response at 
last follow-up 
Status at last 
follow-up 
CGPLLU99 53 Male Never Adenocarcinoma IIIA Osimertinib Partial Response 893 Continued response Alive 
CGPLLU97 57 Female Never Adenocarcinoma IV Osimertinib Partial Response 413 Progressive disease Unknown 
CGPLLU89 54 Female Former Adenocarcinoma IV Osimertinib Partial Response 427 Progressive disease Deceased 
CGPLLU88 59 Male Former Adenocarcinoma IIA Osimertinib Partial Response 548 Progressive disease Deceased 
CGPLLU86 55 Male Never Adenocarcinoma IV Osimertinib Stable Disease 986 Progressive disease Alive 
CGPLLU43 57 Female Never Adenocarcinoma IA Erlotinib Non-measurable* 831 Continued response Alive 
CGPLLU271 73 Male Former Adenocarcinoma IV Mavelertinib Stable Disease 273 Progressive disease Deceased 
CGPLLU270 53 Female Never Adenocarcinoma IV Mavelertinib Partial Response 216 Continued response Alive 
CGPLLU269 52 Female Former Adenocarcinoma IV Mavelertinib Stable Disease 47 Progressive disease Deceased 
CGPLLU267 55 Female Never Squamous cell carcinoma IV Erlotinib Stable Disease 238 Progressive disease Alive 
CGPLLU266 78 Male Never Adenocarcinoma IIA Mavelertinib Stable Disease 336 Progressive disease Alive 
CGPLLU265 71 Female Never Adenocarcinoma IA Mavelertinib Stable Disease 715 Progressive disease Alive 
CGPLLU264 84 Male Never Adenocarcinoma IV Osimertinib Stable Disease Ongoing Continued response Alive 
CGPLLU246 65 Female Never Adenocarcinoma IV Osimertinib Progressive Disease 59 Progressive disease Deceased 
CGPLLU245 49 Male Never Adenocarcinoma IV Osimertinib Progressive Disease 134 Progressive disease Alive 
CGPLLU244 66 Female Never Adenocarcinoma IV Osimertinib Progressive Disease 90 Progressive disease Deceased 
CGPLLU18 50 Female Never Adenocarcinoma IIA Osimertinib Partial Response 104 Progressive disease Deceased 
CGPLLU14 55 Female Never Adenocarcinoma IIA Osimertinib Partial Response 713 Progressive disease Deceased 
CGPLLU13 72 Female Never Adenocarcinoma IV Osimertinib Stable Disease 136 Progressive disease Deceased 
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CGPLLU12 67 Female Never Adenocarcinoma IV Osimertinib Partial Response 431 Progressive disease Deceased 
CGLU373 56 Female Never Adenocarcinoma IIIA Afatinib Non-measurable* Ongoing Continued response Alive 
CGLU369 48 Female Never Adenocarcinoma IV Erlotinib Partial response 352 Progressive disease Alive 
CGLU344 65 Female Never Adenocarcinoma IV Osimertinib Partial response Ongoing Continued response Alive 
CGLU324 60 Female Former Adenocarcinoma IV Afatinib Partial response 212 Progressive disease Alive 
CGLU319 74 Female Never Adenocarcinoma IV Afatinib Partial response Ongoing Continued response Alive 
CGLU316 50 Female Former Mixed carcinoma IIIA Osimertinib Progressive Disease 73 Progressive disease Alive 
CGLU315 54 Male Never Adenocarcinoma IV Afatinib Non-measurable* Ongoing Continued response Alive 
CGLU294 51 Male Never Adenocarcinoma IV Afatinib Progressive Disease 57 Progressive disease Alive 
*Not measurable by RECIST; patient derives partial clinical benefit from treatment. 
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Table 2.2.  Summary of serial timepoints analyzed. 
Patient ID Patient Timepoint Significance of Timepoint Days since Treatment Volume of Plasma  (ml) 
cfDNA Extracted  
(ng) 
cfDNA Input  
(ng) 
CGPLLU12 CGPLLU12P_6 Pre Osimertinib -150.0 5.00 350.30 350.30 
CGPLLU12 CGPLLU12P_22 Pre Osimertinib 0.0 7.00 1254.20 250.00 
CGPLLU12 CGPLLU12P_18 Post Osimertinib 0.2 6.80 559.60 250.00 
CGPLLU12 CGPLLU12P_20 Post Osimertinib 10.0 6.00 324.30 250.00 
CGPLLU12 CGPLLU12P_34 Post Osimertinib 227.0 5.00 191.00 191.00 
CGPLLU14 CGPLLU14P_8 Pre Osimertinib -38.0 4.20 59.50 59.50 
CGPLLU14 CGPLLU14P_12 Pre Osimertinib -16.0 4.20 47.00 47.00 
CGPLLU14 CGPLLU14P_15 Pre Osimertinib -3.0 5.00 72.00 72.00 
CGPLLU14 CGPLLU14P_21 Pre Osimertinib 0.0 5.00 16.82 16.82 
CGPLLU14 CGPLLU14P_19 Post Osimertinib 0.3 4.60 121.60 121.60 
CGPLLU14 CGPLLU14P_23 Post Osimertinib 7.0 3.20 19.26 19.26 
CGPLLU18 CGPLLU18P_4 Pre Osimertinib -1.0 5.00 2196.70 250.00 
CGPLLU18 CGPLLU18P_15 Post Osimertinib 6.0 6.00 446.30 250.00 
CGPLLU18 CGPLLU18P_11 Post Osimertinib 20.0 3.00 24.00 24.00 
CGPLLU244 CGPLLU244P_1 Pre Osimertinib -7.0 4.50 80.26 80.26 
CGPLLU244 CGPLLU244P_2 Pre Osimertinib -1.0 4.10 132.44 125.00 
CGPLLU244 CGPLLU244P_3 Post Osimertinib 6.0 4.70 255.79 125.00 
CGPLLU244 CGPLLU244P_4 Post Osimertinib 62.0 2.90 74.95 74.95 
CGPLLU245 CGPLLU245P_1 Pre Osimertinib -32.0 4.70 91.28 91.28 
CGPLLU245 CGPLLU245P_2 Pre Osimertinib 0.0 4.30 468.58 125.00 
CGPLLU245 CGPLLU245P_3 Post Osimertinib 7.0 3.00 314.40 125.00 
CGPLLU245 CGPLLU245P_4 Post Osimertinib 21.0 3.30 161.49 125.00 
CGPLLU246 CGPLLU246P_1 Pre Osimertinib -21.0 5.50 101.78 101.78 
CGPLLU246 CGPLLU246P_2 Pre Osimertinib 0.0 5.00 118.00 118.00 
CGPLLU246 CGPLLU246P_4 Post Osimertinib 9.0 3.30 43.48 43.48 
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CGPLLU246 CGPLLU246P_5 Post Osimertinib 42.0 3.40 46.51 46.51 
CGPLLU86 CGPLLU86P_6 Pre Osimertinib 0.0 4.00 31.60 31.60 
CGPLLU86 CGPLLU86P_1 Post Osimertinib 0.5 4.00 14.50 14.50 
CGPLLU86 CGPLLU86P_8 Post Osimertinib 7.0 4.60 14.50 14.50 
CGPLLU86 CGPLLU86P_9 Post Osimertinib 17.0 5.00 19.90 19.90 
CGPLLU88 CGPLLU88P_2 Pre Osimertinib 0.0 5.00 138.31 138.31 
CGPLLU88 CGPLLU88P Post Osimertinib 7.0 5.00 32.43 32.43 
CGPLLU88 CGPLLU88P_5 Post Osimertinib 297.0 4.00 12.16 12.16 
CGPLLU89 CGPLLU89P Pre Osimertinib 0.0 8.00 67.40 67.40 
CGPLLU89 CGPLLU89P_2 Post Osimertinib 7.0 6.50 40.60 40.60 
CGPLLU89 CGPLLU89P_5 Post Osimertinib 22.0 6.00 17.90 17.90 
CGPLLU97 CGPLLU97P_11 Pre Osimertinib 0.0 6.50 26.10 26.10 
CGPLLU97 CGPLLU97P_4 Post Osimertinib 7.0 6.40 22.23 22.23 
CGPLLU97 CGPLLU97P_20 Post Osimertinib 273.0 6.00 27.54 27.54 
CGPLLU99 CGPLLU99P_8 Pre Osimertinib 0.0 6.00 50.60 50.60 
CGPLLU99 CGPLLU99P_10 Post Osimertinib 0.3 5.00 45.99 45.99 
CGPLLU99 CGPLLU99P_12 Post Osimertinib 9.0 5.00 24.99 24.99 
CGPLLU99 CGPLLU99P_11 Post Osimertinib 21.0 4.00 18.76 18.76 
CGLU294 CGLU294P_1 Pre Afatinib 0.0 5.00 17.36 17.36 
CGLU294 CGLU294P1_1 Post Afatinib 0.2 5.00 15.52 15.52 
CGLU294 CGLU294P2_1 Post Afatinib 3.0 5.00 16.59 16.59 
CGLU294 CGLU294P3_2 Post Afatinib 7.0 5.00 10.73 10.73 
CGLU294 CGLU294P4_1 Post Afatinib 29.0 5.00 12.22 12.22 
CGLU315 CGLU315P_1 Pre Afatinib 0.0 5.00 25.96 25.96 
CGLU315 CGLU315P1_1 Post Afatinib 0.2 5.00 22.48 22.48 
CGLU315 CGLU315P2_1 Post Afatinib 20.0 5.00 22.62 22.62 
CGLU319 CGLU319P_1 Pre Afatinib 0.0 5.00 53.14 53.14 
CGLU319 CGLU319P1_1 Post Afatinib 14.0 5.00 48.26 48.26 
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CGLU324 CGLU324P_1 Post Afatinib 1.0 5.00 32.96 32.96 
CGLU324 CGLU324P1_1 Post Afatinib 20.0 5.00 26.71 26.71 
CGLU373 CGLU373P_1 Pre Afatinib -2.0 5.00 31.76 31.76 
CGLU373 CGLU373P1_1 Post Afatinib 0.1 5.00 31.42 31.42 
CGLU373 CGLU373P2_1 Post Afatinib 7.0 5.00 19.11 19.11 
CGLU373 CGLU373P3_1 Post Afatinib 47.0 3.50 19.41 19.41 
CGLU316 CGLU316P6_1 Pre Osimertinib -53.0 5.00 11.90 11.90 
CGLU316 CGLU316P7_1 Pre Osimertinib -4.0 5.00 10.54 10.54 
CGLU316 CGLU316P8_1 Post Osimertinib 18.0 5.00 4.36 5.37 
CGLU316 CGLU316P9_1 Post Osimertinib 87.0 2.00 17.49 17.49 
CGLU369 CGLU369P_1 Pre Erlotinib -2.0 2.00 22.56 22.56 
CGLU369 CGLU369P1_1 Post Erlotinib 12.0 5.00 50.43 50.43 
CGLU369 CGLU369P2_1 Post Erlotinib 68.0 5.00 33.47 33.50 
CGLU369 CGLU369P3_1 Post Erlotinib 110.0 5.00 42.06 42.10 
CGLU344 CGLU344P1_1 Pre Osimertinib -21.0 5.00 173.87 125.00 
CGLU344 CGLU344P2_1 Pre Osimertinib 0.0 5.00 78.15 78.20 
CGLU344 CGLU344P3_1 Post Osimertinib 0.2 5.00 46.11 46.10 
CGLU344 CGLU344P5_1 Post Osimertinib 59.0 5.00 26.57 26.60 
CGPLLU13 CGPLLU13P27 Pre Osimertinib -2.0 5.00 38.37 38.37 
CGPLLU13 CGPLLU13P28 Post Osimertinib 5.0 4.50 37.75 37.75 
CGPLLU13 CGPLLU13P29 Post Osimertinib 28.0 3.20 27.71 27.71 
CGPLLU13 CGPLLU13P30 Post Osimertinib 91.0 5.00 29.87 29.87 
CGPLLU43 CGPLLU43P3 Pre Erlotinib -1.0 4.90 10.65 10.65 
CGPLLU43 CGPLLU43P4 Post Erlotinib 6.0 3.70 12.07 12.07 
CGPLLU43 CGPLLU43P5 Post Erlotinib 27.0 4.00 16.46 16.46 
CGPLLU43 CGPLLU43P6 Post Erlotinib 83.0 3.70 30.35 30.35 
CGPLLU267 CGPLLU267P Pre Erlotinib -1.0 4.50 12.93 12.93 
CGPLLU267 CGPLLU267P2 Post Erlotinib 34.0 4.50 15.04 15.04 
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CGPLLU267 CGPLLU267P3 Post Erlotinib 90.0 3.50 10.51 10.51 
CGPLLU269 CGPLLU269P1 Pre PF7775 0.0 5.00 57.02 57.02 
CGPLLU269 CGPLLU269P2 Post PF7775 9.0 5.00 41.77 41.77 
CGPLLU269 CGPLLU269P3 Post PF7775 28.0 3.50 62.26 62.26 
CGPLLU271 CGPLLU271P Pre PF7775 0.0 5.00 94.30 94.30 
CGPLLU271 CGPLLU271P1 Post PF7775 6.0 4.50 62.26 62.26 
CGPLLU271 CGPLLU271P2 Post PF7775 20.0 3.50 47.12 47.12 
CGPLLU271 CGPLLU271P3 Post PF7775 104.0 4.00 55.09 55.09 
CGPLLU271 CGPLLU271P4 Post PF7775 259.0 4.00 18.80 18.80 
CGPLLU264 CGPLLU264P Pre Osimertinib -1.0 4.00 91.89 91.89 
CGPLLU264 CGPLLU264P1 Post Osimertinib 6.0 4.50 47.38 47.38 
CGPLLU264 CGPLLU264P2 Post Osimertinib 27.0 3.00 21.44 21.44 
CGPLLU264 CGPLLU264P3 Post Osimertinib 69.0 4.00 38.39 38.39 
CGPLLU266 CGPLLU266P Pre PF7775 0.0 5.00 26.61 26.61 
CGPLLU266 CGPLLU266P2 Post PF7775 16.0 3.50 22.10 22.10 
CGPLLU266 CGPLLU266P3 Post PF7775 83.0 5.00 38.22 38.22 
CGPLLU266 CGPLLU266P4 Post PF7775 328.0 5.00 71.94 71.94 
CGPLLU265 CGPLLU265P Pre PF7775 0.0 4.20 30.09 30.09 
CGPLLU265 CGPLLU265P1 Post PF7775 3.0 4.00 32.43 32.43 
CGPLLU265 CGPLLU265P2 Post PF7775 7.0 4.20 31.62 31.62 
CGPLLU265 CGPLLU265P3 Post PF7775 84.0 5.00 80.83 80.83 
CGPLLU270 CGPLLU270P Pre PF7775 0.0 5.00 25.64 25.64 
CGPLLU270 CGPLLU270P2 Post PF7775 12.0 3.50 14.58 14.58 




Table 2.3.  Summary of genes analyzed. 
Gene Region Analyzed Gene Category 
ABL1 Specific Exons Cancer Driver Gene 
AKT1 Specific Exons Cancer Driver Gene 
ALK Full Coding Region Cancer Driver Gene 
APC Specific Exons Cancer Driver Gene 
AR Full Coding Region Cancer Driver Gene 
ATM Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
BRAF Full Coding Region Cancer Driver Gene 
CDH1 Specific Exons Cancer Driver Gene 
CDK4 Full Coding Region Cancer Driver Gene 
CDK6 Full Coding Region Cancer Driver Gene 
CDKN2A Specific Exons Cancer Driver Gene 
CSF1R Specific Exons Cancer Driver Gene 
CTNNB1 Specific Exons Cancer Driver Gene 
DNMT3A Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
EGFR Full Coding Region Cancer Driver Gene 
ERBB2 Specific Exons Cancer Driver Gene 
ERBB4 Full Coding Region Cancer Driver Gene 
ESR1 Full Coding Region Cancer Driver Gene 
EZH2 Specific Exons Cancer Driver Gene 
FBXW7 Specific Exons Cancer Driver Gene 
FGFR1 Specific Exons Cancer Driver Gene 
FGFR2 Specific Exons Cancer Driver Gene 
FGFR3 Specific Exons Cancer Driver Gene 
FLT3 Specific Exons Cancer Driver Gene 
GNA11 Specific Exons Cancer Driver Gene 
GNAQ Specific Exons Cancer Driver Gene 
GNAS Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
HNF1A Specific Exons Cancer Driver Gene 
HRAS Full Coding Region Cancer Driver Gene 
IDH1 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
IDH2 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
JAK2 Full Coding Region Cancer Driver and Clonal Hematopoiesis Gene 
JAK3 Specific Exons Cancer Driver Gene 
KDR Specific Exons Cancer Driver Gene 
KIT Full Coding Region Cancer Driver Gene 
KRAS Full Coding Region Cancer Driver Gene 
MAP2K1 Specific Exons Cancer Driver Gene 
MET Specific Exons Cancer Driver Gene 
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MLH1 Specific Exons Cancer Driver Gene 
MPL Specific Exons Cancer Driver Gene 
MYC Specific Exons Cancer Driver Gene 
NPM1 Specific Exons Cancer Driver Gene 
NRAS Full Coding Region Cancer Driver Gene 
PDGFRA Full Coding Region Cancer Driver Gene 
PIK3CA Full Coding Region Cancer Driver Gene 
PIK3R1 Specific Exons Cancer Driver Gene 
PTEN Full Coding Region Cancer Driver Gene 
PTPN11 Specific Exons Cancer Driver Gene 
RB1 Specific Exons Cancer Driver Gene 
RET Specific Exons Cancer Driver Gene 
SMAD4 Specific Exons Cancer Driver Gene 
SMARCB1 Specific Exons Cancer Driver Gene 
SMO Specific Exons Cancer Driver Gene 
SRC Specific Exons Cancer Driver Gene 
STK11 Full Coding Region Cancer Driver Gene 
TERT Specific Exons Cancer Driver Gene 
TP53 Full Coding Region Cancer Driver Gene 
VHL Specific Exons Cancer Driver Gene 
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Table 2.4.  Summary of genomic analyses. 







































CGPLLU12 CGPLLU12P_18 100 7,900,133,500 80,930 3,863,298,051 49% 45,929 8,508 2,846,140,175 1,855,865,100 23% 0.6521 
CGPLLU12 CGPLLU12P_20 100 7,756,705,100 80,930 3,517,430,064 45% 40,943 5,816 2,846,140,175 2,302,262,600 30% 0.8089 
CGPLLU12 CGPLLU12P_22 100 8,057,252,300 80,930 3,802,086,289 47% 45,136 7,805 2,846,140,175 2,071,248,200 26% 0.7277 
CGPLLU12 CGPLLU12P_34 100 8,777,269,900 80,930 4,524,962,642 52% 52,841 5,766 2,846,140,175 1,905,315,600 22% 0.6694 
CGPLLU12 CGPLLU12P_6 100 7,201,712,800 80,930 3,608,246,175 50% 44,081 2,867 2,846,140,175 1,580,319,900 22% 0.5553 
CGPLLU14 CGPLLU14P_12 100 8,668,655,700 80,930 3,980,731,089 46% 48,628 3,148 2,846,140,175 2,405,208,900 28% 0.8451 
CGPLLU14 CGPLLU14P_15 100 8,271,043,600 80,930 4,105,092,738 50% 50,152 4,497 2,846,140,175 1,962,306,900 24% 0.6895 
CGPLLU14 CGPLLU14P_19 100 7,149,809,200 80,930 3,405,754,720 48% 40,382 6,170 2,846,140,175 1,796,929,400 25% 0.6314 
CGPLLU14 CGPLLU14P_21 100 6,556,332,200 80,930 3,289,504,484 50% 39,004 4,081 2,846,140,175 1,354,209,200 21% 0.4758 
CGPLLU14 CGPLLU14P_23 100 7,410,378,300 80,930 3,464,236,558 47% 41,108 4,259 2,846,140,175 1,982,005,900 27% 0.6964 
CGPLLU14 CGPLLU14P_8 100 7,530,190,700 80,930 3,752,054,349 50% 45,839 2,469 2,846,140,175 1,630,985,900 22% 0.5731 
CGPLLU18 CGPLLU18P_11 100 8,873,158,100 80,930 4,118,821,432 46% 48,136 5,160 2,846,140,175 2,493,973,600 28% 0.8763 
CGPLLU18 CGPLLU18P_15 100 6,258,355,400 80,930 3,199,373,401 51% 37,270 7,926 2,846,140,175 1,319,217,600 21% 0.4635 
CGPLLU18 CGPLLU18P_4 100 9,997,401,400 80,930 4,940,336,941 49% 57,994 6,805 2,846,140,175 2,212,495,700 22% 0.7774 
CGPLLU244 CGPLLU244P_1 100 8,305,560,600 80,930 4,182,616,104 50% 50,851 7,569 2,846,140,175 1,933,915,900 23% 0.6795 
CGPLLU244 CGPLLU244P_2 100 7,739,951,100 80,930 3,788,487,116 49% 45,925 8,552 2,846,140,175 1,972,044,700 25% 0.6929 
CGPLLU244 CGPLLU244P_3 100 8,061,928,000 80,930 4,225,322,272 52% 51,279 8,646 2,846,140,175 1,700,788,200 21% 0.5976 
CGPLLU244 CGPLLU244P_4 100 8,894,936,700 80,930 4,437,962,639 50% 53,862 7,361 2,846,140,175 2,219,056,500 25% 0.7797 
CGPLLU245 CGPLLU245P_1 100 7,679,235,200 80,930 3,935,822,054 51% 47,768 7,266 2,846,140,175 1,633,713,800 21% 0.5740 
CGPLLU245 CGPLLU245P_2 100 8,985,252,500 80,930 4,824,268,339 54% 58,338 10,394 2,846,140,175 1,897,728,900 21% 0.6668 
CGPLLU245 CGPLLU245P_3 100 8,518,229,300 80,930 4,480,236,927 53% 54,083 10,125 2,846,140,175 1,958,617,000 23% 0.6882 
CGPLLU245 CGPLLU245P_4 100 9,031,131,000 80,930 4,824,738,475 53% 58,313 10,598 2,846,140,175 1,871,678,500 21% 0.6576 
CGPLLU246 CGPLLU246P_1 100 8,520,360,800 80,930 3,509,660,305 41% 42,349 8,086 2,846,140,175 3,090,140,500 36% 1.0857 
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CGPLLU246 CGPLLU246P_2 100 5,451,467,800 80,930 2,828,351,657 52% 34,243 8,256 2,846,140,175 1,183,329,500 22% 0.4158 
CGPLLU246 CGPLLU246P_4 100 8,137,616,600 80,930 4,135,036,174 51% 50,121 6,466 2,846,140,175 1,889,464,200 23% 0.6639 
CGPLLU246 CGPLLU246P_5 100 8,385,724,600 80,930 4,413,323,333 53% 53,495 7,303 2,846,140,175 1,673,217,100 20% 0.5879 
CGPLLU86 CGPLLU86P_1 100 8,222,093,400 80,930 3,523,035,056 43% 41,165 3,614 2,846,140,175 2,702,667,600 33% 0.9496 
CGPLLU86 CGPLLU86P_6 100 8,305,719,500 80,930 4,271,264,008 51% 49,508 6,681 2,846,140,175 1,787,964,500 22% 0.6282 
CGPLLU86 CGPLLU86P_8 100 6,787,785,300 80,930 3,443,658,418 51% 40,192 3,643 2,846,140,175 1,430,288,100 21% 0.5025 
CGPLLU86 CGPLLU86P_9 100 6,213,229,400 80,930 3,120,325,926 50% 36,413 3,560 2,846,140,175 1,301,442,800 21% 0.4573 
CGPLLU88 CGPLLU88P 100 7,679,995,800 80,930 4,004,738,253 52% 46,951 6,387 2,846,140,175 1,458,370,000 19% 0.5124 
CGPLLU88 CGPLLU88P_2 100 7,252,433,900 80,930 3,621,678,746 50% 42,719 8,599 2,846,140,175 1,578,804,800 22% 0.5547 
CGPLLU88 CGPLLU88P_5 100 6,509,178,000 80,930 3,316,053,733 51% 39,274 2,661 2,846,140,175 1,275,075,600 20% 0.4480 
CGPLLU89 CGPLLU89P 100 7,662,496,600 80,930 3,781,536,306 49% 44,097 7,909 2,846,140,175 1,795,332,800 23% 0.6308 
CGPLLU89 CGPLLU89P_2 100 7,005,599,500 80,930 3,339,612,564 48% 38,977 5,034 2,846,140,175 1,753,053,800 25% 0.6159 
CGPLLU89 CGPLLU89P_5 100 8,325,998,600 80,930 3,094,796,789 37% 36,061 2,822 2,846,140,175 3,367,580,600 40% 1.1832 
CGPLLU97 CGPLLU97P_11 100 9,607,549,400 80,930 4,714,483,715 49% 55,065 3,275 2,846,140,175 2,049,397,700 21% 0.7201 
CGPLLU97 CGPLLU97P_20 100 7,977,402,200 80,930 3,981,840,609 50% 46,594 4,592 2,846,140,175 1,733,523,000 22% 0.6091 
CGPLLU97 CGPLLU97P_4 100 7,975,580,500 80,930 3,458,563,174 43% 40,224 4,228 2,846,140,175 2,490,544,100 31% 0.8751 
CGPLLU99 CGPLLU99P_10 100 8,350,456,400 80,930 4,112,640,680 49% 48,035 7,434 2,846,140,175 1,849,135,400 22% 0.6497 
CGPLLU99 CGPLLU99P_11 100 8,455,525,300 80,930 4,248,480,856 50% 49,401 3,388 2,846,140,175 1,723,529,200 20% 0.6056 
CGPLLU99 CGPLLU99P_12 100 8,172,750,100 80,930 3,937,309,188 48% 46,100 3,983 2,846,140,175 1,970,825,300 24% 0.6925 
CGPLLU99 CGPLLU99P_8 100 6,563,589,000 80,930 3,167,459,274 48% 36,917 7,020 2,846,140,175 1,606,184,600 24% 0.5643 
CGLU294 CGLU294P_1 100 13,391,053,400 80,930 6,557,523,556 49% 78,449 4,975 2,846,140,175 3,021,967,400 23% 1.0618 
CGLU294 CGLU294P1_1 100 6,123,688,700 80,930 2,559,160,575 42% 30,475 2,658 2,846,140,175 1,906,657,800 31% 0.6699 
CGLU294 CGLU294P2_1 100 6,826,939,100 80,930 2,696,933,517 40% 32,177 2,227 2,846,140,175 2,343,809,200 34% 0.8235 
CGLU294 CGLU294P3_2 100 6,537,975,900 80,930 2,964,372,304 45% 35,429 2,504 2,846,140,175 1,698,272,400 26% 0.5967 
CGLU294 CGLU294P4_1 100 4,382,617,500 80,930 2,052,259,803 47% 24,503 764 2,846,140,175 1,002,848,200 23% 0.3524 
CGLU315 CGLU315P_1 100 1,511,727,500 80,930 772,328,073 51% 9,226 498 2,846,140,175 295,051,200 20% 0.1037 
CGLU315 CGLU315P1_1 100 3,516,057,800 80,930 1,651,476,480 47% 19,709 1,923 2,846,140,175 862,931,400 25% 0.3032 
CGLU315 CGLU315P2_1 100 2,406,092,800 80,930 1,154,037,968 48% 13,766 956 2,846,140,175 521,497,300 22% 0.1832 
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CGLU319 CGLU319P_1 100 6,167,692,000 80,930 3,135,436,369 51% 37,285 3,583 2,846,140,175 1,336,584,600 22% 0.4696 
CGLU319 CGLU319P1_1 100 5,458,775,500 80,930 2,458,429,678 45% 29,096 2,715 2,846,140,175 1,604,345,600 29% 0.5637 
CGLU324 CGLU324P_1 100 6,404,352,500 80,930 3,124,992,053 49% 37,062 2,071 2,846,140,175 1,379,187,100 22% 0.4846 
CGLU324 CGLU324P1_1 100 5,622,041,400 80,930 2,679,400,008 48% 31,829 2,574 2,846,140,175 1,354,233,400 24% 0.4758 
CGLU373 CGLU373P_1 100 6,346,267,200 80,930 3,053,520,676 48% 36,137 6,251 2,846,140,175 ND ND ND 
CGLU373 CGLU373P1_1 100 6,517,189,900 80,930 3,192,984,468 49% 38,066 8,040 2,846,140,175 ND ND ND 
CGLU373 CGLU373P2_1 100 7,767,146,300 80,930 3,572,598,842 46% 42,378 5,306 2,846,140,175 ND ND ND 
CGLU373 CGLU373P3_1 100 7,190,999,100 80,930 3,273,648,804 46% 38,784 4,454 2,846,140,175 ND ND ND 
CGLU316 CGLU316P6_1 100 7,864,415,100 80,930 1,991,331,171 25% 23,601 3,565 2,846,140,175 ND ND ND 
CGLU316 CGLU316P7_1 100 7,502,591,600 80,930 3,730,963,390 50% 44,262 3,966 2,846,140,175 ND ND ND 
CGLU316 CGLU316P8_1 100 6,582,515,900 80,930 3,187,059,470 48% 37,813 3,539 2,846,140,175 ND ND ND 
CGLU316 CGLU316P9_1 100 6,587,281,800 80,930 1,947,630,979 30% 23,094 4,439 2,846,140,175 ND ND ND 
CGLU369 CGLU369P_1 100 7,080,245,300 80,930 1,271,457,982 18% 15,109 2,364 2,846,140,175 ND ND ND 
CGLU369 CGLU369P1_1 100 7,078,131,900 80,930 1,482,448,715 21% 17,583 4,275 2,846,140,175 ND ND ND 
CGLU369 CGLU369P2_1 100 6,904,701,700 80,930 2,124,660,124 31% 25,230 5,278 2,846,140,175 ND ND ND 
CGLU369 CGLU369P3_1 100 7,003,452,200 80,930 3,162,195,578 45% 37,509 6,062 2,846,140,175 ND ND ND 
CGLU344 CGLU344P1_1 100 6,151,628,500 80,930 2,748,983,603 45% 32,462 8,063 2,846,140,175 ND ND ND 
CGLU344 CGLU344P2_1 100 7,842,910,900 80,930 1,147,703,178 15% 13,565 4,303 2,846,140,175 ND ND ND 
CGLU344 CGLU344P3_1 100 5,838,083,100 80,930 2,291,108,925 39% 27,067 4,287 2,846,140,175 ND ND ND 
CGLU344 CGLU344P5_1 100 7,685,989,200 80,930 3,722,274,529 48% 43,945 3,471 2,846,140,175 ND ND ND 
CGPLLU13 CGPLLU13P27 100 5,659,546,100 80,930 1,721,618,955 30% 20,587 6,025 2,846,140,175 ND ND ND 
CGPLLU13 CGPLLU13P28 100 6,199,049,700 80,930 2,563,659,840 41% 30,728 6,514 2,846,140,175 ND ND ND 
CGPLLU13 CGPLLU13P29 100 5,864,396,500 80,930 1,194,237,002 20% 14,331 3,952 2,846,140,175 ND ND ND 
CGPLLU13 CGPLLU13P30 100 5,080,197,700 80,930 1,373,550,586 27% 16,480 5,389 2,846,140,175 ND ND ND 
CGPLLU264 CGPLLU264P 100 6,254,777,700 80,930 3,016,326,208 48% 36,164 12,138 2,846,140,175 ND ND ND 
CGPLLU264 CGPLLU264P1 100 6,185,331,000 80,930 3,087,883,231 50% 37,003 8,388 2,846,140,175 ND ND ND 
CGPLLU264 CGPLLU264P2 100 6,274,540,300 80,930 2,861,143,666 46% 34,308 6,817 2,846,140,175 ND ND ND 
CGPLLU264 CGPLLU264P3 100 5,701,274,000 80,930 1,241,270,938 22% 14,886 4,273 2,846,140,175 ND ND ND 
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CGPLLU265 CGPLLU265P 100 6,091,276,800 80,930 2,922,585,558 48% 35,004 7,742 2,846,140,175 ND ND ND 
CGPLLU265 CGPLLU265P1 100 6,430,107,900 80,930 2,945,953,499 46% 35,219 8,574 2,846,140,175 ND ND ND 
CGPLLU265 CGPLLU265P2 100 5,869,510,300 80,930 2,792,208,995 48% 33,423 8,423 2,846,140,175 ND ND ND 
CGPLLU265 CGPLLU265P3 100 5,884,330,900 80,930 2,588,386,038 44% 30,977 9,803 2,846,140,175 ND ND ND 
CGPLLU266 CGPLLU266P 100 5,807,524,900 80,930 2,347,651,479 40% 28,146 5,793 2,846,140,175 ND ND ND 
CGPLLU266 CGPLLU266P2 100 6,064,269,800 80,930 2,086,938,782 34% 24,994 6,221 2,846,140,175 ND ND ND 
CGPLLU266 CGPLLU266P3 100 6,785,913,900 80,930 3,458,588,505 51% 41,432 7,765 2,846,140,175 ND ND ND 
CGPLLU266 CGPLLU266P4 100 6,513,702,000 80,930 2,096,370,387 32% 25,142 6,598 2,846,140,175 ND ND ND 
CGPLLU267 CGPLLU267P 100 6,610,761,200 80,930 2,576,886,619 39% 31,095 4,485 2,846,140,175 ND ND ND 
CGPLLU267 CGPLLU267P2 100 6,156,102,000 80,930 2,586,081,726 42% 30,714 5,309 2,846,140,175 ND ND ND 
CGPLLU267 CGPLLU267P3 100 6,180,799,700 80,930 2,013,434,756 33% 23,902 3,885 2,846,140,175 ND ND ND 
CGPLLU269 CGPLLU269P1 100 6,221,168,600 80,930 1,499,602,843 24% 17,799 6,098 2,846,140,175 ND ND ND 
CGPLLU269 CGPLLU269P2 100 5,353,961,600 80,930 1,698,331,125 32% 20,094 5,252 2,846,140,175 ND ND ND 
CGPLLU269 CGPLLU269P3 100 5,831,612,800 80,930 1,521,114,956 26% 18,067 6,210 2,846,140,175 ND ND ND 
CGPLLU270 CGPLLU270P 100 5,950,217,300 80,930 2,535,494,178 43% 30,291 5,666 2,846,140,175 ND ND ND 
CGPLLU270 CGPLLU270P2 100 5,549,812,500 80,930 1,611,923,056 29% 19,275 4,080 2,846,140,175 ND ND ND 
CGPLLU270 CGPLLU270P3 100 6,180,818,300 80,930 2,898,765,742 47% 34,697 5,488 2,846,140,175 ND ND ND 
CGPLLU271 CGPLLU271P 100 6,134,366,400 80,930 1,351,029,627 22% 16,170 7,024 2,846,140,175 ND ND ND 
CGPLLU271 CGPLLU271P1 100 6,491,884,900 80,930 1,622,578,435 25% 19,433 5,792 2,846,140,175 ND ND ND 
CGPLLU271 CGPLLU271P2 100 5,742,881,200 80,930 2,349,421,128 41% 28,171 5,723 2,846,140,175 ND ND ND 
CGPLLU271 CGPLLU271P3 100 5,503,999,300 80,930 1,695,782,705 31% 20,320 5,907 2,846,140,175 ND ND ND 
CGPLLU271 CGPLLU271P4 100 6,229,704,000 80,930 1,481,468,974 24% 17,608 4,633 2,846,140,175 ND ND ND 
CGPLLU43 CGPLLU43P3 100 6,575,907,000 80,930 3,002,048,491 46% 35,997 5,445 2,846,140,175 ND ND ND 
CGPLLU43 CGPLLU43P4 100 6,204,350,900 80,930 3,016,077,187 49% 36,162 5,704 2,846,140,175 ND ND ND 
CGPLLU43 CGPLLU43P5 100 5,997,724,300 80,930 2,989,608,757 50% 35,873 6,228 2,846,140,175 ND ND ND 
CGPLLU43 CGPLLU43P6 100 6,026,261,500 80,930 2,881,177,658 48% 34,568 7,221 2,846,140,175 ND ND ND 
* Bases mapped to off-target region include those not overlapping the targeted region or adjacent regions within 200 bases.
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Table 2.5.  Summary of somatic sequence alterations detected in cfDNA. 





















CGLU294 CGLU294P_1 0.0 ERBB2 CCDS32642.1 E770_A771insAYVM Insertion In-frame insertion 2.39% 4,098 98 No 
CGLU294 CGLU294P_1 0.0 TP53 CCDS11118.1 S166* Substitution Nonsense 0.88% 3,864 34 No 
CGLU294 CGLU294P1_1 0.2 ERBB2 CCDS32642.1 G776Yfs*17 Insertion Frameshift 0.36% 2480 9 No 
CGLU294 CGLU294P1_1 0.2 ERBB2 CCDS32642.1 E770_A771insAYVM Insertion In-frame insertion 7.01% 2410 169 No 
CGLU294 CGLU294P1_1 0.2 TP53 CCDS11118.1 S166* Substitution Nonsense 2.41% 1909 46 No 
CGLU294 CGLU294P2_1 3.0 ERBB2 CCDS32642.1 E770_A771insAYVM Insertion In-frame insertion 4.39% 1891 83 No 
CGLU294 CGLU294P2_1 3.0 TP53 CCDS11118.1 S166* Substitution Nonsense 1.69% 1543 26 No 
CGLU294 CGLU294P3_2 7.0 ERBB2 CCDS32642.1 E770_A771insAYVM Insertion In-frame insertion 4.80% 2227 107 No 
CGLU294 CGLU294P3_2 7.0 TP53 CCDS11118.1 S166* Substitution Nonsense 2.13% 1782 38 No 
CGLU294 CGLU294P4_1 29.0 ERBB2 CCDS32642.1 E770_A771insAYVM Insertion In-frame insertion 1.63% 490 8 No 
CGLU315 CGLU315P_1 0.0 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 2.91% 413 12 Yes 
CGLU315 CGLU315P1_1 0.2 CTNNB1 CCDS2694.1 S45P Substitution Nonsynonymous 1.34% 1,417 19 Yes 
CGLU315 CGLU315P1_1 0.2 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 1.95% 1,592 31 Yes 
CGLU315 CGLU315P1_1 0.2 TP53 CCDS11118.1 R273H Substitution Nonsynonymous 1.70% 1,232 21 Yes 
CGLU316 CGLU316P6_1 -53.0 EGFR CCDS5514.1 G719A Substitution Nonsynonymous 13.06% 2497 326 Yes 
CGLU316 CGLU316P6_1 -53.0 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 15.72% 2849 448 Yes 
CGLU316 CGLU316P6_1 -53.0 TP53 CCDS11118.1 C242F Substitution Nonsynonymous 6.57% 1462 96 Yes 
CGLU316 CGLU316P6_1 -53.0 TP53 CCDS11118.1 I195T Substitution Nonsynonymous 1.65% 2118 35 Yes 
CGLU316 CGLU316P7_1 -4.0 EGFR CCDS5514.1 G719A Substitution Nonsynonymous 40.03% 3837 1536 Yes 
CGLU316 CGLU316P7_1 -4.0 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 45.67% 4342 1983 Yes 
CGLU316 CGLU316P7_1 -4.0 TP53 CCDS11118.1 C242F Substitution Nonsynonymous 19.06% 1836 350 Yes 
CGLU316 CGLU316P7_1 -4.0 TP53 CCDS11118.1 I195T Substitution Nonsynonymous 1.04% 2206 23 Yes 
CGLU316 CGLU316P8_1 18.0 EGFR CCDS5514.1 G719A Substitution Nonsynonymous 33.38% 3247 1084 Yes 
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CGLU316 CGLU316P8_1 18.0 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 32.63% 3543 1156 Yes 
CGLU316 CGLU316P8_1 18.0 TP53 CCDS11118.1 C242F Substitution Nonsynonymous 8.91% 1661 148 Yes 
CGLU316 CGLU316P8_1 18.0 TP53 CCDS11118.1 I195T Substitution Nonsynonymous 1.33% 2035 27 Yes 
CGLU316 CGLU316P9_1 87.0 EGFR CCDS5514.1 G719A Substitution Nonsynonymous 64.89% 5754 3734 Yes 
CGLU316 CGLU316P9_1 87.0 EGFR CCDS5514.1 L861Q Substitution Nonsynonymous 66.01% 7629 5036 Yes 
CGLU316 CGLU316P9_1 87.0 TP53 CCDS11118.1 C242F Substitution Nonsynonymous 50.91% 1707 869 Yes 
CGLU316 CGLU316P9_1 87.0 TP53 CCDS11118.1 Y205C Substitution Nonsynonymous 0.12% 2437 3 Yes 
CGLU316 CGLU316P9_1 87.0 TP53 CCDS11118.1 I195T Substitution Nonsynonymous 0.90% 2105 19 Yes 
CGLU319 CGLU319P_1 0.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.10%  3 Yes 
CGLU324 CGLU324P_1 1.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.38% 1325 5 Yes 
CGLU324 CGLU324P_1 1.0 STK11 CCDS45896.1 L353H Substitution Nonsynonymous 0.53% 1137 6 No 
CGLU344 CGLU344P2_1 0.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.22% 2240 5 Yes 
CGLU344 CGLU344P2_1 0.0 TP53 CCDS11118.1 P278S Substitution Nonsynonymous 0.19% 2156 4 Yes 
CGLU344 CGLU344P3_1 0.2 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.40% 2999 12 Yes 
CGLU344 CGLU344P3_1 0.2 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 0.15% 3412 5 Yes 
CGLU369 CGLU369P_1 -2.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 20.61% 1946 401 Yes 
CGLU369 CGLU369P1_1 12.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.22% 2307 5 Yes 
CGLU369 CGLU369P2_1 68.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.16% 3071 5 Yes 
CGLU369 CGLU369P3_1 110.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.10% 4190 4 Yes 
CGLU373 CGLU373P_1 -2.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.82% 4155 34 Yes 
CGLU373 CGLU373P2_1 7.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.15% 3255 5 Yes 
CGLU373 CGLU373P2_1 7.0 TP53 CCDS11118.1 H214R Substitution Nonsynonymous 0.12% 3313 4 Yes 
CGPLLU12 CGPLLU12P_6 -150.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 10.20% 2705 276 Yes 
CGPLLU12 CGPLLU12P_6 -150.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 5.03% 3182 160 Yes 
CGPLLU12 CGPLLU12P_6 -150.0 TP53 CCDS11118.1 258E>K Substitution Nonsynonymous 3.79% 1928 73 No 
CGPLLU12 CGPLLU12P_22 0.0 RB1 CCDS31973.1 I680Yfs*13 Insertion Frameshift 0.24% 4183 10 No 
CGPLLU12 CGPLLU12P_22 0.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 20.19% 5141 1038 Yes 
CGPLLU12 CGPLLU12P_22 0.0 STK11 CCDS45896.1 137Q>X Substitution Nonsense 0.98% 1326 13 No 
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CGPLLU12 CGPLLU12P_22 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 8.09% 7649 619 Yes 
CGPLLU12 CGPLLU12P_22 0.0 TP53 CCDS11118.1 258E>K Substitution Nonsynonymous 10.37% 3356 348 No 
CGPLLU12 CGPLLU12P_18 0.2 RB1 CCDS31973.1 I680Yfs*13 Insertion Frameshift 0.74% 4480 33 No 
CGPLLU12 CGPLLU12P_18 0.2 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 21.55% 5712 1231 Yes 
CGPLLU12 CGPLLU12P_18 0.2 EGFR CCDS5514.1 745->KTSP Insertion In-frame insertion 0.16% 5498 9 No 
CGPLLU12 CGPLLU12P_18 0.2 STK11 CCDS45896.1 137Q>X Substitution Nonsense 1.49% 1410 21 No 
CGPLLU12 CGPLLU12P_18 0.2 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 9.37% 8897 834 Yes 
CGPLLU12 CGPLLU12P_18 0.2 ERBB4 CCDS2394.1 733Y>N Substitution Nonsynonymous 0.38% 3438 13 No 
CGPLLU12 CGPLLU12P_18 0.2 TP53 CCDS11118.1 258E>K Substitution Nonsynonymous 10.93% 3768 412 No 
CGPLLU12 CGPLLU12P_20 10.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 0.17% 4095 7 Yes 
CGPLLU12 CGPLLU12P_20 10.0 TP53 CCDS11118.1 258E>K Substitution Nonsynonymous 0.16% 3688 6 No 
CGPLLU12 CGPLLU12P_34 227.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 7.09% 4189 297 Yes 
CGPLLU12 CGPLLU12P_34 227.0 TP53 CCDS11118.1 258E>K Substitution Nonsynonymous 3.47% 3802 132 No 
CGPLLU13 CGPLLU13P27 -2.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 7.66% 2978 228 Yes 
CGPLLU13 CGPLLU13P27 -2.0 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 0.13% 3763 5 Yes 
CGPLLU13 CGPLLU13P28 5.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 13.10% 3504 459 Yes 
CGPLLU13 CGPLLU13P28 5.0 EGFR CCDS5514.1 E931Q Substitution Nonsynonymous 0.13% 6128 8 No 
CGPLLU13 CGPLLU13P29 28.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 6.09% 1889 115 Yes 
CGPLLU13 CGPLLU13P30 91.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 9.28% 2512 233 Yes 
CGPLLU13 CGPLLU13P30 91.0 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 0.16% 3032 5 Yes 
CGPLLU14 CGPLLU14P_8 -38.0 EGFR CCDS5514.1 719G>S Substitution Nonsynonymous 0.75% 2141 16 Yes 
CGPLLU14 CGPLLU14P_8 -38.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.45% 2456 11 Yes 
CGPLLU14 CGPLLU14P_8 -38.0 EGFR CCDS5514.1 861L>Q Substitution Nonsynonymous 0.89% 2357 21 Yes 
CGPLLU14 CGPLLU14P_12 -16.0 EGFR CCDS5514.1 719G>S Substitution Nonsynonymous 0.15% 2722 4 Yes 
CGPLLU14 CGPLLU14P_12 -16.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.16% 3196 5 Yes 
CGPLLU14 CGPLLU14P_12 -16.0 EGFR CCDS5514.1 861L>Q Substitution Nonsynonymous 0.18% 2823 5 Yes 
CGPLLU14 CGPLLU14P_15 -3.0 EGFR CCDS5514.1 719G>S Substitution Nonsynonymous 0.49% 3888 19 Yes 
CGPLLU14 CGPLLU14P_15 -3.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.48% 5004 24 Yes 
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CGPLLU14 CGPLLU14P_15 -3.0 EGFR CCDS5514.1 861L>Q Substitution Nonsynonymous 0.45% 4233 19 Yes 
CGPLLU14 CGPLLU14P_21 0.0 EGFR CCDS5514.1 719G>S Substitution Nonsynonymous 0.79% 2801 22 Yes 
CGPLLU14 CGPLLU14P_21 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.98% 3281 32 Yes 
CGPLLU14 CGPLLU14P_21 0.0 EGFR CCDS5514.1 861L>Q Substitution Nonsynonymous 1.39% 2876 40 Yes 
CGPLLU14 CGPLLU14P_19 0.3 EGFR CCDS5514.1 719G>S Substitution Nonsynonymous 1.05% 3697 39 Yes 
CGPLLU14 CGPLLU14P_19 0.3 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.90% 4760 43 Yes 
CGPLLU14 CGPLLU14P_19 0.3 EGFR CCDS5514.1 861L>Q Substitution Nonsynonymous 0.96% 4383 42 Yes 
CGPLLU14 CGPLLU14P_19 0.3 MYC CCDS6359.2 98R>W Substitution Nonsynonymous 0.28% 3894 11 No 
CGPLLU18 CGPLLU18P_4 -1.0 ABL1 CCDS35166.1 422V>I Substitution Nonsynonymous 0.17% 4028 7 No 
CGPLLU18 CGPLLU18P_4 -1.0 BRAF CCDS5863.1 145A>S Substitution Nonsynonymous 0.20% 3949 8 No 
CGPLLU18 CGPLLU18P_4 -1.0 CDKN2A CCDS56565.1 12S>L Substitution Nonsynonymous 0.52% 2478 13 No 
CGPLLU18 CGPLLU18P_4 -1.0 CTNNB1 CCDS2694.1 60S>T Substitution Nonsynonymous 0.37% 3251 12 No 
CGPLLU18 CGPLLU18P_4 -1.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 10.09% 17897 1806 Yes 
CGPLLU18 CGPLLU18P_4 -1.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 53.71% 14755 7925 Yes 
CGPLLU18 CGPLLU18P_4 -1.0 ERBB2 CCDS32642.1 827M>V Substitution Nonsynonymous 0.27% 5137 14 No 
CGPLLU18 CGPLLU18P_4 -1.0 ERBB4 CCDS2394.1 566L>I Substitution Nonsynonymous 0.26% 3892 10 No 
CGPLLU18 CGPLLU18P_4 -1.0 ESR1 CCDS5234.1 44L>M Substitution Nonsynonymous 0.75% 4528 34 No 
CGPLLU18 CGPLLU18P_4 -1.0 ESR1 CCDS5234.1 61E>D Substitution Nonsynonymous 0.36% 3624 13 No 
CGPLLU18 CGPLLU18P_4 -1.0 MYC CCDS6359.2 174S>G Substitution Nonsynonymous 0.14% 4935 7 No 
CGPLLU18 CGPLLU18P_4 -1.0 MYC CCDS6359.2 48Q>H Substitution Nonsynonymous 0.36% 3939 14 No 
CGPLLU18 CGPLLU18P_4 -1.0 MYC CCDS6359.2 98R>W Substitution Nonsynonymous 0.15% 4728 7 No 
CGPLLU18 CGPLLU18P_4 -1.0 PDGFRA CCDS3495.1 37K>R Substitution Nonsynonymous 0.20% 4030 8 No 
CGPLLU18 CGPLLU18P_15 6.0 AR CCDS14387.1 31R>L Substitution Nonsynonymous 0.18% 3995 7 No 
CGPLLU18 CGPLLU18P_15 6.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.26% 6660 17 Yes 
CGPLLU18 CGPLLU18P_15 6.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 1.30% 5625 73 Yes 
CGPLLU18 CGPLLU18P_11 20.0 AR CCDS14387.1 31R>L Substitution Nonsynonymous 0.17% 3554 6 No 
CGPLLU18 CGPLLU18P_11 20.0 CDKN2A CCDS56565.1 12S>L Substitution Nonsynonymous 0.15% 2592 4 No 
CGPLLU18 CGPLLU18P_11 20.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.63% 4423 28 Yes 
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CGPLLU18 CGPLLU18P_11 20.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 1.68% 4101 69 Yes 
CGPLLU244 CGPLLU244P_1 -7.0 EGFR CCDS5514.1 62L>R Substitution Nonsynonymous 4.48% 5898 264 No 
CGPLLU244 CGPLLU244P_1 -7.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 4.13% 6681 276 Yes 
CGPLLU244 CGPLLU244P_1 -7.0 TP53 CCDS11118.1 134F>L Substitution Nonsynonymous 4.98% 7524 375 No 
CGPLLU244 CGPLLU244P_2 -1.0 EGFR CCDS5514.1 62L>R Substitution Nonsynonymous 3.41% 5746 196 No 
CGPLLU244 CGPLLU244P_2 -1.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 2.84% 7348 209 Yes 
CGPLLU244 CGPLLU244P_2 -1.0 TP53 CCDS11118.1 134F>L Substitution Nonsynonymous 2.83% 8797 249 No 
CGPLLU244 CGPLLU244P_3 6.0 EGFR CCDS5514.1 62L>R Substitution Nonsynonymous 5.14% 6240 321 No 
CGPLLU244 CGPLLU244P_3 6.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 5.57% 7526 419 Yes 
CGPLLU244 CGPLLU244P_3 6.0 TP53 CCDS11118.1 134F>L Substitution Nonsynonymous 4.76% 8721 415 No 
CGPLLU244 CGPLLU244P_4 62.0 EGFR CCDS5514.1 62L>R Substitution Nonsynonymous 10.98% 6602 725 No 
CGPLLU244 CGPLLU244P_4 62.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 11.80% 7043 831 Yes 
CGPLLU244 CGPLLU244P_4 62.0 TP53 CCDS11118.1 134F>L Substitution Nonsynonymous 11.23% 8098 909 No 
CGPLLU245 CGPLLU245P_1 -32.0 EGFR CCDS5514.1 745KELREA>K Deletion In-frame deletion 10.60% 5869 622 Yes 
CGPLLU245 CGPLLU245P_1 -32.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 5.56% 9722 541 Yes 
CGPLLU245 CGPLLU245P_1 -32.0 PDGFRA CCDS3495.1 293R>H Substitution Nonsynonymous 0.44% 6374 28 No 
CGPLLU245 CGPLLU245P_2 0.0 EGFR CCDS5514.1 745KELREA>K Deletion In-frame deletion 14.10% 8086 1140 Yes 
CGPLLU245 CGPLLU245P_2 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 6.76% 14582 986 Yes 
CGPLLU245 CGPLLU245P_2 0.0 PDGFRA CCDS3495.1 293R>H Substitution Nonsynonymous 0.92% 8550 79 No 
CGPLLU245 CGPLLU245P_3 7.0 EGFR CCDS5514.1 745KELREA>K Deletion In-frame deletion 8.56% 6892 590 Yes 
CGPLLU245 CGPLLU245P_3 7.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 4.07% 11765 479 Yes 
CGPLLU245 CGPLLU245P_3 7.0 PDGFRA CCDS3495.1 293R>H Substitution Nonsynonymous 0.60% 7673 46 No 
CGPLLU245 CGPLLU245P_4 21.0 EGFR CCDS5514.1 745KELREA>K Deletion In-frame deletion 10.69% 7287 779 Yes 
CGPLLU245 CGPLLU245P_4 21.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 4.59% 13165 604 Yes 
CGPLLU245 CGPLLU245P_4 21.0 PDGFRA CCDS3495.1 293R>H Substitution Nonsynonymous 1.00% 8020 80 No 
CGPLLU246 CGPLLU246P_1 -21.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.49% 7780 38 Yes 
CGPLLU246 CGPLLU246P_1 -21.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 0.48% 5826 28 Yes 
CGPLLU246 CGPLLU246P_1 -21.0 MAP2K1 CCDS10216.1 67D>N Substitution Nonsynonymous 0.18% 7080 13 No 
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CGPLLU246 CGPLLU246P_2 0.0 TP53 CCDS11118.1 P34Sfs*4 Deletion Frameshift 2.48% 2181 54 No 
CGPLLU246 CGPLLU246P_2 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 6.06% 8612 522 Yes 
CGPLLU246 CGPLLU246P_2 0.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 6.17% 5933 366 Yes 
CGPLLU246 CGPLLU246P_4 9.0 TP53 CCDS11118.1 P34Sfs*4 Deletion Frameshift 0.20% 2461 5 No 
CGPLLU246 CGPLLU246P_4 9.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 1.31% 6170 81 Yes 
CGPLLU246 CGPLLU246P_4 9.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 1.72% 5051 87 Yes 
CGPLLU246 CGPLLU246P_5 42.0 TP53 CCDS11118.1 P34Sfs*4 Deletion Frameshift 1.87% 2669 50 No 
CGPLLU246 CGPLLU246P_5 42.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 4.30% 7229 311 Yes 
CGPLLU246 CGPLLU246P_5 42.0 EGFR CCDS5514.1 858L>R Substitution Nonsynonymous 5.29% 5932 314 Yes 
CGPLLU246 CGPLLU246P_5 42.0 MAP2K1 CCDS10216.1 67D>N Substitution Nonsynonymous 0.11% 6149 7 No 
CGPLLU264 CGPLLU264P -1.0 STK11 CCDS45896.1 V236M Substitution Nonsynonymous 0.30% 4293 13 No 
CGPLLU264 CGPLLU264P1 6.0 EGFR CCDS5514.1 D761N Substitution Nonsynonymous 0.16% 4358 7 No 
CGPLLU264 CGPLLU264P2 27.0 FGFR3 CCDS3353.1 Y379S Substitution Nonsynonymous 0.18% 4455 8 No 
CGPLLU265 CGPLLU265P 0.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.21% 4374 9 Yes 
CGPLLU265 CGPLLU265P1 3.0 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 0.10% 5836 6 Yes 
CGPLLU265 CGPLLU265P1 3.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.21% 4769 10 Yes 
CGPLLU265 CGPLLU265P2 7.0 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 0.21% 5129 11 Yes 
CGPLLU265 CGPLLU265P2 7.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.14% 4279 6 Yes 
CGPLLU266 CGPLLU266P3 83.0 TP53 CCDS11118.1 R282G Substitution Nonsynonymous 0.15% 4691 7 Yes 
CGPLLU267 CGPLLU267P -1.0 PTEN CCDS31238.1 Y225Ifs*18 Insertion Frameshift 1.69% 2603 44 No 
CGPLLU267 CGPLLU267P -1.0 ALK CCDS33172.1 G35_P36insL Insertion In-frame insertion 0.28% 2168 6 No 
CGPLLU267 CGPLLU267P -1.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 1.93% 2957 57 Yes 
CGPLLU267 CGPLLU267P -1.0 ERBB2 CCDS32642.1 R340L Substitution Nonsynonymous 0.20% 2953 6 No 
CGPLLU267 CGPLLU267P -1.0 RB1 CCDS31973.1 L700F Substitution Nonsynonymous 0.28% 2106 6 No 
CGPLLU267 CGPLLU267P -1.0 TP53 CCDS11118.1 M246L Substitution Nonsynonymous 0.66% 2276 15 No 
CGPLLU267 CGPLLU267P2 34.0 MPL CCDS483.1 V495Dfs*49 Deletion Frameshift 0.33% 2105 7 No 
CGPLLU267 CGPLLU267P2 34.0 TP53 CCDS11118.1 S183Rfs*2 Deletion Frameshift 0.19% 3676 7 No 
CGPLLU267 CGPLLU267P2 34.0 ALK CCDS33172.1 E1158K Substitution Nonsynonymous 0.23% 3045 7 No 
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CGPLLU267 CGPLLU267P2 34.0 AR CCDS14387.1 S397R Substitution Nonsynonymous 0.21% 2821 6 No 
CGPLLU267 CGPLLU267P2 34.0 CDH1 CCDS10869.1 E35K Substitution Nonsynonymous 0.23% 3866 9 No 
CGPLLU267 CGPLLU267P2 34.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.14% 3532 5 Yes 
CGPLLU267 CGPLLU267P2 34.0 FBXW7 CCDS3777.1 C466F Substitution Nonsynonymous 0.55% 2379 13 No 
CGPLLU267 CGPLLU267P2 34.0 KIT CCDS3496.1 K167N Substitution Nonsynonymous 0.22% 3211 7 No 
CGPLLU267 CGPLLU267P2 34.0 VHL CCDS2597.1 R79C Substitution Nonsynonymous 0.39% 1808 7 No 
CGPLLU267 CGPLLU267P3 90.0 PTEN CCDS31238.1 Y225Ifs*18 Insertion Frameshift 0.34% 2040 7 No 
CGPLLU267 CGPLLU267P3 90.0 ALK CCDS33172.1 E343V Substitution Nonsynonymous 0.51% 1370 7 No 
CGPLLU267 CGPLLU267P3 90.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.38% 2394 9 Yes 
CGPLLU269 CGPLLU269P1 0.0 EGFR CCDS5514.1 L858R Substitution Nonsynonymous 0.10% 2894 3 Yes 
CGPLLU271 CGPLLU271P 0.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 3.36% 2533 85 Yes 
CGPLLU271 CGPLLU271P 0.0 EGFR CCDS5514.1 T790M Substitution Nonsynonymous 1.80% 3440 62 Yes 
CGPLLU271 CGPLLU271P 0.0 PTEN CCDS31238.1 H196Y Substitution Nonsynonymous 0.68% 1476 10 No 
CGPLLU271 CGPLLU271P 0.0 TP53 CCDS11118.1 R267W Substitution Nonsynonymous 0.23% 1749 4 Yes 
CGPLLU271 CGPLLU271P 0.0 TP53 CCDS11118.1 R248W Substitution Nonsynonymous 2.28% 2197 50 Yes 
CGPLLU271 CGPLLU271P1 6.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.17% 2859 5 Yes 
CGPLLU271 CGPLLU271P2 20.0 TP53 CCDS11118.1 R267W Substitution Nonsynonymous 0.18% 2712 5 Yes 
CGPLLU271 CGPLLU271P3 104.0 TP53 CCDS11118.1 R267W Substitution Nonsynonymous 0.33% 2458 8 Yes 
CGPLLU271 CGPLLU271P4 259.0 EGFR CCDS5514.1 E746_A750del Deletion In-frame deletion 0.44% 2251 10 Yes 
CGPLLU271 CGPLLU271P4 259.0 TP53 CCDS11118.1 R248W Substitution Nonsynonymous 0.24% 2082 5 Yes 
CGPLLU86 CGPLLU86P_1 0.5 EGFR CCDS5514.1 746ELREATS>D Deletion In-frame deletion 0.19% 2626 5 Yes 
CGPLLU88 CGPLLU88P_2 0.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 9.06% 6447 584 Yes 
CGPLLU88 CGPLLU88P_2 0.0 CTNNB1 CCDS2694.1 32D>V Substitution Nonsynonymous 12.17% 5474 666 Yes 
CGPLLU88 CGPLLU88P_2 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 8.65% 10829 937 Yes 
CGPLLU88 CGPLLU88P_2 0.0 MYC CCDS6359.2 47Y>F Substitution Nonsynonymous 0.11% 6119 7 No 
CGPLLU88 CGPLLU88P_2 0.0 PIK3CA CCDS43171.1 624T>R Substitution Nonsynonymous 2.57% 3188 82 No 
CGPLLU88 CGPLLU88P 7.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 0.11% 3568 4 Yes 
CGPLLU88 CGPLLU88P 7.0 CTNNB1 CCDS2694.1 32D>V Substitution Nonsynonymous 0.22% 3623 8 Yes 
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CGPLLU88 CGPLLU88P 7.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.15% 4095 6 Yes 
CGPLLU88 CGPLLU88P 7.0 FGFR2 CCDS31298.1 304D>N Substitution Nonsynonymous 0.24% 3746 9 No 
CGPLLU88 CGPLLU88P_5 297.0 EGFR CCDS5514.1 745KELREA>T Deletion In-frame deletion 0.93% 2155 20 Yes 
CGPLLU88 CGPLLU88P_5 297.0 CTNNB1 CCDS2694.1 32D>V Substitution Nonsynonymous 2.42% 2229 54 Yes 
CGPLLU88 CGPLLU88P_5 297.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.13% 2394 3 Yes 
CGPLLU89 CGPLLU89P 0.0 TP53 CCDS11118.1 656_672+6 Deletion Frameshift 0.36% 5598 20 No 
CGPLLU89 CGPLLU89P 0.0 EGFR CCDS5514.1 747LREATS>- Deletion In-frame deletion 0.42% 5434 23 Yes 
CGPLLU89 CGPLLU89P 0.0 CTNNB1 CCDS2694.1 32D>G Substitution Nonsynonymous 0.27% 5556 15 Yes 
CGPLLU89 CGPLLU89P 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.17% 6320 11 Yes 
CGPLLU89 CGPLLU89P_2 7.0 EGFR CCDS5514.1 747LREATS>- Deletion In-frame deletion 0.20% 3540 7 Yes 
CGPLLU89 CGPLLU89P_2 7.0 CTNNB1 CCDS2694.1 32D>G Substitution Nonsynonymous 0.28% 3595 10 Yes 
CGPLLU89 CGPLLU89P_2 7.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 0.19% 3715 7 Yes 
CGPLLU89 CGPLLU89P_5 22.0 TP53 CCDS11118.1 656_672+6 Deletion Frameshift 0.26% 1929 5 No 
CGPLLU89 CGPLLU89P_5 22.0 CTNNB1 CCDS2694.1 32D>G Substitution Nonsynonymous 0.21% 1870 4 Yes 
CGPLLU99 CGPLLU99P_8 0.0 EGFR CCDS5514.1 E746Afs*5 Insertion Frameshift 0.62% 6095 38 No 
CGPLLU99 CGPLLU99P_8 0.0 EGFR CCDS5514.1 746ELREA>- Deletion In-frame deletion 19.65% 6533 1284 No 
CGPLLU99 CGPLLU99P_8 0.0 TP53 CCDS11118.1 306R>X Substitution Nonsense 19.69% 5003 985 Yes 
CGPLLU99 CGPLLU99P_8 0.0 EGFR CCDS5514.1 790T>M Substitution Nonsynonymous 7.24% 9626 697 Yes 
CGPLLU99 CGPLLU99P_10 0.3 EGFR CCDS5514.1 E746Afs*5 Insertion Frameshift 0.51% 6246 32 No 
CGPLLU99 CGPLLU99P_10 0.3 EGFR CCDS5514.1 746ELREA>- Deletion In-frame deletion 15.67% 6626 1038 No 
CGPLLU99 CGPLLU99P_10 0.3 TP53 CCDS11118.1 306R>X Substitution Nonsense 13.76% 5573 767 Yes 




Table 2.6.  Summary of blood cell proliferation alterations detected in cfDNA. 
Patient ID Patient Timepoint Gene Symbol Transcript Accession 
Amino Acid 












CGLU294 CGLU294P_1 DNMT3A CCDS33157.1 G532S Substitution Nonsynonymous 0.63% 3026 19 No 
CGLU344 CGLU344P3_1 DNMT3A CCDS33157.1 N/A Substitution Splice site donor 0.22% 2709 6 No 
CGLU344 CGLU344P5_1 DNMT3A CCDS33157.1 R882H Substitution Nonsynonymous 0.22% 2779 6 Yes 
CGLU369 CGLU369P_1 TP53 CCDS11118.1 R306* Substitution Nonsense 4.16% 1755 73 Yes 
CGLU369 CGLU369P_1 JAK2 CCDS6457.1 V617F Substitution Nonsynonymous 4.05% 1407 57 Yes 
CGLU369 CGLU369P1_1 TP53 CCDS11118.1 R306* Substitution Nonsense 0.13% 3107 4 Yes 
CGLU369 CGLU369P1_1 JAK2 CCDS6457.1 V617F Substitution Nonsynonymous 5.26% 1824 96 Yes 
CGLU369 CGLU369P2_1 TP53 CCDS11118.1 R306* Substitution Nonsense 0.13% 3825 5 Yes 
CGLU369 CGLU369P2_1 JAK2 CCDS6457.1 V617F Substitution Nonsynonymous 3.93% 2316 91 Yes 
CGLU369 CGLU369P3_1 JAK2 CCDS6457.1 V617F Substitution Nonsynonymous 2.37% 3251 77 Yes 
CGPLLU12 CGPLLU12P_18 DNMT3A CCDS33157.1 538T>A Substitution Nonsynonymous 0.17% 5740 10 No 
CGPLLU12 CGPLLU12P_20 DNMT3A CCDS33157.1 538T>A Substitution Nonsynonymous 0.25% 4323 11 No 
CGPLLU12 CGPLLU12P_22 DNMT3A CCDS33157.1 538T>A Substitution Nonsynonymous 0.28% 5282 15 No 
CGPLLU12 CGPLLU12P_34 DNMT3A CCDS33157.1 538T>A Substitution Nonsynonymous 0.25% 4828 12 No 
CGPLLU12 CGPLLU12P_34 DNMT3A CCDS33157.1 2173+1G>A Substitution Splice site donor 0.23% 4329 10 No 
CGPLLU12 CGPLLU12P_6 DNMT3A CCDS33157.1 538T>A Substitution Nonsynonymous 0.23% 2573 6 No 
CGPLLU13 CGPLLU13P27 TP53 CCDS11118.1 R273H Substitution Nonsynonymous 0.27% 2640 7 Yes 
CGPLLU13 CGPLLU13P30 TP53 CCDS11118.1 R273H Substitution Nonsynonymous 0.23% 2175 5 Yes 
CGPLLU14 CGPLLU14P_12 DNMT3A CCDS33157.1 905L>R Substitution Nonsynonymous 0.28% 2896 8 No 
CGPLLU14 CGPLLU14P_12 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 0.26% 3106 8 Yes 
CGPLLU14 CGPLLU14P_12 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 0.85% 2576 22 No 
CGPLLU14 CGPLLU14P_15 DNMT3A CCDS33157.1 905L>R Substitution Nonsynonymous 0.22% 4454 10 No 
CGPLLU14 CGPLLU14P_15 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 0.46% 5178 24 Yes 
CGPLLU14 CGPLLU14P_15 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 0.60% 3834 23 No 
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CGPLLU14 CGPLLU14P_19 DNMT3A CCDS33157.1 905L>R Substitution Nonsynonymous 0.20% 4085 8 No 
CGPLLU14 CGPLLU14P_19 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 0.86% 4877 42 Yes 
CGPLLU14 CGPLLU14P_19 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 0.65% 3679 24 No 
CGPLLU14 CGPLLU14P_21 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 0.77% 3254 25 Yes 
CGPLLU14 CGPLLU14P_21 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 1.26% 2545 32 No 
CGPLLU14 CGPLLU14P_23 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 0.77% 3254 25 Yes 
CGPLLU14 CGPLLU14P_23 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 1.26% 2545 32 No 
CGPLLU14 CGPLLU14P_23 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 0.68% 2349 16 No 
CGPLLU14 CGPLLU14P_8 TP53 CCDS11118.1 157V>F Substitution Nonsynonymous 1.06% 2080 22 Yes 
CGPLLU14 CGPLLU14P_8 TP53 CCDS11118.1 248R>G Substitution Nonsynonymous 1.64% 1890 31 No 
CGPLLU18 CGPLLU18P_11 TP53 CCDS11118.1 Q104Rfs*19 Deletion Frameshift 0.43% 3022 13 No 
CGPLLU18 CGPLLU18P_11 DNMT3A CCDS33157.1 2322+3A>G Substitution Splice site donor 1.70% 3295 56 No 
CGPLLU18 CGPLLU18P_15 TP53 CCDS11118.1 Q104Rfs*19 Deletion Frameshift 0.24% 3270 8 No 
CGPLLU18 CGPLLU18P_15 DNMT3A CCDS33157.1 2322+3A>G Substitution Splice site donor 0.97% 3913 38 No 
CGPLLU18 CGPLLU18P_4 TP53 CCDS11118.1 Q104Rfs*19 Deletion Frameshift 47.18% 2961 1397 No 
CGPLLU18 CGPLLU18P_4 DNMT3A CCDS33157.1 2322+3A>G Substitution Splice site donor 0.49% 3650 18 No 
CGPLLU245 CGPLLU245P_2 TP53 CCDS11118.1 220Y>N Substitution Nonsynonymous 0.10% 7725 8 No 
CGPLLU246 CGPLLU246P_1 DNMT3A CCDS33157.1 536Y>X Substitution Nonsense 1.25% 6946 87 No 
CGPLLU246 CGPLLU246P_1 DNMT3A CCDS33157.1 882R>C Substitution Nonsynonymous 0.24% 6640 16 Yes 
CGPLLU246 CGPLLU246P_1 DNMT3A CCDS33157.1 735Y>S Substitution Nonsynonymous 0.34% 4939 17 No 
CGPLLU246 CGPLLU246P_2 DNMT3A CCDS33157.1 536Y>X Substitution Nonsense 1.37% 6783 93 No 
CGPLLU246 CGPLLU246P_2 DNMT3A CCDS33157.1 735Y>S Substitution Nonsynonymous 0.20% 3964 8 No 
CGPLLU246 CGPLLU246P_2 DNMT3A CCDS33157.1 882R>C Substitution Nonsynonymous 0.23% 5984 14 Yes 
CGPLLU246 CGPLLU246P_4 DNMT3A CCDS33157.1 536Y>X Substitution Nonsense 1.46% 5749 84 No 
CGPLLU246 CGPLLU246P_4 DNMT3A CCDS33157.1 882R>C Substitution Nonsynonymous 0.17% 5422 9 Yes 
CGPLLU246 CGPLLU246P_4 DNMT3A CCDS33157.1 735Y>S Substitution Nonsynonymous 0.28% 4264 12 No 
CGPLLU246 CGPLLU246P_5 DNMT3A CCDS33157.1 536Y>X Substitution Nonsense 1.65% 6068 100 No 
CGPLLU246 CGPLLU246P_5 DNMT3A CCDS33157.1 735Y>S Substitution Nonsynonymous 0.24% 4666 11 No 
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CGPLLU246 CGPLLU246P_5 DNMT3A CCDS33157.1 882R>C Substitution Nonsynonymous 0.32% 6282 20 Yes 
CGPLLU266 CGPLLU266P DNMT3A CCDS33157.1 E774K Substitution Nonsynonymous 0.63% 2388 15 No 
CGPLLU266 CGPLLU266P2 DNMT3A CCDS33157.1 E774K Substitution Nonsynonymous 0.24% 2947 7 No 
CGPLLU266 CGPLLU266P3 DNMT3A CCDS33157.1 E774K Substitution Nonsynonymous 0.32% 4064 13 No 
CGPLLU266 CGPLLU266P4 DNMT3A CCDS33157.1 E774K Substitution Nonsynonymous 0.62% 2742 17 No 
CGPLLU267 CGPLLU267P2 DNMT3A CCDS33157.1 A903S Substitution Nonsynonymous 0.22% 3193 7 No 
CGPLLU269 CGPLLU269P1 TP53 CCDS11118.1 Y220C Substitution Nonsynonymous 0.15% 2662 4 Yes 
CGPLLU269 CGPLLU269P2 DNMT3A CCDS33157.1 D529Y Substitution Nonsynonymous 0.22% 2762 6 No 
CGPLLU86 CGPLLU86P_1 DNMT3A CCDS33157.1 720R>C Substitution Nonsynonymous 0.54% 2962 16 No 
CGPLLU86 CGPLLU86P_6 DNMT3A CCDS33157.1 720R>C Substitution Nonsynonymous 0.32% 5575 18 No 
CGPLLU86 CGPLLU86P_8 DNMT3A CCDS33157.1 720R>C Substitution Nonsynonymous 0.42% 2888 12 No 
CGPLLU86 CGPLLU86P_9 DNMT3A CCDS33157.1 720R>C Substitution Nonsynonymous 0.35% 2857 10 No 
CGPLLU88 CGPLLU88P DNMT3A CCDS33157.1 1667+1G>A Substitution Splice site donor 1.98% 2678 53 No 
CGPLLU88 CGPLLU88P_2 DNMT3A CCDS33157.1 879N>D Substitution Nonsynonymous 0.19% 6691 13 No 
CGPLLU88 CGPLLU88P_2 DNMT3A CCDS33157.1 1667+1G>A Substitution Splice site donor 1.31% 4440 58 No 




Table 2.7.  Summary of somatic structural alterations detected in cfDNA. 
Patient ID Z scores chr1p chr1q chr2p chr2q chr3p chr3q chr4p chr4q chr5p chr5q chr6p chr6q chr7p chr7q chr8p chr8q chr9p chr9q chr10p chr10q 
CGPLLU244 Day -7 -1.98 2.30 0.56 -0.71 -4.89 -0.08 -0.95 -3.78 1.27 -0.27 0.31 -1.12 7.07 4.62 -2.33 0.12 -0.43 -0.34 -3.05 -2.80 
CGPLLU244 Day -1 -1.76 1.42 -0.97 -1.07 -3.34 -1.03 0.15 -1.85 1.58 -1.75 -0.76 -1.29 5.95 4.85 -1.09 0.22 0.22 -0.62 -2.46 -2.94 
CGPLLU244 Day 6 -2.56 3.19 -0.01 0.57 -5.40 -1.19 -1.37 -4.28 2.61 -1.00 0.84 0.41 10.44 4.83 -3.37 1.93 1.07 -0.33 -2.44 -4.83 
CGPLLU244 Day 62 -1.92 7.13 2.18 -2.35 -9.22 1.89 -1.24 -7.79 2.09 -3.79 0.71 -5.05 17.92 8.98 -5.79 2.18 -1.48 -2.52 -4.98 -7.72 
CGPLLU245 Day -32 -5.09 7.23 -1.34 0.17 -5.05 -3.07 -2.39 -1.49 11.49 4.94 0.07 -7.48 25.65 19.49 -1.25 2.48 0.27 1.41 -0.70 -0.96 
CGPLLU245 Day 0 -6.36 10.12 -2.51 1.46 -6.07 -4.63 -2.68 -4.02 20.30 6.19 0.46 -10.17 41.91 29.09 -3.82 2.77 0.26 1.95 0.09 -2.36 
CGPLLU245 Day 7 -3.94 4.45 -1.11 0.49 -5.23 -2.91 -1.14 -1.86 10.93 4.06 -0.21 -6.26 22.45 15.83 -1.46 -1.20 0.68 3.02 1.32 -1.76 
CGPLLU245 Day 21 -4.69 6.53 -2.38 1.14 -5.22 -1.67 -2.17 -3.14 12.83 5.70 1.10 -6.19 29.01 21.51 -2.00 0.58 0.43 2.59 -0.01 -0.39 
CGPLLU246 Day -21 -0.99 -1.31 -0.87 -0.38 -0.39 -0.84 0.89 0.86 1.18 0.89 -1.03 -0.16 0.82 1.61 0.76 -0.64 -0.07 0.10 0.93 0.82 
CGPLLU246 Day 0 -1.18 -0.64 -4.76 -1.60 -5.93 -2.94 -0.76 -2.62 5.46 4.74 0.57 -2.21 16.05 15.95 -0.08 6.04 0.11 1.69 -3.54 -3.44 
CGPLLU246 Day 9 -0.75 0.00 -0.28 0.74 -2.00 -3.28 -0.34 -0.71 1.89 -0.07 -0.60 -0.86 3.56 4.73 0.79 0.14 0.38 1.41 -0.71 -1.31 
CGPLLU246 Day 42 -2.30 1.21 -2.10 0.71 -5.03 -3.29 -1.33 -1.68 2.59 3.62 0.45 1.08 9.75 10.37 0.34 6.18 1.83 1.89 -0.55 -4.57 
CGLU294 Day 0 -1.32 2.07 1.02 2.39 -0.35 -2.08 -1.09 -0.93 -0.47 0.50 0.86 -1.33 1.46 3.19 0.80 0.48 0.57 0.87 -1.35 -1.64 
CGLU294 Day 0.2 -1.49 0.08 0.28 1.45 0.02 -0.08 1.21 -0.86 0.90 -0.01 -1.83 -0.15 3.13 5.40 1.21 -0.54 -0.07 -0.36 0.33 -3.09 
CGLU294 Day 3 -1.26 -0.03 -0.80 0.75 0.78 -0.70 1.19 0.60 0.30 1.57 -1.63 -0.44 2.42 6.24 0.34 -0.46 -0.07 -0.71 -0.65 -2.25 
CGLU294 Day 7 -1.30 0.10 -0.04 2.19 -0.55 -2.00 -0.40 -0.78 0.12 1.51 -0.32 -1.94 1.85 4.59 0.86 -1.39 1.66 1.00 0.13 -3.11 
CGLU294 Day 29 -0.01 2.93 -1.14 0.36 -1.48 -3.11 -0.99 -2.48 -0.31 11.33 0.92 -0.91 0.12 2.35 -1.35 -1.72 3.72 1.77 -0.71 1.50 
CGLU315 Day 0 -0.21 3.25 -1.62 1.18 -1.27 -3.52 -2.11 -6.44 -0.34 10.53 1.42 -7.97 -1.43 1.49 -1.15 -3.16 6.54 4.51 2.15 2.64 
CGLU315 Day 0.2 -1.69 0.51 -0.91 0.63 0.78 -0.81 -0.24 -0.17 1.07 1.88 -0.99 -1.54 0.87 0.97 0.41 -1.85 1.55 1.20 -0.87 0.49 
CGLU315 Day 20 -0.17 1.54 -2.54 2.35 -2.54 -2.60 -1.86 -3.27 4.22 3.84 1.55 -5.86 -1.14 -1.21 0.78 -0.35 4.48 3.00 -0.33 2.96 
CGLU319 Day 0 -1.21 2.43 0.22 1.28 -0.61 -1.48 -1.53 -0.09 0.03 3.91 0.65 -1.27 -1.51 1.98 0.88 0.38 0.91 0.55 -1.44 -2.42 
CGLU319 Day 14 -0.74 0.51 0.75 -0.37 -0.90 0.05 0.07 -0.33 -1.20 3.83 -0.01 -0.82 -1.67 1.60 0.42 -1.59 0.36 0.95 -0.04 -0.21 
CGLU324 Day 1 0.36 3.82 -1.84 1.31 -0.92 -0.80 -1.62 -0.96 3.93 3.03 -0.06 -2.94 0.12 -0.98 -0.25 -3.87 1.45 1.01 0.20 1.77 
CGLU324 Day 20 -0.15 1.18 -1.04 1.43 -0.59 -1.71 -0.62 0.18 2.47 0.55 -0.10 -1.29 -0.85 -0.41 0.88 -3.28 1.35 1.35 -1.66 2.13 
CGPLLU14 Day 0 3.19 1.71 0.89 2.31 -4.55 0.47 -2.38 -0.25 -0.65 -2.44 0.93 1.97 5.52 -0.47 -1.79 1.24 2.29 3.68 -3.87 -3.77 
CGPLLU14 Day 0.33 1.12 -0.88 -0.55 1.50 -1.92 0.02 -1.65 -1.61 -1.43 -1.84 0.15 1.03 3.85 1.44 -0.79 -0.43 1.04 2.95 -2.48 -1.34 
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CGPLLU14 Day 7 0.31 -0.49 0.18 0.26 -0.56 0.65 -0.97 0.44 -1.10 -1.76 -0.76 0.79 1.04 0.49 -0.44 -0.94 1.32 2.74 -0.49 -0.48 
CGPLLU14 Day -38 -0.49 1.88 0.13 1.48 -0.71 -0.90 -2.35 -1.50 -2.04 1.56 2.12 2.42 4.62 1.79 0.45 -1.53 1.73 1.98 -0.96 -0.91 
CGPLLU14 Day -16 -0.16 0.64 0.30 1.06 -0.58 0.32 -1.81 -0.22 -2.49 1.30 1.59 0.46 0.49 1.59 -0.37 -0.84 0.60 2.35 -1.04 0.60 
CGPLLU14 Day -3 -1.50 1.59 -0.97 1.30 -1.19 -1.74 -1.62 -2.39 -0.68 -0.51 1.91 -0.96 0.92 0.99 1.55 0.43 1.47 2.51 0.07 0.65 
CGPLLU12 Day 0.17 -5.42 4.72 5.92 1.70 -8.47 3.30 -3.94 -6.89 14.83 -9.73 -2.62 -10.80 38.73 34.33 -6.15 -4.38 2.31 5.20 -6.84 -11.72 
CGPLLU12 Day 10 0.03 -0.68 0.68 0.59 -0.55 0.74 -0.04 0.32 1.59 -0.91 -1.51 -0.65 1.28 1.67 0.85 -1.10 0.10 1.21 -1.84 -1.00 
CGPLLU12 Day 227 -0.33 2.48 1.14 0.45 -5.84 -0.03 -2.82 -2.39 6.34 -4.08 -0.50 -3.04 10.36 4.65 1.15 -1.66 1.72 2.85 -3.59 -3.87 
CGPLLU12 Day -150 -3.33 3.06 2.54 2.16 -3.14 0.00 -1.67 -3.19 3.98 -0.98 0.27 -1.66 12.73 8.33 -0.88 -1.73 2.44 2.67 -3.84 -3.09 
CGPLLU12 Day 0 -4.87 3.94 6.01 0.96 -6.27 2.89 -3.31 -6.17 14.65 -8.36 -2.77 -9.99 34.17 28.68 -5.79 -2.12 1.55 4.27 -6.03 -9.94 
CGPLLU18 Day 6 0.47 -0.34 0.29 1.84 -3.34 0.14 -1.99 -0.49 5.67 -4.50 1.92 2.63 4.10 -0.40 0.82 1.72 1.43 3.18 -4.46 -4.93 
CGPLLU18 Day 20 -0.56 -0.92 0.01 -0.03 -1.43 0.39 -0.32 0.58 1.60 -1.11 -0.47 0.34 1.47 0.91 1.53 -0.29 0.33 1.05 -1.67 -1.43 
CGPLLU18 Day -1 3.83 21.65 -5.72 -12.46 -22.73 9.29 -9.95 -16.07 43.29 15.48 15.51 4.07 72.46 -23.49 -8.98 -1.37 -1.45 -6.43 -8.21 -13.17 
CGPLLU86 Day 0.5 -0.28 -0.88 0.53 -0.42 -0.38 -0.04 0.21 1.29 0.82 2.97 -0.48 -0.49 -0.40 0.46 0.61 -0.25 -0.18 0.06 0.66 1.19 
CGPLLU86 Day 7 0.53 0.49 0.41 1.95 -2.24 -0.14 -2.14 -1.45 1.69 0.91 1.97 2.84 2.22 -0.98 -0.05 -0.66 1.32 1.53 -1.86 -0.44 
CGPLLU86 Day 17 1.03 -0.08 0.89 3.14 -3.01 -0.40 -2.48 0.05 2.01 1.36 0.83 -0.54 2.78 -2.40 -0.11 2.28 1.33 2.97 -0.97 -1.94 
CGPLLU86 Day 0 1.23 -0.26 -0.65 0.56 -1.71 -1.68 -1.52 -0.08 2.16 -2.76 0.41 0.17 0.63 0.78 1.89 0.91 0.88 1.53 -0.79 -1.97 
CGPLLU89 Day 7 0.87 -0.33 0.83 0.13 -0.46 0.67 -0.88 -1.19 0.74 -3.39 -0.01 0.29 3.38 -1.27 0.51 -1.25 0.84 1.90 -2.03 -1.40 
CGPLLU89 Day 22 0.00 -0.63 -0.65 -0.83 1.71 0.35 1.07 1.38 0.76 0.08 -1.26 0.06 -0.04 -0.10 0.42 -1.01 0.40 0.64 -0.22 -0.18 
CGPLLU89 Day 0 0.85 -0.50 0.68 1.28 -3.68 -0.82 -2.15 -1.03 1.66 -2.61 1.20 0.77 4.38 -1.61 0.43 0.14 1.12 3.28 -4.39 -2.96 
CGPLLU97 Day 7 1.18 -0.08 -0.24 -0.09 -0.02 -0.07 0.94 -0.28 0.80 -1.26 -0.13 -0.99 -1.21 0.92 0.26 -0.68 0.21 1.15 -0.51 -0.29 
CGPLLU97 Day 273 0.63 -0.24 0.99 1.47 -1.95 0.53 -2.28 -0.90 2.25 -1.22 1.95 1.65 1.57 -0.31 0.60 0.51 2.13 2.80 -2.53 -3.66 
CGPLLU97 Day 0 1.24 -0.17 1.23 0.87 -2.30 0.31 -1.64 0.10 0.56 -2.89 -0.02 0.81 4.26 0.95 -1.42 1.89 1.34 2.94 -0.57 -1.64 
CGPLLU99 Day 0.33 6.40 3.42 -7.00 -4.80 -8.61 -0.72 -2.88 -2.51 19.91 20.52 -0.27 -18.85 48.38 1.65 -6.59 33.46 -1.50 -1.86 -4.56 -4.14 
CGPLLU99 Day 9 1.39 0.09 2.21 1.61 -1.02 -0.98 -1.68 -0.84 -0.61 -0.15 -0.06 0.82 3.35 -1.05 -1.09 1.36 0.29 1.57 -1.18 -0.53 
CGPLLU99 Day 21 2.11 1.05 1.97 0.77 -3.09 -0.70 -2.32 0.15 -0.14 0.34 -0.54 -0.05 2.92 -1.31 -0.44 0.64 1.10 2.08 -2.78 0.47 
CGPLLU99 Day 0 6.82 5.32 -11.33 -8.79 -11.15 -1.03 -1.90 -2.41 29.40 31.04 -1.14 -29.03 61.00 6.24 -8.16 43.94 -3.25 -3.84 -3.60 -2.78 
CGPLLU88 Day 0 -7.34 12.14 -4.36 -2.02 -11.59 3.61 -3.29 -9.61 17.24 -4.40 9.38 -16.83 22.10 23.46 -3.01 20.82 -2.04 -3.23 -3.57 -5.77 
CGPLLU88 Day 297 -3.47 2.75 -0.51 2.30 -0.20 -0.63 -2.38 -2.43 1.66 1.42 3.82 1.56 6.25 2.18 1.31 5.00 0.60 -0.48 0.53 -2.38 
CGPLLU88 Day 7 -2.43 1.39 -1.31 2.82 -0.78 -0.67 -1.60 -1.54 0.55 0.96 3.77 2.38 2.16 -1.40 2.61 5.26 0.73 0.79 -1.04 -2.53 
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Patient ID Z scores chr11p chr11q chr12p chr12q chr13q chr14q chr15q chr16p chr16q chr17p chr17q chr18p chr18q chr19p chr19q chr20p chr20q chr21q chr22q PA score 
CGPLLU244 Day -7 -0.97 -0.33 -1.41 -0.77 -4.35 7.34 1.53 1.80 -1.06 1.34 1.28 3.42 -1.56 0.76 2.14 0.60 -0.01 1.02 1.40 4.85 
CGPLLU244 Day -1 -0.76 -0.45 -0.94 -0.86 -3.68 5.57 1.14 2.24 -0.41 0.70 1.13 2.64 -1.61 1.09 1.53 0.51 0.33 0.78 1.61 3.98 
CGPLLU244 Day 6 -1.79 -1.38 -2.58 -1.80 -3.75 7.76 2.71 2.06 -1.48 1.66 1.63 3.42 -1.51 -0.42 1.48 0.90 -1.87 -1.47 1.08 5.52 
CGPLLU244 Day 62 -1.18 0.95 -1.61 -0.64 -12.40 13.96 3.34 3.07 -1.10 0.34 1.46 4.98 -4.45 0.60 4.69 3.53 1.12 1.07 0.85 8.68 
CGPLLU245 Day -32 -1.48 -3.99 -0.03 -1.64 -8.83 -3.77 -0.24 2.31 -1.64 -3.91 1.58 -6.46 -3.05 -1.42 -1.47 -2.42 -6.29 0.44 -0.04 9.08 
CGPLLU245 Day 0 -1.92 -6.38 -1.01 -2.22 -9.48 -5.10 -1.58 3.60 -2.19 -4.31 1.76 -9.63 -4.46 -2.58 -1.85 -1.89 -8.97 -0.47 -2.23 11.00 
CGPLLU245 Day 7 -1.69 -3.87 -0.75 -1.27 -7.40 -2.74 0.01 2.21 -1.30 -1.50 1.23 -2.51 -1.92 -1.03 -1.49 -1.30 -5.09 0.16 0.52 8.34 
CGPLLU245 Day 21 -2.31 -4.55 -0.21 -2.93 -8.67 -3.89 0.25 1.65 -1.98 -2.09 1.81 -6.85 -3.30 -2.25 -2.15 -2.31 -8.27 -0.27 -0.62 9.50 
CGPLLU246 Day -21 0.29 -0.48 0.13 0.12 0.19 0.57 -0.30 0.85 0.35 -0.77 -0.23 -0.45 -0.87 1.03 -0.33 -0.86 -0.16 2.15 0.11 0.31 
CGPLLU246 Day 0 -0.34 -0.49 -2.04 -3.33 -6.98 5.99 0.91 1.84 -1.25 0.43 1.16 -2.43 -0.98 -1.48 -1.17 1.14 -4.23 5.59 0.80 7.33 
CGPLLU246 Day 9 -1.48 -1.58 -1.15 -1.06 0.33 0.21 1.02 1.07 -0.78 0.64 1.04 1.55 -0.72 0.28 -0.44 0.14 -0.39 1.29 1.40 2.12 
CGPLLU246 Day 42 -2.21 -2.25 -2.00 -2.74 -1.69 2.35 1.37 2.26 -2.17 -0.53 1.35 -0.15 0.29 -1.45 -2.09 -0.40 -4.45 0.55 -0.09 5.85 
CGLU294 Day 0 -1.11 -0.96 -1.38 -1.74 -0.96 -1.05 0.99 0.44 -1.23 0.07 1.48 2.21 -0.23 -0.23 -1.11 0.00 0.24 -2.37 0.35 1.33 
CGLU294 Day 0.2 1.21 0.36 -0.91 -0.99 -2.84 -2.28 0.11 0.73 -0.40 -2.36 1.01 0.63 -2.21 1.15 -0.13 -0.99 1.21 0.34 0.25 2.49 
CGLU294 Day 3 1.54 0.28 -0.56 -0.87 -3.14 -0.56 -0.08 0.96 -0.46 -1.62 0.78 1.03 -3.10 1.28 -0.02 -1.13 -0.34 -0.45 -0.23 2.48 
CGLU294 Day 7 -0.18 0.02 -1.66 -1.13 -1.75 -1.40 1.19 0.89 -1.31 -1.13 1.42 1.79 -1.43 0.42 -0.63 -1.30 -0.29 -1.92 0.57 1.68 
CGLU294 Day 29 -1.76 -2.02 -1.99 -2.66 -5.99 -2.96 1.26 2.62 -1.48 -2.36 1.66 1.71 -2.72 0.27 -1.08 -2.41 -0.98 1.62 1.29 4.20 
CGLU315 Day 0 -2.51 -2.75 -2.60 -2.95 -9.18 -1.95 2.99 1.05 -1.15 1.24 2.07 0.19 1.12 -0.62 -1.11 -0.63 0.30 -3.63 1.08 6.63 
CGLU315 Day 0.2 -1.06 -0.87 -1.04 -1.03 -3.69 0.68 1.60 0.43 -0.24 0.13 1.12 -1.67 -1.98 0.86 -1.29 -0.80 0.44 -0.39 0.75 0.91 
CGLU315 Day 20 -1.69 -1.86 -1.44 -2.17 -6.23 -2.25 2.93 0.87 -2.18 1.34 2.03 5.99 0.45 0.55 -1.74 -1.56 -0.56 -4.06 -0.77 4.65 
CGLU319 Day 0 -1.78 -0.39 -1.54 -1.79 -3.60 0.73 0.95 0.64 -1.39 1.69 1.65 0.81 0.61 0.60 -1.31 -0.94 -0.74 -2.47 0.17 2.04 
CGLU319 Day 14 -0.15 -0.90 -0.47 -0.28 -3.46 0.61 -0.25 -0.21 -0.52 0.75 0.88 0.78 -0.94 1.50 0.07 -0.78 0.47 -0.40 0.22 1.18 
CGLU324 Day 1 -1.51 -0.92 -1.02 -1.79 -4.74 0.59 1.15 -0.35 -1.45 1.65 1.61 -0.02 -0.10 0.44 -1.27 -1.16 -0.10 -3.54 2.09 3.32 
CGLU324 Day 20 -1.33 -0.12 -0.69 -0.88 -3.86 -0.56 0.49 0.27 -0.94 1.48 1.14 1.00 -0.98 0.72 -0.39 -1.84 0.94 -1.75 1.43 1.67 
CGPLLU14 Day 0 -3.31 -0.13 -1.17 -0.81 -6.22 0.06 2.32 -2.60 -2.65 1.35 2.18 6.46 -1.23 -1.87 -3.23 -1.73 -6.43 2.68 1.37 5.07 
CGPLLU14 Day 0.33 -0.33 0.67 -0.14 -0.21 -3.34 0.19 0.90 -0.64 -1.20 1.15 1.11 3.68 -1.69 -0.55 -1.58 -0.59 -2.52 2.55 1.56 2.47 
CGPLLU14 Day 7 -0.16 0.09 0.42 0.44 -2.09 -1.41 0.31 -0.47 -0.68 -0.10 0.59 0.25 -1.51 0.10 -1.10 -1.23 -2.42 0.67 0.60 0.79 
CGPLLU14 Day -38 0.08 -2.60 -1.77 -1.78 0.59 0.99 1.12 -1.21 -1.61 -1.35 1.28 -1.25 1.36 -2.12 -2.78 0.65 -4.48 -0.43 1.00 2.52 
61 
 
CGPLLU14 Day -16 -0.05 -0.61 -0.04 -0.78 -0.74 -0.74 0.23 -1.11 -0.84 -1.43 0.78 -1.79 -0.39 -0.82 -2.14 -0.69 -0.77 1.19 1.23 0.82 
CGPLLU14 Day -3 -0.81 -1.68 -1.31 -1.74 -0.04 1.99 0.60 0.03 -1.02 0.26 1.71 -0.30 -0.54 -0.39 -1.78 -0.35 -1.70 0.78 1.41 0.81 
CGPLLU12 Day 0.17 -2.51 -5.06 -2.71 -3.84 2.01 14.32 -5.86 -1.95 -5.24 -6.73 2.41 -1.88 0.77 0.75 5.62 0.44 -3.19 3.37 -1.26 11.26 
CGPLLU12 Day 10 -0.30 -0.22 -0.49 0.08 -3.35 0.72 0.01 -0.14 -0.18 1.46 0.65 0.68 -2.39 0.56 -0.20 -0.87 -1.36 1.16 1.33 0.85 
CGPLLU12 Day 227 -1.83 -0.21 -1.78 -0.64 -1.99 4.01 -0.54 -1.19 -2.34 2.68 2.77 3.19 -1.22 -0.16 -0.06 -2.71 -3.38 0.76 1.26 5.20 
CGPLLU12 Day -150 -0.41 -3.10 -2.12 -2.17 1.84 5.63 -0.97 -0.39 -3.10 -3.46 1.24 -2.12 1.71 -1.04 0.30 -0.23 -3.83 -2.79 0.07 5.45 
CGPLLU12 Day 0 -1.52 -3.87 -2.34 -3.22 0.66 12.90 -5.14 -1.40 -4.34 -7.19 1.57 -1.19 -0.13 1.37 5.00 0.83 -1.97 3.07 -1.21 10.67 
CGPLLU18 Day 6 -2.34 -0.90 -1.80 -1.33 -3.44 2.84 1.27 -0.61 -2.31 3.53 2.35 5.75 -1.72 -1.08 -2.24 -1.04 -4.04 0.66 1.04 4.41 
CGPLLU18 Day 20 0.19 -0.58 -0.09 -0.16 -3.76 0.98 0.00 0.50 -0.55 1.19 0.68 1.61 -1.32 1.32 -0.33 -1.36 -1.81 0.95 1.43 0.69 
CGPLLU18 Day -1 -6.01 -3.20 -5.96 -10.27 -6.77 69.49 -7.35 17.13 -5.90 -8.85 3.57 -19.21 -7.74 -4.23 -5.16 -7.91 10.18 12.39 -8.20 14.86 
CGPLLU86 Day 0.5 0.17 0.00 0.43 -0.02 -3.27 -0.31 -0.38 -0.07 0.07 -0.25 -0.06 2.05 -2.12 0.85 0.01 -0.62 -0.92 1.04 0.01 1.11 
CGPLLU86 Day 7 -1.84 -0.24 -1.30 -0.83 -2.79 -1.04 1.60 0.06 -1.98 1.19 1.39 4.09 -1.29 -1.19 -1.73 -0.19 -5.08 0.89 0.62 2.54 
CGPLLU86 Day 17 -2.36 -0.66 -1.23 -0.25 -2.33 -1.88 2.03 -0.44 -2.24 0.19 1.06 4.35 0.00 -1.88 -2.34 0.29 -6.07 -0.25 0.26 3.12 
CGPLLU86 Day 0 -2.03 -0.23 -0.90 -0.59 -3.11 -0.54 1.28 0.10 -1.42 4.77 1.84 4.30 -1.89 -0.43 -0.74 -1.51 -1.79 0.36 2.02 2.57 
CGPLLU89 Day 7 -0.70 0.77 -0.15 0.15 -2.31 1.01 0.34 -0.36 -0.66 1.87 0.63 2.99 -2.31 0.34 -0.32 -0.84 -2.05 0.38 1.83 1.94 
CGPLLU89 Day 22 0.56 -0.15 0.42 1.03 -0.87 -0.25 -1.32 -0.37 0.32 -0.92 -0.32 -0.25 -1.76 1.73 0.16 -0.65 -1.79 1.10 -1.13 0.09 
CGPLLU89 Day 0 -2.02 -0.32 -0.57 -0.14 -3.30 1.13 1.01 -0.47 -1.42 3.04 1.52 4.24 -1.15 -0.44 -0.77 0.21 -3.04 0.84 2.41 3.34 
CGPLLU97 Day 7 -0.10 0.03 0.12 -0.38 -3.24 -0.62 -0.29 0.76 -0.18 1.51 0.53 1.52 -2.35 0.74 0.09 -0.40 -0.57 0.58 1.30 0.55 
CGPLLU97 Day 273 -2.33 -1.13 -1.54 -1.66 -1.92 -0.15 1.34 -0.81 -2.28 2.89 1.70 2.73 0.11 -1.23 -1.73 -0.56 -4.02 2.23 1.32 2.39 
CGPLLU97 Day 0 -2.11 -0.71 -1.20 -0.15 -3.50 -2.63 1.72 -0.37 -1.70 1.19 0.85 5.10 -0.79 -0.29 -1.20 -1.08 -2.65 1.05 1.10 2.99 
CGPLLU99 Day 0.33 -1.48 -1.34 -1.26 -0.89 -25.72 -1.51 -1.65 7.60 3.97 -8.33 1.08 4.89 -7.45 -4.56 -3.67 -9.22 1.85 1.92 -4.28 12.91 
CGPLLU99 Day 9 -0.23 -0.37 -0.44 -0.36 -3.00 -0.59 1.57 -0.61 -1.39 -0.66 0.42 4.02 -0.79 -1.24 -1.78 0.61 -3.76 2.02 2.56 2.54 
CGPLLU99 Day 21 -0.84 0.00 -0.98 0.29 -4.49 -1.70 1.82 -1.08 -1.74 -0.73 1.24 5.44 -1.92 -0.98 -2.06 -0.67 -3.71 0.88 2.38 3.20 
CGPLLU99 Day 0 -1.53 -1.36 -0.85 -0.98 -36.10 -2.02 -4.66 12.25 7.23 -10.65 0.72 2.01 -10.19 -4.73 -3.78 -13.23 6.75 4.62 -6.64 14.58 
CGPLLU88 Day 0 -2.54 -2.85 -1.15 2.94 -7.41 8.22 -3.45 -0.75 -1.69 -4.63 3.64 -5.62 -7.75 -0.75 -0.89 -3.30 9.19 -2.83 3.91 11.20 
CGPLLU88 Day 297 -1.51 -2.21 -2.40 -1.39 3.52 0.22 1.38 -0.22 -2.19 -2.96 0.97 1.20 2.40 -2.23 -2.19 -0.06 -2.91 -3.71 -0.24 3.76 
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Experimental study design 
The current study is a planned exploratory analysis of the predictive value of cfDNA assessment in 
50 randomly selected patients from the CRITICS study (NCT00407186) who had plasma samples 
available and suitable for genomic analyses from at least two timepoints (Figures 3.1 A, 3.2, and 
Table 3.1).  The CRITICS study is an investigator-initiated, open-label, multi-center, phase III 
randomized controlled trial of perioperative chemotherapy (chemotherapy group) versus 
preoperative chemotherapy with postoperative chemoradiotherapy (chemoradiotherapy group) in 
patients with resectable gastric cancer (77).  A total of 788 patients from 56 hospitals in the 
Netherlands, Sweden, and Denmark were randomized upfront to receive three preoperative 21-day 
cycles of intravenous epirubicin, cisplatin or oxaliplatin, and oral capecitabine followed by three 
postoperative cycles of intravenous epirubicin, cisplatin or oxaliplatin, and oral capecitabine 
(chemotherapy group) or to receive the same preoperative regimen followed by postoperative 
radiotherapy combined with daily capecitabine and weekly cisplatin (chemoradiotherapy group) 
(Figures 3.1 A, 3.2, and Table 3.1).  Baseline blood samples at the time of trial enrollment were 
used for both cfDNA and white blood cell targeted deep sequencing (30,000X), followed by 
independent variant calling and further tumor-specific mutation detection using the white blood 
cell filtering approach (Figure 3.1 A).  Tumor-specific mutations from the consecutive timepoints 
were identified using the white blood cell sequencing data from the same patient at baseline. 
Patients and characteristics 
Patients were eligible for the study if they had histologically proven gastric adenocarcinoma (as 
defined by the American Joint Committee on Cancer, 6th edition), stage IB-IVA (78), as assessed 
by esophagogastroduodenoscopy and CT of the chest, abdomen, and pelvis.  Patients with tumors 
of the gastroesophageal junction were permitted to enroll when the bulk of the tumor was 
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predominantly located in the stomach and could therefore consist of Siewert types II (true 
gastroesophageal junction) and III (subcardial stomach) tumors.  Patients with Siewert type I (distal 
esophagus) tumors were not eligible. An exploratory laparoscopy was indicated when the 
preoperative CT scan suggested peritoneal carcinomatosis. Patient enrollment and genomic studies 
were conducted in accordance with the Declaration of Helsinki, were approved by the Institutional 
Review Board (IRB) and all patients provided written informed consent for sample acquisition for 
research purposes.  
Pathological assessment of response, mismatch repair status and EBV status determination 
Pathology slides from the resection specimen from each patient were collected and centrally 
reviewed by NCTvG to confirm histologic subtypes according to the Lauren’s classification criteria 
(79).  Histopathological regression was determined by NCTvG according to Mandard’s tumor 
regression grade (TRG) system:  i) TRG1, no residual tumor left (pathological complete response); 
ii) TRG2, scattered tumor cells left; iii) TRG3, fibrosis outgrows tumor; iv) TRG4, tumor outgrows 
fibrosis; and v) TRG5, no histological signs of regression (Table 3.1).  For detection of Epstein-
Barr virus (EBV), the tumor areas were demarcated on H&E slides of the resection specimens.  In 
case of sufficient amount of tumor tissue, 3 cores per tumor were taken for construction of a tissue 
microarray (TMA).  TMA sections were cut and used for Epstein-Barr virus encoded RNA in-situ 
hybridization (EBER-ISH).  In case little or no tumor was left in the resection specimen due to 
chemotherapy-induced pathological (near) complete response EBER-ISH was performed on the 
diagnostic biopsy specimen.  EBER-ISH was performed using the U INFORM iViEW Blue ISH 
(v1.02.0023) and the INFORM EBER probe on the Benchmark Ultra IHC/ISH staining module 
(Roche Diagnostics, the Netherlands) according to the manufacturer’s protocol (Table 3.1).  
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from the diagnostic biopsy specimen were 
used for MSI analysis.  The tumor area was demarcated on an H&E slide.  DNA was isolated from 
65 
 
the demarcated tumor area.  MSI analysis was performed using the MSI Analysis System (MSI 
Multiplex System Version 1.2, Promega) consisting of five nearly monomorphic mononucleotide 
markers (BAT-25, BAT-26, NR-21, NR-24, MONO-27) according to the manufacturer's instructions.  
PCR products were separated by capillary electrophoresis using an ABI 3500 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA), and analyzed using GeneMapper Software (Applied 
Biosystems, Foster City, CA, USA).  An internal lane size standard was added to the PCR samples 
for accurate sizing of alleles and to adjust for run-to run variations.  When all markers were stable, 
the tumor was interpreted as microsatellite stable (MSS).  The tumor was interpreted as MSI-low 
(MSI-L) if one marker was unstable and MSI-high (MSI-H) if two or more markers showed 
instability.  MSI-L tumors were included in the MSS category (Table 3.1). 
Sample preparation and next-generation sequencing of cfDNA and genomic DNA from 
white blood cells 
Whole blood was collected in K2EDTA tubes, sent to the central pathology lab at VUmc, 
Amsterdam, and processed within 1 day after collection. Plasma and cellular components were 
separated by centrifugation at 1,300 rpm for 5 minutes in 1.5 ml microcentrifuge tubes at 4°C and 
therefore stored at -20°C until the time of DNA extraction. cfDNA was isolated from plasma using 
the Qiagen Circulating Nucleic Acids Kit (Qiagen GmbH) and eluted in LoBind tubes (Eppendorf 
AG).  High-molecular weight DNA from white blood cells was extracted using the Qiagen DNA 
Blood Mini Kit (Qiagen GmbH) followed by shearing using a focused-ultrasonicator (Covaris).  
Concentration and quality of cfDNA was assessed using the Bioanalyzer 2100 (Agilent 
Technologies).  cfDNA samples with saturated concentrations of high-molecular weight DNA 
based on fluorescence intensity were excluded from the study. 
Next-generation sequencing libraries from cfDNA and sheared high-molecular weight DNA from 
white blood cells were prepared from 8.4 to 250 ng (Table 3.2).  Genomic libraries were prepared 
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as previously described (15). Briefly, the NEBNext DNA Library Prep Kit for Illumina [New 
England Biolabs (NEB)] was used with four main modifications to the manufacturer’s guidelines: 
i) the library purification steps utilized the on-bead Ampure XP approach, ii) reagent volumes were 
adjusted accordingly to accommodate the on-bead strategy, iii) a pool of 8 unique Illumina dual 
index adapters with 8 bp barcodes were used in the ligation reaction, and iv) cfDNA libraries were 
amplified with HotStart Phusion Polymerase. Genomic library preparation was performed as 
previously described (15).  Concentration and quality of cfDNA genomic libraries were assessed 
using the Bioanalyzer 2100 (Agilent Technologies).  Targeted capture was performed using the 
Agilent SureSelect reagents and a custom set of hybridization probes targeting 58 genes (Table 3.3) 
per the manufacturer’s guidelines.  The captured library was amplified with HotStart Phusion 
Polymerase (NEB).  The concentration and quality of captured cfDNA libraries was assessed on 
the Bioanalyzer (Agilent Technologies).  Libraries were sequenced using 100-bp paired end runs 
on the Illumina HiSeq 2500 (Illumina).  
Primary processing of next-generation sequencing data and identification of putative somatic 
mutations using the white blood cell filtering approach 
Primary processing of next-generation sequence data for analyses of sequence alterations in cfDNA 
and white blood cell samples were performed as previously described (15).  Briefly, Illumina 
CASAVA (Consensus Assessment of Sequence and Variation) software (version 1.8) was used for 
demultiplexing and masking of dual index adapter sequences. Sequence reads were aligned against 
the human reference genome (hg19) using NovoAlign with additional realignment of select regions 
using the Needleman-Wunsch methods (71).  
Candidate tumor-specific mutations in cfDNA, consisting of point mutations, small insertions, and 
deletions were identified using VariantDx (71) (Personal Genome Diagnostics) across the targeted 
regions of interest as previously described (15).  Briefly, an alteration was considered a candidate 
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somatic mutation only when: (i) Three distinct paired reads contained the mutation in the cfDNA 
and the number of distinct paired reads containing a particular mutation in the plasma was at least 
0.05% of the total distinct read pairs; or (ii) one distinct paired read contained the mutation in the 
cfDNA and the mutation had also been detected in at least one additional timepoint at the level 
specified in (i); (iii) the mismatched base or small indel was not identified in matched white blood 
cell sequencing data of samples collected at baseline at the level of one distinct read; (iv) the 
mismatched base or small indel was not present in a custom database of common germline variants 
derived from dbSNP; (v) the altered base did not arise from misplaced genome alignments 
including paralogous sequences; and (vi) the mutation fell within a protein coding region and was 
classified as a missense, nonsense, frameshift, or splice site alteration.  Candidate alterations were 
defined as somatic hotspots if the nucleotide change and amino acid change were identical to an 
alteration observed in ≥ 20 cancer cases reported in the COSMIC database.  
Statistical analyses 
Significance was determined using a variety of methods.  Wilcoxon rank sum test or Kruskal-Wallis 
test were performed for continuous variables and Fisher’s exact test for categorical variables.  
Analyses of groups of mutations were carried out in R using the package maftools (80).  Correlation 
coefficients were determined for the association between WBC variants and their correspondent 
alterations identified in cfDNA, as well as for the association between the number of WBC variants 
and age. Univariate survival analyses and a multivariate Cox proportional-hazards model were 
carried out in R using packages survival and coxphf (https://cran.r-project.org). 
For mutations identified by cfDNA sequencing but not identified by WBC sequencing, we 
computed the probability for the model that the mutation was tumor derived relative to the 
probability for the model that the mutation was hematopoietic.  The sampling distribution of the 
observed number of reads with an altered mutation in cfDNA and WBC sequencing is a binomial 
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parameterized by the total coverage at that mutation and unknown probability theta.  Under the 
tumor derived model, theta_WBC is zero and only theta_plasma is unknown.  For the 
hematopoietic model, we assume that theta_WBC and theta_plasma are the same.  As a prior for 
theta_plasma, we used a beta distribution with shape parameters 2.4 and 340 that loosely centers 
most of the mass on the observed mutation allele frequencies in samples for which mutations were 
identified in both cfDNA and WBC sequencing.  This prior is equivalent to a sample with 2.4 
altered reads per 340 distinct molecules.  Simulating a large number of theta’s from the prior, we 
computed the probability of the observed data for each simulated theta.  The ergodic average of 
these probabilities approximates the likelihood of the observed data conditional on the model but 
unconditional on theta.  Assuming a prior odds of 1, the posterior odds (PO) was the same as the 
Bayes factor and we obtained the probability that the mutation was tumor derived by PO/(1+PO).  






The current study was an exploratory analysis of the predictive value of ctDNA assessment in a 
subset of patients from CRITICS study (NCT00407186), an investigator-initiated, open-label, 
multi-center, phase III randomized controlled trial of perioperative chemotherapy (chemotherapy 
group) versus preoperative chemotherapy with postoperative chemoradiotherapy 
(chemoradiotherapy group) for patients with resectable gastric cancer (77).  Between Jan 11, 2007, 
and April 17, 2015, a total of 788 patients from 56 hospitals in the Netherlands, Sweden, and 
Denmark were randomized upfront to receive three preoperative 21-day cycles of intravenous 
epirubicin, cisplatin or oxaliplatin, and oral capecitabine followed by three postoperative cycles of 
intravenous epirubicin, cisplatin or oxaliplatin, and oral capecitabine (chemotherapy group) or to 
receive the same preoperative regimen followed by radiation combined with daily capecitabine and 
weekly cisplatin (chemoradiotherapy group) (Figures 3.1 A, 3.2, and Table 3.1). 
As a proof-of-principle study, we sequenced and analyzed matched cfDNA and WBC samples from 
50 treatment-naïve patients from the Netherlands who had plasma samples available for genomic 
analyses at two or more timepoints to detect tumor-specific mutations in ctDNA (Figures 3.1 A, 
3.2, and Table 3.1).  Our goal was to predict survival outcomes based on ctDNA assessment after 
preoperative therapy and minimal residual disease analyses after surgery with curative intent.  Of 
the patients analyzed, 24 had diffuse subtype, 24 had intestinal subtype according to Lauren’s 
classification, and one was diagnosed with adenosquamous gastric carcinoma (Figure 3.1 B and 
Table 3.1).  Twenty-one patients were surgically treated with distal gastrectomy, 17 with total 
gastrectomy, four with esophagocardiac resection, and one with proximal gastrectomy (Figure 3.1 
B and Table 3.1).  Despite initial eligibility at the time of treatment enrollment, six patients showed 
evidence of advanced disease during the exploratory laparotomy and were not submitted to surgical 
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resection.  One additional patient did not undergo surgical treatment for unknown reasons.  
Histopathological regression after preoperative therapy was determined according to Mandard’s 
tumor regression grade (TRG).  Three patients achieved complete regression after three cycles of 
preoperative chemotherapy at the time of surgery (TRG 1) while 10, 15, 13, and 2 patients presented 
with pathological stage I, II, III, and IV, respectively (Figure 3.1 B and Table 3.1).  Centrally 
reviewed pathological assessment of resection specimens after three cycles of preoperative 
chemotherapy showed that 20 patients did not have evidence of lymph node involvement (ypN0), 
while 23 patients had lymph node infiltration, including 10 patients with ypN1 (including 3 
ypN1mi), 7 patients with ypN2, and 6 patients with ypN3 disease (Table 3.1).  Twenty-six patients 
received postoperative treatment with radiation combined with cisplatin and capecitabine, and 24 
patients were postoperatively treated with three cycles of epirubicin, cisplatin, and capecitabine 
without radiation after surgery (Figure 3.1 B and Table 3.1). 
For each patient, plasma and buffy coat were collected at the time of trial enrollment (baseline 
timepoint), after patients received three cycles of preoperative chemotherapy (preoperative 
timepoint), and after surgery but before the initiation of the adjuvant treatment (postoperative 
timepoint) (Figure 3.1 A, Tables 3.1 and 3.2).  We developed an approach to identify tumor-specific 
alterations in the circulation independent of tissue analyses by parallel deep sequencing of cfDNA 
and WBCs, followed by identification of cfDNA alterations and removal of hematopoietic-related 
changes detected in WBCs (Figure 3.1 A).  For sequencing analyses of cfDNA and WBCs, we used 
a next generation deep sequencing approach to evaluate 58 cancer driver genes (Figure 3.1 A and 
Tables 3.3, 3.4, and 3.5).  This method is based on targeted capture and deep sequencing (>30,000x) 
of DNA fragments to identify single base substitutions and small insertions or deletions in cfDNA 
across 80,930 bp of coding gene regions while distinguishing these from PCR amplification and 
sequencing artifacts (15).  For alterations detected in cfDNA that were not identified by matched 
white blood cell sequencing, we determined the posterior probability that such an alteration was 
71 
 
tumor derived from a Bayesian statistical model using the frequency of altered alleles and total 
coverage of cfDNA and WBCs sequences.   
To estimate the theoretical sensitivity of detection of the sequencing approach in gastric cancer, we 
determined the proportion of gastric adenocarcinomas in the TCGA Pan-Cancer Atlas (81) with 
alterations in one or more of the 58 analyzed genes.  These analyses showed that our targeted panel 
would have a sensitivity of ~88% as 384 of 436 gastric cancer cases had at least one alteration in 
these genes (Figure 3.3).  Overall, we observed that median levels of mutant allele fractions at 
baseline were significantly higher in patients with intestinal subtype when compared to diffuse 
subtype (0.295% vs 0%, p = 0.015, Wilcoxon rank sum test) (Figure 3.4 A).  There was no 
statistically significant difference among levels of mutant allele fractions among well, moderately, 
or poorly differentiated tumors (p = 0.07, Kruskal-Wallis test) (Figure 3.4 B).  In our study, patients 
with intestinal and diffuse gastric adenocarcinoma experienced similar event-free (Figure 3.4 C and 
Table 3.1) and overall survival (Figure 3.4 D and Table 3.1).  Consistent with the findings of the 
original trial (77), we did not observe significant differences in survival outcomes related to the 
postoperative treatment arm in which patients had been randomized (Figures 3.4 E, 3.4 F and Table 
3.1). 
Detection of clonal hematopoiesis and identification of tumor-specific alterations 
We evaluated cfDNA in all 50 patients at baseline and after 3 cycles of preoperative chemotherapy.  
At baseline, we detected sequence alterations in cfDNA from 40 patients (80%) (Figure 3.5 A and 
Table 3.6) and in WBCs from 31 patients (62%) (Figure 3.5 B and Table 3.7).  After removing 
WBC-derived alterations from cfDNA data, we detected 54 alterations that were likely tumor-
specific in 27 patients (54%) (Figure 3.5 C and Table 3.8).  The most frequently altered genes 
detected in WBCs were DNMT3A (45%), TP53 (29%), EGFR (10%), APC (6%), AR (6%), ATM 
(6%), and MLH1 (6%), while the most frequently altered genes detected in ctDNA were TP53 
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(22%), MYC (15%), PIK3CA (15%), KRAS (11%), HRAS (11%), BRAF (11%), ALK (11%), ATM 
(11%), KIT (11%), and CDH1 (7%) (Figures 3.5 B, 3.5 C and Table 3.8).  In accord with the 
molecular classification of gastric adenocarcinomas proposed by the TCGA (82), we found a higher 
frequency (60%) of PIK3CA mutations in the blood of patients with EBV positive (n = 3) or MSI-
high tumors (n = 2) compared to the frequency (3%) in EBV negative (n = 36) and MSS tumors (n 
= 37).  The median mutant allele fraction among 43 WBC-derived variants was 0.31% (IQR 0.18% 
– 0.63%), which was similar to the median mutant allele fraction among 53 tumor-specific variants 
identified in cfDNA (0.31%, IQR 0.20% – 0.55%, p = 0.96, Wilcoxon rank sum test) (Figure 3.5 
D).  We observed a high correlation between levels of mutant allele fractions in WBCs and levels 
of corresponding alterations in cfDNA (Pearson correlation coefficient = 0.91) (Figure 3.5 E).  As 
expected, the number of alterations detected in WBCs increased with age (r2 = 0.36, exponential 
correlation) (Figure 3.5 F).   
We detected 21 sequence alterations in TP53 in cfDNA, including 17 missense mutations, two 
nonsense mutations, one in-frame deletion, and one splice site mutation (Figure 3.5 G and Table 
3.6).  Of the cfDNA sequence changes observed in TP53, we identified 15 in WBC sequences as 
well as three alterations in WBC’s that were not present in matched cfDNA (Figure 3.5 G and Table 
3.7).  From the 21 TP53 alterations initially detected in cfDNA at baseline, only 6 were identified 
as tumor-specific mutations, including two with stop alterations (Q192* and S166*) as well as four 
missense mutations (R175H, V216M, N239S, R248W).  We further evaluated fragment length 
distributions of the 21 TP53 alterations detected in cfDNA.  We observed that fragments harboring 
tumor-specific TP53 mutations in the circulation were significantly shorter than fragments 
harboring TP53 variants associated with clonal hematopoiesis (p < 0.001, Kolmogorov–Smirnov 
test), as well as fragments harboring wild-type TP53 coding regions (p < 0.001, Kolmogorov–
Smirnov test) (Figure 3.5 H and Tables 3.7, 3.8, and 3.9).  Interestingly, we detected WBC variants 
in DNMT3A, TP53, ERBB4, MLH1, PDGFRA, FGFR3, ESR1, IDH2, and ATM among multiple 
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time points analyzed in 11 patients that did not harbor any tumor-specific alterations in cfDNA 
(Figures 3.6 A-K).  Overall, detection of WBC variants or tumor-derived ctDNA variants at 
baseline did not reveal statistically significant differences in event-free or overall survival (Figures 
3.7 A-D). 
Preoperative ctDNA is a surrogate biomarker for pathological response in gastric cancer 
After identification of ctDNA alterations using the parallel sequencing of cfDNA and WBCs 
indicated above, we evaluated ctDNA levels before and after preoperative chemotherapy.  Of the 
30 patients with measurable ctDNA at baseline or at the preoperative time point after filtering WBC 
sequence alterations (Figure 3.5 C), 11 experienced a complete elimination of ctDNA levels after 
nine weeks of systemic treatment (Figures 3.8, 3.9, and Table 3.5).  As an example, patient 
CGST33, who presented with intestinal subtype gastric adenocarcinoma at diagnosis had mutant 
allele fraction concentrations of 2.32% and 0.64% for TP53 Q192* and ERBB2 R756Cfs*2, 
respectively that were completely eliminated at the preoperative timepoint.  This drop in ctDNA 
occurred in conjunction with a major pathological response (TRG 2) in the specimen obtained at 
the time of surgery (Figure 3.10 A).  In contrast, 19 patients had detectable ctDNA at the 
preoperative timepoint (Figures 3.8, 3.9, and Table 3.5), including as an example in patient 
CGST110 who had mutant allele fractions of 0.15% for ERBB4 T639M at baseline and 0.12% at 
the preoperative timepoint (Figure 3.10 B).  This patient did not experience tumor regression after 
nine weeks of systemic treatment (TRG 5) and eventually died from recurrent disease 35 months 
after the initial diagnosis (Supplementary Table S1).   
After preoperative chemotherapy, we identified seven responders of whom three achieved complete 
pathological response (TRG 1) and four achieved a major pathological response, exhibiting fibrotic 
surgical specimens with scattered tumor cells (TRG 2). All seven responders had no ctDNA 
detected at the preoperative timepoint (Figure 3.10 C).  We observed that patients with lower 
degrees of tumor regression (TRG 3-5) and at least one involved lymph node (ypN1, ypN2, and 
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ypN3) presented more frequently with detectable ctDNA at the preoperative timepoint (Figures 
3.10 C and 3.11 A).  In contrast, the absence of ctDNA at the preoperative timepoint was 
significantly associated with major pathological regression (TRG 1-2) at the time of surgery (p = 
0.03, Fisher’s exact test) (Figure 3.10 D).  As expected, recurrence was also associated with lower 
degrees of pathological response (p = 0.03, Fisher’s exact test) (Figure 3.10 E), at least one involved 
lymph node (p = 0.002, Fisher’s exact test) (Figure 3.10 F), and detectable ctDNA at the 
preoperative timepoint (p = 0.02, Fisher’s exact test) (Figure 3.10 G).  TRG score (TRG 1-2 versus 
TRG 3-5) and pathological lymph node status (ypN0 versus ypN+) were strongly associated with 
survival outcomes (Figures 3.11 B and 3.11 C).  It is noteworthy that detection of mutations in 
cfDNA without a WBC sequence filter at the preoperative timepoint did not predict risk of 
recurrence (Figure 3.10 H) or death (Figure 3.12 A).  However, when we applied the WBC-guided 
hematopoietic filter, we observed that ctDNA detected at the preoperative timepoint was associated 
with a significantly higher risk of recurrence and shorter median event-free survival (18.4 months 
versus median not reached) (Log-rank p = 0.012; HR = 3.0; 95% CI = 1.3-6.9) (Figure 3.10 I) as 
well as higher risk of death and shorter median overall survival (28.7 months versus median not 
reached) (Log-rank p = 0.03; HR = 2.7; 95% CI = 1.1-6.7) (Figure 3.12 B).  
Minimal residual disease predicts survival outcome after surgery in gastric cancer 
We used the WBC-filtering approach to evaluate minimal residual disease after surgery from all 20 
patients with blood samples available from a postoperative timepoint.  Blood samples were 
collected at a median time of 6.5 weeks after surgery (Table 3.1).  We observed complete 
elimination of tumor-specific mutations in cfDNA at the postoperative time point for four patients 
with major tumor responses (TRG 1 and TRG 2), including in patient CGST32, who exhibited 
baseline mutant allele fraction concentrations of 0.65% and 0.24% for BRAF G469A and KRAS 
G13R, respectively (Figure 3.13 A).  The two hotspot ctDNA mutations in this patient were not 
detected at either the pre- or postoperative timepoint, in agreement with the surgical specimen 
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assessment that showed major tumor regression (TRG 2) (Figure 3.13 A, Tables 3.1 and 3.8).  In 
contrast, we detected postoperative tumor specific mutations in nine out of 16 patients with minor 
or no pathologic tumor responses (TRG 3-5), including in patient CGST68, who presented with 
mutant allele fraction of 0.03% for HRAS D54Efs*53 frameshift mutation at the baseline timepoint.  
This patient exhibited progressive increases in mutant allele fractions of HRAS at preoperative and 
postoperative timepoints, followed by the emergence of ERBB4 D1184*, detected at 0.16% mutant 
allele fraction after surgery (Figure 3.13 B, Tables 3.1 and 3.8).  After a median follow-up of 42 
months, we observed that all eleven patients without detectable tumor-specific mutations at the 
postoperative timepoint were alive and free of recurrence (Figure 3.13 C and Table 3.1).  On the 
other hand, six out of nine patients with detectable tumor-specific mutations at the postoperative 
timepoint developed disease recurrence and died from metastatic disease (Figure 3.13 C and Table 
3.1).  Again, detection of mutations in cfDNA without a WBC filter after surgery did not predict 
recurrence (Figure 3.14 A) or death (Figure 3.13 D).  In contrast, with the WBC-guided 
hematopoietic filter, we observed a significant shorter median event-free survival and a higher risk 
of disease recurrence for patients with detectable tumor-specific mutations after surgery (18.7 
months versus median not reached; Log-rank p < 0.001; HR = 21.8; 95% CI = 3.9-123.1) (Figure 
3.14 B) as well as a significantly shorter median overall survival (28.7 versus median not reached; 
Log-rank p < 0.001; HR = 21.8; 95% CI = 3.9-123.1) (Figure 3.13 E). 
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Figure 3.1. Analysis of cfDNA in patients with resectable gastric cancer. A, Study schematic. Patients 
with confirmed stage IB-IVA gastric adenocarcinoma eligible for perioperative treatment with systemic 
chemotherapy were randomized upfront to receive three cycles of preoperative chemotherapy followed by 
three cycles of postoperative chemotherapy or to receive the same preoperative regimen followed by 
postoperative radiotherapy combined with chemotherapy. A blood draw was collected for each patient at 
the time of study enrollment (baseline), after three cycles of preoperative chemotherapy (preoperative 
timepoint), and after surgery (postoperative timepoint). Blood samples were initially processed to allow 
proper extraction of cfDNA from plasma and genomic DNA (gDNA) from white blood cells (WBC). Both 
cfDNA and WBC gDNA libraries were hybrid captured with custom RNA oligo pools encompassing 
80,930 bases across 58 cancer driver genes. Capture libraries were sequenced at high coverage (>30,000X), 
followed by sequence alignment, error correction, and variant calling. Mutations detected in WBCs were 
identified in cfDNA and removed, allowing the identification of tumor-specific mutations in cfDNA. B, 
Clinicopathological characteristics, type of surgical treatment, pathological stage, and type of postoperative 
treatment for the subset of patients analyzed in this translational study (n = 50). MSI, microsatellite 
instability; MSS, microsatellite stability; EBV, Epstein-Barr virus; ECC, epirubicin, cisplatin, capecitabine; 
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Figure 3.2. Consort diagram of patients enrolled in the CRITICS trial cohort. Patients with operable stage IB-IVA gastric cancer (n=788) were initially 
treated with three cycles of preoperative chemotherapy with epirubicin, cisplatin or oxaliplatin, and oral capecitabine followed by surgery. They were randomly 
assigned to receive postoperative treatment with the same chemotherapy regimen (n=393) or postoperative radiation with cisplatin and oral capecitabine (n=395). 
Plasma samples used for ctDNA analyses were provided by study centers in The Netherlands.
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Figure 3.3. Theoretical sensitivity of detection of ultrasensitive NGS approach in gastric cancer. 
Analyses of TCGA Pan-Cancer Atlas gastric adenocarcinoma cohort showed a theoretical sensitivity of 88 
% for the 58-gene panel (81 Kb) used in this study, with 385 out of 436 cases potentially identified using 
this approach.
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Figure 3.4. Pathological features and ctDNA levels of gastric cancers analyzed.  A, Mutant allele fractions of ctDNA at base line in patients with diffuse and   
intestinal subtype s (Wilcoxon rank sum test, p= 0. 02). B, Mutant allele fractions of ctDNA at baseline in patients with well, moderately, and poorly differentiate 
d tumors (Kruskal -Wallis test, p= 0.07). C - D, Kaplan-Meier estimates for event- free survival [Log-rank p = 0.90; HR = 1.0 (95% CI = 0.4-2.1)] (C) and 
overall survival [Log-rank p = 0.59; HR  = 0.8 [(95% CI = 0.3-1.9)] (D) of patients with intestinal and diffuse subtype s. E-F, Kaplan-Meier estimates for e vent-
free  survival  [Log-rank p = 0.48; HR = 1.3 (95% CI = 0.6-3. 0)] (E) and overall survival [Log-rank p = 0.83; HR = 1.1 (95% CI = 0.5-2.5)] (F) of patients 
treated with adjuvant chemotherapy or chemoradiotherapy.
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Figure 3.5. Identification of white blood cell and ctDNA variants in cfDNA of patients with localized gastric 
cancer. A-B, Ultrasensitive targeted sequencing were used to detect mutations in cfDNA (A) and WBCs (B) in 50 
patients, with only those cases having alterations indicated. C, Tumor-specific mutations in ctDNA were identified in 
27 individuals after subtraction of WBC derived variants in cfDNA. D, Density plots showing the mutant allele fraction 
distribution of cfDNA variants (top, yellow), WBC variants (middle, purple), and resulting ctDNA variants (bottom, 
blue). E, Levels of mutant allele fractions in WBCs (horizontal axis) and their correspondent levels in cfDNA (vertical 
axis) suggest that WBC alterations are identified at similar levels in cfDNA (Pearson correlation coefficient = 0.91, p < 
0.001). The probability that an identified variant is tumor-derived when the alteration is not detected in WBCs is 
indicated by the shading of the blue dots. F, Association between age (horizontal axis) and absolute number of WBC 
variants detected in each patient (vertical axis) suggests that the number of WBC alterations increase with age (r2 = 
0.36, exponential correlation). G, Positions and frequencies of mutations in TP53 detected in cfDNA (top plot) and 
WBCs (bottom plot) demonstrate that the majority of TP53 alterations in cfDNA are from WBCs. One TP53 splice site 
mutation detected in both datasets is not shown. H, Cumulative fraction of cfDNA fragments based on cfDNA fragment 
length (bp) shows an altered distribution for cfDNA fragments harboring tumor-derived TP53 alterations (blue) 
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Figure 3.6. Longitudinal detection of white blood cell (WBC) sequence alterations in patients with gastric cancer. A-K, Mutant allele fractions of WBC 
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Figure 3.7. Survival outcomes based on WBC variants or tumor-specific alterations in cfDNA at the baseline timepoint. A-B, Kaplan-Meier estimates for 
event-free survival [Log-rank p = 0.18; HR = 1.7 (95% CI = 0.8-3.8)] (A) and overall survival [Log-rank p = 0.46; HR = 1.4 (95% CI = 0.6-3.2)] (B) of patients 
with or without WBCs variants in cfDNA at the time of  study enrollment. C-D, Kaplan-Meier estimates for event -free survival  [Log-rank p = 0.45; HR = 1.4 
(95% CI = 0.6-3.0)] (C) and overall survival [Log-rank p = 0.55; HR = 1.3 (95% CI = 0.6-3.0)] (D) of patients  with or  without ctDNA detected at the time of 
study enrollment. 
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Figure 3.8. Dynamic changes in ctDNA during the preoperative chemotherapy interval. A-Q, ctDNA alterations in each patient were detected during the 


























































































































































































































































































Figure 3.10. Preoperative ctDNA as a biomarker for pathologic response and clinical outcome in gastric cancer. 
A-B, Levels of ctDNA variants at baseline and the preoperative timepoint in a molecular responder (CGST33) (A) and 
in a non-responder (CGST110) (B). Variant MAFs in the molecular responder show elimination of ctDNA, while 
ctDNA levels are relatively unchanged in the molecular non-responder. A representative H&E image (20X) depicting 
Mandard’s tumor regression grade is shown for each case on the right. C, Heatmap representing the pathological 
features (TRG and lymph node status) and highest mutant allele fraction detected for each of the 43 patients that 
underwent surgical resection. Lauren’s classifications are depicted in the bottom for each case. D, Dichotomized 
association between degree of tumor regression and ctDNA status at the preoperative timepoint (p = 0.03, Fisher's exact 
test), E, between degree of tumor regression and disease recurrence (p = 0.03, Fisher's exact test), F, between 
pathological lymph node status and disease recurrence (p = 0.002, Fisher's exact test), and G, between ctDNA status at 
the preoperative timepoint and disease recurrence (p = 0.02, Fisher's exact test). H-I, Kaplan-Meier estimates for event-
free survival of patients with detected versus non-detected variants at the preoperative timepoint using all cfDNA 
sequence changes (Log-rank p = 0.76; HR = 0.9; 95% CI = 0.4-2.1) (H) or using only ctDNA alterations identified 
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Figure 3.11. Pathological response at the preoperative timepoint and survival outcomes. A, Heatmap showing the Spearman’s rank correlation coefficients 
between mutant allele fractions at the preoperative timepoint and pathological features after surgery (ypN, pathological lymph node assessment; ypT, 
pathological tumor assessment; TRG, tumor regression grade). B, Kaplan-Meier estimates for event-free survival of patients with minor or no pathological 
response (TRG 3-5) and major pathological responses (TRG 1-2) to preoperative chemotherapy [Log-rank p = 0.03; HR = 3.6 (95% CI = 1.1-11.3)]. C, Kaplan-
Meier estimates for event-free survival of patients with (ypN1-3) and without (ypN0) lymph node tumor infiltration [Log-rank p = 0.002; HR = 4.5 (95% CI = 
1.8-11.6)]. 
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Figure 3.12. Detection of cfDNA and ctDNA variants at the preoperative timepoint and overall survival. A-B, Kaplan-Meier estimates for overall 
survival of patients with detected versus non-detected variants at the preoperative timepoint using all cfDNA sequence changes [Log-rank p = 0.74; HR = 0.9 
(95% CI = 0.4-2.1)] (A) or using only ctDNA alterations identified from the WBC-filtered approach [Log-rank p = 0.03; HR = 2.7 (95 % CI = 1.1-6.7)] (B).
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Figure 3.13. Assessment of ctDNA as a minimal residual disease biomarker in resectable gastric 
cancer. A-B, Levels of ctDNA variants from baseline to postoperative timepoint in a molecular responder 
(CGST32) (A) and in a non-responder (CGST68) (B). Variant MAFs in the molecular responder show 
elimination of ctDNA, while ctDNA levels continue to rise in the molecular non-responder. A 
representative H&E image (20X magnification) depicting Mandard’s tumor regression grade is shown for 
each case on the right. C, Longitudinal representation of ctDNA results from 20 patients with a 
postoperative timepoint available.  Black vertical line represents the time of surgery. Green arrows depict 
patients with no evidence of disease at last follow-up. D-E, Kaplan-Meier estimates for overall survival of 
patients with detected versus non-detected variants at the postoperative timepoint using all cfDNA 
sequence changes (Log-rank p = 0.28; HR = 3.3; 95% CI = 0.4-29) (D) or using only ctDNA alterations 
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Figure 3.14. Detection of cfDNA and ctDNA variants at the postoperative timepoint and event-free survival. A-B, Kaplan-Meier estimates for event-free 
survival of patients with detected versus non-detected variants at the postoperative timepoint using all cfDNA sequence data [Log-rank p = 0.28; HR = 3.3 
(95% CI = 0.4-29.3)] (A) or using only ctDNA alterations identified from the WBC-filtered approach [Log-rank p < 0.001; HR = 21.8 (95% CI = 3.9-123.1)] 
(B). 
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Table 3.1.  Summary of clinical characteristics of patients analyzed. 
Patient 
ID Age Gender 
Preoperative 


















CGST102 76 Female 3x ECC Distal gastrectomy 45Gy + 5w CC Intestinal ypT3 ypN0 ypM0 MSI negative IIA Negative TRG 5 0% 
CGST105 66 Female 3x ECC Distal gastrectomy 3x ECC Intestinal ypT3 ypN0 ypM0 MSI negative IIA Negative TRG 5 0% 
CGST114 65 Male 3x ECC Distal gastrectomy 3x ECC Intestinal ypT4a ypN1 ypM0 MSS negative IIIA Negative TRG 4 10-19% 
CGST121 75 Male 3x ECC Distal gastrectomy 3x ECC Intestinal ypT1b ypN0 ypM0 MSS negative IA Negative TRG 3 80-89% 
CGST122 56 Male 3x ECC Distal gastrectomy 45Gy + 5w CC Intestinal ypT1a ypN0 ypM0 MSS negative IA Negative TRG 4 20-29% 
CGST134 74 Male 3x ECC Distal gastrectomy 3x ECC Intestinal ypT3 ypN1 ypM0 MSS negative IIB Negative TRG 5 0% 
CGST143 67 Female 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT0 ypN0 ypM0 NA NA 0 Negative TRG 1 100% 
CGST148 49 Female 3x ECC Distal gastrectomy 3x ECC Diffuse ypT4a ypN2 ypMX MSS negative IIIB Positive TRG 5 1-9% 
CGST24 76 Female 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT3 ypN2 ypM0 MSS negative IIIA Positive TRG 4 30-39% 
CGST38 71 Female 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT0 ypN0 ypM0 NA negative 0 Negative TRG 1 100% 
CGST44 66 Male 3x ECC Distal gastrectomy 3x ECC Diffuse ypT3 ypN1 (mi) ypM0 MSS negative IIB Negative TRG 3 50-59% 
CGST47 74 Female 3x ECC Distal gastrectomy 3x ECC Intestinal ypT1a ypN0 ypM0 MSS negative IA Negative TRG 2 90-99% 
CGST49 30 Female 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT2 ypN1 ypM0 MSS negative IIA Negative TRG 4 40-49% 
CGST57 51 Male 3x ECC Distal gastrectomy 3x ECC Diffuse ypT1b ypN1 (mi) ypM0 MSS negative IB Negative TRG 4 10-19% 
CGST62 63 Male 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT4a ypN0 ypMX NA NA IIB Negative TRG 5 0% 
CGST67 69 Male 3x ECC Distal gastrectomy 3x ECC Intestinal ypT1b ypN0 ypM0 MSS negative IA Negative TRG 2 90-99% 
CGST68 53 Male 3x ECC Distal gastrectomy 45Gy + 5w CC Other* ypT4a ypN3a ypM1 MSS negative IV Negative TRG 5 0% 
CGST69 53 Male 3x ECC Distal gastrectomy 45Gy + 5w CC Diffuse ypT2 ypN0 ypM0 MSS negative IB Negative TRG 3 50-59% 
CGST79 45 Male 3x ECC Distal gastrectomy 3x ECC Diffuse ypT2 ypN0 ypM0 MSS negative IB Negative TRG 3 60-69% 
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CGST80 58 Male 3x ECC Distal gastrectomy 3x ECC Diffuse ypT3 ypN3a ypM0 NA NA IIIB Negative TRG 2 90-99% 
CGST91 56 Male 3x ECC Distal gastrectomy 3x ECC Intestinal ypT3 ypN2 ypM0 MSS negative IIIA Negative TRG 5 0% 
CGST113 64 Male 3x ECC Esophagocardial resection 45Gy + 5w CC Intestinal ypT3 ypN2 ypM0 MSS NA IIIA Negative TRG 5 0% 
CGST176 66 Male 3x ECC Esophagocardial resection 45Gy + 5w CC Intestinal ypT3 ypN0 ypMX NA NA IIA Negative TRG 4 10-19% 
CGST30 64 Female 3x ECC Esophagocardial resection 45Gy + 5w CC Diffuse ypT3 ypN2 ypM0 NA NA IIIA Positive TRG 4 10-19% 
CGST33 61 Male 3x ECC Esophagocardial resection 45Gy + 5w CC Intestinal ypT2 ypN0 ypM0 MSS negative IB Negative TRG 2 90-99% 
CGST28 55 Male 3x ECC Not performed 3x ECC Intestinal ypTx ypNx ypMX MSS positive X No resection No resection 
No 
resection 
CGST22 75 Male 3x ECC Exploratory laparotomy 3x ECC Intestinal ypTx ypNx ypM1 MSS negative IV No resection No resection 
No 
resection 
CGST26 51 Male 3x ECC Exploratory laparotomy 3x ECC Diffuse ypTx ypNx ypM1 MSS negative IV No resection No resection 
No 
resection 
CGST39 51 Male 3x ECC Exploratory laparotomy 3x ECC Diffuse ypTx ypNx ypM1 NA NA IV No resection No resection 
No 
resection 
CGST41 66 Female 3x ECC Exploratory laparotomy 3x ECC Diffuse ypTx ypNX ypM1 NA NA IV No resection No resection 
No 
resection 
CGST48 62 Male 3x ECC Exploratory laparotomy 45Gy + 5w CC Intestinal ypTx ypNx ypM1 MSS negative IV No resection No resection 
No 
resection 
CGST64 58 Male 3x ECC Exploratory laparotomy 45Gy + 5w CC Diffuse ypTx ypNx ypM1 NA negative IV No resection No resection 
No 
resection 
CGST158 45 Male 3x ECC Proximal gastrectomy 45Gy + 5w CC Diffuse ypT3 ypN1 ypM0 MSS negative IIB Negative TRG 4 40-49% 
CGST109 63 Male 3x ECC Total gastrectomy 45Gy + 5w CC Intestinal ypT3 ypN2 ypM0 MSS negative IIIA Negative TRG 5 0% 
CGST110 77 Male 3x ECC Total gastrectomy 3x ECC Intestinal ypT4a ypN3a ypM0 MSS NA IIIC Negative TRG 5 0% 
CGST131 63 Male 3x ECC Total gastrectomy 45Gy + 5w CC Diffuse ypT2 ypN3a ypM0 MSS negative IIIA Negative TRG 4 40-49% 
CGST133 70 Male 3x ECC Total gastrectomy 45Gy + 5w CC Intestinal ypT4b ypN1 ypM1 NA NA IV Negative TRG 5 0% 
CGST141 33 Female 3x ECC Total gastrectomy 3x ECC Diffuse ypT3 ypN2 ypM0 MSS negative IIIA Negative TRG 4 20-29% 
CGST142 33 Female 3x ECC Total gastrectomy 45Gy + 5w CC Diffuse ypT4a ypN3a ypM0 MSS negative IIIC Negative TRG 5 0% 
CGST152 65 Male 3x ECC Total gastrectomy 3x ECC Diffuse ypT4a ypN0 ypMX NA NA IIB Positive TRG 4 30-39% 
CGST25 64 Male 3x ECC Total gastrectomy 45Gy + 5w CC Intestinal ypT3 ypN1 (mi) ypM0 MSS negative IIB Negative TRG 3 70-79% 
CGST31 64 Male 3x ECC Total gastrectomy 45Gy + 5w CC Intestinal ypT0 ypN0 ypM0 MSS negative 0 Negative TRG 1 100% 
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CGST32 67 Male 3x ECC Total gastrectomy 3x ECC Intestinal ypT3 ypN1 ypM0 MSS negative IIB Negative TRG 3 60-69% 
CGST45 41 Female 3x ECC Total gastrectomy 45Gy + 5w CC Diffuse ypT3 ypN0 ypM0 MSS negative IIA Negative TRG 5 0% 
CGST58 58 Male 3x ECC Total gastrectomy 45Gy + 5w CC Diffuse ypT4a ypN3b ypM0 MSS negative IIIC Negative TRG 5 10-19% 
CGST63 50 Male 3x ECC Total gastrectomy 3x ECC Intestinal ypT3 ypN0 ypM0 MSS positive IIA Negative TRG 5 0% 
CGST65 73 Male 3x ECC Total gastrectomy 45Gy + 5w CC Intestinal ypT3 ypN0 ypM0 MSS negative IIA Negative TRG 5 0% 
CGST71 53 Male 3x ECC Total gastrectomy 3x ECC Intestinal ypT3 ypN1 ypM0 MSS negative IIB Positive TRG 5 0% 
CGST81 64 Female 3x ECC Total gastrectomy 45Gy + 5w CC Diffuse ypT2 ypN0 ypMX MSS negative IB Negative TRG 3 60-69% 
CGST97 65 Male 3x ECC Total gastrectomy 3x ECC Diffuse ypT2 ypN0 ypM0 MSS positive IB Negative TRG 3 70-79% 





Table 3.2.  Summary of serial timepoints analyzed. 
Patient ID Patient Timepoint Significance of Timepoint Sample Type Sample Volume (ml) cfDNA Extracted (ng) cfDNA Input (ng) 
CGST102 CGST102P Baseline Plasma 4.1 32.9 32.92 
CGST102 CGST102N Baseline Buffy Coat 0.1 1351.6 75.00 
CGST102 CGST102P2 Postoperative Plasma 4.1 19.9 19.95 
CGST102 CGST102P1 Preoperative Plasma 3.9 29.3 29.33 
CGST105 CGST105P Baseline Plasma 4.0 68.7 68.73 
CGST105 CGST105N Baseline Buffy Coat 0.1 1324.8 75.00 
CGST105 CGST105P1 Preoperative Plasma 4.0 151.1 125.00 
CGST109 CGST109P Baseline Plasma 4.0 98.5 98.49 
CGST109 CGST109N Baseline Buffy Coat 0.1 2194.4 75.00 
CGST109 CGST109P2 Postoperative Plasma 3.7 246.3 125.00 
CGST109 CGST109P1 Preoperative Plasma 4.0 196.2 125.00 
CGST110 CGST110P Baseline Plasma 3.8 19.0 19.01 
CGST110 CGST110N Baseline Buffy Coat 0.1 915.6 75.00 
CGST110 CGST110P1 Preoperative Plasma 4.4 89.9 89.92 
CGST113 CGST113P Baseline Plasma 3.5 41.3 41.29 
CGST113 CGST113N Baseline Buffy Coat 0.1 891.0 75.00 
CGST113 CGST113P2 Postoperative Plasma 2.9 31.8 31.84 
CGST113 CGST113P1 Preoperative Plasma 3.8 82.5 82.55 
CGST114 CGST114P Baseline Plasma 4.4 45.5 45.54 
CGST114 CGST114N Baseline Buffy Coat 0.1 1947.0 75.00 
CGST114 CGST114P1 Preoperative Plasma 4.5 118.4 118.40 
CGST121 CGST121P Baseline Plasma 3.8 22.8 22.83 
CGST121 CGST121N Baseline Buffy Coat 0.1 983.7 75.00 
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CGST121 CGST121P1 Preoperative Plasma 3.6 39.6 39.56 
CGST122 CGST122P Baseline Plasma 3.5 59.2 59.15 
CGST122 CGST122N Baseline Buffy Coat 0.1 704.2 75.00 
CGST122 CGST122P1 Preoperative Plasma 3.5 128.4 125.00 
CGST131 CGST131P Baseline Plasma 4.0 17.1 17.13 
CGST131 CGST131N Baseline Buffy Coat 0.1 2484.0 75.00 
CGST131 CGST131P1 Preoperative Plasma 4.4 131.2 125.00 
CGST133 CGST133P Baseline Plasma 4.5 182.2 125.00 
CGST133 CGST133N Baseline Buffy Coat 0.1 891.5 75.00 
CGST133 CGST133P1 Preoperative Plasma 4.5 43.7 43.65 
CGST134 CGST134P Baseline Plasma 4.5 46.1 46.12 
CGST134 CGST134N Baseline Buffy Coat 0.1 1056.8 75.00 
CGST134 CGST134P2 Postoperative Plasma 4.7 229.8 125.00 
CGST134 CGST134P1 Preoperative Plasma 4.0 32.6 32.63 
CGST141 CGST141P Baseline Plasma 4.4 47.7 47.67 
CGST141 CGST141N Baseline Buffy Coat 0.1 700.0 75.00 
CGST141 CGST141P1 Preoperative Plasma 4.4 69.9 69.94 
CGST142 CGST142P Baseline Plasma 4.0 10.2 10.19 
CGST142 CGST142N Baseline Buffy Coat 0.1 942.5 75.00 
CGST142 CGST142P1 Preoperative Plasma 4.5 42.7 42.74 
CGST143 CGST143P Baseline Plasma 4.4 21.6 21.64 
CGST143 CGST143N Baseline Buffy Coat 0.1 946.8 75.00 
CGST143 CGST143P1 Preoperative Plasma 4.2 47.7 47.65 
CGST148 CGST148P Baseline Plasma 2.5 9.9 9.86 
CGST148 CGST148N Baseline Buffy Coat 0.1 1190.4 75.00 
CGST148 CGST148P2 Postoperative Plasma 4.1 45.1 45.15 
CGST148 CGST148P1 Preoperative Plasma 2.0 21.4 21.42 
CGST152 CGST152P Baseline Plasma 3.0 59.6 59.64 
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CGST152 CGST152N Baseline Buffy Coat 0.1 1091.2 75.00 
CGST152 CGST152P1 Preoperative Plasma 3.8 257.2 125.00 
CGST158 CGST158P Baseline Plasma 4.0 89.5 89.48 
CGST158 CGST158N Baseline Buffy Coat 0.1 1036.8 75.00 
CGST158 CGST158P1 Preoperative Plasma 4.5 49.6 49.62 
CGST176 CGST176P Baseline Plasma 3.0 40.3 40.26 
CGST176 CGST176N Baseline Buffy Coat 0.1 543.7 75.00 
CGST176 CGST176P1 Preoperative Plasma 3.4 45.2 45.19 
CGST22 CGST22P Baseline Plasma 2.5 31.3 31.33 
CGST22 CGST22N Baseline Buffy Coat 0.1 877.2 75.00 
CGST22 CGST22P1 Preoperative Plasma 2.5 31.3 31.33 
CGST24 CGST24P Baseline Plasma 4.0 119.9 119.93 
CGST24 CGST24N Baseline Buffy Coat 0.1 1258.0 75.00 
CGST24 CGST24P2 Postoperative Plasma 4.0 144.9 125.00 
CGST24 CGST24P1 Preoperative Plasma 3.8 194.9 125.00 
CGST25 CGST25P Baseline Plasma 3.0 14.0 14.04 
CGST25 CGST25N Baseline Buffy Coat 0.1 734.7 75.00 
CGST25 CGST25P2 Postoperative Plasma 4.1 138.7 125.00 
CGST25 CGST25P1 Preoperative Plasma 3.9 40.4 40.42 
CGST26 CGST26P Baseline Plasma 3.5 19.5 19.46 
CGST26 CGST26N Baseline Buffy Coat 0.1 995.7 75.00 
CGST26 CGST26P1 Preoperative Plasma 2.5 46.0 45.96 
CGST28 CGST28P Baseline Plasma 4.0 23.5 23.45 
CGST28 CGST28N Baseline Buffy Coat 0.1 1900.0 75.00 
CGST28 CGST28P1 Preoperative Plasma 4.0 33.6 33.62 
CGST30 CGST30P Baseline Plasma 3.0 12.7 12.66 
CGST30 CGST30N Baseline Buffy Coat 0.1 1254.4 75.00 
CGST30 CGST30P1 Preoperative Plasma 3.5 72.7 72.65 
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CGST31 CGST31P Baseline Plasma 4.0 103.0 102.99 
CGST31 CGST31N Baseline Buffy Coat 0.1 1831.8 75.00 
CGST31 CGST31P2 Postoperative Plasma 4.0 57.5 57.46 
CGST31 CGST31P1 Preoperative Plasma 3.5 28.4 28.45 
CGST32 CGST32P Baseline Plasma 4.0 46.0 45.96 
CGST32 CGST32N Baseline Buffy Coat 0.1 2219.6 75.00 
CGST32 CGST32P2 Postoperative Plasma 4.0 17.3 17.26 
CGST32 CGST32P1 Preoperative Plasma 3.5 147.8 125.00 
CGST33 CGST33P Baseline Plasma 3.5 20.0 19.98 
CGST33 CGST33N Baseline Buffy Coat 0.1 1776.0 75.00 
CGST33 CGST33P1 Preoperative Plasma 4.0 34.8 34.84 
CGST38 CGST38P Baseline Plasma 4.0 46.0 45.96 
CGST38 CGST38N Baseline Buffy Coat 0.1 837.4 75.00 
CGST38 CGST38P2 Postoperative Plasma 4.0 49.6 49.63 
CGST38 CGST38P1 Preoperative Plasma 4.5 17.0 16.95 
CGST39 CGST39P Baseline Plasma 3.5 72.4 72.42 
CGST39 CGST39N Baseline Buffy Coat 0.1 1064.0 75.00 
CGST39 CGST39P1 Preoperative Plasma 4.5 28.3 28.35 
CGST41 CGST41P Baseline Plasma 3.5 27.4 27.42 
CGST41 CGST41N Baseline Buffy Coat 0.1 864.0 75.00 
CGST41 CGST41P1 Preoperative Plasma 4.0 46.4 46.35 
CGST44 CGST44P Baseline Plasma 3.5 76.0 76.01 
CGST44 CGST44N Baseline Buffy Coat 0.1 693.6 75.00 
CGST44 CGST44P2 Postoperative Plasma 3.2 75.8 75.76 
CGST44 CGST44P1 Preoperative Plasma 5.0 124.7 124.71 
CGST45 CGST45P Baseline Plasma 3.8 27.1 27.15 
CGST45 CGST45N Baseline Buffy Coat 0.1 1159.2 75.00 
CGST45 CGST45P2 Postoperative Plasma 4.5 43.9 43.90 
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CGST45 CGST45P1 Preoperative Plasma 3.5 30.9 30.91 
CGST47 CGST47P Baseline Plasma 4.0 18.2 18.22 
CGST47 CGST47N Baseline Buffy Coat 0.1 652.1 75.00 
CGST47 CGST47P2 Postoperative Plasma 3.8 65.8 65.76 
CGST47 CGST47P1 Preoperative Plasma 3.5 26.1 26.06 
CGST48 CGST48P Baseline Plasma 4.5 39.5 39.54 
CGST48 CGST48N Baseline Buffy Coat 0.1 924.0 75.00 
CGST48 CGST48P1 Preoperative Plasma 3.8 111.4 111.39 
CGST49 CGST49P Baseline Plasma 4.0 53.8 53.81 
CGST49 CGST49N Baseline Buffy Coat 0.1 2189.0 75.00 
CGST49 CGST49P2 Postoperative Plasma 4.5 17.8 17.80 
CGST49 CGST49P1 Preoperative Plasma 4.0 23.8 23.83 
CGST57 CGST57P Baseline Plasma 4.0 30.0 30.05 
CGST57 CGST57N Baseline Buffy Coat 0.1 703.1 75.00 
CGST57 CGST57P2 Postoperative Plasma 4.5 44.2 44.15 
CGST57 CGST57P1 Preoperative Plasma 4.5 82.5 82.46 
CGST58 CGST58P Baseline Plasma 3.8 75.3 75.29 
CGST58 CGST58N Baseline Buffy Coat 0.1 1688.4 75.00 
CGST58 CGST58P1 Preoperative Plasma 4.0 179.2 125.00 
CGST62 CGST62P Baseline Plasma 3.7 41.4 41.43 
CGST62 CGST62N Baseline Buffy Coat 0.1 482.2 75.00 
CGST62 CGST62P1 Preoperative Plasma 4.0 45.0 44.98 
CGST63 CGST63P Baseline Plasma 4.0 32.3 32.31 
CGST63 CGST63N Baseline Buffy Coat 0.1 1242.0 75.00 
CGST63 CGST63P2 Postoperative Plasma 4.1 413.6 125.00 
CGST63 CGST63P1 Preoperative Plasma 3.8 230.3 125.00 
CGST64 CGST64P Baseline Plasma 3.0 29.0 29.02 
CGST64 CGST64N Baseline Buffy Coat 0.1 746.8 75.00 
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CGST64 CGST64P1 Preoperative Plasma 4.5 43.7 43.67 
CGST65 CGST65P Baseline Plasma 4.5 283.1 125.00 
CGST65 CGST65N Baseline Buffy Coat 0.1 1421.4 75.00 
CGST65 CGST65P1 Preoperative Plasma 4.0 136.7 125.00 
CGST67 CGST67P Baseline Plasma 3.0 69.0 69.02 
CGST67 CGST67N Baseline Buffy Coat 0.1 1460.0 75.00 
CGST67 CGST67P2 Postoperative Plasma 4.5 479.9 125.00 
CGST67 CGST67P1 Preoperative Plasma 4.5 245.0 125.00 
CGST68 CGST68P Baseline Plasma 3.5 169.2 125.00 
CGST68 CGST68N Baseline Buffy Coat 0.1 2714.0 75.00 
CGST68 CGST68P2 Postoperative Plasma 4.5 39.9 39.94 
CGST68 CGST68P1 Preoperative Plasma 4.5 8.4 8.38 
CGST69 CGST69P Baseline Plasma 4.0 20.4 20.35 
CGST69 CGST69N Baseline Buffy Coat 0.1 1402.2 75.00 
CGST69 CGST69P2 Postoperative Plasma 4.5 21.0 20.97 
CGST69 CGST69P1 Preoperative Plasma 4.5 64.0 64.00 
CGST71 CGST71P Baseline Plasma 4.0 43.4 43.43 
CGST71 CGST71N Baseline Buffy Coat 0.1 1531.2 75.00 
CGST71 CGST71P1 Preoperative Plasma 4.5 35.9 35.94 
CGST79 CGST79P Baseline Plasma 4.5 20.2 20.16 
CGST79 CGST79P1 Preoperative Plasma 4.2 55.9 55.86 
CGST80 CGST80P Baseline Plasma 4.5 38.5 38.51 
CGST80 CGST80N Baseline Buffy Coat 0.1 1078.8 75.00 
CGST80 CGST80P1 Preoperative Plasma 4.3 46.0 45.96 
CGST81 CGST81P Baseline Plasma 3.5 130.6 125.00 
CGST81 CGST81N Baseline Buffy Coat 0.1 1918.4 75.00 
CGST81 CGST81P1 Preoperative Plasma 2.5 307.5 125.00 
CGST91 CGST91P Baseline Plasma 4.0 147.8 125.00 
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CGST91 CGST91N Baseline Buffy Coat 0.1 555.3 75.00 
CGST91 CGST91P1 Preoperative Plasma 4.0 348.8 125.00 
CGST97 CGST97P Baseline Plasma 4.4 76.8 76.75 
CGST97 CGST97N Baseline Buffy Coat 0.1 1895.4 75.00 
CGST97 CGST97P2 Postoperative Plasma 3.0 35.3 35.28 




Table 3.3.  Summary of genes analyzed. 
Gene Region Analyzed Gene Category 
ABL1 Specific Exons Cancer Driver Gene 
AKT1 Specific Exons Cancer Driver Gene 
ALK Full Coding Region Cancer Driver Gene 
APC Specific Exons Cancer Driver Gene 
AR Full Coding Region Cancer Driver Gene 
ATM Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
BRAF Full Coding Region Cancer Driver Gene 
CDH1 Specific Exons Cancer Driver Gene 
CDK4 Full Coding Region Cancer Driver Gene 
CDK6 Full Coding Region Cancer Driver Gene 
CDKN2A Specific Exons Cancer Driver Gene 
CSF1R Specific Exons Cancer Driver Gene 
CTNNB1 Specific Exons Cancer Driver Gene 
DNMT3A Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
EGFR Full Coding Region Cancer Driver Gene 
ERBB2 Specific Exons Cancer Driver Gene 
ERBB4 Full Coding Region Cancer Driver Gene 
ESR1 Full Coding Region Cancer Driver Gene 
EZH2 Specific Exons Cancer Driver Gene 
FBXW7 Specific Exons Cancer Driver Gene 
FGFR1 Specific Exons Cancer Driver Gene 
FGFR2 Specific Exons Cancer Driver Gene 
FGFR3 Specific Exons Cancer Driver Gene 
FLT3 Specific Exons Cancer Driver Gene 
GNA11 Specific Exons Cancer Driver Gene 
GNAQ Specific Exons Cancer Driver Gene 
GNAS Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
HNF1A Specific Exons Cancer Driver Gene 
HRAS Full Coding Region Cancer Driver Gene 
IDH1 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
IDH2 Specific Exons Cancer Driver and Clonal Hematopoiesis Gene 
JAK2 Full Coding Region Cancer Driver and Clonal Hematopoiesis Gene 
JAK3 Specific Exons Cancer Driver Gene 
KDR Specific Exons Cancer Driver Gene 
KIT Full Coding Region Cancer Driver Gene 
KRAS Full Coding Region Cancer Driver Gene 
MAP2K1 Specific Exons Cancer Driver Gene 
MET Specific Exons Cancer Driver Gene 
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MLH1 Specific Exons Cancer Driver Gene 
MPL Specific Exons Cancer Driver Gene 
MYC Specific Exons Cancer Driver Gene 
NPM1 Specific Exons Cancer Driver Gene 
NRAS Full Coding Region Cancer Driver Gene 
PDGFRA Full Coding Region Cancer Driver Gene 
PIK3CA Full Coding Region Cancer Driver Gene 
PIK3R1 Specific Exons Cancer Driver Gene 
PTEN Full Coding Region Cancer Driver Gene 
PTPN11 Specific Exons Cancer Driver Gene 
RB1 Specific Exons Cancer Driver Gene 
RET Specific Exons Cancer Driver Gene 
SMAD4 Specific Exons Cancer Driver Gene 
SMARCB1 Specific Exons Cancer Driver Gene 
SMO Specific Exons Cancer Driver Gene 
SRC Specific Exons Cancer Driver Gene 
STK11 Full Coding Region Cancer Driver Gene 
TERT Specific Exons Cancer Driver Gene 
TP53 Full Coding Region Cancer Driver Gene 
VHL Specific Exons Cancer Driver Gene 
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Table 3.4.  Summary of genomic analyses of plasma samples. 









Bases Mapped to 
Target Regions 
Percent Mapped to 
Target Regions 
Total Coverage of 
Target Regions 
Distinct Coverage 
of Target Regions 
CGST102 CGST102P TEC-Seq 100 5,715,504,500 80930 2,644,902,854 46% 31,309 4,503 
CGST102 CGST102P1 TEC-Seq 100 5,998,109,300 80930 2,987,328,937 50% 35,356 4,709 
CGST102 CGST102P2 TEC-Seq 100 6,793,240,800 80930 3,123,029,034 46% 37,211 4,632 
CGST105 CGST105P TEC-Seq 100 5,860,142,600 80930 2,920,684,685 50% 34,346 6,943 
CGST105 CGST105P1 TEC-Seq 100 5,904,082,100 80930 3,055,802,485 52% 35,916 6,585 
CGST109 CGST109P TEC-Seq 100 6,295,967,400 80930 3,248,425,068 52% 38,199 7,053 
CGST109 CGST109P1 TEC-Seq 100 6,013,317,300 80930 2,815,835,970 47% 33,100 9,321 
CGST109 CGST109P2 TEC-Seq 100 6,619,965,600 80930 2,951,306,546 45% 35,132 9,595 
CGST110 CGST110P TEC-Seq 100 9,179,291,500 80,930 4,298,269,268 47% 51,666 3,873 
CGST110 CGST110P1 TEC-Seq 100 8,406,412,800 80,930 4,142,725,047 49% 49,829 7,358 
CGST113 CGST113P TEC-Seq 100 7,800,665,800 80930 1,225,827,874 16% 14,534 2,850 
CGST113 CGST113P1 TEC-Seq 100 3,847,385,800 80930 1,796,935,810 47% 20,617 4,527 
CGST113 CGST113P2 TEC-Seq 100 6,489,592,600 80930 2,839,487,561 44% 33,777 4,334 
CGST114 CGST114P TEC-Seq 100 7,151,572,200 80,930 3,254,967,293 46% 38,496 4,839 
CGST114 CGST114P1 TEC-Seq 100 7,470,020,200 80,930 3,979,321,082 53% 47,176 8,923 
CGST121 CGST121P TEC-Seq 100 5,017,934,500 80,930 2,207,136,971 44% 26,020 5,472 
CGST121 CGST121P1 TEC-Seq 100 5,941,381,100 80,930 2,349,841,475 40% 27,709 5,746 
CGST122 CGST122P TEC-Seq 100 5,928,880,500 80,930 2,281,502,089 38% 26,935 8,859 
CGST122 CGST122P1 TEC-Seq 100 5,955,730,600 80,930 2,488,111,598 42% 29,306 11,127 
CGST131 CGST131P TEC-Seq 100 6,040,318,900 80,930 2,670,580,911 44% 31,516 4,859 
CGST131 CGST131P1 TEC-Seq 100 6,894,739,500 80,930 3,634,605,240 53% 43,086 8,516 
CGST133 CGST133P TEC-Seq 100 4,519,145,400 80930 1,569,298,193 35% 18,034 4,361 
CGST133 CGST133P1 TEC-Seq 100 3,778,347,400 80930 1,740,693,788 46% 19,974 7,148 
CGST134 CGST134P TEC-Seq 100 4,762,925,800 80930 2,182,666,734 46% 25,777 6,351 
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CGST134 CGST134P1 TEC-Seq 100 6,909,633,600 80930 1,625,372,101 24% 19,223 9,958 
CGST134 CGST134P2 TEC-Seq 100 5,926,486,300 80930 2,833,507,638 48% 33,929 7,896 
CGST141 CGST141P TEC-Seq 100 6,781,001,300 80930 3,440,927,391 51% 40,762 5,404 
CGST141 CGST141P1 TEC-Seq 100 6,712,701,900 80930 3,385,290,681 50% 40,037 7,747 
CGST142 CGST142P TEC-Seq 100 7,361,933,400 80930 3,522,503,790 48% 40,655 5,564 
CGST142 CGST142P1 TEC-Seq 100 3,901,705,000 80930 1,635,312,539 42% 18,877 3,406 
CGST143 CGST143P TEC-Seq 100 6,554,500,600 80,930 1,484,918,070 23% 17,583 2,495 
CGST143 CGST143P1 TEC-Seq 100 6,315,804,700 80,930 2,921,644,628 46% 34,571 4,683 
CGST148 CGST148P TEC-Seq 100 3,846,279,100 80930 1,452,859,818 38% 16,792 2,005 
CGST148 CGST148P1 TEC-Seq 100 4,137,104,400 80930 1,722,641,701 42% 19,861 1,866 
CGST148 CGST148P2 TEC-Seq 100 8,115,750,600 80930 3,180,887,811 39% 38,458 6,766 
CGST152 CGST152P TEC-Seq 100 3,353,885,300 80930 1,526,513,135 46% 17,631 3,667 
CGST152 CGST152P1 TEC-Seq 100 6,154,888,700 80930 2,411,352,498 39% 27,781 8,626 
CGST158 CGST158P TEC-Seq 100 5,147,112,700 80,930 2,295,516,038 45% 27,138 5,233 
CGST158 CGST158P1 TEC-Seq 100 6,006,041,400 80,930 1,552,248,828 26% 15,109 4,181 
CGST176 CGST176P TEC-Seq 100 5,277,972,500 80930 2,287,430,177 43% 26,266 8,093 
CGST176 CGST176P1 TEC-Seq 100 4,649,933,000 80930 1,736,286,998 37% 19,916 5,790 
CGST22 CGST22P TEC-Seq 100 5,887,803,000 80930 2,449,271,468 42% 28,702 3,601 
CGST22 CGST22P1 TEC-Seq 100 3,809,398,300 80930 1,305,798,697 34% 15,073 3,839 
CGST24 CGST24P TEC-Seq 100 9,043,109,900 80930 4,151,550,042 46% 50,067 10,317 
CGST24 CGST24P1 TEC-Seq 100 6,571,692,600 80930 2,841,136,771 43% 34,030 3,327 
CGST24 CGST24P2 TEC-Seq 100 4,263,908,500 80930 2,198,635,683 52% 25,136 7,992 
CGST25 CGST25P TEC-Seq 100 6,914,308,700 80930 3,008,397,120 44% 35,837 4,451 
CGST25 CGST25P1 TEC-Seq 100 5,138,989,000 80930 2,212,593,275 43% 26,099 8,343 
CGST25 CGST25P2 TEC-Seq 100 6,583,579,300 80930 2,964,750,497 45% 35,208 9,462 
CGST26 CGST26P TEC-Seq 100 5,197,445,200 80930 2,241,760,526 43% 26,834 2,764 
CGST26 CGST26P1 TEC-Seq 100 5,026,542,800 80930 1,342,021,803 27% 15,184 2,278 
CGST28 CGST28P TEC-Seq 100 6,288,486,100 80930 2,884,997,993 46% 34,538 2,586 
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CGST28 CGST28P1 TEC-Seq 100 6,937,938,400 80930 1,635,435,940 24% 19,404 1,561 
CGST30 CGST30P TEC-Seq 100 6,141,213,100 80930 3,109,994,564 51% 37,194 2,555 
CGST30 CGST30P1 TEC-Seq 100 4,309,015,500 80930 1,981,934,757 46% 22,849 4,840 
CGST31 CGST31P TEC-Seq 100 5,630,437,800 80,930 2,042,169,995 36% 24,282 1,220 
CGST31 CGST31P1 TEC-Seq 100 6,716,001,300 80,930 3,196,877,907 48% 37,990 8,384 
CGST31 CGST31P2 TEC-Seq 100 7,178,183,100 80,930 3,672,017,873 51% 43,634 7,429 
CGST32 CGST32P TEC-Seq 100 6,969,139,300 80,930 3,099,120,469 44% 36,726 3,935 
CGST32 CGST32P1 TEC-Seq 100 6,739,502,000 80,930 3,545,231,854 53% 42,170 9,073 
CGST32 CGST32P2 TEC-Seq 100 6,114,722,100 80,930 1,310,653,630 21% 15,542 2,413 
CGST33 CGST33P TEC-Seq 100 6,560,309,400 80,930 3,168,371,917 48% 37,916 4,597 
CGST33 CGST33P1 TEC-Seq 100 6,109,550,400 80,930 2,383,268,213 39% 27,743 6,622 
CGST38 CGST38P TEC-Seq 100 6,914,087,800 80930 3,364,615,563 49% 39,918 2,669 
CGST38 CGST38P1 TEC-Seq 100 6,792,524,700 80930 3,453,432,793 51% 41,040 3,184 
CGST38 CGST38P2 TEC-Seq 100 7,077,217,200 80930 3,690,973,158 52% 43,827 4,771 
CGST39 CGST39P TEC-Seq 100 7,043,791,400 80930 2,992,801,875 42% 35,620 6,737 
CGST39 CGST39P1 TEC-Seq 100 7,190,291,400 80930 3,676,474,263 51% 43,674 4,221 
CGST41 CGST41P TEC-Seq 100 6,975,053,100 80,930 3,224,065,662 46% 38,300 4,016 
CGST41 CGST41P1 TEC-Seq 100 5,053,505,000 80,930 2,630,170,488 52% 31,538 4,523 
CGST44 CGST44P TEC-Seq 100 6,617,597,800 80930 2,819,442,093 43% 33,500 5,086 
CGST44 CGST44P1 TEC-Seq 100 6,599,597,300 80930 1,996,464,970 30% 23,365 10,484 
CGST44 CGST44P2 TEC-Seq 100 6,559,486,700 80930 1,882,852,044 29% 22,374 6,462 
CGST45 CGST45P TEC-Seq 100 6,130,812,200 80,930 2,944,524,278 48% 35,264 4,745 
CGST45 CGST45P1 TEC-Seq 100 5,141,669,800 80,930 2,517,511,584 49% 30,257 4,063 
CGST45 CGST45P2 TEC-Seq 100 5,058,317,000 80,930 2,836,133,105 56% 34,129 3,173 
CGST47 CGST47P TEC-Seq 100 5,961,400,000 80,930 3,083,523,351 52% 37,008 3,112 
CGST47 CGST47P1 TEC-Seq 100 5,512,507,200 80,930 2,739,158,303 50% 32,912 3,827 
CGST47 CGST47P2 TEC-Seq 100 3,767,665,100 80,930 1,661,884,444 44% 19,699 4,936 
CGST48 CGST48P TEC-Seq 100 6,418,652,700 80,930 1,497,230,327 23% 17,782 2,410 
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CGST48 CGST48P1 TEC-Seq 100 6,383,392,100 80,930 3,459,431,552 54% 41,093 9,184 
CGST49 CGST49P TEC-Seq 100 5,472,227,600 80,930 2,370,408,567 43% 28,332 2,383 
CGST49 CGST49P1 TEC-Seq 100 5,908,475,400 80,930 3,032,025,653 51% 36,455 3,802 
CGST49 CGST49P2 TEC-Seq 100 5,659,634,300 80,930 1,822,487,750 32% 21,945 3,037 
CGST57 CGST57P TEC-Seq 100 4,348,848,500 80,930 2,146,269,880 49% 25,722 2,261 
CGST57 CGST57P1 TEC-Seq 100 5,885,101,900 80,930 1,555,343,429 26% 18,522 2,964 
CGST57 CGST57P2 TEC-Seq 100 6,246,025,500 80,930 1,758,717,326 28% 21,153 3,139 
CGST58 CGST58P TEC-Seq 100 5,818,344,500 80,930 1,274,708,429 22% 15,281 2,924 
CGST58 CGST58P1 TEC-Seq 100 6,317,592,400 80,930 3,085,307,789 49% 35,909 13,524 
CGST62 CGST62P TEC-Seq 100 5,893,688,000 80930 2,468,833,173 42% 29,637 4,878 
CGST62 CGST62P1 TEC-Seq 100 5,532,879,600 80930 2,459,461,654 44% 28,276 6,522 
CGST63 CGST63P TEC-Seq 100 9,691,297,400 80930 4,263,233,224 44% 51,805 4,578 
CGST63 CGST63P1 TEC-Seq 100 4,267,392,400 80930 1,358,856,933 32% 15,787 6,039 
CGST63 CGST63P2 TEC-Seq 100 7,800,940,600 80930 3,694,883,659 47% 44,200 13,580 
CGST64 CGST64P TEC-Seq 100 1,039,325,300 80930 491,124,993 47% 5,805 569 
CGST64 CGST64P1 TEC-Seq 100 4,481,165,500 80930 1,873,316,247 42% 22,100 6,413 
CGST65 CGST65P TEC-Seq 100 6,623,122,300 80,930 3,354,942,634 51% 40,340 8,129 
CGST65 CGST65P1 TEC-Seq 100 5,461,226,100 80,930 2,183,094,789 40% 25,833 11,395 
CGST67 CGST67P TEC-Seq 100 5,268,060,800 80930 2,636,276,768 50% 31,722 3,769 
CGST67 CGST67P1 TEC-Seq 100 6,612,674,300 80930 3,000,041,572 45% 35,719 6,228 
CGST67 CGST67P2 TEC-Seq 100 6,525,344,900 80930 1,547,996,128 24% 18,443 4,647 
CGST68 CGST68P TEC-Seq 100 7,460,521,500 80,930 2,483,281,621 33% 29,734 5,351 
CGST68 CGST68P1 TEC-Seq 100 7,539,795,800 80,930 3,745,488,233 50% 44,815 3,096 
CGST68 CGST68P2 TEC-Seq 100 8,234,458,000 80,930 4,134,050,485 50% 49,372 7,134 
CGST69 CGST69P TEC-Seq 100 7,181,374,600 80,930 1,659,017,269 23% 19,729 2,859 
CGST69 CGST69P1 TEC-Seq 100 7,692,923,500 80,930 3,149,678,548 41% 37,595 7,021 
CGST69 CGST69P2 TEC-Seq 100 7,695,301,500 80,930 3,738,347,074 49% 43,959 6,196 
CGST71 CGST71P TEC-Seq 100 6,920,751,100 80930 2,676,513,996 39% 31,859 3,982 
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CGST71 CGST71P1 TEC-Seq 100 4,806,898,600 80930 2,010,702,082 42% 23,755 6,087 
CGST79 CGST79P TEC-Seq 100 5,751,410,700 80,930 2,857,360,446 50% 34,355 4,059 
CGST79 CGST79P1 TEC-Seq 100 4,608,100,300 80930 2,351,565,191 51% 27,744 9,023 
CGST80 CGST80P TEC-Seq 100 6,368,064,600 80930 3,298,497,188 52% 39,692 5,280 
CGST80 CGST80P1 TEC-Seq 100 4,644,341,200 80930 1,924,333,584 41% 22,613 547 
CGST81 CGST81P TEC-Seq 100 8,655,691,400 80930 1,519,121,452 18% 17,988 6,419 
CGST81 CGST81P1 TEC-Seq 100 6,299,242,900 80930 2,904,512,762 46% 34,274 10,293 
CGST91 CGST91P TEC-Seq 100 5,792,398,700 80930 2,326,866,089 40% 26,358 5,654 
CGST91 CGST91P1 TEC-Seq 100 5,274,928,600 80930 2,005,984,185 38% 22,722 8,176 
CGST97 CGST97P TEC-Seq 100 596,719,000 80,930 297,518,719 50% 3,524 894 
CGST97 CGST97P1 TEC-Seq 100 7,564,129,200 80,930 2,350,459,556 31% 27,883 5,481 




Table 3.5.  Summary of genomic analyses of white blood cell samples. 
Patient ID Patient Timepoint Analysis Type 
Read 
Length 
Bases Mapped to 
Genome 
Bases in Target 
Region 
Bases Mapped to 
Target Regions 
Percent Mapped to 
Target Regions 
Total Coverage of 
Target Regions 
Distinct Coverage 
of Target Regions 
CGST102 CGST102N Targeted NGS 100 6,195,634,700 80,930 2,863,951,939 46% 34,359 5,536 
CGST105 CGST105N Targeted NGS 100 6,284,700,700 80,930 2,925,783,638 47% 34,939 5,403 
CGST109 CGST109N Targeted NGS 100 7,820,998,800 80,930 3,840,198,215 49% 45,909 7,261 
CGST110 CGST110N Targeted NGS 100 7,235,895,300 80,930 3,176,811,726 44% 37,828 6,013 
CGST113 CGST113N Targeted NGS 100 6,730,493,500 80,930 3,049,171,631 45% 36,327 5,595 
CGST114 CGST114N Targeted NGS 100 7,389,659,000 80,930 3,550,259,484 48% 42,347 5,852 
CGST121 CGST121N Targeted NGS 100 7,294,075,400 80,930 3,595,800,814 49% 42,878 5,256 
CGST122 CGST122N Targeted NGS 100 7,218,344,200 80,930 3,191,080,807 44% 38,087 4,115 
CGST131 CGST131N Targeted NGS 100 6,391,134,300 80,930 2,637,110,909 41% 31,673 5,115 
CGST133 CGST133N Targeted NGS 100 7,516,524,800 80,930 3,478,702,025 46% 41,402 5,710 
CGST134 CGST134N Targeted NGS 100 6,970,616,400 80,930 3,161,421,788 45% 37,556 5,589 
CGST141 CGST141N Targeted NGS 100 6,806,738,800 80,930 2,903,065,706 43% 34,532 4,966 
CGST142 CGST142N Targeted NGS 100 7,802,988,500 80,930 3,473,339,304 45% 41,413 5,131 
CGST143 CGST143N Targeted NGS 100 7,214,764,900 80,930 2,840,601,982 39% 33,713 4,597 
CGST148 CGST148N Targeted NGS 100 6,381,761,000 80,930 3,012,876,406 47% 35,988 5,380 
CGST152 CGST152N Targeted NGS 100 7,536,990,700 80,930 3,346,738,961 44% 40,271 5,850 
CGST158 CGST158N Targeted NGS 100 6,575,033,600 80,930 2,941,340,317 45% 34,952 6,131 
CGST176 CGST176N Targeted NGS 100 7,408,525,500 80,930 3,568,504,771 48% 42,451 5,899 
CGST22 CGST22N Targeted NGS 100 7,017,843,200 80,930 3,046,997,907 43% 36,555 5,758 
CGST24 CGST24N Targeted NGS 100 6,031,439,500 80,930 2,600,962,106 43% 31,116 4,629 
CGST25 CGST25N Targeted NGS 100 7,628,153,000 80,930 2,867,232,470 38% 34,509 5,252 
CGST26 CGST26N Targeted NGS 100 6,848,908,800 80,930 3,010,566,003 44% 35,769 5,851 
CGST28 CGST28N Targeted NGS 100 7,088,090,300 80,930 1,860,318,810 26% 22,093 4,936 
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CGST30 CGST30N Targeted NGS 100 6,443,455,500 80,930 2,408,385,115 37% 28,497 5,139 
CGST31 CGST31N Targeted NGS 100 7,391,554,100 80,930 1,995,510,669 27% 23,806 4,907 
CGST32 CGST32N Targeted NGS 100 6,602,195,900 80,930 3,047,662,118 46% 36,222 6,165 
CGST33 CGST33N Targeted NGS 100 6,528,986,900 80,930 3,141,629,807 48% 37,298 5,441 
CGST38 CGST38N Targeted NGS 100 7,641,335,900 80,930 3,221,456,102 42% 38,339 5,592 
CGST39 CGST39N Targeted NGS 100 7,240,196,600 80,930 3,318,695,433 46% 39,607 6,715 
CGST41 CGST41N Targeted NGS 100 7,533,950,900 80,930 3,465,686,126 46% 41,253 6,348 
CGST44 CGST44N Targeted NGS 100 7,254,063,600 80,930 2,005,128,421 28% 23,889 5,797 
CGST45 CGST45N Targeted NGS 100 6,257,089,600 80,930 2,949,372,085 47% 35,166 5,670 
CGST47 CGST47N Targeted NGS 100 7,348,319,800 80,930 3,266,126,327 44% 38,867 6,146 
CGST48 CGST48N Targeted NGS 100 6,846,646,900 80,930 3,150,453,485 46% 37,532 6,130 
CGST49 CGST49N Targeted NGS 100 8,539,596,100 80,930 3,408,355,429 40% 40,448 4,317 
CGST57 CGST57N Targeted NGS 100 6,039,413,200 80,930 2,953,736,278 49% 35,127 4,995 
CGST58 CGST58N Targeted NGS 100 6,930,306,600 80,930 3,298,094,768 48% 39,172 5,684 
CGST62 CGST62N Targeted NGS 100 7,369,061,300 80,930 3,566,181,334 48% 42,380 5,631 
CGST63 CGST63N Targeted NGS 100 7,061,323,300 80,930 2,297,686,683 33% 27,334 5,445 
CGST64 CGST64N Targeted NGS 100 7,281,306,400 80,930 2,165,252,030 30% 25,867 4,143 
CGST65 CGST65N Targeted NGS 100 6,914,494,900 80,930 3,417,164,449 49% 40,861 4,737 
CGST67 CGST67N Targeted NGS 100 6,813,029,900 80,930 2,675,216,687 39% 31,866 4,427 
CGST68 CGST68N Targeted NGS 100 6,674,736,700 80,930 3,293,565,113 49% 39,316 4,607 
CGST69 CGST69N Targeted NGS 100 6,865,458,700 80,930 2,803,579,545 41% 33,489 6,562 
CGST71 CGST71N Targeted NGS 100 7,345,327,200 80,930 3,398,613,398 46% 40,390 5,379 
CGST80 CGST80N Targeted NGS 100 7,781,481,700 80,930 3,472,259,854 45% 41,285 5,414 
CGST81 CGST81N Targeted NGS 100 8,329,032,000 80,930 3,923,705,794 47% 46,682 7,299 
CGST91 CGST91N Targeted NGS 100 7,107,909,300 80,930 3,324,593,160 47% 39,586 5,275 




Table 3.6.  Summary of sequence alterations detected in cfDNA. 






















CGST148 CGST148P2 Postoperative STK11 V128Dfs*34 CCDS45896.1 Deletion Frameshift ctDNA 0.26% 1924 5 No 
CGST152 CGST152P1 Preoperative ALK P36* CCDS33172.1 Insertion Frameshift ctDNA 0.71% 983 7 No 
CGST33 CGST33P Baseline ERBB2 R756Cfs*2 CCDS32642.1 Insertion Frameshift ctDNA 0.64% 2331 15 No 
CGST68 CGST68P Baseline HRAS D54Efs*53 CCDS7698.1 Insertion Frameshift ctDNA 0.03% 3174 1 No 
CGST68 CGST68P2 Postoperative ERBB4 D1184* CCDS2394.1 Insertion Frameshift ctDNA 0.16% 3857 6 No 
CGST68 CGST68P2 Postoperative HRAS D54Efs*53 CCDS7698.1 Insertion Frameshift ctDNA 0.29% 5856 17 No 
CGST102 CGST102P Baseline PIK3CA E109del CCDS43171.1 Deletion In-frame deletion ctDNA 0.43% 2577 11 No 
CGST109 CGST109P Baseline BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion ctDNA 0.43% 1380 6 No 
CGST109 CGST109P2 Postoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion ctDNA 0.07% 1456 1 No 
CGST109 CGST109P1 Preoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion ctDNA 0.08% 1250 1 No 
CGST134 CGST134P2 Postoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion ctDNA 0.25% 2384 6 No 
CGST134 CGST134P1 Preoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion ctDNA 0.22% 459 1 No 
CGST25 CGST25P Baseline TP53 H179del CCDS11118.1 Deletion In-frame deletion CHIP 0.59% 3029 18 No 
CGST25 CGST25P2 Postoperative TP53 H179del CCDS11118.1 Deletion In-frame deletion CHIP 0.28% 6442 18 No 
CGST25 CGST25P1 Preoperative TP53 H179del CCDS11118.1 Deletion In-frame deletion CHIP 0.66% 3325 22 No 
CGST28 CGST28P Baseline PIK3R1 R577_L581del CCDS3993.1 Deletion In-frame deletion ctDNA 1.62% 1170 19 No 
CGST28 CGST28P1 Preoperative PIK3R1 R577_L581del CCDS3993.1 Deletion In-frame deletion ctDNA 0.70% 712 5 No 
CGST141 CGST141P Baseline ERBB2 L785delinsHHVCF CCDS32642.1 Insertion In-frame insertion ctDNA 0.06% 4903 3 No 
CGST141 CGST141P1 Preoperative ERBB2 L785delinsHHVCF CCDS32642.1 Insertion In-frame insertion ctDNA 0.09% 7024 6 No 
CGST22 CGST22P Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion CHIP 0.10% 1918 2 No 
CGST22 CGST22P1 Preoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion CHIP 0.56% 2325 13 No 
CGST44 CGST44P Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion CHIP 1.12% 3380 38 No 
CGST44 CGST44P2 Postoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion CHIP 0.67% 3154 21 No 
110 
 
CGST44 CGST44P1 Preoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion CHIP 0.37% 3208 12 No 
CGST57 CGST57P Baseline APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion CHIP 0.76% 1048 8 No 
CGST57 CGST57P2 Postoperative APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion CHIP 1.78% 1962 35 No 
CGST57 CGST57P1 Preoperative APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion CHIP 2.22% 1804 40 No 
CGST68 CGST68P Baseline ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.04% 2619 1 No 
CGST68 CGST68P2 Postoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.56% 2522 14 No 
CGST68 CGST68P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.04% 2230 1 No 
CGST68 CGST68P1 Preoperative HRAS D54Efs*53 CCDS7698.1 Insertion In-frame insertion ctDNA 0.12% 2443 3 No 
CGST69 CGST69P2 Postoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.16% 3732 6 No 
CGST81 CGST81P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.41% 2413 10 No 
CGST91 CGST91P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion ctDNA 0.16% 3734 6 No 
CGST105 CGST105P Baseline PTEN R335* CCDS31238.1 Substitution Nonsense ctDNA 4.85% 1959 95 Yes 
CGST105 CGST105P1 Preoperative PTEN R335* CCDS31238.1 Substitution Nonsense ctDNA 0.46% 1954 9 Yes 
CGST158 CGST158P Baseline ERBB4 R114* CCDS2394.1 Substitution Nonsense ctDNA 0.16% 4412 7 No 
CGST30 CGST30P Baseline STK11 K64* CCDS45896.1 Substitution Nonsense ctDNA 0.39% 1281 5 No 
CGST33 CGST33P Baseline TP53 Q192* CCDS11118.1 Substitution Nonsense ctDNA 2.32% 2628 61 Yes 
CGST45 CGST45P2 Postoperative TP53 E294* CCDS11118.1 Substitution Nonsense ctDNA 0.14% 2787 4 Yes 
CGST47 CGST47P Baseline FBXW7 E664* CCDS3777.1 Substitution Nonsense ctDNA 0.45% 2015 9 No 
CGST65 CGST65P Baseline DNMT3A R771* CCDS33157.1 Substitution Nonsense CHIP 0.33% 4611 15 No 
CGST65 CGST65P1 Preoperative DNMT3A R771* CCDS33157.1 Substitution Nonsense CHIP 0.11% 2828 3 No 
CGST80 CGST80P Baseline TP53 S166* CCDS11118.1 Substitution Nonsense ctDNA 1.04% 4823 50 No 
CGST102 CGST102P Baseline DNMT3A V895L CCDS33157.1 Substitution Nonsynonymous CHIP 0.24% 2879 7 No 
CGST102 CGST102P Baseline SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous CHIP 0.40% 3214 13 No 
CGST102 CGST102P Baseline DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous CHIP 1.27% 2677 34 No 
CGST102 CGST102P2 Postoperative DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous CHIP 0.50% 2788 14 No 
CGST102 CGST102P2 Postoperative SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous CHIP 0.71% 2943 21 No 
CGST102 CGST102P1 Preoperative SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous CHIP 0.54% 3326 18 No 
CGST102 CGST102P1 Preoperative DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous CHIP 0.85% 2957 25 No 
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CGST105 CGST105P Baseline PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous ctDNA 0.19% 5304 10 Yes 
CGST105 CGST105P Baseline KRAS G12C NM_033360 Substitution Nonsynonymous ctDNA 1.21% 2561 31 Yes 
CGST105 CGST105P Baseline ATM R2832H CCDS31669.1 Substitution Nonsynonymous ctDNA 2.63% 2736 72 No 
CGST105 CGST105P1 Preoperative PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous ctDNA 0.04% 4910 2 Yes 
CGST105 CGST105P1 Preoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous ctDNA 0.24% 2482 6 No 
CGST105 CGST105P1 Preoperative KRAS G12C NM_033360 Substitution Nonsynonymous ctDNA 0.42% 2646 11 Yes 
CGST109 CGST109P2 Postoperative TP53 R267W CCDS11118.1 Substitution Nonsynonymous CHIP 0.07% 4195 3 Yes 
CGST110 CGST110P Baseline TP53 V216M CCDS11118.1 Substitution Nonsynonymous CHIP 0.04% 2763 1 Yes 
CGST110 CGST110P Baseline DNMT3A H873R CCDS33157.1 Substitution Nonsynonymous CHIP 0.03% 3207 1 No 
CGST110 CGST110P Baseline ERBB4 T639M CCDS2394.1 Substitution Nonsynonymous ctDNA 0.15% 2697 4 No 
CGST110 CGST110P1 Preoperative DNMT3A H873R CCDS33157.1 Substitution Nonsynonymous CHIP 0.10% 5871 6 No 
CGST110 CGST110P1 Preoperative ERBB4 T639M CCDS2394.1 Substitution Nonsynonymous ctDNA 0.12% 5089 6 No 
CGST110 CGST110P1 Preoperative TP53 V216M CCDS11118.1 Substitution Nonsynonymous CHIP 0.07% 5600 4 Yes 
CGST113 CGST113P Baseline TP53 R248W CCDS11118.1 Substitution Nonsynonymous CHIP 1.35% 1699 23 Yes 
CGST113 CGST113P Baseline CDH1 V425I CCDS10869.1 Substitution Nonsynonymous ctDNA 0.43% 1845 8 No 
CGST113 CGST113P Baseline KIT S241Y CCDS3496.1 Substitution Nonsynonymous ctDNA 0.92% 1625 15 No 
CGST113 CGST113P2 Postoperative TP53 R248W CCDS11118.1 Substitution Nonsynonymous CHIP 1.41% 2898 41 Yes 
CGST113 CGST113P2 Postoperative KIT S241Y CCDS3496.1 Substitution Nonsynonymous ctDNA 0.03% 3005 1 Yes 
CGST113 CGST113P1 Preoperative KIT S241Y CCDS3496.1 Substitution Nonsynonymous ctDNA 0.04% 2735 1 No 
CGST113 CGST113P1 Preoperative STK11 Y340N CCDS45896.1 Substitution Nonsynonymous ctDNA 0.25% 2038 5 No 
CGST113 CGST113P1 Preoperative TP53 R248W CCDS11118.1 Substitution Nonsynonymous CHIP 1.16% 2161 25 Yes 
CGST121 CGST121P Baseline DNMT3A R749G CCDS33157.1 Substitution Nonsynonymous CHIP 0.04% 2695 1 No 
CGST121 CGST121P1 Preoperative DNMT3A R749G CCDS33157.1 Substitution Nonsynonymous CHIP 0.22% 2742 6 No 
CGST122 CGST122P Baseline KIT P733S CCDS3496.1 Substitution Nonsynonymous CHIP 0.18% 4981 9 No 
CGST122 CGST122P Baseline MYC R98W CCDS6359.2 Substitution Nonsynonymous ctDNA 0.20% 3506 7 No 
CGST122 CGST122P Baseline JAK2 V617F CCDS6457.1 Substitution Nonsynonymous CHIP 6.32% 2293 145 Yes 
CGST122 CGST122P1 Preoperative MYC R98W CCDS6359.2 Substitution Nonsynonymous ctDNA 0.05% 4000 2 No 
CGST122 CGST122P1 Preoperative JAK2 V617F CCDS6457.1 Substitution Nonsynonymous CHIP 0.63% 1897 12 Yes 
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CGST133 CGST133P Baseline SMAD4 R361C CCDS11950.1 Substitution Nonsynonymous ctDNA 0.29% 2761 8 Yes 
CGST133 CGST133P Baseline KRAS G12V NM_033360 Substitution Nonsynonymous ctDNA 0.44% 1806 8 Yes 
CGST133 CGST133P1 Preoperative KRAS G12V NM_033360 Substitution Nonsynonymous ctDNA 0.06% 1802 1 Yes 
CGST134 CGST134P Baseline TP53 R282W CCDS11118.1 Substitution Nonsynonymous CHIP 0.06% 3634 2 Yes 
CGST134 CGST134P Baseline MYC S225L CCDS6359.2 Substitution Nonsynonymous ctDNA 0.17% 3536 6 No 
CGST134 CGST134P Baseline AR N757S CCDS14387.1 Substitution Nonsynonymous CHIP 0.44% 1836 8 No 
CGST134 CGST134P Baseline DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous CHIP 0.95% 3773 36 No 
CGST134 CGST134P2 Postoperative TP53 R282W CCDS11118.1 Substitution Nonsynonymous CHIP 0.12% 6029 7 Yes 
CGST134 CGST134P2 Postoperative MYC S225L CCDS6359.2 Substitution Nonsynonymous ctDNA 0.02% 5746 1 No 
CGST134 CGST134P2 Postoperative AR N757S CCDS14387.1 Substitution Nonsynonymous CHIP 0.60% 3337 20 No 
CGST134 CGST134P2 Postoperative DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous CHIP 0.88% 6217 55 No 
CGST134 CGST134P1 Preoperative MYC S225L CCDS6359.2 Substitution Nonsynonymous ctDNA 0.04% 2687 1 No 
CGST134 CGST134P1 Preoperative AR N757S CCDS14387.1 Substitution Nonsynonymous CHIP 0.08% 1259 4 No 
CGST134 CGST134P1 Preoperative TP53 R282W CCDS11118.1 Substitution Nonsynonymous CHIP 0.03% 3183 1 Yes 
CGST134 CGST134P1 Preoperative DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous CHIP 0.48% 2724 13 No 
CGST142 CGST142P Baseline PTEN F241L CCDS31238.1 Substitution Nonsynonymous ctDNA 0.18% 3290 6 No 
CGST143 CGST143P Baseline TP53 Y234C CCDS11118.1 Substitution Nonsynonymous CHIP 0.15% 1314 2 Yes 
CGST143 CGST143P Baseline FGFR3 V298M CCDS3353.1 Substitution Nonsynonymous CHIP 0.24% 1655 4 No 
CGST143 CGST143P1 Preoperative FGFR3 V298M CCDS3353.1 Substitution Nonsynonymous CHIP 0.20% 3033 6 No 
CGST143 CGST143P1 Preoperative TP53 Y234C CCDS11118.1 Substitution Nonsynonymous CHIP 0.77% 2081 16 Yes 
CGST148 CGST148P Baseline DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous CHIP 0.13% 780 1 Yes 
CGST148 CGST148P2 Postoperative KIT G745R CCDS3496.1 Substitution Nonsynonymous ctDNA 0.44% 5023 22 No 
CGST148 CGST148P2 Postoperative DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous CHIP 0.49% 4271 21 Yes 
CGST148 CGST148P1 Preoperative DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous CHIP 0.11% 925 1 Yes 
CGST158 CGST158P Baseline EGFR D942N CCDS5514.1 Substitution Nonsynonymous ctDNA 0.15% 3972 6 No 
CGST176 CGST176P Baseline DNMT3A L737F CCDS33157.1 Substitution Nonsynonymous CHIP 0.41% 2202 9 No 
CGST176 CGST176P1 Preoperative DNMT3A V897I CCDS33157.1 Substitution Nonsynonymous CHIP 0.24% 2079 5 No 
CGST176 CGST176P1 Preoperative DNMT3A L737F CCDS33157.1 Substitution Nonsynonymous CHIP 0.58% 2054 12 No 
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CGST22 CGST22P Baseline TP53 R175H CCDS11118.1 Substitution Nonsynonymous CHIP 0.16% 1930 3 Yes 
CGST22 CGST22P Baseline ERBB4 N1190S CCDS2394.1 Substitution Nonsynonymous CHIP 0.31% 2235 7 No 
CGST22 CGST22P1 Preoperative ERBB4 N1190S CCDS2394.1 Substitution Nonsynonymous CHIP 0.47% 2349 11 No 
CGST22 CGST22P1 Preoperative TP53 R175H CCDS11118.1 Substitution Nonsynonymous CHIP 0.21% 1896 4 Yes 
CGST24 CGST24P Baseline TP53 C238Y CCDS11118.1 Substitution Nonsynonymous CHIP 0.30% 1690 5 Yes 
CGST24 CGST24P Baseline KIT L939V CCDS3496.1 Substitution Nonsynonymous ctDNA 0.22% 2244 5 No 
CGST24 CGST24P2 Postoperative KIT L939V CCDS3496.1 Substitution Nonsynonymous ctDNA 0.03% 6498 2 No 
CGST24 CGST24P2 Postoperative AR E323K CCDS14387.1 Substitution Nonsynonymous ctDNA 0.12% 8506 10 No 
CGST24 CGST24P2 Postoperative EGFR D1175G CCDS5514.1 Substitution Nonsynonymous CHIP 0.16% 8145 13 No 
CGST24 CGST24P2 Postoperative TP53 C238Y CCDS11118.1 Substitution Nonsynonymous CHIP 0.21% 6721 14 Yes 
CGST24 CGST24P1 Preoperative AR E323K CCDS14387.1 Substitution Nonsynonymous ctDNA 0.02% 4408 1 Yes 
CGST24 CGST24P1 Preoperative KIT L939V CCDS3496.1 Substitution Nonsynonymous ctDNA 0.08% 3829 3 Yes 
CGST24 CGST24P1 Preoperative EGFR D1175G CCDS5514.1 Substitution Nonsynonymous CHIP 0.10% 4997 5 No 
CGST24 CGST24P1 Preoperative TP53 C238Y CCDS11118.1 Substitution Nonsynonymous CHIP 0.41% 2709 11 Yes 
CGST25 CGST25P Baseline TP53 G245S CCDS11118.1 Substitution Nonsynonymous CHIP 0.26% 1934 5 Yes 
CGST25 CGST25P Baseline ATM R2832H CCDS31669.1 Substitution Nonsynonymous CHIP 7.25% 2040 148 No 
CGST25 CGST25P2 Postoperative TP53 G245S CCDS11118.1 Substitution Nonsynonymous CHIP 0.06% 4965 3 Yes 
CGST25 CGST25P2 Postoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous CHIP 3.17% 2744 87 No 
CGST25 CGST25P1 Preoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous CHIP 9.84% 2856 281 No 
CGST25 CGST25P1 Preoperative TP53 G245S CCDS11118.1 Substitution Nonsynonymous CHIP 0.45% 2215 10 Yes 
CGST26 CGST26P Baseline CDK4 L125Q CCDS8953.1 Substitution Nonsynonymous ctDNA 0.32% 1551 5 No 
CGST26 CGST26P1 Preoperative CDK4 L125Q CCDS8953.1 Substitution Nonsynonymous ctDNA 0.07% 1429 1 No 
CGST28 CGST28P Baseline JAK2 L611S CCDS6457.1 Substitution Nonsynonymous ctDNA 11.77% 1775 209 No 
CGST28 CGST28P1 Preoperative JAK2 L611S CCDS6457.1 Substitution Nonsynonymous ctDNA 13.50% 1030 139 No 
CGST30 CGST30P Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous CHIP 0.31% 1590 5 Yes 
CGST30 CGST30P Baseline CDH1 I326F CCDS10869.1 Substitution Nonsynonymous ctDNA 0.29% 1754 5 No 
CGST30 CGST30P Baseline AR L341Q CCDS14387.1 Substitution Nonsynonymous ctDNA 0.39% 1291 5 No 
CGST30 CGST30P Baseline MYC H256L CCDS6359.2 Substitution Nonsynonymous ctDNA 0.42% 1420 6 No 
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CGST30 CGST30P1 Preoperative TP53 R273H CCDS11118.1 Substitution Nonsynonymous CHIP 0.20% 2503 5 Yes 
CGST31 CGST31P Baseline IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous CHIP 0.35% 579 2 No 
CGST31 CGST31P Baseline ESR1 T311M CCDS5234.1 Substitution Nonsynonymous CHIP 9.47% 602 57 No 
CGST31 CGST31P2 Postoperative DNMT3A L888P CCDS33157.1 Substitution Nonsynonymous CHIP 0.10% 5911 6 No 
CGST31 CGST31P2 Postoperative IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous CHIP 0.39% 4389 17 No 
CGST31 CGST31P2 Postoperative ESR1 T311M CCDS5234.1 Substitution Nonsynonymous CHIP 8.88% 5115 454 No 
CGST31 CGST31P1 Preoperative DNMT3A L888P CCDS33157.1 Substitution Nonsynonymous CHIP 0.13% 5932 8 No 
CGST31 CGST31P1 Preoperative IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous CHIP 0.20% 4938 10 No 
CGST31 CGST31P1 Preoperative ESR1 T311M CCDS5234.1 Substitution Nonsynonymous CHIP 7.36% 5478 403 No 
CGST32 CGST32P Baseline ALK N1497I CCDS33172.1 Substitution Nonsynonymous ctDNA 0.21% 2855 6 No 
CGST32 CGST32P Baseline ALK E172V CCDS33172.1 Substitution Nonsynonymous ctDNA 0.21% 2807 6 No 
CGST32 CGST32P Baseline KRAS G13R NM_033360 Substitution Nonsynonymous ctDNA 0.24% 2080 5 Yes 
CGST32 CGST32P Baseline ALK L347Q CCDS33172.1 Substitution Nonsynonymous ctDNA 0.26% 1918 5 No 
CGST32 CGST32P Baseline BRAF G469A CCDS5863.1 Substitution Nonsynonymous ctDNA 0.65% 2445 16 Yes 
CGST32 CGST32P Baseline TP53 R248W CCDS11118.1 Substitution Nonsynonymous ctDNA 2.99% 2138 64 Yes 
CGST38 CGST38P Baseline DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous CHIP 0.29% 1724 5 No 
CGST38 CGST38P Baseline DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous CHIP 0.39% 1778 7 No 
CGST38 CGST38P2 Postoperative DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous CHIP 0.21% 3368 7 No 
CGST38 CGST38P2 Postoperative DNMT3A P743L CCDS33157.1 Substitution Nonsynonymous CHIP 0.29% 3827 11 No 
CGST38 CGST38P2 Postoperative DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous CHIP 0.34% 3498 12 No 
CGST38 CGST38P1 Preoperative DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous CHIP 0.28% 2163 6 No 
CGST38 CGST38P1 Preoperative DNMT3A P743L CCDS33157.1 Substitution Nonsynonymous CHIP 0.29% 2413 7 No 
CGST38 CGST38P1 Preoperative DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous CHIP 0.50% 2184 11 No 
CGST45 CGST45P Baseline HRAS G13V CCDS7698.1 Substitution Nonsynonymous ctDNA 0.04% 2226 1 Yes 
CGST45 CGST45P2 Postoperative PTEN A137E CCDS31238.1 Substitution Nonsynonymous ctDNA 0.24% 2552 6 No 
CGST45 CGST45P2 Postoperative APC H2591N CCDS4107.1 Substitution Nonsynonymous ctDNA 0.30% 1645 5 No 
CGST45 CGST45P2 Postoperative HRAS G13V CCDS7698.1 Substitution Nonsynonymous ctDNA 0.31% 1624 5 Yes 
CGST45 CGST45P1 Preoperative PTEN A137E CCDS31238.1 Substitution Nonsynonymous ctDNA 0.07% 3001 2 No 
115 
 
CGST47 CGST47P Baseline TP53 R175H CCDS11118.1 Substitution Nonsynonymous ctDNA 0.28% 1431 4 Yes 
CGST48 CGST48P Baseline EGFR G514D CCDS5514.1 Substitution Nonsynonymous ctDNA 0.27% 2230 6 No 
CGST48 CGST48P Baseline EGFR L417F CCDS5514.1 Substitution Nonsynonymous CHIP 0.43% 1872 8 No 
CGST48 CGST48P Baseline FBXW7 R505L CCDS3777.1 Substitution Nonsynonymous ctDNA 1.55% 1806 28 No 
CGST48 CGST48P Baseline TP53 N239S CCDS11118.1 Substitution Nonsynonymous ctDNA 4.21% 1259 53 Yes 
CGST48 CGST48P1 Preoperative EGFR L417F CCDS5514.1 Substitution Nonsynonymous CHIP 0.10% 7003 7 No 
CGST48 CGST48P1 Preoperative FBXW7 R505L CCDS3777.1 Substitution Nonsynonymous ctDNA 0.23% 5603 13 No 
CGST48 CGST48P1 Preoperative TP53 N239S CCDS11118.1 Substitution Nonsynonymous ctDNA 0.50% 4396 22 Yes 
CGST57 CGST57P Baseline ABL1 G254R CCDS35166.1 Substitution Nonsynonymous ctDNA 0.25% 1217 3 No 
CGST57 CGST57P Baseline KIT A895T CCDS3496.1 Substitution Nonsynonymous ctDNA 0.36% 1406 5 No 
CGST57 CGST57P1 Preoperative KIT A895T CCDS3496.1 Substitution Nonsynonymous ctDNA 0.09% 2277 2 No 
CGST57 CGST57P1 Preoperative ABL1 G254R CCDS35166.1 Substitution Nonsynonymous ctDNA 0.33% 2095 7 No 
CGST62 CGST62P Baseline DNMT3A F732I CCDS33157.1 Substitution Nonsynonymous CHIP 0.11% 1747 2 No 
CGST62 CGST62P Baseline PTEN R130Q CCDS31238.1 Substitution Nonsynonymous CHIP 0.10% 3091 3 Yes 
CGST62 CGST62P Baseline ALK S1487L CCDS33172.1 Substitution Nonsynonymous ctDNA 0.25% 3613 9 No 
CGST62 CGST62P Baseline DNMT3A R882L CCDS33157.1 Substitution Nonsynonymous CHIP 0.26% 2701 7 No 
CGST62 CGST62P1 Preoperative PTEN R130Q CCDS31238.1 Substitution Nonsynonymous CHIP 0.02% 5000 1 Yes 
CGST62 CGST62P1 Preoperative DNMT3A R882L CCDS33157.1 Substitution Nonsynonymous CHIP 0.16% 2579 4 No 
CGST62 CGST62P1 Preoperative DNMT3A F732I CCDS33157.1 Substitution Nonsynonymous CHIP 0.39% 2297 9 No 
CGST63 CGST63P Baseline TP53 N239K CCDS11118.1 Substitution Nonsynonymous CHIP 0.23% 3522 8 No 
CGST63 CGST63P Baseline ATM K3043R CCDS31669.1 Substitution Nonsynonymous ctDNA 0.15% 4120 6 No 
CGST63 CGST63P Baseline CTNNB1 G34E CCDS2694.1 Substitution Nonsynonymous ctDNA 0.25% 3964 10 Yes 
CGST63 CGST63P Baseline ATM T547P CCDS31669.1 Substitution Nonsynonymous ctDNA 0.35% 3125 11 No 
CGST63 CGST63P Baseline PIK3CA C420R CCDS43171.1 Substitution Nonsynonymous ctDNA 0.39% 2788 11 Yes 
CGST63 CGST63P2 Postoperative TP53 N239K CCDS11118.1 Substitution Nonsynonymous CHIP 0.12% 5799 7 No 
CGST63 CGST63P2 Postoperative CTNNB1 S37F CCDS2694.1 Substitution Nonsynonymous ctDNA 0.06% 6340 4 Yes 
CGST63 CGST63P2 Postoperative MYC S154L CCDS6359.2 Substitution Nonsynonymous ctDNA 0.15% 9254 14 No 
CGST63 CGST63P1 Preoperative ATM K3043R CCDS31669.1 Substitution Nonsynonymous ctDNA 0.06% 3091 2 No 
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CGST63 CGST63P1 Preoperative ATM T547P CCDS31669.1 Substitution Nonsynonymous ctDNA 0.17% 1786 3 No 
CGST63 CGST63P1 Preoperative PIK3CA C420R CCDS43171.1 Substitution Nonsynonymous ctDNA 0.21% 1436 3 Yes 
CGST63 CGST63P1 Preoperative CTNNB1 G34E CCDS2694.1 Substitution Nonsynonymous ctDNA 0.27% 2620 7 Yes 
CGST63 CGST63P1 Preoperative TP53 N239K CCDS11118.1 Substitution Nonsynonymous CHIP 0.29% 1752 5 No 
CGST64 CGST64P Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous CHIP 6.14% 293 18 Yes 
CGST64 CGST64P1 Preoperative TP53 H179R CCDS11118.1 Substitution Nonsynonymous CHIP 0.25% 3640 9 Yes 
CGST64 CGST64P1 Preoperative TP53 V272M CCDS11118.1 Substitution Nonsynonymous CHIP 0.77% 2970 23 Yes 
CGST64 CGST64P1 Preoperative TP53 R273H CCDS11118.1 Substitution Nonsynonymous CHIP 12.59% 3184 401 Yes 
CGST65 CGST65P Baseline PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous ctDNA 0.07% 5704 4 Yes 
CGST65 CGST65P Baseline TP53 V216M CCDS11118.1 Substitution Nonsynonymous ctDNA 0.55% 5987 33 Yes 
CGST67 CGST67P Baseline PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous CHIP 0.18% 2778 5 No 
CGST67 CGST67P Baseline DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous CHIP 0.66% 2573 17 No 
CGST67 CGST67P2 Postoperative PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous CHIP 0.19% 3749 7 No 
CGST67 CGST67P2 Postoperative DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous CHIP 0.42% 3846 16 No 
CGST67 CGST67P1 Preoperative PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous CHIP 0.09% 5556 5 No 
CGST67 CGST67P1 Preoperative DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous CHIP 0.47% 5555 26 No 
CGST69 CGST69P2 Postoperative CDH1 E35K CCDS10869.1 Substitution Nonsynonymous ctDNA 0.12% 5212 6 No 
CGST79 CGST79P Baseline MYC R98W CCDS6359.2 Substitution Nonsynonymous ctDNA 0.22% 2745 6 No 
CGST80 CGST80P Baseline HRAS G161E CCDS7698.1 Substitution Nonsynonymous ctDNA 0.36% 3059 11 No 
CGST81 CGST81P Baseline TP53 C135F CCDS11118.1 Substitution Nonsynonymous CHIP 0.20% 3509 7 Yes 
CGST97 CGST97P Baseline TP53 P151S CCDS11118.1 Substitution Nonsynonymous CHIP 0.15% 682 1 Yes 
CGST97 CGST97P Baseline TP53 Y220C CCDS11118.1 Substitution Nonsynonymous CHIP 0.37% 539 2 Yes 
CGST97 CGST97P2 Postoperative TP53 P151S CCDS11118.1 Substitution Nonsynonymous CHIP 0.16% 3783 6 Yes 
CGST97 CGST97P2 Postoperative TP53 Y220C CCDS11118.1 Substitution Nonsynonymous CHIP 1.48% 3443 51 Yes 
CGST97 CGST97P1 Preoperative TP53 P151S CCDS11118.1 Substitution Nonsynonymous CHIP 0.12% 4015 5 Yes 
CGST97 CGST97P1 Preoperative TP53 Y220C CCDS11118.1 Substitution Nonsynonymous CHIP 1.70% 3596 61 Yes 
CGST24 CGST24P Baseline TP53 NA CCDS11118.1 Substitution Splice site acceptor CHIP 0.22% 2296 5 Yes 
CGST24 CGST24P2 Postoperative TP53 NA CCDS11118.1 Substitution Splice site acceptor CHIP 0.22% 6922 15 Yes 
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CGST24 CGST24P1 Preoperative TP53 NA CCDS11118.1 Substitution Splice site acceptor CHIP 0.10% 4149 4 Yes 
CGST64 CGST64P1 Preoperative DNMT3A N/A CCDS33157.1 Deletion Splice site acceptor CHIP 0.35% 3417 12 No 
CGST68 CGST68P Baseline ATM N/A CCDS31669.1 Substitution Splice site donor ctDNA 0.11% 2683 3 No 
CGST68 CGST68P2 Postoperative ATM N/A CCDS31669.1 Substitution Splice site donor ctDNA 0.18% 3318 6 No 





Table 3.7.  Summary of sequence alterations detected in WBCs. 


















CGST58 Baseline DNMT3A S714Hfs*19 CCDS33157.1 Deletion Frameshift 0.16% 4904 8 No 
CGST81 Baseline EGFR G632Vfs*73 CCDS5514.1 Deletion Frameshift 0.19% 3611 7 No 
CGST25 Baseline TP53 H179del CCDS11118.1 Deletion In-frame deletion 0.15% 4707 7 No 
CGST22 Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 1.97% 3849 76 No 
CGST44 Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 1.45% 3460 50 No 
CGST57 Baseline APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion 2.77% 3682 102 No 
CGST65 Baseline DNMT3A R771* CCDS33157.1 Substitution Nonsense 0.51% 3533 18 No 
CGST102 Baseline DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous 1.72% 3537 61 No 
CGST102 Baseline SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous 0.20% 4028 8 No 
CGST110 Baseline DNMT3A H873R CCDS33157.1 Substitution Nonsynonymous 0.18% 3833 7 No 
CGST110 Baseline HNF1A G151D CCDS9209.1 Substitution Nonsynonymous 0.35% 5080 18 No 
CGST110 Baseline TP53 V216M CCDS11118.1 Substitution Nonsynonymous 0.13% 4485 6 Yes 
CGST113 Baseline TP53 R248W CCDS11118.1 Substitution Nonsynonymous 0.26% 3799 10 Yes 
CGST121 Baseline AKT1 E17K CCDS9994.1 Substitution Nonsynonymous 0.15% 4073 6 Yes 
CGST121 Baseline DNMT3A R749G CCDS33157.1 Substitution Nonsynonymous 1.55% 3995 62 No 
CGST121 Baseline PIK3R1 N564K CCDS3993.1 Substitution Nonsynonymous 0.23% 3449 8 No 
CGST122 Baseline JAK2 V617F CCDS6457.1 Substitution Nonsynonymous 2.17% 2808 61 Yes 
CGST131 Baseline AR R775C CCDS14387.1 Substitution Nonsynonymous 0.54% 1863 10 No 
CGST134 Baseline AR N757S CCDS14387.1 Substitution Nonsynonymous 0.58% 2074 12 No 
CGST134 Baseline DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous 1.28% 4135 53 No 
CGST143 Baseline DNMT3A Y735C CCDS33157.1 Substitution Nonsynonymous 0.42% 2842 12 No 
CGST143 Baseline TP53 Y234C CCDS11118.1 Substitution Nonsynonymous 0.30% 2990 9 Yes 
CGST148 Baseline DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous 0.31% 3845 12 Yes 
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CGST152 Baseline DNMT3A R882C CCDS33157.1 Substitution Nonsynonymous 0.12% 4268 5 Yes 
CGST176 Baseline DNMT3A L737F CCDS33157.1 Substitution Nonsynonymous 1.47% 3603 53 No 
CGST176 Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous 0.06% 5223 3 Yes 
CGST22 Baseline ERBB4 N1190S CCDS2394.1 Substitution Nonsynonymous 0.19% 4215 8 No 
CGST22 Baseline ERBB4 V673F CCDS2394.1 Substitution Nonsynonymous 0.24% 2919 7 No 
CGST24 Baseline EGFR D1175G CCDS5514.1 Substitution Nonsynonymous 0.22% 4010 9 No 
CGST24 Baseline TP53 C238Y CCDS11118.1 Substitution Nonsynonymous 0.22% 3237 7 Yes 
CGST25 Baseline ATM R2832H CCDS31669.1 Substitution Nonsynonymous 7.01% 2467 173 No 
CGST25 Baseline TP53 G245S CCDS11118.1 Substitution Nonsynonymous 0.18% 3793 7 Yes 
CGST30 Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous 0.15% 4096 6 Yes 
CGST31 Baseline ESR1 T311M CCDS5234.1 Substitution Nonsynonymous 8.40% 3073 258 No 
CGST31 Baseline IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous 0.32% 3141 10 No 
CGST38 Baseline DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous 0.24% 3360 8 No 
CGST38 Baseline DNMT3A P743L CCDS33157.1 Substitution Nonsynonymous 0.48% 3527 17 No 
CGST38 Baseline DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous 0.48% 3725 18 No 
CGST41 Baseline ATM A2040P CCDS31669.1 Substitution Nonsynonymous 0.14% 4300 6 No 
CGST47 Baseline FLT3 S585L CCDS31953.1 Substitution Nonsynonymous 0.53% 2635 14 No 
CGST48 Baseline EGFR L417F CCDS5514.1 Substitution Nonsynonymous 0.29% 4822 14 No 
CGST58 Baseline DNMT3A D876Y CCDS33157.1 Substitution Nonsynonymous 0.17% 4089 7 No 
CGST62 Baseline DNMT3A I705T CCDS33157.1 Substitution Nonsynonymous 0.29% 4764 14 No 
CGST62 Baseline DNMT3A F732I CCDS33157.1 Substitution Nonsynonymous 0.37% 3477 13 No 
CGST64 Baseline PDGFRA T1052M CCDS3495.1 Substitution Nonsynonymous 0.24% 4089 10 No 
CGST64 Baseline TP53 H179R CCDS11118.1 Substitution Nonsynonymous 0.07% 4213 3 Yes 
CGST64 Baseline TP53 V272M CCDS11118.1 Substitution Nonsynonymous 0.13% 3889 5 Yes 
CGST64 Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous 4.66% 3884 181 Yes 
CGST67 Baseline DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous 0.70% 3885 27 No 
CGST71 Baseline APC T1493A CCDS4107.1 Substitution Nonsynonymous 0.26% 4178 11 No 
CGST71 Baseline KRAS G13D NM_033360 Substitution Nonsynonymous 0.10% 3105 3 Yes 
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CGST80 Baseline DNMT3A R882C CCDS33157.1 Substitution Nonsynonymous 0.08% 3873 3 Yes 
CGST81 Baseline FGFR2 S282I CCDS31298.1 Substitution Nonsynonymous 0.16% 4905 8 No 
CGST97 Baseline TP53 Y220C CCDS11118.1 Substitution Nonsynonymous 0.64% 4823 31 Yes 
CGST24 Baseline TP53 N/A CCDS11118.1 Substitution Splice site acceptor 0.32% 4022 13 Yes 




Table 3.8.  Summary of sequence alterations detected in ctDNA. 






















CGST33 CGST33P Baseline ERBB2 R756Cfs*2 CCDS32642.1 Insertion Frameshift 0.64% 2331 15 No 
CGST68 CGST68P Baseline HRAS D54Efs*53 CCDS7698.1 Insertion Frameshift 0.03% 3174 1 No 
CGST148 CGST148P2 Postoperative STK11 V128Dfs*34 CCDS45896.1 Deletion Frameshift 0.26% 1924 5 No 
CGST68 CGST68P2 Postoperative ERBB4 D1184* CCDS2394.1 Insertion Frameshift 0.16% 3857 6 No 
CGST68 CGST68P2 Postoperative HRAS D54Efs*53 CCDS7698.1 Insertion Frameshift 0.29% 5856 17 No 
CGST152 CGST152P1 Preoperative ALK P36* CCDS33172.1 Insertion Frameshift 0.71% 983 7 No 
CGST102 CGST102P Baseline PIK3CA E109del CCDS43171.1 Deletion In-frame deletion 0.43% 2577 11 No 
CGST109 CGST109P Baseline BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion 0.43% 1380 6 No 
CGST28 CGST28P Baseline PIK3R1 R577_L581del CCDS3993.1 Deletion In-frame deletion 1.62% 1170 19 No 
CGST109 CGST109P2 Postoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion 0.07% 1456 1 No 
CGST134 CGST134P2 Postoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion 0.25% 2384 6 No 
CGST109 CGST109P1 Preoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion 0.08% 1250 1 No 
CGST134 CGST134P1 Preoperative BRAF G32_A33del CCDS5863.1 Deletion In-frame deletion 0.22% 459 1 No 
CGST28 CGST28P1 Preoperative PIK3R1 R577_L581del CCDS3993.1 Deletion In-frame deletion 0.70% 712 5 No 
CGST141 CGST141P Baseline ERBB2 L785delinsHHVCF CCDS32642.1 Insertion In-frame insertion 0.06% 4903 3 No 
CGST68 CGST68P Baseline ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.04% 2619 1 No 
CGST68 CGST68P2 Postoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.56% 2522 14 No 
CGST69 CGST69P2 Postoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.16% 3732 6 No 
CGST141 CGST141P1 Preoperative ERBB2 L785delinsHHVCF CCDS32642.1 Insertion In-frame insertion 0.09% 7024 6 No 
CGST68 CGST68P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.04% 2230 1 No 
CGST68 CGST68P1 Preoperative HRAS D54Efs*53 CCDS7698.1 Insertion In-frame insertion 0.12% 2443 3 No 
CGST81 CGST81P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.41% 2413 10 No 
CGST91 CGST91P1 Preoperative ALK G35_P36insL CCDS33172.1 Insertion In-frame insertion 0.16% 3734 6 No 
CGST105 CGST105P Baseline PTEN R335* CCDS31238.1 Substitution Nonsense 4.85% 1959 95 Yes 
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CGST158 CGST158P Baseline ERBB4 R114* CCDS2394.1 Substitution Nonsense 0.16% 4412 7 No 
CGST30 CGST30P Baseline STK11 K64* CCDS45896.1 Substitution Nonsense 0.39% 1281 5 No 
CGST33 CGST33P Baseline TP53 Q192* CCDS11118.1 Substitution Nonsense 2.32% 2628 61 Yes 
CGST47 CGST47P Baseline FBXW7 E664* CCDS3777.1 Substitution Nonsense 0.45% 2015 9 No 
CGST80 CGST80P Baseline TP53 S166* CCDS11118.1 Substitution Nonsense 1.04% 4823 50 No 
CGST45 CGST45P2 Postoperative TP53 E294* CCDS11118.1 Substitution Nonsense 0.14% 2787 4 Yes 
CGST105 CGST105P1 Preoperative PTEN R335* CCDS31238.1 Substitution Nonsense 0.46% 1954 9 Yes 
CGST105 CGST105P Baseline ATM R2832H CCDS31669.1 Substitution Nonsynonymous 2.63% 2736 72 No 
CGST105 CGST105P Baseline KRAS G12C NM_033360 Substitution Nonsynonymous 1.21% 2561 31 Yes 
CGST105 CGST105P Baseline PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous 0.19% 5304 10 Yes 
CGST110 CGST110P Baseline ERBB4 T639M CCDS2394.1 Substitution Nonsynonymous 0.15% 2697 4 No 
CGST113 CGST113P Baseline CDH1 V425I CCDS10869.1 Substitution Nonsynonymous 0.43% 1845 8 No 
CGST113 CGST113P Baseline KIT S241Y CCDS3496.1 Substitution Nonsynonymous 0.92% 1625 15 No 
CGST122 CGST122P Baseline MYC R98W CCDS6359.2 Substitution Nonsynonymous 0.20% 3506 7 No 
CGST133 CGST133P Baseline KRAS G12V NM_033360 Substitution Nonsynonymous 0.44% 1806 8 Yes 
CGST133 CGST133P Baseline SMAD4 R361C CCDS11950.1 Substitution Nonsynonymous 0.29% 2761 8 Yes 
CGST134 CGST134P Baseline MYC S225L CCDS6359.2 Substitution Nonsynonymous 0.17% 3536 6 No 
CGST142 CGST142P Baseline PTEN F241L CCDS31238.1 Substitution Nonsynonymous 0.18% 3290 6 No 
CGST158 CGST158P Baseline EGFR D942N CCDS5514.1 Substitution Nonsynonymous 0.15% 3972 6 No 
CGST24 CGST24P Baseline KIT L939V CCDS3496.1 Substitution Nonsynonymous 0.22% 2244 5 No 
CGST26 CGST26P Baseline CDK4 L125Q CCDS8953.1 Substitution Nonsynonymous 0.32% 1551 5 No 
CGST28 CGST28P Baseline JAK2 L611S CCDS6457.1 Substitution Nonsynonymous 11.77% 1775 209 No 
CGST30 CGST30P Baseline AR L341Q CCDS14387.1 Substitution Nonsynonymous 0.39% 1291 5 No 
CGST30 CGST30P Baseline CDH1 I326F CCDS10869.1 Substitution Nonsynonymous 0.29% 1754 5 No 
CGST30 CGST30P Baseline MYC H256L CCDS6359.2 Substitution Nonsynonymous 0.42% 1420 6 No 
CGST32 CGST32P Baseline ALK L347Q CCDS33172.1 Substitution Nonsynonymous 0.26% 1918 5 No 
CGST32 CGST32P Baseline ALK N1497I CCDS33172.1 Substitution Nonsynonymous 0.21% 2855 6 No 
CGST32 CGST32P Baseline ALK E172V CCDS33172.1 Substitution Nonsynonymous 0.21% 2807 6 No 
CGST32 CGST32P Baseline BRAF G469A CCDS5863.1 Substitution Nonsynonymous 0.65% 2445 16 Yes 
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CGST32 CGST32P Baseline KRAS G13R NM_033360 Substitution Nonsynonymous 0.24% 2080 5 Yes 
CGST32 CGST32P Baseline TP53 R248W CCDS11118.1 Substitution Nonsynonymous 2.99% 2138 64 Yes 
CGST45 CGST45P Baseline HRAS G13V CCDS7698.1 Substitution Nonsynonymous 0.04% 2226 1 Yes 
CGST47 CGST47P Baseline TP53 R175H CCDS11118.1 Substitution Nonsynonymous 0.28% 1431 4 Yes 
CGST48 CGST48P Baseline EGFR G514D CCDS5514.1 Substitution Nonsynonymous 0.27% 2230 6 No 
CGST48 CGST48P Baseline FBXW7 R505L CCDS3777.1 Substitution Nonsynonymous 1.55% 1806 28 No 
CGST48 CGST48P Baseline TP53 N239S CCDS11118.1 Substitution Nonsynonymous 4.21% 1259 53 Yes 
CGST57 CGST57P Baseline ABL1 G254R CCDS35166.1 Substitution Nonsynonymous 0.25% 1217 3 No 
CGST57 CGST57P Baseline KIT A895T CCDS3496.1 Substitution Nonsynonymous 0.36% 1406 5 No 
CGST62 CGST62P Baseline ALK S1487L CCDS33172.1 Substitution Nonsynonymous 0.25% 3613 9 No 
CGST63 CGST63P Baseline ATM K3043R CCDS31669.1 Substitution Nonsynonymous 0.15% 4120 6 No 
CGST63 CGST63P Baseline ATM T547P CCDS31669.1 Substitution Nonsynonymous 0.35% 3125 11 No 
CGST63 CGST63P Baseline CTNNB1 G34E CCDS2694.1 Substitution Nonsynonymous 0.25% 3964 10 Yes 
CGST63 CGST63P Baseline PIK3CA C420R CCDS43171.1 Substitution Nonsynonymous 0.39% 2788 11 Yes 
CGST65 CGST65P Baseline PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous 0.07% 5704 4 Yes 
CGST65 CGST65P Baseline TP53 V216M CCDS11118.1 Substitution Nonsynonymous 0.55% 5987 33 Yes 
CGST79 CGST79P Baseline MYC R98W CCDS6359.2 Substitution Nonsynonymous 0.22% 2745 6 No 
CGST80 CGST80P Baseline HRAS G161E CCDS7698.1 Substitution Nonsynonymous 0.36% 3059 11 No 
CGST113 CGST113P2 Postoperative KIT S241Y CCDS3496.1 Substitution Nonsynonymous 0.03% 3005 1 Yes 
CGST134 CGST134P2 Postoperative MYC S225L CCDS6359.2 Substitution Nonsynonymous 0.02% 5746 1 No 
CGST148 CGST148P2 Postoperative KIT G745R CCDS3496.1 Substitution Nonsynonymous 0.44% 5023 22 No 
CGST24 CGST24P2 Postoperative KIT L939V CCDS3496.1 Substitution Nonsynonymous 0.03% 6498 2 No 
CGST24 CGST24P2 Postoperative AR E323K CCDS14387.1 Substitution Nonsynonymous 0.12% 8506 10 No 
CGST45 CGST45P2 Postoperative APC H2591N CCDS4107.1 Substitution Nonsynonymous 0.30% 1645 5 No 
CGST45 CGST45P2 Postoperative HRAS G13V CCDS7698.1 Substitution Nonsynonymous 0.31% 1624 5 Yes 
CGST45 CGST45P2 Postoperative PTEN A137E CCDS31238.1 Substitution Nonsynonymous 0.24% 2552 6 No 
CGST63 CGST63P2 Postoperative CTNNB1 S37F CCDS2694.1 Substitution Nonsynonymous 0.06% 6340 4 Yes 
CGST63 CGST63P2 Postoperative MYC S154L CCDS6359.2 Substitution Nonsynonymous 0.15% 9254 14 No 
CGST69 CGST69P2 Postoperative CDH1 E35K CCDS10869.1 Substitution Nonsynonymous 0.12% 5212 6 No 
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CGST105 CGST105P1 Preoperative PIK3CA Y1021C CCDS43171.1 Substitution Nonsynonymous 0.04% 4910 2 Yes 
CGST105 CGST105P1 Preoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous 0.24% 2482 6 No 
CGST105 CGST105P1 Preoperative KRAS G12C NM_033360 Substitution Nonsynonymous 0.42% 2646 11 Yes 
CGST110 CGST110P1 Preoperative ERBB4 T639M CCDS2394.1 Substitution Nonsynonymous 0.12% 5089 6 No 
CGST113 CGST113P1 Preoperative KIT S241Y CCDS3496.1 Substitution Nonsynonymous 0.04% 2735 1 No 
CGST113 CGST113P1 Preoperative STK11 Y340N CCDS45896.1 Substitution Nonsynonymous 0.25% 2038 5 No 
CGST122 CGST122P1 Preoperative MYC R98W CCDS6359.2 Substitution Nonsynonymous 0.05% 4000 2 No 
CGST133 CGST133P1 Preoperative KRAS G12V NM_033360 Substitution Nonsynonymous 0.06% 1802 1 Yes 
CGST134 CGST134P1 Preoperative MYC S225L CCDS6359.2 Substitution Nonsynonymous 0.04% 2687 1 No 
CGST24 CGST24P1 Preoperative AR E323K CCDS14387.1 Substitution Nonsynonymous 0.02% 4408 1 Yes 
CGST24 CGST24P1 Preoperative KIT L939V CCDS3496.1 Substitution Nonsynonymous 0.08% 3829 3 Yes 
CGST26 CGST26P1 Preoperative CDK4 L125Q CCDS8953.1 Substitution Nonsynonymous 0.07% 1429 1 No 
CGST28 CGST28P1 Preoperative JAK2 L611S CCDS6457.1 Substitution Nonsynonymous 13.50% 1030 139 No 
CGST45 CGST45P1 Preoperative PTEN A137E CCDS31238.1 Substitution Nonsynonymous 0.07% 3001 2 No 
CGST48 CGST48P1 Preoperative FBXW7 R505L CCDS3777.1 Substitution Nonsynonymous 0.23% 5603 13 No 
CGST48 CGST48P1 Preoperative TP53 N239S CCDS11118.1 Substitution Nonsynonymous 0.50% 4396 22 Yes 
CGST57 CGST57P1 Preoperative KIT A895T CCDS3496.1 Substitution Nonsynonymous 0.09% 2277 2 No 
CGST57 CGST57P1 Preoperative ABL1 G254R CCDS35166.1 Substitution Nonsynonymous 0.33% 2095 7 No 
CGST63 CGST63P1 Preoperative ATM K3043R CCDS31669.1 Substitution Nonsynonymous 0.06% 3091 2 No 
CGST63 CGST63P1 Preoperative ATM T547P CCDS31669.1 Substitution Nonsynonymous 0.17% 1786 3 No 
CGST63 CGST63P1 Preoperative PIK3CA C420R CCDS43171.1 Substitution Nonsynonymous 0.21% 1436 3 Yes 
CGST63 CGST63P1 Preoperative CTNNB1 G34E CCDS2694.1 Substitution Nonsynonymous 0.27% 2620 7 Yes 
CGST68 CGST68P Baseline ATM N/A CCDS31669.1 Substitution Splice site donor 0.11% 2683 3 No 
CGST68 CGST68P2 Postoperative ATM N/A CCDS31669.1 Substitution Splice site donor 0.18% 3318 6 No 




Table 3.9. Summary of white blood cells sequence alterations detected in cfDNA. 
Patient ID Patient Timepoint 
Timepoint 


















CGST25 CGST25P Baseline TP53 H179del CCDS11118.1 Deletion In-frame deletion 0.59% 3029 18 No 
CGST25 CGST25P2 Postoperative TP53 H179del CCDS11118.1 Deletion In-frame deletion 0.28% 6442 18 No 
CGST25 CGST25P1 Preoperative TP53 H179del CCDS11118.1 Deletion In-frame deletion 0.66% 3325 22 No 
CGST22 CGST22P Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 0.10% 1918 2 No 
CGST22 CGST22P1 Preoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 0.56% 2325 13 No 
CGST44 CGST44P Baseline MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 1.12% 3380 38 No 
CGST44 CGST44P2 Postoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 0.67% 3154 21 No 
CGST44 CGST44P1 Preoperative MLH1 K618_A619insA CCDS2663.1 Insertion In-frame insertion 0.37% 3208 12 No 
CGST57 CGST57P Baseline APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion 0.76% 1048 8 No 
CGST57 CGST57P2 Postoperative APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion 1.78% 1962 35 No 
CGST57 CGST57P1 Preoperative APC A1755_S1756insS CCDS4107.1 Insertion In-frame insertion 2.22% 1804 40 No 
CGST65 CGST65P Baseline DNMT3A R771* CCDS33157.1 Substitution Nonsense 0.33% 4611 15 No 
CGST65 CGST65P1 Preoperative DNMT3A R771* CCDS33157.1 Substitution Nonsense 0.11% 2828 3 No 
CGST102 CGST102P Baseline DNMT3A V895L CCDS33157.1 Substitution Nonsynonymous 0.24% 2879 7 No 
CGST102 CGST102P Baseline DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous 1.27% 2677 34 No 
CGST102 CGST102P Baseline SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous 0.40% 3214 13 No 
CGST102 CGST102P2 Postoperative DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous 0.50% 2788 14 No 
CGST102 CGST102P2 Postoperative SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous 0.71% 2943 21 No 
CGST102 CGST102P1 Preoperative SMARCB1 T214M CCDS13817.1 Substitution Nonsynonymous 0.54% 3326 18 No 
CGST102 CGST102P1 Preoperative DNMT3A C911Y CCDS33157.1 Substitution Nonsynonymous 0.85% 2957 25 No 
CGST109 CGST109P2 Postoperative TP53 R267W CCDS11118.1 Substitution Nonsynonymous 0.07% 4195 3 Yes 
CGST110 CGST110P Baseline DNMT3A H873R CCDS33157.1 Substitution Nonsynonymous 0.03% 3207 1 No 
CGST110 CGST110P Baseline TP53 V216M CCDS11118.1 Substitution Nonsynonymous 0.04% 2763 1 Yes 
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CGST110 CGST110P1 Preoperative TP53 V216M CCDS11118.1 Substitution Nonsynonymous 0.07% 5600 4 Yes 
CGST110 CGST110P1 Preoperative DNMT3A H873R CCDS33157.1 Substitution Nonsynonymous 0.10% 5871 6 No 
CGST113 CGST113P Baseline TP53 R248W CCDS11118.1 Substitution Nonsynonymous 1.35% 1699 23 Yes 
CGST113 CGST113P2 Postoperative TP53 R248W CCDS11118.1 Substitution Nonsynonymous 1.41% 2898 41 Yes 
CGST113 CGST113P1 Preoperative TP53 R248W CCDS11118.1 Substitution Nonsynonymous 1.16% 2161 25 Yes 
CGST121 CGST121P Baseline DNMT3A R749G CCDS33157.1 Substitution Nonsynonymous 0.04% 2695 1 No 
CGST121 CGST121P1 Preoperative DNMT3A R749G CCDS33157.1 Substitution Nonsynonymous 0.22% 2742 6 No 
CGST122 CGST122P Baseline JAK2 V617F CCDS6457.1 Substitution Nonsynonymous 6.32% 2293 145 Yes 
CGST122 CGST122P Baseline KIT P733S CCDS3496.1 Substitution Nonsynonymous 0.18% 4981 9 No 
CGST122 CGST122P1 Preoperative JAK2 V617F CCDS6457.1 Substitution Nonsynonymous 0.63% 1897 12 Yes 
CGST134 CGST134P Baseline AR N757S CCDS14387.1 Substitution Nonsynonymous 0.44% 1836 8 No 
CGST134 CGST134P Baseline DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous 0.95% 3773 36 No 
CGST134 CGST134P Baseline TP53 R282W CCDS11118.1 Substitution Nonsynonymous 0.06% 3634 2 Yes 
CGST134 CGST134P2 Postoperative TP53 R282W CCDS11118.1 Substitution Nonsynonymous 0.12% 6029 7 Yes 
CGST134 CGST134P2 Postoperative AR N757S CCDS14387.1 Substitution Nonsynonymous 0.60% 3337 20 No 
CGST134 CGST134P2 Postoperative DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous 0.88% 6217 55 No 
CGST134 CGST134P1 Preoperative TP53 R282W CCDS11118.1 Substitution Nonsynonymous 0.03% 3183 1 Yes 
CGST134 CGST134P1 Preoperative AR N757S CCDS14387.1 Substitution Nonsynonymous 0.08% 1259 4 No 
CGST134 CGST134P1 Preoperative DNMT3A S714F CCDS33157.1 Substitution Nonsynonymous 0.48% 2724 13 No 
CGST143 CGST143P Baseline FGFR3 V298M CCDS3353.1 Substitution Nonsynonymous 0.24% 1655 4 No 
CGST143 CGST143P Baseline TP53 Y234C CCDS11118.1 Substitution Nonsynonymous 0.15% 1314 2 Yes 
CGST143 CGST143P1 Preoperative FGFR3 V298M CCDS3353.1 Substitution Nonsynonymous 0.20% 3033 6 No 
CGST143 CGST143P1 Preoperative TP53 Y234C CCDS11118.1 Substitution Nonsynonymous 0.77% 2081 16 Yes 
CGST148 CGST148P Baseline DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous 0.13% 780 1 Yes 
CGST148 CGST148P2 Postoperative DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous 0.49% 4271 21 Yes 
CGST148 CGST148P1 Preoperative DNMT3A R882H CCDS33157.1 Substitution Nonsynonymous 0.11% 925 1 Yes 
CGST176 CGST176P Baseline DNMT3A L737F CCDS33157.1 Substitution Nonsynonymous 0.41% 2202 9 No 
CGST176 CGST176P1 Preoperative DNMT3A V897I CCDS33157.1 Substitution Nonsynonymous 0.24% 2079 5 No 
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CGST176 CGST176P1 Preoperative DNMT3A L737F CCDS33157.1 Substitution Nonsynonymous 0.58% 2054 12 No 
CGST22 CGST22P Baseline ERBB4 N1190S CCDS2394.1 Substitution Nonsynonymous 0.31% 2235 7 No 
CGST22 CGST22P Baseline TP53 R175H CCDS11118.1 Substitution Nonsynonymous 0.16% 1930 3 Yes 
CGST22 CGST22P1 Preoperative TP53 R175H CCDS11118.1 Substitution Nonsynonymous 0.21% 1896 4 Yes 
CGST22 CGST22P1 Preoperative ERBB4 N1190S CCDS2394.1 Substitution Nonsynonymous 0.47% 2349 11 No 
CGST24 CGST24P Baseline TP53 C238Y CCDS11118.1 Substitution Nonsynonymous 0.30% 1690 5 Yes 
CGST24 CGST24P2 Postoperative EGFR D1175G CCDS5514.1 Substitution Nonsynonymous 0.16% 8145 13 No 
CGST24 CGST24P2 Postoperative TP53 C238Y CCDS11118.1 Substitution Nonsynonymous 0.21% 6721 14 Yes 
CGST24 CGST24P1 Preoperative EGFR D1175G CCDS5514.1 Substitution Nonsynonymous 0.10% 4997 5 No 
CGST24 CGST24P1 Preoperative TP53 C238Y CCDS11118.1 Substitution Nonsynonymous 0.41% 2709 11 Yes 
CGST25 CGST25P Baseline ATM R2832H CCDS31669.1 Substitution Nonsynonymous 7.25% 2040 148 No 
CGST25 CGST25P Baseline TP53 G245S CCDS11118.1 Substitution Nonsynonymous 0.26% 1934 5 Yes 
CGST25 CGST25P2 Postoperative TP53 G245S CCDS11118.1 Substitution Nonsynonymous 0.06% 4965 3 Yes 
CGST25 CGST25P2 Postoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous 3.17% 2744 87 No 
CGST25 CGST25P1 Preoperative TP53 G245S CCDS11118.1 Substitution Nonsynonymous 0.45% 2215 10 Yes 
CGST25 CGST25P1 Preoperative ATM R2832H CCDS31669.1 Substitution Nonsynonymous 9.84% 2856 281 No 
CGST30 CGST30P Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous 0.31% 1590 5 Yes 
CGST30 CGST30P1 Preoperative TP53 R273H CCDS11118.1 Substitution Nonsynonymous 0.20% 2503 5 Yes 
CGST31 CGST31P Baseline ESR1 T311M CCDS5234.1 Substitution Nonsynonymous 9.47% 602 57 No 
CGST31 CGST31P Baseline IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous 0.35% 579 2 No 
CGST31 CGST31P2 Postoperative DNMT3A L888P CCDS33157.1 Substitution Nonsynonymous 0.10% 5911 6 No 
CGST31 CGST31P2 Postoperative IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous 0.39% 4389 17 No 
CGST31 CGST31P2 Postoperative ESR1 T311M CCDS5234.1 Substitution Nonsynonymous 8.88% 5115 454 No 
CGST31 CGST31P1 Preoperative DNMT3A L888P CCDS33157.1 Substitution Nonsynonymous 0.13% 5932 8 No 
CGST31 CGST31P1 Preoperative IDH2 R149Q CCDS10359.1 Substitution Nonsynonymous 0.20% 4938 10 No 
CGST31 CGST31P1 Preoperative ESR1 T311M CCDS5234.1 Substitution Nonsynonymous 7.36% 5478 403 No 
CGST38 CGST38P Baseline DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous 0.29% 1724 5 No 
CGST38 CGST38P Baseline DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous 0.39% 1778 7 No 
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CGST38 CGST38P2 Postoperative DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous 0.21% 3368 7 No 
CGST38 CGST38P2 Postoperative DNMT3A P743L CCDS33157.1 Substitution Nonsynonymous 0.29% 3827 11 No 
CGST38 CGST38P2 Postoperative DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous 0.34% 3498 12 No 
CGST38 CGST38P1 Preoperative DNMT3A I769V CCDS33157.1 Substitution Nonsynonymous 0.28% 2163 6 No 
CGST38 CGST38P1 Preoperative DNMT3A P743L CCDS33157.1 Substitution Nonsynonymous 0.29% 2413 7 No 
CGST38 CGST38P1 Preoperative DNMT3A R736H CCDS33157.1 Substitution Nonsynonymous 0.50% 2184 11 No 
CGST48 CGST48P Baseline EGFR L417F CCDS5514.1 Substitution Nonsynonymous 0.43% 1872 8 No 
CGST48 CGST48P1 Preoperative EGFR L417F CCDS5514.1 Substitution Nonsynonymous 0.10% 7003 7 No 
CGST62 CGST62P Baseline DNMT3A F732I CCDS33157.1 Substitution Nonsynonymous 0.11% 1747 2 No 
CGST62 CGST62P Baseline DNMT3A R882L CCDS33157.1 Substitution Nonsynonymous 0.26% 2701 7 No 
CGST62 CGST62P Baseline PTEN R130Q CCDS31238.1 Substitution Nonsynonymous 0.10% 3091 3 Yes 
CGST62 CGST62P1 Preoperative PTEN R130Q CCDS31238.1 Substitution Nonsynonymous 0.02% 5000 1 Yes 
CGST62 CGST62P1 Preoperative DNMT3A R882L CCDS33157.1 Substitution Nonsynonymous 0.16% 2579 4 No 
CGST62 CGST62P1 Preoperative DNMT3A F732I CCDS33157.1 Substitution Nonsynonymous 0.39% 2297 9 No 
CGST63 CGST63P Baseline TP53 N239K CCDS11118.1 Substitution Nonsynonymous 0.23% 3522 8 No 
CGST63 CGST63P2 Postoperative TP53 N239K CCDS11118.1 Substitution Nonsynonymous 0.12% 5799 7 No 
CGST63 CGST63P1 Preoperative TP53 N239K CCDS11118.1 Substitution Nonsynonymous 0.29% 1752 5 No 
CGST64 CGST64P Baseline TP53 R273H CCDS11118.1 Substitution Nonsynonymous 6.14% 293 18 Yes 
CGST64 CGST64P1 Preoperative TP53 H179R CCDS11118.1 Substitution Nonsynonymous 0.25% 3640 9 Yes 
CGST64 CGST64P1 Preoperative TP53 V272M CCDS11118.1 Substitution Nonsynonymous 0.77% 2970 23 Yes 
CGST64 CGST64P1 Preoperative TP53 R273H CCDS11118.1 Substitution Nonsynonymous 12.59% 3184 401 Yes 
CGST67 CGST67P Baseline DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous 0.66% 2573 17 No 
CGST67 CGST67P Baseline PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous 0.18% 2778 5 No 
CGST67 CGST67P2 Postoperative PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous 0.19% 3749 7 No 
CGST67 CGST67P2 Postoperative DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous 0.42% 3846 16 No 
CGST67 CGST67P1 Preoperative PDGFRA G166E CCDS3495.1 Substitution Nonsynonymous 0.09% 5556 5 No 
CGST67 CGST67P1 Preoperative DNMT3A S708N CCDS33157.1 Substitution Nonsynonymous 0.47% 5555 26 No 
CGST81 CGST81P Baseline TP53 C135F CCDS11118.1 Substitution Nonsynonymous 0.20% 3509 7 Yes 
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CGST97 CGST97P Baseline TP53 P151S CCDS11118.1 Substitution Nonsynonymous 0.15% 682 1 Yes 
CGST97 CGST97P Baseline TP53 Y220C CCDS11118.1 Substitution Nonsynonymous 0.37% 539 2 Yes 
CGST97 CGST97P2 Postoperative TP53 P151S CCDS11118.1 Substitution Nonsynonymous 0.16% 3783 6 Yes 
CGST97 CGST97P2 Postoperative TP53 Y220C CCDS11118.1 Substitution Nonsynonymous 1.48% 3443 51 Yes 
CGST97 CGST97P1 Preoperative TP53 P151S CCDS11118.1 Substitution Nonsynonymous 0.12% 4015 5 Yes 
CGST97 CGST97P1 Preoperative TP53 Y220C CCDS11118.1 Substitution Nonsynonymous 1.70% 3596 61 Yes 
CGST24 CGST24P Baseline TP53 NA CCDS11118.1 Substitution Splice site acceptor 0.22% 2296 5 Yes 
CGST24 CGST24P2 Postoperative TP53 NA CCDS11118.1 Substitution Splice site acceptor 0.22% 6922 15 Yes 
CGST24 CGST24P1 Preoperative TP53 NA CCDS11118.1 Substitution Splice site acceptor 0.10% 4149 4 Yes 
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Source of plasma samples 
Plasma samples from healthy individuals and plasma and tissue samples from patients with breast, 
lung, ovarian, colorectal, bile duct, and gastric cancers were obtained from ILSBio/Bioreclamation, 
Aarhus University, Herlev Hospital of the University of Copenhagen, Hvidovre Hospital, the 
University Medical Center of the University of Utrecht, the Academic Medical Center of the 
University of Amsterdam, the Netherlands Cancer Institute, and the University of California, San 
Diego.  All samples were obtained under Institutional Review Board approved protocols with 
informed consent for research use at participating institutions.  Plasma samples from healthy 
individuals were obtained at the time of routine screening, including for colonoscopies or Pap 
smears.  Individuals were considered healthy if they had no previous history of cancer and negative 
screening results.   
Plasma samples from individuals with breast, colorectal, gastric, lung, ovarian, pancreatic and bile 
duct cancer were obtained at the time of diagnosis, prior to tumor resection or therapy.  Nineteen 
lung cancer patients analyzed for change in cfDNA fragmentation profiles across multiple time 
points were undergoing treatment with anti-EGFR or anti-ERBB2 therapy (19). Clinical data for 
all patients included in this study are listed in table S1.  Gender was confirmed through genomic 
analyses of X and Y chromosome representation.  Pathologic staging of gastric cancer patients was 
performed after neoadjuvant therapy.  Samples where the tumor stage was unknown were indicated 
as stage X or unknown.   
Nucleosomal DNA purification 
Viably frozen lymphocytes were elutriated from leukocytes obtained from a healthy male (C0618) 
and female (D0808-L) (Advanced Biotechnologies Inc., Eldersburg, MD).  Aliquots of 1 x 106 cells 
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were used for nucleosomal DNA purification using EZ Nucleosomal DNA Prep Kit (Zymo 
Research, Irvine, CA).  Cells were initially treated with 100μl of Nuclei Prep Buffer and incubated 
on ice for 5 minutes. After centrifugation at 200g for 5 minutes, supernatant was discarded, and 
pelleted nuclei were treated twice with 100μl of Atlantis Digestion Buffer or with 100μl of 
micrococcal nuclease (MN) Digestion Buffer.  Finally, cellular nucleic DNA was fragmented with 
0.5U of Atlantis dsDNase at 42oC for 20 minutes or 1.5U of MNase at 37oC for 20 minutes.  
Reactions were stopped using 5X MN Stop Buffer and DNA was purified using Zymo-Spin™ IIC 
Columns. Concentration and quality of eluted cellular nucleic DNA were analyzed using the 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). 
Sample preparation and sequencing of cfDNA 
Whole blood was collected in EDTA tubes and processed immediately or within one day after 
storage at 4°C or were collected in Streck tubes and processed within two days of collection for 
three cancer patients who were part of the monitoring analysis.  Plasma and cellular components 
were separated by centrifugation at 800g for 10 min at 4°C.  Plasma was centrifuged a second time 
at 18,000g at room temperature to remove any remaining cellular debris and stored at −80°C until 
the time of DNA extraction. DNA was isolated from plasma using the Qiagen Circulating Nucleic 
Acids Kit (Qiagen GmbH) and eluted in LoBind tubes (Eppendorf AG). Concentration and quality 
of cfDNA were assessed using the Bioanalyzer 2100 (Agilent Technologies). 
NGS cfDNA libraries were prepared for whole genome sequencing and targeted sequencing using 
5 to 250 ng of cfDNA as previously described (15).  Briefly, genomic libraries were prepared using 
the NEBNext DNA Library Prep Kit for Illumina [New England Biolabs (NEB)] with four main 
modifications to the manufacturer’s guidelines: (i) The library purification steps used the on-bead 
AMPure XP approach to minimize sample loss during elution and tube transfer steps (83); (ii) 
NEBNext End Repair, A-tailing, and adapter ligation enzyme and buffer volumes were adjusted as 
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appropriate to accommodate the on-bead AMPure XP purification strategy; (iii) a pool of eight 
unique Illumina dual index adapters with 8–base pair (bp) barcodes was used in the ligation reaction 
instead of the standard Illumina single or dual index adapters with 6- or 8-bp barcodes, respectively; 
and (iv) cfDNA libraries were amplified with Phusion Hot Start Polymerase. 
Whole genome libraries were sequenced directly.  For targeted libraries, capture was performed 
using Agilent SureSelect reagents and a custom set of hybridization probes targeting 58 genes (15) 
per the manufacturer’s guidelines. The captured library was amplified with Phusion Hot Start 
Polymerase (NEB).  Concentration and quality of captured cfDNA libraries were assessed on the 
Bioanalyzer 2100 using theDNA1000 Kit (Agilent Technologies).  Targeted libraries were 
sequenced using 100-bp paired-end runs on the Illumina HiSeq 2000/2500 (Illumina). 
Analyses of targeted sequencing data from cfDNA 
Analyses of targeted NGS data for cfDNA samples was performed as previously described (15).  
Briefly, primary processing was completed using Illumina CASAVA (Consensus Assessment of 
Sequence and Variation) software (version 1.8), including demultiplexing and masking of dual-
index adapter sequences.  Sequence reads were aligned against the human reference genome 
(version hg18 or hg19) using NovoAlign with additional realignment of select regions using the 
Needleman-Wunsch method (71).  The positions of sequence alterations we identified have not 
been affected by the different genome builds. Candidate mutations, consisting of point mutations, 
small insertions, and deletions, were identified using VariantDx (71) (Personal Genome 
Diagnostics, Baltimore, MD) across the targeted regions of interest. 
To analyze the fragment lengths of cfDNA molecules, we required that each read pair from a 
cfDNA molecule have a Phred quality score ≥ 30. We removed all duplicate ctDNA fragments, 
defined as having the same start, end, and index barcode.  For each mutation, we only included 
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fragments for which one or both of the read pairs contained the mutated (or wild-type) base at the 
given position. This analysis was done using the R packages Rsamtools and GenomicAlignments. 
For each genomic locus where a somatic mutation was identified, we compared the lengths of 
fragments containing the mutant allele to the lengths of fragments with the wild-type allele.  If more 
than 100 mutant fragments were identified, we used Welch's two-sample t-test to compare the mean 
fragment lengths. For loci with fewer than 100 mutant fragments, we implemented a bootstrap 
procedure.  Specifically, we sampled with replacement N fragments containing the wild-type allele, 
where N denotes the number of fragments with the mutation. For each bootstrap replicate of wild 
type fragments, we computed their median length. The p-value was estimated as the fraction of 
bootstrap replicates with a median wild-type fragment length as or more extreme than the observed 
median mutant fragment length. 
Analyses of whole genome sequencing data from cfDNA 
Primary processing of whole genome NGS data for cfDNA samples was performed using Illumina 
CASAVA (Consensus Assessment of Sequence and Variation) software (version 1.8.2), including 
demultiplexing and masking of dual-index adapter sequences.  Sequence reads were aligned against 
the human reference genome (version hg19) using ELAND. 
Read pairs with a MAPQ score below 30 for either read and PCR duplicates were removed.  We 
tiled the hg19 autosomes into 26,236 adjacent, non-overlapping 100 kb bins.  We excluded regions 
of low mappability based on previous work (84) where 10% of bins with the lowest coverage were 
removed, and excluded reads falling in the Duke blacklisted regions 
(http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeMapability/).  Using this 
approach, we excluded 361 Mb (13%) of the hg19 reference genome, including centromeric and 
telomeric regions.  Short fragments were defined as having lengths between 100 and 150 bp and 
long fragments as having lengths between 151 and 220 bp.   
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To account for biases in coverage attributable to GC content of the genome, we applied the locally 
weighted smoother loess with span ¾ to the scatterplot of average fragment GC versus coverage 
calculated for each 100kb bin. This loess regression was performed separately for short and long 
fragments to account for possible differences in GC effects on coverage in plasma by fragment 
length, an approach loosely motivated by Benjamini et al (85).  We subtracted the predictions for 
short and long coverage explained by GC from the loess model, obtaining residuals for short and 
long that were uncorrelated with GC.  We returned the residuals to the original scale by adding 
back the genome-wide median short and long estimates of coverage.  This procedure was repeated 
for each sample to account for possible differences in GC effects on coverage between samples.   
To further reduce the feature space and noise, we calculated the total GC-adjusted coverage in 5 
Mb bins. 
To compare the variability of fragment lengths from healthy subjects to fragments in patients with 
cancer, we calculated the standard deviation of the short to long fragmentation profiles for each 
individual.  We compared the standard deviations in the two groups by a Wilcoxon rank sum test. 
Analyses of chromosome arm copy number changes 
To develop arm-level statistics for copy number changes, we adopted a previously described 
approach for aneuploidy detection in plasma (9).  This approach divides the genome into non-
overlapping 50KB bins for which GC-corrected log2 read depth was obtained after correction by 
loess with span 3/4.  This loess-based correction is comparable to the approach outlined above but 
is evaluated on a log2 scale to increase robustness to outliers in the smaller bins and does not stratify 
by fragment length.  To obtain an arm-specific Z-score for copy number changes, the mean GC-
adjusted read depth for each arm (GR) was centered and scaled by the average and standard 
deviation, respectively, of GR scores obtained from an independent set of 50 healthy samples. 
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Analyses of mitochondrial-aligned reads from cfDNA 
Whole genome sequence reads that initially mapped to the mitochondrial genome were extracted 
from bam files and realigned to the hg19 reference genome in end-to-end mode with Bowtie2 as 
previously described (86).  The resulting aligned reads were filtered such that both mates aligned 
to the mitochondrial genome with MAPQ >= 30.  The number of fragments mapping to the 
mitochondrial genome was counted and converted to a percentage of the total number of fragments 
in the original bam files. 
Prediction model for cancer classification 
To distinguish healthy from cancer patients using fragmentation profiles, we used a stochastic 
gradient boosting machine (gbm) (87, 88).  GC-corrected total and short fragment coverage for all 
504 bins were centered and scaled for each sample to have mean 0 and unit standard deviation. 
Additional features included Z-scores for each of the 39 autosomal arms and mitochondrial 
representation (log10-transformed proportion of reads mapped to the mitochondria). To estimate 
the prediction error of this approach, we used 10-fold cross-validation. Feature selection, 
performed only on the training data in each cross-validation run, removed bins that were highly 
correlated (correlation > 0.9) or had near zero variance.  Stochastic gradient boosted machine 
learning was implemented using the R package gbm package with parameters n.trees=150, 
interaction.depth=3, shrinkage=0.1, and n.minobsinside=10.   To average over the prediction error 
from the randomization of patients to folds, we repeated the 10-fold cross validation procedure 10 
times.  Confidence intervals for sensitivity fixed at 98% and 95% specificity were obtained from 
2000 bootstrap replicates. 
Prediction model for tumor tissue of origin classification 
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For samples correctly classified as cancer patients at 90% specificity (n = 174), a separate stochastic 
gradient boosting model was trained to classify the tissue type. To account for the small number of 
lung samples used for prediction, we included 18 late stage lung cancer patients from the 
monitoring analyses of our study, using the cfDNA analyses from the baseline blood samples. 
Performance characteristics of the model were evaluated by 10-fold cross-validation repeated 10 
times. This gbm model was trained using the same features as in the cancer classification model.  
As previously described, features that displayed correlation above 0.9 to each other or had near 
zero variance were removed within each training dataset during cross-validation. The tissue class 
probabilities were averaged across the 10 replicates for each patient and the class with the highest 
probability was taken as the predicted tissue. 
Analyses of nucleosomal DNA from human lymphocytes and cfDNA 
From the nuclease treated lymphocytes, fragment sizes were analyzed in 5 Mb bins as described 
above for whole genome cfDNA analyses.  A genome-wide map of nucleosome positions was 
constructed from the nuclease treated lymphocyte cell-lines.  This approach identified local biases 
in the coverage of circulating fragments, indicating a region protected from degradation. A 
“Window positioning score” (WPS) was used to score each base pair in the genome (65).  Using a 
sliding window of 60bp centered around each base, the WPS was calculated as the number of 
fragments completely spanning the window minus the number of fragments with only one end in 
the window.  Since fragments arising from nucleosomes have a median length of 167 bp, a high 
WPS indicated a possible nucleosomal position.  WPS scores were centered at zero using a running 
median and smoothed using a Kolmogorov-Zurbenko filter (89).  For spans of positive WPS 
between 50 and 450 bp, a nucleosome peak was defined as the set of base pairs with a WPS above 
the median in that window.  The calculation of nucleosome positions for cfDNA from 30 healthy 
individuals with sequence coverage of 9x was determined in the same manner as for lymphocyte 
DNA.  To ensure that nucleosomes in healthy cfDNA were representative, we defined a consensus 
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track of nucleosomes consisting only of nucleosomes identified in two or more individuals.  Median 
distances between adjacent nucleosomes were calculated from the consensus track.  
Monte Carlo simulation of detection sensitivity 
We used Monte Carlo simulation to estimate the probability of detecting a molecule with a tumor-
derived alteration (Figure 4.1). Briefly, we generated 1 million molecules from a multinomial 
distribution.  For a simulation with m alterations, wild-type molecules were simulated with 
probability p and each of the m tumor alterations were simulated with probability (1-p)/m.  Next, 
we sampled g * m molecules randomly with replacement, where g denotes the number of genome 
equivalents in 1 ml of plasma.  If a tumor alteration was sampled s or more times, we classified the 
sample as cancer-derived.  We repeated the simulation 1000 times, estimating the probability that 
the in silico sample would be correctly classified as cancer by the mean of the cancer indicator.   
Setting g = 2000 and s = 5, we varied the number of tumor alterations by powers of 2 from 1 to 256 
and the fraction of tumor-derived molecules from 0.0001% to 1%.  
Statistical analyses 
All statistical analyses were perform using R version 3.4.3.  The R packages caret (version 6.0-79) 
and gbm (version 2.1-4) were used to implement the classification of healthy versus cancer and 
tissue of origin. Confidence intervals from the model output were obtained with the pROC (version 
1.13) R packages (90).  Assuming the prevalence of undiagnosed cancer cases in this population is 
high (1 or 2 cases per 100 healthy), a genomic assay with a specificity of 0.95 and sensitivity of 0.8 
would have useful operating characteristics (positive predictive value of 0.25 and negative 
predictive value near 1). Power calculations suggest that an analysis of more than 200 cancer 
patients and an approximately equal number of healthy controls, enable an estimation of the 
sensitivity with a margin of error of 0.06 at the desired specificity of 0.95 or greater. 
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RESULTS 
As an initial proof of principle, we used 5 Mb windows for evaluating cfDNA fragmentation 
patterns as this would provide over 20,000 reads per window even at 1-2x genome coverage.  
Within each window, we examined the coverage and size distribution of cfDNA fragments.  We 
used this approach to evaluate the variation of genome-wide fragmentation profiles in healthy and 
cancer populations (Table 4.1).  The genome-wide pattern from an individual can be compared to 
reference populations to determine if the pattern is likely healthy or cancer-derived.  As genome-
wide profiles reveal positional differences associated with specific tissues that may be missed in 
overall fragment size distributions, these patterns may also indicate the tissue source of cfDNA 
(Figure 4.2). 
We initially focused on the fragmentation size of cfDNA as we found that cancer-derived cfDNA 
molecules may be more variable in size than cfDNA derived from non-cancer cells.  We examined 
cfDNA fragments from targeted regions that were captured and sequenced at high coverage (43,706 
total coverage, 8,044 distinct coverage) from patients with breast, colorectal, lung or ovarian cancer 
(15) (Tables 4.1, 4.2, 4.3).  Analyses of loci containing 165 tumor-specific alterations from 81 
patients (range of 1-7 alterations per patient) revealed an average absolute difference of 6.5 bp 
(95% CI, 5.4-7.6 bp) between lengths of median mutant and wild-type cfDNA fragments (Figure 
4.3 and Table 4.3).  The median size of mutant cfDNA fragments ranged from 30 bases smaller at 
chromosome 3 position 41,266,124 to 47 bases larger at chromosome 11 position 108,117,753 than 
the wild-type sequences at these regions (Table 4.3).  GC content was similar for mutated and non-
mutated fragments (Figure 4.4 A), and there was no correlation between GC content and fragment 
length (Figure 4.4 B).  Similar analyses of 44 germline alterations from 38 patients identified 
median cfDNA size differences of less than 1 bp between fragment lengths of different alleles 
(Figure 4.5 and Table 4.3).  Additionally, we identified 41 alterations related to clonal 
hematopoiesis through a previous sequence comparison of DNA from plasma, buffy coat, and 
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tumors of the same individuals (15).  Unlike tumor-derived fragments, there were no significant 
differences between fragments with hematopoietic alterations and wild type fragments (Figure 4.6 
and Table 4.3).  Overall, cancer-derived cfDNA fragment lengths were significantly more variable 
compared to non-cancer cfDNA fragments at certain genomic regions (p<0.001, variance ratio test).  
We hypothesized that these differences may be due to changes in higher-order chromatin structure 
as well as other genomic and epigenomic abnormalities in cancer (91, 92) and that cfDNA 
fragmentation in a position-specific manner could therefore serve as a unique biomarker for cancer 
detection.  
As targeted sequencing only analyzes a limited number of loci, we investigated whether larger-
scale genome-wide analyses would detect additional abnormalities in cfDNA fragmentation.  In a 
pilot analysis, we isolated cfDNA from ~4 ml of plasma from 8 lung cancer patients with stage I-
III disease as well as from 30 healthy individuals (Tables 4.1, 4.4, and 4.5).  We used a high 
efficiency approach to convert cfDNA to next generation sequencing libraries and performed whole 
genome sequencing at ~9x coverage (Table 4.4).  As expected from previous studies (57, 65, 66), 
overall cfDNA fragment lengths of healthy individuals were larger, with a median fragment size of 
167.3 bp, while patients with cancer had median fragment sizes of 163.8 (p<0.01, Welch’s t-test) 
(Table 4.5).  To examine differences in fragment size and coverage in a position dependent manner 
across the genome, we mapped sequenced fragments to their genomic origin and evaluated 
fragment lengths in 504 windows that were 5 Mb in size, covering ~2.6 Gb of the genome.  For 
each window, we determined the fraction of small cfDNA fragments (100 to 150 bp in length) to 
larger cfDNA fragments (151 to 220 bp) and overall coverage to obtain genome-wide 
fragmentation profiles for each sample.  
We found that healthy individuals had very similar fragmentation profiles throughout the genome 
(Figures 4.7 A, 4.7 B, and 4.8 A).  To examine the origins of fragmentation patterns normally 
observed in cfDNA, we isolated nuclei from elutriated lymphocytes of two healthy individuals and 
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treated these with DNA nucleases to obtain nucleosomal DNA fragments.  Analyses of cfDNA 
patterns in observed healthy individuals revealed a high correlation to lymphocyte nucleosomal 
DNA fragmentation profiles (Figures 4.7 B and 4.8 B) and nucleosome distances (Figures 4.7 C 
and 4.8 C).  We also found that the median distances between nucleosomes in lymphocytes were 
correlated to open (A) and closed (B) compartments of lymphoblastoid cells as revealed using the 
Hi-C method for examining the three-dimensional architecture of genomes (Figure 4.7 C) (84, 93) 
These analyses suggest that the fragmentation patterns of normal cfDNA are the result of 
nucleosomal DNA patterns that largely reflect the chromatin structure of normal blood cells.  
In contrast to healthy cfDNA, patients with cancer had multiple distinct genomic differences with 
increases and decreases in fragment sizes at different regions (Figures 4.7 A and 4.7 B).  Similar to 
our observations from targeted analyses, there was also greater variation in fragment lengths 
genome-wide for patients with cancer compared to healthy individuals.  To determine whether 
cfDNA fragment length patterns could be used to distinguish patients with cancer from healthy 
individuals, we performed genome-wide correlation analyses of the fraction of short to long cfDNA 
fragments for each sample compared to the median fragment length profile calculated from healthy 
individuals (Figures 4.7 A, 4.7 B, 4.8 D).  While the profiles of cfDNA fragments were remarkably 
consistent among healthy individuals (median correlation of 0.99), the median correlation of 
genome-wide fragment ratios among cancer patients was 0.84 (0.15 lower, 95% CI 0.07-0.50, 
p<0.001, Wilcoxon rank sum test) (Table 4.5).  Similar differences were observed when comparing 
fragmentation profiles of cancer patients to fragmentation profiles or nucleosome distances in 
healthy lymphocytes (Figures 4.7 C, 4.8 B, 4.8 C).  To account for potential biases in the 
fragmentation profiles attributable to GC content, we applied a locally weighted smoother 
independently to each sample and found that differences in fragmentation profiles between healthy 
individuals and cancer patients remained after this adjustment (median correlation of cancer 
patients to healthy = 0.83) (Table 4.5). 
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We performed subsampling analyses of whole genome sequence data at 9x coverage from cfDNA 
of patients with cancer at ~2x, ~1x, ~0.5x, ~0.2x, and ~0.1x genome coverage, and determined that 
altered fragmentation profiles were readily identified even at 0.5x genome coverage (Figures 4.8 E 
and 4.8 F).  Based on these observations, we performed whole genome sequencing with coverage 
of 1-2x to evaluate whether fragmentation profiles may change during the course of targeted 
therapy in a manner similar to monitoring of sequence alterations (19, 20, 56).  We evaluated 
cfDNA from 19 non-small cell lung cancer patients, including 5 with partial radiographic response, 
8 with stable disease, 4 with progressive disease, and 2 with non-measureable disease, during the 
course of anti-EGFR or anti-ERBB2 therapy (Table 4.6).  As shown in Figure 4.9, the degree of 
abnormality in the fragmentation profiles during therapy closely matched levels of EGFR or 
ERBB2 mutant allele fractions as determined using targeted sequencing (Spearman correlation of 
mutant allele fractions to fragmentation profiles = 0.74) (19).  This correlation is remarkable as 
genome-wide and mutation-based methods are orthogonal and examine different cfDNA alterations 
that may be suppressed in these patients due to prior therapy. Notably all cases that had progression 
free survival of six or more months displayed a drop of or had extremely low levels of ctDNA after 
initiation of therapy as determined by fragmentation profiles, while cases with poor clinical 
outcome had increases in ctDNA.  These results demonstrate the feasibility of fragmentation 
analyses for detecting the presence of tumor-derived cfDNA and suggests that such analyses may 
also be useful for quantitative monitoring of cancer patients during treatment.    
As fragmentation profiles would be expected to reflect both epigenomic and genomic alterations, 
we examined the fragmentation profiles in the context of known copy number changes in a patient 
where parallel analyses of tumor tissue were obtained. These analyses demonstrated that altered 
fragmentation profiles were present in regions of the genome that were copy neutral and that these 
may be further affected in regions with copy number changes (Figures 4.10 A and 4.11 A).  Position 
dependent differences in fragmentation patterns could be used to distinguish cancer-derived cfDNA 
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from healthy cfDNA in these regions (Figures 4.11 A and 4.11 B), while overall cfDNA fragment 
size measurements would have missed such differences (Figure 4.11 A). 
We extended these analyses to an independent cohort of cancer patients and healthy individuals.  
We performed whole genome sequencing of cfDNA at 1-2x coverage from a total of 208 patients 
with cancer, including breast (n=54), colorectal (n=27), lung (n=12), ovarian (n=28), pancreatic 
(n=34), gastric (n=27), or bile duct cancers (n=26), as well as 215 individuals without cancer 
(Tables 4.1 and 4.4).   All cancer patients were treatment naïve and the majority had resectable 
disease (n=183).  After GC adjustment of short and long cfDNA fragment coverage (Figure 4.12 
A), we examined coverage and size characteristics of fragments in windows throughout the genome 
(Figure 4.10 B and Tables 4.4 and 4.7).  Genome-wide correlations of coverage to GC content were 
limited and we observed no differences in these correlations between cancer patients and healthy 
individuals (p = 0.2, Welch’s t-test) (Figure 4.12 B). As we previously observed in the pilot 
analyses, healthy individuals had highly concordant fragmentation profiles, while patients with 
cancer had high variability with decreased correlation to the median healthy profile (Table 4.7).  
An analysis of the most commonly altered fragmentation windows in the genome among cancer 
patients revealed a median of 60 affected windows across the cancer types analyzed, highlighting 
the multitude of position dependent alterations in fragmentation of cfDNA in individuals with 
cancer (Figure 4.10 C).  
To determine if position dependent fragmentation changes can be used to detect individuals with 
cancer, we implemented a gradient tree boosting machine learning model to examine whether 
cfDNA can be categorized as having characteristics of a cancer patient or healthy individual and 
estimated performance characteristics of this approach by ten-fold cross validation repeated ten 
times (87, 88, 94) (Figures 4.13 A, 4.13 B).  The machine learning model included GC-adjusted 
short and long fragment coverage characteristics in windows throughout the genome.  We also 
developed a machine learning classifier for copy number changes from chromosomal arm 
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dependent features rather than a single score (9, 55) (Figure 4.14 A and Table 4.8) as well as 
mitochondrial copy number changes (57) (Figure 4.14 B) as these could also help distinguish cancer 
from healthy individuals.  Using this implementation of DELFI, we obtained a score that could be 
used to classify patients as healthy or having cancer.  We detected 152 of the 208 cancer patients 
(73% sensitivity, 95% CI 67%-79%) while misclassifying four of the 215 healthy individuals (98% 
specificity) (Table 4.9).  At a threshold of 95% specificity, we detected 80% of patients with cancer 
(95% CI, 74%-85%), including 79% of resectable (stage I – III) patients (145 of 183) and 82% of 
metastatic (stage IV) patients (18 out of 22) (Table 4.9).  Receiver operator characteristic analyses 
for detection of patients with cancer had an AUC of 0.94 (95% CI 0.92 – 0.96), ranged among 
cancer types from 0.86 for pancreatic cancer to ≥0.99 for lung and ovarian cancers (Figures 4.15 
and 4.16 A), and had AUCs ≥0.92 across all stages (Figure 4.16 B).  The DELFI classifier score 
did not differ with age among either cancer patients or healthy individuals (Table 4.1).  To assess 
the contribution of fragment size and coverage, chromosome arm copy number, or mitochondrial 
mapping to the predictive accuracy of the model, we implemented the repeated 10-fold cross-
validation procedure to assess performance characteristics of these features in isolation.  We 
observed that fragment coverage features alone (AUC = 0.94) were nearly identical to the classifier 
that combined all features (AUC = 0.94).  In contrast, analyses of chromosomal copy number 
changes had lower performance (AUC = 0.88) but were still more predictive than copy number 
changes based on individual scores (AUC=0.78) or mitochondrial mapping (AUC = 0.72) (Figure 
4.15). These results suggest that fragment coverage is the major contributor to our classifier, but 
we have included all features in our prediction model as they can be obtained from the same genome 
sequence data and may contribute in a complementary fashion for detection of patients with cancer.  
As fragmentation profiles reveal regional differences in fragmentation that may differ between 
tissues, we used a similar machine learning approach to examine whether cfDNA patterns could 
identify the tissue of origin of these tumors.  We found that this approach had a 61% accuracy (95% 
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CI 53%-67%), including 76% for breast, 44% for bile duct, 71% for colorectal, 67% for gastric, 
53% for lung, 48% for ovarian, and 50% for pancreatic cancers (Figure 4.16 C and Table 4.10).  
The accuracy increased to 75% (95% CI 69%-81%) when considering assigning patients with 
abnormal cfDNA to one of two sites of origin (Table 4.10).  For all tumor types the classification 
of the tissue of origin by DELFI was significantly higher than determined by random assignment 
(p<0.01, binomial test, Table 4.10). 
As cancer-specific sequence alterations can also be used to identify patients with cancer, we 
evaluated whether combining DELFI with this approach could increase the sensitivity of cancer 
detection (Figure 4.17).  We previously analyzed cfDNA from a subset of the treatment naïve 
cancer patients in this study using targeted error correction sequencing (15).  An evaluation of all 
cases analyzed using both DELFI and targeted sequencing revealed that 82% (103 of 126) of 
patients had fragmentation profile alterations while 66% (83 of 126) had sequence alterations.  Over 
89% of cases with mutant allele fractions >1% were detected by DELFI while for cases with mutant 
allele fractions <1% the fraction detected by DELFI was 80%, including for cases that were 
undetectable using targeted sequencing (Table 4.7).  When these approaches were used together 
the combined sensitivity of detection increased to 91% (115 of 126 patients) with a specificity of 
98% (Figure 4.17). 
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Figure 4.1. Simulations of noninvasive cancer detection based on number of alterations analyzed. 
Monte Carlo simulations were performed using different numbers of tumor-specific alterations to evaluate 
the probability of detecting cancer alterations in cfDNA at the indicated fraction of tumor-derived 
molecules. The simulations were performed assuming an average of 2000 genome equivalents of cfDNA 
and the requirement of five or more observations of any alteration. These analyses indicate that increasing 
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Figure 4.2. Schematic of DELFI approach. Blood is collected from a cohort of healthy individuals and 
patients with cancer. Nucleosome protected cfDNA is extracted from the plasma fraction, processed into 
sequencing libraries, examined through whole genome sequencing, mapped to the genome, and analyzed to 
determine cfDNA fragment profiles in different windows across the genome. Machine learning approaches 
are used to categorize individuals as healthy or as having cancer and to identify the tumor tissue of origin 
using genome-wide cfDNA fragmentation patterns.  
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Figure 4.3. Tumor‐derived cfDNA fragment distributions. Cumulative density functions of cfDNA 
fragment lengths of 42 loci containing tumor‐specific alterations from 30 patients with breast, colorectal, 
lung, or ovarian cancer are shown with 95% confidence bands (red). Lengths of mutant cfDNA fragments 
were significantly different in size compared to wild‐type cfDNA fragments (blue) at these loci. 
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Figure 4.4. Tumor‐derived cfDNA GC content and fragment length. A) GC content was similar for 
mutated and non-mutated fragments. B) GC content was not correlated to fragment length. 
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Figure 4.5. Germline cfDNA fragment distributions. Cumulative density functions of fragment lengths 
at 44 loci containing germline alterations (non‐tumor derived) from 38 patients with breast, colorectal, 
lung, or ovarian cancer are shown with 95% confidence bands.  Fragments with germline mutations (red) 
were comparable in length to wild‐type cfDNA fragment lengths (blue).   
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Figure 4.6. Hematopoietic cfDNA fragment distributions. Cumulative density functions of fragment 
lengths at 41 loci containing hematopoietic alterations (non-tumor derived) from 28 patients with breast, 
colorectal, lung, or ovarian cancer are shown with 95% confidence bands. After correction for multiple 
testing, there were no significant differences (α=0.05) in the size distributions of mutated hematopoietic 
cfDNA fragments (orange) and wild-type cfDNA fragments (blue). 
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Figure 4.6. Hematopoietic cfDNA fragment distributions. Cumulative density functions of fragment lengths at 41 loci containing 
hematopoietic alterations (non-tumor derived) from 28 patients with breast, colorectal, lung, or ovarian cancer are shown with 95% 
confidence bands. After correction for multiple testing, there were no significant differences (α=0.05) in the size distributions of mutated
hematopoietic cfDNA fragments (orange) and wild-type cfDNA fragments (blue). 
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confidence bands. After correction for multiple testing, there were no significant differences (α=0.05) in the size distributions of mutated
hematopoietic cfDNA fragments (orange) and wild-type cfDNA fragments (blue). 
Figure 4.7. cfDNA fragmentation profiles in healthy individuals and patients with cancer. A) Genome-wide cfDNA fragmentation profiles (defined as the 
ratio of short to long fragments) from ~9x whole genome sequencing are shown in 5 Mb bins for 30 healthy individuals (top) and 8 lung cancer patients 
(bottom). B)  An analysis of healthy cfDNA (top), lung cancer cfDNA (middle), and healthy lymphocyte (bottom) fragmentation profiles and lymphocyte 
profiles from chromosome 1 at 1 Mb resolution.  The healthy lymphocyte profiles were scaled with a standard deviation equal to that of the median healthy 
cfDNA profiles.  Healthy cfDNA patterns closely mirrored those in healthy lymphocytes while lung cancer cfDNA profiles were more varied and differed from 
both healthy and lymphocyte profiles. C) Smoothed median distances between adjacent nucleosome centered at zero using 100 kb bins from healthy cfDNA 
(top) and nuclease-digested healthy lymphocytes (middle) are depicted together with the first eigenvector for the genome contact matrix obtained through 
previously reported Hi-C analyses of lymphoblastoid cells (84) (bottom). Healthy cfDNA nucleosome distances closely mirrored those in nuclease-digested 
lymphocytes as well as those from lymphoblastoid Hi-C analyses.















































































































































































































































Figure 4.8. cfDNA fragmentation in healthy individuals and patients with lung cancer. A) cfDNA 
fragments lengths are shown for healthy individuals (n=30, gray) and patients with lung cancer (n=8, blue). 
B-D) cfDNA fragmentation profiles from healthy individuals (n=30) had high correlations while patients 
with lung cancer (n=8) had lower correlations to median fragmentation profiles of B, lymphocytes, C, 
lymphocyte nucleosome distances, and, D, healthy cfDNA. Pearson correlations are shown with box plots 
depicting minimum, 25th percentile, median, 75th percentile, and maximum values. E) High coverage (9x) 
whole-genome sequencing data were subsampled to 2x, 1x, 0.5x, 0.2x, and 0.1x fold coverage. Mean 
centered genome-wide fragmentation profiles in 5 Mb bins for 30 healthy individuals and 8 patients with 
lung cancer are depicted for each subsampled fold coverage with median profiles shown in blue. F) Pearson 
Correlation of subsampled profiles to initial profile at 9x coverage for healthy individuals and patients with 
lung cancer. 
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Figure 4.9. cfDNA fragmentation profiles and sequence alterations during therapy.  Detection and monitoring of cancer 
in serial blood draws from NSCLC patients (n=19) undergoing treatment with targeted tyrosine kinase inhibitors (black 
arrows) was performed using targeted sequencing (top) as previously reported and genome-wide fragmentation profiles 
(bottom).  For each case, the vertical axis of the lower panel displays -1 times the Pearson correlation of each sample to the 
median healthy cfDNA fragmentation profile.  Error bars depict confidence intervals from binomial tests for mutant allele 
fractions and confidence intervals calculated using Fisher transformation for genome-wide fragmentation profiles.  Although 
the approaches analyze different aspects of cfDNA (whole genome compared to specific alterations) the targeted sequencing 
and fragmentation profiles were similar for patients responding to therapy as well as those with stable or progressive disease.  
As fragmentation profiles reflect both genomic and epigenomic alterations, while mutant allele fractions only reflect 
individual mutations, mutant allele fractions alone may not reflect the absolute level of correlation of fragmentation profiles to 
healthy individuals. 
156 
Figure 4.10. cfDNA fragmentation profiles in patients with cancer. cfDNA fragmentation profiles in 
patients with cancer. A) Fragmentation profiles (bottom) in the context of known copy number changes 
(top) in a colorectal cancer patient where parallel analyses of tumor tissue were performed. The distribution 
of segment means corresponding to the inferred integer copy numbers are shown at top right in the 
indicated colors. Altered fragmentation profiles were present in regions of the genome that were copy 
neutral and were further affected in regions with copy number changes. B) GC adjusted fragmentation 
profiles from 1-2x whole genome sequencing for healthy individuals and patients with cancer are depicted 
per cancer type using 5 Mb windows. The median healthy profile is indicated in black and the 98% 
confidence band is shown in gray. For patients with cancer, individual profiles are colored based on their 
Pearson correlation to the healthy median. C) Windows are indicated in orange if more than 10% of the 
cancer samples had a fragment ratio more than three standard deviations from the median healthy fragment 
ratio. These analyses highlight the multitude of position dependent alterations across the genome in cfDNA 
of individuals with cancer. 





































































































































































































































Figure 4.11. Profiles of cfDNA fragment lengths in copy neutral regions in healthy individuals and one patient with colorectal cancer. A) The 
fragmentation profile in 211 copy neutral windows in chromosomes 1-6 for 25 randomly selected healthy individuals (gray).  For a patient with colorectal cancer 
(CGCRC291) with an estimated mutant allele fraction of 20%, we diluted the cancer fragment length profile to an approximate 10% tumor contribution (blue). 
A-B) While the marginal densities of the fragment profiles for the healthy samples and cancer patient show substantial overlap (a, right), the fragmentation 
profiles are different as can be seen visualization of the fragmentation profiles (A, left) and by the separation of the colorectal cancer patient from the healthy 
samples (n=25) in a principal component analysis (B).



































































Figure 4.12.  Genome-wide GC correction of cfDNA fragments. To estimate and control for the effects 
of GC content on sequencing coverage, we calculated coverage in non-overlapping 100kb genomic 
windows across the autosomes. For each window, we calculated the average GC of the aligned fragments. 
A) Loess smoothing of raw coverage (top row) for two randomly selected healthy subjects (CGPLH189 
and CGPLH380) and two cancer patients (CGPLLU161 and CGPLBR24) with undetectable aneuploidy 
(PA score < 2.35).  After subtracting the average coverage predicted by the loess model, the residuals were 
rescaled to the median autosomal coverage (bottom row). As fragment length may also result in coverage 
biases, we performed this GC correction procedure separately for short (≤ 150 bp) and long (> 150 bp) 
fragments. While the 100 kb bins on chromosome 19 (blue points) consistently have less coverage than 
predicted by the loess model, we did not implement a chromosome-specific correction as such an approach 
would remove the effects of chromosomal copy number on coverage. B) Overall, we found a limited 
correlation between short or long fragment coverage and GC content after correction among healthy 
subjects (n=211, inter-quartile range: -0.03-0.03) and cancer patients (n=128, inter-quartile range: 
-0.06-0.02) with a PA score <3. Box plots depict minimum, 25th percentile, median, 75th percentile, and 




Figure 4.13. Machine learning model. A) We used gradient tree boosting machine learning to examine whether cfDNA can be categorized as having 
characteristics of a cancer patient or healthy individual. The machine learning model included fragmentation size and coverage characteristics in windows 
throughout the genome, as well as chromosomal arm and mitochondrial DNA copy numbers.  We employed a 10-fold cross-validation approach in which each 
sample is randomly assigned to a fold and 9 of the folds (90% of the data) are used for training and one-fold (10% of the data) is used for testing. The prediction 
accuracy from a single cross-validation is an average over the 10 possible combinations of test and training sets. As this prediction accuracy can reflect bias from 
the initial randomization of patients, we repeat the entire procedure, including the randomization of patients to folds, 10 times. For all cases, feature selection and 
model estimation were performed on training data and were validated on test data and the test data were never used for feature selection. Ultimately, we obtained 
a DELFI score that could be used to classify individuals as likely healthy or having cancer. B) Distribution of AUCs across the repeated 10-fold cross-validation. 
























Figure 4.15. Detection of cancer using DELFI. Receiver operator characteristics for detection of cancer 
using cfDNA fragmentation profiles and other genome-wide features in a machine learning approach are 
depicted for a cohort of 215 healthy individuals and 208 patients with cancer (DELFI, AUC = 0.94), with ≥ 
95% specificity shaded in blue.  Machine learning analyses of chromosomal arm copy number (Chr copy 
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Figure 4.16. DELFI detection of cancer and tissue of origin prediction. DELFI detection of cancer 
and tissue of origin prediction. A) Analyses of individual cancer types using the DELFI-combined 
approach had AUCs ranging from 0.86 to >0.99. B) Receiver operatorcharacteristics for detection of cancer
using cfDNA fragmentation profiles and other genome-wide features in a machine learning approach are 
depicted for a cohort of 215 healthy individuals and each stage of 208 patients with cancer with ≥ 95% 
specificity shaded in blue. C) Receiver operator characteristics for DELFI tissue prediction of bile duct, 
breast, colorectal, gastric, lung, ovarian, or pancreatic cancer are depicted.  In order to increase sample sizes 
within cancer type classes, we included cases detected with a 90% specificity, and the lung cancer cohort 
was supplemented with the addition of baseline cfDNA data from 18 lung cancer patients with prior 
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126 103 82% 74%-88%
126 83 66% 57%-74%
126 115 91% 85%-96%
I 32 27 84% 67%-95%
II 52 48 92% 81%-98%
III 25 23 92% 74%-99%







*Cancer detection using DELFI, sequence mutations, and the combination of DELFI and mutations was performed at specificities of 98%,
>99%, and 98%, respectively.  Per stage sensitivities are included for all cases except for one patient with stage X.
164 
Table 4.1.  Summary of patients and samples analyzed. 
Patient Patient Type Sample Type 
Age at 
Diagnosis Sex Stage 


















CGPLPA114 Bile Duct Cancer cfDNA NA F II Intra Pancreatic Bile Duct 
Intra Pancreatic 
Bile Duct NA None 4.8 26.43 26.43 
CGPLPA115 Bile Duct Cancer cfDNA NA M IV Intra Hepatic Bile Duct 
Intra Hepatic Bile 
Duct NA NA 5.0 31.41 31.41 
CGPLPA117 Bile Duct Cancer cfDNA NA M II Intra Pancreatic Bile Duct 
Intra Pancreatic 
Bile Duct NA None 3.4 2.29 2.29 
CGPLPA118 Bile Duct Cancer cfDNA 68 F I Bile Duct Intra-Ampullary Bile Duct NA None 3.8 9.93 9.93 
CGPLPA122 Bile Duct Cancer cfDNA 62 F II Bile Duct Intra-Pancreatic Bile Duct NA None 3.8 66.54 32.89 
CGPLPA124 Bile Duct Cancer cfDNA 83 F II Bile Duct Intra-Ampullary Bile Duct moderate None 4.6 29.24 27.17 
CGPLPA125 Bile Duct Cancer cfDNA 58 M II Bile Duct Intra-Pancreatic Bile Duct poor None 2.7 8.31 8.31 
CGPLPA126 Bile Duct Cancer cfDNA 60 M II Bile Duct Intra-Pancreatic Bile Duct NA None 4.3 80.56 29.07 
CGPLPA127 Bile Duct Cancer cfDNA 71 F IV Bile Duct Extra-Pancreatic Bile Duct NA NA 3.0 20.60 20.60 
CGPLPA128 Bile Duct Cancer cfDNA 67 M II Bile Duct Intra-Pancreatic Bile Duct NA None 3.9 5.91 5.91 
CGPLPA129 Bile Duct Cancer cfDNA 56 F II Bile Duct Intra-Pancreatic Bile Duct NA None 4.6 27.07 27.07 
CGPLPA130 Bile Duct Cancer cfDNA 82 F II Bile Duct Intra-Ampullary Bile Duct well None 4.0 4.34 4.34 
CGPLPA131 Bile Duct Cancer cfDNA 71 M II Bile Duct Intra-Pancreatic Bile Duct NA None 3.9 68.95 32.05 
CGPLPA134 Bile Duct Cancer cfDNA 68 M II Bile Duct Intra-Pancreatic Bile Duct NA None 4.1 58.08 30.49 
CGPLPA135 Bile Duct Cancer cfDNA 67 F I Bile Duct Intra-Pancreatic Bile Duct NA NA 3.9 4.22 4.22 
CGPLPA136 Bile Duct Cancer cfDNA 69 F II Bile Duct Intra-Pancreatic Bile Duct NA None 4.1 20.23 20.23 
CGPLPA137 Bile Duct Cancer cfDNA NA M II Bile Duct Bile Duct NA NA 4.0 5.75 5.75 
CGPLPA139 Bile Duct Cancer cfDNA NA M IV Bile Duct Bile Duct NA NA 4.0 14.89 14.89 
CGPLPA140 Bile Duct Cancer cfDNA 52 M II Extra Hepatic Bile Duct  
Intra-Pancreatic 
Bile Duct Poor None 4.7 29.34 26.60 
CGPLPA141 Bile Duct Cancer cfDNA 68 F II Extra Hepatic Bile Duct  
Intra-Pancreatic 
Bile Duct Moderate None 2.8 53.67 44.64 
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CGPLPA155 Bile Duct Cancer cfDNA NA F II Bile Duct Bile Duct NA NA 4.0 25.72 25.72 
CGPLPA165 Bile Duct Cancer cfDNA 42 M I Bile Duct 
Intra-Pancreatic 
Bile Duct with 
Medullary 
Features 
well None 3.9 10.48 10.48 
CGPLPA168 Bile Duct Cancer cfDNA 58 M II Bile Duct Extra-Pancreatic Bile Duct NA NA 3.6 139.12 34.72 
CGPLPA184 Bile Duct Cancer cfDNA 75 F II Bile Duct Intra-Pancreatic Bile Duct NA None NA NA NA 
CGPLPA187 Bile Duct Cancer cfDNA 67 F II Bile Duct Intra-Pancreatic Bile Duct NA None NA NA NA 
CGPLBR100 Breast Cancer cfDNA 44 F III Left Breast Infiltrating Ductal Carcinoma NA None 4.0 4.25 4.25 




Moderate None 4.0 37.88 37.88 
CGPLBR102 Breast Cancer cfDNA 47 F II Right Breast Infiltrating Ductal Carcinoma Moderate None 3.6 13.67 13.67 
CGPLBR103 Breast Cancer cfDNA 48 F II Left Breast Infiltrating Ductal Carcinoma Moderate None 3.6 7.11 7.11 




Moderate None 4.7 19.89 19.89 




NA NA 4.3 4.21 4.21 




NA NA 4.1 40.39 30.49 
CGPLBR23 Breast Cancer cfDNA 53 F II Breast Infiltrating Ductal Carcinoma NA None 4.7 20.09 20.09 
CGPLBR24 Breast Cancer cfDNA 53 F II Breast Infiltrating Ductal Carcinoma NA None 3.6 58.33 34.72 
CGPLBR28 Breast Cancer cfDNA 59 F III Breast Infiltrating Ductal Carcinoma NA None 4.2 12.86 12.86 
CGPLBR30 Breast Cancer cfDNA 61 F II Breast Infiltrating Ductal Carcinoma NA None 4.1 59.73 30.49 
CGPLBR31 Breast Cancer cfDNA 54 F II Breast Infiltrating Ductal Carcinoma NA None 3.4 23.94 23.94 
CGPLBR32 Breast Cancer cfDNA NA F II Breast Infiltrating Ductal Carcinoma NA None 4.4 71.23 28.41 




NA None 4.4 11.00 11.00 
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NA None 4.4 23.61 23.61 




NA None 4.5 22.58 22.58 
CGPLBR36 Breast Cancer cfDNA 36 F II Breast Infiltrating Ductal Carcinoma NA None 4.4 17.73 17.73 
CGPLBR37 Breast Cancer cfDNA 58 F II Breast Infiltrating Ductal Carcinoma NA None 4.4 9.39 9.39 
CGPLBR38 Breast Cancer cfDNA 54 F I Left Breast Infiltrating Ductal Carcinoma Moderate None 4.0 5.77 5.77 
CGPLBR40 Breast Cancer cfDNA 66 F III Left Breast Infiltrating Ductal Carcinoma Poor None 4.6 15.69 15.69 
CGPLBR41 Breast Cancer cfDNA 51 F III Left Breast Infiltrating Ductal Carcinoma Moderate None 4.5 11.56 11.56 
CGPLBR45 Breast Cancer cfDNA 57 F II Breast Infiltrating Ductal Carcinoma NA None 4.5 20.36 20.36 
CGPLBR46 Breast Cancer cfDNA 54 F III Breast Infiltrating Ductal Carcinoma NA None 3.5 20.17 20.17 
CGPLBR47 Breast Cancer cfDNA 54 F I Breast Infiltrating Ductal Carcinoma NA None 4.5 13.89 13.89 
CGPLBR48 Breast Cancer cfDNA 47 F II Left Breast Infiltrating Ductal Carcinoma Poor None 3.9 7.07 7.07 
CGPLBR49 Breast Cancer cfDNA 37 F II Left Breast Infiltrating Ductal Carcinoma Poor None 4.0 5.74 5.74 
CGPLBR50 Breast Cancer cfDNA 51 F I Breast Infiltrating Ductal Carcinoma NA None 4.5 45.58 27.78 
CGPLBR51 Breast Cancer cfDNA 53 F II Breast Infiltrating Ductal Carcinoma NA None 4.0 8.83 8.83 
CGPLBR52 Breast Cancer cfDNA 68 F III Breast Infiltrating Ductal Carcinoma NA None 4.5 80.71 27.78 
CGPLBR55 Breast Cancer cfDNA 53 F III Right Breast Infiltrating Ductal Carcinoma Poor None 4.3 4.57 4.57 
CGPLBR56 Breast Cancer cfDNA 56 F II Breast Infiltrating Ductal Carcinoma NA None 4.5 22.16 22.16 
CGPLBR57 Breast Cancer cfDNA 54 F III Left Breast Infiltrating Ductal Carcinoma NA None 4.3 4.02 4.02 
CGPLBR59 Breast Cancer cfDNA 42 F I Left Breast Infiltrating Ductal Carcinoma Moderate None 4.1 8.24 8.24 
CGPLBR60 Breast Cancer cfDNA 61 F II Left Breast Infiltrating Ductal Carcinoma NA None 4.5 11.09 11.09 
CGPLBR61 Breast Cancer cfDNA 67 F II Left Breast Infiltrating Ductal Carcinoma Moderate None 4.1 13.25 13.25 
CGPLBR63 Breast Cancer cfDNA 48 F II Left Breast Infiltrating Ductal Carcinoma Moderate None 4.0 6.19 6.19 
167 
 
CGPLBR65 Breast Cancer cfDNA 50 F II Left Breast Infiltrating Ductal Carcinoma NA None 3.5 41.75 35.71 
CGPLBR68 Breast Cancer cfDNA 64 F III Breast Infiltrating Ductal Carcinoma Poor None 3.4 10.41 10.41 
CGPLBR69 Breast Cancer cfDNA 43 F II Breast Infiltrating Ductal Carcinoma Moderate None 4.4 4.07 4.07 
CGPLBR70 Breast Cancer cfDNA 60 F II Breast Infiltrating Ductal Carcinoma Moderate None 3.4 11.94 11.94 
CGPLBR71 Breast Cancer cfDNA 65 F II Breast Infiltrating Ductal Carcinoma Poor None 3.1 7.64 7.64 
CGPLBR72 Breast Cancer cfDNA 67 F II Breast Infiltrating Ductal Carcinoma Well None 3.9 4.43 4.43 
CGPLBR73 Breast Cancer cfDNA 60 F II Breast Infiltrating Ductal Carcinoma Moderate None 3.3 14.69 14.69 
CGPLBR76 Breast Cancer cfDNA 53 F II Right Breast Infiltrating Ductal Carcinoma Well None 4.9 8.71 8.71 
CGPLBR81 Breast Cancer cfDNA 54 F II Breast Infiltrating Ductal Carcinoma NA None 2.5 83.14 50.00 




Moderate None 4.8 23.39 23.39 
CGPLBR83 Breast Cancer cfDNA 53 F II Right Breast Infiltrating Ductal Carcinoma Moderate None 3.7 100.17 100.17 
CGPLBR84 Breast Cancer cfDNA NA F III Breast Infiltrating Ductal Carcinoma NA NA 3.6 16.95 16.95 
CGPLBR87 Breast Cancer cfDNA 80 F II Right Breast Papillary Carcinoma Well None 3.6 277.39 69.44 
CGPLBR88 Breast Cancer cfDNA 48 F II Left Breast Infiltrating Ductal Carcinoma Poor None 3.6 49.75 49.75 
CGPLBR90 Breast Cancer cfDNA 51 F II Right Breast Infiltrating Ductal Carcinoma NA None 3.0 14.24 14.24 




Poor None 3.2 22.41 22.41 




Poor None 3.1 81.00 81.00 
CGPLBR93 Breast Cancer cfDNA 59 F II Breast Infiltrating Ductal Carcinoma Moderate None 3.3 27.94 27.94 
CGCRC291 Colorectal Cancer cfDNA 69 F IV Coecum Adenocarcinoma Moderate Synchronous Liver 7.9 7.80 7.80 
CGCRC292 Colorectal Cancer cfDNA 51 M IV Sigmoid Colon Adenocarcinoma Moderate Synchronous Liver, Lung 7.9 6.73 6.73 
CGCRC293 Colorectal Cancer cfDNA 55 M IV Rectum Adenocarcinoma Moderate Synchronous Liver 7.2 3.83 3.83 
CGCRC294 Colorectal Cancer cfDNA 67 F II Sigmoid Colon Adenocarcinoma Moderate None 8.4 18.87 18.87 
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CGCRC296 Colorectal Cancer cfDNA 76 F II Coecum Adenocarcinoma Poor None 4.3 31.24 31.24 
CGCRC299 Colorectal Cancer cfDNA 71 M I Rectum Adenocarcinoma Moderate None 8.8 10.18 10.18 
CGCRC300 Colorectal Cancer cfDNA 65 M I Rectum Adenocarcinoma Moderate None 4.3 10.48 10.48 
CGCRC301 Colorectal Cancer cfDNA 76 F I Rectum Adenocarcinoma Moderate None 4.1 6.51 6.51 
CGCRC302 Colorectal Cancer cfDNA 73 M II Transverse Colon Adenocarcinoma Moderate None 4.3 52.13 52.13 
CGCRC304 Colorectal Cancer cfDNA 86 F II Rectum Adenocarcinoma Moderate None 4.1 30.19 30.19 
CGCRC305 Colorectal Cancer cfDNA 83 F II Transverse Colon Adenocarcinoma Moderate None 8.6 9.10 9.10 
CGCRC306 Colorectal Cancer cfDNA 80 F II Ascending Colon Adenocarcinoma Moderate None 4.5 24.31 24.31 
CGCRC307 Colorectal Cancer cfDNA 78 F II Ascending Colon Adenocarcinoma Moderate None 8.5 14.26 14.26 
CGCRC308 Colorectal Cancer cfDNA 72 F III Ascending Colon Adenocarcinoma Moderate None 4.3 46.87 46.87 
CGCRC311 Colorectal Cancer cfDNA 59 M I Sigmoid Colon Adenocarcinoma Moderate None 8.5 3.91 3.91 
CGCRC315 Colorectal Cancer cfDNA 74 M III Sigmoid Colon Adenocarcinoma Moderate None 8.6 9.67 9.67 
CGCRC316 Colorectal Cancer cfDNA 80 M III Transverse Colon Adenocarcinoma Moderate None 4.9 52.16 52.16 
CGCRC317 Colorectal Cancer cfDNA 74 M III Descending Colon Adenocarcinoma Moderate None 8.8 16.08 16.08 
CGCRC318 Colorectal Cancer cfDNA 81 M I Coecum Adenocarcinoma Moderate None 9.8 18.24 18.24 
CGCRC319 Colorectal Cancer cfDNA 80 F III Descending Colon Adenocarcinoma Moderate None 4.2 53.54 53.54 
CGCRC320 Colorectal Cancer cfDNA 73 F I Ascending Colon Adenocarcinoma Moderate None 4.5 30.37 30.37 
CGCRC321 Colorectal Cancer cfDNA 68 M I Rectum Adenocarcinoma Moderate None 9.3 4.25 4.25 
CGCRC333 Colorectal Cancer cfDNA NA F IV Colon/Rectum Adenocarcinoma NA Liver 4.0 113.88 113.88 
CGCRC336 Colorectal Cancer cfDNA NA M IV Colon/Rectum Adenocarcinoma NA Liver 4.4 211.74 211.74 
CGCRC338 Colorectal Cancer cfDNA NA F IV Colon/Rectum Adenocarcinoma NA Liver 2.3 109.76 109.76 
CGCRC341 Colorectal Cancer cfDNA NA F IV Colon/Rectum Adenocarcinoma NA Liver 4.6 156.62 156.62 
CGCRC342 Colorectal Cancer cfDNA NA M IV Colon/Rectum Adenocarcinoma NA Liver 3.9 56.09 56.09 
CGPLPA113 Duodenal Cancer cfDNA 71 M I Intra Pancreatic Bile Duct 
Intra Pancreatic 
Bile Duct NA None 4.8 8.24 8.24 
CGST102 Gastric cancer cfDNA 76 F II Stomach Tubular Adenocarcinoma Moderate None 4.1 8.03 8.03 
CGST11 Gastric cancer cfDNA 49 M IV Stomach Mixed Carcinoma Moderate None 3.8 3.57 3.57 
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CGST110 Gastric cancer cfDNA 77 M III Stomach Tubular Adenocarcinoma Moderate None 3.8 5.00 5.00 
CGST114 Gastric cancer cfDNA 65 M III Stomach Tubular Adenocarcinoma Poor None 4.4 10.35 10.35 
CGST13 Gastric cancer cfDNA 72 F II Stomach Signet Ring Cell Carcinoma Poor None 4.4 24.33 24.33 
CGST131 Gastric cancer cfDNA 63 M III Stomach Signet ring cell carcinoma Poor None 4.0 4.28 4.28 
CGST141 Gastric cancer cfDNA 33 F III Stomach Signet Ring Cell Carcinoma Poor None 4.4 10.84 10.84 
CGST16 Gastric cancer cfDNA 78 M III Stomach Tubular Adenocarcinoma Poor None 4.0 40.69 40.69 
CGST18 Gastric cancer cfDNA 56 M II Stomach Mucinous Adenocarcinoma Well None 4.3 9.78 9.78 
CGST21 Gastric cancer cfDNA 39 M II Stomach Papillary Adenocarcinoma Moderate None 4.0 0.83 0.83 
CGST26 Gastric cancer cfDNA 51 M IV Stomach Signet ring cell carcinoma Poor None 3.5 5.56 5.56 
CGST28 Gastric cancer cfDNA 55 M X Stomach Undifferentiated Carcinoma Poor None 4.0 5.86 5.86 
CGST30 Gastric cancer cfDNA 64 F III Stomach Signet Ring Cell Carcinoma Poor None 3.0 4.22 4.22 
CGST32 Gastric cancer cfDNA 67 M II Stomach Tubular Adenocarcinoma Moderate None 4.0 11.49 11.49 
CGST33 Gastric cancer cfDNA 61 M I Stomach Tubular Adenocarcinoma Moderate None 3.5 5.71 5.71 
CGST38 Gastric cancer cfDNA 71 F X Stomach Mucinous adenocarcinoma NA None 4.0 NA NA 
CGST39 Gastric cancer cfDNA 51 M IV Stomach Signet Ring Cell Carcinoma Poor None 3.5 20.69 20.69 
CGST41 Gastric cancer cfDNA 66 F IV Stomach Signet Ring Cell Carcinoma Poor None 3.5 7.83 7.83 
CGST45 Gastric cancer cfDNA 41 F II Stomach Signet Ring Cell Carcinoma Poor None 3.8 7.14 7.14 
CGST47 Gastric cancer cfDNA 74 F I Stomach Tubular Adenocarcinoma Moderate None 4.0 4.55 4.55 
CGST48 Gastric cancer cfDNA 62 M IV Stomach Tubular Adenocarcinoma Poor None 4.5 8.79 8.79 
CGST53 Gastric cancer cfDNA 70 M X Stomach Stomach NA None 3.8 15.82 15.82 
CGST58 Gastric cancer cfDNA 58 M III Stomach Signet Ring Cell Carcinoma Poor None 3.8 19.81 19.81 
CGST67 Gastric cancer cfDNA 69 M I Stomach Tubular adenocarcinoma Moderate None 3.0 23.01 23.01 
CGST77 Gastric cancer cfDNA 70 M IV Stomach Tubular adenocarcinoma Moderate None 4.5 15.09 15.09 
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CGST80 Gastric cancer cfDNA 58 M III Stomach Mucinous Adenocarcinoma Poor None 4.5 8.56 8.56 














NA F NA NA NA NA NA NA NA NA 
CGPLH189 Healthy cfDNA 74 M NA NA NA NA NA 5.0 5.84 5.84 
CGPLH190 Healthy cfDNA 67 M NA NA NA NA NA 4.7 18.07 18.07 
CGPLH192 Healthy cfDNA 74 M NA NA NA NA NA 4.7 12.19 12.19 
CGPLH193 Healthy cfDNA 72 F NA NA NA NA NA 5.0 5.47 5.47 
CGPLH194 Healthy cfDNA 75 F NA NA NA NA NA 5.0 9.98 9.98 
CGPLH196 Healthy cfDNA 64 M NA NA NA NA NA 5.0 11.69 11.69 
CGPLH197 Healthy cfDNA 74 M NA NA NA NA NA 5.0 5.69 5.69 
CGPLH198 Healthy cfDNA 66 M NA NA NA NA NA 5.0 4.36 4.36 
CGPLH199 Healthy cfDNA 75 F NA NA NA NA NA 5.0 9.77 9.77 
CGPLH200 Healthy cfDNA 51 M NA NA NA NA NA 5.0 5.60 5.60 
CGPLH201 Healthy cfDNA 68 F NA NA NA NA NA 5.0 8.82 8.82 
CGPLH202 Healthy cfDNA 73 M NA NA NA NA NA 5.0 5.54 5.54 
CGPLH203 Healthy cfDNA 59 M NA NA NA NA NA 5.0 9.03 9.03 
CGPLH205 Healthy cfDNA 68 F NA NA NA NA NA 5.0 4.74 4.74 
CGPLH208 Healthy cfDNA 75 F NA NA NA NA NA 5.0 4.67 4.67 
CGPLH209 Healthy cfDNA 74 M NA NA NA NA NA 5.0 5.15 5.15 
CGPLH210 Healthy cfDNA 75 M NA NA NA NA NA 5.0 5.41 5.41 
CGPLH211 Healthy cfDNA 75 F NA NA NA NA NA 5.0 6.24 6.24 
CGPLH300 Healthy cfDNA 72 F NA NA NA NA NA 4.4 6.75 6.75 
CGPLH307 Healthy cfDNA 53 M NA NA NA NA NA 4.5 3.50 3.50 
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CGPLH308 Healthy cfDNA 60 M NA NA NA NA NA 4.5 6.01 6.01 
CGPLH309 Healthy cfDNA 61 F NA NA NA NA NA 4.5 5.21 5.21 
CGPLH310 Healthy cfDNA 55 F NA NA NA NA NA 4.5 15.25 15.25 
CGPLH311 Healthy cfDNA 50 M NA NA NA NA NA 4.5 4.47 4.47 





59 M NA NA NA NA NA 4.4 16.24 16.24 
CGPLH315 Healthy cfDNA 59 F NA NA NA NA NA 4.2 11.55 11.55 
CGPLH316 Healthy cfDNA 64 M NA NA NA NA NA 4.5 28.92 27.78 
CGPLH317 Healthy cfDNA 53 F NA NA NA NA NA 4.5 7.62 7.62 
CGPLH319 Healthy cfDNA 60 F NA NA NA NA NA 4.2 4.41 4.41 
CGPLH320 Healthy cfDNA 75 F NA NA NA NA NA 4.5 6.93 6.93 
CGPLH322 Healthy cfDNA 53 F NA NA NA NA NA 4.2 8.17 8.17 
CGPLH324 Healthy cfDNA 59 F NA NA NA NA NA 5.0 6.63 6.63 
CGPLH325 Healthy cfDNA 54 M NA NA NA NA NA 4.6 4.15 4.15 
CGPLH326 Healthy cfDNA 67 F NA NA NA NA NA 4.5 6.06 6.06 
CGPLH327 Healthy cfDNA 50 M NA NA NA NA NA 4.8 1.24 1.24 





68 F NA NA NA NA NA 4.9 5.47 5.47 
CGPLH329 Healthy cfDNA 59 M NA NA NA NA NA 4.5 5.27 5.27 
CGPLH330 Healthy cfDNA 75 M NA NA NA NA NA 4.3 10.21 10.21 





55 M NA NA NA NA NA 4.3 4.15 4.15 
CGPLH333 Healthy cfDNA 60 M NA NA NA NA NA 4.7 4.06 4.06 
CGPLH335 Healthy cfDNA 74 M NA NA NA NA NA 4.4 9.39 9.39 
CGPLH336 Healthy cfDNA 53 F NA NA NA NA NA 4.6 6.64 6.64 
CGPLH337 Healthy cfDNA 53 F NA NA NA NA NA 4.2 4.48 4.48 
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CGPLH338 Healthy cfDNA 75 M NA NA NA NA NA 4.5 59.44 27.78 
CGPLH339 Healthy cfDNA 70 M NA NA NA NA NA 4.5 12.27 12.27 
CGPLH340 Healthy cfDNA 62 M NA NA NA NA NA 4.5 4.86 4.86 
CGPLH341 Healthy cfDNA 61 F NA NA NA NA NA 4.1 7.62 7.62 
CGPLH342 Healthy cfDNA 49 F NA NA NA NA NA 4.2 18.29 18.29 
CGPLH343 Healthy cfDNA 58 M NA NA NA NA NA 4.5 3.49 3.49 
CGPLH344 Healthy cfDNA 50 M NA NA NA NA NA 4.2 8.41 8.41 
CGPLH345 Healthy cfDNA 55 F NA NA NA NA NA 4.5 9.73 9.73 
CGPLH346 Healthy cfDNA 50 F NA NA NA NA NA 4.5 7.86 7.86 
CGPLH35 Healthy cfDNA 48 F NA NA NA NA NA 4.0 13.15 13.15 
CGPLH350 Healthy cfDNA 65 M NA NA NA NA NA 3.5 6.09 6.09 
CGPLH351 Healthy cfDNA 71 M NA NA NA NA NA 4.0 15.91 15.91 
CGPLH352 Healthy cfDNA 50 F NA NA NA NA NA 4.2 6.47 6.47 
CGPLH353 Healthy cfDNA 50 F NA NA NA NA NA 4.2 4.47 4.47 
CGPLH354 Healthy cfDNA 50 F NA NA NA NA NA 4.2 17.49 17.49 
CGPLH355 Healthy cfDNA 70 M NA NA NA NA NA 4.2 11.58 11.58 
CGPLH356 Healthy cfDNA 50 F NA NA NA NA NA 4.5 3.94 3.94 
CGPLH357 Healthy cfDNA 52 F NA NA NA NA NA 4.2 11.79 11.79 
CGPLH358 Healthy cfDNA 55 M NA NA NA NA NA 4.2 21.06 21.06 
CGPLH36 Healthy cfDNA 36 F NA NA NA NA NA 4.0 13.00 13.00 
CGPLH360 Healthy cfDNA 60 M NA NA NA NA NA 4.2 3.48 3.48 
CGPLH361 Healthy cfDNA 50 M NA NA NA NA NA 4.3 6.98 6.98 
CGPLH362 Healthy cfDNA 72 F NA NA NA NA NA 4.4 8.49 8.49 
CGPLH363 Healthy cfDNA 68 F NA NA NA NA NA 4.5 4.44 4.44 
CGPLH364 Healthy cfDNA 50 F NA NA NA NA NA 4.5 17.31 17.31 
CGPLH365 Healthy cfDNA 68 F NA NA NA NA NA 4.5 0.55 0.55 
CGPLH366 Healthy cfDNA 61 M NA NA NA NA NA 4.5 4.88 4.88 
CGPLH367 Healthy cfDNA 50 F NA NA NA NA NA 4.4 6.48 6.48 
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CGPLH368 Healthy cfDNA 50 M NA NA NA NA NA 4.3 2.63 2.63 





55 F NA NA NA NA NA 4.4 10.71 10.71 
CGPLH37 Healthy cfDNA 39 F NA NA NA NA NA 4.0 9.73 9.73 
CGPLH370 Healthy cfDNA 50 F NA NA NA NA NA 4.5 7.22 7.22 
CGPLH371 Healthy cfDNA 57 F NA NA NA NA NA 4.6 5.62 5.62 
CGPLH380 Healthy cfDNA 53 F NA NA NA NA NA 4.2 6.61 6.61 
CGPLH381 Healthy cfDNA 56 F NA NA NA NA NA 4.2 27.38 27.38 
CGPLH382 Healthy cfDNA 53 F NA NA NA NA NA 4.5 11.58 11.58 
CGPLH383 Healthy cfDNA 62 F NA NA NA NA NA 4.5 25.50 25.50 
CGPLH384 Healthy cfDNA 50 M NA NA NA NA NA 4.5 15.66 15.66 
CGPLH385 Healthy cfDNA 69 M NA NA NA NA NA 4.5 19.35 19.35 





62 M NA NA NA NA NA 4.6 6.54 6.54 
CGPLH387 Healthy cfDNA 71 F NA NA NA NA NA 4.5 6.19 6.19 
CGPLH388 Healthy cfDNA 57 F NA NA NA NA NA 4.5 6.62 6.62 
CGPLH389 Healthy cfDNA 73 F NA NA NA NA NA 4.6 14.78 14.78 
CGPLH390 Healthy cfDNA 50 F NA NA NA NA NA 4.5 12.14 12.14 





58 M NA NA NA NA NA 4.5 8.37 8.37 
CGPLH392 Healthy cfDNA 57 F NA NA NA NA NA 4.5 8.39 8.39 
CGPLH393 Healthy cfDNA 54 M NA NA NA NA NA 4.5 5.27 5.27 
CGPLH394 Healthy cfDNA 55 F NA NA NA NA NA 4.4 3.79 3.79 





56 F NA NA NA NA NA 4.4 5.40 5.40 
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CGPLH396 Healthy cfDNA 50 M NA NA NA NA NA 4.4 20.31 20.31 
CGPLH398 Healthy cfDNA 68 M NA NA NA NA NA 4.3 13.01 13.01 
CGPLH399 Healthy cfDNA 62 F NA NA NA NA NA 4.4 4.79 4.79 





64 M NA NA NA NA NA 4.4 6.26 6.26 





50 M NA NA NA NA NA 4.4 11.13 11.13 
CGPLH402 Healthy cfDNA 57 F NA NA NA NA NA 4.5 2.89 2.89 
CGPLH403 Healthy cfDNA 64 M NA NA NA NA NA 4.3 4.41 4.41 
CGPLH404 Healthy cfDNA 50 M NA NA NA NA NA 4.2 6.38 6.38 
CGPLH405 Healthy cfDNA 50 F NA NA NA NA NA 4.4 7.28 7.28 
CGPLH406 Healthy cfDNA 57 M NA NA NA NA NA 4.2 5.40 5.40 
CGPLH407 Healthy cfDNA 75 F NA NA NA NA NA 4.0 13.30 13.30 
CGPLH408 Healthy cfDNA 50 F NA NA NA NA NA 4.2 5.18 5.18 
CGPLH409 Healthy cfDNA 53 M NA NA NA NA NA 3.7 3.98 3.98 
CGPLH410 Healthy cfDNA 52 M NA NA NA NA NA 4.1 6.91 6.91 
CGPLH411 Healthy cfDNA 50 F NA NA NA NA NA 4.1 3.30 3.30 
CGPLH412 Healthy cfDNA 53 F NA NA NA NA NA 4.1 5.55 5.55 
CGPLH413 Healthy cfDNA 54 F NA NA NA NA NA 4.5 8.18 8.18 
CGPLH414 Healthy cfDNA 56 M NA NA NA NA NA 3.8 5.85 5.85 
CGPLH415 Healthy cfDNA 59 M NA NA NA NA NA 4.7 10.20 10.20 
CGPLH416 Healthy cfDNA 58 F NA NA NA NA NA 4.5 11.73 11.73 
CGPLH417 Healthy cfDNA 70 M NA NA NA NA NA 4.2 10.98 10.98 
CGPLH418 Healthy cfDNA 70 F NA NA NA NA NA 4.5 10.96 10.96 
CGPLH419 Healthy cfDNA 65 F NA NA NA NA NA 4.5 10.17 10.17 
CGPLH42 Healthy cfDNA 54 F NA NA NA NA NA 4.0 14.30 14.30 
CGPLH420 Healthy cfDNA 51 M NA NA NA NA NA 4.2 12.32 12.32 
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CGPLH422 Healthy cfDNA 68 F NA NA NA NA NA 4.6 5.42 5.42 
CGPLH423 Healthy cfDNA 54 M NA NA NA NA NA 4.2 2.85 2.85 
CGPLH424 Healthy cfDNA 53 F NA NA NA NA NA 4.7 1.66 1.66 
CGPLH425 Healthy cfDNA 53 F NA NA NA NA NA 4.4 5.98 5.98 
CGPLH426 Healthy cfDNA 68 M NA NA NA NA NA 4.4 2.84 2.84 
CGPLH427 Healthy cfDNA 68 M NA NA NA NA NA 4.4 10.86 10.86 
CGPLH428 Healthy cfDNA 50 F NA NA NA NA NA 4.5 6.27 6.27 
CGPLH429 Healthy cfDNA 63 F NA NA NA NA NA 4.5 3.89 3.89 
CGPLH43 Healthy cfDNA 49 F NA NA NA NA NA 4.0 8.50 8.50 
CGPLH430 Healthy cfDNA 69 F NA NA NA NA NA 4.2 10.33 10.33 
CGPLH431 Healthy cfDNA 59 F NA NA NA NA NA 4.8 12.81 12.81 
CGPLH432 Healthy cfDNA 59 F NA NA NA NA NA 4.8 2.42 2.42 
CGPLH434 Healthy cfDNA 59 M NA NA NA NA NA 4.6 8.83 8.83 
CGPLH435 Healthy cfDNA 50 M NA NA NA NA NA 4.5 8.95 8.95 
CGPLH436 Healthy cfDNA 50 F NA NA NA NA NA 4.5 4.29 4.29 
CGPLH437 Healthy cfDNA 56 M NA NA NA NA NA 4.6 18.07 18.07 
CGPLH438 Healthy cfDNA 69 M NA NA NA NA NA 4.8 16.62 16.62 
CGPLH439 Healthy cfDNA 50 F NA NA NA NA NA 4.7 4.38 4.38 
CGPLH440 Healthy cfDNA 72 M NA NA NA NA NA 4.7 4.32 4.32 
CGPLH441 Healthy cfDNA 50 F NA NA NA NA NA 4.7 7.80 7.80 
CGPLH442 Healthy cfDNA 59 F NA NA NA NA NA 4.5 6.15 6.15 
CGPLH443 Healthy cfDNA 52 F NA NA NA NA NA 4.4 3.44 3.44 
CGPLH444 Healthy cfDNA 60 F NA NA NA NA NA 4.4 4.12 4.12 
CGPLH445 Healthy cfDNA 53 F NA NA NA NA NA 4.4 4.38 4.38 
CGPLH446 Healthy cfDNA 51 F NA NA NA NA NA 4.4 2.92 2.92 
CGPLH447 Healthy cfDNA 50 F NA NA NA NA NA 4.6 3.87 3.87 
CGPLH448 Healthy cfDNA 51 F NA NA NA NA NA 4.4 5.29 5.29 
CGPLH449 Healthy cfDNA 51 F NA NA NA NA NA 4.5 3.77 3.77 
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CGPLH45 Healthy cfDNA 58 F NA NA NA NA NA 4.0 10.85 10.85 
CGPLH450 Healthy cfDNA 50 F NA NA NA NA NA 4.5 5.62 5.62 
CGPLH451 Healthy cfDNA 54 F NA NA NA NA NA 4.6 7.24 7.24 
CGPLH452 Healthy cfDNA 69 M NA NA NA NA NA 4.4 2.54 2.54 
CGPLH453 Healthy cfDNA 53 F NA NA NA NA NA 4.6 9.11 9.11 





55 F NA NA NA NA NA 4.5 2.42 2.42 
CGPLH456 Healthy cfDNA 54 F NA NA NA NA NA 4.5 3.11 3.11 
CGPLH457 Healthy cfDNA 54 F NA NA NA NA NA 4.4 5.92 5.92 
CGPLH458 Healthy cfDNA 52 F NA NA NA NA NA 4.5 16.04 16.04 
CGPLH459 Healthy cfDNA 50 F NA NA NA NA NA 4.4 6.52 6.52 
CGPLH46 Healthy cfDNA 35 F NA NA NA NA NA 4.0 8.25 8.25 
CGPLH460 Healthy cfDNA 50 F NA NA NA NA NA 4.6 5.24 5.24 
CGPLH463 Healthy cfDNA 53 F NA NA NA NA NA 4.5 22.77 22.77 
CGPLH464 Healthy cfDNA 50 F NA NA NA NA NA 4.4 2.90 2.90 
CGPLH465 Healthy cfDNA 50 F NA NA NA NA NA 4.5 4.76 4.76 





50 F NA NA NA NA NA 4.5 6.75 6.75 
CGPLH467 Healthy cfDNA 50 F NA NA NA NA NA 4.5 4.59 4.59 
CGPLH468 Healthy cfDNA 53 M NA NA NA NA NA 4.5 11.19 11.19 
CGPLH469 Healthy cfDNA 50 F NA NA NA NA NA 4.5 3.25 3.25 
CGPLH47 Healthy cfDNA 50 F NA NA NA NA NA 4.0 7.43 7.43 
CGPLH470 Healthy cfDNA 68 F NA NA NA NA NA 4.5 13.64 13.64 
CGPLH471 Healthy cfDNA 70 F NA NA NA NA NA 4.3 13.00 13.00 
CGPLH472 Healthy cfDNA 69 F NA NA NA NA NA 4.2 10.17 10.17 
CGPLH473 Healthy cfDNA 62 M NA NA NA NA NA 4.3 2.98 2.98 
CGPLH474 Healthy cfDNA 63 M NA NA NA NA NA 4.3 29.15 29.15 
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CGPLH475 Healthy cfDNA 67 F NA NA NA NA NA 4.0 7.26 7.26 
CGPLH476 Healthy cfDNA 65 F NA NA NA NA NA 4.3 6.16 6.16 
CGPLH477 Healthy cfDNA 61 F NA NA NA NA NA 4.3 15.21 15.21 
CGPLH478 Healthy cfDNA 51 F NA NA NA NA NA 4.4 7.29 7.29 
CGPLH479 Healthy cfDNA 52 M NA NA NA NA NA 4.5 8.73 8.73 
CGPLH48 Healthy cfDNA 38 F NA NA NA NA NA 4.0 6.38 6.38 
CGPLH480 Healthy cfDNA 50 F NA NA NA NA NA 4.4 10.62 10.62 
CGPLH481 Healthy cfDNA 53 F NA NA NA NA NA 4.3 6.75 6.75 
CGPLH482 Healthy cfDNA 50 M NA NA NA NA NA 4.3 23.58 23.58 
CGPLH483 Healthy cfDNA 66 M NA NA NA NA NA 4.4 14.44 14.44 
CGPLH484 Healthy cfDNA 72 M NA NA NA NA NA 4.2 14.32 14.32 
CGPLH485 Healthy cfDNA 50 F NA NA NA NA NA 4.3 9.64 9.64 
CGPLH486 Healthy cfDNA 50 F NA NA NA NA NA 4.3 10.16 10.16 
CGPLH487 Healthy cfDNA 50 M NA NA NA NA NA 4.4 6.11 6.11 
CGPLH488 Healthy cfDNA 50 F NA NA NA NA NA 4.5 7.88 7.88 
CGPLH49 Healthy cfDNA 39 F NA NA NA NA NA 4.0 6.60 6.60 
CGPLH490 Healthy cfDNA 50 F NA NA NA NA NA 4.5 4.18 4.18 
CGPLH491 Healthy cfDNA 50 F NA NA NA NA NA 4.5 13.16 13.16 
CGPLH492 Healthy cfDNA 51 F NA NA NA NA NA 4.5 3.83 3.83 
CGPLH493 Healthy cfDNA 64 M NA NA NA NA NA 4.5 25.06 25.06 
CGPLH494 Healthy cfDNA 53 F NA NA NA NA NA 4.4 5.24 5.24 
CGPLH495 Healthy cfDNA 50 F NA NA NA NA NA 4.4 5.03 5.03 
CGPLH496 Healthy cfDNA 74 M NA NA NA NA NA 4.5 34.01 27.78 





68 F NA NA NA NA NA 4.4 5.88 5.88 
CGPLH498 Healthy cfDNA 54 F NA NA NA NA NA 4.4 5.33 5.33 
CGPLH499 Healthy cfDNA 52 F NA NA NA NA NA 4.5 7.85 7.85 
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CGPLH50 Healthy cfDNA 55 F NA NA NA NA NA 4.0 7.05 7.05 
CGPLH500 Healthy cfDNA 51 F NA NA NA NA NA 4.5 3.49 3.49 
CGPLH501 Healthy cfDNA 50 F NA NA NA NA NA 4.3 6.29 6.29 
CGPLH502 Healthy cfDNA 53 F NA NA NA NA NA 4.5 2.24 2.24 
CGPLH503 Healthy cfDNA 67 M NA NA NA NA NA 4.5 11.01 11.01 





57 F NA NA NA NA NA 4.2 10.02 10.02 
CGPLH505 Healthy cfDNA 50 F NA NA NA NA NA 4.1 5.23 5.23 
CGPLH506 Healthy cfDNA 51 F NA NA NA NA NA 4.5 12.23 12.23 
CGPLH507 Healthy cfDNA 56 M NA NA NA NA NA 4.1 9.89 9.89 





54 F NA NA NA NA NA 4.4 9.55 9.55 
CGPLH509 Healthy cfDNA 60 M NA NA NA NA NA 4.0 9.79 9.79 
CGPLH51 Healthy cfDNA 48 F NA NA NA NA NA 4.0 7.85 7.85 
CGPLH510 Healthy cfDNA 67 M NA NA NA NA NA 4.2 14.20 14.20 
CGPLH511 Healthy cfDNA 75 M NA NA NA NA NA 4.5 12.94 12.94 
CGPLH512 Healthy cfDNA 52 M NA NA NA NA NA 4.3 8.60 8.60 
CGPLH513 Healthy cfDNA 57 M NA NA NA NA NA 4.3 6.54 6.54 
CGPLH514 Healthy cfDNA 55 F NA NA NA NA NA 4.4 10.94 10.94 
CGPLH515 Healthy cfDNA 68 F NA NA NA NA NA 4.5 8.71 8.71 
CGPLH516 Healthy cfDNA 65 F NA NA NA NA NA 4.5 7.32 7.32 





54 F NA NA NA NA NA 4.5 9.74 9.74 
CGPLH518 Healthy cfDNA 50 F NA NA NA NA NA 4.4 5.92 5.92 
CGPLH519 Healthy cfDNA 54 M NA NA NA NA NA 4.4 6.96 6.96 
CGPLH52 Healthy cfDNA 40 F NA NA NA NA NA 4.0 9.90 9.90 
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CGPLH520 Healthy cfDNA 51 F NA NA NA NA NA 4.3 8.27 8.27 
CGPLH54 Healthy cfDNA 47 F NA NA NA NA NA 4.0 14.18 14.18 
CGPLH55 Healthy cfDNA 46 F NA NA NA NA NA 4.0 7.35 7.35 
CGPLH56 Healthy cfDNA 42 F NA NA NA NA NA 4.0 5.20 5.20 
CGPLH57 Healthy cfDNA 39 F NA NA NA NA NA 4.0 7.15 7.15 
CGPLH59 Healthy cfDNA 34 F NA NA NA NA NA 4.0 6.03 6.03 





50 F NA NA NA NA NA 4.0 11.12 11.12 
CGPLH626 Healthy cfDNA 53 F NA NA NA NA NA 4.5 2.69 2.69 
CGPLH63 Healthy cfDNA 47 F NA NA NA NA NA 4.0 10.10 10.10 
CGPLH639 Healthy cfDNA 50 F NA NA NA NA NA 4.5 2.00 2.00 
CGPLH64 Healthy cfDNA 55 F NA NA NA NA NA 4.0 8.03 8.03 
CGPLH640 Healthy cfDNA 50 F NA NA NA NA NA 4.5 9.36 9.36 
CGPLH642 Healthy cfDNA 54 F NA NA NA NA NA 4.5 4.99 4.99 
CGPLH643 Healthy cfDNA 55 F NA NA NA NA NA 4.4 7.12 7.12 
CGPLH644 Healthy cfDNA 50 F NA NA NA NA NA 4.4 5.06 5.06 
CGPLH646 Healthy cfDNA 50 F NA NA NA NA NA 4.4 6.75 6.75 
CGPLH75 Healthy cfDNA 46 F NA NA NA NA NA 4.0 3.87 3.87 
CGPLH76 Healthy cfDNA 53 F NA NA NA NA NA 4.0 4.03 4.03 
CGPLH77 Healthy cfDNA 46 F NA NA NA NA NA 4.0 5.89 5.89 
CGPLH78 Healthy cfDNA 34 F NA NA NA NA NA 4.0 2.51 2.51 
CGPLH79 Healthy cfDNA 37 F NA NA NA NA NA 4.0 3.68 3.68 
CGPLH80 Healthy cfDNA 37 F NA NA NA NA NA 4.0 1.94 1.94 
CGPLH81 Healthy cfDNA 54 F NA NA NA NA NA 4.0 5.16 5.16 
CGPLH82 Healthy cfDNA 38 F NA NA NA NA NA 4.0 3.30 3.30 
CGPLH83 Healthy cfDNA 60 F NA NA NA NA NA 4.0 5.04 5.04 
CGPLH84 Healthy cfDNA 45 F NA NA NA NA NA 4.0 3.33 3.33 
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Poor Lung 5.0 0.87 1.07 




Poor Lung 2.0 8.74 8.75 




Poor Lung 5.0 2.11 2.11 




Poor Lung 5.0 2.38 2.38 
CGLU344 Lung Cancer cfDNA 65 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Pleura, Liver, 
Peritoneum 5.0 9.22 9.22 
CGLU344 Lung Cancer cfDNA 65 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Pleura, Liver, 
Peritoneum 5.0 5.31 5.32 
CGLU344 Lung Cancer cfDNA 65 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Pleura, Liver, 
Peritoneum 5.0 15.63 15.64 
CGLU344 Lung Cancer cfDNA 65 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Pleura, Liver, 
Peritoneum 5.0 34.77 25.00 
CGLU369 Lung Cancer cfDNA 48 F IV Right Upper Lobe of Lung Adenocarcinoma NA Brain 5.0 8.41 8.42 
CGLU369 Lung Cancer cfDNA 48 F IV Right Upper Lobe of Lung Adenocarcinoma NA Brain 5.0 10.09 10.09 
CGLU369 Lung Cancer cfDNA 48 F IV Right Upper Lobe of Lung Adenocarcinoma NA Brain 5.0 6.69 6.70 
CGLU369 Lung Cancer cfDNA 48 F IV Right Upper Lobe of Lung Adenocarcinoma NA Brain 2.0 11.28 11.28 
CGLU373 Lung Cancer cfDNA 56 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate None 5.0 6.28 6.28 
CGLU373 Lung Cancer cfDNA 56 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate None 3.5 5.55 5.55 
CGLU373 Lung Cancer cfDNA 56 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate None 5.0 3.82 3.82 
CGLU373 Lung Cancer cfDNA 56 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate None 5.0 6.35 6.35 
CGPLLU13 Lung Cancer cfDNA 72 F IV Right Lung Adenocarcinoma NA Bone 3.2 8.66 8.66 
CGPLLU13 Lung Cancer cfDNA 72 F IV Right Lung Adenocarcinoma NA Bone 4.5 8.39 8.39 
CGPLLU13 Lung Cancer cfDNA 72 F IV Right Lung Adenocarcinoma NA Bone 5.0 5.97 5.97 
CGPLLU13 Lung Cancer cfDNA 72 F IV Right Lung Adenocarcinoma NA Bone 5.0 7.67 7.67 
CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
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CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
CGPLLU14 Lung Cancer cfDNA 55 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate NA 2.0 2.55 2.55 
CGPLLU144 Lung Cancer cfDNA 52 M II Lung Adenocarcinoma Poor None 3.5 31.51 31.51 
CGPLLU147 Lung Cancer cfDNA 60 M III Lung Adenosquamous Carcinoma Poor None 3.8 6.72 6.72 
CGPLLU161 Lung Cancer cfDNA 41 F II Lung Adenocarcinoma Well None 4.0 83.04 83.04 
CGPLLU162 Lung Cancer cfDNA 38 M II Right Lung Adenocarcinoma Moderate None 3.1 40.32 40.32 
CGPLLU163 Lung Cancer cfDNA 66 M II Left Lung Adenocarcinoma Poor None 5.0 54.03 54.03 
CGPLLU165 Lung Cancer cfDNA 68 F II Right Lung Adenocarcinoma Well None 4.5 20.13 20.13 
CGPLLU168 Lung Cancer cfDNA 70 F I Lung Adenocarcinoma Poor None 4.3 19.38 19.38 
CGPLLU169 Lung Cancer cfDNA 64 M I Lung Squamous Cell Carcinoma Moderate None 4.2 13.70 13.70 
CGPLLU175 Lung Cancer cfDNA 47 M I Lung Squamous Cell Carcinoma Moderate None 4.4 16.84 16.84 
CGPLLU176 Lung Cancer cfDNA 58 M I Lung Adenosquamous Carcinoma Moderate None 3.2 7.86 7.86 
CGPLLU177 Lung Cancer cfDNA 45 M II Right Lung Adenocarcinoma NA None 3.9 19.07 19.07 
CGPLLU180 Lung Cancer cfDNA 57 M I Right Lung Large Cell Carcinoma   Poor None 3.2 19.31 19.31 
CGPLLU198 Lung Cancer cfDNA 49 F I Left Lung Adenocarcinoma Moderate None 4.2 14.09 14.09 
CGPLLU202 Lung Cancer cfDNA 68 M I Right Lung Adenocarcinoma NA None 4.4 24.72 24.72 
CGPLLU203 Lung Cancer cfDNA 66 M II Right Lung Squamous Cell Carcinoma Well None 4.2 26.24 26.24 
CGPLLU205 Lung Cancer cfDNA 65 M II Left Lung Adenocarcinoma Poor None 4.0 18.56 18.56 
CGPLLU206 Lung Cancer cfDNA 55 M III Right Lung Squamous Cell Carcinoma Poor None 3.5 18.24 18.24 
CGPLLU207 Lung Cancer cfDNA 60 F II Lung Adenocarcinoma Well None 4.0 17.29 17.29 
CGPLLU208 Lung Cancer cfDNA 56 F II Lung Adenocarcinoma Moderate None 3.0 24.34 24.34 
CGPLLU209 Lung Cancer cfDNA 65 M II Lung Large Cell Carcinoma   Poor None 5.5 53.95 53.95 
CGPLLU244 Lung Cancer cfDNA 66 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate/Poor 
Liver, Rib, Brain, 
Pleura 4.5 17.84 17.84 
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CGPLLU244 Lung Cancer cfDNA 66 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate/Poor 
Liver, Rib, Brain, 
Pleura 4.5 17.84 17.84 
CGPLLU244 Lung Cancer cfDNA 66 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate/Poor 
Liver, Rib, Brain, 
Pleura 4.5 17.84 17.84 
CGPLLU244 Lung Cancer cfDNA 66 F IV Right Upper Lobe of Lung Adenocarcinoma Moderate/Poor 
Liver, Rib, Brain, 
Pleura 4.5 17.84 17.84 
CGPLLU245 Lung Cancer cfDNA 49 M IV Left Upper Lobe of Lung Adenocarcinoma NA Brain 4.7 19.42 19.42 
CGPLLU245 Lung Cancer cfDNA 49 M IV Left Upper Lobe of Lung Adenocarcinoma NA Brain 4.7 19.42 19.42 
CGPLLU245 Lung Cancer cfDNA 49 M IV Left Upper Lobe of Lung Adenocarcinoma NA Brain 4.7 19.42 19.42 
CGPLLU245 Lung Cancer cfDNA 49 M IV Left Upper Lobe of Lung Adenocarcinoma NA Brain 4.7 19.42 19.42 
CGPLLU246 Lung Cancer cfDNA 65 F IV Right Lower Lobe of Lung Adenocarcinoma Poor Pleura 5.5 18.51 18.51 
CGPLLU246 Lung Cancer cfDNA 65 F IV Right Lower Lobe of Lung Adenocarcinoma Poor Pleura 5.5 18.51 18.51 
CGPLLU246 Lung Cancer cfDNA 65 F IV Right Lower Lobe of Lung Adenocarcinoma Poor Pleura 5.5 18.51 18.51 
CGPLLU246 Lung Cancer cfDNA 65 F IV Right Lower Lobe of Lung Adenocarcinoma Poor Pleura 5.5 18.51 18.51 
CGPLLU264 Lung Cancer cfDNA 84 M IV Left Middle Lung Adenocarcinoma NA Lung 3.0 7.15 7.15 
CGPLLU264 Lung Cancer cfDNA 84 M IV Left Middle Lung Adenocarcinoma NA Lung 4.5 10.53 10.53 
CGPLLU264 Lung Cancer cfDNA 84 M IV Left Middle Lung Adenocarcinoma NA Lung 4.0 9.60 9.60 
CGPLLU264 Lung Cancer cfDNA 84 M IV Left Middle Lung Adenocarcinoma NA Lung 4.0 22.97 22.97 
CGPLLU265 Lung Cancer cfDNA 71 F IV Left Lower Lobe of Lung Adenocarcinoma NA None 4.0 8.11 8.11 
CGPLLU265 Lung Cancer cfDNA 71 F IV Left Lower Lobe of Lung Adenocarcinoma NA None 4.2 7.53 7.53 
CGPLLU265 Lung Cancer cfDNA 71 F IV Left Lower Lobe of Lung Adenocarcinoma NA None 5.0 16.17 16.17 
CGPLLU265 Lung Cancer cfDNA 71 F IV Left Lower Lobe of Lung Adenocarcinoma NA None 4.2 7.16 7.16 
CGPLLU266 Lung Cancer cfDNA 78 M IV Left Lower Lobe of Lung Adenocarcinoma Moderate None 3.5 6.31 6.31 
CGPLLU266 Lung Cancer cfDNA 78 M IV Left Lower Lobe of Lung Adenocarcinoma Moderate None 5.0 14.39 14.39 
CGPLLU266 Lung Cancer cfDNA 78 M IV Left Lower Lobe of Lung Adenocarcinoma Moderate None 5.0 7.64 7.64 
CGPLLU266 Lung Cancer cfDNA 78 M IV Left Lower Lobe of Lung Adenocarcinoma Moderate None 5.0 5.32 5.32 
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CGPLLU267 Lung Cancer cfDNA 55 F IV Right Upper Lobe of Lung 
Squamous Cell 
Carcinoma Poor Lung 4.5 3.34 3.34 
CGPLLU267 Lung Cancer cfDNA 55 F IV Right Upper Lobe of Lung 
Squamous Cell 
Carcinoma Poor Lung 3.5 3.00 3.00 
CGPLLU267 Lung Cancer cfDNA 55 F IV Right Upper Lobe of Lung 
Squamous Cell 
Carcinoma Poor Lung 4.5 2.87 2.87 




Adenocarcinoma NA Brain, Liver, Bone, Pleura 3.5 17.79 17.79 




Adenocarcinoma NA Brain, Liver, Bone, Pleura 5.0 8.35 8.35 




Adenocarcinoma NA Brain, Liver, Bone, Pleura 5.0 11.40 11.40 
CGPLLU271 Lung Cancer cfDNA 73 M IV Left Upper Lobe of Lung Adenocarcinoma NA Pleura 4.0 13.77 13.77 
CGPLLU271 Lung Cancer cfDNA 73 M IV Left Upper Lobe of Lung Adenocarcinoma NA Pleura 3.5 13.46 13.46 
CGPLLU271 Lung Cancer cfDNA 73 M IV Left Upper Lobe of Lung Adenocarcinoma NA Pleura 4.0 4.70 4.70 
CGPLLU271 Lung Cancer cfDNA 73 M IV Left Upper Lobe of Lung Adenocarcinoma NA Pleura 4.5 13.84 13.84 
CGPLLU271 Lung Cancer cfDNA 73 M IV Left Upper Lobe of Lung Adenocarcinoma NA Pleura 5.0 18.86 18.86 
CGPLLU43 Lung Cancer cfDNA 57 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate None 4.0 4.12 4.12 
CGPLLU43 Lung Cancer cfDNA 57 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate None 3.7 3.26 3.26 
CGPLLU43 Lung Cancer cfDNA 57 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate None 3.7 8.20 8.20 
CGPLLU43 Lung Cancer cfDNA 57 F IV Right Lower Lobe of Lung Adenocarcinoma Moderate None 4.9 2.17 2.17 
CGPLLU86 Lung Cancer cfDNA 55 M IV Left Upper Lobe of Lung Adenocarcinoma NA Lung 4.0 7.90 7.90 
CGPLLU86 Lung Cancer cfDNA 55 M IV Left Upper Lobe of Lung Adenocarcinoma NA Lung 4.0 7.90 7.90 
CGPLLU86 Lung Cancer cfDNA 55 M IV Left Upper Lobe of Lung Adenocarcinoma NA Lung 4.0 7.90 7.90 
CGPLLU86 Lung Cancer cfDNA 55 M IV Left Upper Lobe of Lung Adenocarcinoma NA Lung 4.0 7.90 7.90 
CGPLLU88 Lung Cancer cfDNA 59 M IV Right Middle Lobe of Lung Adenocarcinoma NA None 4.0 3.04 3.04 
CGPLLU88 Lung Cancer cfDNA 59 M IV Right Middle Lobe of Lung Adenocarcinoma NA None 5.0 6.49 6.49 
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CGPLLU88 Lung Cancer cfDNA 59 M IV Right Middle Lobe of Lung Adenocarcinoma NA None 5.0 27.66 27.66 
CGPLLU89 Lung Cancer cfDNA 54 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Brain, Bone, 
Lung 8.0 8.43 8.43 
CGPLLU89 Lung Cancer cfDNA 54 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Brain, Bone, 
Lung 8.0 8.43 8.43 
CGPLLU89 Lung Cancer cfDNA 54 F IV Right Upper Lobe of Lung Adenocarcinoma NA 
Brain, Bone, 
Lung 8.0 8.43 8.43 
CGPLOV11 Ovarian Cancer cfDNA 51 F IV Right Ovary Endometrioid Adenoarcinoma Moderate Omentum 3.4 17.35 17.35 
CGPLOV12 Ovarian Cancer cfDNA 45 F I Ovary Endometrioid Adenoarcinoma NA None 3.2 12.44 12.44 
CGPLOV13 Ovarian Cancer cfDNA 62 F IV Right Ovary Endometrioid Adenoarcinoma Poor Omentum 3.8 27.00 27.00 
CGPLOV15 Ovarian Cancer cfDNA 54 F III Ovary Adenocarcinoma Poor None 5.0 4.77 4.77 
CGPLOV16 Ovarian Cancer cfDNA 40 F III Ovary Serous Adenocarcinoma Moderate None 4.5 27.28 27.28 
CGPLOV19 Ovarian Cancer cfDNA 52 F II Ovary Endometrioid Adenoarcinoma Moderate None 5.0 23.46 23.46 
CGPLOV20 Ovarian Cancer cfDNA 52 F II Left Ovary Endometrioid Adenoarcinoma Poor None 4.2 5.67 5.67 
CGPLOV21 Ovarian Cancer cfDNA 51 M IV Ovary Serous Adenocarcinoma Poor 
Omentum, 
Appendix 4.3 56.32 56.32 
CGPLOV22 Ovarian Cancer cfDNA 64 F III Left Ovary Serous Adenocarcinoma Well None 4.6 17.42 17.42 
CGPLOV23 Ovarian Cancer cfDNA 47 F I Ovary Serous Adenocarcinoma Poor None 5.0 26.73 26.73 
CGPLOV24 Ovarian Cancer cfDNA 14 F I Ovary Germ Cell Tumor Poor None 4.2 10.71 10.71 
CGPLOV25 Ovarian Cancer cfDNA 18 F I Ovary Germ Cell Tumor Poor None 4.8 6.78 6.78 
CGPLOV26 Ovarian Cancer cfDNA 35 F I Ovary Germ Cell Tumor Poor None 4.5 27.90 27.90 
CGPLOV28 Ovarian Cancer cfDNA 63 F I Right Ovary Serous Carcinoma NA None 3.2 10.74 10.74 
CGPLOV31 Ovarian Cancer cfDNA 45 F III Right Ovary Clear Cell adenocarcinoma NA None 4.0 14.45 14.45 
CGPLOV32 Ovarian Cancer cfDNA 53 F I Left Ovary Mucinous Cystadenoma NA None 3.2 27.36 27.36 
CGPLOV37 Ovarian Cancer cfDNA 40 F I Ovary Serous Carcinoma NA None 3.2 46.88 46.88 
CGPLOV38 Ovarian Cancer cfDNA 46 F I Ovary Serous Carcinoma NA None 2.4 34.29 34.29 
CGPLOV40 Ovarian Cancer cfDNA 53 F IV Ovary Serous Carcinoma NA  Omentum, Uterus, Appendix 1.6 193.60 156.25 
CGPLOV41 Ovarian Cancer cfDNA 57 F IV Ovary Serous Carcinoma NA Omentum, Uterus, Cervix 4.4 10.03 10.03 
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CGPLOV42 Ovarian Cancer cfDNA 52 F I Ovary Serous Carcinoma NA None 4.2 49.51 49.51 




NA None 4.4 9.09 9.09 
CGPLOV44 Ovarian Cancer cfDNA 69 F I Ovary Mucinous Adenocarcinoma NA None 4.5 8.79 8.79 
CGPLOV46 Ovarian Cancer cfDNA 58 F I Ovary Serous Carcinoma NA None 4.1 8.97 8.97 
CGPLOV47 Ovarian Cancer cfDNA 41 F I Ovary Serous Cystadenoma NA None 4.5 19.35 19.35 
CGPLOV48 Ovarian Cancer cfDNA 52 F I Ovary Serous Carcinoma NA None 3.5 22.80 22.80 
CGPLOV49 Ovarian Cancer cfDNA 68 F III Ovary Serous Carcinoma NA None 4.2 16.48 16.48 
CGPLOV50 Ovarian Cancer cfDNA 30 F III Ovary Serous Carcinoma NA None 4.5 8.89 8.89 
CGPLPA112 Pancreatic Cancer cfDNA 58 M II Intra Pancreatic Bile Duct 
Intra Pancreatic 
Bile Duct NA None 3.5 18.52 18.52 
CGPLPA14 Pancreatic Cancer cfDNA 68 M II Pancreas Ductal Adenocarcinoma Poor None 4.0 1.30 1.30 
CGPLPA15 Pancreatic Cancer cfDNA 70 F II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 1.92 1.92 
CGPLPA156 Pancreatic Cancer cfDNA 73 F II Pancreas Ductal Adenocarcinoma Poor Lymph Node 4.5 7.54 7.54 
CGPLPA17 Pancreatic Cancer cfDNA 65 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 13.08 13.08 
CGPLPA23 Pancreatic Cancer cfDNA 58 F II Pancreas Ductal Adenocarcinoma Moderate Lymph Node 4.0 16.62 16.62 
CGPLPA25 Pancreatic Cancer cfDNA 69 F II Pancreas Ductal Adenocarcinoma Poor Lymph Node 4.0 8.71 8.71 
CGPLPA26 Pancreatic Cancer cfDNA 64 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 6.97 6.97 
CGPLPA28 Pancreatic Cancer cfDNA 79 F II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 18.13 18.13 
CGPLPA33 Pancreatic Cancer cfDNA 67 F II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 1.80 1.80 
CGPLPA34 Pancreatic Cancer cfDNA 73 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 3.36 3.36 
CGPLPA37 Pancreatic Cancer cfDNA 67 F II Pancreas Ductal Adenocarcinoma NA Lymph Node 4.0 21.83 21.83 
CGPLPA38 Pancreatic Cancer cfDNA 65 M II Pancreas Ductal Adenocarcinoma Moderate None 4.0 5.29 5.29 
CGPLPA39 Pancreatic Cancer cfDNA 67 F II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 11.73 11.73 
CGPLPA40 Pancreatic Cancer cfDNA 64 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 4.78 4.78 
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CGPLPA42 Pancreatic Cancer cfDNA 73 M II Pancreas Ductal Adenocarcinoma Moderate Lymph Node 4.0 3.41 3.41 
CGPLPA46 Pancreatic Cancer cfDNA 59 F II Pancreas Ductal Adenocarcinoma Poor Lymph Node 4.0 0.74 0.74 
CGPLPA47 Pancreatic Cancer cfDNA 67 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 4.0 6.01 6.01 
CGPLPA48 Pancreatic Cancer cfDNA 72 F I Pancreas Ductal Adenocarcinoma Well None NA NA NA 
CGPLPA52 Pancreatic Cancer cfDNA 63 M II Pancreas Ductal Adenocarcinoma Moderate None 2.5 9.86 9.86 
CGPLPA53 Pancreatic Cancer cfDNA 46 M I Pancreas Ductal Adenocarcinoma Poor Lymph Node 3.0 14.48 14.48 
CGPLPA58 Pancreatic Cancer cfDNA 74 F II Pancreas Ductal Adenocarcinoma NA None 3.0 6.87 6.87 




Well Lymph Node NA NA NA 
CGPLPA67 Pancreatic Cancer cfDNA 55 M III Pancreas Ductal Adenocarcinoma Well Lymph Node 3.2 9.72 9.72 
CGPLPA69 Pancreatic Cancer cfDNA 70 M I Pancreas Ductal Adenocarcinoma Well None 2.0 1.72 1.72 
CGPLPA71 Pancreatic Cancer cfDNA 64 M II Pancreas Ductal Adenocarcinoma Well Lymph Node 2.2 39.07 39.07 
CGPLPA74 Pancreatic Cancer cfDNA 71 F II Pancreas Ductal Adenocarcinoma Moderate Lymph Node 2.5 4.99 4.99 
CGPLPA76 Pancreatic Cancer cfDNA 69 M II Pancreas Ductal Adenocarcinoma Poor None 2.5 23.19 23.19 
CGPLPA85 Pancreatic Cancer cfDNA 77 F II Pancreas Ductal Adenocarcinoma Poor Lymph Node 3.0 152.46 41.67 
CGPLPA86 Pancreatic Cancer cfDNA 66 M II Pancreas Ductal Adenocarcinoma Moderate Lymph Node 2.5 11.02 11.02 
CGPLPA92 Pancreatic Cancer cfDNA 72 M II Pancreas Ductal Adenocarcinoma NA Lymph Node 2.0 5.34 5.34 
CGPLPA93 Pancreatic Cancer cfDNA 48 M II Pancreas Ductal Adenocarcinoma Poor None 3.0 96.28 41.67 
CGPLPA94 Pancreatic Cancer cfDNA 72 F II Pancreas Ductal Adenocarcinoma NA Lymph Node 3.0 29.66 29.66 
CGPLPA95 Pancreatic Cancer cfDNA 64 F II Pancreas Ductal Adenocarcinoma Well Lymph Node NA NA NA 




Table 4.2.  Summary of targeted cfDNA analyses. 




Bases Mapped to 
Genome 
Bases Mapped to 
Target Regions 






CGCRC291 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7501485600 3771359756 50% 44345 10359 
CGCRC292 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6736035200 3098886973 46% 36448 8603 
CGCRC293 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6300244000 2818734206 45% 33117 5953 
CGCRC294 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7786872600 3911796709 50% 46016 12071 
CGCRC295 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8240660200 3478059753 42% 40787 5826 
CGCRC296 Colorectal Cancer Preoperative, Treatment naïve 100 80930 5718556500 2898549356 51% 33912 10180 
CGCRC297 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7550826100 3717222432 49% 43545 5870 
CGCRC298 Colorectal Cancer Preoperative, Treatment naïve 100 80930 12501036400 6096393764 49% 71196 9617 
CGCRC299 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7812602900 4121569690 53% 48098 10338 
CGCRC300 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8648090300 3962285136 46% 46364 5756 
CGCRC301 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7538758100 3695480348 49% 43024 6618 
CGCRC302 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8573658300 4349420574 51% 51006 13799 
CGCRC303 Colorectal Cancer Preoperative, Treatment naïve 100 80930 5224046400 2505714343 48% 29365 8372 
CGCRC304 Colorectal Cancer Preoperative, Treatment naïve 100 80930 5762112600 2942170530 51% 34462 10208 
CGCRC305 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7213384100 3726953480 52% 43516 8589 
CGCRC306 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7075579700 3552441899 50% 41507 7372 
CGCRC307 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7572687100 3492191519 46% 40793 9680 
CGCRC308 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7945738000 3895908986 49% 45224 11809 
CGCRC309 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8487455800 3921079811 46% 45736 10739 
CGCRC310 Colorectal Cancer Preoperative, Treatment naïve 100 80930 9003580500 4678812441 52% 54713 11139 
CGCRC311 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6528162700 3276653864 50% 38324 6044 
CGCRC312 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7683294300 3316719187 43% 38652 4622 
CGCRC313 Colorectal Cancer Preoperative, Treatment naïve 100 80930 5874099200 2896148722 49% 33821 6506 
CGCRC314 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6883148500 3382767492 49% 39414 6664 
CGCRC315 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7497252500 3775556051 50% 44034 8666 
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CGCRC316 Colorectal Cancer Preoperative, Treatment naïve 100 80930 10684720400 5533857153 52% 64693 14289 
CGCRC317 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7086877600 3669434216 52% 43538 10944 
CGCRC318 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6880041100 3326357413 48% 39077 11571 
CGCRC319 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7485342900 3982677483 53% 47327 10502 
CGCRC320 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7058703200 3450648135 49% 40888 10198 
CGCRC321 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7203625900 3633396892 50% 43065 6499 
CGCRC332 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7202969100 3758323705 52% 44580 3243 
CGCRC333 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8767144700 4199126827 48% 49781 8336 
CGCRC334 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7771869100 3944578280 51% 46518 5014 
CGCRC335 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7972524600 4064901201 51% 48308 6151 
CGCRC336 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8597346400 4333410573 50% 51390 7551 
CGCRC337 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7399611700 3800666199 51% 45083 8092 
CGCRC338 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8029493700 4179383804 52% 49380 5831 
CGCRC339 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7938963600 4095555110 52% 48397 3808 
CGCRC340 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7214889500 3706643098 51% 43805 3014 
CGCRC341 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8803159200 3668208527 42% 43106 11957 
CGCRC342 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8478811500 3425540889 40% 40328 9592 
CGCRC344 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6942167800 3098232737 45% 36823 2300 
CGCRC345 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8182868200 2383173431 29% 28233 7973 
CGCRC346 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7448272300 3925056341 53% 46679 5582 
CGCRC347 Colorectal Cancer Preoperative, Treatment naïve 100 80930 5804744500 2986809912 51% 35490 4141 
CGCRC349 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6943451600 3533145275 51% 41908 5762 
CGCRC350 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7434818400 3848923016 52% 45678 4652 
CGCRC351 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7306546400 3636910409 50% 43162 5205 
CGCRC352 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7864655000 3336939252 42% 39587 4502 
CGCRC353 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7501674800 3642919375 49% 43379 4666 
CGCRC354 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7938270200 2379068977 30% 28256 4858 
CGCRC356 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6013175900 3046754994 51% 36127 3425 
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CGCRC357 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6013454600 3022035300 50% 35813 4259 
CGCRC358 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7227212400 3188723303 44% 37992 5286 
CGCRC359 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7818567700 425110101 5% 5040 2566 
CGCRC367 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6582043200 3363063597 51% 39844 5839 
CGCRC368 Colorectal Cancer Preoperative, Treatment naïve 100 80930 8042242400 4101646000 51% 48636 11471 
CGCRC370 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6940330100 3198954121 46% 38153 4826 
CGCRC373 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6587201700 3120088035 47% 37234 5190 
CGCRC376 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6727983100 3162416807 47% 37735 3445 
CGCRC377 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6716339200 3131415570 47% 37160 4524 
CGCRC378 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6523969900 2411096720 37% 28728 3239 
CGCRC379 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6996252100 3371081103 48% 39999 2891 
CGCRC380 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7097496300 2710244446 38% 32020 3261 
CGCRC381 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6961936100 3287050681 47% 38749 9357 
CGCRC382 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6959048700 2552325859 37% 30040 5148 
CGCRC384 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7012798900 3293884583 47% 39158 3653 
CGCRC385 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7542017900 3356570505 45% 39884 3686 
CGCRC386 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6876059600 3064412286 45% 36431 2787 
CGCRC387 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7399564700 3047254560 41% 36141 6675 
CGCRC388 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6592692900 3137284885 48% 37285 5114 
CGCRC389 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6651206300 3102100941 47% 36764 6123 
CGCRC390 Colorectal Cancer Preoperative, Treatment naïve 100 80930 7260616800 3376667585 47% 40048 4368 
CGCRC391 Colorectal Cancer Preoperative, Treatment naïve 100 80930 6883624500 3202877881 47% 37978 5029 
CGLU316 Lung Cancer Pre-treatment, Day -53 100 80930 7864415100 1991331171 25% 23601 3565 
CGLU316 Lung Cancer Pre-treatment, Day -53 100 80930 7502591600 3730963390 50% 44262 3966 
CGLU316 Lung Cancer Pre-treatment, Day -53 100 80930 6582515900 3187059470 48% 37813 3539 
CGLU316 Lung Cancer Pre-treatment, Day -53 100 80930 6587281800 1947630979 30% 23094 4439 
CGLU344 Lung Cancer Pre-treatment, Day -21 100 80930 6151628500 2748983603 45% 32462 8063 
CGLU344 Lung Cancer Pre-treatment, Day -21 100 80930 7842910900 1147703178 15% 13565 4303 
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CGLU344 Lung Cancer Pre-treatment, Day -21 100 80930 5838083100 2291108925 39% 27067 4287 
CGLU344 Lung Cancer Pre-treatment, Day -21 100 80930 7685989200 3722274529 48% 43945 3471 
CGLU369 Lung Cancer Pre-treatment, Day -2 100 80930 7080245300 1271457982 18% 15109 2364 
CGLU369 Lung Cancer Pre-treatment, Day -2 100 80930 7078131900 1482448715 21% 17583 4275 
CGLU369 Lung Cancer Pre-treatment, Day -2 100 80930 6904701700 2124660124 31% 25230 5278 
CGLU369 Lung Cancer Pre-treatment, Day -2 100 80930 7003452200 3162195578 45% 37509 6062 
CGLU373 Lung Cancer Pre-treatment, Day -2 100 80930 6346267200 3053520676 48% 36137 6251 
CGLU373 Lung Cancer Pre-treatment, Day -2 100 80930 6517189900 3192984468 49% 38066 8040 
CGLU373 Lung Cancer Pre-treatment, Day -2 100 80930 7767146300 3572598842 46% 42378 5306 
CGLU373 Lung Cancer Pre-treatment, Day -2 100 80930 7190999100 3273648804 46% 38784 4454 
CGPLBR100 Breast Cancer Preoperative, Treatment naïve 100 80930 7299964400 3750278051 51% 44794 3249 
CGPLBR101 Breast Cancer Preoperative, Treatment naïve 100 80930 7420822800 3810365416 51% 45565 9784 
CGPLBR102 Breast Cancer Preoperative, Treatment naïve 100 80930 6679304900 3269688319 49% 38679 7613 
CGPLBR103 Breast Cancer Preoperative, Treatment naïve 100 80930 7040304400 3495542468 50% 41786 6748 
CGPLBR104 Breast Cancer Preoperative, Treatment naïve 100 80930 7188389200 3716096781 52% 44316 9448 
CGPLBR38 Breast Cancer Preoperative, Treatment naïve 100 80930 7810293900 4057576306 52% 48098 9868 
CGPLBR39 Breast Cancer Preoperative, Treatment naïve 100 80930 7745701500 3805623239 49% 45084 11065 
CGPLBR40 Breast Cancer Preoperative, Treatment naïve 100 80930 7558990500 3652442341 48% 43333 12948 
CGPLBR41 Breast Cancer Preoperative, Treatment naïve 100 80930 7900994600 3836600101 49% 45535 10847 
CGPLBR44 Breast Cancer Preoperative, Treatment naïve 100 80930 7017744200 3269110569 47% 38672 8344 
CGPLBR48 Breast Cancer Preoperative, Treatment naïve 100 80930 5629044200 2611554623 46% 30860 8652 
CGPLBR49 Breast Cancer Preoperative, Treatment naïve 100 80930 5784711600 2673457893 46% 31274 10429 
CGPLBR55 Breast Cancer Preoperative, Treatment naïve 100 80930 8309154900 4306956261 52% 51143 8328 
CGPLBR57 Breast Cancer Preoperative, Treatment naïve 100 80930 8636181000 4391502618 51% 52108 5857 
CGPLBR59 Breast Cancer Preoperative, Treatment naïve 100 80930 8799457700 4152328555 47% 49281 5855 
CGPLBR61 Breast Cancer Preoperative, Treatment naïve 100 80930 8163706700 3952010628 48% 46755 8522 
CGPLBR63 Breast Cancer Preoperative, Treatment naïve 100 80930 7020533100 3542447304 50% 41956 4773 
CGPLBR67 Breast Cancer Preoperative, Treatment naïve 100 80930 8264353900 3686093696 45% 43516 7752 
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CGPLBR68 Breast Cancer Preoperative, Treatment naïve 100 80930 7629312300 4078969547 53% 48389 7402 
CGPLBR69 Breast Cancer Preoperative, Treatment naïve 100 80930 7571501500 3857354512 51% 45322 7047 
CGPLBR70 Breast Cancer Preoperative, Treatment naïve 100 80930 7251760700 3641333708 50% 43203 8884 
CGPLBR71 Breast Cancer Preoperative, Treatment naïve 100 80930 8515402600 4496696391 53% 53340 6805 
CGPLBR72 Breast Cancer Preoperative, Treatment naïve 100 80930 8556946900 4389761697 51% 52081 5632 
CGPLBR73 Breast Cancer Preoperative, Treatment naïve 100 80930 7959392300 4006933338 50% 47555 8791 
CGPLBR74 Breast Cancer Preoperative, Treatment naïve 100 80930 8524536400 4063900599 48% 48252 7013 
CGPLBR75 Breast Cancer Preoperative, Treatment naïve 100 80930 8260379100 3960599885 48% 46955 6319 
CGPLBR76 Breast Cancer Preoperative, Treatment naïve 100 80930 7774235200 3893622420 50% 46192 9628 
CGPLBR77 Breast Cancer Preoperative, Treatment naïve 100 80930 7572797600 3255963429 43% 38568 8263 
CGPLBR80 Breast Cancer Preoperative, Treatment naïve 100 80930 6845325800 3147476693 46% 37201 5595 
CGPLBR82 Breast Cancer Preoperative, Treatment naïve 100 80930 8236705200 4170465005 51% 49361 12319 
CGPLBR83 Breast Cancer Preoperative, Treatment naïve 100 80930 7434568100 3676855019 49% 43628 5458 
CGPLBR86 Breast Cancer Preoperative, Treatment naïve 100 80930 7616282500 3644791327 48% 43490 7048 
CGPLBR87 Breast Cancer Preoperative, Treatment naïve 100 80930 6194021300 3004882010 49% 35765 5306 
CGPLBR88 Breast Cancer Preoperative, Treatment naïve 100 80930 6071567200 2847926237 47% 33945 10319 
CGPLBR91 Breast Cancer Preoperative, Treatment naïve 100 80930 7192457700 3480203404 48% 41570 9912 
CGPLBR92 Breast Cancer Preoperative, Treatment naïve 100 80930 7678981800 3600279233 47% 42975 13580 
CGPLBR93 Breast Cancer Preoperative, Treatment naïve 100 80930 7605717800 3998713397 53% 47866 10329 
CGPLBR96 Breast Cancer Preoperative, Treatment naïve 100 80930 6297446700 2463064737 39% 29341 7937 
CGPLBR97 Breast Cancer Preoperative, Treatment naïve 100 80930 7114921600 3557069027 50% 42488 10712 
CGPLH35 Healthy Preoperative, Treatment naïve 100 80930 6919126300 2312758764 33% 25570 1989 
CGPLH36 Healthy Preoperative, Treatment naïve 100 80930 6089923400 2038548115 33% 22719 1478 
CGPLH37 Healthy Preoperative, Treatment naïve 100 80930 5557270200 1935301929 35% 21673 2312 
CGPLH42 Healthy Preoperative, Treatment naïve 100 80930 5792045400 2388036949 41% 27197 2523 
CGPLH43 Healthy Preoperative, Treatment naïve 100 80930 5568321700 2017813329 36% 23228 1650 
CGPLH45 Healthy Preoperative, Treatment naïve 100 80930 8485593200 2770176078 33% 32829 3114 
CGPLH46 Healthy Preoperative, Treatment naïve 100 80930 5083171100 1899395790 37% 21821 1678 
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CGPLH47 Healthy Preoperative, Treatment naïve 100 80930 6016388500 2062392156 34% 23459 1431 
CGPLH48 Healthy Preoperative, Treatment naïve 100 80930 4958945900 1809825992 36% 20702 1698 
CGPLH49 Healthy Preoperative, Treatment naïve 100 80930 7953812200 2511365904 32% 27006 1440 
CGPLH50 Healthy Preoperative, Treatment naïve 100 80930 6989407600 2561288100 37% 29177 2591 
CGPLH51 Healthy Preoperative, Treatment naïve 100 80930 7862073200 2525091396 32% 29999 1293 
CGPLH52 Healthy Preoperative, Treatment naïve 100 80930 6939636800 2397922699 35% 27029 2501 
CGPLH54 Healthy Preoperative, Treatment naïve 100 80930 10611934700 2290823134 22% 27175 3306 
CGPLH55 Healthy Preoperative, Treatment naïve 100 80930 9912569200 2521962244 25% 27082 3161 
CGPLH56 Healthy Preoperative, Treatment naïve 100 80930 5777591900 2023874863 35% 22916 1301 
CGPLH57 Healthy Preoperative, Treatment naïve 100 80930 9234904800 1493926244 16% 15843 1655 
CGPLH59 Healthy Preoperative, Treatment naïve 100 80930 9726052100 2987875484 31% 35427 2143 
CGPLH63 Healthy Preoperative, Treatment naïve 100 80930 8696405000 2521574759 29% 26689 1851 
CGPLH64 Healthy Preoperative, Treatment naïve 100 80930 5438852600 996198502 18% 11477 1443 
CGPLH75 Healthy Preoperative, Treatment naïve 100 80930 3446444000 1505718480 44% 17805 3016 
CGPLH76 Healthy Preoperative, Treatment naïve 100 80930 7499116400 3685762725 49% 43682 4643 
CGPLH77 Healthy Preoperative, Treatment naïve 100 80930 6512408400 2537359345 39% 30280 3131 
CGPLH78 Healthy Preoperative, Treatment naïve 100 80930 7642949300 3946069680 52% 46316 5358 
CGPLH79 Healthy Preoperative, Treatment naïve 100 80930 7785475700 3910639227 50% 45280 6714 
CGPLH80 Healthy Preoperative, Treatment naïve 100 80930 7918361500 3558236955 45% 42171 5062 
CGPLH81 Healthy Preoperative, Treatment naïve 100 80930 6646268900 3112369850 47% 37119 3678 
CGPLH82 Healthy Preoperative, Treatment naïve 100 80930 7744065000 3941700596 51% 46820 5723 
CGPLH83 Healthy Preoperative, Treatment naïve 100 80930 6957686000 1447603106 21% 17280 2875 
CGPLH84 Healthy Preoperative, Treatment naïve 100 80930 8326493200 3969908122 48% 47464 3647 
CGPLH86 Healthy Preoperative, Treatment naïve 100 80930 8664194700 4470145091 52% 53398 5094 
CGPLH90 Healthy Preoperative, Treatment naïve 100 80930 7516078800 3841504088 51% 45907 4414 
CGPLLU13 Lung Cancer Pre-treatment, Day -2 100 80930 5659546100 1721618955 30% 20587 6025 
CGPLLU13 Lung Cancer Pre-treatment, Day -2 100 80930 6199049700 2563659840 41% 30728 6514 
CGPLLU13 Lung Cancer Pre-treatment, Day -2 100 80930 5864396500 1194237002 20% 14331 3952 
193 
 
CGPLLU13 Lung Cancer Pre-treatment, Day -2 100 80930 5080197700 1373550586 27% 16480 5389 
CGPLLU14 Lung Cancer Pre-treatment, Day -38 100 80930 8668655700 3980731089 46% 48628 3148 
CGPLLU14 Lung Cancer Pre-treatment, Day -16 100 80930 8271043600 4105092738 50% 50152 4497 
CGPLLU14 Lung Cancer Pre-treatment, Day -3 100 80930 7149809200 3405754720 48% 40382 6170 
CGPLLU14 Lung Cancer Pre-treatment, Day 0 100 80930 6556332200 3289504484 50% 39004 4081 
CGPLLU14 Lung Cancer Post-treatment, Day 0.33 100 80930 7410378300 3464236558 47% 41108 4259 
CGPLLU14 Lung Cancer Post-treatment, Day 7 100 80930 7530190700 3752054349 50% 45839 2469 
CGPLLU144 Lung Cancer Preoperative, Treatment naïve 100 80930 8716827400 4216576624 48% 49370 10771 
CGPLLU146 Lung Cancer Preoperative, Treatment naïve 100 80930 8506844200 4195033049 49% 49084 6968 
CGPLLU147 Lung Cancer Preoperative, Treatment naïve 100 80930 7416300600 3530746046 48% 41302 4691 
CGPLLU161 Lung Cancer Preoperative, Treatment naïve 100 80930 7789148700 3280139772 42% 38568 12229 
CGPLLU162 Lung Cancer Preoperative, Treatment naïve 100 80930 7625462000 3470147667 46% 40918 10099 
CGPLLU163 Lung Cancer Preoperative, Treatment naïve 100 80930 8019293200 3946533983 49% 46471 12108 
CGPLLU164 Lung Cancer Preoperative, Treatment naïve 100 80930 8110030900 3592748235 44% 42161 6947 
CGPLLU165 Lung Cancer Preoperative, Treatment naïve 100 80930 8389514600 4147501817 49% 48770 8996 
CGPLLU168 Lung Cancer Preoperative, Treatment naïve 100 80930 7690630000 3868237773 50% 45625 9711 
CGPLLU169 Lung Cancer Preoperative, Treatment naïve 100 80930 9378353000 4800407624 51% 56547 10261 
CGPLLU174 Lung Cancer Preoperative, Treatment naïve 100 80930 7481844600 3067532518 41% 36321 6137 
CGPLLU175 Lung Cancer Preoperative, Treatment naïve 100 80930 8532324200 4002541569 47% 47084 7862 
CGPLLU176 Lung Cancer Preoperative, Treatment naïve 100 80930 8143905000 4054098929 50% 47708 5588 
CGPLLU177 Lung Cancer Preoperative, Treatment naïve 100 80930 8421611300 4197108809 50% 49476 8780 
CGPLLU178 Lung Cancer Preoperative, Treatment naïve 100 80930 8483124700 4169577489 49% 48580 6445 
CGPLLU179 Lung Cancer Preoperative, Treatment naïve 100 80930 7774358700 3304915738 43% 38768 6862 
CGPLLU180 Lung Cancer Preoperative, Treatment naïve 100 80930 8192813800 3937552475 48% 46498 6568 
CGPLLU197 Lung Cancer Preoperative, Treatment naïve 100 80930 7996779200 3082397881 39% 36381 5388 
CGPLLU198 Lung Cancer Preoperative, Treatment naïve 100 80930 7175247200 3545719100 49% 42008 6817 
CGPLLU202 Lung Cancer Preoperative, Treatment naïve 100 80930 6840112800 3427820669 50% 40670 7951 
CGPLLU203 Lung Cancer Preoperative, Treatment naïve 100 80930 7468749900 3762726574 50% 44500 9917 
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CGPLLU204 Lung Cancer Preoperative, Treatment naïve 100 80930 7445026400 3703545153 50% 44317 6856 
CGPLLU205 Lung Cancer Preoperative, Treatment naïve 100 80930 9205429100 4350573991 47% 51627 9810 
CGPLLU206 Lung Cancer Preoperative, Treatment naïve 100 80930 7397914600 3635210205 49% 43016 7124 
CGPLLU207 Lung Cancer Preoperative, Treatment naïve 100 80930 7133043900 3736258011 52% 44291 8499 
CGPLLU208 Lung Cancer Preoperative, Treatment naïve 100 80930 7346976400 3855814032 52% 45782 8940 
CGPLLU209 Lung Cancer Preoperative, Treatment naïve 100 80930 6723337800 3362944595 50% 39531 11946 
CGPLLU244 Lung Cancer Pre-treatment, Day -7 100 80930 8305560600 4182616104 50% 50851 7569 
CGPLLU244 Lung Cancer Pre-treatment, Day -1 100 80930 7739951100 3788487116 49% 45925 8552 
CGPLLU244 Lung Cancer Post-treatment, Day 6 100 80930 8061928000 4225322272 52% 51279 8646 
CGPLLU244 Lung Cancer Post-treatment, Day 62 100 80930 8894936700 4437962639 50% 53862 7361 
CGPLLU245 Lung Cancer Pre-treatment, Day -32 100 80930 7679235200 3935822054 51% 47768 7266 
CGPLLU245 Lung Cancer Pre-treatment, Day 0 100 80930 8985252500 4824268339 54% 58338 10394 
CGPLLU245 Lung Cancer Post-treatment, Day 7 100 80930 8518229300 4480236927 53% 54083 10125 
CGPLLU245 Lung Cancer Post-treatment, Day 21 100 80930 9031131000 4824738475 53% 58313 10598 
CGPLLU246 Lung Cancer Pre-treatment, Day -21 100 80930 8520360800 3509660305 41% 42349 8086 
CGPLLU246 Lung Cancer Pre-treatment, Day 0 100 80930 5451467800 2828351657 52% 34243 8256 
CGPLLU246 Lung Cancer Post-treatment, Day 9 100 80930 8137616600 4135036174 51% 50121 6466 
CGPLLU246 Lung Cancer Post-treatment, Day 42 100 80930 8385724600 4413323333 53% 53495 7303 
CGPLLU264 Lung Cancer Pre-treatment, Day -1 100 80930 6254777700 3016326208 48% 36164 12138 
CGPLLU264 Lung Cancer Pre-treatment, Day -1 100 80930 6185331000 3087883231 50% 37003 8388 
CGPLLU264 Lung Cancer Pre-treatment, Day -1 100 80930 6274540300 2861143666 46% 34308 6817 
CGPLLU264 Lung Cancer Pre-treatment, Day -1 100 80930 5701274000 1241270938 22% 14886 4273 
CGPLLU265 Lung Cancer Pre-treatment, Day 0 100 80930 6091276800 2922585558 48% 35004 7742 
CGPLLU265 Lung Cancer Pre-treatment, Day 0 100 80930 6430107900 2945953499 46% 35219 8574 
CGPLLU265 Lung Cancer Pre-treatment, Day 0 100 80930 5869510300 2792208995 48% 33423 8423 
CGPLLU265 Lung Cancer Pre-treatment, Day 0 100 80930 5884330900 2588386038 44% 30977 9803 
CGPLLU266 Lung Cancer Pre-treatment, Day 0 100 80930 5807524900 2347651479 40% 28146 5793 
CGPLLU266 Lung Cancer Pre-treatment, Day 0 100 80930 6064269800 2086938782 34% 24994 6221 
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CGPLLU266 Lung Cancer Pre-treatment, Day 0 100 80930 6785913900 3458588505 51% 41432 7765 
CGPLLU266 Lung Cancer Pre-treatment, Day 0 100 80930 6513702000 2096370387 32% 25142 6598 
CGPLLU267 Lung Cancer Pre-treatment, Day -1 100 80930 6610761200 2576886619 39% 31095 4485 
CGPLLU267 Lung Cancer Pre-treatment, Day -1 100 80930 6156102000 2586081726 42% 30714 5309 
CGPLLU267 Lung Cancer Pre-treatment, Day -1 100 80930 6180799700 2013434756 33% 23902 3885 
CGPLLU269 Lung Cancer Pre-treatment, Day 0 100 80930 6221168600 1499602843 24% 17799 6098 
CGPLLU269 Lung Cancer Pre-treatment, Day 0 100 80930 5353961600 1698331125 32% 20094 5252 
CGPLLU269 Lung Cancer Pre-treatment, Day 0 100 80930 5831612800 1521114956 26% 18067 6210 
CGPLLU271 Lung Cancer Post-treatment, Day 259 100 80930 6229704000 1481468974 24% 17608 4633 
CGPLLU271 Lung Cancer Post-treatment, Day 259 100 80930 6134366400 1351029627 22% 16170 7024 
CGPLLU271 Lung Cancer Post-treatment, Day 259 100 80930 6491884900 1622578435 25% 19433 5792 
CGPLLU271 Lung Cancer Post-treatment, Day 259 100 80930 5742881200 2349421128 41% 28171 5723 
CGPLLU271 Lung Cancer Post-treatment, Day 259 100 80930 5503999300 1695782705 31% 20320 5907 
CGPLLU43 Lung Cancer Pre-treatment, Day -1 100 80930 6575907000 3002048491 46% 35997 5445 
CGPLLU43 Lung Cancer Pre-treatment, Day -1 100 80930 6204350900 3016077187 49% 36162 5704 
CGPLLU43 Lung Cancer Pre-treatment, Day -1 100 80930 5997724300 2989608757 50% 35873 6228 
CGPLLU43 Lung Cancer Pre-treatment, Day -1 100 80930 6026261500 2881177658 48% 34568 7221 
CGPLLU86 Lung Cancer Pre-treatment, Day 0 100 80930 8222093400 3523035056 43% 41165 3614 
CGPLLU86 Lung Cancer Post-treatment, Day 0.5 100 80930 8305719500 4271264008 51% 49508 6681 
CGPLLU86 Lung Cancer Post-treatment, Day 7 100 80930 6787785300 3443658418 51% 40192 3643 
CGPLLU86 Lung Cancer Post-treatment, Day 17 100 80930 6213229400 3120325926 50% 36413 3560 
CGPLLU88 Lung Cancer Pre-treatment, Day 0 100 80930 7252433900 3621678746 50% 42719 8599 
CGPLLU88 Lung Cancer Pre-treatment, Day 0 100 80930 7679995800 4004738253 52% 46951 6387 
CGPLLU88 Lung Cancer Pre-treatment, Day 0 100 80930 6509178000 3316053733 51% 39274 2661 
CGPLLU89 Lung Cancer Pre-treatment, Day 0 100 80930 7662496600 3781536306 49% 44097 7909 
CGPLLU89 Lung Cancer Post-treatment, Day 7 100 80930 7005599500 3339612564 48% 38977 5034 
CGPLLU89 Lung Cancer Post-treatment, Day 22 100 80930 8325998600 3094796789 37% 36061 2822 
CGPLOV10 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7073534200 3402308123 48% 39820 4059 
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CGPLOV11 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6924062200 3324593050 48% 38796 7185 
CGPLOV12 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6552080100 3181854993 49% 37340 6114 
CGPLOV13 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6796755500 3264897084 48% 38340 7931 
CGPLOV14 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7856573900 3408425065 43% 39997 7712 
CGPLOV15 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7239201500 3322285607 46% 38953 6644 
CGPLOV16 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8570755900 4344288233 51% 51009 11947 
CGPLOV17 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6910310400 2805243492 41% 32828 4307 
CGPLOV18 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8173037600 4064432407 50% 47714 5182 
CGPLOV19 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7732198900 3672564399 47% 43020 11127 
CGPLOV20 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7559602000 3678700179 49% 43230 4872 
CGPLOV21 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8949032900 4616255499 52% 54012 12777 
CGPLOV22 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8680136500 4049934586 47% 46912 9715 
CGPLOV23 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6660696600 3422631774 51% 40810 9460 
CGPLOV24 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8634287200 4272258165 49% 50736 8689 
CGPLOV25 Ovarian Cancer Preoperative, Treatment naïve 100 80930 6978295000 3390206388 49% 40188 5856 
CGPLOV26 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7041038300 3728879661 53% 44341 8950 
CGPLOV28 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7429236900 3753051715 51% 45430 4155 
CGPLOV31 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8981384000 4621838729 51% 55429 5458 
CGPLOV32 Ovarian Cancer Preoperative, Treatment naïve 100 80930 9344536800 4737698323 51% 57234 6165 
CGPLOV37 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8158083200 4184432898 51% 50648 6934 
CGPLOV38 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8654435400 4492987085 52% 53789 6124 
CGPLOV40 Ovarian Cancer Preoperative, Treatment naïve 100 80930 9868640700 4934400809 50% 59049 7721 
CGPLOV41 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7689013600 3861448829 50% 46292 4469 
CGPLOV42 Ovarian Cancer Preoperative, Treatment naïve 100 80930 9836516300 4864154366 49% 58302 7632 
CGPLOV43 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8756507100 4515479918 52% 54661 4310 
CGPLOV44 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7576310800 4120933922 54% 49903 4969 
CGPLOV46 Ovarian Cancer Preoperative, Treatment naïve 100 80930 9346036300 5037820346 54% 61204 3927 
CGPLOV47 Ovarian Cancer Preoperative, Treatment naïve 100 80930 10880620200 5491357828 50% 66363 6895 
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CGPLOV48 Ovarian Cancer Preoperative, Treatment naïve 100 80930 7658787800 3335991337 44% 40332 4066 
CGPLOV49 Ovarian Cancer Preoperative, Treatment naïve 100 80930 10076208000 5519656698 55% 67117 5097 
CGPLOV50 Ovarian Cancer Preoperative, Treatment naïve 100 80930 8239290400 4472380276 54% 54150 3836 
CGPLPA118 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 9094827600 4828332902 53% 57021 4802 
CGPLPA122 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7303323100 3990160379 55% 47240 7875 
CGPLPA124 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7573482800 3965807442 52% 46388 8658 
CGPLPA126 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7904953600 4061463168 51% 47812 10498 
CGPLPA128 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7249238300 2244188735 31% 26436 3413 
CGPLPA129 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7559858900 4003725804 53% 47182 5733 
CGPLPA130 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 6973946500 1247144905 18% 14691 1723 
CGPLPA131 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7226237900 3370664342 47% 39661 5054 
CGPLPA134 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7268866100 3754945844 52% 44306 7023 
CGPLPA136 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7476690700 4073978408 54% 48134 5244 
CGPLPA140 Bile Duct Cancer Preoperative, Treatment naïve 100 80930 7364654600 3771765342 51% 44479 7080 
CGST102 Gastric Cancer Preoperative, Treatment naïve 100 80930 5715504500 2644902854 46% 31309 4503 
CGST110 Gastric Cancer Preoperative, Treatment naïve 100 80930 9179291500 4298269268 47% 51666 3873 
CGST114 Gastric Cancer Preoperative, Treatment naïve 100 80930 7151572200 3254967293 46% 38496 4839 
CGST13 Gastric Cancer Preoperative, Treatment naïve 100 80930 6449701500 3198545984 50% 38515 6731 
CGST141 Gastric Cancer Preoperative, Treatment naïve 100 80930 6781001300 3440927391 51% 40762 5404 
CGST16 Gastric Cancer Preoperative, Treatment naïve 100 80930 6396470600 2931380289 46% 35354 8148 
CGST18 Gastric Cancer Preoperative, Treatment naïve 100 80930 6647324000 3138967777 47% 37401 4992 
CGST28 Gastric Cancer Preoperative, Treatment naïve 100 80930 6288486100 2884997993 46% 34538 2586 
CGST30 Gastric Cancer Preoperative, Treatment naïve 100 80930 6141213100 3109994564 51% 37194 2555 
CGST32 Gastric Cancer Preoperative, Treatment naïve 100 80930 6969139300 3099120469 44% 36726 3935 
CGST33 Gastric Cancer Preoperative, Treatment naïve 100 80930 6560309400 3168371917 48% 37916 4597 
CGST39 Gastric Cancer Preoperative, Treatment naïve 100 80930 7043791400 2992801875 42% 35620 6737 
CGST41 Gastric Cancer Preoperative, Treatment naïve 100 80930 6975053100 3224065662 46% 38300 4016 
CGST45 Gastric Cancer Preoperative, Treatment naïve 100 80930 6130812200 2944524278 48% 35264 4745 
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CGST47 Gastric Cancer Preoperative, Treatment naïve 100 80930 5961400000 3083523351 52% 37008 3112 
CGST48 Gastric Cancer Preoperative, Treatment naïve 100 80930 6418652700 1497230327 23% 17782 2410 
CGST58 Gastric Cancer Preoperative, Treatment naïve 100 80930 5818344500 1274708429 22% 15281 2924 
CGST80 Gastric Cancer Preoperative, Treatment naïve 100 80930 6368064600 3298497188 52% 39692 5280 





Table 4.3.  Summary of targeted cfDNA fragment analyses in cancer patients. 















CGCRC291 Colorectal Cancer IV Tumor-derived STK11 39R>C chr19_1207027-1207027_C_T Substitution No No 0.14% 
CGCRC291 Colorectal Cancer IV Tumor-derived TP53 272V>M chr17_7577124-7577124_C_T Substitution Yes No 0.10% 
CGCRC291 Colorectal Cancer IV Tumor-derived TP53 167Q>X chr17_7578431-7578431_G_A Substitution Yes Yes 22.85% 
CGCRC291 Colorectal Cancer IV Tumor-derived KRAS 12G>A chr12_25398284-25398284_C_G Substitution Yes Yes 14.65% 
CGCRC291 Colorectal Cancer IV Tumor-derived APC 1260Q>X chr5_112175069-112175069_C_T Substitution No Yes 11.23% 
CGCRC291 Colorectal Cancer IV Tumor-derived APC 1450R>X chr5_112175639-112175639_C_T Substitution Yes Yes 11.05% 
CGCRC291 Colorectal Cancer IV Tumor-derived PIK3CA 542E>K chr3_178936082-178936082_G_A Substitution Yes Yes 18.11% 
CGCRC292 Colorectal Cancer IV Tumor-derived KRAS 146A>V chr12_25378561-25378561_G_A Substitution Yes No 1.41% 
CGCRC292 Colorectal Cancer IV Tumor-derived CTNNB1 41T>A chr3_41266124-41266124_A_G Substitution Yes Yes 0.13% 
CGCRC292 Colorectal Cancer IV Germline EGFR 2284-4C>G chr7_55248982-55248982_C_G Substitution NA Yes 31.99% 
CGCRC293 Colorectal Cancer IV Tumor-derived TP53 176C>S chr17_7578404-7578404_A_T Substitution No No 0.35% 
CGCRC294 Colorectal Cancer II Tumor-derived APC 213R>X chr5_112116592-112116592_C_T Substitution Yes Yes 0.14% 
CGCRC294 Colorectal Cancer II Tumor-derived APC 1367Q>X chr5_112175390-112175390_C_T Substitution Yes Yes 0.13% 
CGCRC295 Colorectal Cancer IV Tumor-derived PDGFRA 49+4C>T chr4_55124988-55124988_C_T Substitution No No 0.45% 
CGCRC295 Colorectal Cancer IV Hematopoietic IDH1 104G>V chr2_209113196-209113196_C_A Substitution No Yes 0.34% 
CGCRC296 Colorectal Cancer II Germline EGFR 922E>K chr7_55266472-55266472_G_A Substitution NA Yes 30.48% 
CGCRC297 Colorectal Cancer III Germline KIT 18L>F chr4_55524233-55524233_C_T Substitution NA Yes 41.39% 
CGCRC298 Colorectal Cancer II Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes Yes 0.08% 
CGCRC298 Colorectal Cancer II Hematopoietic DNMT3A 714S>C chr2_25463541-25463541_G_C Substitution No No 0.11% 
CGCRC298 Colorectal Cancer II Tumor-derived PIK3CA 414G>V chr3_178927478-178927478_G_T Substitution No No 0.55% 
CGCRC299 Colorectal Cancer I Hematopoietic DNMT3A 735Y>C chr2_25463289-25463289_T_C Substitution No Yes 0.30% 
CGCRC299 Colorectal Cancer I Hematopoietic DNMT3A 710C>S chr2_25463553-25463553_C_G Substitution No Yes 0.12% 
CGCRC300 Colorectal Cancer I Hematopoietic DNMT3A 720R>G chr2_25463524-25463524_G_C Substitution No No 0.15% 
CGCRC301 Colorectal Cancer I Tumor-derived ATM 2397Q>X chr11_108199847-108199847_C_T Substitution No No 0.21% 
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CGCRC302 Colorectal Cancer II Tumor-derived TP53 141C>Y chr17_7578508-7578508_C_T Substitution Yes Yes 0.05% 
CGCRC302 Colorectal Cancer II Tumor-derived BRAF 600V>E chr7_140453136-140453136_A_T Substitution Yes Yes 0.12% 
CGCRC303 Colorectal Cancer III Tumor-derived TP53 173V>L chr17_7578413-7578413_C_A Substitution Yes Yes 0.08% 
CGCRC303 Colorectal Cancer III Hematopoietic DNMT3A 755F>S chr2_25463229-25463229_A_G Substitution No No 0.21% 
CGCRC303 Colorectal Cancer III Hematopoietic DNMT3A 2173+1G>A chr2_25463508-25463508_C_T Substitution No No 0.17% 
CGCRC304 Colorectal Cancer II Tumor-derived EGFR 1131T>S chr7_55273068-55273068_A_T Substitution No No 0.22% 
CGCRC304 Colorectal Cancer II Tumor-derived ATM 3077+1G>A chr11_108142134-108142134_G_A Substitution No No 0.27% 
CGCRC304 Colorectal Cancer II Hematopoietic ATM 3008R>C chr11_108236086-108236086_C_T Substitution No Yes 0.43% 
CGCRC305 Colorectal Cancer II Tumor-derived GNA11 213R>Q chr19_3118954-3118954_G_A Substitution No Yes 0.11% 
CGCRC305 Colorectal Cancer II Tumor-derived TP53 273R>H chr17_7577120-7577120_C_T Substitution Yes No 0.19% 
CGCRC306 Colorectal Cancer II Tumor-derived TP53 196R>X chr17_7578263-7578263_G_A Substitution Yes No 0.12% 
CGCRC306 Colorectal Cancer II Tumor-derived CDKN2A 107R>C chr9_21971039-21971039_G_A Substitution No Yes 8.02% 
CGCRC306 Colorectal Cancer II Tumor-derived KRAS 61Q>K chr12_25380277-25380277_G_T Substitution Yes Yes 7.30% 
CGCRC306 Colorectal Cancer II Germline PDGFRA 200T>S chr4_55130065-55130065_C_G Substitution NA Yes 34.78% 
CGCRC306 Colorectal Cancer II Tumor-derived EGFR 618H>R chr7_55233103-55233103_A_G Substitution No Yes 6.32% 
CGCRC306 Colorectal Cancer II Tumor-derived PIK3CA 545E>A chr3_178936092-178936092_A_C Substitution Yes No 0.96% 
CGCRC306 Colorectal Cancer II Germline ERBB4 1155R>X chr2_212251596-212251596_G_A Substitution NA Yes 38.70% 
CGCRC307 Colorectal Cancer II Tumor-derived JAK2 805L>V chr9_5080662-5080662_C_G Substitution No No 0.56% 
CGCRC307 Colorectal Cancer II Tumor-derived SMARCB1 501-2A>G chr22_24145480-24145480_A_G Substitution No Yes 0.34% 
CGCRC307 Colorectal Cancer II Tumor-derived GNAS 201R>C chr20_57484420-57484420_C_T Substitution Yes Yes# 0.24% 
CGCRC307 Colorectal Cancer II Tumor-derived BRAF 600V>E chr7_140453136-140453136_A_T Substitution Yes Yes 0.38% 
CGCRC307 Colorectal Cancer II Tumor-derived FBXW7 465R>C chr4_153249385-153249385_G_A Substitution Yes Yes 0.31% 
CGCRC307 Colorectal Cancer II Tumor-derived ERBB4 17A>V chr2_213403205-213403205_G_A Substitution No No 0.15% 
CGCRC308 Colorectal Cancer III Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes No 0.06% 
CGCRC308 Colorectal Cancer III Germline EGFR 848P>L chr7_55259485-55259485_C_T Substitution NA Yes 27.69% 
CGCRC308 Colorectal Cancer III Tumor-derived APC 1480Q>X chr5_112175729-112175729_C_T Substitution No Yes 0.11% 
CGCRC309 Colorectal Cancer III Tumor-derived AKT1 17E>K chr14_105246551-105246551_C_T Substitution Yes Yes 2.70% 
CGCRC309 Colorectal Cancer III Tumor-derived BRAF 600V>E chr7_140453136-140453136_A_T Substitution Yes Yes 3.00% 
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CGCRC310 Colorectal Cancer II Tumor-derived KRAS 12G>V chr12_25398284-25398284_C_A Substitution Yes Yes 0.13% 
CGCRC310 Colorectal Cancer II Tumor-derived APC 1513E>X chr5_112175828-112175828_G_T Substitution No Yes 0.11% 
CGCRC310 Colorectal Cancer II Tumor-derived APC 1521E>X chr5_112175852-112175852_G_T Substitution No Yes 0.15% 
CGCRC311 Colorectal Cancer I Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes No 0.86% 
CGCRC312 Colorectal Cancer III Tumor-derived APC 960S>X chr5_112174170-112174170_C_G Substitution No Yes 0.59% 
CGCRC312 Colorectal Cancer III Tumor-derived NRAS 61Q>K chr1_115256530-115256530_G_T Substitution Yes Yes 0.47% 
CGCRC313 Colorectal Cancer III Tumor-derived KRAS 12G>S chr12_25398285-25398285_C_T Substitution Yes Yes 0.17% 
CGCRC313 Colorectal Cancer III Tumor-derived APC 876R>X chr5_112173917-112173917_C_T Substitution Yes Yes 0.07% 
CGCRC314 Colorectal Cancer I Tumor-derived KRAS 12G>D chr12_25398284-25398284_C_T Substitution Yes Yes 0.30% 
CGCRC314 Colorectal Cancer I Hematopoietic DNMT3A 738L>Q chr2_25463280-25463280_A_T Substitution No Yes 2.50% 
CGCRC314 Colorectal Cancer I Tumor-derived APC 1379E>X chr5_112175426-112175426_G_T Substitution Yes Yes 0.38% 
CGCRC315 Colorectal Cancer III Tumor-derived NRAS 12G>D chr1_115258747-115258747_C_T Substitution Yes Yes 0.27% 
CGCRC315 Colorectal Cancer III Tumor-derived FBXW7 505R>C chr4_153247289-153247289_G_A Substitution Yes Yes 0.25% 
CGCRC316 Colorectal Cancer III Tumor-derived TP53 245G>S chr17_7577548-7577548_C_T Substitution Yes Yes 6.52% 
CGCRC316 Colorectal Cancer III Tumor-derived CDKN2A 1M>R chr9_21974825-21974825_A_C Substitution No Yes 5.74% 
CGCRC316 Colorectal Cancer III Tumor-derived CTNNB1 37S>C chr3_41266113-41266113_C_G Substitution Yes Yes 5.47% 
CGCRC316 Colorectal Cancer III Tumor-derived EGFR 2702-3C>T chr7_55266407-55266407_C_T Substitution No No 0.11% 
CGCRC316 Colorectal Cancer III Hematopoietic ATM 3008R>P chr11_108236087-108236087_G_C Substitution No Yes 0.13% 
CGCRC317 Colorectal Cancer III Tumor-derived TP53 220Y>C chr17_7578190-7578190_T_C Substitution Yes Yes 0.36% 
CGCRC317 Colorectal Cancer III Tumor-derived ATM 1026W>R chr11_108142132-108142132_T_C Substitution No Yes 0.23% 
CGCRC317 Colorectal Cancer III Tumor-derived APC 216R>X chr5_112128143-112128143_C_T Substitution Yes No 0.29% 
CGCRC318 Colorectal Cancer I Hematopoietic DNMT3A 698W>X chr2_25463589-25463589_C_T Substitution No Yes 0.25% 
CGCRC320 Colorectal Cancer I Germline KIT 18L>F chr4_55524233-55524233_C_T Substitution NA Yes 34.76% 
CGCRC320 Colorectal Cancer I Tumor-derived ERBB4 78R>W chr2_212989479-212989479_G_A Substitution No No 0.12% 
CGCRC321 Colorectal Cancer I Tumor-derived CDKN2A 12S>L chr9_21974792-21974792_G_A Substitution No No 0.20% 
CGCRC321 Colorectal Cancer I Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes No 0.08% 
CGCRC321 Colorectal Cancer I Germline EGFR 511S>Y chr7_55229225-55229225_C_A Substitution NA Yes 41.86% 
CGCRC332 Colorectal Cancer IV Tumor-derived TP53 125T>R chr17_7579313-7579313_G_C Substitution No Yes 19.98% 
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CGCRC333 Colorectal Cancer IV Tumor-derived TP53 673-2A>G chr17_7577610-7577610_T_C Substitution No Yes 43.03% 
CGCRC333 Colorectal Cancer IV Tumor-derived BRAF 600V>E chr7_140453136-140453136_A_T Substitution Yes Yes 22.26% 
CGCRC333 Colorectal Cancer IV Tumor-derived ERBB4 691E>A chr2_212495194-212495194_T_G Substitution No No 1.00% 
CGCRC334 Colorectal Cancer IV Tumor-derived TP53 245G>S chr17_7577548-7577548_C_T Substitution Yes Yes 13.44% 
CGCRC334 Colorectal Cancer IV Germline EGFR 638T>M chr7_55238900-55238900_C_T Substitution NA Yes 35.28% 
CGCRC334 Colorectal Cancer IV Tumor-derived PIK3CA 104P>R chr3_178916924-178916924_C_G Substitution No No 3.85% 
CGCRC335 Colorectal Cancer IV Tumor-derived BRAF 600V>E chr7_140453136-140453136_A_T Substitution Yes Yes 0.32% 
CGCRC336 Colorectal Cancer IV Tumor-derived TP53 175R>H chr17_7578406-7578406_C_T Substitution Yes Yes 75.26% 
CGCRC336 Colorectal Cancer IV Tumor-derived KRAS 12G>V chr12_25398284-25398284_C_A Substitution Yes Yes 42.87% 
CGCRC336 Colorectal Cancer IV Tumor-derived APC 1286E>X chr5_112175147-112175147_G_T Substitution No Yes 81.61% 
CGCRC337 Colorectal Cancer IV Tumor-derived STK11 734+2T>A chr19_1220718-1220718_T_A Substitution No No 0.12% 
CGCRC337 Colorectal Cancer IV Germline APC 485M>I chr5_112162851-112162851_G_A Substitution NA Yes 46.26% 
CGCRC338 Colorectal Cancer IV Tumor-derived KRAS 12G>D chr12_25398284-25398284_C_T Substitution Yes Yes 27.03% 
CGCRC339 Colorectal Cancer IV Tumor-derived KRAS 13G>D chr12_25398281-25398281_C_T Substitution Yes Yes 1.94% 
CGCRC339 Colorectal Cancer IV Tumor-derived APC 876R>X chr5_112173917-112173917_C_T Substitution Yes Yes 2.35% 
CGCRC339 Colorectal Cancer IV Tumor-derived PIK3CA 407C>F chr3_178927457-178927457_G_T Substitution No Yes 3.14% 
CGCRC339 Colorectal Cancer IV Tumor-derived PIK3CA 1047H>L chr3_178952085-178952085_A_T Substitution Yes Yes 1.71% 
CGCRC340 Colorectal Cancer IV Tumor-derived TP53 196R>X chr17_7578263-7578263_G_A Substitution Yes Yes 18.26% 
CGCRC340 Colorectal Cancer IV Tumor-derived APC 1306E>X chr5_112175207-112175207_G_T Substitution Yes Yes 22.57% 
CGPLBR38 Breast Cancer I Tumor-derived TP53 241S>P chr17_7577560-7577560_A_G Substitution No Yes 0.53% 
CGPLBR40 Breast Cancer III Germline AR 392P>R chrX_66766163-66766163_C_G Substitution NA Yes 28.99% 
CGPLBR44 Breast Cancer III Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes Yes 1.82% 
CGPLBR44 Breast Cancer III Hematopoietic DNMT3A 705I>T chr2_25463568-25463568_A_G Substitution No Yes 0.41% 
CGPLBR44 Breast Cancer III Tumor-derived PDGFRA 859V>M chr4_55153609-55153609_G_A Substitution No Yes 0.13% 
CGPLBR48 Breast Cancer II Germline ALK 1231R>Q chr2_29436901-29436901_C_T Substitution NA Yes 34.61% 
CGPLBR48 Breast Cancer II Tumor-derived EGFR 669R>Q chr7_55240762-55240762_G_A Substitution No No 0.18% 
CGPLBR55 Breast Cancer III Hematopoietic DNMT3A 743P>S chr2_25463266-25463266_G_A Substitution No No 0.18% 
CGPLBR55 Breast Cancer III Tumor-derived GNAS 201R>H chr20_57484421-57484421_G_A Substitution Yes Yes 0.68% 
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CGPLBR55 Breast Cancer III Tumor-derived PIK3CA 345N>K chr3_178921553-178921553_T_A Substitution Yes Yes 0.42% 
CGPLBR63 Breast Cancer II Germline FGFR3 403K>E chr4_1806188-1806188_A_G Substitution NA Yes 34.82% 
CGPLBR67 Breast Cancer III Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes Yes 0.11% 
CGPLBR67 Breast Cancer III Tumor-derived PIK3CA 545E>K chr3_178936091-178936091_G_A Substitution Yes Yes 0.68% 
CGPLBR67 Breast Cancer III Tumor-derived ERBB4 1000D>A chr2_212285302-212285302_T_G Substitution No No 0.28% 
CGPLBR69 Breast Cancer II Hematopoietic DNMT3A 774E>V chr2_25463172-25463172_T_A Substitution No No 0.29% 
CGPLBR69 Breast Cancer II Germline CTNNB1 30Y>S chr3_41266092-41266092_A_C Substitution NA Yes 41.74% 
CGPLBR69 Breast Cancer II Germline IDH1 231Y>N chr2_209108158-209108158_A_T Substitution NA Yes 41.66% 
CGPLBR70 Breast Cancer II Tumor-derived ATM 2832R>H chr11_108216546-108216546_G_A Substitution No No 0.36% 
CGPLBR70 Breast Cancer II Germline APC 1577E>D chr5_112176022-112176022_A_C Substitution NA Yes 40.28% 
CGPLBR71 Breast Cancer II Tumor-derived TP53 273R>H chr17_7577120-7577120_C_T Substitution Yes Yes 0.10% 
CGPLBR72 Breast Cancer II Germline APC 1532D>G chr5_112175886-112175886_A_G Substitution NA Yes 44.03% 
CGPLBR73 Breast Cancer II Tumor-derived ALK 708S>P chr2_29474053-29474053_A_G Substitution No No 0.27% 
CGPLBR73 Breast Cancer II Germline ERBB4 158A>E chr2_212652833-212652833_G_T Substitution NA Yes 35.58% 
CGPLBR74 Breast Cancer II Germline AR 20+1G>T chrX_66788865-66788865_G_T Substitution NA Yes 36.23% 
CGPLBR75 Breast Cancer II Tumor-derived PIK3CA 1047H>R chr3_178952085-178952085_A_G Substitution Yes Yes 0.14% 
CGPLBR76 Breast Cancer II Germline KDR 1290S>N chr4_55946310-55946310_C_T Substitution NA Yes 36.57% 
CGPLBR76 Breast Cancer II Tumor-derived PIK3CA 1047H>R chr3_178952085-178952085_A_G Substitution Yes Yes 0.12% 
CGPLBR77 Breast Cancer III Tumor-derived PTEN 170S>I chr10_89711891-89711891_G_T Substitution No Yes 2.29% 
CGPLBR80 Breast Cancer II Tumor-derived CDKN2A 12S>L chr9_21974792-21974792_G_A Substitution No No 0.54% 
CGPLBR83 Breast Cancer II Germline AR 728N>D chrX_66937328-66937328_A_G Substitution NA Yes 42.66% 
CGPLBR83 Breast Cancer II Tumor-derived ATM 322E>K chr11_108117753-108117753_G_A Substitution No No 0.28% 
CGPLBR83 Breast Cancer II Germline ERBB4 539Y>S chr2_212543783-212543783_T_G Substitution NA Yes 44.91% 
CGPLBR86 Breast Cancer II Germline STK11 354F>L chr19_1223125-1223125_C_G Substitution NA Yes 42.32% 
CGPLBR86 Breast Cancer II Germline SMARCB1 795+3A>G chr22_24159126-24159126_A_G Substitution NA Yes 43.38% 
CGPLBR87 Breast Cancer II Tumor-derived JAK2 215R>X chr9_5054591-5054591_C_T Substitution No No 0.35% 
CGPLBR87 Breast Cancer II Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes No 0.31% 
CGPLBR87 Breast Cancer II Tumor-derived SMAD4 496R>C chr18_48604664-48604664_C_T Substitution No No 0.40% 
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CGPLBR87 Breast Cancer II Germline AR 651S>N chrX_66931310-66931310_G_A Substitution NA Yes 42.94% 
CGPLBR88 Breast Cancer II Tumor-derived CDK6 51E>K chr7_92462487-92462487_C_T Substitution No No 0.13% 
CGPLBR88 Breast Cancer II Germline APC 1125V>A chr5_112174665-112174665_T_C Substitution NA Yes 31.19% 
CGPLBR92 Breast Cancer II Tumor-derived TP53 257L>P chr17_7577511-7577511_A_G Substitution No Yes 0.20% 
CGPLBR96 Breast Cancer II Tumor-derived TP53 213R>X chr17.fa:7578212-7578212_G_A Substitution Yes No 0.10% 
CGPLBR96 Breast Cancer II Hematopoietic DNMT3A 531D>G chr2_25467484-25467484_T_C Substitution No Yes 5.81% 
CGPLBR96 Breast Cancer II Tumor-derived AR 13R>Q chrX_66765026-66765026_G_A Substitution No No 0.60% 
CGPLBR97 Breast Cancer II Hematopoietic DNMT3A 882R>H chr2_25457242-25457242_C_T Substitution Yes Yes 0.11% 
CGPLBR97 Breast Cancer II Germline PDGFRA 401A>D chr4_55136880-55136880_C_A Substitution NA Yes 34.12% 
CGPLBR97 Breast Cancer II Tumor-derived GNAS 201R>H chr20_57484421-57484421_G_A Substitution Yes Yes 0.13% 
CGPLLU144 Lung Cancer II Tumor-derived TP53 241S>F chr17_7577559-7577559_G_A Substitution Yes Yes 1.95% 
CGPLLU144 Lung Cancer II Tumor-derived KRAS 12G>C chr12_25398285-25398285_C_A Substitution Yes Yes 5.10% 
CGPLLU144 Lung Cancer II Tumor-derived EGFR 373P>S chr7_55224336-55224336_C_T Substitution No Yes 0.16% 
CGPLLU144 Lung Cancer II Tumor-derived ATM 292P>L chr11_108115727-108115727_C_T Substitution No No 0.22% 
CGPLLU144 Lung Cancer II Tumor-derived PIK3CA 545E>K chr3_178936091-178936091_G_A Substitution Yes Yes 2.94% 
CGPLLU144 Lung Cancer II Tumor-derived ERBB4 426R>K chr2_212568841-212568841_C_T Substitution No No 0.18% 
CGPLLU146 Lung Cancer II Hematopoietic JAK2 617V>F chr9_5073770-5073770_G_T Substitution Yes No 0.25% 
CGPLLU146 Lung Cancer II Tumor-derived TP53 282R>P chr17_7577093-7577093_C_G Substitution No Yes 1.30% 
CGPLLU146 Lung Cancer II Hematopoietic DNMT3A 737L>H chr2_25463283-25463283_A_T Substitution No Yes 0.84% 
CGPLLU146 Lung Cancer II Tumor-derived RB1 861+2T>C chr13_48937095-48937095_T_C Substitution No Yes 0.87% 
CGPLLU146 Lung Cancer II Tumor-derived ATM 581L>F chr11_108122699-108122699_A_T Substitution No No 0.20% 
CGPLLU147 Lung Cancer III Tumor-derived TP53 248R>Q chr17_7577538-7577538_C_T Substitution Yes No 0.15% 
CGPLLU147 Lung Cancer III Tumor-derived TP53 201L>X chr17_7578247-7578247_A_T Substitution No Yes 0.55% 
CGPLLU147 Lung Cancer III Tumor-derived ALK 1537G>E chr2_29416343-29416343_C_T Substitution No Yes 0.94% 
CGPLLU147 Lung Cancer III Germline PDGFRA 200T>S chr4_55130065-55130065_C_G Substitution NA Yes 43.47% 
CGPLLU162 Lung Cancer II Tumor-derived CDKN2A 12S>L chr9_21974792-21974792_G_A Substitution No No 0.22% 
CGPLLU162 Lung Cancer II Tumor-derived EGFR 858L>R chr7_55259515-55259515_T_G Substitution Yes Yes 0.22% 
CGPLLU162 Lung Cancer II Tumor-derived BRAF 354R>Q chr7_140494187-140494187_C_T Substitution No No 0.14% 
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CGPLLU163 Lung Cancer II Tumor-derived CDKN2A 12S>L chr9_21974792-21974792_G_A Substitution No No 0.21% 
CGPLLU163 Lung Cancer II Hematopoietic DNMT3A 528Y>D chr2_25467494-25467494_A_C Substitution No Yes 0.15% 
CGPLLU164 Lung Cancer II Tumor-derived STK11 216S>Y chr19_1220629-1220629_C_A Substitution No Yes 1.23% 
CGPLLU164 Lung Cancer II Germline STK11 354F>L chr19_1223125-1223125_C_G Substitution NA Yes 42.52% 
CGPLLU164 Lung Cancer II Tumor-derived GNA11 606-3C>T chr19_3118919-3118919_C_T Substitution No No 0.20% 
CGPLLU164 Lung Cancer II Tumor-derived TP53 278P>S chr17_7577106-7577106_G_A Substitution Yes No 0.10% 
CGPLLU164 Lung Cancer II Tumor-derived TP53 161A>S chr17_7578449-7578449_C_A Substitution No Yes 1.78% 
CGPLLU164 Lung Cancer II Tumor-derived TP53 160M>I chr17_7578450-7578450_C_A Substitution No Yes 1.86% 
CGPLLU164 Lung Cancer II Tumor-derived ERBB4 1299P>L chr2_212248371-212248371_G_A Substitution No Yes 0.96% 
CGPLLU164 Lung Cancer II Tumor-derived ERBB4 253N>S chr2_212587243-212587243_T_C Substitution No No 0.22% 
CGPLLU165 Lung Cancer II Germline STK11 354F>L chr19_1223125-1223125_C_G Substitution NA Yes 36.62% 
CGPLLU165 Lung Cancer II Tumor-derived GNAS 201R>H chr20_57484421-57484421_G_A Substitution Yes Yes 0.16% 
CGPLLU168 Lung Cancer I Tumor-derived TP53 136Q>X chr17.fa:7578524-7578524_G_A Substitution Yes Yes 0.06% 
CGPLLU168 Lung Cancer I Hematopoietic DNMT3A 736R>S chr2_25463287-25463287_G_T Substitution No No 0.39% 
CGPLLU168 Lung Cancer I Tumor-derived EGFR 858L>R chr7.fa:55259515-55259515_T_G Substitution Yes Yes 0.07% 
CGPLLU174 Lung Cancer I Tumor-derived STK11 597+1G>T chr19_1220505-1220505_G_T Substitution No Yes 0.33% 
CGPLLU174 Lung Cancer I Tumor-derived JAK2 160D>Y chr9_5050695-5050695_G_T Substitution No Yes 0.40% 
CGPLLU174 Lung Cancer I Tumor-derived KRAS 12G>C chr12_25398285-25398285_C_A Substitution Yes Yes 0.16% 
CGPLLU174 Lung Cancer I Hematopoietic DNMT3A 891R>W chr2_25457216-25457216_G_A Substitution No Yes 0.29% 
CGPLLU174 Lung Cancer I Hematopoietic DNMT3A 715I>M chr2_25463537-25463537_G_C Substitution No Yes 0.26% 
CGPLLU175 Lung Cancer I Tumor-derived TP53 179H>R chr17_7578394-7578394_T_C Substitution Yes Yes 8.03% 
CGPLLU175 Lung Cancer I Hematopoietic DNMT3A 2598-1G>A chr2_25457290-25457290_C_T Substitution No No 0.21% 
CGPLLU175 Lung Cancer I Hematopoietic DNMT3A 755F>L chr2_25463230-25463230_A_G Substitution No Yes 0.15% 
CGPLLU175 Lung Cancer I Germline ATM 337R>C chr11_108117798-108117798_C_T Substitution NA Yes 43.84% 
CGPLLU175 Lung Cancer I Tumor-derived ERBB4 941Q>X chr2_212288925-212288925_G_A Substitution No Yes 3.64% 
CGPLLU176 Lung Cancer I Hematopoietic DNMT3A 750P>S chr2_25463245-25463245_G_A Substitution No Yes 0.92% 
CGPLLU176 Lung Cancer I Hematopoietic DNMT3A 735Y>C chr2_25463289-25463289_T_C Substitution No Yes 0.21% 
CGPLLU177 Lung Cancer II Tumor-derived KRAS 12G>V chr12_25398284-25398284_C_A Substitution Yes Yes 2.49% 
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CGPLLU177 Lung Cancer II Hematopoietic DNMT3A 897V>G chr2_25457197-25457197_A_C Substitution No Yes 1.53% 
CGPLLU177 Lung Cancer II Hematopoietic DNMT3A 882R>C chr2_25457243-25457243_G_A Substitution Yes No 0.29% 
CGPLLU177 Lung Cancer II Hematopoietic DNMT3A 2173+1G>A chr2_25463508-25463508_C_T Substitution No No 0.13% 
CGPLLU178 Lung Cancer I Tumor-derived CDH1 251T>M chr16_68844164-68844164_C_T Substitution No No 0.29% 
CGPLLU178 Lung Cancer I Tumor-derived PIK3CA 861Q>X chr3_178947145-178947145_C_T Substitution No No 0.17% 
CGPLLU179 Lung Cancer I Hematopoietic DNMT3A 879N>D chr2_25457252-25457252_T_C Substitution No Yes 0.38% 
CGPLLU179 Lung Cancer I Germline APC 2611T>I chr5_112179123-112179123_C_T Substitution NA Yes 39.91% 
CGPLLU180 Lung Cancer I Tumor-derived STK11 237D>Y chr19_1220691-1220691_G_T Substitution No Yes 2.43% 
CGPLLU180 Lung Cancer I Tumor-derived TP53 293G>V chr17_7577060-7577060_C_A Substitution No Yes 2.07% 
CGPLLU180 Lung Cancer I Tumor-derived TP53 282R>P chr17_7577093-7577093_C_G Substitution No Yes 1.94% 
CGPLLU180 Lung Cancer I Tumor-derived TP53 177P>L chr17.fa:7578400-7578400_G_A Substitution Yes No 0.08% 
CGPLLU180 Lung Cancer I Tumor-derived RB1 565S>X chr13_48955578-48955578_C_G Substitution No Yes 1.01% 
CGPLLU197 Lung Cancer I Hematopoietic DNMT3A 882R>C chr2_25457243-25457243_G_A Substitution Yes No 0.16% 
CGPLLU197 Lung Cancer I Hematopoietic DNMT3A 879N>D chr2_25457252-25457252_T_C Substitution No No 0.38% 
CGPLLU198 Lung Cancer I Tumor-derived TP53 162I>N chr17_7578445-7578445_A_T Substitution No Yes 0.87% 
CGPLLU198 Lung Cancer I Tumor-derived EGFR 858L>R chr7_55259515-55259515_T_G Substitution Yes Yes 0.52% 
CGPLLU202 Lung Cancer I Tumor-derived EGFR 790T>M chr7.fa:55249071-55249071_C_T Substitution Yes Yes 0.05% 
CGPLLU202 Lung Cancer I Tumor-derived EGFR 868E>X chr7_55259544-55259544_G_T Substitution No No 0.13% 
CGPLLU204 Lung Cancer I Tumor-derived KIT 956R>Q chr4_55604659-55604659_G_A Substitution No No 0.26% 
CGPLLU205 Lung Cancer II Hematopoietic DNMT3A 736R>C chr2_25463287-25463287_G_A Substitution No Yes 0.70% 
CGPLLU205 Lung Cancer II Hematopoietic DNMT3A 696Q>X chr2_25463596-25463596_G_A Substitution No Yes 3.47% 
CGPLLU206 Lung Cancer III Tumor-derived TP53 672+1G>A chr17_7578176-7578176_C_T Substitution Yes Yes 26.13% 
CGPLLU206 Lung Cancer III Tumor-derived TP53 131N>S chr17_7578538-7578538_T_C Substitution No No 0.21% 
CGPLLU207 Lung Cancer II Tumor-derived TP53 376-1G>A chr17_7578555-7578555_C_T Substitution Yes Yes 0.32% 
CGPLLU207 Lung Cancer II Germline ALK 419F>L chr2_29606625-29606625_A_G Substitution NA Yes 34.58% 
CGPLLU207 Lung Cancer II Tumor-derived EGFR 790T>M chr7.fa:55249071-55249071_C_T Substitution Yes No 0.09% 
CGPLLU208 Lung Cancer II Tumor-derived TP53 250P>L chr17_7577532-7577532_G_A Substitution Yes Yes 1.33% 
CGPLLU208 Lung Cancer II Germline EGFR 224R>H chr7_55220281-55220281_G_A Substitution NA Yes 39.34% 
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CGPLLU208 Lung Cancer II Tumor-derived EGFR 858L>R chr7_55259515-55259515_T_G Substitution Yes Yes 0.86% 
CGPLLU208 Lung Cancer II Tumor-derived MYC 98R>W chr8_128750755-128750755_C_T Substitution No No 0.17% 
CGPLLU209 Lung Cancer II Germline STK11 354F>L chr19_1223125-1223125_C_G Substitution NA Yes 26.84% 
CGPLLU209 Lung Cancer II Tumor-derived TP53 100Q>X chr17_7579389-7579389_G_A Substitution No Yes 9.97% 
CGPLLU209 Lung Cancer II Tumor-derived CDKN2A 88E>X chr9_21971096-21971096_C_A Substitution Yes Yes 9.13% 
CGPLLU209 Lung Cancer II Tumor-derived PDGFRA 921A>T chr4_55155052-55155052_G_A Substitution No Yes 9.82% 
CGPLLU209 Lung Cancer II Germline EGFR 567M>V chr7_55231493-55231493_A_G Substitution NA Yes 30.41% 
CGPLOV10 Ovarian Cancer I Tumor-derived TP53 342R>X chr17_7574003-7574003_G_A Substitution Yes Yes 3.14% 
CGPLOV11 Ovarian Cancer IV Tumor-derived TP53 248R>Q chr17_7577538-7577538_C_T Substitution Yes Yes 0.87% 
CGPLOV11 Ovarian Cancer IV Germline TP53 63A>V chr17_7579499-7579499_G_A Substitution NA Yes 37.77% 
CGPLOV13 Ovarian Cancer IV Tumor-derived ALK 444W>C chr2_29551298-29551298_C_A Substitution No Yes 0.12% 
CGPLOV13 Ovarian Cancer IV Germline PDGFRA 401A>D chr4_55136880-55136880_C_A Substitution NA Yes 37.98% 
CGPLOV13 Ovarian Cancer IV Tumor-derived KIT 135R>H chr4_55564516-55564516_G_A Substitution No Yes 0.35% 
CGPLOV14 Ovarian Cancer I Tumor-derived HNF1A 230E>K chr12_121431484-121431484_G_A Substitution No No 0.14% 
CGPLOV15 Ovarian Cancer III Tumor-derived TP53 278P>S chr17_7577106-7577106_G_A Substitution Yes Yes 3.54% 
CGPLOV15 Ovarian Cancer III Tumor-derived EGFR 433H>D chr7_55225445-55225445_C_G Substitution No No 0.19% 
CGPLOV17 Ovarian Cancer I Tumor-derived TP53 248R>Q chr17_7577538-7577538_C_T Substitution Yes Yes 0.32% 
CGPLOV17 Ovarian Cancer I Germline PDGFRA 1071D>N chr4_55161380-55161380_G_A Substitution NA Yes 44.10% 
CGPLOV18 Ovarian Cancer I Germline APC 1125V>A chr5_112174665-112174665_T_C Substitution NA Yes 40.81% 
CGPLOV19 Ovarian Cancer II Germline FGFR3 403K>E chr4_1806188-1806188_A_G Substitution NA Yes 23.80% 
CGPLOV19 Ovarian Cancer II Tumor-derived TP53 273R>H chr17_7577120-7577120_C_T Substitution Yes Yes 36.83% 
CGPLOV19 Ovarian Cancer II Germline AR 176S>R chrX_66765516-66765516_C_A Substitution NA Yes 65.29% 
CGPLOV19 Ovarian Cancer II Tumor-derived APC 1378Q>X chr5_112175423-112175423_C_T Substitution Yes Yes 46.35% 
CGPLOV20 Ovarian Cancer II Tumor-derived TP53 195I>T chr17_7578265-7578265_A_G Substitution Yes Yes 0.21% 
CGPLOV20 Ovarian Cancer II Germline EGFR 253K>R chr7_55221714-55221714_A_G Substitution NA Yes 44.05% 
CGPLOV21 Ovarian Cancer IV Germline STK11 354F>L chr19_1223125-1223125_C_G Substitution NA Yes 7.68% 
CGPLOV21 Ovarian Cancer IV Tumor-derived TP53 275C>Y chr17_7577114-7577114_C_T Substitution No Yes 2.04% 
CGPLOV21 Ovarian Cancer IV Tumor-derived ERBB4 602S>T chr2_212530114-212530114_C_G Substitution No No 14.36% 
208 
 
CGPLOV22 Ovarian Cancer III Tumor-derived TP53 193H>P chr17_7578271-7578271_T_G Substitution No Yes 0.49% 
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cfDNA Fragment Size 
(bp) 
Maximum cfDNA 
Fragment Size (bp) 
CGCRC291 11688 100 151 167 169 179 188 400 
CGCRC291 11779 100 155 171 169 182 185 400 
CGCRC291 11026 100 156 166 169 180 183 400 
CGCRC291 7632 97 152 169 167 177 182 400 
CGCRC291 7218 101 155 167 169 184 185 400 
CGCRC291 10757 86 154 166 167 181 182 400 
CGCRC291 5429 100 151 171 167 176 180 400 
CGCRC292 6120 101 157 167 169 176 183 399 
CGCRC292 10693 100 155 169 168 177 182 400 
CGCRC292 7587 97 158 166 171 183 188 399 
CGCRC293 7672 95 159 168 170 188 186 400 
CGCRC294 7339 84 155 166 167 175 179 396 
CGCRC294 12054 89 159 167 170 184 185 400 
CGCRC295 5602 101 157 164 170 179 185 397 
CGCRC295 8330 100 157 166 169 179 182 397 
CGCRC296 8375 89 161 166 172 185 188 400 
CGCRC297 3580 102 159 164 170 187 188 400 
CGCRC298 13032 100 159 168 171 184 187 399 
CGCRC298 13475 93 158 169 170 183 185 400 
CGCRC298 5815 100 156 168 169 181 182 397 
CGCRC299 11995 100 154 164 165 172 175 400 
CGCRC299 15363 96 151 166 164 169 174 400 
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CGCRC300 7487 100 162 170 173 189 187 399 
CGCRC301 5881 100 156 169 169 176 183 400 
CGCRC302 24784 84 153 165 164 169 175 397 
CGCRC302 11763 95 154 165 165 166 173 397 
CGCRC303 13967 95 159 169 171 184 186 400 
CGCRC303 10167 81 160 169 172 185 186 400 
CGCRC303 10845 100 160 169 172 185 187 400 
CGCRC304 16168 90 153 167 164 167 175 394 
CGCRC304 10502 100 152 165 163 167 173 397 
CGCRC304 12987 101 154 165 165 170 175 398 
CGCRC305 12507 100 159 169 171 190 189 400 
CGCRC305 10301 100 156 168 168 182 182 399 
CGCRC306 8594 101 157 165 169 189 187 399 
CGCRC306 9437 90 159 167 171 192 193 400 
CGCRC306 6090 100 152 163 166 173 179 391 
CGCRC306 4585 103 158 167 170 181 185 399 
CGCRC306 7395 81 160 166 171 178 184 399 
CGCRC306 4885 100 152 170 167 175 179 398 
CGCRC306 3700 100 159 168 171 181 186 396 
CGCRC307 6860 100 158 170 170 180 183 399 
CGCRC307 10065 95 157 168 169 183 184 397 
CGCRC307 7520 102 156 167 168 185 184 400 
CGCRC307 8623 76 157 169 168 176 180 400 
CGCRC307 10606 100 155 167 168 180 184 399 
CGCRC307 13189 90 158 168 171 185 187 400 
CGCRC308 16287 90 159 168 169 179 182 399 
CGCRC308 7729 100 160 164 170 176 184 398 
CGCRC308 14067 92 157 170 169 182 182 399 
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CGCRC309 13036 85 157 170 169 181 182 395 
CGCRC309 9084 101 157 166 168 175 180 397 
CGCRC310 7393 100 153 165 164 165 172 397 
CGCRC310 11689 100 152 166 164 170 173 398 
CGCRC310 10273 100 153 166 164 171 173 400 
CGCRC311 8456 94 160 171 172 189 189 400 
CGCRC312 4719 100 160 165 173 189 189 400 
CGCRC312 3391 101 157 172 170 178 184 399 
CGCRC313 5013 100 163 166 174 188 189 399 
CGCRC313 8150 72 161 171 174 194 192 400 
CGCRC314 4684 100 158 165 169 180 183 394 
CGCRC314 6902 85 159 165 170 183 185 399 
CGCRC314 7229 102 158 167 170 186 186 398 
CGCRC315 8739 94 155 167 169 192 195 399 
CGCRC315 9623 101 158 166 170 182 184 399 
CGCRC316 12880 100 150 166 163 166 172 396 
CGCRC316 7479 93 157 164 168 175 180 400 
CGCRC316 13682 100 149 165 162 165 172 399 
CGCRC316 16716 85 153 166 166 170 177 397 
CGCRC316 17060 100 150 166 163 166 173 398 
CGCRC317 14587 84 152 166 164 180 178 400 
CGCRC317 10483 100 152 164 165 172 177 400 
CGCRC317 3497 101 149 166 163 171 174 386 
CGCRC318 16436 98 158 170 170 180 183 400 
CGCRC320 6521 100 163 170 175 194 199 399 
CGCRC320 11633 100 162 174 174 184 188 400 
CGCRC321 6918 88 161 167 174 194 198 399 
CGCRC321 9559 94 159 171 170 182 184 399 
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CGCRC321 5545 100 159 172 172 183 186 397 
CGCRC332 605 104 164 170 176 202 203 393 
CGCRC333 1265 89 159 165 171 195 195 397 
CGCRC333 3338 102 153 165 169 185 189 400 
CGCRC333 3008 102 153 169 169 185 189 396 
CGCRC334 1725 105 160 170 175 203 210 391 
CGCRC334 1168 100 159 164 174 188 194 399 
CGCRC334 1798 103 159 166 173 193 193 396 
CGCRC335 2411 99 155 167 167 172 179 396 
CGCRC336 757 104 156 171 170 186 188 387 
CGCRC336 1080 102 150 166 167 177 183 392 
CGCRC336 391 102 161 165 171 194 200 377 
CGCRC337 6497 72 153 169 177 202 259 400 
CGCRC337 1686 100 147 170 163 171 178 395 
CGCRC338 1408 105 153 164 166 178 182 374 
CGCRC339 1256 106 158 168 169 179 184 397 
CGCRC339 1639 101 158 165 172 195 194 400 
CGCRC339 1143 100 154 170 167 176 179 397 
CGCRC339 1584 108 161 171 173 188 191 390 
CGCRC340 876 101 162 170 175 205 207 399 
CGCRC340 796 105 159 164 174 196 195 397 
CGPLBR38 9684 95 156 166 168 186 184 400 
CGPLBR40 10277 78 162 168 173 179 186 400 
CGPLBR44 10715 99 162 171 173 191 190 400 
CGPLBR44 10837 100 159 169 171 191 189 400 
CGPLBR44 12640 100 159 168 171 187 189 400 
CGPLBR48 5631 100 164 170 179 202 202 400 
CGPLBR48 12467 101 167 174 180 196 201 400 
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CGPLBR55 10527 101 158 169 169 181 182 397 
CGPLBR55 6011 101 153 166 167 181 181 400 
CGPLBR55 3973 101 153 166 166 176 179 398 
CGPLBR63 3405 97 165 170 176 191 192 398 
CGPLBR67 10259 87 157 168 168 179 181 399 
CGPLBR67 5163 100 151 167 166 171 177 399 
CGPLBR67 6250 100 155 166 167 172 179 399 
CGPLBR69 7558 100 159 166 170 186 184 398 
CGPLBR69 3938 101 154 169 166 176 178 397 
CGPLBR69 2387 101 157 166 168 176 178 385 
CGPLBR70 6916 100 158 171 169 182 184 400 
CGPLBR70 3580 107 160 169 173 194 193 400 
CGPLBR71 7930 85 156 166 168 179 180 398 
CGPLBR72 2389 100 157 160 170 188 187 400 
CGPLBR73 11348 95 161 173 174 189 192 400 
CGPLBR73 3422 102 157 168 169 178 184 399 
CGPLBR74 3784 101 163 175 174 179 187 391 
CGPLBR75 7290 103 162 173 172 183 186 398 
CGPLBR76 4342 104 166 171 179 197 201 400 
CGPLBR76 11785 100 165 168 177 191 194 400 
CGPLBR77 6161 100 158 166 169 183 183 400 
CGPLBR80 3643 96 166 166 185 211 230 400 
CGPLBR83 3479 106 162 164 174 193 193 400 
CGPLBR83 3496 103 165 170 177 197 199 400 
CGPLBR83 1748 100 164 173 175 193 195 399 
CGPLBR86 4241 98 160 168 175 204 207 400 
CGPLBR86 3096 88 160 167 174 196 195 400 
CGPLBR87 3680 101 162 168 175 202 203 400 
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CGPLBR87 6180 101 163 164 175 205 203 400 
CGPLBR87 7746 86 160 167 175 195 196 400 
CGPLBR87 2266 106 160 166 172 195 192 400 
CGPLBR88 17537 89 185 200 223 238 280 400 
CGPLBR88 5919 101 162 172 173 197 194 400 
CGPLBR92 15530 77 150 164 162 172 173 398 
CGPLBR96 9893 100 159 164 171 196 191 399 
CGPLBR96 8620 95 162 167 173 189 190 400 
CGPLBR96 8036 85 162 169 175 194 195 400 
CGPLBR97 14856 93 160 168 170 184 184 400 
CGPLBR97 5329 100 161 165 171 179 184 399 
CGPLBR97 7010 97 158 169 170 187 185 399 
CGPLLU144 11371 100 156 165 167 179 179 395 
CGPLLU144 7641 100 155 167 166 172 177 399 
CGPLLU144 9996 100 158 168 169 179 183 400 
CGPLLU144 4956 101 159 166 169 182 182 397 
CGPLLU144 6540 100 153 170 166 172 177 397 
CGPLLU144 7648 101 156 164 166 171 177 399 
CGPLLU146 5920 100 155 164 168 180 183 399 
CGPLLU146 9356 100 155 166 168 184 184 400 
CGPLLU146 7284 101 158 165 170 186 187 399 
CGPLLU146 4183 103 160 166 170 183 185 400 
CGPLLU146 6778 100 157 166 168 182 184 400 
CGPLLU147 4807 100 155 166 170 192 191 400 
CGPLLU147 5282 100 156 167 171 199 205 400 
CGPLLU147 7122 100 158 174 173 191 193 400 
CGPLLU147 2825 101 160 165 173 190 191 389 
CGPLLU162 9940 95 161 164 174 192 197 400 
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CGPLLU162 13855 87 160 174 173 183 189 400 
CGPLLU162 11251 100 153 167 166 175 178 400 
CGPLLU163 10805 85 159 165 173 194 202 400 
CGPLLU163 20185 83 158 166 170 184 186 400 
CGPLLU164 6795 91 156 161 169 191 190 396 
CGPLLU164 4561 92 157 164 169 188 185 394 
CGPLLU164 8097 100 158 170 170 186 186 399 
CGPLLU164 9241 100 155 165 167 180 180 397 
CGPLLU164 10806 100 157 168 169 182 182 400 
CGPLLU164 10919 100 157 168 169 182 182 400 
CGPLLU164 5412 103 159 175 171 180 182 395 
CGPLLU164 5151 101 160 166 169 177 182 400 
CGPLLU165 7448 95 155 167 167 185 184 399 
CGPLLU165 5822 102 154 166 166 181 179 394 
CGPLLU168 15985 97 152 165 166 177 180 400 
CGPLLU168 11070 100 156 165 168 179 181 400 
CGPLLU168 11063 83 157 166 169 177 182 400 
CGPLLU174 5881 88 162 165 174 200 199 399 
CGPLLU174 3696 100 162 167 172 184 185 392 
CGPLLU174 4941 101 162 167 172 182 184 395 
CGPLLU174 7527 100 163 168 173 186 187 399 
CGPLLU174 8353 101 162 168 173 186 186 396 
CGPLLU175 10214 100 160 166 170 185 183 399 
CGPLLU175 9739 100 157 168 168 179 180 400 
CGPLLU175 9509 100 157 165 168 181 181 400 
CGPLLU175 2710 101 157 165 167 176 179 392 
CGPLLU175 6565 100 158 166 168 174 180 399 
CGPLLU176 6513 101 164 168 175 197 194 399 
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CGPLLU176 5962 100 164 174 175 195 194 399 
CGPLLU177 7044 102 160 165 170 178 182 395 
CGPLLU177 9950 88 160 169 171 183 185 398 
CGPLLU177 11233 100 160 168 171 185 184 397 
CGPLLU177 10966 75 160 169 172 190 188 395 
CGPLLU178 8378 100 162 176 172 186 187 398 
CGPLLU178 7235 101 159 167 170 179 184 400 
CGPLLU179 8350 103 161 169 171 185 185 394 
CGPLLU179 2609 108 162 171 173 189 187 398 
CGPLLU180 6085 91 158 165 170 198 200 398 
CGPLLU180 8680 92 158 164 169 190 188 400 
CGPLLU180 7790 92 158 167 168 184 184 400 
CGPLLU180 9036 101 160 169 171 191 189 397 
CGPLLU180 4679 100 157 169 168 181 182 398 
CGPLLU197 7196 102 162 166 172 191 189 399 
CGPLLU197 7147 100 161 166 172 191 189 399 
CGPLLU198 9322 97 157 165 168 180 181 399 
CGPLLU198 8303 100 160 173 172 181 186 400 
CGPLLU202 14197 90 151 165 166 169 179 398 
CGPLLU202 9279 51 150 168 167 170 181 398 
CGPLLU204 7185 100 157 165 168 175 181 391 
CGPLLU205 10739 96 156 165 166 175 177 400 
CGPLLU205 12065 100 154 165 165 172 176 400 
CGPLLU206 6746 94 148 165 164 179 178 398 
CGPLLU206 11225 100 147 167 164 175 178 399 
CGPLLU207 11224 100 159 165 170 187 186 400 
CGPLLU207 4960 101 160 166 170 181 184 400 
CGPLLU207 13216 85 161 165 172 182 187 400 
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CGPLLU208 9211 101 156 166 168 181 183 400 
CGPLLU208 5253 100 159 164 170 179 184 400 
CGPLLU208 10233 100 160 170 171 181 186 400 
CGPLLU208 11421 100 158 165 171 187 190 397 
CGPLLU209 11695 96 153 166 169 190 192 400 
CGPLLU209 12771 94 155 163 168 174 182 400 
CGPLLU209 16557 92 157 169 170 185 188 400 
CGPLLU209 13057 97 158 167 171 182 187 400 
CGPLLU209 8521 100 155 167 169 176 183 396 
CGPLOV10 4421 101 161 165 172 186 188 399 
CGPLOV11 7987 100 157 164 169 186 185 399 
CGPLOV11 3782 97 160 166 171 183 185 392 
CGPLOV13 12072 88 157 165 169 182 183 399 
CGPLOV13 4107 103 159 166 169 177 181 399 
CGPLOV13 8427 100 161 165 171 181 184 400 
CGPLOV14 11418 92 154 167 171 183 191 400 
CGPLOV15 7689 102 157 164 169 187 185 399 
CGPLOV15 7617 101 159 167 171 182 188 400 
CGPLOV17 4463 96 156 168 169 186 187 397 
CGPLOV17 2884 110 157 170 170 188 189 400 
CGPLOV18 2945 101 159 164 169 183 183 391 
CGPLOV19 9727 95 158 167 172 185 189 395 
CGPLOV19 4387 100 158 165 169 184 184 398 
CGPLOV19 2775 93 161 171 171 182 187 400 
CGPLOV19 3818 102 156 170 170 186 185 400 
CGPLOV20 5404 94 159 165 170 193 190 400 
CGPLOV20 3744 102 158 166 169 182 185 394 
CGPLOV21 21823 81 158 166 169 179 180 400 
218 
 
CGPLOV21 18806 101 159 165 169 175 179 400 
CGPLOV21 10801 89 160 166 169 175 180 394 
CGPLOV22 11952 100 155 165 167 184 182 400 





Table 4.3.  Summary of targeted cfDNA fragment analyses in cancer patients (cont.). 
Patient 





















































CGCRC291 19 100 142 233 165 180 230 305 -4.0 1.54 0.475 
CGCRC291 21 132 166 182 176 191 198 309 7.0 8.33 0.250 
CGCRC291 5411 92 152 167 169 186 191 399 0.0 5.89 0.000 
CGCRC291 1903 100 148 166 166 177 183 383 -1.0 -0.25 0.874 
CGCRC291 1344 108 155 167 170 189 191 398 1.0 5.37 0.009 
CGCRC291 2108 100 153 166 168 185 187 386 1.0 3.80 0.025 
CGCRC291 1951 101 149 175 167 179 182 397 0.0 2.65 0.148 
CGCRC292 75 123 162 167 172 182 190 370 3.0 5.31 0.368 
CGCRC292 28 101 130 130 139 164 155 345 -29.5 -12.79 0.000 
CGCRC292 6863 100 160 168 173 186 189 400 2.0 3.13 0.002 
CGCRC293 34 77 154 171 170 177 192 335 -0.5 -11.46 0.571 
CGCRC294 9 138 147 176 171 177 176 290 4.0 1.22 0.475 
CGCRC294 21 115 145 155 159 176 175 368 -11.0 -7.99 0.052 
CGCRC295 30 137 149 181 162 182 181 369 -8.0 3.49 0.061 
CGCRC295 44 125 155 155 169 185 194 338 0.0 5.78 0.623 
CGCRC296 8167 101 160 166 171 184 187 400 -1.0 -1.27 0.212 
CGCRC297 3562 102 158 168 170 185 185 399 0.0 -2.62 0.114 
CGCRC298 15 93 137 127 174 173 193 261 3.0 -11.00 0.507 
CGCRC298 26 137 163 166 167 179 180 364 -3.0 -4.34 0.430 
CGCRC298 35 118 147 176 163 172 176 336 -6.0 -9.35 0.166 
CGCRC299 71 133 152 170 165 169 173 301 0.0 -3.57 0.668 
CGCRC299 55 130 153 165 164 166 168 325 0.0 -2.15 0.630 
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CGCRC300 17 149 155 326 170 221 301 387 -3.0 32.43 0.453 
CGCRC301 18 156 170 174 174 210 219 372 5.0 33.84 0.368 
CGCRC302 51 108 143 268 152 164 178 268 -12.0 -5.12 0.000 
CGCRC302 26 118 147 153 156 174 168 327 -9.5 8.37 0.036 
CGCRC303 45 116 151 168 163 175 177 346 -8.0 -8.84 0.057 
CGCRC303 25 157 165 191 175 207 199 350 3.0 22.93 0.465 
CGCRC303 25 124 168 180 180 189 191 338 8.0 4.06 0.154 
CGCRC304 86 121 155 169 166 168 175 309 2.0 0.46 0.445 
CGCRC304 45 124 143 197 162 166 168 377 -1.0 -0.91 0.482 
CGCRC304 108 126 147 162 162 164 174 302 -3.0 -6.74 0.064 
CGCRC305 23 131 148 145 166 189 205 333 -5.0 -0.80 0.297 
CGCRC305 42 138 155 155 174 177 187 343 5.5 -4.51 0.171 
CGCRC306 25 126 153 176 176 188 229 305 7.0 -0.19 0.234 
CGCRC306 977 101 149 189 170 182 192 380 -1.0 -9.76 0.000 
CGCRC306 525 102 140 168 159 168 176 382 -7.0 -5.57 0.052 
CGCRC306 4010 100 158 166 170 181 185 398 0.0 0.37 0.770 
CGCRC306 625 100 140 167 162 172 181 380 -9.0 -6.68 0.009 
CGCRC306 37 111 143 142 166 172 186 321 -1.0 -2.38 0.572 
CGCRC306 3184 102 159 168 172 182 187 400 0.5 0.95 0.564 
CGCRC307 47 111 148 144 169 176 183 353 -1.0 -4.83 0.598 
CGCRC307 39 111 146 182 162 182 185 337 -7.0 -0.44 0.064 
CGCRC307 24 110 146 309 182 208 284 355 14.0 22.31 0.031 
CGCRC307 32 117 146 154 157 167 166 298 -11.0 -8.94 0.013 
CGCRC307 43 111 143 144 177 187 212 319 9.0 7.22 0.062 
CGCRC307 29 109 140 204 159 188 204 387 -12.0 3.32 0.031 
CGCRC308 20 128 152 180 163 166 180 219 -6.5 -13.04 0.155 
CGCRC308 7515 101 160 170 171 177 185 400 1.0 1.08 0.166 
CGCRC308 31 85 146 137 166 167 176 316 -3.0 -14.62 0.469 
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CGCRC309 428 100 135 138 149 158 166 340 -20.0 -23.47 0.000 
CGCRC309 352 97 136 132 147 149 159 326 -21.0 -26.04 0.000 
CGCRC310 15 131 137 132 144 163 171 323 -20.0 -1.73 0.000 
CGCRC310 25 107 138 159 161 175 190 299 -3.0 4.83 0.384 
CGCRC310 27 122 147 161 161 173 171 342 -3.0 2.54 0.354 
CGCRC311 91 112 165 168 173 196 192 379 1.0 6.83 0.571 
CGCRC312 27 124 144 154 154 167 172 320 -19.0 -22.39 0.000 
CGCRC312 24 105 143 132 159 183 190 367 -11.0 4.67 0.054 
CGCRC313 8 122 143 122 161 168 195 241 -13.0 -19.21 0.100 
CGCRC313 17 144 163 173 173 213 261 372 -1.0 19.22 0.587 
CGCRC314 15 132 159 186 166 174 185 265 -3.0 -5.62 0.461 
CGCRC314 233 131 162 167 172 190 187 394 2.0 7.27 0.137 
CGCRC314 27 136 155 183 163 170 178 262 -7.0 -16.03 0.131 
CGCRC315 23 137 144 175 152 190 212 327 -17.0 -1.78 0.018 
CGCRC315 29 131 157 177 171 183 179 319 1.0 0.74 0.564 
CGCRC316 1616 100 146 164 159 163 170 354 -3.5 -3.57 0.000 
CGCRC316 806 96 158 169 169 179 184 366 1.0 3.80 0.054 
CGCRC316 1410 102 140 149 154 164 170 398 -8.0 -0.35 0.816 
CGCRC316 49 99 153 143 182 206 284 333 16.0 36.25 0.000 
CGCRC316 33 140 155 154 170 180 180 296 7.0 14.38 0.104 
CGCRC317 73 95 140 140 155 173 178 324 -9.0 -6.66 0.000 
CGCRC317 38 115 160 164 167 182 179 329 1.5 10.09 0.479 
CGCRC317 6 124 137 170 156 153 168 178 -7.5 -18.98 0.411 
CGCRC318 70 124 151 151 164 182 183 385 -6.0 1.71 0.064 
CGCRC320 6586 96 162 168 175 193 196 399 0.0 -1.79 0.166 
CGCRC320 41 112 172 176 177 195 195 373 3.0 11.02 0.397 
CGCRC321 35 149 168 175 175 181 186 312 1.0 -13.40 0.587 
CGCRC321 20 166 180 185 191 205 219 357 21.0 23.48 0.013 
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CGCRC321 5338 102 159 175 171 183 185 394 -1.0 0.03 0.984 
CGCRC332 178 101 150 168 171 198 240 357 -5.0 -4.34 0.571 
CGCRC333 1350 104 153 163 171 201 258 400 0.0 5.94 0.066 
CGCRC333 1257 100 153 168 170 189 202 392 1.0 4.37 0.064 
CGCRC333 30 117 163 164 172 175 179 372 3.0 -10.29 0.463 
CGCRC334 336 105 153 141 171 200 240 399 -4.0 -3.10 0.571 
CGCRC334 741 101 161 169 176 190 194 400 2.0 1.96 0.571 
CGCRC334 89 100 145 171 171 197 229 393 -2.0 3.42 0.479 
CGCRC335 12 129 143 143 153 163 166 275 -14.0 -8.99 0.084 
CGCRC336 3559 91 155 164 173 195 211 398 3.0 8.92 0.001 
CGCRC336 873 102 149 163 164 177 181 400 -3.0 -0.39 0.880 
CGCRC336 1909 100 158 167 176 202 242 398 5.0 7.98 0.061 
CGCRC337 27 122 157 164 179 199 231 350 2.0 -3.82 0.685 
CGCRC337 1818 103 147 169 162 173 180 396 -1.0 1.92 0.372 
CGCRC338 546 102 151 166 166 180 182 381 0.0 2.87 0.416 
CGCRC339 26 132 142 138 171 183 188 351 1.5 3.29 0.572 
CGCRC339 53 117 157 166 169 192 198 336 -3.0 -2.86 0.451 
CGCRC339 40 124 150 169 166 181 176 309 -1.0 4.53 0.539 
CGCRC339 38 107 153 180 174 185 210 326 0.5 -2.59 0.576 
CGCRC340 217 102 146 144 163 188 212 360 -12.0 -17.11 0.004 
CGCRC340 266 111 147 150 166 188 204 379 -8.0 -7.53 0.208 
CGPLBR38 76 123 157 171 169 182 182 346 1.0 -3.64 0.479 
CGPLBR40 9832 93 161 166 172 180 186 399 -1.0 1.04 0.155 
CGPLBR44 277 104 162 160 176 201 200 384 3.0 9.95 0.061 
CGPLBR44 65 123 165 166 172 198 192 371 1.0 7.08 0.560 
CGPLBR44 31 136 163 171 167 201 199 387 -4.0 14.14 0.341 
CGPLBR48 5286 102 166 168 181 201 203 400 2.0 -0.88 0.587 
CGPLBR48 102 138 166 161 179 199 209 372 -1.5 2.90 0.679 
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CGPLBR55 30 138 158 189 185 191 191 311 16.0 9.25 0.000 
CGPLBR55 64 113 158 163 167 179 176 318 0.0 -2.85 0.679 
CGPLBR55 27 121 163 200 171 187 190 392 5.0 10.89 0.314 
CGPLBR63 2943 100 165 176 176 187 192 398 0.0 -3.83 0.015 
CGPLBR67 25 138 153 138 167 181 184 340 -1.0 2.00 0.571 
CGPLBR67 60 110 136 147 147 161 159 327 -19.0 -9.77 0.000 
CGPLBR67 26 139 147 180 176 176 184 344 9.0 3.52 0.015 
CGPLBR69 35 121 149 360 161 197 195 360 -9.0 10.77 0.314 
CGPLBR69 4000 103 155 166 167 176 178 397 0.5 0.65 0.610 
CGPLBR69 2390 99 157 164 168 178 180 400 0.0 1.78 0.314 
CGPLBR70 28 131 160 168 167 177 179 338 -2.0 -5.83 0.463 
CGPLBR70 3545 100 161 169 173 194 192 399 0.0 0.40 0.825 
CGPLBR71 15 121 146 166 166 172 204 221 -2.0 -7.32 0.564 
CGPLBR72 2587 103 158 162 169 189 186 399 -1.0 1.12 0.598 
CGPLBR73 86 121 165 183 177 189 193 373 3.0 -0.01 0.293 
CGPLBR73 3339 101 157 165 169 177 184 400 0.0 -1.73 0.598 
CGPLBR74 3193 101 163 178 173 180 186 389 -1.0 0.22 0.839 
CGPLBR75 13 111 153 153 161 171 179 323 -11.0 -12.36 0.061 
CGPLBR76 4140 102 166 169 179 197 200 400 0.0 -0.32 0.839 
CGPLBR76 16 130 143 143 157 173 173 325 -20.0 -18.40 0.000 
CGPLBR77 209 125 154 175 170 196 233 357 1.0 12.55 0.025 
CGPLBR80 41 158 176 197 186 215 220 374 1.0 3.72 0.603 
CGPLBR83 3445 94 162 175 174 194 194 399 0.0 0.65 0.714 
CGPLBR83 23 123 182 248 224 232 260 359 47.0 34.97 0.000 
CGPLBR83 1787 100 163 163 176 192 194 400 1.0 -0.85 0.718 
CGPLBR86 4100 100 159 164 173 200 202 400 -2.0 -3.65 0.062 
CGPLBR86 3096 79 159 161 173 194 191 397 -1.0 -2.45 0.251 
CGPLBR87 73 142 178 178 184 237 338 377 9.0 35.30 0.114 
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CGPLBR87 23 161 168 168 171 189 186 380 -4.0 -16.38 0.435 
CGPLBR87 170 125 158 173 173 188 190 400 -2.0 -6.17 0.293 
CGPLBR87 2089 101 162 169 176 203 203 400 4.5 8.80 0.000 
CGPLBR88 125 84 192 194 207 243 324 400 -16.0 5.51 0.574 
CGPLBR88 5715 108 163 164 174 200 196 400 1.0 2.87 0.065 
CGPLBR92 109 78 148 149 158 166 173 302 -4.0 -5.94 0.190 
CGPLBR96 35 119 161 172 171 191 180 390 0.0 -4.34 0.627 
CGPLBR96 826 102 162 166 171 187 187 395 -2.0 -1.94 0.475 
CGPLBR96 95 135 160 161 170 182 184 400 -5.0 -11.54 0.155 
CGPLBR97 27 128 150 150 169 174 185 319 -1.0 -9.68 0.571 
CGPLBR97 4771 103 161 168 171 179 183 400 0.0 0.15 0.880 
CGPLBR97 7 147 154 154 167 164 174 177 -3.0 -22.90 0.155 
CGPLLU144 330 106 152 166 166 178 178 361 -1.0 -1.35 0.685 
CGPLLU144 536 106 151 167 163 172 175 363 -3.0 -0.34 0.880 
CGPLLU144 45 138 163 175 172 185 191 380 3.0 6.52 0.368 
CGPLLU144 16 138 146 146 155 162 170 224 -14.0 -19.82 0.007 
CGPLLU144 293 101 152 169 164 170 174 392 -2.0 -1.37 0.646 
CGPLLU144 23 130 152 162 162 163 177 232 -4.0 -7.62 0.252 
CGPLLU146 54 104 161 154 176 195 206 383 7.5 14.58 0.064 
CGPLLU146 154 96 149 157 163 176 185 347 -5.5 -7.87 0.154 
CGPLLU146 79 102 163 177 174 200 203 372 4.0 14.61 0.270 
CGPLLU146 44 118 149 163 163 185 188 338 -7.0 1.98 0.039 
CGPLLU146 35 136 164 204 181 194 203 369 13.0 11.80 0.039 
CGPLLU147 13 138 164 169 169 198 173 333 -1.0 6.05 0.610 
CGPLLU147 50 128 155 161 171 216 301 360 0.0 17.02 0.623 
CGPLLU147 81 108 150 108 173 198 224 385 0.0 6.48 0.624 
CGPLLU147 2597 101 159 165 172 185 187 397 -1.0 -5.17 0.005 
CGPLLU162 58 92 173 192 192 202 200 397 18.0 9.79 0.007 
225 
 
CGPLLU162 74 90 147 142 167 176 182 391 -6.5 -6.78 0.061 
CGPLLU162 37 144 163 185 172 192 186 375 6.0 17.15 0.005 
CGPLLU163 61 93 164 181 181 197 211 370 8.0 3.34 0.169 
CGPLLU163 66 104 158 194 174 189 194 379 3.5 4.60 0.270 
CGPLLU164 101 126 155 176 176 194 213 331 7.0 2.50 0.718 
CGPLLU164 4718 100 156 164 168 190 187 393 -1.0 2.54 0.113 
CGPLLU164 30 134 161 175 175 190 208 339 5.0 4.07 0.302 
CGPLLU164 34 139 163 165 170 178 175 349 3.0 -1.65 0.407 
CGPLLU164 262 101 150 152 165 181 186 393 -4.0 -0.65 0.876 
CGPLLU164 277 101 150 147 166 182 185 393 -3.0 0.36 0.926 
CGPLLU164 65 121 158 161 167 186 188 338 -4.0 6.15 0.234 
CGPLLU164 16 144 172 179 179 187 180 376 10.0 9.98 0.130 
CGPLLU165 7186 100 154 167 166 183 181 396 -1.0 -1.73 0.154 
CGPLLU165 21 108 164 164 173 196 200 357 7.0 14.95 0.213 
CGPLLU168 18 111 127 127 158 189 186 352 -8.0 12.47 0.179 
CGPLLU168 72 121 156 173 166 183 179 396 -2.0 4.31 0.427 
CGPLLU168 30 106 160 174 174 180 186 282 5.0 3.09 0.252 
CGPLLU174 36 131 147 143 177 196 227 298 2.5 -4.24 0.479 
CGPLLU174 20 144 173 266 178 199 215 269 6.0 15.13 0.252 
CGPLLU174 16 147 156 156 164 177 169 302 -8.0 -4.82 0.119 
CGPLLU174 34 159 168 168 176 206 196 365 3.0 20.55 0.415 
CGPLLU174 5 116 182 182 185 201 192 329 12.0 14.62 0.263 
CGPLLU175 1073 100 142 164 152 157 164 346 -18.0 -27.67 0.000 
CGPLLU175 46 109 151 143 175 174 183 325 7.0 -5.22 0.054 
CGPLLU175 30 146 154 146 168 186 181 367 -0.5 5.19 0.568 
CGPLLU175 2742 102 154 164 166 176 178 387 -1.0 -0.24 0.874 
CGPLLU175 298 103 140 148 150 152 162 288 -18.0 -22.25 0.000 
CGPLLU176 67 115 164 250 173 187 201 366 -2.0 -9.89 0.425 
226 
 
CGPLLU176 19 156 165 165 185 197 199 361 10.0 2.20 0.154 
CGPLLU177 189 105 138 141 150 164 175 348 -20.0 -14.58 0.000 
CGPLLU177 227 123 160 168 169 185 184 396 -2.0 1.68 0.706 
CGPLLU177 53 78 161 175 175 189 188 392 4.0 3.80 0.241 
CGPLLU177 50 130 161 168 168 184 175 377 -4.5 -5.86 0.234 
CGPLLU178 28 139 150 173 170 170 173 354 -2.5 -15.88 0.416 
CGPLLU178 24 130 153 176 170 193 199 359 0.0 13.13 0.598 
CGPLLU179 48 111 154 170 168 173 183 295 -3.0 -11.80 0.270 
CGPLLU179 2337 100 163 166 172 187 185 394 -1.0 -1.27 0.564 
CGPLLU180 172 83 152 160 166 193 226 396 -4.0 -4.93 0.490 
CGPLLU180 215 123 151 159 163 188 196 365 -6.0 -1.72 0.735 
CGPLLU180 207 121 151 157 161 181 179 365 -7.0 -3.01 0.571 
CGPLLU180 17 143 170 217 214 198 217 294 43.0 7.08 0.000 
CGPLLU180 52 122 152 167 164 179 173 372 -4.5 -2.07 0.137 
CGPLLU197 17 109 161 173 171 181 174 293 -1.0 -9.24 0.576 
CGPLLU197 40 136 164 166 171 185 185 335 -1.0 -5.86 0.571 
CGPLLU198 127 88 149 131 162 168 178 311 -6.0 -11.80 0.005 
CGPLLU198 68 141 166 175 176 198 207 387 4.0 17.11 0.184 
CGPLLU202 10 81 167 167 167 159 176 182 1.0 -10.20 0.589 
CGPLLU202 33 107 162 167 167 174 185 322 0.0 4.57 0.636 
CGPLLU204 23 112 156 190 164 175 190 349 -4.0 -0.92 0.308 
CGPLLU205 109 130 153 169 166 175 178 382 0.0 -0.09 0.987 
CGPLLU205 684 105 153 167 166 172 175 385 1.0 0.00 0.999 
CGPLLU206 2946 100 138 157 155 172 174 398 -9.0 -7.28 0.000 
CGPLLU206 30 121 165 165 176 198 219 325 12.0 22.37 0.007 
CGPLLU207 63 140 155 154 167 201 215 372 -3.0 13.70 0.286 
CGPLLU207 4754 101 160 170 170 179 181 393 0.0 -1.72 0.154 
CGPLLU207 31 131 162 162 174 180 185 352 2.0 -2.26 0.494 
227 
 
CGPLLU208 150 110 144 166 162 176 173 385 -6.0 -5.86 0.314 
CGPLLU208 5290 95 159 167 169 179 184 400 -1.0 0.11 0.909 
CGPLLU208 140 101 155 175 167 179 180 352 -4.5 -2.77 0.589 
CGPLLU208 20 92 141 241 168 178 209 283 -3.0 -9.82 0.479 
CGPLLU209 8065 85 156 164 169 190 190 399 0.0 -0.08 0.942 
CGPLLU209 2586 101 147 165 165 169 179 386 -3.5 -4.59 0.000 
CGPLLU209 2808 100 150 158 167 189 200 399 -3.0 4.17 0.007 
CGPLLU209 2227 100 154 162 171 183 190 398 0.0 1.00 0.564 
CGPLLU209 8425 100 155 165 169 176 184 400 0.0 0.54 0.568 
CGPLOV10 142 112 146 140 159 180 193 352 -13.0 -5.41 0.463 
CGPLOV11 104 132 158 159 167 189 180 331 -2.0 3.05 0.657 
CGPLOV11 3462 101 160 173 172 184 187 396 1.0 0.82 0.576 
CGPLOV13 25 94 140 140 158 159 163 341 -11.0 -23.47 0.027 
CGPLOV13 3789 101 159 168 169 176 181 395 0.0 -0.66 0.576 
CGPLOV13 57 131 152 170 170 179 184 327 -1.0 -2.41 0.568 
CGPLOV14 36 118 154 201 182 187 201 328 11.0 3.60 0.114 
CGPLOV15 362 110 152 143 180 207 268 389 11.0 20.70 0.000 
CGPLOV15 20 158 163 311 174 198 209 311 3.0 15.25 0.475 
CGPLOV17 23 126 151 184 168 185 185 328 -1.0 -1.49 0.571 
CGPLOV17 2980 100 158 169 170 187 189 398 0.0 -0.84 0.637 
CGPLOV18 2793 91 158 167 170 181 182 389 1.0 -2.30 0.171 
CGPLOV19 7357 100 158 175 171 182 187 399 -1.0 -2.37 0.008 
CGPLOV19 5186 101 157 165 170 185 186 400 1.0 1.72 0.240 
CGPLOV19 15595 64 159 167 170 181 185 397 -1.0 -1.39 0.245 
CGPLOV19 6749 101 158 167 170 185 187 400 0.0 -0.52 0.702 
CGPLOV20 23 127 148 148 194 222 292 378 24.0 29.58 0.027 
CGPLOV20 3901 101 160 167 171 182 185 398 2.0 0.32 0.821 
CGPLOV21 4633 100 158 169 170 185 187 400 1.0 6.16 0.000 
228 
 
CGPLOV21 734 101 151 155 165 176 178 366 -4.0 0.48 0.823 
CGPLOV21 4022 101 159 167 168 172 178 399 -1.0 -2.84 0.000 
CGPLOV22 117 116 156 156 172 199 184 399 5.0 15.08 0.084 






Table 4.4.  Summary of whole genome cfDNA analyses. 
Patient Timepoint Analysis type Patient Type Read Length Total Bases Sequenced High Quality Bases Analyzed Coverage 
CGCRC291 Preoperative treatment naïve WGS Colorectal Cancer 100 7232125000 4695396600 1.86 
CGCRC292 Preoperative treatment naïve WGS Colorectal Cancer 100 6794092800 4471065400 1.77 
CGCRC293 Preoperative treatment naïve WGS Colorectal Cancer 100 8373899600 5686176000 2.26 
CGCRC294 Preoperative treatment naïve WGS Colorectal Cancer 100 8081312000 5347045800 2.12 
CGCRC296 Preoperative treatment naïve WGS Colorectal Cancer 100 10072029200 6770998200 2.69 
CGCRC299 Preoperative treatment naïve WGS Colorectal Cancer 100 10971591600 7632723200 3.03 
CGCRC300 Preoperative treatment naïve WGS Colorectal Cancer 100 9894332600 6699951000 2.66 
CGCRC301 Preoperative treatment naïve WGS Colorectal Cancer 100 7857346200 5021002000 1.99 
CGCRC302 Preoperative treatment naïve WGS Colorectal Cancer 100 11671913000 8335275800 3.31 
CGCRC304 Preoperative treatment naïve WGS Colorectal Cancer 100 19011739200 12957614200 5.14 
CGCRC305 Preoperative treatment naïve WGS Colorectal Cancer 100 7177341400 4809957200 1.91 
CGCRC306 Preoperative treatment naïve WGS Colorectal Cancer 100 8302233200 5608043600 2.23 
CGCRC307 Preoperative treatment naïve WGS Colorectal Cancer 100 8034729400 5342620000 2.12 
CGCRC308 Preoperative treatment naïve WGS Colorectal Cancer 100 8670084800 5934037200 2.35 
CGCRC311 Preoperative treatment naïve WGS Colorectal Cancer 100 6947634400 4704601800 1.87 
CGCRC315 Preoperative treatment naïve WGS Colorectal Cancer 100 5205544000 3419565400 1.36 
CGCRC316 Preoperative treatment naïve WGS Colorectal Cancer 100 6405388600 4447534800 1.76 
CGCRC317 Preoperative treatment naïve WGS Colorectal Cancer 100 6060390400 4104616600 1.63 
CGCRC318 Preoperative treatment naïve WGS Colorectal Cancer 100 6848768600 4439404800 1.76 
CGCRC319 Preoperative treatment naïve WGS Colorectal Cancer 100 10545294400 7355181600 2.92 
CGCRC320 Preoperative treatment naïve WGS Colorectal Cancer 100 5961999200 3945054000 1.57 
CGCRC321 Preoperative treatment naïve WGS Colorectal Cancer 100 8248095400 5614355000 2.23 
CGCRC333 Preoperative treatment naïve WGS Colorectal Cancer 100 10540267600 6915490600 2.74 
CGCRC336 Preoperative treatment naïve WGS Colorectal Cancer 100 10675581800 7087691800 2.81 
CGCRC338 Preoperative treatment naïve WGS Colorectal Cancer 100 13788172600 8970308600 3.56 
CGCRC341 Preoperative treatment naïve WGS Colorectal Cancer 100 10753467600 7311539200 2.90 
230 
 
CGCRC342 Preoperative treatment naïve WGS Colorectal Cancer 100 11836966000 7552793200 3.00 
CGH14 Human adult elutriated lymphocytes WGS Healthy 100 36525427600 24950300200 9.90 
CGH15 Human adult elutriated lymphocytes WGS Healthy 100 29930855000 23754049400 9.43 
CGLU316 Pre-treatment, Day -53 WGS Lung Cancer 100 10354123200 6896471400 2.74 
CGLU316 Pre-treatment, Day -4 WGS Lung Cancer 100 7870039200 5254938800 2.09 
CGLU316 Post-treatment, Day 18 WGS Lung Cancer 100 8155322000 5416262400 2.15 
CGLU316 Post-treatment, Day 87 WGS Lung Cancer 100 9442310400 6087893400 2.42 
CGLU344 Pre-treatment, Day -21 WGS Lung Cancer 100 8728318600 5769097200 2.29 
CGLU344 Pre-treatment, Day 0 WGS Lung Cancer 100 11710249400 7826902600 3.11 
CGLU344 Post-treatment, Day 0.1875 WGS Lung Cancer 100 11569683000 7654701600 3.04 
CGLU344 Post-treatment, Day 59 WGS Lung Cancer 100 11042459200 6320138800 2.51 
CGLU369 Pre-treatment, Day -2 WGS Lung Cancer 100 8630932800 5779595800 2.29 
CGLU369 Post-treatment, Day 12 WGS Lung Cancer 100 9227709600 6136755200 2.44 
CGLU369 Post-treatment, Day 68 WGS Lung Cancer 100 7995282600 5239077200 2.08 
CGLU369 Post-treatment, Day 110 WGS Lung Cancer 100 8750541000 5626139000 2.23 
CGLU373 Pre-treatment, Day -2 WGS Lung Cancer 100 11746059600 7547485800 3.00 
CGLU373 Post-treatment, Day 0.125 WGS Lung Cancer 100 13801136800 9255579400 3.67 
CGLU373 Post-treatment, Day 7 WGS Lung Cancer 100 11537896800 7654111200 3.04 
CGLU373 Post-treatment, Day 47 WGS Lung Cancer 100 8046326400 5397702400 2.14 
CGPLBR100 Preoperative treatment naïve WGS Breast Cancer 100 8440532400 5729474800 2.27 
CGPLBR101 Preoperative treatment naïve WGS Breast Cancer 100 9786253600 6673495200 2.65 
CGPLBR102 Preoperative treatment naïve WGS Breast Cancer 100 8664980400 5669781600 2.25 
CGPLBR103 Preoperative treatment naïve WGS Breast Cancer 100 9846936200 6662883400 2.64 
CGPLBR104 Preoperative treatment naïve WGS Breast Cancer 100 9443375400 6497061000 2.58 
CGPLBR12 Preoperative treatment naïve WGS Breast Cancer 100 7017577800 4823327400 1.91 
CGPLBR18 Preoperative treatment naïve WGS Breast Cancer 100 10309652800 7130386000 2.83 
CGPLBR23 Preoperative treatment naïve WGS Breast Cancer 100 9034484800 6219625800 2.47 
CGPLBR24 Preoperative treatment naïve WGS Breast Cancer 100 9891454200 6601857400 2.62 
231 
 
CGPLBR28 Preoperative treatment naïve WGS Breast Cancer 100 7997607200 5400803200 2.14 
CGPLBR30 Preoperative treatment naïve WGS Breast Cancer 100 8502597200 5885822400 2.34 
CGPLBR31 Preoperative treatment naïve WGS Breast Cancer 100 12660085600 8551995600 3.39 
CGPLBR32 Preoperative treatment naïve WGS Breast Cancer 100 8773498600 5839034600 2.32 
CGPLBR33 Preoperative treatment naïve WGS Breast Cancer 100 10931742800 6967030600 2.76 
CGPLBR34 Preoperative treatment naïve WGS Breast Cancer 100 10861398600 7453225800 2.96 
CGPLBR35 Preoperative treatment naïve WGS Breast Cancer 100 9180193600 6158440200 2.44 
CGPLBR36 Preoperative treatment naïve WGS Breast Cancer 100 9159948400 6091817800 2.42 
CGPLBR37 Preoperative treatment naïve WGS Breast Cancer 100 10307505800 6929530600 2.75 
CGPLBR38 Preoperative treatment naïve WGS Breast Cancer 100 9983824000 6841725400 2.71 
CGPLBR40 Preoperative treatment naïve WGS Breast Cancer 100 10148823800 7024345400 2.79 
CGPLBR41 Preoperative treatment naïve WGS Breast Cancer 100 11168192000 7562945800 3.00 
CGPLBR45 Preoperative treatment naïve WGS Breast Cancer 100 8793780600 6011109400 2.39 
CGPLBR46 Preoperative treatment naïve WGS Breast Cancer 100 7228607600 4706130000 1.87 
CGPLBR47 Preoperative treatment naïve WGS Breast Cancer 100 7906911400 5341655000 2.12 
CGPLBR48 Preoperative treatment naïve WGS Breast Cancer 100 6992032000 4428636200 1.76 
CGPLBR49 Preoperative treatment naïve WGS Breast Cancer 100 7311195000 4559460200 1.81 
CGPLBR50 Preoperative treatment naïve WGS Breast Cancer 100 11107960600 7582776600 3.01 
CGPLBR51 Preoperative treatment naïve WGS Breast Cancer 100 8393547400 5102069000 2.02 
CGPLBR52 Preoperative treatment naïve WGS Breast Cancer 100 9491894800 6141729000 2.44 
CGPLBR55 Preoperative treatment naïve WGS Breast Cancer 100 9380109800 6518855200 2.59 
CGPLBR56 Preoperative treatment naïve WGS Breast Cancer 100 12191816800 8293011200 3.29 
CGPLBR57 Preoperative treatment naïve WGS Breast Cancer 100 9847584400 6713638000 2.66 
CGPLBR59 Preoperative treatment naïve WGS Breast Cancer 100 7476477000 5059878200 2.01 
CGPLBR60 Preoperative treatment naïve WGS Breast Cancer 100 6531354600 4331253800 1.72 
CGPLBR61 Preoperative treatment naïve WGS Breast Cancer 100 9311029200 6430920800 2.55 
CGPLBR63 Preoperative treatment naïve WGS Breast Cancer 100 8971949000 6044009600 2.40 
CGPLBR65 Preoperative treatment naïve WGS Breast Cancer 100 7197301400 4835015200 1.92 
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CGPLBR68 Preoperative treatment naïve WGS Breast Cancer 100 10003774000 6974918800 2.77 
CGPLBR69 Preoperative treatment naïve WGS Breast Cancer 100 10080881800 6903459200 2.74 
CGPLBR70 Preoperative treatment naïve WGS Breast Cancer 100 8824002800 6002533800 2.38 
CGPLBR71 Preoperative treatment naïve WGS Breast Cancer 100 10164136800 6994668600 2.78 
CGPLBR72 Preoperative treatment naïve WGS Breast Cancer 100 18416841400 12328783000 4.89 
CGPLBR73 Preoperative treatment naïve WGS Breast Cancer 100 10281460200 7078613200 2.81 
CGPLBR76 Preoperative treatment naïve WGS Breast Cancer 100 10105270400 6800705000 2.70 
CGPLBR81 Preoperative treatment naïve WGS Breast Cancer 100 5087126000 3273367200 1.30 
CGPLBR82 Preoperative treatment naïve WGS Breast Cancer 100 10576496600 7186662600 2.85 
CGPLBR83 Preoperative treatment naïve WGS Breast Cancer 100 8977124400 5947525000 2.36 
CGPLBR84 Preoperative treatment naïve WGS Breast Cancer 100 6272538600 4066870600 1.61 
CGPLBR87 Preoperative treatment naïve WGS Breast Cancer 100 8460954800 5375710200 2.13 
CGPLBR88 Preoperative treatment naïve WGS Breast Cancer 100 8665810400 5499898200 2.18 
CGPLBR90 Preoperative treatment naïve WGS Breast Cancer 100 6663469200 4392442400 1.74 
CGPLBR91 Preoperative treatment naïve WGS Breast Cancer 100 10933002400 7647842000 3.03 
CGPLBR92 Preoperative treatment naïve WGS Breast Cancer 100 10392674000 6493598000 2.58 
CGPLBR93 Preoperative treatment naïve WGS Breast Cancer 100 5659836000 3931106800 1.56 
CGPLH189 Preoperative treatment naïve WGS Healthy 100 11400610400 7655568800 3.04 
CGPLH190 Preoperative treatment naïve WGS Healthy 100 11444671600 7581175200 3.01 
CGPLH192 Preoperative treatment naïve WGS Healthy 100 12199010800 8126804800 3.22 
CGPLH193 Preoperative treatment naïve WGS Healthy 100 10201897600 6635285400 2.63 
CGPLH194 Preoperative treatment naïve WGS Healthy 100 11005087400 7081652600 2.81 
CGPLH196 Preoperative treatment naïve WGS Healthy 100 12891462800 8646881800 3.43 
CGPLH197 Preoperative treatment naïve WGS Healthy 100 11961841600 8052855200 3.20 
CGPLH198 Preoperative treatment naïve WGS Healthy 100 13605489000 8885716000 3.53 
CGPLH199 Preoperative treatment naïve WGS Healthy 100 1818090200 5615316000 2.23 
CGPLH200 Preoperative treatment naïve WGS Healthy 100 14400027600 9310342000 3.69 
CGPLH201 Preoperative treatment naïve WGS Healthy 100 6208766800 4171848400 1.66 
233 
 
CGPLH202 Preoperative treatment naïve WGS Healthy 100 11282922800 7363530600 2.92 
CGPLH203 Preoperative treatment naïve WGS Healthy 100 13540689600 9068747600 3.60 
CGPLH205 Preoperative treatment naïve WGS Healthy 100 10343537800 6696988600 2.66 
CGPLH208 Preoperative treatment naïve WGS Healthy 100 12796300000 8272073400 3.28 
CGPLH209 Preoperative treatment naïve WGS Healthy 100 13123035400 8531813600 3.39 
CGPLH210 Preoperative treatment naïve WGS Healthy 100 10184218800 6832204600 2.71 
CGPLH211 Preoperative treatment naïve WGS Healthy 100 14655260200 8887067600 3.53 
CGPLH300 Preoperative treatment naïve WGS Healthy 100 7062083400 4553351200 1.81 
CGPLH307 Preoperative treatment naïve WGS Healthy 100 7239128200 4547697200 1.80 
CGPLH308 Preoperative treatment naïve WGS Healthy 100 8512551400 5526653600 2.19 
CGPLH309 Preoperative treatment naïve WGS Healthy 100 11664474200 7431836600 2.95 
CGPLH310 Preoperative treatment naïve WGS Healthy 100 11045691000 7451506200 2.96 
CGPLH311 Preoperative treatment naïve WGS Healthy 100 10406803200 6786479600 2.69 
CGPLH314 Preoperative treatment naïve WGS Healthy 100 10371343800 6925866600 2.75 
CGPLH315 Preoperative treatment naïve WGS Healthy 100 9508538400 6208744600 2.46 
CGPLH316 Preoperative treatment naïve WGS Healthy 100 10131063600 6891181000 2.73 
CGPLH317 Preoperative treatment naïve WGS Healthy 100 8364314400 5302232600 2.10 
CGPLH319 Preoperative treatment naïve WGS Healthy 100 8780528200 5585897000 2.22 
CGPLH320 Preoperative treatment naïve WGS Healthy 100 8956232600 5784619200 2.30 
CGPLH322 Preoperative treatment naïve WGS Healthy 100 9563837800 6445517800 2.56 
CGPLH324 Preoperative treatment naïve WGS Healthy 100 6765038600 4469201600 1.77 
CGPLH325 Preoperative treatment naïve WGS Healthy 100 8008213400 5099262800 2.02 
CGPLH326 Preoperative treatment naïve WGS Healthy 100 9554226200 6112544800 2.43 
CGPLH327 Preoperative treatment naïve WGS Healthy 100 8239168800 5351280200 2.12 
CGPLH328 Preoperative treatment naïve WGS Healthy 100 7197086800 4516894800 1.79 
CGPLH329 Preoperative treatment naïve WGS Healthy 100 8921554800 5493709800 2.18 
CGPLH330 Preoperative treatment naïve WGS Healthy 100 10693603400 7077793600 2.81 
CGPLH331 Preoperative treatment naïve WGS Healthy 100 8982792000 5538096200 2.20 
234 
 
CGPLH333 Preoperative treatment naïve WGS Healthy 100 7856985400 5178829600 2.06 
CGPLH335 Preoperative treatment naïve WGS Healthy 100 9370663400 6035739400 2.40 
CGPLH336 Preoperative treatment naïve WGS Healthy 100 8002498200 5340331400 2.12 
CGPLH337 Preoperative treatment naïve WGS Healthy 100 7399022000 4954467600 1.97 
CGPLH338 Preoperative treatment naïve WGS Healthy 100 8917121600 6170927200 2.45 
CGPLH339 Preoperative treatment naïve WGS Healthy 100 8591130800 5866411400 2.33 
CGPLH340 Preoperative treatment naïve WGS Healthy 100 8046351000 5368062000 2.13 
CGPLH341 Preoperative treatment naïve WGS Healthy 100 7914788600 5200304800 2.06 
CGPLH342 Preoperative treatment naïve WGS Healthy 100 8633473000 5701972400 2.26 
CGPLH343 Preoperative treatment naïve WGS Healthy 100 6694769800 4410670800 1.75 
CGPLH344 Preoperative treatment naïve WGS Healthy 100 7628192400 4961476600 1.97 
CGPLH345 Preoperative treatment naïve WGS Healthy 100 7121569400 4747223000 1.88 
CGPLH346 Preoperative treatment naïve WGS Healthy 100 7707924600 4873321600 1.93 
CGPLH35 Preoperative treatment naïve WGS Healthy 100 47305985200 4774186200 12.63 
CGPLH350 Preoperative treatment naïve WGS Healthy 100 9745839800 6054055200 2.40 
CGPLH351 Preoperative treatment naïve WGS Healthy 100 13317435800 8714465000 3.46 
CGPLH352 Preoperative treatment naïve WGS Healthy 100 7659351600 4752309400 1.89 
CGPLH353 Preoperative treatment naïve WGS Healthy 100 8435782400 5275098200 2.09 
CGPLH354 Preoperative treatment naïve WGS Healthy 100 8018644000 4857577600 1.93 
CGPLH355 Preoperative treatment naïve WGS Healthy 100 8624675800 5709726400 2.27 
CGPLH356 Preoperative treatment naïve WGS Healthy 100 8817952800 5729595200 2.27 
CGPLH357 Preoperative treatment naïve WGS Healthy 100 11931696200 7690004400 3.05 
CGPLH358 Preoperative treatment naïve WGS Healthy 100 12802561200 8451274800 3.35 
CGPLH36 Preoperative treatment naïve WGS Healthy 100 40173545600 3974810400 10.52 
CGPLH360 Preoperative treatment naïve WGS Healthy 100 7280078400 4918566200 1.95 
CGPLH361 Preoperative treatment naïve WGS Healthy 100 7493498400 4966813800 1.97 
CGPLH362 Preoperative treatment naïve WGS Healthy 100 11345644200 7532133600 2.99 
CGPLH363 Preoperative treatment naïve WGS Healthy 100 6117382800 3965952400 1.57 
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CGPLH364 Preoperative treatment naïve WGS Healthy 100 10823498400 7195657000 2.86 
CGPLH365 Preoperative treatment naïve WGS Healthy 100 5938367400 3954556200 1.57 
CGPLH366 Preoperative treatment naïve WGS Healthy 100 7063168600 4731853000 1.88 
CGPLH367 Preoperative treatment naïve WGS Healthy 100 7119631800 4627888200 1.84 
CGPLH368 Preoperative treatment naïve WGS Healthy 100 7726718400 4975233400 1.97 
CGPLH369 Preoperative treatment naïve WGS Healthy 100 10967584200 7130956800 2.83 
CGPLH37 Preoperative treatment naïve WGS Healthy 100 45970545400 4591328800 12.15 
CGPLH370 Preoperative treatment naïve WGS Healthy 100 9237170600 6106373800 2.42 
CGPLH371 Preoperative treatment naïve WGS Healthy 100 8077798800 5237070600 2.08 
CGPLH380 Preoperative treatment naïve WGS Healthy 100 14049589200 8614241200 3.42 
CGPLH381 Preoperative treatment naïve WGS Healthy 100 16743792000 10767882800 4.27 
CGPLH382 Preoperative treatment naïve WGS Healthy 100 18474025200 12276437200 4.87 
CGPLH383 Preoperative treatment naïve WGS Healthy 100 13215954000 8430420600 3.35 
CGPLH384 Preoperative treatment naïve WGS Healthy 100 8481814000 5463636200 2.17 
CGPLH385 Preoperative treatment naïve WGS Healthy 100 9596118800 6445445600 2.56 
CGPLH386 Preoperative treatment naïve WGS Healthy 100 7399540400 4915484800 1.95 
CGPLH387 Preoperative treatment naïve WGS Healthy 100 6860332600 4339724400 1.72 
CGPLH388 Preoperative treatment naïve WGS Healthy 100 8679705600 5463945400 2.17 
CGPLH389 Preoperative treatment naïve WGS Healthy 100 7266863600 4702386000 1.87 
CGPLH390 Preoperative treatment naïve WGS Healthy 100 7509035600 4913901800 1.95 
CGPLH391 Preoperative treatment naïve WGS Healthy 100 7252286000 4702404800 1.87 
CGPLH392 Preoperative treatment naïve WGS Healthy 100 7302618200 4722407000 1.87 
CGPLH393 Preoperative treatment naïve WGS Healthy 100 8879138000 5947871800 2.36 
CGPLH394 Preoperative treatment naïve WGS Healthy 100 8737031000 5599777400 2.22 
CGPLH395 Preoperative treatment naïve WGS Healthy 100 7783904800 4907146000 1.95 
CGPLH396 Preoperative treatment naïve WGS Healthy 100 7585567200 5076638200 2.01 
CGPLH398 Preoperative treatment naïve WGS Healthy 100 13001418200 8607025000 3.42 
CGPLH399 Preoperative treatment naïve WGS Healthy 100 9867699200 5526646000 2.19 
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CGPLH400 Preoperative treatment naïve WGS Healthy 100 10573939000 6290438200 2.50 
CGPLH401 Preoperative treatment naïve WGS Healthy 100 9415150000 6139638000 2.44 
CGPLH402 Preoperative treatment naïve WGS Healthy 100 5541458000 2972027800 1.18 
CGPLH403 Preoperative treatment naïve WGS Healthy 100 6470913200 3549772600 1.41 
CGPLH404 Preoperative treatment naïve WGS Healthy 100 7369651800 4120205000 1.64 
CGPLH405 Preoperative treatment naïve WGS Healthy 100 7360239000 4293522600 1.70 
CGPLH406 Preoperative treatment naïve WGS Healthy 100 6026125400 3426007400 1.36 
CGPLH407 Preoperative treatment naïve WGS Healthy 100 7073375200 4079286800 1.62 
CGPLH408 Preoperative treatment naïve WGS Healthy 100 8006103200 5121285600 2.03 
CGPLH409 Preoperative treatment naïve WGS Healthy 100 7343124600 4432335600 1.76 
CGPLH410 Preoperative treatment naïve WGS Healthy 100 7551842000 4818779600 1.91 
CGPLH411 Preoperative treatment naïve WGS Healthy 100 6119676400 3636478400 1.44 
CGPLH412 Preoperative treatment naïve WGS Healthy 100 7960821200 4935752200 1.96 
CGPLH413 Preoperative treatment naïve WGS Healthy 100 7623405400 4827888400 1.92 
CGPLH414 Preoperative treatment naïve WGS Healthy 100 7381312400 4743337200 1.88 
CGPLH415 Preoperative treatment naïve WGS Healthy 100 7240754200 4162208800 1.65 
CGPLH416 Preoperative treatment naïve WGS Healthy 100 7745658600 4670226000 1.85 
CGPLH417 Preoperative treatment naïve WGS Healthy 100 7627498600 4403085600 1.75 
CGPLH418 Preoperative treatment naïve WGS Healthy 100 9090285000 5094814000 2.02 
CGPLH419 Preoperative treatment naïve WGS Healthy 100 7914120200 5078389800 2.02 
CGPLH42 Preoperative treatment naïve WGS Healthy 100 39492040600 3901039400 10.32 
CGPLH420 Preoperative treatment naïve WGS Healthy 100 7014307800 4711393600 1.87 
CGPLH422 Preoperative treatment naïve WGS Healthy 100 9103972800 6053559800 2.40 
CGPLH423 Preoperative treatment naïve WGS Healthy 100 10154714200 6128800200 2.43 
CGPLH424 Preoperative treatment naïve WGS Healthy 100 11002394000 6573756000 2.61 
CGPLH425 Preoperative treatment naïve WGS Healthy 100 14681352600 9272557000 3.68 
CGPLH426 Preoperative treatment naïve WGS Healthy 100 8336731000 5177430800 2.05 
CGPLH427 Preoperative treatment naïve WGS Healthy 100 8242924400 5632991800 2.24 
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CGPLH428 Preoperative treatment naïve WGS Healthy 100 8512550400 5604756600 2.22 
CGPLH429 Preoperative treatment naïve WGS Healthy 100 8369802800 5477121400 2.17 
CGPLH43 Preoperative treatment naïve WGS Healthy 100 38513193400 3815698400 10.10 
CGPLH430 Preoperative treatment naïve WGS Healthy 100 10357365400 6841611000 2.71 
CGPLH431 Preoperative treatment naïve WGS Healthy 100 7599875800 5006909000 1.99 
CGPLH432 Preoperative treatment naïve WGS Healthy 100 7932532400 4932304200 1.96 
CGPLH434 Preoperative treatment naïve WGS Healthy 100 10417028600 6965998800 2.76 
CGPLH435 Preoperative treatment naïve WGS Healthy 100 8747793800 5677115200 2.25 
CGPLH436 Preoperative treatment naïve WGS Healthy 100 7990589400 5228737800 2.07 
CGPLH437 Preoperative treatment naïve WGS Healthy 100 10156991200 6935537200 2.75 
CGPLH438 Preoperative treatment naïve WGS Healthy 100 9473604000 6445455600 2.56 
CGPLH439 Preoperative treatment naïve WGS Healthy 100 8303723400 5439877200 2.16 
CGPLH440 Preoperative treatment naïve WGS Healthy 100 9055233800 6018631400 2.39 
CGPLH441 Preoperative treatment naïve WGS Healthy 100 10290682000 6896415200 2.74 
CGPLH442 Preoperative treatment naïve WGS Healthy 100 9876551600 6591249800 2.62 
CGPLH443 Preoperative treatment naïve WGS Healthy 100 9837225800 6360740800 2.52 
CGPLH444 Preoperative treatment naïve WGS Healthy 100 9199271400 5755941600 2.28 
CGPLH445 Preoperative treatment naïve WGS Healthy 100 8089236400 5218259800 2.07 
CGPLH446 Preoperative treatment naïve WGS Healthy 100 7890664200 5181606000 2.06 
CGPLH447 Preoperative treatment naïve WGS Healthy 100 7775775000 5120239800 2.03 
CGPLH448 Preoperative treatment naïve WGS Healthy 100 8686964800 5605079200 2.22 
CGPLH449 Preoperative treatment naïve WGS Healthy 100 8604545400 5527726600 2.19 
CGPLH45 Preoperative treatment naïve WGS Healthy 100 39029653000 3771601200 9.98 
CGPLH450 Preoperative treatment naïve WGS Healthy 100 8428254800 5439950000 2.16 
CGPLH451 Preoperative treatment naïve WGS Healthy 100 8128977600 5186265600 2.06 
CGPLH452 Preoperative treatment naïve WGS Healthy 100 6474313400 4216316400 1.67 
CGPLH453 Preoperative treatment naïve WGS Healthy 100 9831832800 6224917600 2.47 
CGPLH455 Preoperative treatment naïve WGS Healthy 100 7373753000 4593473600 1.82 
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CGPLH456 Preoperative treatment naïve WGS Healthy 100 8455416200 5457148200 2.17 
CGPLH457 Preoperative treatment naïve WGS Healthy 100 8647618000 5534503800 2.20 
CGPLH458 Preoperative treatment naïve WGS Healthy 100 6633156400 4415186000 1.75 
CGPLH459 Preoperative treatment naïve WGS Healthy 100 8361048200 5497193800 2.18 
CGPLH46 Preoperative treatment naïve WGS Healthy 100 35361484600 3516232800 9.30 
CGPLH460 Preoperative treatment naïve WGS Healthy 100 6788835400 4472282800 1.77 
CGPLH463 Preoperative treatment naïve WGS Healthy 100 8534880800 5481759200 2.18 
CGPLH464 Preoperative treatment naïve WGS Healthy 100 6692520000 4184463400 1.66 
CGPLH465 Preoperative treatment naïve WGS Healthy 100 7772884600 4878430800 1.94 
CGPLH466 Preoperative treatment naïve WGS Healthy 100 9056275000 5830877400 2.31 
CGPLH467 Preoperative treatment naïve WGS Healthy 100 6931419200 4585861000 1.82 
CGPLH468 Preoperative treatment naïve WGS Healthy 100 9334067400 6314830400 2.51 
CGPLH469 Preoperative treatment naïve WGS Healthy 100 7376691000 4545246600 1.80 
CGPLH47 Preoperative treatment naïve WGS Healthy 100 38485647600 3534883600 9.35 
CGPLH470 Preoperative treatment naïve WGS Healthy 100 7899727600 5221650600 2.07 
CGPLH471 Preoperative treatment naïve WGS Healthy 100 9200430600 6102371000 2.42 
CGPLH472 Preoperative treatment naïve WGS Healthy 100 8143742400 5399946600 2.14 
CGPLH473 Preoperative treatment naïve WGS Healthy 100 8123924600 5419825400 2.15 
CGPLH474 Preoperative treatment naïve WGS Healthy 100 8853071400 6084059400 2.41 
CGPLH475 Preoperative treatment naïve WGS Healthy 100 8115374000 5291718000 2.10 
CGPLH476 Preoperative treatment naïve WGS Healthy 100 8163162600 5096869600 2.02 
CGPLH477 Preoperative treatment naïve WGS Healthy 100 8350093200 5465468600 2.17 
CGPLH478 Preoperative treatment naïve WGS Healthy 100 8259642200 5406516200 2.15 
CGPLH479 Preoperative treatment naïve WGS Healthy 100 8027598600 5417376800 2.15 
CGPLH48 Preoperative treatment naïve WGS Healthy 100 42232410000 4165893400 11.02 
CGPLH480 Preoperative treatment naïve WGS Healthy 100 7832983200 5020127000 1.99 
CGPLH481 Preoperative treatment naïve WGS Healthy 100 7578518800 4883280800 1.94 
CGPLH482 Preoperative treatment naïve WGS Healthy 100 8279364800 5652263600 2.24 
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CGPLH483 Preoperative treatment naïve WGS Healthy 100 8660338800 5823859200 2.31 
CGPLH484 Preoperative treatment naïve WGS Healthy 100 8445420000 5794328000 2.30 
CGPLH485 Preoperative treatment naïve WGS Healthy 100 8371255400 5490207800 2.18 
CGPLH486 Preoperative treatment naïve WGS Healthy 100 8216712200 5506871000 2.19 
CGPLH487 Preoperative treatment naïve WGS Healthy 100 7936294200 5309250200 2.11 
CGPLH488 Preoperative treatment naïve WGS Healthy 100 8355603600 5453160000 2.16 
CGPLH49 Preoperative treatment naïve WGS Healthy 100 33912191800 3310056000 8.76 
CGPLH490 Preoperative treatment naïve WGS Healthy 100 7768712400 5175567800 2.05 
CGPLH491 Preoperative treatment naïve WGS Healthy 100 9070904000 6011275000 2.39 
CGPLH492 Preoperative treatment naïve WGS Healthy 100 7208727200 4753213800 1.89 
CGPLH493 Preoperative treatment naïve WGS Healthy 100 10542882600 7225870800 2.87 
CGPLH494 Preoperative treatment naïve WGS Healthy 100 10908197600 7046645000 2.80 
CGPLH495 Preoperative treatment naïve WGS Healthy 100 8945040400 5891697800 2.34 
CGPLH496 Preoperative treatment naïve WGS Healthy 100 10859729400 7549608000 3.00 
CGPLH497 Preoperative treatment naïve WGS Healthy 100 9630507400 6473162800 2.57 
CGPLH498 Preoperative treatment naïve WGS Healthy 100 10060232600 6744622800 2.68 
CGPLH499 Preoperative treatment naïve WGS Healthy 100 10221293600 6951282800 2.76 
CGPLH50 Preoperative treatment naïve WGS Healthy 100 41248860600 4073272800 10.78 
CGPLH500 Preoperative treatment naïve WGS Healthy 100 9703168200 6239893800 2.48 
CGPLH501 Preoperative treatment naïve WGS Healthy 100 9104779800 6161602800 2.45 
CGPLH502 Preoperative treatment naïve WGS Healthy 100 8514467400 5290881400 2.10 
CGPLH503 Preoperative treatment naïve WGS Healthy 100 9019992200 6100383400 2.42 
CGPLH504 Preoperative treatment naïve WGS Healthy 100 9320330200 6199750200 2.46 
CGPLH505 Preoperative treatment naïve WGS Healthy 100 7499497400 4914559000 1.95 
CGPLH506 Preoperative treatment naïve WGS Healthy 100 10526142000 6963312600 2.76 
CGPLH507 Preoperative treatment naïve WGS Healthy 100 9091018400 6146678600 2.44 
CGPLH508 Preoperative treatment naïve WGS Healthy 100 10989315600 7360201400 2.92 
CGPLH509 Preoperative treatment naïve WGS Healthy 100 9729084600 6702691600 2.66 
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CGPLH51 Preoperative treatment naïve WGS Healthy 100 35967451400 3492833200 9.24 
CGPLH510 Preoperative treatment naïve WGS Healthy 100 11162691600 7626795400 3.03 
CGPLH511 Preoperative treatment naïve WGS Healthy 100 11888619600 8110427600 3.22 
CGPLH512 Preoperative treatment naïve WGS Healthy 100 10726438400 7110078000 2.82 
CGPLH513 Preoperative treatment naïve WGS Healthy 100 10701564200 7155271400 2.84 
CGPLH514 Preoperative treatment naïve WGS Healthy 100 8822067000 5958773800 2.36 
CGPLH515 Preoperative treatment naïve WGS Healthy 100 7792074800 5317464600 2.11 
CGPLH516 Preoperative treatment naïve WGS Healthy 100 8642620000 5846439400 2.32 
CGPLH517 Preoperative treatment naïve WGS Healthy 100 11915929600 8013937000 3.18 
CGPLH518 Preoperative treatment naïve WGS Healthy 100 12804517400 8606661600 3.42 
CGPLH519 Preoperative treatment naïve WGS Healthy 100 11513222200 7922798400 3.14 
CGPLH52 Preoperative treatment naïve WGS Healthy 100 49247304200 4849631400 12.83 
CGPLH520 Preoperative treatment naïve WGS Healthy 100 8942102400 6030683400 2.39 
CGPLH54 Preoperative treatment naïve WGS Healthy 100 45399346400 4466164600 11.82 
CGPLH55 Preoperative treatment naïve WGS Healthy 100 42547725000 4283337600 11.33 
CGPLH56 Preoperative treatment naïve WGS Healthy 100 33460308000 3226338000 8.53 
CGPLH57 Preoperative treatment naïve WGS Healthy 100 36504735200 3509125000 9.28 
CGPLH59 Preoperative treatment naïve WGS Healthy 100 39642810600 3820011000 10.11 
CGPLH625 Preoperative treatment naïve WGS Healthy 100 6408225000 4115487600 1.63 
CGPLH626 Preoperative treatment naïve WGS Healthy 100 9915193600 6391657000 2.54 
CGPLH63 Preoperative treatment naïve WGS Healthy 100 37447047600 3506737000 9.28 
CGPLH639 Preoperative treatment naïve WGS Healthy 100 8158965800 5216049600 2.07 
CGPLH64 Preoperative treatment naïve WGS Healthy 100 34275506800 3264508000 8.63 
CGPLH640 Preoperative treatment naïve WGS Healthy 100 8058876800 5333551800 2.12 
CGPLH642 Preoperative treatment naïve WGS Healthy 100 7545555600 4909732800 1.95 
CGPLH643 Preoperative treatment naïve WGS Healthy 100 7865776800 5254772000 2.09 
CGPLH644 Preoperative treatment naïve WGS Healthy 100 6890139000 4599387400 1.83 
CGPLH646 Preoperative treatment naïve WGS Healthy 100 7757219400 5077408200 2.01 
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CGPLH75 Preoperative treatment naïve WGS Healthy 100 23882926000 2250344400 5.95 
CGPLH76 Preoperative treatment naïve WGS Healthy 100 30631483600 3086042200 8.16 
CGPLH77 Preoperative treatment naïve WGS Healthy 100 31651741400 3041290200 8.04 
CGPLH78 Preoperative treatment naïve WGS Healthy 100 31165831200 3130079800 8.28 
CGPLH79 Preoperative treatment naïve WGS Healthy 100 31935043000 3128488200 8.27 
CGPLH80 Preoperative treatment naïve WGS Healthy 100 32965093000 3311371800 8.76 
CGPLH81 Preoperative treatment naïve WGS Healthy 100 27035311200 2455084400 6.49 
CGPLH82 Preoperative treatment naïve WGS Healthy 100 28447051200 2893358200 7.65 
CGPLH83 Preoperative treatment naïve WGS Healthy 100 26702240200 2459494000 6.50 
CGPLH84 Preoperative treatment naïve WGS Healthy 100 25176861400 2524467400 6.68 
CGPLLU13 Pre-treatment, Day -2 WGS Lung Cancer 100 9126585600 5915061800 2.35 
CGPLLU13 Post-treatment, Day 5 WGS Lung Cancer 100 7739120200 5071745800 2.01 
CGPLLU13 Post-treatment, Day 28 WGS Lung Cancer 100 9081585400 5764371600 2.29 
CGPLLU13 Post-treatment, Day 91 WGS Lung Cancer 100 9576557000 6160760200 2.44 
CGPLLU14 Pre-treatment, Day -38 WGS Lung Cancer 100 13659198400 9033455800 3.58 
CGPLLU14 Pre-treatment, Day -16 WGS Lung Cancer 100 7178855800 4856648600 1.93 
CGPLLU14 Pre-treatment, Day -3 WGS Lung Cancer 100 7653473000 4816193600 1.91 
CGPLLU14 Pre-treatment, Day 0 WGS Lung Cancer 100 7851997400 5193256600 2.06 
CGPLLU14 Post-treatment, Day 0.33 WGS Lung Cancer 100 7193040800 4869701600 1.93 
CGPLLU14 Post-treatment, Day 7 WGS Lung Cancer 100 7102050000 4741432600 1.88 
CGPLLU144 Preoperative treatment naïve WGS Lung Cancer 100 4934813600 3415936400 1.36 
CGPLLU147 Preoperative treatment naïve WGS Lung Cancer 100 24409561000 2118672800 5.61 
CGPLLU161 Preoperative treatment naïve WGS Lung Cancer 100 8998813400 6016145000 2.39 
CGPLLU162 Preoperative treatment naïve WGS Lung Cancer 100 9709792400 6407866400 2.54 
CGPLLU163 Preoperative treatment naïve WGS Lung Cancer 100 9150620200 6063569800 2.41 
CGPLLU165 Preoperative treatment naïve WGS Lung Cancer 100 28374436400 2651138600 7.01 
CGPLLU168 Preoperative treatment naïve WGS Lung Cancer 100 5692739400 3695191000 1.47 
CGPLLU169 Preoperative treatment naïve WGS Lung Cancer 100 9093975600 5805320800 2.30 
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CGPLLU175 Preoperative treatment naïve WGS Lung Cancer 100 33794816800 3418750400 9.04 
CGPLLU176 Preoperative treatment naïve WGS Lung Cancer 100 8778553800 5794950200 2.30 
CGPLLU177 Preoperative treatment naïve WGS Lung Cancer 100 3734614800 2578696200 1.02 
CGPLLU180 Preoperative treatment naïve WGS Lung Cancer 100 28305936600 2756034200 7.29 
CGPLLU198 Preoperative treatment naïve WGS Lung Cancer 100 23244959200 2218577200 5.86 
CGPLLU202 Preoperative treatment naïve WGS Lung Cancer 100 21110128200 1831279400 4.84 
CGPLLU203 Preoperative treatment naïve WGS Lung Cancer 100 4304235600 2896429000 1.15 
CGPLLU205 Preoperative treatment naïve WGS Lung Cancer 100 10502467000 7386984800 2.93 
CGPLLU206 Preoperative treatment naïve WGS Lung Cancer 100 21888248200 2026666000 5.36 
CGPLLU207 Preoperative treatment naïve WGS Lung Cancer 100 10806230600 7363049000 2.92 
CGPLLU208 Preoperative treatment naïve WGS Lung Cancer 100 7795426800 5199545800 2.06 
CGPLLU209 Preoperative treatment naïve WGS Lung Cancer 100 26174542000 2621961800 6.93 
CGPLLU244 Pre-treatment, Day -7 WGS Lung Cancer 100 9967531400 6704365800 2.66 
CGPLLU244 Pre-treatment, Day -1 WGS Lung Cancer 100 9547119200 5785172600 2.30 
CGPLLU244 Post-treatment, Day 6 WGS Lung Cancer 100 9535898600 6452174000 2.56 
CGPLLU244 Post-treatment, Day 62 WGS Lung Cancer 100 8783628600 5914149000 2.35 
CGPLLU245 Pre-treatment, Day -32 WGS Lung Cancer 100 10025823200 6313303800 2.51 
CGPLLU245 Pre-treatment, Day 0 WGS Lung Cancer 100 9462480400 6612867800 2.62 
CGPLLU245 Post-treatment, Day 7 WGS Lung Cancer 100 9143825000 6431013200 2.55 
CGPLLU245 Post-treatment, Day 21 WGS Lung Cancer 100 9072713800 6368533000 2.53 
CGPLLU246 Pre-treatment, Day -21 WGS Lung Cancer 100 9579787000 6458003400 2.56 
CGPLLU246 Pre-treatment, Day 0 WGS Lung Cancer 100 9512703600 6440535600 2.56 
CGPLLU246 Post-treatment, Day 9 WGS Lung Cancer 100 9512646000 6300939200 2.50 
CGPLLU246 Post-treatment, Day 42 WGS Lung Cancer 100 11136103000 7358747400 2.92 
CGPLLU264 Pre-treatment, Day -1 WGS Lung Cancer 100 9196305000 6239803600 2.48 
CGPLLU264 Post-treatment, Day 6 WGS Lung Cancer 100 8247416600 5600454200 2.22 
CGPLLU264 Post-treatment, Day 27 WGS Lung Cancer 100 8681022200 5856109000 2.32 
CGPLLU264 Post-treatment, Day 69 WGS Lung Cancer 100 8931976400 5974246000 2.37 
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CGPLLU265 Pre-treatment, Day 0 WGS Lung Cancer 100 9460534000 6111185200 2.43 
CGPLLU265 Post-treatment, Day 3 WGS Lung Cancer 100 8051601200 4984166600 1.98 
CGPLLU265 Post-treatment, Day 7 WGS Lung Cancer 100 8082224600 5110092600 2.03 
CGPLLU265 Post-treatment, Day 84 WGS Lung Cancer 100 8368637400 5369526400 2.13 
CGPLLU266 Pre-treatment, Day 0 WGS Lung Cancer 100 8583766400 5846473600 2.32 
CGPLLU266 Post-treatment, Day 16 WGS Lung Cancer 100 8795793600 5984531400 2.37 
CGPLLU266 Post-treatment, Day 83 WGS Lung Cancer 100 9157947600 6227735000 2.47 
CGPLLU266 Post-treatment, Day 328 WGS Lung Cancer 100 7299455400 5049379000 2.00 
CGPLLU267 Pre-treatment, Day -1 WGS Lung Cancer 100 10658657800 6892067000 2.73 
CGPLLU267 Post-treatment, Day 34 WGS Lung Cancer 100 8492833400 5101097800 2.02 
CGPLLU267 Post-treatment, Day 90 WGS Lung Cancer 100 12030314800 7757930400 3.08 
CGPLLU269 Pre-treatment, Day 0 WGS Lung Cancer 100 9170168000 5830454400 2.31 
CGPLLU269 Post-treatment, Day 9 WGS Lung Cancer 100 8905640400 5298461400 2.10 
CGPLLU269 Post-treatment, Day 28 WGS Lung Cancer 100 8455306600 5387927400 2.14 
CGPLLU271 Post-treatment, Day 259 WGS Lung Cancer 100 8112060400 5404979000 2.14 
CGPLLU271 Pre-treatment, Day 0 WGS Lung Cancer 100 13150818200 8570453400 3.40 
CGPLLU271 Post-treatment, Day 6 WGS Lung Cancer 100 9008880600 5854051400 2.32 
CGPLLU271 Post-treatment, Day 20 WGS Lung Cancer 100 8670913000 5461577000 2.17 
CGPLLU271 Post-treatment, Day 104 WGS Lung Cancer 100 8887441400 5609039000 2.23 
CGPLLU43 Pre-treatment, Day -1 WGS Lung Cancer 100 8407811200 5203486400 2.06 
CGPLLU43 Post-treatment, Day 6 WGS Lung Cancer 100 9264335200 5626714400 2.23 
CGPLLU43 Post-treatment, Day 27 WGS Lung Cancer 100 8902283000 5485656200 2.18 
CGPLLU43 Post-treatment, Day 83 WGS Lung Cancer 100 9201509200 5875084200 2.33 
CGPLLU86 Pre-treatment, Day 0 WGS Lung Cancer 100 9152729200 6248173200 2.48 
CGPLLU86 Post-treatment, Day 0.5 WGS Lung Cancer 100 6703253000 4663026800 1.85 
CGPLLU86 Post-treatment, Day 7 WGS Lung Cancer 100 6590121400 4559562400 1.81 
CGPLLU86 Post-treatment, Day 17 WGS Lung Cancer 100 8653551800 5900136000 2.34 
CGPLLU88 Pre-treatment, Day 0 WGS Lung Cancer 100 8096528000 5505475400 2.18 
244 
 
CGPLLU88 Post-treatment, Day 7 WGS Lung Cancer 100 8283192200 5784217600 2.30 
CGPLLU88 Post-treatment, Day 297 WGS Lung Cancer 100 9297110800 6407258000 2.54 
CGPLLU89 Pre-treatment, Day 0 WGS Lung Cancer 100 7842145200 5356095400 2.13 
CGPLLU89 Post-treatment, Day 7 WGS Lung Cancer 100 7234220200 4930375200 1.96 
CGPLLU89 Post-treatment, Day 22 WGS Lung Cancer 100 6242889800 4057361000 1.61 
CGPLOV11 Preoperative treatment naïve WGS Ovarian Cancer 100 8985130400 5871959600 2.33 
CGPLOV12 Preoperative treatment naïve WGS Ovarian Cancer 100 9705820000 6430505400 2.55 
CGPLOV13 Preoperative treatment naïve WGS Ovarian Cancer 100 10307949400 7029712000 2.79 
CGPLOV15 Preoperative treatment naïve WGS Ovarian Cancer 100 8472829400 5562142400 2.21 
CGPLOV16 Preoperative treatment naïve WGS Ovarian Cancer 100 10977781000 7538581600 2.99 
CGPLOV19 Preoperative treatment naïve WGS Ovarian Cancer 100 8800876200 5855304000 2.32 
CGPLOV20 Preoperative treatment naïve WGS Ovarian Cancer 100 8714443600 5695165800 2.26 
CGPLOV21 Preoperative treatment naïve WGS Ovarian Cancer 100 10180394800 7120260400 2.83 
CGPLOV22 Preoperative treatment naïve WGS Ovarian Cancer 100 10107760000 6821916800 2.71 
CGPLOV23 Preoperative treatment naïve WGS Ovarian Cancer 100 10643399800 7206330800 2.86 
CGPLOV24 Preoperative treatment naïve WGS Ovarian Cancer 100 6780929000 4623300400 1.83 
CGPLOV25 Preoperative treatment naïve WGS Ovarian Cancer 100 7817548600 5359975200 2.13 
CGPLOV26 Preoperative treatment naïve WGS Ovarian Cancer 100 11763101400 8178024400 3.25 
CGPLOV28 Preoperative treatment naïve WGS Ovarian Cancer 100 9522546400 6259423400 2.48 
CGPLOV31 Preoperative treatment naïve WGS Ovarian Cancer 100 9104831200 6109358400 2.42 
CGPLOV32 Preoperative treatment naïve WGS Ovarian Cancer 100 9222073600 6035150000 2.39 
CGPLOV37 Preoperative treatment naïve WGS Ovarian Cancer 100 8898328600 5971018200 2.37 
CGPLOV38 Preoperative treatment naïve WGS Ovarian Cancer 100 8756825200 5861536600 2.33 
CGPLOV40 Preoperative treatment naïve WGS Ovarian Cancer 100 9709391600 6654707200 2.64 
CGPLOV41 Preoperative treatment naïve WGS Ovarian Cancer 100 8923625000 5973070400 2.37 
CGPLOV42 Preoperative treatment naïve WGS Ovarian Cancer 100 10719380400 7353214200 2.92 
CGPLOV43 Preoperative treatment naïve WGS Ovarian Cancer 100 10272189000 6423288600 2.55 
CGPLOV44 Preoperative treatment naïve WGS Ovarian Cancer 100 9861862600 6769185800 2.69 
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CGPLOV46 Preoperative treatment naïve WGS Ovarian Cancer 100 8788956400 5789863400 2.30 
CGPLOV47 Preoperative treatment naïve WGS Ovarian Cancer 100 9380561800 6480763600 2.57 
CGPLOV48 Preoperative treatment naïve WGS Ovarian Cancer 100 9258552600 6380106400 2.53 
CGPLOV49 Preoperative treatment naïve WGS Ovarian Cancer 100 8787025400 6134503600 2.43 
CGPLOV50 Preoperative treatment naïve WGS Ovarian Cancer 100 10144154400 6984721400 2.77 
CGPLPA112 Preoperative treatment naïve WGS Pancreatic Cancer 100 12740651400 9045622000 3.59 
CGPLPA113 Preoperative treatment naïve WGS Duodenal Cancer 100 8802479000 5909030800 2.34 
CGPLPA114 Preoperative treatment naïve WGS Bile Duct Cancer 100 8792313600 6019061000 2.39 
CGPLPA115 Preoperative treatment naïve WGS Bile Duct Cancer 100 8636551400 5958809000 2.36 
CGPLPA117 Preoperative treatment naïve WGS Bile Duct Cancer 100 9128885200 6288833200 2.50 
CGPLPA118 Preoperative treatment naïve WGS Bile Duct Cancer 100 7931485800 5407532800 2.15 
CGPLPA122 Preoperative treatment naïve WGS Bile Duct Cancer 100 10888985000 7530118800 2.99 
CGPLPA124 Preoperative treatment naïve WGS Bile Duct Cancer 100 8562012400 5860171000 2.33 
CGPLPA125 Preoperative treatment naïve WGS Bile Duct Cancer 100 9715576600 6390321000 2.54 
CGPLPA126 Preoperative treatment naïve WGS Bile Duct Cancer 100 8056768800 5651600800 2.24 
CGPLPA127 Preoperative treatment naïve WGS Bile Duct Cancer 100 8000301000 5382987600 2.14 
CGPLPA128 Preoperative treatment naïve WGS Bile Duct Cancer 100 6165751600 4256521400 1.69 
CGPLPA129 Preoperative treatment naïve WGS Bile Duct Cancer 100 7143147400 4917370400 1.95 
CGPLPA130 Preoperative treatment naïve WGS Bile Duct Cancer 100 5664335000 3603919400 1.43 
CGPLPA131 Preoperative treatment naïve WGS Bile Duct Cancer 100 8292982000 5844942000 2.32 
CGPLPA134 Preoperative treatment naïve WGS Bile Duct Cancer 100 7088917000 5048887600 2.00 
CGPLPA135 Preoperative treatment naïve WGS Bile Duct Cancer 100 8759665600 5800618200 2.30 
CGPLPA136 Preoperative treatment naïve WGS Bile Duct Cancer 100 7539715800 5248227600 2.08 
CGPLPA137 Preoperative treatment naïve WGS Bile Duct Cancer 100 8391815400 5901273800 2.34 
CGPLPA139 Preoperative treatment naïve WGS Bile Duct Cancer 100 8992280200 6328314400 2.51 
CGPLPA14 Preoperative treatment naïve WGS Pancreatic Cancer 100 8787706200 5731317600 2.27 
CGPLPA140 Preoperative treatment naïve WGS Bile Duct Cancer 100 16365641800 11216732000 4.45 
CGPLPA141 Preoperative treatment naïve WGS Bile Duct Cancer 100 15086298000 10114790200 4.01 
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CGPLPA15 Preoperative treatment naïve WGS Pancreatic Cancer 100 8255566800 5531677600 2.20 
CGPLPA155 Preoperative treatment naïve WGS Bile Duct Cancer 100 9457155800 6621881800 2.63 
CGPLPA156 Preoperative treatment naïve WGS Pancreatic Cancer 100 9845385800 6728653000 2.67 
CGPLPA165 Preoperative treatment naïve WGS Bile Duct Cancer 100 8356604600 5829895800 2.31 
CGPLPA168 Preoperative treatment naïve WGS Bile Duct Cancer 100 10365661600 7048115600 2.80 
CGPLPA17 Preoperative treatment naïve WGS Pancreatic Cancer 100 8073547400 4687808000 1.86 
CGPLPA184 Preoperative treatment naïve WGS Bile Duct Cancer 100 9014218400 6230922200 2.47 
CGPLPA187 Preoperative treatment naïve WGS Bile Duct Cancer 100 8883536200 6140874400 2.44 
CGPLPA23 Preoperative treatment naïve WGS Pancreatic Cancer 100 9835452000 6246525400 2.48 
CGPLPA25 Preoperative treatment naïve WGS Pancreatic Cancer 100 10077515400 6103322200 2.42 
CGPLPA26 Preoperative treatment naïve WGS Pancreatic Cancer 100 8354272400 5725781000 2.27 
CGPLPA28 Preoperative treatment naïve WGS Pancreatic Cancer 100 8477461600 5688846800 2.26 
CGPLPA33 Preoperative treatment naïve WGS Pancreatic Cancer 100 7287615600 4596723800 1.82 
CGPLPA34 Preoperative treatment naïve WGS Pancreatic Cancer 100 6122902400 4094828000 1.62 
CGPLPA37 Preoperative treatment naïve WGS Pancreatic Cancer 100 12714888200 8527779200 3.38 
CGPLPA38 Preoperative treatment naïve WGS Pancreatic Cancer 100 8525500600 5501341400 2.18 
CGPLPA39 Preoperative treatment naïve WGS Pancreatic Cancer 100 10502663600 6812333000 2.70 
CGPLPA40 Preoperative treatment naïve WGS Pancreatic Cancer 100 9083670000 5394717800 2.14 
CGPLPA42 Preoperative treatment naïve WGS Pancreatic Cancer 100 5972126600 3890395200 1.54 
CGPLPA46 Preoperative treatment naïve WGS Pancreatic Cancer 100 4720090200 2626298800 1.04 
CGPLPA47 Preoperative treatment naïve WGS Pancreatic Cancer 100 7317385800 4543833000 1.80 
CGPLPA48 Preoperative treatment naïve WGS Pancreatic Cancer 100 7553856200 5022695600 1.99 
CGPLPA52 Preoperative treatment naïve WGS Pancreatic Cancer 100 5655875000 3551861600 1.41 
CGPLPA53 Preoperative treatment naïve WGS Pancreatic Cancer 100 9504749000 6323344800 2.51 
CGPLPA58 Preoperative treatment naïve WGS Pancreatic Cancer 100 8088090200 5118138200 2.03 
CGPLPA59 Preoperative treatment naïve WGS Pancreatic Cancer 100 14547364600 9617778600 3.82 
CGPLPA67 Preoperative treatment naïve WGS Pancreatic Cancer 100 8222177400 5351172600 2.12 
CGPLPA69 Preoperative treatment naïve WGS Pancreatic Cancer 100 7899181400 5006114800 1.99 
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CGPLPA71 Preoperative treatment naïve WGS Pancreatic Cancer 100 7349620400 4955417400 1.97 
CGPLPA74 Preoperative treatment naïve WGS Pancreatic Cancer 100 6666371400 4571394200 1.81 
CGPLPA76 Preoperative treatment naïve WGS Pancreatic Cancer 100 9755658600 6412606800 2.54 
CGPLPA85 Preoperative treatment naïve WGS Pancreatic Cancer 100 10856223000 7309498600 2.90 
CGPLPA86 Preoperative treatment naïve WGS Pancreatic Cancer 100 8744365400 5514523200 2.19 
CGPLPA92 Preoperative treatment naïve WGS Pancreatic Cancer 100 8073791200 5390492800 2.14 
CGPLPA93 Preoperative treatment naïve WGS Pancreatic Cancer 100 10390273000 7186589400 2.85 
CGPLPA94 Preoperative treatment naïve WGS Pancreatic Cancer 100 11060347600 7641336400 3.03 
CGPLPA95 Preoperative treatment naïve WGS Pancreatic Cancer 100 12416627200 7206503800 2.86 
CGST102 Preoperative treatment naïve WGS Gastric cancer 100 6637004600 4545072600 1.80 
CGST11 Preoperative treatment naïve WGS Gastric cancer 100 9718427800 6259679600 2.48 
CGST110 Preoperative treatment naïve WGS Gastric cancer 100 9319661600 6359317400 2.52 
CGST114 Preoperative treatment naïve WGS Gastric cancer 100 6865213000 4841171600 1.92 
CGST13 Preoperative treatment naïve WGS Gastric cancer 100 9284554800 6360843800 2.52 
CGST131 Preoperative treatment naïve WGS Gastric cancer 100 5924382000 3860677200 1.53 
CGST141 Preoperative treatment naïve WGS Gastric cancer 100 8486380800 5860491000 2.33 
CGST16 Preoperative treatment naïve WGS Gastric cancer 100 13820725800 9377828000 3.72 
CGST18 Preoperative treatment naïve WGS Gastric cancer 100 7781288000 5278862400 2.09 
CGST21 Preoperative treatment naïve WGS Gastric cancer 100 7171165400 4103970800 1.63 
CGST26 Preoperative treatment naïve WGS Gastric cancer 100 8983961800 6053405600 2.40 
CGST28 Preoperative treatment naïve WGS Gastric cancer 100 9683035400 6745116400 2.68 
CGST30 Preoperative treatment naïve WGS Gastric cancer 100 8684086600 5741416000 2.28 
CGST32 Preoperative treatment naïve WGS Gastric cancer 100 8568194600 5783369200 2.29 
CGST33 Preoperative treatment naïve WGS Gastric cancer 100 9351699600 6448718400 2.56 
CGST38 Preoperative treatment naïve WGS Gastric cancer 100 8409876400 5770989200 2.29 
CGST39 Preoperative treatment naïve WGS Gastric cancer 100 10573763000 7597016000 3.01 
CGST41 Preoperative treatment naïve WGS Gastric cancer 100 9434854200 6609415400 2.62 
CGST45 Preoperative treatment naïve WGS Gastric cancer 100 8203868600 5625223000 2.23 
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CGST47 Preoperative treatment naïve WGS Gastric cancer 100 8938597600 6178990600 2.45 
CGST48 Preoperative treatment naïve WGS Gastric cancer 100 9106628800 6517085200 2.59 
CGST53 Preoperative treatment naïve WGS Gastric cancer 100 9005374200 5854996200 2.32 
CGST58 Preoperative treatment naïve WGS Gastric cancer 100 10020368600 6133458400 2.43 
CGST67 Preoperative treatment naïve WGS Gastric cancer 100 9198135600 5911071000 2.35 
CGST77 Preoperative treatment naïve WGS Gastric cancer 100 8228789400 5119116800 2.03 
CGST80 Preoperative treatment naïve WGS Gastric cancer 100 10596963400 7283152800 2.89 





Table 4.5.  Summary of high coverage whole genome cfDNA analyses. 







Correlation of Fragment 
Ratio Profile to Median 
Fragment Ratio Profile of 
Healthy Individuals* 
Correlation of GC Corrected 
Fragment Ratio Profile to 
Median Fragment Ratio 
Profile of Healthy 
Individuals* 
Correlation of Fragment 
Ratio Profile to Median 
Fragment Ratio Profile of 
Lymphocytes* 
Correlation of Fragment 
Ratio Profile to 
Lymphocyte 
Nucleosome Distances* 
CGPLH75 Healthy WGS NA 168 0.977 0.952 0.920 -0.886 
CGPLH77 Healthy WGS NA 166 0.970 0.960 0.904 -0.912 
CGPLH80 Healthy WGS NA 168 0.955 0.949 0.960 -0.917 
CGPLH81 Healthy WGS NA 167 0.949 0.953 0.869 -0.883 
CGPLH82 Healthy WGS NA 166 0.969 0.949 0.954 -0.917 
CGPLH83 Healthy WGS NA 167 0.949 0.939 0.919 -0.904 
CGPLH84 Healthy WGS NA 168 0.967 0.948 0.951 -0.913 
CGPLH52 Healthy WGS NA 167 0.946 0.968 0.952 -0.924 
CGPLH35 Healthy WGS NA 166 0.981 0.973 0.945 -0.921 
CGPLH37 Healthy WGS NA 168 0.968 0.970 0.951 -0.922 
CGPLH54 Healthy WGS NA 167 0.968 0.976 0.948 -0.925 
CGPLH55 Healthy WGS NA 166 0.947 0.964 0.948 -0.917 
CGPLH48 Healthy WGS NA 168 0.959 0.965 0.960 -0.923 
CGPLH50 Healthy WGS NA 167 0.960 0.968 0.952 -0.921 
CGPLH36 Healthy WGS NA 168 0.955 0.954 0.955 -0.919 
CGPLH42 Healthy WGS NA 167 0.973 0.963 0.948 -0.918 
CGPLH43 Healthy WGS NA 166 0.952 0.958 0.953 -0.928 
CGPLH59 Healthy WGS NA 168 0.970 0.965 0.951 -0.925 
CGPLH45 Healthy WGS NA 168 0.965 0.950 0.949 -0.911 
CGPLH47 Healthy WGS NA 167 0.952 0.944 0.954 -0.921 
CGPLH46 Healthy WGS NA 168 0.966 0.965 0.953 -0.923 
CGPLH63 Healthy WGS NA 168 0.977 0.968 0.939 -0.920 
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CGPLH51 Healthy WGS NA 168 0.935 0.955 0.957 -0.914 
CGPLH57 Healthy WGS NA 169 0.965 0.954 0.955 -0.917 
CGPLH49 Healthy WGS NA 168 0.958 0.951 0.950 -0.924 
CGPLH56 Healthy WGS NA 166 0.940 0.957 0.959 -0.911 
CGPLH64 Healthy WGS NA 169 0.960 0.940 0.949 -0.918 
CGPLH78 Healthy WGS NA 166 0.956 0.936 0.958 -0.911 
CGPLH79 Healthy WGS NA 168 0.960 0.957 0.953 -0.917 
CGPLH76 Healthy WGS NA 167 0.969 0.965 0.953 -0.917 
CGPLLU175 Lung Cancer WGS I 165 0.316 0.284 0.244 -0.262 
CGPLLU180 Lung Cancer WGS I 166 0.907 0.846 0.826 -0.819 
CGPLLU198 Lung Cancer WGS I 166 0.972 0.946 0.928 -0.911 
CGPLLU202 Lung Cancer WGS I 163 0.821 0.605 0.905 -0.843 
CGPLLU165 Lung Cancer WGS II 163 0.924 0.961 0.815 -0.851 
CGPLLU209 Lung Cancer WGS II 163 0.578 0.526 0.513 -0.534 
CGPLLU147 Lung Cancer WGS III 166 0.953 0.919 0.939 -0.912 
CGPLLU206 Lung Cancer WGS III 158 0.488 0.343 0.460 -0.481 
*Pearson correlation.  
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Table 4.6.  Summary of monitoring response to therapy using whole genome and targeted analyses. 




Correlation of Fragment 
Ratio Profile to Median 
Fragment Ratio Profile of 
Healthy Individuals* 
Correlation of Fragment 







CGPLLU14 Lung Cancer Pre-treatment, Day -38 IV 15.4 0.941 -0.841 EGFR 861L>Q 0.89% 
CGPLLU14 Lung Cancer Pre-treatment, Day -16 IV 15.4 0.933 -0.833 EGFR 861L>Q 0.18% 
CGPLLU14 Lung Cancer Pre-treatment, Day -3 IV 15.4 0.908 -0.814 EGFR 719G>S 0.49% 
CGPLLU14 Lung Cancer Pre-treatment, Day 0 IV 15.4 0.883 -0.752 EGFR 861L>Q 1.39% 
CGPLLU14 Lung Cancer Post-treatment, Day 0.33 IV 15.4 0.820 -0.692 EGFR 719G>S 1.05% 
CGPLLU14 Lung Cancer Post-treatment, Day 7 IV 15.4 0.927 -0.887 EGFR 861L>Q 0.00% 
CGPLLU88 Lung Cancer Pre-treatment, Day 0 IV 18.0 0.657 -0.584 EGFR 745KELREA>T 9.06% 
CGPLLU88 Lung Cancer Post-treatment, Day 7 IV 18.0 0.939 -0.799 EGFR 790T>M 0.15% 
CGPLLU88 Lung Cancer Post-treatment, Day 297 IV 18.0 0.946 -0.869 EGFR 745KELREA>T 0.93% 
CGPLLU244 Lung Cancer Pre-treatment, Day -7 IV 1.2 0.850 -0.706 EGFR 858L>R 4.98% 
CGPLLU244 Lung Cancer Pre-treatment, Day -1 IV 1.2 0.867 -0.764 EGFR 62L>R 3.41% 
CGPLLU244 Lung Cancer Post-treatment, Day 6 IV 1.2 0.703 -0.639 EGFR 858L>R 5.57% 
CGPLLU244 Lung Cancer Post-treatment, Day 62 IV 1.2 0.659 -0.660 EGFR 858L>R 11.80% 
CGPLLU245 Lung Cancer Pre-treatment, Day -32 IV 1.7 0.871 -0.724 EGFR 745KELREA>K 10.60% 
CGPLLU245 Lung Cancer Pre-treatment, Day 0 IV 1.7 0.738 -0.608 EGFR 745KELREA>K 14.10% 
CGPLLU245 Lung Cancer Post-treatment, Day 7 IV 1.7 0.731 -0.559 EGFR 745KELREA>K 8.56% 
CGPLLU245 Lung Cancer Post-treatment, Day 21 IV 1.7 0.613 -0.426 EGFR 745KELREA>K 10.69% 
CGPLLU246 Lung Cancer Pre-treatment, Day -21 IV 1.3 0.897 -0.757 EGFR 790T>M 0.49% 
CGPLLU246 Lung Cancer Pre-treatment, Day 0 IV 1.3 0.469 -0.376 EGFR 858L>R 6.17% 
CGPLLU246 Lung Cancer Post-treatment, Day 9 IV 1.3 0.874 -0.746 EGFR 858L>R 1.72% 
CGPLLU246 Lung Cancer Post-treatment, Day 42 IV 1.3 0.775 -0.665 EGFR 858L>R 5.29% 
CGPLLU86 Lung Cancer Pre-treatment, Day 0 IV 12.4 0.817 -0.630 EGFR 746ELREATS>D 0.00% 
CGPLLU86 Lung Cancer Post-treatment, Day 0.5 IV 12.4 0.916 -0.811 EGFR 746ELREATS>D 0.19% 
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CGPLLU86 Lung Cancer Post-treatment, Day 7 IV 12.4 0.859 -0.694 EGFR 746ELREATS>D 0.00% 
CGPLLU86 Lung Cancer Post-treatment, Day 17 IV 12.4 0.932 -0.848 EGFR 746ELREATS>D 0.00% 
CGPLLU89 Lung Cancer Pre-treatment, Day 0 IV 6.7 0.864 -0.729 EGFR 747LREATS>- 0.42% 
CGPLLU89 Lung Cancer Post-treatment, Day 7 IV 6.7 0.908 -0.803 EGFR 747LREATS>- 0.20% 
CGPLLU89 Lung Cancer Post-treatment, Day 22 IV 6.7 0.853 -0.881 EGFR 747LREATS>- 0.00% 
CGLU316 Lung Cancer Pre-treatment, Day -53 IV 1.4 0.331 -0.351 EGFR L861Q 15.72% 
CGLU316 Lung Cancer Pre-treatment, Day -4 IV 1.4 0.225 -0.253 EGFR L861Q 45.67% 
CGLU316 Lung Cancer Post-treatment, Day 18 IV 1.4 0.336 -0.364 EGFR G719A 33.38% 
CGLU316 Lung Cancer Post-treatment, Day 87 IV 1.4 0.340 -0.364 EGFR L861Q 66.01% 
CGLU344 Lung Cancer Pre-treatment, Day -21 IV Ongoing 0.935 -0.818 EGFR E746_A750del 0.00% 
CGLU344 Lung Cancer Pre-treatment, Day 0 IV Ongoing 0.919 -0.774 EGFR E746_A750del 0.22% 
CGLU344 Lung Cancer Post-treatment, Day 0.1875 IV Ongoing 0.953 -0.860 EGFR E746_A750del 0.40% 
CGLU344 Lung Cancer Post-treatment, Day 59 IV Ongoing 0.944 -0.832 EGFR E746_A750del 0.00% 
CGLU369 Lung Cancer Pre-treatment, Day -2 IV 7.5 0.825 -0.826 EGFR L858R 20.61% 
CGLU369 Lung Cancer Post-treatment, Day 12 IV 7.5 0.950 -0.903 EGFR L858R 0.22% 
CGLU369 Lung Cancer Post-treatment, Day 68 IV 7.5 0.945 -0.889 EGFR L858R 0.16% 
CGLU369 Lung Cancer Post-treatment, Day 110 IV 7.5 0.886 -0.883 EGFR L858R 0.10% 
CGLU373 Lung Cancer Pre-treatment, Day -2 IV Ongoing 0.922 -0.804 EGFR E746_A750del 0.82% 
CGLU373 Lung Cancer Post-treatment, Day 0.125 IV Ongoing 0.959 -0.853 EGFR E746_A750del 0.00% 
CGLU373 Lung Cancer Post-treatment, Day 7 IV Ongoing 0.967 -0.886 EGFR E746_A750del 0.15% 
CGLU373 Lung Cancer Post-treatment, Day 47 IV Ongoing 0.951 -0.890 EGFR E746_A750del 0.00% 
CGPLLU13 Lung Cancer Pre-treatment, Day -2 IV 1.5 0.425 -0.400 EGFR E746_A750del 7.66% 
CGPLLU13 Lung Cancer Post-treatment, Day 5 IV 1.5 0.272 -0.257 EGFR E746_A750del 13.10% 
CGPLLU13 Lung Cancer Post-treatment, Day 28 IV 1.5 0.584 -0.536 EGFR E746_A750del 6.09% 
CGPLLU13 Lung Cancer Post-treatment, Day 91 IV 1.5 0.530 -0.513 EGFR E746_A750del 9.28% 
CGPLLU264 Lung Cancer Pre-treatment, Day -1 IV Ongoing 0.946 -0.824 EGFR D761N 0.00% 
CGPLLU264 Lung Cancer Post-treatment, Day 6 IV Ongoing 0.927 -0.788 EGFR D761N 0.16% 
CGPLLU264 Lung Cancer Post-treatment, Day 27 IV Ongoing 0.962 -0.856 EGFR D761N 0.00% 
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CGPLLU264 Lung Cancer Post-treatment, Day 69 IV Ongoing 0.960 -0.894 EGFR D761N 0.00% 
CGPLLU265 Lung Cancer Pre-treatment, Day 0 IV Ongoing 0.953 -0.859 EGFR L858R 0.21% 
CGPLLU265 Lung Cancer Post-treatment, Day 3 IV Ongoing 0.949 -0.842 EGFR L858R 0.21% 
CGPLLU265 Lung Cancer Post-treatment, Day 7 IV Ongoing 0.955 -0.844 EGFR T790M 0.21% 
CGPLLU265 Lung Cancer Post-treatment, Day 84 IV Ongoing 0.946 -0.825 EGFR L858R 0.00% 
CGPLLU266 Lung Cancer Pre-treatment, Day 0 IV 9.6 0.961 -0.904 NA 0.00% 
CGPLLU266 Lung Cancer Post-treatment, Day 16 IV 9.6 0.959 -0.886 NA 0.00% 
CGPLLU266 Lung Cancer Post-treatment, Day 83 IV 9.6 0.961 -0.880 NA 0.00% 
CGPLLU266 Lung Cancer Post-treatment, Day 328 IV 9.6 0.958 -0.855 NA 0.00% 
CGPLLU267 Lung Cancer Pre-treatment, Day -1 IV 3.9 0.919 -0.863 EGFR L858R 1.93% 
CGPLLU267 Lung Cancer Post-treatment, Day 34 IV 3.9 0.863 -0.889 EGFR L858R 0.14% 
CGPLLU267 Lung Cancer Post-treatment, Day 90 IV 3.9 0.962 -0.876 EGFR L858R 0.38% 
CGPLLU269 Lung Cancer Pre-treatment, Day 0 IV Ongoing 0.951 -0.864 EGFR L858R 0.10% 
CGPLLU269 Lung Cancer Post-treatment, Day 9 IV Ongoing 0.941 -0.894 EGFR L858R 0.00% 
CGPLLU269 Lung Cancer Post-treatment, Day 28 IV Ongoing 0.957 -0.876 EGFR L858R 0.00% 
CGPLLU271 Lung Cancer Pre-treatment, Day 0 IV 8.2 0.371 -0.284 EGFR E746_A750del 3.36% 
CGPLLU271 Lung Cancer Post-treatment, Day 6 IV 8.2 0.947 -0.826 EGFR E746_A750del 0.17% 
CGPLLU271 Lung Cancer Post-treatment, Day 20 IV 8.2 0.952 -0.839 EGFR E746_A750del 0.00% 
CGPLLU271 Lung Cancer Post-treatment, Day 104 IV 8.2 0.944 -0.810 EGFR E746_A750del 0.00% 
CGPLLU271 Lung Cancer Post-treatment, Day 259 IV 8.2 0.950 -0.831 EGFR E746_A750del 0.44% 
CGPLLU43 Lung Cancer Pre-treatment, Day -1 IV Ongoing 0.944 -0.903 NA 0.00% 
CGPLLU43 Lung Cancer Post-treatment, Day 6 IV Ongoing 0.956 -0.899 NA 0.00% 
CGPLLU43 Lung Cancer Post-treatment, Day 27 IV Ongoing 0.959 -0.901 NA 0.00% 
CGPLLU43 Lung Cancer Post-treatment, Day 83 IV Ongoing 0.965 -0.896 NA 0.00% 
*Pearson correlation.  ᶥPlease see reference 36 for more information on targeted mutation analyses.  
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Table 4.7.  Summary of whole genome cfDNA analyses in healthy individuals and cancer patients. 







Profile to Median 
Fragment Ratio 
Profile of Healthy 
Individuals* 
Correlation of GC 
Corrected Fragment 
Ratio Profile to 
Median Fragment 
Ratio Profile of 
Healthy Individuals* 





















CGPLPA114 Bile Duct Cancer II 166 0.9098 0.9246 0.0836% 0.7598 Y Y  -  
CGPLPA115 Bile Duct Cancer IV 165 0.8053 0.8310 0.0763% 0.9974 Y Y  -  
CGPLPA117 Bile Duct Cancer II 165 0.9395 0.8767 0.1084% 0.9049 Y Y  -  
CGPLPA118 Bile Duct Cancer I 167 0.9406 0.9001 0.1842% 0.9859 Y Y 0.14% 
CGPLPA122 Bile Duct Cancer II 164 0.8231 0.8058 0.2047% 0.9983 Y Y 37.22% 
CGPLPA124 Bile Duct Cancer II 166 0.9108 0.9238 0.1542% 0.8791 Y Y 0.62% 
CGPLPA125 Bile Duct Cancer II 166 0.9675 0.9373 0.0273% 0.0228 N N  -  
CGPLPA126 Bile Duct Cancer II 166 0.9155 0.9139 0.4349% 0.9908 Y Y ND 
CGPLPA127 Bile Duct Cancer IV 167 0.8916 0.8117 0.4371% 0.9789 Y Y  -  
CGPLPA128 Bile Duct Cancer II 167 0.9262 0.9003 0.1317% 0.9812 Y Y ND 
CGPLPA129 Bile Duct Cancer II 166 0.9220 0.9155 0.0642% 0.9839 Y Y ND 
CGPLPA130 Bile Duct Cancer II 169 0.8586 0.8499 0.1005% 0.9895 Y Y ND 
CGPLPA131 Bile Duct Cancer II 165 0.7707 0.9195 0.0780% 0.9885 Y Y 0.21% 
CGPLPA134 Bile Duct Cancer II 160 0.7502 0.8847 0.0260% 0.9896 Y Y 0.93% 
CGPLPA135 Bile Duct Cancer I 165 0.9495 0.9184 0.0558% 0.6594 Y N  -  
CGPLPA136 Bile Duct Cancer II 164 0.9289 0.9050 0.0769% 0.9596 Y Y 0.10% 
CGPLPA137 Bile Duct Cancer II 166 0.9568 0.9320 0.0499% 0.7282 Y N  -  
CGPLPA139 Bile Duct Cancer IV 166 0.9511 0.9374 0.0465% 0.0743 N N  -  
CGPLPA140 Bile Duct Cancer II 166 0.9215 0.9548 0.0330% 0.9761 Y Y 0.21% 
CGPLPA141 Bile Duct Cancer II 165 0.9172 0.9381 0.0920% 0.9988 Y Y  -  
CGPLPA155 Bile Duct Cancer II 165 0.9496 0.9313 0.0260% 0.8013 Y Y  -  
CGPLPA165 Bile Duct Cancer I 168 0.9596 0.9309 0.0558% 0.2158 N N  -  
CGPLPA168 Bile Duct Cancer II 162 0.7838 0.7757 0.3123% 0.9878 Y Y  -  
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CGPLPA184 Bile Duct Cancer II 165 0.9100 0.9203 0.0897% 0.9926 Y Y  -  
CGPLPA187 Bile Duct Cancer II 165 0.8577 0.8968 0.0658% 0.9675 Y Y  -  
CGPLBR100 Breast Cancer III 166 0.9440 0.8946 0.1234% 0.8664 Y Y ND 
CGPLBR101 Breast Cancer II 169 0.8864 0.9304 0.0709% 0.9385 Y Y ND 
CGPLBR102 Breast Cancer II 169 0.9617 0.9345 0.4742% 0.9052 Y Y 0.25% 
CGPLBR103 Breast Cancer II 168 0.9498 0.9251 0.0775% 0.5994 N N ND 
CGPLBR104 Breast Cancer II 167 0.8490 0.9192 0.0532% 0.9950 Y Y 0.13% 
CGPLBR12 Breast Cancer III 164 0.8350 0.7760 0.1407% 0.7598 Y Y  -  
CGPLBR18 Breast Cancer III 163 0.8411 0.9534 0.0267% 0.3886 N N  -  
CGPLBR23 Breast Cancer II 166 0.9714 0.9312 0.0144% 0.1235 N N  -  
CGPLBR24 Breast Cancer II 156 0.8402 0.8766 0.0210% 0.7480 Y Y  -  
CGPLBR28 Breast Cancer III 166 0.9584 0.9120 0.1456% 0.9630 Y Y  -  
CGPLBR30 Breast Cancer II 161 0.6951 0.6611 0.0952% 0.9956 Y Y  -  
CGPLBR31 Breast Cancer II 167 0.9719 0.9556 0.0427% 0.2227 N N  -  
CGPLBR32 Breast Cancer II 166 0.9590 0.9229 0.0306% 0.9815 Y Y  -  
CGPLBR33 Breast Cancer II 166 0.9706 0.9432 0.0617% 0.2863 N N  -  
CGPLBR34 Breast Cancer II 163 0.8735 0.9425 0.0115% 0.1637 N N  -  
CGPLBR35 Breast Cancer II 168 0.9655 0.9348 0.1371% 0.5057 N N  -  
CGPLBR36 Breast Cancer II 169 0.9394 0.8884 0.0813% 0.4017 N N  -  
CGPLBR37 Breast Cancer II 167 0.9691 0.9496 0.0518% 0.0314 N N  -  
CGPLBR38 Breast Cancer I 165 0.9105 0.9349 0.1352% 0.8983 Y Y 0.53% 
CGPLBR40 Breast Cancer III 167 0.9273 0.9244 0.0929% 0.9046 Y Y ND 
CGPLBR41 Breast Cancer III 168 0.9626 0.9346 0.0544% 0.9416 Y Y 0.32% 
CGPLBR45 Breast Cancer II 164 0.9615 0.9286 0.0296% 0.3860 N N  -  
CGPLBR46 Breast Cancer III 168 0.9322 0.9005 0.0345% 0.7270 Y N  -  
CGPLBR47 Breast Cancer I 166 0.9461 0.9028 0.0591% 0.8247 Y Y  -  
CGPLBR48 Breast Cancer II 169 0.7686 0.8246 0.0504% 0.9973 Y Y 0.18% 
CGPLBR49 Breast Cancer II 171 0.8867 0.7887 0.0377% 0.9946 Y Y ND 
256 
 
CGPLBR50 Breast Cancer I 160 0.8593 0.9332 0.0137% 0.6820 Y N  -  
CGPLBR51 Breast Cancer II 165 0.9359 0.9160 0.0863% 0.6915 Y N  -  
CGPLBR52 Breast Cancer III 164 0.8688 0.9196 0.0165% 0.6390 Y N  -  
CGPLBR55 Breast Cancer III 165 0.9634 0.9341 0.0356% 0.9494 Y Y 0.68% 
CGPLBR56 Breast Cancer II 163 0.9469 0.9428 0.2025% 0.4700 N N  -  
CGPLBR57 Breast Cancer III 166 0.9672 0.9416 0.0902% 0.9090 Y Y ND 
CGPLBR59 Breast Cancer I 168 0.9438 0.9130 0.0761% 0.5828 N N ND 
CGPLBR60 Breast Cancer II 167 0.9479 0.8916 0.0626% 0.8779 Y Y  -  
CGPLBR61 Breast Cancer II 165 0.9611 0.9422 0.0601% 0.4417 N N 0.44% 
CGPLBR63 Breast Cancer II 168 0.9555 0.9132 0.0514% 0.8788 Y Y ND 
CGPLBR65 Breast Cancer II 167 0.9506 0.8970 0.0264% 0.9048 Y Y  -  
CGPLBR68 Breast Cancer III 163 0.9154 0.9532 0.0164% 0.7863 Y Y ND 
CGPLBR69 Breast Cancer II 165 0.9460 0.9474 0.0279% 0.0600 N N ND 
CGPLBR70 Breast Cancer II 168 0.9651 0.9388 0.0171% 0.6447 Y N 0.36% 
CGPLBR71 Breast Cancer II 165 0.9577 0.9368 0.0271% 0.6706 Y N 0.10% 
CGPLBR72 Breast Cancer II 167 0.9786 0.9640 0.0263% 0.6129 N N ND 
CGPLBR73 Breast Cancer II 167 0.9576 0.9421 0.0142% 0.0746 N N 0.27% 
CGPLBR76 Breast Cancer II 170 0.9410 0.9254 0.0775% 0.9334 Y Y 0.12% 
CGPLBR81 Breast Cancer II 170 0.9043 0.8193 0.0241% 0.9899 Y Y  -  
CGPLBR82 Breast Cancer I  166 0.9254 0.9288 0.1640% 0.9834 Y Y 0.12% 
CGPLBR83 Breast Cancer II 169 0.9451 0.9138 0.0419% 0.9810 Y Y 0.28% 
CGPLBR84 Breast Cancer III 169 0.9315 0.8659 0.0274% 0.9901 Y Y  -  
CGPLBR87 Breast Cancer II 166 0.9154 0.8797 0.0294% 0.9968 Y Y 0.45% 
CGPLBR88 Breast Cancer II 169 0.9370 0.8547 0.0181% 0.9988 Y Y 0.38% 
CGPLBR90 Breast Cancer II 169 0.9002 0.8330 0.0417% 0.9667 Y Y  -  
CGPLBR91 Breast Cancer III 164 0.7955 0.9408 0.0799% 0.8710 Y Y ND 
CGPLBR92 Breast Cancer II 162 0.6774 0.8835 0.1042% 0.9866 Y Y 0.20% 
CGPLBR93 Breast Cancer II 164 0.8773 0.9072 0.0352% 0.7253 Y N ND 
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CGCRC291 Colorectal Cancer IV 163 0.1972 0.5268 0.0484% 0.9976 Y Y 22.85% 
CGCRC292 Colorectal Cancer IV 166 0.7804 0.8835 0.0270% 0.7299 Y N 1.41% 
CGCRC293 Colorectal Cancer IV 166 0.9335 0.9206 0.0748% 0.5234 N N 0.35% 
CGCRC294 Colorectal Cancer II 166 0.6531 0.8904 0.0188% 0.8757 Y Y 0.17% 
CGCRC296 Colorectal Cancer II 166 0.8161 0.8695 0.0369% 0.9951 Y Y ND 
CGCRC299 Colorectal Cancer I 162 0.7325 0.9268 0.0392% 0.9648 Y Y ND 
CGCRC300 Colorectal Cancer I 167 0.9382 0.9303 0.0235% 0.4447 N N ND 
CGCRC301 Colorectal Cancer I 165 0.8252 0.9151 0.0310% 0.2190 N N 0.21% 
CGCRC302 Colorectal Cancer II 163 0.7499 0.9243 0.0112% 0.9897 Y Y 0.12% 
CGCRC304 Colorectal Cancer II 162 0.4642 0.9360 0.0093% 0.9358 Y Y 0.27% 
CGCRC305 Colorectal Cancer II 165 0.8909 0.9250 0.0120% 0.8988 Y Y 0.19% 
CGCRC306 Colorectal Cancer II 165 0.8523 0.8186 0.0781% 0.9466 Y Y 8.02% 
CGCRC307 Colorectal Cancer II 165 0.9140 0.9342 0.0181% 0.7042 Y N 0.56% 
CGCRC308 Colorectal Cancer III 165 0.8734 0.9324 0.0078% 0.9082 Y Y 0.11% 
CGCRC311 Colorectal Cancer I 166 0.8535 0.9156 0.0173% 0.1867 N N ND 
CGCRC315 Colorectal Cancer III 167 0.6083 0.8846 0.0241% 0.6422 Y N 0.27% 
CGCRC316 Colorectal Cancer III 161 0.1546 0.5879 0.0315% 0.9971 Y Y 6.52% 
CGCRC317 Colorectal Cancer III 163 0.6242 0.8944 0.0184% 0.9855 Y Y 0.36% 
CGCRC318 Colorectal Cancer I 166 0.8824 0.9140 0.0156% 0.5615 N N ND 
CGCRC319 Colorectal Cancer III 160 0.5979 0.8230 0.1259% 0.9925 Y Y 0.11% 
CGCRC320 Colorectal Cancer I 167 0.7949 0.9101 0.0383% 0.8019 Y Y 0.64% 
CGCRC321 Colorectal Cancer I 164 0.7804 0.9091 0.0829% 0.9759 Y Y 0.20% 
CGCRC333 Colorectal Cancer IV 163 0.4263 0.4355 0.4284% 0.9974 Y Y 43.03% 
CGCRC336 Colorectal Cancer IV 162 0.6466 0.6856 0.1154% 0.9887 Y Y 81.61% 
CGCRC338 Colorectal Cancer IV 162 0.7740 0.7573 0.1436% 0.9976 Y Y 36.00% 
CGCRC341 Colorectal Cancer IV 164 0.8995 0.9191 0.0197% 0.9670 Y Y ND 
CGCRC342 Colorectal Cancer IV 158 0.2524 0.1845 0.1732% 0.9987 Y Y 30.72% 
CGPLPA113 Duodenal Cancer I 170 0.8751 0.7674 1.0116% 0.9935 Y Y  -  
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CGST102 Gastric cancer II 167 0.9496 0.9057 0.0704% 0.8581 Y Y 0.43% 
CGST11 Gastric cancer IV 169 0.9419 0.9161 0.0651% 0.1435 N N  -  
CGST110 Gastric cancer III 167 0.9626 0.9232 0.0817% 0.8900 Y Y ND 
CGST114 Gastric cancer III 164 0.9535 0.9038 0.0317% 0.5893 N N ND 
CGST13 Gastric cancer II 166 0.9369 0.9156 0.0321% 0.9754 Y Y ND 
CGST131 Gastric cancer III 171 0.9428 0.8886 0.2752% 0.9409 Y Y  -  
CGST141 Gastric cancer III 168 0.9621 0.9206 0.0388% 0.2008 N N ND 
CGST16 Gastric cancer III 166 0.7804 0.8355 0.1744% 0.9974 Y Y 0.93% 
CGST18 Gastric cancer II 169 0.9523 0.9111 0.0299% 0.3842 N N 0.14% 
CGST21 Gastric cancer II 165 -0.4778 0.2687 0.2299% 0.9910 Y Y  -  
CGST26 Gastric cancer IV 166 0.9554 0.9140 0.0399% 0.5009 N N  -  
CGST28 Gastric cancer X 169 0.9076 0.7832 0.1295% 0.9955 Y Y 1.62% 
CGST30 Gastric cancer III 169 0.9246 0.9121 0.0338% 0.9183 Y Y 0.42% 
CGST32 Gastric cancer II 169 0.9431 0.8639 0.0247% 0.9612 Y Y 2.99% 
CGST33 Gastric cancer I 168 0.7999 0.7770 0.0799% 0.9805 Y Y 2.32% 
CGST38 Gastric cancer X 168 0.9368 0.8758 0.0640% 0.9416 Y Y  -  
CGST39 Gastric cancer IV 164 0.8742 0.9401 0.0287% 0.8480 Y Y ND 
CGST41 Gastric cancer IV 168 0.8194 0.9284 0.0398% 0.9263 Y Y ND 
CGST45 Gastric cancer II 168 0.9576 0.9036 0.0220% 0.9713 Y Y ND 
CGST47 Gastric cancer I 168 0.9611 0.9096 0.0157% 0.9687 Y Y 0.45% 
CGST48 Gastric cancer IV 167 0.7469 0.5445 0.0220% 0.9975 Y Y 4.21% 
CGST53 Gastric cancer X 173 -0.0019 0.7888 0.1140% 0.9914 Y Y  -  
CGST58 Gastric cancer III 169 0.9470 0.9094 0.0696% 0.9705 Y Y ND 
CGST67 Gastric cancer I 170 0.9352 0.8853 0.3245% 0.9032 Y Y  -  
CGST77 Gastric cancer IV 170 0.0043 0.8295 0.1851% 0.9981 Y Y  -  
CGST80 Gastric cancer III 168 0.9313 0.8846 0.0490% 0.9513 Y Y 1.04% 
CGST81 Gastric cancer I 168 0.9480 0.8851 0.0138% 0.9748 Y Y 0.20% 
CGPLH189 Healthy NA 168 0.9325 0.8947 0.0591% 0.1748 N N  -  
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CGPLH190 Healthy NA 167 0.9433 0.9369 0.1193% 0.5168 N N  -  
CGPLH192 Healthy NA 167 0.9646 0.9487 0.0276% 0.0178 N N  -  
CGPLH193 Healthy NA 167 0.9423 0.9442 0.0420% 0.5794 N N  -  
CGPLH194 Healthy NA 168 0.9567 0.9289 0.0407% 0.1616 N N  -  
CGPLH196 Healthy NA 167 0.9709 0.9512 0.0266% 0.0999 N N  -  
CGPLH197 Healthy NA 166 0.9605 0.9416 0.0334% 0.4699 N N  -  
CGPLH198 Healthy NA 167 0.9238 0.9457 0.0302% 0.6571 Y N  -  
CGPLH199 Healthy NA 165 0.9618 0.9439 0.0170% 0.5564 N N  -  
CGPLH200 Healthy NA 167 0.9183 0.9391 0.0362% 0.3833 N N  -  
CGPLH201 Healthy NA 168 0.9548 0.9180 0.0470% 0.8395 Y Y  -  
CGPLH202 Healthy NA 168 0.9471 0.9436 0.0501% 0.1088 N N  -  
CGPLH203 Healthy NA 167 0.9534 0.9575 0.0455% 0.2485 N N  -  
CGPLH205 Healthy NA 168 0.9075 0.9283 0.0409% 0.4401 N N  -  
CGPLH208 Healthy NA 168 0.9422 0.9409 0.0371% 0.2706 N N  -  
CGPLH209 Healthy NA 169 0.9556 0.9367 0.0427% 0.2213 N N  -  
CGPLH210 Healthy NA 169 0.9447 0.9181 0.0279% 0.3500 N N  -  
CGPLH211 Healthy NA 169 0.9538 0.9410 0.0317% 0.1752 N N  -  
CGPLH300 Healthy NA 168 0.9019 0.9200 0.0397% 0.0226 N N  -  
CGPLH307 Healthy NA 168 0.9576 0.9167 0.0388% 0.1789 N N  -  
CGPLH308 Healthy NA 168 0.9481 0.9352 0.0311% 0.0185 N N  -  
CGPLH309 Healthy NA 168 0.9672 0.9451 0.0226% 0.0441 N N  -  
CGPLH310 Healthy NA 165 0.9547 0.9527 0.0145% 0.7135 Y N  -  
CGPLH311 Healthy NA 167 0.9302 0.9348 0.0202% 0.2589 N N  -  
CGPLH314 Healthy NA 167 0.9482 0.9491 0.0212% 0.1632 N N  -  
CGPLH315 Healthy NA 167 0.8659 0.9427 0.0071% 0.3450 N N  -  
CGPLH316 Healthy NA 165 0.9374 0.9552 0.0191% 0.4697 N N  -  
CGPLH317 Healthy NA 169 0.9542 0.9352 0.0232% 0.1330 N N  -  
CGPLH319 Healthy NA 167 0.9578 0.9189 0.0263% 0.2232 N N  -  
260 
 
CGPLH320 Healthy NA 164 0.8913 0.9166 0.0222% 0.1095 N N  -  
CGPLH322 Healthy NA 167 0.8751 0.9411 0.0248% 0.0749 N N  -  
CGPLH324 Healthy NA 169 0.9519 0.9133 0.0402% 0.0128 N N  -  
CGPLH325 Healthy NA 167 0.9124 0.9202 0.0711% 0.0102 N N  -  
CGPLH326 Healthy NA 166 0.9574 0.9408 0.0213% 0.0475 N N  -  
CGPLH327 Healthy NA 168 0.9533 0.9071 0.1275% 0.4891 N N  -  
CGPLH328 Healthy NA 166 0.9643 0.9332 0.0256% 0.0234 N N  -  
CGPLH329 Healthy NA 167 0.9609 0.9396 0.0269% 0.0139 N N  -  
CGPLH330 Healthy NA 167 0.9118 0.9403 0.0203% 0.2642 N N  -  
CGPLH331 Healthy NA 166 0.9679 0.9377 0.0314% 0.0304 N N  -  
CGPLH333 Healthy NA 169 0.9474 0.9132 0.0350% 0.1633 N N  -  
CGPLH335 Healthy NA 167 0.8909 0.9333 0.0285% 0.0096 N N  -  
CGPLH336 Healthy NA 169 0.9248 0.9159 0.0159% 0.3872 N N  -  
CGPLH337 Healthy NA 167 0.9533 0.9262 0.0367% 0.2976 N N  -  
CGPLH338 Healthy NA 165 0.9388 0.9303 0.0103% 0.0431 N N  -  
CGPLH339 Healthy NA 167 0.9396 0.9338 0.0280% 0.0379 N N  -  
CGPLH340 Healthy NA 167 0.9488 0.9321 0.0210% 0.0379 N N  -  
CGPLH341 Healthy NA 166 0.9533 0.9187 0.0448% 0.1775 N N  -  
CGPLH342 Healthy NA 166 0.7858 0.8986 0.0283% 0.0904 N N  -  
CGPLH343 Healthy NA 167 0.9421 0.9067 0.0632% 0.0160 N N  -  
CGPLH344 Healthy NA 169 0.9192 0.8998 0.0257% 0.0120 N N  -  
CGPLH345 Healthy NA 169 0.9345 0.9107 0.0445% 0.0031 N N  -  
CGPLH346 Healthy NA 169 0.9475 0.9074 0.0208% 0.0686 N N  -  
CGPLH350 Healthy NA 171 0.9570 0.9288 0.0284% 0.0071 N N  -  
CGPLH351 Healthy NA 168 0.8176 0.9294 0.0223% 0.0207 N N  -  
CGPLH352 Healthy NA 168 0.9521 0.9190 0.0613% 0.0512 N N  -  
CGPLH353 Healthy NA 167 0.9435 0.9130 0.0408% 0.0132 N N  -  
CGPLH354 Healthy NA 168 0.9481 0.9121 0.0318% 0.0082 N N  -  
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CGPLH355 Healthy NA 167 0.9613 0.9308 0.0400% 0.6407 Y N  -  
CGPLH356 Healthy NA 168 0.9474 0.9312 0.0427% 0.2437 N N  -  
CGPLH357 Healthy NA 167 0.9255 0.9540 0.0217% 0.0070 N N  -  
CGPLH358 Healthy NA 167 0.7777 0.9372 0.0174% 0.1451 N N  -  
CGPLH360 Healthy NA 168 0.8500 0.8775 0.0395% 0.0048 N N  -  
CGPLH361 Healthy NA 167 0.9261 0.9283 0.0268% 0.1524 N N  -  
CGPLH362 Healthy NA 167 0.9236 0.9503 0.0309% 0.4832 N N  -  
CGPLH363 Healthy NA 167 0.9488 0.9187 0.0620% 0.0199 N N  -  
CGPLH364 Healthy NA 168 0.9311 0.9480 0.0282% 0.8719 Y Y  -  
CGPLH365 Healthy NA 165 0.9371 0.9051 0.1740% 0.9683 Y Y  -  
CGPLH366 Healthy NA 167 0.9536 0.9170 0.0344% 0.0952 N N  -  
CGPLH367 Healthy NA 166 0.8748 0.9181 0.0353% 0.1235 N N  -  
CGPLH368 Healthy NA 169 0.9490 0.9076 0.1073% 0.1252 N N  -  
CGPLH369 Healthy NA 167 0.9428 0.9541 0.0246% 0.2821 N N  -  
CGPLH370 Healthy NA 167 0.9642 0.9423 0.0410% 0.0989 N N  -  
CGPLH371 Healthy NA 168 0.9621 0.9414 0.0734% 0.2173 N N  -  
CGPLH380 Healthy NA 170 0.9662 0.9424 0.0523% 0.0128 N N  -  
CGPLH381 Healthy NA 169 0.9541 0.9501 0.0435% 0.0152 N N  -  
CGPLH382 Healthy NA 167 0.9380 0.9584 0.0340% 0.0326 N N  -  
CGPLH383 Healthy NA 168 0.9700 0.9407 0.0389% 0.0035 N N  -  
CGPLH384 Healthy NA 169 0.8061 0.9043 0.0207% 0.0258 N N  -  
CGPLH385 Healthy NA 167 0.8866 0.9246 0.0165% 0.0566 N N  -  
CGPLH386 Healthy NA 167 0.6920 0.8859 0.0502% 0.2677 N N  -  
CGPLH387 Healthy NA 169 0.9583 0.9223 0.0375% 0.0081 N N  -  
CGPLH388 Healthy NA 167 0.9348 0.9266 0.0527% 0.0499 N N  -  
CGPLH389 Healthy NA 168 0.9409 0.9035 0.0667% 0.6565 Y N  -  
CGPLH390 Healthy NA 167 0.9216 0.9182 0.0229% 0.0837 N N  -  
CGPLH391 Healthy NA 166 0.9334 0.9162 0.0223% 0.0716 N N  -  
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CGPLH392 Healthy NA 167 0.9165 0.9014 0.0424% 0.1305 N N  -  
CGPLH393 Healthy NA 169 0.9256 0.9045 0.0407% 0.0037 N N  -  
CGPLH394 Healthy NA 167 0.9257 0.9292 0.0522% 0.1073 N N  -  
CGPLH395 Healthy NA 166 0.8611 0.9254 0.0424% 0.0171 N N  -  
CGPLH396 Healthy NA 167 0.7884 0.8928 0.0393% 0.0303 N N  -  
CGPLH398 Healthy NA 167 0.9463 0.9578 0.0242% 0.3195 N N  -  
CGPLH399 Healthy NA 169 0.8780 0.9195 0.0679% 0.0685 N N  -  
CGPLH400 Healthy NA 168 0.6862 0.9047 0.0300% 0.2103 N N  -  
CGPLH401 Healthy NA 167 0.9428 0.9339 0.0146% 0.0620 N N  -  
CGPLH402 Healthy NA 167 0.9353 0.8800 0.1516% 0.0395 N N  -  
CGPLH403 Healthy NA 168 0.9329 0.8829 0.0515% 0.0223 N N  -  
CGPLH404 Healthy NA 169 0.9402 0.8948 0.0528% 0.0027 N N  -  
CGPLH405 Healthy NA 166 0.9579 0.9204 0.0359% 0.0188 N N  -  
CGPLH406 Healthy NA 167 0.8188 0.8592 0.0667% 0.0206 N N  -  
CGPLH407 Healthy NA 169 0.9527 0.9099 0.0229% 0.0040 N N  -  
CGPLH408 Healthy NA 167 0.9584 0.9192 0.0415% 0.1257 N N  -  
CGPLH409 Healthy NA 168 0.9220 0.8950 0.0302% 0.0056 N N  -  
CGPLH410 Healthy NA 168 0.9102 0.9006 0.0453% 0.0019 N N  -  
CGPLH411 Healthy NA 167 0.9392 0.8857 0.0621% 0.0188 N N  -  
CGPLH412 Healthy NA 167 0.9561 0.9191 0.0140% 0.0417 N N  -  
CGPLH413 Healthy NA 167 0.9461 0.9145 0.0355% 0.0084 N N  -  
CGPLH414 Healthy NA 168 0.9258 0.9127 0.0290% 0.0284 N N  -  
CGPLH415 Healthy NA 169 0.9217 0.9025 0.0296% 0.0131 N N  -  
CGPLH416 Healthy NA 167 0.9672 0.9388 0.0198% 0.0645 N N  -  
CGPLH417 Healthy NA 168 0.9578 0.9192 0.0241% 0.0836 N N  -  
CGPLH418 Healthy NA 169 0.9376 0.9234 0.0306% 0.0052 N N  -  
CGPLH419 Healthy NA 167 0.9228 0.9295 0.0280% 0.0469 N N  -  
CGPLH420 Healthy NA 169 0.9164 0.9108 0.0187% 0.0420 N N  -  
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CGPLH422 Healthy NA 166 0.9069 0.9006 0.0209% 0.0324 N N  -  
CGPLH423 Healthy NA 169 0.9606 0.9289 0.0832% 0.0139 N N  -  
CGPLH424 Healthy NA 167 0.9553 0.9265 0.1119% 0.0864 N N  -  
CGPLH425 Healthy NA 168 0.9722 0.9488 0.0722% 0.0156 N N  -  
CGPLH426 Healthy NA 168 0.9560 0.9080 0.0548% 0.1075 N N  -  
CGPLH427 Healthy NA 167 0.9594 0.9257 0.0182% 0.0470 N N  -  
CGPLH428 Healthy NA 167 0.9591 0.9272 0.0346% 0.0182 N N  -  
CGPLH429 Healthy NA 168 0.9358 0.8757 0.0593% 0.8143 Y Y  -  
CGPLH430 Healthy NA 167 0.9639 0.9307 0.0258% 0.0369 N N  -  
CGPLH431 Healthy NA 167 0.9570 0.9185 0.0234% 0.0174 N N  -  
CGPLH432 Healthy NA 168 0.9485 0.9082 0.0433% 0.0181 N N  -  
CGPLH434 Healthy NA 168 0.9671 0.9442 0.0297% 0.0060 N N  -  
CGPLH435 Healthy NA 170 0.9133 0.9097 0.0179% 0.0441 N N  -  
CGPLH436 Healthy NA 168 0.9360 0.9158 0.0290% 0.0958 N N  -  
CGPLH437 Healthy NA 170 0.9445 0.9245 0.0156% 0.0136 N N  -  
CGPLH438 Healthy NA 170 0.9537 0.9138 0.0169% 0.1041 N N  -  
CGPLH439 Healthy NA 171 0.9547 0.9028 0.0226% 0.0078 N N  -  
CGPLH440 Healthy NA 169 0.9562 0.9295 0.0330% 0.0867 N N  -  
CGPLH441 Healthy NA 167 0.9660 0.9430 0.0178% 0.0085 N N  -  
CGPLH442 Healthy NA 167 0.9569 0.9406 0.0169% 0.0562 N N  -  
CGPLH443 Healthy NA 170 0.9431 0.8801 0.0207% 0.0578 N N  -  
CGPLH444 Healthy NA 171 0.9429 0.9066 0.0464% 0.0097 N N  -  
CGPLH445 Healthy NA 171 0.9446 0.8750 0.0267% 0.1939 N N  -  
CGPLH446 Healthy NA 167 0.9502 0.9257 0.0281% 0.0340 N N  -  
CGPLH447 Healthy NA 169 0.9421 0.8968 0.0167% 0.0017 N N  -  
CGPLH448 Healthy NA 167 0.9553 0.9191 0.0401% 0.0389 N N  -  
CGPLH449 Healthy NA 167 0.9550 0.9254 0.0236% 0.0116 N N  -  
CGPLH450 Healthy NA 167 0.9572 0.9195 0.0331% 0.0597 N N  -  
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CGPLH451 Healthy NA 169 0.9548 0.9167 0.0262% 0.0104 N N  -  
CGPLH452 Healthy NA 167 0.9498 0.8948 0.0480% 0.4722 N N  -  
CGPLH453 Healthy NA 166 0.9572 0.9339 0.0186% 0.3419 N N  -  
CGPLH455 Healthy NA 166 0.9626 0.9322 0.0455% 0.4536 N N  -  
CGPLH456 Healthy NA 168 0.9537 0.9098 0.0207% 0.0365 N N  -  
CGPLH457 Healthy NA 167 0.9429 0.9022 0.0298% 0.0364 N N  -  
CGPLH458 Healthy NA 167 0.9511 0.9275 0.0298% 0.1891 N N  -  
CGPLH459 Healthy NA 168 0.9609 0.9209 0.0281% 0.0371 N N  -  
CGPLH460 Healthy NA 168 0.9331 0.8863 0.0227% 0.1157 N N  -  
CGPLH463 Healthy NA 167 0.9506 0.9372 0.0130% 0.0865 N N  -  
CGPLH464 Healthy NA 170 0.9133 0.8511 0.0659% 0.2040 N N  -  
CGPLH465 Healthy NA 167 0.9251 0.9164 0.0325% 0.0124 N N  -  
CGPLH466 Healthy NA 167 0.9679 0.9408 0.0155% 0.1733 N N  -  
CGPLH467 Healthy NA 168 0.9273 0.9024 0.0229% 0.2303 N N  -  
CGPLH468 Healthy NA 167 0.8353 0.9345 0.0247% 0.5427 N N  -  
CGPLH469 Healthy NA 169 0.8225 0.8799 0.0201% 0.5351 N N  -  
CGPLH470 Healthy NA 168 0.9073 0.9228 0.0715% 0.0327 N N  -  
CGPLH471 Healthy NA 167 0.9354 0.9333 0.0150% 0.0406 N N  -  
CGPLH472 Healthy NA 166 0.8509 0.8915 0.0481% 0.6152 N N  -  
CGPLH473 Healthy NA 167 0.9206 0.9128 0.0443% 0.2995 N N  -  
CGPLH474 Healthy NA 168 0.8474 0.9245 0.0316% 0.6246 Y N  -  
CGPLH475 Healthy NA 167 0.9155 0.9233 0.0269% 0.0736 N N  -  
CGPLH476 Healthy NA 169 0.8807 0.9059 0.0236% 0.0143 N N  -  
CGPLH477 Healthy NA 169 0.9129 0.9376 0.0382% 0.1111 N N  -  
CGPLH478 Healthy NA 167 0.9588 0.9344 0.0256% 0.0828 N N  -  
CGPLH479 Healthy NA 167 0.9303 0.9207 0.0221% 0.0648 N N  -  
CGPLH480 Healthy NA 169 0.9522 0.9046 0.0672% 0.7473 Y N  -  
CGPLH481 Healthy NA 168 0.9568 0.9113 0.0311% 0.0282 N N  -  
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CGPLH482 Healthy NA 168 0.9379 0.9336 0.0162% 0.0058 N N  -  
CGPLH483 Healthy NA 168 0.9518 0.9275 0.0251% 0.0495 N N  -  
CGPLH484 Healthy NA 166 0.9630 0.9366 0.0261% 0.0048 N N  -  
CGPLH485 Healthy NA 168 0.9547 0.9128 0.0291% 0.1064 N N  -  
CGPLH486 Healthy NA 169 0.9199 0.9042 0.0220% 0.0820 N N  -  
CGPLH487 Healthy NA 169 0.9575 0.9098 0.0594% 0.2154 N N  -  
CGPLH488 Healthy NA 167 0.9618 0.9298 0.0409% 0.0903 N N  -  
CGPLH490 Healthy NA 167 0.8950 0.8794 0.0432% 0.0424 N N  -  
CGPLH491 Healthy NA 168 0.9631 0.9332 0.0144% 0.0223 N N  -  
CGPLH492 Healthy NA 170 0.9335 0.8799 0.0322% 0.0311 N N  -  
CGPLH493 Healthy NA 168 0.8718 0.9330 0.0065% 0.0280 N N  -  
CGPLH494 Healthy NA 169 0.9623 0.9303 0.0232% 0.0824 N N  -  
CGPLH495 Healthy NA 166 0.8777 0.8908 0.0513% 0.0465 N N  -  
CGPLH496 Healthy NA 166 0.8788 0.9398 0.0208% 0.0572 N N  -  
CGPLH497 Healthy NA 167 0.9576 0.9330 0.0335% 0.0404 N N  -  
CGPLH498 Healthy NA 167 0.9526 0.9315 0.0403% 0.0752 N N  -  
CGPLH499 Healthy NA 167 0.9733 0.9442 0.0198% 0.0149 N N  -  
CGPLH500 Healthy NA 168 0.9542 0.9240 0.0433% 0.0754 N N  -  
CGPLH501 Healthy NA 169 0.9526 0.9308 0.0300% 0.0159 N N  -  
CGPLH502 Healthy NA 167 0.9512 0.9200 0.0351% 0.0841 N N  -  
CGPLH503 Healthy NA 169 0.8947 0.8939 0.0398% 0.0649 N N  -  
CGPLH504 Healthy NA 167 0.9561 0.9324 0.0440% 0.1231 N N  -  
CGPLH505 Healthy NA 166 0.9554 0.9243 0.0605% 0.1869 N N  -  
CGPLH506 Healthy NA 167 0.9733 0.9498 0.0284% 0.0180 N N  -  
CGPLH507 Healthy NA 168 0.9222 0.9192 0.0186% 0.0848 N N  -  
CGPLH508 Healthy NA 167 0.9674 0.9410 0.0150% 0.1077 N N  -  
CGPLH509 Healthy NA 167 0.9475 0.9323 0.0163% 0.0828 N N  -  
CGPLH510 Healthy NA 167 0.9459 0.9548 0.0128% 0.0378 N N  -  
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CGPLH511 Healthy NA 168 0.9714 0.9493 0.0224% 0.1779 N N  -  
CGPLH512 Healthy NA 168 0.9442 0.9244 0.0094% 0.0076 N N  -  
CGPLH513 Healthy NA 166 0.9705 0.9595 0.0441% 0.5250 N N  -  
CGPLH514 Healthy NA 167 0.9690 0.9369 0.0114% 0.3131 N N  -  
CGPLH515 Healthy NA 167 0.9568 0.9283 0.0352% 0.4936 N N  -  
CGPLH516 Healthy NA 168 0.9508 0.9298 0.0175% 0.0916 N N  -  
CGPLH517 Healthy NA 168 0.9635 0.9494 0.0161% 0.0059 N N  -  
CGPLH518 Healthy NA 168 0.9647 0.9432 0.0274% 0.0130 N N  -  
CGPLH519 Healthy NA 166 0.9366 0.9351 0.0171% 0.0949 N N  -  
CGPLH520 Healthy NA 166 0.9649 0.9476 0.0241% 0.0944 N N  -  
CGPLH625 Healthy NA 166 0.8766 0.9231 0.0697% 0.4977 N N  -  
CGPLH626 Healthy NA 170 0.9011 0.9269 0.0231% 0.3100 N N  -  
CGPLH639 Healthy NA 165 0.9482 0.9410 0.0549% 0.0773 N N  -  
CGPLH640 Healthy NA 166 0.9131 0.9264 0.0232% 0.0327 N N  -  
CGPLH642 Healthy NA 167 0.9641 0.9376 0.0768% 0.0555 N N  -  
CGPLH643 Healthy NA 169 0.9450 0.9271 0.0579% 0.1325 N N  -  
CGPLH644 Healthy NA 170 0.9398 0.8948 0.0621% 0.3819 N N  -  
CGPLH646 Healthy NA 172 0.9296 0.8691 0.0462% 0.2423 N N  -  
CGPLLU144 Lung Cancer II 164 0.8702 0.8681 0.0423% 0.9892 Y Y 5.10% 
CGPLLU161 Lung Cancer II 165 0.9128 0.9187 0.0273% 0.9955 Y Y 0.20% 
CGPLLU162 Lung Cancer II 165 0.7753 0.8836 0.1410% 0.9986 Y Y 0.22% 
CGPLLU163 Lung Cancer II 166 0.4770 0.3033 0.0724% 0.9940 Y Y 0.21% 
CGPLLU168 Lung Cancer I 163 0.9164 0.8842 0.0712% 0.9861 Y Y 0.07% 
CGPLLU169 Lung Cancer I 163 0.9326 0.9189 0.0846% 0.9866 Y Y 0.13% 
CGPLLU176 Lung Cancer I 168 0.9572 0.9081 0.0626% 0.8769 Y Y ND 
CGPLLU177 Lung Cancer II 166 0.8472 0.6790 0.0564% 0.9924 Y Y 3.22% 
CGPLLU203 Lung Cancer II 164 0.9119 0.8741 0.0568% 0.9178 Y Y 0.11% 
CGPLLU205 Lung Cancer II 163 0.9518 0.9476 0.0495% 0.9877 Y Y ND 
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CGPLLU207 Lung Cancer II 166 0.9344 0.9379 0.0421% 0.9908 Y Y 0.32% 
CGPLLU208 Lung Cancer II 164 0.9091 0.8942 0.0815% 0.9273 Y Y 1.33% 
CGPLOV11 Ovarian Cancer IV 166 0.8902 0.8872 0.0469% 0.9343 Y Y 0.87% 
CGPLOV12 Ovarian Cancer I 167 0.8779 0.8973 0.2767% 0.9764 Y Y ND 
CGPLOV13 Ovarian Cancer IV 166 0.7560 0.9146 0.1017% 0.9690 Y Y 0.35% 
CGPLOV15 Ovarian Cancer III 165 0.8585 0.8552 0.0876% 0.9945 Y Y 3.54% 
CGPLOV16 Ovarian Cancer III 165 0.9052 0.9046 0.0400% 0.9983 Y Y 1.12% 
CGPLOV19 Ovarian Cancer II 165 0.7854 0.7578 0.1089% 0.9989 Y Y 46.35% 
CGPLOV20 Ovarian Cancer II 165 0.8711 0.9154 0.0581% 0.9749 Y Y 0.21% 
CGPLOV21 Ovarian Cancer IV 167 0.8942 0.8889 0.0677% 0.9961 Y Y 14.36% 
CGPLOV22 Ovarian Cancer III 164 0.8944 0.9355 0.0251% 0.9775 Y Y 0.49% 
CGPLOV23 Ovarian Cancer I 169 0.8510 0.8850 0.1520% 0.9916 Y Y 1.39% 
CGPLOV24 Ovarian Cancer I 166 0.9449 0.8995 0.0303% 0.9856 Y Y ND 
CGPLOV25 Ovarian Cancer I 166 0.9590 0.9228 0.0141% 0.8544 Y Y ND 
CGPLOV26 Ovarian Cancer I 161 0.8148 0.9351 0.0646% 0.9946 Y Y ND 
CGPLOV28 Ovarian Cancer I 167 0.9635 0.9378 0.0647% 0.8160 Y Y ND 
CGPLOV31 Ovarian Cancer III 167 0.9461 0.9293 0.1606% 0.9795 Y Y ND 
CGPLOV32 Ovarian Cancer I 168 0.9582 0.9338 0.1351% 0.8609 Y Y ND 
CGPLOV37 Ovarian Cancer I 170 0.9397 0.8831 0.0986% 0.9849 Y Y 0.29% 
CGPLOV38 Ovarian Cancer I 166 0.5779 0.6502 0.0490% 0.9990 Y Y 4.89% 
CGPLOV40 Ovarian Cancer IV 170 0.6097 0.8127 0.6145% 0.9983 Y Y 6.73% 
CGPLOV41 Ovarian Cancer IV 167 0.9403 0.8929 0.1110% 0.9484 Y Y 0.60% 
CGPLOV42 Ovarian Cancer I 166 0.9265 0.9086 0.0489% 0.9979 Y Y 1.24% 
CGPLOV43 Ovarian Cancer I 167 0.9626 0.9342 0.0432% 0.6042 N N ND 
CGPLOV44 Ovarian Cancer I 164 0.9536 0.9173 0.1946% 0.9962 Y Y 0.37% 
CGPLOV46 Ovarian Cancer I 166 0.9622 0.9291 0.0801% 0.9128 Y Y ND 
CGPLOV47 Ovarian Cancer I 165 0.9704 0.9461 0.0270% 0.3410 N N 3.20% 
CGPLOV48 Ovarian Cancer I 167 0.9675 0.9429 0.0422% 0.4874 N N 10.70% 
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CGPLOV49 Ovarian Cancer III 164 0.8998 0.8083 0.1527% 0.9897 Y Y 2.03% 
CGPLOV50 Ovarian Cancer III 165 0.9682 0.9382 0.0807% 0.9955 Y Y ND 
CGPLPA112 Pancreatic Cancer II 164 0.8914 0.9429 0.0268% 0.0856 N N  -  
CGPLPA14 Pancreatic Cancer II 167 0.8718 0.9069 0.0515% 0.9824 Y Y  -  
CGPLPA15 Pancreatic Cancer II 167 0.9111 0.8927 0.0160% 0.8737 Y Y  -  
CGPLPA156 Pancreatic Cancer II 167 0.9479 0.9432 0.0290% 0.0159 N N  -  
CGPLPA17 Pancreatic Cancer II 166 0.8624 0.6771 1.2600% 0.9956 Y Y  -  
CGPLPA23 Pancreatic Cancer II 165 0.7887 0.6938 0.5785% 0.9984 Y Y  -  
CGPLPA25 Pancreatic Cancer II 166 0.9549 0.9239 0.0380% 0.8103 Y Y  -  
CGPLPA26 Pancreatic Cancer II 166 0.9598 0.9356 0.0247% 0.8231 Y Y  -  
CGPLPA28 Pancreatic Cancer II 165 0.9069 0.8938 0.0546% 0.9036 Y Y  -  
CGPLPA33 Pancreatic Cancer II 166 0.8361 0.8553 0.0894% 0.9967 Y Y  -  
CGPLPA34 Pancreatic Cancer II 168 0.8946 0.8885 0.0439% 0.7977 Y Y  -  
CGPLPA37 Pancreatic Cancer II 165 0.8840 0.9294 0.0410% 0.9924 Y Y  -  
CGPLPA38 Pancreatic Cancer II 167 0.8746 0.8941 0.0372% 0.9851 Y Y  -  
CGPLPA39 Pancreatic Cancer II 167 0.8562 0.7972 0.5058% 0.9951 Y Y  -  
CGPLPA40 Pancreatic Cancer II 165 0.8563 0.8865 0.2268% 0.9920 Y Y  -  
CGPLPA42 Pancreatic Cancer II 167 0.9126 0.8863 0.0283% 0.3544 N N  -  
CGPLPA46 Pancreatic Cancer II 169 0.8274 0.7525 1.0982% 0.9952 Y Y  -  
CGPLPA47 Pancreatic Cancer II 166 0.8376 0.8439 0.1596% 0.9946 Y Y  -  
CGPLPA48 Pancreatic Cancer I 167 0.9391 0.9207 1.0232% 0.2251 N N  -  
CGPLPA52 Pancreatic Cancer II 167 0.9452 0.8863 0.0154% 0.0963 N N  -  
CGPLPA53 Pancreatic Cancer I 163 0.9175 0.8776 0.1824% 0.8946 Y Y  -  
CGPLPA58 Pancreatic Cancer II 165 0.9587 0.9224 0.0803% 0.9056 Y Y  -  
CGPLPA59 Pancreatic Cancer II 163 0.9230 0.9193 0.1479% 0.9759 Y Y  -  
CGPLPA67 Pancreatic Cancer III 166 0.9574 0.9248 0.0329% 0.6716 Y N  -  
CGPLPA69 Pancreatic Cancer I 168 0.9172 0.8592 0.0459% 0.1245 N N  -  
CGPLPA71 Pancreatic Cancer II 167 0.9424 0.8888 0.0479% 0.0524 N N  -  
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CGPLPA74 Pancreatic Cancer II 166 0.9688 0.9372 0.0292% 0.0108 N N  -  
CGPLPA76 Pancreatic Cancer II 163 0.9681 0.9441 0.0345% 0.0897 N N  -  
CGPLPA85 Pancreatic Cancer II 165 0.9137 0.9337 0.0363% 0.0508 N N  -  
CGPLPA86 Pancreatic Cancer II 165 0.8875 0.8042 0.7564% 0.9864 Y Y  -  
CGPLPA92 Pancreatic Cancer II 167 0.9389 0.9003 0.1458% 0.7061 Y N  -  
CGPLPA93 Pancreatic Cancer II 166 0.8585 0.8023 0.6250% 0.9978 Y Y  -  
CGPLPA94 Pancreatic Cancer II 162 0.9365 0.9433 0.0180% 0.9025 Y Y  -  
CGPLPA95 Pancreatic Cancer II 163 0.8542 0.8571 0.0815% 0.9941 Y Y  -  
*Pearson correlation.  ᶥND indicates not detected.  Please see reference 10 for additional information on targeted sequencing analyes.  DELFI cancer detection at 95% and 98% specificity is based on 
scores greater than 0.6200 and 0.7500, respectively.  
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chr1p chr1q chr2p chr2q chr3p chr3q chr4p chr4q chr5p chr5q chr6p chr6q chr7p chr7q chr8p chr8q chr9p chr9q chr10p chr10q 
CGCRC291 -20.27 -18.19 25.09 26.20 -102.97 24.14 -17.90 -33.11 -13.32 -42.14 3.90 7.19 39.64 32.59 -72.09 93.57 13.16 23.03 -13.87 -19.62 
CGCRC292 -1.36 -1.69 -1.42 -1.35 -2.31 -2.02 1.11 0.47 1.57 -3.57 -1.69 -0.63 2.53 -0.07 -1.22 0.00 -0.40 -0.59 -1.14 -0.98 
CGCRC293 5.38 5.64 5.38 5.56 6.74 5.42 3.75 4.92 2.42 8.51 2.63 -3.51 -2.68 0.67 -2.27 -2.18 -1.39 -0.98 -1.37 -1.08 
CGCRC294 -1.43 -1.59 -0.84 -1.04 -3.69 -3.10 0.82 -1.98 0.69 -4.36 -1.69 -1.82 0.88 -0.37 0.01 -0.26 -1.51 -0.17 0.22 -0.46 
CGCRC296 -1.99 -1.63 -0.16 -0.60 -0.92 -3.45 1.62 -0.42 2.83 -2.37 -1.74 -0.75 2.85 0.60 0.32 1.03 -1.15 -0.67 0.80 0.04 
CGCRC299 1.36 2.15 1.37 0.55 -2.17 1.12 -1.57 -1.00 -1.66 -0.11 2.41 -1.16 2.49 -2.14 -2.33 0.12 -2.50 1.76 2.69 0.94 
CGCRC300 1.58 1.20 1.06 0.39 -0.11 0.60 -1.44 -0.97 -1.40 1.92 1.35 -1.36 0.70 -2.47 0.36 1.47 -1.06 2.45 0.58 1.03 
CGCRC301 1.05 0.08 1.35 -0.49 -2.17 -0.78 0.41 -0.03 -0.84 -1.44 0.96 -1.33 -0.67 -1.95 0.12 0.26 -1.25 1.63 0.60 0.83 
CGCRC302 -0.37 0.39 1.03 0.49 -3.76 -0.60 -1.06 -2.12 -1.40 -2.12 0.51 0.10 3.58 -2.24 -1.80 -0.41 -3.49 2.37 1.68 1.49 
CGCRC304 0.05 1.23 2.03 1.19 -2.95 -1.01 -0.62 -1.81 -0.80 -1.89 1.46 -0.49 3.76 -2.02 -1.94 -0.80 -4.10 2.76 1.46 1.12 
CGCRC305 -0.51 0.28 0.15 -0.53 -1.53 -0.52 0.16 -0.57 -0.10 -2.89 -0.09 -1.28 -1.25 -0.82 -0.71 -1.40 -0.88 0.82 0.77 0.09 
CGCRC306 -1.33 -0.99 -0.57 -0.85 -1.51 -0.04 0.87 -0.20 1.19 -1.25 -1.28 0.14 0.07 0.25 0.43 -0.15 -0.34 -1.72 -1.55 -1.14 
CGCRC307 0.36 0.26 0.35 0.29 -1.14 -0.37 1.56 -0.39 0.73 -2.22 -0.25 -0.85 0.56 -1.02 -0.87 0.34 -0.53 0.56 0.41 -0.45 
CGCRC308 -1.45 -1.03 -0.11 -0.30 -2.31 -2.19 1.94 -1.29 1.23 -2.40 -2.35 0.69 1.15 -0.44 2.27 0.65 -1.38 -0.95 -0.06 -0.23 
CGCRC311 -0.48 0.75 0.97 -0.37 -1.21 -0.62 0.63 0.49 1.00 -0.27 0.09 1.06 -0.32 -0.74 2.00 0.29 0.31 0.84 -0.15 0.59 
CGCRC315 -0.97 -0.91 -1.48 -1.27 -4.08 -2.63 0.16 -1.80 0.58 -5.40 -0.74 0.46 -0.37 -0.75 -0.47 -1.84 -0.81 0.05 0.09 -1.32 
CGCRC316 -17.67 -10.90 9.05 0.74 -49.91 -24.51 -8.57 -10.51 11.54 -15.05 -3.79 -27.22 3.89 55.18 -49.45 36.06 20.38 11.90 33.86 -16.28 
CGCRC317 -3.34 -1.43 -0.82 -0.47 -3.99 -2.29 1.01 -1.36 0.30 -3.49 -1.26 0.01 3.95 0.40 8.64 14.60 -3.20 -0.24 0.99 -1.16 
CGCRC318 -1.99 -2.70 -1.10 -1.84 -3.82 -3.74 0.63 -1.51 2.50 -5.10 -2.28 -0.51 4.14 -1.62 -0.59 -1.35 -1.82 -0.24 0.03 -0.40 
CGCRC319 -1.60 0.24 0.03 -0.55 -3.81 -1.74 -0.04 -0.71 0.41 -3.65 0.13 0.01 3.66 0.59 -2.34 -0.67 -2.70 -0.30 1.45 -0.76 
CGCRC320 -1.14 -1.89 0.18 0.82 -3.74 -1.40 0.26 0.24 1.01 -1.73 -1.51 2.63 2.93 -1.92 0.18 -0.12 -2.63 1.36 0.66 -0.04 
CGCRC321 -1.64 -0.37 -0.14 -0.30 0.01 -1.03 1.49 -0.38 1.84 -0.91 -0.78 -0.05 0.60 0.85 -0.38 0.34 0.10 -0.38 -0.17 -0.25 
CGCRC333 -10.99 7.54 31.44 57.46 -109.86 -86.92 -10.67 -79.07 60.37 -64.37 15.86 75.31 -7.50 82.29 -79.21 176.22 -58.84 -69.05 -13.05 17.55 
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CGCRC336 -1.71 1.38 30.93 23.56 -19.48 -9.92 -16.06 -30.59 -17.64 -42.34 39.01 103.82 93.53 76.11 -15.78 27.73 3.97 6.93 68.25 -2.00 
CGCRC338 -21.29 9.04 27.36 30.26 -31.15 -28.63 -16.13 -28.70 -11.91 -38.27 -15.12 -35.38 49.64 41.37 12.65 57.75 -16.52 -24.11 13.68 -9.74 
CGCRC341 -2.63 -0.72 -1.69 -1.58 -3.63 -1.60 1.11 -1.27 1.41 -2.53 -1.87 0.01 3.10 0.65 0.50 -0.99 -0.38 -1.34 -0.38 -1.25 
CGCRC342 -22.85 -17.62 -22.09 -26.52 -27.22 -26.44 -33.61 -53.05 -5.40 -30.70 21.70 38.60 242.92 202.28 -150.81 98.92 44.48 61.88 14.05 16.66 
CGPLBR100 -1.08 -0.27 -1.04 -0.27 0.93 0.65 1.25 2.97 2.13 1.19 -0.91 1.12 0.05 2.58 1.49 0.62 1.94 -1.29 -0.85 -0.89 
CGPLBR101 -0.45 -1.07 -1.30 -0.53 -0.48 -1.11 1.49 0.81 1.82 -1.11 -1.83 0.05 0.84 0.83 0.37 0.50 0.87 -1.66 -0.87 -0.28 
CGPLBR102 -0.35 -0.60 -0.08 -0.27 -0.47 -0.12 0.76 0.32 1.26 -0.84 -0.54 0.67 0.88 0.26 1.29 2.80 1.14 0.36 -1.52 -0.60 
CGPLBR103 -0.15 -1.17 -1.07 -0.96 0.14 -0.98 0.93 0.92 1.58 -1.82 -1.90 -0.78 -0.59 -0.27 1.09 -0.14 2.14 -0.69 -1.56 -0.41 
CGPLBR104 -1.76 -0.02 -0.22 1.33 0.22 0.79 2.68 2.30 2.70 2.13 -1.80 3.50 2.07 1.76 2.55 3.17 1.45 -0.61 -1.50 0.18 
CGPLBR12 0.44 4.71 3.71 -0.12 -2.21 0.09 -2.94 0.28 -0.10 -3.04 2.94 2.37 -0.77 -0.71 -5.56 -2.08 -0.69 0.32 1.30 0.63 
CGPLBR18 1.24 1.31 0.86 -0.71 -1.29 0.19 -1.74 -1.04 -1.77 -2.69 2.21 -1.86 -0.31 -1.07 -1.67 -1.52 -1.43 0.93 0.71 -0.36 
CGPLBR23 0.04 0.45 0.93 -0.78 -0.91 -1.56 0.10 -1.23 0.09 -1.48 -0.10 -1.36 -0.98 -1.38 0.45 -1.17 -0.55 0.58 0.31 1.14 
CGPLBR24 -1.02 -0.45 -0.29 -0.79 -2.66 -0.64 0.02 -1.49 0.19 -2.49 -0.45 0.10 1.55 -0.59 -0.80 -0.28 -1.27 0.53 0.78 -0.42 
CGPLBR28 -0.80 0.34 -1.42 -0.82 -0.48 1.06 1.54 2.73 1.94 0.93 -1.05 1.08 -0.35 1.98 0.66 1.95 2.15 -2.36 -0.78 -1.10 
CGPLBR30 17.04 19.77 21.37 20.63 -50.27 21.81 -24.45 -25.93 53.83 -92.42 -12.81 -43.32 24.81 29.62 -46.58 150.52 -4.47 -9.73 9.12 -15.62 
CGPLBR31 0.56 0.98 -0.51 0.29 0.00 1.53 0.09 0.52 -0.54 0.10 0.36 0.94 -0.47 0.01 -1.04 0.26 -0.47 0.37 -0.38 -0.33 
CGPLBR32 -0.60 1.36 1.01 2.68 0.92 2.92 0.94 4.91 1.12 4.15 -0.28 5.45 0.62 1.78 1.01 3.65 0.95 -0.59 -0.72 0.58 
CGPLBR33 -0.52 0.65 -0.06 -0.59 0.12 -0.07 0.82 0.14 1.03 -1.10 -0.97 0.93 0.34 0.46 0.70 -0.04 0.91 -1.55 -1.36 0.06 
CGPLBR34 -0.01 1.16 1.00 0.56 -0.25 -0.09 0.57 0.39 0.11 -0.54 0.50 0.03 -0.62 0.26 -0.71 0.00 -0.86 -0.86 1.47 -0.02 
CGPLBR35 0.25 -0.04 -0.25 -0.83 -0.31 0.37 0.84 1.55 2.12 -1.79 -0.89 0.39 0.21 0.33 1.38 -0.01 0.83 -0.73 -0.19 -0.65 
CGPLBR36 -1.38 -1.10 -3.11 -4.53 -2.33 -2.39 -0.54 -1.10 1.90 -5.36 -2.28 -2.40 -1.67 -1.10 1.19 1.51 1.05 -2.07 -1.08 -2.13 
CGPLBR37 -0.76 -0.14 -0.24 -1.08 -0.53 0.22 0.26 0.56 0.88 -1.27 -0.17 0.93 0.11 0.56 -0.31 -0.24 0.04 -0.50 -0.76 -0.13 
CGPLBR38 1.12 1.55 1.34 0.21 -0.30 1.46 -0.53 0.46 -1.49 0.82 1.28 -0.02 1.74 -0.14 -1.84 0.54 -1.59 1.29 1.87 1.72 
CGPLBR40 -0.49 -1.20 -1.00 -0.35 -0.58 -1.04 1.63 1.45 3.30 -0.85 -2.25 -0.05 2.86 0.78 2.85 0.49 1.07 -0.33 -0.69 0.49 
CGPLBR41 -0.66 0.03 -0.36 -0.86 -1.49 -0.58 1.24 -0.43 1.40 -0.97 -1.05 -0.93 1.49 0.28 0.49 0.11 0.47 -1.52 -0.53 -0.30 
CGPLBR45 1.38 2.47 1.70 -0.27 -1.31 1.46 -1.88 -0.77 -0.99 -0.75 2.33 -1.34 -0.73 -0.46 -2.34 -0.99 -1.11 1.14 0.51 0.90 
CGPLBR46 -0.93 1.93 -0.99 0.49 0.52 1.76 0.59 2.51 1.01 1.35 -0.82 3.24 0.24 0.57 0.27 5.43 1.10 -0.78 0.29 -0.46 
CGPLBR47 0.71 2.23 1.84 1.36 -0.68 0.88 -1.19 0.82 -1.32 0.30 1.43 0.04 0.11 -1.67 0.12 0.68 -0.76 0.97 0.83 1.18 
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CGPLBR48 0.80 5.04 0.43 6.12 -0.71 7.96 -0.45 6.24 -3.09 10.19 1.15 12.92 3.72 3.24 -0.38 7.95 -0.34 1.33 2.56 0.73 
CGPLBR49 1.71 4.54 -0.98 5.51 -1.97 7.73 -2.30 6.63 -4.89 9.84 2.03 11.07 3.75 4.03 -1.71 4.71 -1.33 1.51 2.09 -1.05 
CGPLBR50 -0.75 -0.40 -0.84 -0.05 -0.47 -0.23 1.54 0.53 1.62 -1.44 -1.10 0.52 1.77 0.38 0.93 1.61 0.55 0.31 -0.86 -0.17 
CGPLBR51 1.13 2.07 0.42 0.53 0.93 1.33 1.20 0.19 -0.84 0.87 0.82 0.61 -2.34 -0.89 -1.13 2.72 -0.87 1.08 -0.82 0.56 
CGPLBR52 -0.54 -0.84 -2.45 -2.54 -1.46 -1.48 0.51 -5.05 1.55 -3.74 -1.90 -2.25 0.14 -1.27 -0.74 0.83 0.14 -1.41 -1.35 -1.43 
CGPLBR55 -0.54 2.24 -0.32 -0.29 0.44 -0.57 3.15 0.55 1.83 -0.18 -1.29 0.92 -0.16 1.19 0.52 2.15 1.28 -0.54 -0.83 0.47 
CGPLBR56 -0.37 0.66 0.05 0.11 -0.27 -0.61 -0.15 -1.29 0.24 -0.66 0.48 -0.91 0.27 -1.30 -2.06 0.33 -1.28 -0.01 0.29 0.31 
CGPLBR57 -0.68 -0.04 -1.00 -0.41 -0.35 -0.87 0.07 0.94 1.34 0.65 -1.50 0.26 -0.50 0.93 0.33 1.34 0.82 -1.07 0.22 -0.22 
CGPLBR59 0.19 0.18 -0.07 -0.70 -0.47 0.16 0.72 -0.85 0.43 -0.43 -0.31 -1.33 0.31 0.45 -1.61 0.67 0.11 -0.62 -0.49 0.46 
CGPLBR60 -0.32 0.73 0.28 1.59 0.73 -0.05 1.09 1.08 0.25 0.72 -0.53 0.84 -0.43 -0.01 1.53 1.39 1.14 -0.87 -1.21 0.28 
CGPLBR61 -0.09 0.88 0.52 0.63 -0.33 -0.35 0.28 -0.93 0.18 0.07 0.01 0.18 -1.40 -0.73 0.28 -0.37 -0.41 0.79 -0.47 0.49 
CGPLBR63 0.78 0.59 0.04 0.94 0.30 2.86 0.45 2.81 0.58 2.42 -0.55 3.15 0.79 1.23 0.29 2.68 1.21 -0.32 0.38 -0.39 
CGPLBR65 0.58 1.54 -0.59 1.00 -0.15 2.96 0.40 3.27 0.32 2.09 -0.37 2.70 0.02 2.05 0.70 2.00 1.04 0.16 0.55 -0.85 
CGPLBR68 1.38 2.13 2.11 0.53 0.69 0.02 -1.47 -2.01 -0.99 -0.52 2.73 -1.75 0.69 -2.68 -0.10 0.13 -2.00 2.49 1.06 2.41 
CGPLBR69 0.27 0.56 2.08 -0.51 -0.23 0.35 0.45 0.21 0.94 -0.62 -0.26 -0.37 1.04 -0.61 -0.03 0.89 -0.01 -0.38 -0.32 0.42 
CGPLBR70 -1.04 -0.87 -0.51 -0.77 -0.36 -1.29 1.31 0.77 2.21 -1.02 -0.94 0.27 1.16 0.05 1.01 0.24 1.16 -0.52 -0.58 0.13 
CGPLBR71 -1.06 0.37 -0.08 -0.51 0.49 0.68 1.55 1.11 1.69 0.16 -0.18 1.63 0.72 0.91 -0.29 1.58 0.18 -0.84 -1.38 -0.18 
CGPLBR72 -1.20 -0.49 -1.03 -1.88 -1.17 -1.68 -0.07 -0.89 0.99 -1.90 -0.82 -1.27 0.07 -0.01 0.26 -0.80 -0.18 -0.98 -0.78 -0.88 
CGPLBR73 0.21 -0.41 -0.75 -1.52 -1.15 -1.28 0.64 -0.64 0.68 -1.79 -0.35 -0.89 0.26 -1.68 0.60 1.26 0.02 0.13 -1.08 0.91 
CGPLBR76 -0.32 -1.39 -1.33 0.30 -0.44 0.24 1.81 2.26 2.00 -1.81 -2.13 0.93 1.81 1.36 2.87 2.07 1.98 -0.15 -0.04 0.26 
CGPLBR81 0.73 3.17 -0.25 4.93 0.97 6.20 0.41 7.32 -0.78 8.60 1.01 8.61 2.88 3.60 1.59 5.96 -0.12 0.83 1.12 0.90 
CGPLBR82 -0.21 0.57 0.48 1.78 -1.00 0.86 -0.06 0.77 -0.20 0.46 0.47 2.25 1.96 0.18 0.69 1.36 -2.10 1.05 1.77 0.43 
CGPLBR83 0.66 1.06 0.20 2.15 0.66 2.36 -0.20 2.52 -0.42 1.16 0.65 2.79 1.76 0.38 1.34 2.84 0.30 0.40 1.86 0.36 
CGPLBR84 1.39 2.34 -0.91 4.14 1.26 5.40 0.80 5.69 0.07 7.09 -0.29 7.01 2.43 3.19 1.21 7.04 1.98 0.02 -0.27 0.27 
CGPLBR87 1.47 2.50 -1.31 4.83 -0.82 5.43 -0.55 6.92 -2.13 8.22 0.40 9.23 1.81 3.80 3.19 6.73 0.31 1.30 1.74 0.54 
CGPLBR88 -2.25 0.28 -0.49 4.05 -2.17 2.55 0.63 5.78 1.05 4.70 -0.40 9.82 5.89 3.37 5.22 6.97 0.10 -0.21 2.42 0.65 
CGPLBR90 0.96 1.78 -0.68 3.72 -0.43 6.04 0.03 5.93 -0.89 7.21 0.52 9.34 1.91 3.84 0.56 4.26 1.86 0.11 2.06 0.43 
CGPLBR91 -0.06 0.34 0.40 -0.46 0.03 0.42 0.88 0.12 1.11 -0.27 -0.42 0.92 0.93 0.42 1.06 0.56 0.01 -0.04 0.02 0.48 
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CGPLBR92 -1.92 -1.03 -0.04 -1.69 -5.51 -4.59 -0.68 -4.02 0.44 -6.77 -0.09 -2.73 3.49 -2.36 0.61 -1.80 -4.10 0.07 3.89 0.46 
CGPLBR93 0.22 0.06 -0.13 -0.46 -0.10 -0.20 1.06 0.23 0.92 -1.31 -0.05 -1.26 1.67 0.38 -0.16 0.97 -0.91 0.06 0.68 0.36 
CGPLH189 0.87 0.62 1.69 0.70 0.95 0.35 -0.24 0.64 -0.04 0.40 0.42 0.11 0.64 -1.17 0.11 0.40 -0.03 1.33 -0.22 0.73 
CGPLH190 -0.59 -0.63 0.10 0.62 1.47 -0.04 0.98 0.44 2.06 -0.22 -0.96 0.14 1.31 -0.24 0.60 1.68 0.68 0.03 -0.62 0.36 
CGPLH192 0.56 0.58 0.44 0.52 -0.13 0.53 -0.55 0.81 -0.30 0.75 0.36 -0.70 0.27 0.38 -1.13 -0.12 -1.00 -0.22 -0.42 0.38 
CGPLH193 -0.35 -0.15 0.29 0.13 0.64 0.32 1.08 0.14 0.26 -0.63 -0.38 1.18 0.11 -0.39 -0.19 0.60 0.23 -0.40 -1.42 -1.32 
CGPLH194 1.45 2.35 3.16 3.03 -0.44 1.15 -1.62 -0.18 -1.32 1.10 2.11 0.54 1.54 -1.87 -0.13 0.29 -1.94 2.42 1.51 2.60 
CGPLH196 0.13 1.20 0.89 -0.72 0.45 -0.08 -0.27 -0.48 -0.44 0.12 0.92 -0.58 0.65 -1.78 -1.35 -0.36 -0.77 0.52 -0.11 0.46 
CGPLH197 -0.89 1.12 0.75 0.92 0.76 1.75 0.81 2.55 0.97 1.25 -0.60 2.31 0.33 2.43 0.24 1.48 1.35 -1.14 -1.13 -0.38 
CGPLH198 -0.57 0.28 0.72 -0.34 1.00 -1.25 0.25 -1.31 0.90 -0.61 0.55 -1.31 0.17 -1.31 0.38 0.00 -0.43 0.37 0.35 0.40 
CGPLH199 -0.39 -0.20 -1.74 -1.70 1.14 -0.86 1.00 -0.33 0.75 -0.76 0.03 -0.54 -3.50 -0.94 0.95 -0.13 0.38 -0.01 -1.17 -0.26 
CGPLH200 -0.97 -0.42 -0.96 -1.55 0.03 -0.61 0.80 0.24 0.63 -0.90 -0.96 -1.25 -0.52 1.19 0.28 -0.86 0.21 -0.82 -0.82 -1.06 
CGPLH201 -1.10 -0.69 -0.77 -1.00 -0.22 -0.42 1.21 0.91 0.81 -0.16 -0.97 -0.24 -2.02 0.74 5.42 0.30 1.28 -1.46 -2.08 -0.70 
CGPLH202 0.41 0.32 0.84 -0.19 0.13 0.62 -0.43 0.74 -0.04 0.39 0.22 -0.39 -0.34 -0.67 0.05 0.18 -0.32 -0.03 -0.30 0.91 
CGPLH203 1.54 1.76 0.77 0.99 -0.41 1.39 -0.70 0.78 -1.22 0.58 1.21 0.02 0.86 -1.78 -1.38 1.21 -1.31 1.23 -0.31 0.45 
CGPLH205 1.66 1.74 2.37 1.33 0.62 1.44 -1.40 -0.02 -1.52 0.65 2.19 0.20 1.08 -0.20 -1.79 0.42 -1.27 1.17 1.31 1.73 
CGPLH208 -0.23 0.21 0.06 0.29 1.86 -0.29 0.63 -0.08 0.68 -0.08 -0.36 0.21 1.23 0.39 1.01 0.41 -0.11 -0.65 -1.17 0.15 
CGPLH209 -0.70 -0.31 -0.36 -0.30 0.31 -0.52 1.25 -0.33 1.47 -0.08 -1.51 0.76 0.73 0.02 1.52 0.68 0.31 -0.22 -1.36 0.42 
CGPLH210 -0.02 -0.07 0.14 0.44 0.85 0.21 1.02 0.81 1.00 1.71 -0.82 0.05 1.92 0.33 1.67 1.22 0.73 0.56 -0.11 0.75 
CGPLH211 0.58 0.84 0.07 1.02 -0.08 1.34 -0.41 1.24 -0.43 0.85 0.23 0.49 0.62 0.23 0.09 0.61 -0.14 0.65 0.33 0.80 
CGPLH300 0.88 1.03 -0.11 -0.04 0.41 1.01 -0.15 1.24 0.80 1.85 0.13 0.81 -0.60 -0.15 0.60 0.01 -0.56 0.27 -0.95 0.40 
CGPLH307 0.35 1.03 0.01 0.54 -0.85 1.61 0.50 0.97 0.26 1.35 0.48 2.52 0.96 1.19 0.50 1.10 0.90 -0.03 -0.14 0.03 
CGPLH308 1.04 1.47 0.57 0.73 -0.33 0.72 0.32 0.95 0.25 0.12 1.06 0.06 -1.46 -0.53 -1.14 0.25 -0.06 0.25 -0.12 0.88 
CGPLH309 1.23 1.23 1.11 0.16 -0.46 0.13 -0.79 -0.04 -0.13 -0.89 1.10 0.12 -0.50 -0.36 -0.57 -0.12 -0.20 1.48 0.74 1.05 
CGPLH310 -0.54 -0.34 0.70 0.26 0.31 -1.10 1.97 1.17 1.68 -1.12 -0.88 -0.57 1.43 -0.30 0.25 0.86 -0.36 0.12 -0.12 0.86 
CGPLH311 -0.02 0.58 -0.33 -0.74 -0.63 -0.23 0.13 -0.12 0.59 -0.79 -0.48 -0.28 -0.46 0.06 -0.04 -0.73 0.75 -0.79 -0.44 -0.31 
CGPLH314 0.98 0.80 0.92 -0.63 -0.18 -0.76 -0.88 -1.86 -0.19 -2.07 1.08 -2.12 -0.89 -2.15 0.39 -0.65 -0.11 1.56 0.44 1.01 
CGPLH315 -0.84 -0.32 -0.21 -1.20 -1.39 -1.61 0.82 -1.84 0.36 -2.77 -0.48 -0.72 -0.64 -0.37 -1.38 -0.68 -0.98 0.13 -0.73 -1.11 
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CGPLH316 -0.41 0.58 0.94 -0.35 0.31 -1.05 -0.08 -2.53 0.55 -0.67 -0.07 -0.95 0.10 -2.28 -0.18 0.06 -0.82 0.81 -0.43 1.12 
CGPLH317 1.02 0.48 0.15 0.82 0.71 0.55 -0.05 1.18 1.25 -0.38 -0.81 0.95 0.52 0.14 1.34 1.53 0.51 0.58 -0.85 0.52 
CGPLH319 -0.38 0.29 -0.17 -0.41 0.85 0.22 1.16 1.69 1.63 0.23 -1.29 1.47 0.61 2.09 1.59 0.85 0.77 -0.56 -0.58 -0.16 
CGPLH320 0.23 0.37 -0.83 -0.20 -0.53 -0.19 0.51 -0.55 0.61 0.72 -0.14 -0.34 0.54 -0.34 0.42 0.38 0.18 -0.39 -1.27 -0.37 
CGPLH322 0.73 0.95 0.18 -0.24 -0.75 -0.16 -1.04 -0.80 -0.58 -0.89 1.19 -1.78 0.16 -1.05 -1.28 -0.16 -0.38 0.69 -0.15 1.40 
CGPLH324 0.59 0.48 0.32 -0.52 -0.38 -0.49 0.12 0.08 -0.08 -1.36 0.34 -1.17 0.36 -0.57 0.19 0.89 0.04 -0.68 0.60 0.99 
CGPLH325 -0.08 0.79 -0.74 -0.08 0.01 0.73 0.57 0.93 0.68 -0.66 0.51 0.60 0.33 0.75 1.09 0.33 -0.48 -1.14 -0.41 -0.12 
CGPLH326 -0.16 0.66 0.86 0.57 -1.09 0.24 0.31 0.99 -0.33 -0.98 0.56 -0.31 -0.71 -0.74 0.33 1.29 -0.97 1.10 -0.05 0.36 
CGPLH327 -0.35 0.23 -0.57 -0.51 -0.40 -0.28 0.67 0.62 0.56 -1.30 -1.12 0.81 -0.04 0.63 0.28 -0.02 0.56 -1.56 -1.19 -0.37 
CGPLH328 -1.48 0.24 -0.93 -1.03 -0.53 -0.22 1.21 0.88 1.87 -1.49 -1.60 0.16 -0.47 1.29 -1.04 0.23 -0.60 -1.70 -1.43 -1.28 
CGPLH329 0.65 1.73 0.55 0.59 -0.92 0.87 -0.25 0.67 -0.07 0.34 0.33 0.85 1.13 -0.16 -0.45 0.07 0.07 0.80 -0.24 0.05 
CGPLH330 0.01 0.29 -0.25 -1.33 -0.60 -0.03 0.40 0.92 0.10 -1.54 -0.81 0.36 0.74 0.61 -0.24 -0.80 -0.05 -0.25 -0.57 -1.62 
CGPLH331 0.43 1.03 -0.18 -1.05 -2.32 -0.78 -0.47 -0.65 -0.96 -1.59 0.08 -1.04 -1.01 -0.16 -0.69 -1.17 -0.39 -1.12 0.58 -0.63 
CGPLH333 0.74 -0.01 -0.25 0.10 -0.01 0.88 0.28 1.75 0.75 -1.25 -0.89 0.46 -1.53 0.02 -0.86 0.63 0.98 -0.09 -0.77 0.51 
CGPLH335 0.09 0.75 -0.48 0.00 0.05 0.55 -0.45 0.33 0.12 0.19 -0.41 0.69 -0.41 0.18 -0.30 -0.04 0.01 0.56 -0.34 0.30 
CGPLH336 0.52 -0.49 -0.57 -0.38 -0.06 0.79 0.46 1.54 0.51 -0.35 -0.58 -0.10 -0.67 0.96 0.21 0.34 1.36 -0.92 -1.41 -0.31 
CGPLH337 0.75 1.49 0.65 0.44 -0.11 0.94 -0.76 1.38 -0.84 -0.25 0.64 -0.16 -0.11 -0.48 -0.32 0.29 0.16 0.43 0.15 0.61 
CGPLH338 -0.69 1.08 0.49 0.37 -0.23 -0.40 1.79 -0.12 1.10 0.34 -0.15 0.17 1.10 -1.33 1.31 0.81 -0.67 0.20 -1.41 0.26 
CGPLH339 1.33 1.10 0.71 0.28 0.50 1.20 -0.34 0.43 0.02 0.08 0.25 0.23 -1.88 -0.27 -0.27 1.20 -0.45 -0.66 -0.49 -0.04 
CGPLH340 0.26 0.95 0.30 0.17 0.64 1.61 0.63 -0.19 0.30 -0.55 0.13 0.19 -0.98 -0.51 -1.25 -0.58 -0.55 -0.08 -0.92 -0.51 
CGPLH341 -0.60 -0.81 -1.38 -0.73 0.64 1.41 2.31 2.99 2.15 0.15 -1.62 2.03 -0.12 1.48 2.11 1.33 1.62 -2.79 -1.52 -0.77 
CGPLH342 -0.58 0.60 0.00 -0.45 0.44 -0.71 0.61 -0.16 1.40 -0.36 -1.10 0.19 0.03 0.10 0.18 -0.65 0.19 -0.19 -1.49 0.18 
CGPLH343 -0.15 0.27 -1.01 -1.54 -2.05 -0.70 -0.54 -0.14 -0.03 -2.57 -0.11 -1.77 -1.10 -1.97 0.00 -0.48 1.00 -0.87 -0.26 -0.63 
CGPLH344 1.14 0.83 -0.02 0.17 -0.66 -0.70 0.18 0.96 1.17 1.52 -0.80 0.74 1.11 -0.96 1.51 1.09 0.86 0.16 0.15 0.88 
CGPLH345 1.87 -0.10 -1.35 -0.44 -1.75 -0.55 -0.08 1.46 0.39 -1.80 -0.49 0.03 -0.98 -0.93 0.22 0.45 0.31 -0.47 -1.35 0.62 
CGPLH346 0.90 1.12 -0.41 -0.31 -0.51 0.70 0.23 1.09 0.50 -0.80 0.20 -0.26 -1.35 0.51 -0.31 0.53 0.40 -0.65 -0.20 -0.22 
CGPLH350 0.69 -0.05 -0.50 0.41 -2.41 -0.52 0.47 0.49 -0.30 -0.86 -1.42 -0.94 0.65 -1.98 1.18 0.98 -0.64 1.50 -0.10 1.41 
CGPLH351 -0.45 -0.68 -1.49 -1.69 -2.28 -1.69 -0.42 0.03 0.48 -3.05 -1.14 -0.76 -0.19 0.67 -0.05 -1.22 -0.47 -0.45 -0.56 -1.20 
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CGPLH352 0.78 0.59 1.32 -1.30 -1.66 -0.62 -0.76 -1.15 0.32 -2.36 0.24 -1.02 -1.96 -1.60 -0.64 -1.82 0.19 0.58 0.54 0.89 
CGPLH353 2.01 1.85 0.60 0.64 -0.19 1.71 -0.76 1.33 -0.90 0.09 1.42 0.47 -1.48 -0.91 -0.98 -0.42 -0.04 0.36 -0.01 0.80 
CGPLH354 0.56 0.41 0.18 -1.33 0.04 -1.21 0.39 -0.80 0.86 -0.81 -0.51 -0.93 -0.99 -0.20 1.30 -0.91 -0.63 0.30 -0.62 -0.14 
CGPLH355 0.73 2.65 0.68 0.20 -1.15 2.57 -0.67 0.82 -1.20 1.77 1.12 1.71 0.13 -0.20 -0.96 0.10 0.29 -0.27 -0.28 -0.39 
CGPLH356 4.03 3.94 2.87 1.73 -0.29 3.89 -2.66 0.47 -3.08 0.65 3.96 0.63 -0.05 -1.31 -1.43 0.05 -1.90 2.35 1.29 2.16 
CGPLH357 -1.07 -0.04 -0.95 -1.70 -2.96 -2.13 0.86 -0.07 0.65 -2.28 -1.38 -0.99 -0.17 0.02 0.06 -1.27 0.38 -1.11 -0.71 -1.31 
CGPLH358 -0.33 0.45 1.15 0.26 -1.53 -0.09 0.52 1.15 0.43 -1.41 -0.01 1.31 1.62 -0.02 1.32 0.57 -0.54 0.33 0.48 -0.02 
CGPLH360 1.17 0.19 0.29 0.28 -0.10 1.25 -0.16 0.56 0.12 0.03 -0.08 -0.13 -0.21 -0.35 0.35 -0.52 1.05 -0.14 -0.85 -0.17 
CGPLH361 0.86 0.42 0.13 -0.24 -1.47 -0.26 -1.13 0.29 -0.40 -2.03 0.32 -0.36 0.85 -0.97 -0.74 -0.86 -0.69 1.37 -0.81 0.67 
CGPLH362 -0.69 -0.36 -0.16 -0.04 -1.62 -0.15 0.53 0.63 0.85 -2.08 -0.94 1.11 0.87 0.10 -0.25 -0.44 -0.42 -0.36 0.12 -0.60 
CGPLH363 0.00 -0.71 0.63 0.40 1.06 0.01 1.03 0.71 1.94 -0.69 -0.60 0.67 1.35 0.12 0.61 0.55 0.08 -0.52 -2.09 0.28 
CGPLH364 -1.59 -1.29 -0.51 -0.42 -1.18 -2.23 0.92 0.24 1.51 -2.20 -1.85 0.05 1.30 0.29 0.69 -0.24 -0.43 -0.44 0.28 -0.40 
CGPLH365 1.04 2.04 1.18 2.28 -0.86 3.92 -1.17 3.29 0.04 1.48 1.43 3.40 0.81 1.05 -1.40 1.80 0.16 0.26 0.70 0.91 
CGPLH366 1.02 1.46 1.33 1.29 -0.61 0.42 -0.30 0.45 0.39 0.71 1.14 1.36 0.83 -0.70 -0.21 -0.15 -0.53 1.24 0.43 1.35 
CGPLH367 0.07 -0.36 -0.15 -0.28 -1.19 -0.70 1.37 -1.04 1.18 -1.50 -0.88 -0.64 -1.02 -1.87 -0.10 0.14 -0.33 -0.99 -0.94 0.34 
CGPLH368 0.33 0.53 -0.56 -0.05 -0.88 -0.50 0.88 1.34 1.19 0.06 -0.10 1.16 -1.14 0.01 0.35 0.73 0.34 0.17 -0.62 0.33 
CGPLH369 -1.20 -0.47 -0.53 -0.20 -1.42 -1.35 1.67 -0.84 0.72 -2.41 -1.08 -0.44 1.08 -1.34 0.78 -0.23 -0.83 -0.07 -0.83 -0.24 
CGPLH370 0.15 0.17 -0.11 -0.53 0.21 -0.95 1.48 -1.38 1.07 -1.10 -0.24 -0.11 1.14 -1.47 -0.35 0.37 -0.51 0.13 -0.87 1.10 
CGPLH371 0.20 0.18 0.82 -0.26 0.51 -0.59 0.63 -0.56 1.53 0.41 -0.56 0.66 0.92 -0.85 1.52 0.84 -0.05 0.60 -0.79 0.56 
CGPLH380 0.63 -0.04 0.29 -1.63 -3.28 -0.58 -1.23 -0.16 -0.31 -3.32 -0.47 -1.23 -1.31 0.01 -0.75 -2.26 -0.82 -0.21 1.07 -0.50 
CGPLH381 -1.10 -1.02 -0.31 -1.16 -2.26 -1.41 0.14 -0.15 1.02 -4.35 -1.67 -0.02 0.65 0.74 1.15 -0.57 -0.31 -0.34 -0.23 -0.57 
CGPLH382 -0.61 -0.04 -0.36 -0.56 -1.43 -0.29 -0.10 1.14 0.74 -4.25 -1.00 0.17 0.08 0.00 -1.52 -0.30 0.09 -0.25 -0.01 -0.42 
CGPLH383 1.65 1.12 0.78 -1.44 -3.48 -2.08 -2.32 -1.69 -0.96 -3.70 0.84 -3.26 -0.76 -2.43 -0.88 -2.98 -2.56 0.39 1.32 0.43 
CGPLH384 1.50 1.36 0.84 0.70 -0.94 1.43 -0.11 1.06 -0.33 0.48 0.68 0.06 -0.51 -0.62 -0.98 1.14 -0.21 0.88 -0.35 0.82 
CGPLH385 0.40 0.02 -0.64 -0.48 -0.76 -0.83 -0.52 0.18 0.14 -2.06 0.12 -0.56 -1.22 -1.44 -0.09 -1.74 -1.12 0.68 -0.35 -0.40 
CGPLH386 0.91 0.99 0.76 0.14 -0.97 0.57 0.45 1.77 0.72 0.04 -0.26 0.69 0.32 -0.02 0.46 1.70 0.09 0.03 -0.41 0.91 
CGPLH387 1.17 -0.09 -0.61 -0.76 -0.57 -0.24 0.39 0.75 0.97 -1.35 -0.94 0.16 -1.38 0.08 2.11 0.87 0.54 -0.36 -0.82 0.12 
CGPLH388 1.51 1.68 1.39 -0.52 -0.84 0.43 -1.52 -0.76 -1.20 -1.33 1.74 -0.75 0.36 -0.73 -1.34 -2.00 -0.87 0.18 1.60 -0.69 
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CGPLH389 -0.76 0.21 0.37 -0.59 -0.56 -0.70 2.14 0.89 2.11 -0.38 -1.46 0.49 -1.07 2.35 1.08 0.36 1.14 -2.23 -1.00 -0.53 
CGPLH390 1.48 1.42 0.49 -0.02 -1.32 -2.12 -1.92 -3.25 -0.92 -2.68 1.00 -1.79 1.31 -3.36 -0.95 -0.78 -2.58 1.37 0.47 0.68 
CGPLH391 -1.23 0.36 -0.25 -0.52 -0.84 -0.15 1.03 1.75 2.36 -0.20 -0.81 0.44 -1.03 1.05 0.13 0.58 0.88 -1.67 -1.87 -1.03 
CGPLH392 -0.13 0.33 -0.35 0.29 -0.71 2.31 0.33 3.25 0.40 0.30 -0.27 2.31 1.02 1.51 -0.07 -0.07 0.68 -0.85 -0.40 -1.17 
CGPLH393 1.76 1.09 0.93 -0.52 0.11 0.19 -0.35 -0.10 -0.08 0.19 0.32 -0.99 -1.88 -0.11 0.08 -0.25 -0.35 0.38 0.31 0.96 
CGPLH394 1.38 2.02 0.71 0.13 -1.41 1.32 -0.76 0.49 -1.06 0.24 1.28 -0.49 -0.19 -0.13 -0.64 -0.24 -0.59 0.85 -0.09 0.22 
CGPLH395 -0.03 0.60 -0.24 -1.51 -1.94 -0.56 0.42 -0.02 0.73 -1.52 -0.28 -0.78 -1.12 -0.02 -1.74 -0.95 -0.52 -0.76 -0.73 -0.64 
CGPLH396 0.39 0.71 0.40 0.47 -0.79 -0.63 0.47 1.42 0.90 -0.30 -0.36 0.91 -0.84 -0.63 1.02 0.34 0.42 -0.29 0.22 0.54 
CGPLH398 -0.36 0.21 -0.31 0.19 -0.16 -1.15 1.90 -0.51 1.57 -1.59 -0.97 -0.13 1.10 -1.16 0.11 1.48 -1.51 0.53 -1.04 0.53 
CGPLH399 0.25 0.62 0.54 0.27 -0.63 1.66 0.72 2.76 0.90 -0.69 -0.34 1.25 0.02 1.91 -0.13 0.87 0.57 -1.33 0.00 -0.31 
CGPLH400 4.06 3.28 2.01 1.77 -1.72 2.15 -2.47 0.85 -2.20 0.61 2.91 0.07 0.49 -3.61 -1.45 -0.06 -1.91 2.34 2.35 1.51 
CGPLH401 0.10 0.74 0.85 -0.62 -1.34 -1.38 -0.05 -1.63 -0.02 -2.08 0.14 -1.21 0.11 -1.50 -0.09 0.44 -1.89 0.48 -0.33 1.50 
CGPLH402 1.26 1.33 0.03 -1.33 -2.98 -0.68 -1.00 0.32 -0.60 -1.44 0.20 -0.56 -2.25 -0.32 -0.93 -0.19 -0.34 -0.98 -0.22 -1.33 
CGPLH403 0.28 1.34 0.24 -2.31 -4.15 -0.76 -0.98 -0.31 -0.07 -3.94 -0.22 -1.87 -2.12 -0.47 2.48 3.41 -0.14 -1.05 -0.49 -0.47 
CGPLH404 -0.20 0.72 -0.72 -0.85 -1.89 0.52 -0.32 1.61 1.36 -1.98 -1.03 -0.05 0.40 1.92 0.47 -0.33 0.52 -1.36 -1.52 -1.14 
CGPLH405 0.39 2.44 0.35 0.34 -1.58 0.90 -0.16 0.57 -0.29 0.51 0.68 0.69 -0.75 0.27 -1.44 0.29 -1.27 -1.00 -0.21 0.55 
CGPLH406 0.26 1.79 -0.19 -1.67 -1.78 0.60 -0.86 0.81 0.32 -0.59 -0.73 -0.36 1.61 1.14 -1.28 -0.98 -0.92 -1.30 -1.62 -1.01 
CGPLH407 1.76 1.14 1.19 -0.19 -1.37 0.51 0.31 1.07 -0.42 -0.92 0.25 -0.39 -0.67 0.42 -0.69 -0.19 -0.69 0.20 -0.55 -0.33 
CGPLH408 -0.15 -0.20 -0.94 -2.68 -1.02 -2.09 0.58 -1.60 0.57 -3.06 -1.03 -2.36 -0.90 -0.52 -0.51 -1.97 0.86 -0.46 -1.26 -0.38 
CGPLH409 1.14 1.20 0.57 -1.24 -1.33 0.18 -0.92 -0.11 -0.42 -0.84 0.50 -2.07 -0.83 0.36 -1.12 -0.69 -0.66 -0.57 0.50 0.02 
CGPLH410 0.91 1.45 0.30 -0.83 -0.97 -0.22 -0.09 0.24 0.06 -1.55 -0.77 0.23 0.32 -0.60 -0.73 0.00 -0.08 -0.26 -0.41 -1.06 
CGPLH411 -0.17 0.40 -0.24 -1.37 -2.10 -0.53 -0.02 1.13 1.23 -1.69 -0.85 0.20 -0.34 0.60 0.79 0.37 0.96 -1.64 -1.56 -0.44 
CGPLH412 0.25 1.44 -0.24 -0.69 -1.54 0.21 0.05 0.01 -0.27 -1.14 -0.61 -0.34 -1.82 0.23 -0.25 -0.83 -0.28 -1.20 -0.52 -0.97 
CGPLH413 -0.43 0.00 -1.47 -1.97 -2.25 -0.36 0.85 -0.92 1.08 -1.92 -1.81 0.26 -1.85 -0.64 0.50 -0.27 0.38 -0.61 -2.28 -1.35 
CGPLH414 0.75 0.42 0.28 0.14 -1.86 0.36 0.43 0.08 0.07 -0.57 -0.77 0.12 0.27 0.65 0.66 0.33 -0.35 -0.14 -0.40 -0.17 
CGPLH415 0.50 0.75 -0.34 -1.35 -2.31 0.18 0.04 0.63 0.92 -1.73 -1.41 -0.60 -2.30 0.31 0.75 -0.96 -0.08 -0.54 -1.01 -0.11 
CGPLH416 1.98 3.55 1.88 1.25 -1.14 1.51 -3.41 2.40 -2.70 -0.28 2.36 -0.07 -0.86 -1.42 -1.38 0.35 -2.46 1.26 1.26 1.28 
CGPLH417 2.06 3.57 1.93 0.74 -2.34 2.41 -2.09 0.33 -2.49 0.90 2.47 1.24 -1.38 -1.57 -1.32 -0.09 -2.02 0.99 -0.39 1.08 
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CGPLH418 0.75 1.42 0.70 0.53 -1.51 0.74 -1.28 1.13 0.48 -0.61 -0.18 0.46 -0.73 0.64 -0.51 -0.07 -0.50 -0.09 -0.25 0.82 
CGPLH419 0.91 1.12 0.27 -0.03 -1.95 0.44 -0.41 0.46 -0.24 -1.38 0.44 1.06 -1.51 -0.56 0.24 0.23 0.19 0.23 0.26 0.23 
CGPLH420 0.82 0.24 -0.77 -0.58 -0.49 -0.08 0.35 0.44 0.67 -0.57 -0.84 -0.33 -0.46 0.31 0.33 0.85 0.44 0.12 -1.03 0.63 
CGPLH422 1.49 2.05 1.24 -0.01 -1.02 1.65 -1.79 -0.45 -1.47 -0.28 1.84 -0.48 -0.95 -0.78 -1.83 -1.80 -0.69 -0.30 1.03 0.47 
CGPLH423 1.47 0.67 0.07 -0.66 -1.81 0.58 -0.88 0.49 -1.09 -1.64 0.53 -0.56 -1.79 0.13 -0.70 -1.17 -0.82 -0.53 0.92 -0.18 
CGPLH424 -0.51 0.44 -0.75 -1.51 -1.75 -0.18 -0.41 -0.31 -0.09 -2.13 -0.31 -0.31 -1.32 0.38 0.26 -1.93 -0.09 -1.90 -0.07 -0.97 
CGPLH425 0.54 0.96 0.52 -0.10 -0.64 0.57 -0.63 0.11 0.02 -1.16 0.45 -0.38 0.40 0.16 0.14 -0.79 -0.82 -0.10 0.59 -0.07 
CGPLH426 0.67 1.38 0.20 0.26 -0.76 0.34 0.15 0.87 -0.34 -0.20 0.37 0.08 -1.43 -0.61 -0.01 -0.58 -0.23 -0.26 0.35 0.62 
CGPLH427 0.51 1.41 0.12 -0.03 0.14 0.18 -0.30 1.08 0.03 -0.29 -0.12 0.15 -1.50 0.35 0.00 -0.61 -0.06 -0.58 -1.05 -0.56 
CGPLH428 0.80 0.46 -0.30 -0.13 -0.06 -0.56 0.05 0.08 -0.02 -0.62 -0.42 0.32 -0.58 -0.62 0.00 -0.35 0.12 -0.24 -0.41 -0.44 
CGPLH429 1.51 2.10 1.56 1.27 0.23 2.80 -1.06 2.01 -0.09 1.73 1.18 1.66 0.84 0.02 -0.63 2.02 -0.36 -0.07 1.87 1.72 
CGPLH430 -0.48 0.56 0.23 -0.67 -0.85 -0.40 -0.24 0.36 -0.30 -0.69 -0.16 1.17 0.54 -0.24 0.92 -0.86 -0.32 -0.40 0.15 0.00 
CGPLH431 0.75 1.05 -0.32 -0.52 -1.76 0.43 -1.25 -0.77 -0.56 -1.03 0.77 -0.55 -1.21 -0.94 -1.42 -1.23 -1.41 -0.60 0.15 -0.40 
CGPLH432 1.30 0.90 -0.63 -0.34 0.09 0.56 -0.76 2.35 0.03 0.78 -0.13 0.62 0.03 1.00 -1.45 0.12 0.32 -0.79 -0.88 -0.48 
CGPLH434 0.68 0.85 0.23 -0.03 -0.82 -0.30 -0.92 -0.20 -0.08 0.01 -0.16 -0.51 0.15 -0.99 -0.80 0.15 -0.88 -0.29 0.08 0.02 
CGPLH435 0.22 0.26 -0.20 -0.53 -1.86 -1.19 0.42 -0.09 0.76 -2.55 -0.48 -1.14 1.31 -2.07 0.66 -0.13 -1.73 0.16 -0.45 0.94 
CGPLH436 -0.06 0.11 -0.53 -0.58 0.10 0.44 0.86 1.67 0.30 0.47 -0.82 0.90 -1.18 1.44 0.24 -0.17 1.06 -1.18 -0.34 -0.63 
CGPLH437 0.00 0.48 -0.04 -0.97 -0.56 -0.01 0.46 -0.81 0.54 -1.75 -0.90 -0.95 -1.44 -0.58 0.24 -0.70 -0.49 -0.95 -0.65 -0.08 
CGPLH438 0.19 -0.02 -0.56 0.07 -0.29 -0.01 0.75 1.38 0.96 -0.42 -1.13 0.81 0.03 0.70 -0.40 0.13 1.15 -0.47 -1.07 -0.54 
CGPLH439 1.01 -0.70 -1.26 -1.06 -0.91 0.76 0.74 2.43 1.29 -2.18 -1.68 0.45 -1.57 1.47 -0.15 -0.28 2.17 -0.92 -0.86 -0.48 
CGPLH440 0.65 1.15 0.59 -0.25 -1.87 1.21 -0.52 0.87 -0.31 0.46 -0.57 0.36 -0.49 0.74 0.36 -0.33 0.10 -1.20 -0.37 -0.12 
CGPLH441 0.79 -0.03 -1.18 -0.63 -1.07 0.31 -0.31 0.84 0.06 -1.16 -0.29 0.60 0.37 0.50 -0.54 -0.48 0.55 -0.45 -0.64 -0.55 
CGPLH442 0.99 1.62 0.10 0.16 -1.13 1.04 -0.55 -0.33 -0.88 -0.73 0.78 -0.47 -1.76 0.02 -1.89 0.08 -1.70 -0.15 0.23 -0.02 
CGPLH443 0.57 0.85 1.84 0.67 0.06 0.61 0.18 2.62 0.30 0.87 -0.20 1.79 0.96 2.10 0.58 -0.49 0.39 -0.17 0.42 1.32 
CGPLH444 1.29 1.69 1.00 -0.44 -2.29 0.34 -1.59 1.01 -1.35 -1.06 0.91 -0.65 -1.65 -0.96 -0.47 -1.70 -1.08 0.08 1.72 0.99 
CGPLH445 0.33 0.71 -0.40 -0.27 -1.70 1.42 -0.18 1.42 0.58 0.18 -0.70 0.77 0.08 0.57 0.56 0.28 0.82 -1.28 -0.16 0.18 
CGPLH446 1.50 1.32 1.56 0.33 -0.56 0.19 -1.60 1.21 -0.18 -0.35 1.06 0.48 -0.50 0.03 -0.55 0.15 -0.45 0.26 1.33 0.17 
CGPLH447 1.20 0.66 -0.55 -0.32 -1.35 0.49 -0.53 1.13 0.09 -0.98 -0.74 -0.09 -1.60 0.45 -0.15 -0.11 2.74 -0.05 0.15 -0.80 
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CGPLH448 -0.03 0.64 -0.05 -1.29 -1.75 0.74 0.68 0.60 0.61 -1.32 -0.22 0.09 -1.34 1.25 -0.04 -0.94 0.69 -0.97 -0.06 -0.49 
CGPLH449 2.09 1.10 1.38 -0.13 -2.59 0.71 -1.48 0.41 -2.02 -0.94 1.51 -0.82 -0.66 -1.49 -0.46 -1.95 -1.61 1.39 1.09 0.59 
CGPLH450 0.05 0.76 0.11 -1.21 -2.50 -0.48 -0.59 -0.68 -0.13 -1.42 -0.67 -1.65 -1.14 0.25 -1.12 -0.83 -0.22 -0.96 -0.67 -0.55 
CGPLH451 1.43 0.78 0.74 -0.36 -1.74 1.04 -0.83 1.17 -0.58 -1.50 0.03 -0.78 -1.65 -0.90 -0.67 -0.16 -0.08 0.63 0.93 1.00 
CGPLH452 0.29 1.35 1.20 0.57 -1.08 0.88 -0.38 2.38 -0.01 2.40 -0.06 1.42 -0.43 0.66 -1.19 0.84 0.54 -1.11 0.44 -0.40 
CGPLH453 0.26 0.90 0.63 -1.12 -2.14 -0.65 -0.56 -1.75 -0.72 -2.43 1.20 -1.99 -1.73 -1.39 0.24 -0.66 -1.45 0.96 0.61 0.11 
CGPLH455 1.22 1.89 0.91 0.65 0.32 2.26 -0.75 0.87 -1.13 2.00 0.82 1.26 0.49 1.49 -1.62 1.44 -1.69 -0.70 -0.58 -0.61 
CGPLH456 1.11 -0.20 -0.81 -1.24 -1.93 0.41 0.12 2.26 -0.09 -1.18 -1.20 0.78 -1.21 1.03 0.34 -0.22 1.41 -1.34 -0.63 -1.25 
CGPLH457 0.42 0.19 -0.57 -0.86 -1.06 -0.19 -0.37 1.09 1.82 -0.55 -0.97 0.66 -1.34 0.23 -0.20 -0.46 1.14 -1.36 0.72 -0.67 
CGPLH458 1.45 2.02 1.44 1.86 -0.53 3.01 -1.21 2.54 -1.19 0.75 1.08 2.56 -1.70 0.17 -2.46 0.59 -0.38 0.15 0.69 0.35 
CGPLH459 0.39 1.37 0.83 0.11 -1.90 -0.17 -0.64 0.89 -0.66 -0.34 0.74 0.18 0.20 -0.21 0.08 -0.74 -0.37 0.56 1.01 0.30 
CGPLH460 0.19 0.24 -0.55 -2.10 -2.84 -1.19 -0.31 -0.49 -0.16 -3.54 -0.37 -1.29 0.06 -1.10 -0.71 -2.89 -0.71 -1.08 -0.60 -0.79 
CGPLH463 -0.43 -0.06 -0.68 -1.57 -1.26 0.33 -0.36 -0.90 0.79 -1.34 -0.05 -1.11 -1.77 -0.79 -0.35 -1.44 0.45 0.14 -0.65 -0.70 
CGPLH464 1.22 0.44 -0.73 0.27 -1.47 0.26 0.44 3.48 0.23 -0.82 -0.39 0.26 0.37 1.20 -0.14 -0.09 0.53 -0.87 0.37 -0.18 
CGPLH465 1.44 0.42 0.25 -0.27 -0.51 0.09 0.01 1.04 0.01 -0.74 -0.59 -0.03 -2.46 -0.97 -0.47 -0.12 0.81 0.15 0.12 0.16 
CGPLH466 0.74 0.62 -0.44 -1.61 -0.63 -0.20 -0.48 -1.66 -0.49 -0.93 0.85 -1.03 -1.31 -1.73 -1.02 -2.23 -0.91 -0.29 0.69 -1.02 
CGPLH467 0.53 0.87 -0.11 0.99 0.11 1.55 0.09 2.26 0.60 0.75 -0.30 1.38 -0.63 1.40 1.50 1.26 0.14 -0.67 -0.51 -0.21 
CGPLH468 -0.93 -0.18 -0.63 -0.70 -0.95 -0.25 1.10 1.60 1.48 -1.00 -0.92 0.34 0.07 0.35 0.78 0.02 1.09 -0.62 0.05 -1.18 
CGPLH469 1.26 0.91 -0.46 0.83 -0.58 1.12 0.15 3.49 0.59 0.64 -0.61 2.77 -0.40 1.92 0.73 1.78 0.96 -0.93 0.18 -0.29 
CGPLH470 -0.20 0.47 -0.11 -1.08 -0.07 0.10 0.70 -0.77 0.65 -1.93 -0.45 -0.63 -0.51 -0.52 0.10 0.44 -0.36 0.23 -0.86 -0.03 
CGPLH471 -0.35 0.76 -0.70 -0.97 -1.70 -0.76 0.84 -0.84 0.08 -0.82 -0.01 -0.29 -0.96 -0.61 -0.32 -0.16 -1.12 -0.59 0.16 -0.61 
CGPLH472 -1.55 0.44 -0.07 -1.28 -0.36 0.09 1.41 1.13 2.29 -1.12 -0.55 0.08 -0.14 0.48 -0.44 0.63 -0.09 -1.44 -0.17 -1.20 
CGPLH473 -0.78 -0.05 -0.24 -0.91 -1.24 0.37 1.00 2.46 0.64 0.38 -1.29 1.19 -0.43 0.93 0.03 0.28 1.49 -2.04 -1.05 -1.30 
CGPLH474 -1.34 -0.62 -0.65 -0.27 -2.31 -1.70 1.30 0.34 1.70 -1.65 -1.77 1.04 0.06 0.37 1.34 0.21 -0.46 -0.29 -0.39 0.12 
CGPLH475 0.08 0.82 -1.40 -0.77 -1.50 0.53 -0.12 1.27 0.52 -0.69 -0.61 0.79 -1.43 1.25 0.17 0.43 0.40 -0.73 -0.32 -0.51 
CGPLH476 -0.24 0.54 -1.13 -0.92 -1.27 0.35 0.87 0.89 1.34 -0.13 -1.70 0.39 -0.31 2.07 0.02 -0.13 1.55 -0.31 -0.58 -0.64 
CGPLH477 1.64 1.33 1.38 0.45 -0.83 0.37 -0.32 0.28 -1.34 -1.36 1.12 -0.33 -1.09 -0.51 -0.12 -0.92 -0.77 0.86 0.49 0.52 
CGPLH478 -0.30 -0.15 0.95 -0.24 1.97 -0.20 0.62 -0.26 1.09 -0.59 -1.02 0.14 0.89 0.72 0.31 0.32 -0.15 0.34 0.90 0.96 
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CGPLH479 1.93 1.62 0.76 0.47 -0.68 1.64 -1.57 0.43 -0.78 -0.38 1.20 0.04 0.03 -0.65 -1.62 -0.12 -1.23 0.79 1.11 0.93 
CGPLH480 0.54 0.87 0.99 0.48 -1.31 0.82 1.19 2.32 1.79 0.39 -0.77 0.32 1.06 1.80 0.46 2.22 0.22 -0.50 0.37 0.87 
CGPLH481 0.31 0.53 0.15 -0.75 -1.84 -0.23 -0.54 1.74 0.31 -0.81 -0.24 0.27 -2.06 -0.35 0.32 -0.38 0.14 -0.57 0.24 -0.06 
CGPLH482 0.31 0.34 -0.13 0.04 -1.56 -0.68 0.45 0.11 0.37 -0.72 -0.77 -0.47 0.05 -0.21 -0.32 -0.34 -1.18 0.01 -1.22 -0.03 
CGPLH483 -0.20 0.54 -0.33 -1.70 -1.48 -0.17 0.38 -0.07 1.08 -0.27 -1.10 0.90 -0.61 1.01 -0.44 -1.47 0.20 -1.16 -1.04 -0.97 
CGPLH484 0.63 -0.17 -0.42 -1.67 -0.98 -0.62 -0.19 -0.33 0.47 -2.07 -0.36 -1.39 -0.52 0.05 -0.61 -1.24 -0.19 -0.75 -0.13 -0.37 
CGPLH485 -0.63 -0.04 -0.86 -1.47 -1.71 0.38 0.23 1.19 1.09 -1.53 -0.89 0.97 0.05 0.77 0.37 -0.07 0.82 -1.35 -0.04 -1.64 
CGPLH486 1.45 1.41 -0.08 1.52 -1.03 1.39 -0.87 2.49 -0.33 -0.25 0.34 2.28 -0.05 0.33 1.13 0.35 0.82 -0.34 1.01 -0.15 
CGPLH487 0.87 2.06 0.94 0.93 0.34 1.76 0.13 1.50 -0.35 0.94 1.07 0.52 -1.24 -0.35 1.76 0.39 -0.70 0.63 0.94 0.88 
CGPLH488 2.40 0.94 1.58 0.45 -0.05 0.23 -0.58 0.47 -1.27 -1.11 1.71 -0.85 -0.48 -1.17 0.10 -0.90 -1.19 0.72 0.77 1.47 
CGPLH490 3.13 3.57 1.44 1.54 0.28 2.47 -3.36 1.72 -2.75 2.02 3.30 1.36 -0.57 -0.66 -1.70 0.65 -0.45 1.82 1.95 1.92 
CGPLH491 0.15 1.08 0.16 -0.18 -0.06 -0.38 0.10 1.31 0.86 -0.77 -0.26 1.13 -1.35 -1.12 0.44 0.92 0.02 0.01 -0.21 1.09 
CGPLH492 1.16 -0.64 -0.54 -0.27 -0.65 0.27 0.52 2.26 0.87 -1.47 -0.94 0.74 0.28 0.50 0.91 0.96 1.02 -0.69 -0.73 0.21 
CGPLH493 0.24 0.02 -1.07 -0.79 -1.52 -1.25 1.24 0.17 0.88 -2.19 -1.10 -1.13 -0.79 -0.61 0.54 -0.26 0.20 -0.04 -0.50 -1.30 
CGPLH494 -0.38 -0.05 -0.30 -1.41 -1.03 -1.60 0.76 -0.25 0.62 -1.74 -1.47 -0.82 -1.14 -0.69 0.31 -0.93 0.46 -0.85 -0.30 -0.29 
CGPLH495 0.61 0.95 0.46 0.54 -0.42 0.96 -1.55 0.90 -0.48 -0.51 0.85 1.37 -1.13 -1.03 -0.39 -0.91 0.87 0.56 0.20 1.16 
CGPLH496 0.11 0.75 1.21 0.82 -0.11 0.82 0.83 1.48 0.63 0.61 0.18 1.51 1.77 -0.43 0.09 0.65 -0.50 -0.09 -0.12 -0.10 
CGPLH497 0.12 0.35 0.50 0.12 -1.04 0.32 0.33 0.74 0.22 0.13 -0.01 0.59 -1.65 0.25 0.18 -0.44 0.19 -0.41 -0.24 0.36 
CGPLH498 0.87 -0.57 -1.01 -0.44 -1.56 -0.83 -0.58 0.37 0.45 -1.15 -1.46 0.14 -0.21 -0.30 0.64 -0.50 0.74 -0.60 -0.13 0.20 
CGPLH499 -0.02 0.38 -0.15 -0.38 -0.73 0.10 0.52 1.22 0.19 -1.16 -0.30 0.53 -0.48 -0.25 0.21 -0.43 0.38 -0.39 -0.60 0.03 
CGPLH500 -0.77 -0.39 0.16 -0.44 -0.92 -0.68 0.65 0.39 1.23 -2.36 -1.01 0.41 -0.53 0.11 -0.21 -1.06 0.33 -1.47 -0.74 -0.26 
CGPLH501 1.62 0.46 1.13 0.16 0.00 0.02 -0.24 1.30 0.70 -0.84 -0.45 0.17 0.46 -0.06 1.02 0.25 0.53 0.49 0.11 1.45 
CGPLH502 -0.15 -0.37 -0.02 -0.84 -1.89 -0.95 -0.31 -0.11 1.03 -2.39 -1.97 -0.05 1.88 -0.95 0.04 -1.21 -0.34 -0.33 -0.58 -0.58 
CGPLH503 0.53 -0.15 0.55 0.16 0.48 -0.04 0.91 0.33 1.35 0.24 -0.45 0.40 0.59 -1.71 0.72 1.84 -0.16 0.51 0.13 1.44 
CGPLH504 -0.63 -0.21 -0.44 -0.34 -0.55 -0.46 0.69 1.04 1.12 -1.14 -1.19 0.76 0.58 1.14 0.07 -0.61 0.57 -1.33 -0.37 -0.31 
CGPLH505 0.61 1.34 1.83 0.30 -1.16 -0.25 -0.60 -0.33 0.12 0.33 1.11 0.58 1.15 -0.76 -0.45 -1.31 -1.02 0.61 -0.10 1.30 
CGPLH506 -0.47 -0.01 0.26 -0.60 -0.62 -0.78 0.96 0.49 1.35 -0.70 -1.22 -0.19 0.73 -0.65 0.26 -0.30 0.42 -0.57 -1.21 0.13 
CGPLH507 2.67 1.98 2.10 0.57 0.64 1.76 -0.49 0.80 -1.12 1.26 1.18 0.57 1.91 -0.90 -0.23 1.21 -1.66 2.36 1.12 1.85 
280 
 
CGPLH508 1.71 1.51 3.10 0.80 -0.80 -0.60 -1.80 -1.59 -1.33 -0.89 2.01 -1.23 -0.44 -1.95 -0.52 -0.69 -1.31 2.93 1.50 2.82 
CGPLH509 0.69 0.85 0.56 -0.17 0.50 0.03 -0.48 -1.12 -0.21 -0.79 0.63 -0.04 0.69 -1.67 -0.95 -0.44 -1.62 0.44 0.54 2.00 
CGPLH510 1.08 1.39 1.34 0.99 -0.36 -0.28 -0.94 -0.22 -1.05 -0.55 1.71 -1.37 -0.07 -2.40 -0.81 -0.66 -1.87 1.05 1.05 1.08 
CGPLH511 0.46 0.92 1.09 1.89 0.42 0.54 1.59 0.06 1.59 1.97 -1.50 1.32 0.53 -0.72 1.18 2.44 -0.87 0.43 -0.46 1.48 
CGPLH512 0.37 1.07 0.57 0.85 -0.19 0.32 0.09 0.76 0.20 -0.21 0.16 0.84 0.74 -0.95 -0.46 0.70 -0.65 0.08 -0.20 0.84 
CGPLH513 -0.86 -0.65 1.45 -0.26 0.48 -0.45 0.75 0.10 1.48 -0.98 -0.68 -0.02 1.35 -0.86 0.91 -0.78 -0.53 -0.57 -0.70 0.50 
CGPLH514 0.75 0.56 -0.01 0.21 -0.54 0.19 0.08 -0.50 -0.14 -1.23 0.25 0.76 -0.33 -0.83 0.07 0.81 -0.04 0.29 -0.68 -0.13 
CGPLH515 -0.03 0.24 1.15 0.78 1.11 0.74 0.54 0.98 1.14 0.94 0.14 0.61 -0.06 -0.68 0.27 1.13 0.20 0.30 -1.07 1.06 
CGPLH516 0.26 0.50 0.72 -0.46 -0.27 -0.19 -0.09 0.68 0.32 -0.92 -0.06 0.55 0.09 -0.29 0.22 0.38 0.33 -0.46 -0.46 0.46 
CGPLH517 1.02 -0.16 -0.38 -1.29 -0.86 -1.20 0.00 0.15 0.54 -1.50 -0.79 -0.51 -2.46 -0.86 1.41 -0.23 0.32 -0.11 -0.54 -0.55 
CGPLH518 0.62 -0.75 0.03 -0.12 -0.20 -0.49 0.29 0.17 1.20 -1.22 -1.33 -0.30 -0.07 -0.49 -0.11 0.17 0.87 -0.35 -0.34 0.45 
CGPLH519 -0.02 0.27 -0.44 -0.69 0.16 0.75 1.12 0.54 1.15 -0.95 -0.73 0.23 0.62 -0.22 -0.02 0.84 0.14 -0.76 -0.72 -0.17 
CGPLH520 0.08 0.16 -0.10 -1.24 -1.15 -1.49 0.64 -0.44 1.43 -0.85 -0.25 -1.40 0.49 -1.45 -0.09 -1.08 -0.36 -0.76 -0.03 0.47 
CGPLH625 -0.18 0.60 -0.50 0.11 -0.32 1.39 0.92 1.28 0.97 0.39 -0.02 0.41 -0.43 0.53 -1.02 1.09 1.24 -0.56 0.24 -0.17 
CGPLH626 0.15 -1.68 -1.03 -1.24 -1.10 -1.57 0.97 0.33 2.19 -3.21 -2.08 -0.90 0.82 -1.07 1.50 -1.52 0.88 -0.47 -0.12 0.02 
CGPLH639 0.65 1.49 0.43 0.09 0.71 1.35 0.25 1.02 0.70 -0.40 0.13 0.50 -0.75 -0.68 -1.10 0.42 -0.16 0.21 -0.84 0.72 
CGPLH640 0.45 -0.20 -1.94 -0.96 0.26 0.25 1.85 0.72 1.77 -1.97 -1.93 -1.31 -0.96 0.01 0.88 0.28 2.03 -0.91 -2.05 -0.18 
CGPLH642 0.69 1.02 1.03 0.09 1.12 0.16 0.22 0.74 1.20 0.57 0.13 0.88 1.83 -0.21 0.55 0.87 -0.12 0.70 -0.65 0.24 
CGPLH643 -0.24 0.48 -0.72 0.17 0.39 0.67 0.96 0.98 0.95 0.22 -0.59 1.18 -0.40 0.21 0.38 0.71 1.08 0.12 -0.27 -0.13 
CGPLH644 1.69 0.83 0.58 0.64 2.01 1.87 1.27 2.32 1.04 1.50 -0.35 1.40 1.11 0.73 0.15 1.40 1.30 0.79 -0.89 0.49 
CGPLH646 1.12 -0.73 -1.09 -0.73 -0.03 -0.06 0.04 0.14 0.51 -2.06 -0.42 0.05 -0.64 -0.43 -0.11 0.40 1.13 -0.74 -0.42 -0.17 
CGPLLU144 -2.34 2.97 -3.66 -2.71 -8.92 -0.81 4.73 -1.91 9.18 -11.06 -2.04 -7.98 24.38 2.88 -5.74 7.34 4.02 2.59 -3.50 -3.63 
CGPLLU161 -0.78 -0.19 -0.15 1.16 -1.59 0.12 1.02 0.56 -0.05 -0.30 -0.36 1.96 3.64 -0.35 0.95 2.16 -1.10 1.21 0.84 0.51 
CGPLLU162 -1.78 0.45 0.25 0.38 -0.55 0.50 1.75 1.54 1.44 1.45 -0.26 1.21 2.54 1.42 0.95 2.10 -0.18 -1.28 0.56 -0.26 
CGPLLU163 5.82 10.72 12.44 -1.81 -21.42 -3.98 4.82 -8.21 4.24 50.72 -4.70 -22.62 -6.10 20.22 -37.27 22.85 -17.45 -10.59 7.76 27.67 
CGPLLU168 -1.64 0.36 -0.74 -0.19 -0.37 0.19 1.60 0.27 0.97 0.38 -0.17 1.07 -0.80 1.09 -0.81 0.19 0.89 -2.24 -1.13 -2.28 
CGPLLU169 -1.31 0.81 -0.17 -0.81 0.10 0.24 1.44 0.45 1.36 -1.27 -0.39 0.14 -0.39 0.24 -0.06 0.69 0.54 -1.64 -1.32 -1.02 
CGPLLU176 -0.42 0.71 0.42 0.67 -0.29 0.87 0.44 1.10 0.95 0.23 -0.68 1.14 0.64 0.12 0.86 0.56 0.23 -0.79 -0.36 -0.19 
281 
 
CGPLLU177 -2.21 4.18 3.02 1.88 -0.56 0.46 0.19 -3.21 3.59 -4.82 -0.16 -3.71 17.36 -0.01 3.03 11.20 -0.66 -0.53 -0.73 -0.16 
CGPLLU203 -1.17 0.35 -0.78 -1.38 0.21 -0.70 1.23 -0.63 1.56 -1.36 -0.49 0.25 -0.70 1.43 0.46 0.07 1.14 -1.15 -0.75 -0.79 
CGPLLU205 -1.27 0.50 -0.05 -1.06 0.61 0.57 1.12 -0.10 0.90 -1.06 -0.09 -0.30 0.65 0.59 0.37 0.01 0.51 -1.28 -0.72 -0.82 
CGPLLU207 -0.64 0.56 -1.00 -0.96 -0.68 0.46 1.05 1.28 2.19 -1.09 -0.34 -0.24 2.92 1.80 -0.31 1.41 1.50 -2.40 -0.90 -1.47 
CGPLLU208 -0.87 0.56 -2.27 -0.20 -1.74 -1.66 2.08 1.37 2.61 4.79 0.54 -1.46 4.10 4.62 -0.41 0.00 -0.20 -1.39 0.27 -2.29 
CGPLOV11 1.20 1.67 1.86 1.30 -1.07 8.52 -1.66 -1.38 2.53 -1.91 1.28 -1.00 -7.61 1.16 -1.04 6.40 0.25 1.85 2.36 0.35 
CGPLOV12 -1.48 -0.07 0.13 1.09 -0.56 0.21 1.11 1.43 1.64 -0.41 -0.63 0.98 1.50 1.77 0.22 2.02 -0.62 -0.44 0.55 0.48 
CGPLOV13 -0.69 -0.84 -0.39 -0.93 -1.50 -0.88 0.49 -0.99 1.58 -2.13 -0.76 -0.51 0.23 0.16 -1.40 1.74 -0.37 -0.09 -0.09 0.25 
CGPLOV15 3.32 1.00 -0.37 -0.88 -3.97 15.58 0.49 -7.03 6.64 -13.00 5.05 -5.87 1.45 -4.33 -4.49 10.96 5.50 -2.53 11.48 -5.62 
CGPLOV16 -1.60 3.69 3.29 -0.49 -6.81 -1.66 0.09 -4.80 1.03 -5.25 1.81 -3.91 1.97 1.61 -1.61 3.37 2.82 0.08 0.19 0.55 
CGPLOV19 -23.77 6.52 37.96 41.52 -38.08 -35.07 -23.07 -36.72 70.28 -122.55 5.31 -25.80 147.22 123.89 -139.74 270.41 10.05 10.50 -4.69 -4.85 
CGPLOV20 -2.17 -0.02 -0.06 0.20 0.51 1.08 2.56 2.22 2.61 0.37 -1.49 1.03 0.47 2.84 1.30 2.58 1.86 -1.52 -1.32 -1.25 
CGPLOV21 -5.16 -3.11 -2.52 4.58 -6.96 2.39 1.12 -2.29 10.22 -9.45 -1.27 -0.76 3.79 2.59 1.31 -0.21 -3.31 -3.76 3.49 -1.17 
CGPLOV22 -0.75 0.96 0.31 0.09 -0.69 -0.29 -0.77 -0.70 0.17 -1.59 0.09 -1.01 1.07 1.50 -0.65 0.05 -1.05 -0.24 -0.23 -0.77 
CGPLOV23 -2.35 0.55 -2.86 -1.26 -0.11 -0.26 1.57 -0.76 4.10 -5.00 -0.80 -1.22 0.30 5.08 0.66 2.61 1.07 -2.80 0.83 -0.95 
CGPLOV24 -0.06 0.42 -0.25 0.00 0.94 -1.06 1.58 -0.40 1.10 0.85 -0.01 -0.04 -0.03 -0.63 1.56 1.81 1.45 -0.11 -0.97 0.03 
CGPLOV25 -0.06 0.98 0.09 -0.51 1.27 0.49 1.58 1.28 0.89 0.08 0.11 -0.26 -1.42 -0.67 0.79 1.26 0.88 0.07 -1.08 -0.08 
CGPLOV26 -1.30 0.18 -1.26 -0.55 0.45 0.89 2.40 1.95 2.24 0.64 -1.16 0.17 0.41 1.58 1.41 2.10 1.25 -1.79 -1.22 -1.19 
CGPLOV28 -0.55 0.44 -0.70 0.18 -0.42 0.09 0.21 0.77 -0.57 -0.79 -0.59 0.48 0.84 0.89 -0.84 0.00 0.17 -0.60 0.22 -0.70 
CGPLOV31 -0.43 -0.20 -0.66 -0.77 -0.44 -0.99 0.08 0.27 0.48 -0.95 -0.71 -1.21 -0.26 1.41 -0.69 0.25 0.36 -1.14 0.57 -0.33 
CGPLOV32 -0.58 -0.44 -0.37 0.18 -0.04 -0.04 1.01 0.82 1.00 -0.66 -0.93 0.87 2.33 0.91 -0.15 0.38 0.08 -0.91 0.70 0.43 
CGPLOV37 -0.91 -1.01 -1.09 0.47 -1.95 -0.85 1.06 1.30 2.90 -3.94 -1.82 0.62 3.89 3.43 2.34 2.67 1.12 -1.67 0.47 0.68 
CGPLOV38 1.00 1.59 3.58 10.24 9.45 28.92 -8.82 -13.11 5.28 -1.17 2.02 -13.32 -3.26 11.27 -10.25 27.00 3.52 1.24 0.63 -0.76 
CGPLOV40 -4.89 -2.03 0.73 -0.61 -1.98 -2.15 3.55 2.41 6.68 -2.06 -2.80 0.07 4.71 2.67 2.99 3.15 0.74 -4.31 1.30 -0.43 
CGPLOV41 -0.76 -0.27 0.43 0.92 -1.25 2.21 -0.50 -1.12 0.02 -1.89 -0.94 -0.07 2.80 2.80 -0.37 -0.49 -0.56 -0.53 0.20 0.09 
CGPLOV42 -1.22 0.41 0.50 -0.80 -1.63 -0.82 1.81 -4.42 0.35 -1.26 -0.93 -4.31 0.73 1.26 -1.26 9.54 -0.10 -0.37 1.05 -1.96 
CGPLOV43 0.78 1.14 0.64 0.61 -0.39 1.87 -0.18 2.29 0.17 1.14 0.64 1.73 0.85 1.28 0.37 1.11 0.26 0.47 0.30 0.10 
CGPLOV44 -2.11 0.57 -0.45 -0.20 -0.01 -0.03 1.60 2.35 3.25 0.73 -1.19 1.87 1.08 2.61 1.38 1.41 0.93 -2.78 -0.86 -1.06 
282 
 
CGPLOV46 -1.46 -0.28 -0.66 -0.71 -0.99 -0.52 1.47 1.30 2.11 -0.38 -1.92 0.18 -1.24 1.68 0.01 0.57 0.89 -2.38 -0.41 -0.71 
CGPLOV47 0.39 0.33 0.58 0.20 -0.36 0.12 0.45 -0.25 0.80 -0.99 -0.41 -1.66 -1.06 -0.37 0.27 0.22 -0.04 -0.08 -0.85 0.99 
CGPLOV48 1.02 1.56 1.14 1.18 -0.08 2.90 -1.65 0.42 -0.87 -0.21 1.38 -1.10 -0.56 0.52 -1.37 1.17 -0.46 1.87 1.86 1.42 
CGPLOV49 -1.47 -0.32 1.25 5.85 -2.85 2.69 -1.62 -4.03 3.20 -1.10 0.63 -4.05 3.93 2.87 -2.30 17.87 3.93 -0.58 2.68 3.33 
CGPLOV50 -1.73 -0.54 -0.66 -0.80 -0.37 -0.27 1.93 1.70 2.65 -0.60 -2.02 0.79 1.40 2.92 2.55 2.29 1.58 -2.35 -0.70 -0.51 
CGPLPA112 0.64 0.78 0.74 0.47 -0.25 0.29 0.37 -0.60 0.02 -0.31 0.71 -1.04 -0.14 -1.00 0.67 0.84 -1.12 0.45 0.47 0.99 
CGPLPA113 -1.54 -0.21 1.97 1.44 1.80 -0.68 2.48 4.63 3.73 3.89 -1.85 2.75 3.53 1.65 2.87 5.75 1.57 -2.30 0.91 1.42 
CGPLPA114 -0.90 -0.03 -0.03 -0.86 -1.08 -1.48 1.15 -0.65 1.52 -1.11 -1.08 -0.25 1.49 -0.25 0.31 0.37 0.41 -1.13 -0.63 -0.68 
CGPLPA115 -3.51 5.72 10.03 -2.36 25.33 30.59 -5.73 -8.67 2.07 10.88 -4.18 -11.83 21.42 12.41 2.13 11.85 6.68 1.65 -7.17 -7.87 
CGPLPA117 -1.35 0.44 -0.58 -0.54 -1.51 0.68 0.78 3.21 2.06 0.32 -0.80 -0.22 0.39 1.56 -0.40 -0.88 0.29 -2.38 0.31 -2.23 
CGPLPA118 -0.09 0.44 1.18 0.51 1.87 0.47 1.88 1.84 1.61 0.99 0.34 0.48 1.70 -0.43 -0.70 2.66 0.88 -1.13 0.30 0.56 
CGPLPA122 -2.06 0.16 1.25 0.59 2.97 0.12 4.02 2.52 4.22 2.23 -0.86 2.84 4.30 3.60 -5.16 5.54 0.88 -2.09 -0.14 0.65 
CGPLPA124 -0.41 0.50 0.17 0.10 -0.55 -0.69 0.97 1.19 1.44 0.31 -1.41 2.59 -0.80 1.63 0.60 0.81 0.51 -1.55 -0.50 -0.33 
CGPLPA125 1.00 1.16 0.25 0.86 1.25 1.25 0.76 1.91 1.09 0.90 -0.30 1.66 -1.32 0.72 -1.23 0.78 0.98 -0.72 -1.04 0.66 
CGPLPA126 -2.30 -0.73 -0.44 -0.63 0.55 -1.94 2.47 1.40 3.35 -1.34 -1.87 1.61 2.60 1.36 1.10 1.18 -0.31 -1.51 0.55 0.35 
CGPLPA127 -1.50 0.90 1.55 0.75 2.48 0.16 2.57 2.17 2.41 2.72 0.40 2.35 3.23 2.24 -0.49 3.92 0.44 -1.24 -0.14 0.88 
CGPLPA128 -0.50 0.14 0.84 0.68 -1.11 0.09 1.01 1.51 1.25 1.19 -0.15 2.04 0.92 0.70 0.00 -0.22 0.50 -0.16 0.72 0.50 
CGPLPA129 -2.28 -1.13 -0.25 -0.10 0.19 -1.56 2.33 2.35 2.63 0.61 -1.87 2.33 1.92 1.67 2.86 1.71 0.82 -1.49 0.07 0.06 
CGPLPA130 -0.26 -0.08 -0.42 1.16 -0.33 0.46 0.88 2.94 2.20 0.47 -0.65 1.62 1.48 0.26 1.32 2.81 1.30 -0.47 1.30 1.11 
CGPLPA131 -0.75 -0.48 -0.98 0.22 -2.80 -1.61 0.79 -1.66 0.50 -0.65 -2.39 -2.42 0.78 -2.45 -0.82 -0.95 -1.61 -0.39 -0.08 0.30 
CGPLPA134 -1.13 -0.81 1.48 1.47 -1.28 -1.86 1.59 -1.43 1.65 -0.99 -0.40 0.87 2.80 -2.07 0.96 1.00 -1.53 1.04 0.39 1.53 
CGPLPA135 0.62 1.62 1.11 0.97 1.90 0.91 0.52 0.04 0.67 1.40 1.04 0.11 -1.40 -0.54 -0.54 2.19 -0.06 0.14 -0.05 1.85 
CGPLPA136 0.16 0.73 2.02 1.83 0.07 0.03 0.04 0.31 0.04 0.80 0.34 2.47 2.35 -1.37 1.95 1.44 -0.90 1.81 0.87 1.66 
CGPLPA137 0.58 1.51 1.04 1.33 0.61 1.43 0.74 1.10 1.42 1.57 -0.25 1.49 -0.19 -0.89 0.32 2.23 0.69 -0.84 -0.51 0.11 
CGPLPA139 0.75 0.19 1.04 -0.06 0.30 0.16 0.26 -1.57 0.92 0.67 0.04 -1.14 0.48 -1.48 -0.18 1.05 -0.69 1.22 -1.35 1.43 
CGPLPA14 -1.53 -0.59 0.24 0.22 4.62 0.24 1.52 1.00 2.00 0.82 -0.69 0.13 0.70 0.38 2.73 2.55 1.50 -0.81 -0.05 -1.15 
CGPLPA140 -2.71 -1.54 -0.62 -0.47 -2.22 -2.64 1.61 -0.82 1.98 -3.54 -1.70 -0.35 2.96 -0.21 -0.16 -0.02 -0.80 -0.79 -0.12 -0.20 
CGPLPA141 -3.31 -1.59 -0.41 -0.09 1.14 -1.81 1.64 -1.18 1.97 -1.37 -0.41 -0.18 3.76 0.51 1.40 1.73 -1.17 -0.63 0.59 -0.54 
283 
 
CGPLPA15 0.43 0.97 -0.52 1.41 1.39 2.21 1.57 1.25 0.64 0.90 0.44 1.70 0.20 0.64 1.27 2.08 1.38 0.19 -0.81 0.14 
CGPLPA155 1.57 0.94 1.42 2.33 1.88 0.29 1.28 0.59 1.09 2.80 0.13 0.28 1.28 -1.19 1.52 3.49 -0.83 1.26 -1.00 2.09 
CGPLPA156 0.29 0.52 -0.56 -0.11 -0.95 0.29 0.05 -0.07 0.78 -1.10 -0.58 0.00 -0.08 -0.17 0.79 0.52 -0.05 -0.85 -0.46 0.19 
CGPLPA165 0.19 -0.13 0.11 -0.28 1.93 -0.49 1.71 -0.59 1.84 -0.02 -0.47 -0.19 -0.86 -1.08 1.35 -0.16 -0.16 -0.90 -1.40 1.16 
CGPLPA168 -4.21 -1.58 -0.13 0.62 1.56 -0.65 4.62 3.48 6.17 1.33 -2.99 2.25 5.94 2.19 2.16 4.74 0.20 -3.09 0.83 1.10 
CGPLPA17 -7.74 -3.20 -1.69 -3.24 -0.22 -7.59 2.40 -2.64 9.57 -10.23 -3.41 -0.45 7.03 -2.37 7.13 1.49 -6.00 -3.73 3.15 -3.25 
CGPLPA184 -1.25 -0.74 0.61 -0.24 0.18 -1.98 2.11 -1.60 2.07 -0.81 -0.61 -0.98 1.36 -0.87 0.82 2.27 0.09 0.33 -1.06 1.00 
CGPLPA187 0.46 1.48 0.43 1.91 1.13 0.68 1.15 0.19 0.88 1.84 0.51 1.21 2.61 -0.39 0.05 3.14 -0.27 0.40 0.46 1.09 
CGPLPA23 -4.65 -0.99 -0.90 -1.19 3.76 -1.34 4.84 1.29 4.65 0.93 -1.09 0.33 3.32 1.79 -2.64 7.57 0.76 -3.78 -1.10 -3.13 
CGPLPA25 -0.83 0.72 -0.71 -0.39 0.63 -0.59 1.56 -0.54 1.44 1.01 -1.35 -0.02 0.31 0.53 0.47 1.25 0.42 -0.68 -1.14 -0.43 
CGPLPA26 -0.12 0.99 0.65 0.13 1.37 0.69 0.06 -0.26 0.04 -0.72 0.21 -0.46 2.42 -0.93 -0.58 -0.26 -0.64 -0.23 -0.30 0.36 
CGPLPA28 -1.31 0.57 -1.09 -0.42 1.21 0.01 1.86 1.80 2.06 -0.31 -2.43 1.59 1.17 1.10 1.25 1.85 0.94 -1.67 -1.49 -0.72 
CGPLPA33 -2.08 -0.85 -0.09 -0.56 4.22 0.95 3.29 1.94 2.49 2.07 -0.59 -0.08 2.26 2.32 1.65 3.29 1.15 -1.38 0.09 -1.84 
CGPLPA34 -1.23 -0.62 -0.60 -0.01 3.30 0.37 1.31 0.04 1.98 0.81 -1.34 -0.37 -0.92 -0.29 1.77 0.26 -1.12 -1.82 -0.82 -0.77 
CGPLPA37 -1.34 -0.61 -0.58 0.17 3.06 0.27 2.24 0.01 2.24 -0.70 -0.40 0.04 3.27 -0.21 1.84 3.69 -0.38 0.31 -1.27 -0.60 
CGPLPA38 -0.49 -0.82 -0.03 -0.53 3.68 0.76 1.92 0.35 1.28 0.39 -0.64 -1.23 -0.11 0.74 1.38 2.10 0.96 0.01 -1.29 -1.33 
CGPLPA39 -2.82 -0.42 -0.55 -0.96 2.13 -0.93 2.44 -0.08 3.26 1.80 -0.66 -0.71 2.15 1.77 -0.35 3.30 0.89 -3.11 -0.58 -1.05 
CGPLPA40 -1.93 -0.34 0.45 -0.42 4.21 -0.28 1.91 -0.47 3.07 1.60 -0.49 -0.93 2.77 -0.86 1.97 3.01 -0.54 -1.36 -0.42 -1.01 
CGPLPA42 2.12 1.89 0.93 2.19 0.14 3.58 -1.15 0.46 -0.53 2.18 1.86 -0.36 0.44 -0.86 0.47 0.83 -0.11 0.72 0.74 0.27 
CGPLPA46 -6.36 -1.53 -1.33 -2.16 2.68 -4.76 1.38 -1.00 5.85 -5.48 -1.00 -0.65 6.58 -0.72 6.20 3.03 -3.07 -4.05 3.67 -3.54 
CGPLPA47 -4.13 -2.22 -1.14 -1.85 3.51 -3.36 2.94 -3.24 4.67 -3.15 -1.20 -2.08 2.56 -0.50 4.05 2.74 -1.60 -1.66 0.45 -3.24 
CGPLPA48 -0.12 0.38 -0.15 0.49 0.96 -0.49 0.60 -0.30 0.52 -0.01 0.07 1.12 -0.40 -0.24 0.92 1.72 -0.02 -0.57 -0.56 -0.41 
CGPLPA52 0.25 -0.28 -0.48 -1.57 0.57 -0.78 1.00 1.70 1.73 -1.46 -1.27 0.17 -0.84 -0.25 0.13 -0.62 1.08 -0.83 -1.24 -0.43 
CGPLPA53 -0.70 0.67 1.47 0.31 0.51 -0.79 1.75 -0.30 1.72 0.39 0.55 -0.78 1.22 -0.46 -0.08 1.72 0.16 -0.97 -0.91 -0.21 
CGPLPA58 -0.39 0.10 -0.40 -1.17 -0.24 -0.92 -0.03 0.11 0.47 -0.10 -0.59 -1.27 0.05 0.74 -0.56 0.81 0.02 -1.24 0.58 -0.72 
CGPLPA59 -2.28 -0.19 -1.16 -1.53 -0.01 -0.80 2.16 1.39 2.23 -0.27 -1.27 -0.47 -0.18 0.84 0.29 0.62 0.84 -3.70 -1.08 -1.44 
CGPLPA67 0.04 1.64 1.06 0.39 0.41 1.18 0.60 0.54 0.84 0.25 -0.53 0.04 0.99 -1.22 0.79 1.38 0.01 0.34 -0.18 0.62 
CGPLPA69 0.74 1.19 0.39 0.76 -0.83 2.14 -0.95 2.26 -0.58 0.42 0.39 0.67 -0.72 0.59 -0.43 -0.36 0.10 0.19 0.49 0.20 
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CGPLPA71 1.46 0.77 1.01 1.24 0.82 2.07 0.34 2.59 -0.46 0.06 0.54 1.62 1.17 0.69 -0.95 1.16 0.00 -0.45 -0.06 0.44 
CGPLPA74 0.89 1.50 1.13 -0.97 -1.39 -0.95 -0.85 -0.94 -0.22 -0.94 0.64 -1.10 1.02 -1.46 -1.41 -1.08 -1.46 -0.40 0.79 0.60 
CGPLPA76 -0.58 0.47 0.89 -0.64 -0.20 -1.54 0.42 -1.87 0.43 -1.25 0.07 -2.22 0.75 -1.71 -0.76 -0.52 -1.62 0.07 -0.61 0.91 
CGPLPA85 -0.56 1.11 0.06 -0.38 -2.29 1.06 -0.18 0.48 -0.23 -1.20 -0.87 0.91 0.40 1.79 -0.17 0.69 -0.94 -0.19 -0.48 -0.55 
CGPLPA86 -2.21 0.70 0.56 -0.07 2.24 0.03 2.47 2.79 3.66 1.92 -0.28 2.24 0.81 2.12 0.65 3.31 1.19 -3.76 0.00 -0.70 
CGPLPA92 -0.15 0.72 -0.54 -1.43 -0.35 0.34 0.15 0.04 -0.25 -0.09 0.52 0.47 0.05 -0.65 -0.70 -1.08 0.24 -1.27 -0.34 -1.54 
CGPLPA93 -3.48 -0.04 0.36 -0.09 0.97 -1.12 3.77 2.28 3.85 0.71 -2.01 1.30 4.11 4.26 1.07 2.78 0.73 -3.41 0.00 0.03 
CGPLPA94 0.44 1.90 2.59 2.51 1.23 1.27 0.29 0.45 0.11 2.26 0.57 0.63 2.12 1.07 0.55 3.49 -0.65 1.16 1.42 1.25 
CGPLPA95 -2.95 -0.66 -0.18 -0.61 3.29 -0.32 2.70 -0.57 4.29 1.72 -0.62 0.46 3.02 -0.48 0.80 5.63 1.17 -1.60 -0.57 -0.91 
CGST102 1.84 2.14 0.98 1.49 -0.07 3.48 -0.71 1.87 -1.21 1.19 1.86 0.98 -0.08 -1.32 -0.89 2.89 0.33 1.53 1.30 0.98 
CGST11 1.14 1.83 0.93 0.90 -0.98 0.53 -0.50 0.90 -1.18 0.16 1.19 1.41 -0.02 -0.55 -1.33 0.04 -0.19 1.08 0.39 1.05 
CGST110 0.79 1.76 0.23 -0.07 -1.19 1.50 -0.80 -0.16 -0.72 0.04 0.82 0.62 -2.29 0.44 -0.79 0.63 -0.54 0.07 1.06 -1.37 
CGST114 0.14 1.06 0.48 0.55 -1.87 0.05 0.31 0.70 0.65 -0.42 0.59 -0.15 1.19 -0.65 1.08 1.50 -0.17 -0.35 0.38 1.17 
CGST13 -1.67 -0.69 -0.73 0.20 0.10 -0.47 1.94 0.79 2.06 -1.17 -0.85 0.49 0.34 -0.51 0.59 1.31 0.51 0.39 0.04 0.09 
CGST131 1.48 2.14 0.74 3.11 -0.16 3.04 -0.61 2.22 -1.41 3.79 0.89 4.77 0.21 0.08 0.50 3.20 0.91 1.06 1.56 1.24 
CGST141 0.47 0.32 -0.44 -0.70 -0.73 -0.26 0.79 0.57 0.80 -2.09 -0.80 0.58 -2.45 -0.97 1.02 -0.61 1.21 -1.09 -0.89 -0.11 
CGST16 -3.73 -0.92 0.01 0.05 -0.48 -0.73 3.57 1.53 3.96 0.87 -1.17 2.05 4.12 1.54 -4.83 4.10 -0.32 -1.79 -0.05 -0.66 
CGST18 0.73 0.79 1.38 1.12 -0.31 0.24 -0.59 1.15 0.38 -1.50 0.91 0.23 0.28 -1.27 0.39 0.12 -0.39 1.89 2.06 1.74 
CGST21 -6.54 0.61 1.90 0.32 -4.48 2.20 2.65 8.20 4.84 -5.76 -0.58 8.92 6.60 4.16 2.19 -0.85 -2.32 -5.41 2.48 -1.94 
CGST26 1.16 1.32 0.42 0.87 -1.17 2.33 -0.46 2.48 -0.07 1.62 0.90 2.16 -0.82 0.82 -0.35 1.43 -0.08 0.63 0.11 -0.07 
CGST28 0.18 1.84 0.47 0.57 -0.76 2.60 0.10 1.54 -0.85 2.36 1.60 0.51 -0.42 -0.05 4.30 10.78 2.09 -1.06 0.24 0.51 
CGST30 1.72 2.43 0.38 2.03 1.22 4.51 -0.94 2.42 -2.30 4.53 1.42 4.10 -0.79 2.13 -2.18 1.81 0.98 -0.02 -0.02 0.01 
CGST32 -2.96 1.90 8.76 0.90 -4.35 9.48 -2.30 -4.13 0.66 -6.24 0.66 0.19 -0.37 -2.53 -4.43 4.43 1.20 2.92 -1.20 -1.61 
CGST33 1.07 4.23 1.72 2.64 -8.33 5.77 -4.09 1.97 1.90 -4.05 2.84 5.42 2.32 1.62 -2.28 5.84 -4.97 -1.95 2.49 0.20 
CGST38 -0.13 0.90 1.74 2.62 -3.05 0.95 -1.47 4.71 -0.07 1.19 0.42 4.22 0.82 1.90 0.76 1.31 0.30 -0.09 2.59 1.37 
CGST39 -0.85 -0.34 0.01 -0.98 -2.81 -0.69 1.51 1.00 1.87 -2.62 -1.26 1.18 0.11 0.59 1.25 0.15 -0.35 -1.05 1.28 0.10 
CGST41 -0.88 -0.15 -0.06 1.96 -5.00 -0.51 -0.78 1.81 0.68 -3.88 0.05 0.98 4.48 2.05 1.15 6.29 -0.85 -1.05 0.73 -1.24 
CGST45 -1.06 0.19 -0.60 0.61 -2.37 -0.57 1.31 1.36 0.61 -0.32 -0.44 2.35 3.48 0.36 1.19 1.60 -1.01 -0.84 1.95 -0.08 
285 
 
CGST47 -1.13 -0.78 0.81 0.95 -3.31 -0.75 0.37 1.16 0.85 -1.94 -0.72 2.54 1.25 0.32 2.24 0.60 -1.84 -0.19 1.92 1.09 
CGST48 -4.37 -1.18 -2.14 4.10 -4.05 6.33 -4.06 -4.12 1.44 1.86 0.51 -0.01 5.64 13.96 -0.26 9.79 -5.06 -3.17 4.25 -0.95 
CGST53 -3.73 0.70 -0.17 2.92 -2.70 2.46 0.41 4.70 0.11 1.98 -0.99 7.46 9.52 9.30 7.22 8.55 1.99 1.58 2.54 -1.46 
CGST58 -0.73 0.68 -0.64 -0.46 -4.37 -1.49 -0.71 0.36 -1.33 -2.02 0.30 0.16 1.52 0.95 1.90 1.06 -1.34 1.53 1.68 -1.19 
CGST67 0.11 0.79 -2.01 0.70 -3.93 1.22 -1.27 3.59 -1.15 0.77 -0.40 5.10 1.27 2.62 0.11 0.63 -0.75 0.56 2.88 -0.49 
CGST77 -2.61 -0.65 -0.55 2.99 -0.31 0.51 2.89 3.27 0.91 1.40 -0.95 7.26 4.12 3.16 4.07 4.28 -0.65 -0.85 1.14 -0.52 
CGST80 0.11 1.11 1.09 -0.90 -2.51 -2.54 -3.01 -3.70 -1.54 -6.00 0.23 -2.09 0.73 -1.22 1.54 6.81 2.03 0.81 3.47 0.68 









chr11p chr11q chr12p chr12q chr13q chr14q chr15q chr16p chr16q chr17p chr17q chr18p chr18q chr19p chr19q chr20p chr20q chr21q chr22q 
CGCRC291 19.58 27.70 52.78 42.80 196.21 -33.87 -18.31 -6.22 -19.94 -11.38 -16.30 -25.22 -27.27 -0.54 -7.89 26.07 25.47 -8.72 -11.60 
CGCRC292 -1.73 -2.00 -1.97 -3.15 1.34 -0.75 -1.04 2.25 1.73 0.92 -0.73 2.06 -2.02 1.85 1.54 0.00 -0.21 -0.42 0.63 
CGCRC293 -1.09 -2.01 -1.58 -4.05 -3.48 -3.93 -1.39 -0.70 -2.15 -1.75 -0.32 -3.70 -3.86 -0.87 -1.43 -1.09 -0.58 -1.63 -0.66 
CGCRC294 -3.05 -3.12 -2.09 -3.89 0.22 -3.26 -0.99 1.95 1.71 1.44 0.12 3.35 -1.16 2.38 1.89 -1.57 0.09 0.83 2.57 
CGCRC296 0.12 -0.30 -2.12 -1.22 1.51 -2.04 -2.97 1.07 -0.30 0.53 -1.71 1.16 0.64 0.45 1.13 1.12 0.67 0.63 0.66 
CGCRC299 1.25 1.38 0.10 -2.18 1.24 -1.22 1.86 -2.13 -0.87 -0.84 1.75 1.81 -2.73 -0.40 -1.51 -0.09 0.23 2.31 2.00 
CGCRC300 2.10 -0.09 2.01 0.79 -0.31 1.27 1.68 -1.25 -0.57 -0.50 0.41 2.36 -0.06 -2.11 -2.18 1.02 1.95 0.87 1.89 
CGCRC301 1.02 -0.60 -1.80 -1.31 0.86 -1.77 0.22 0.58 0.81 0.62 1.41 0.48 -0.40 -0.18 -1.36 -1.51 2.37 0.93 1.90 
CGCRC302 -1.51 -1.49 -0.66 -3.47 1.53 -1.15 1.51 -0.70 -0.32 1.03 2.11 2.84 -1.46 0.34 -0.89 -0.42 -0.71 3.66 4.14 
CGCRC304 -0.82 -0.72 -1.17 -4.29 1.75 -1.17 0.73 -0.86 -1.00 -0.52 1.19 2.03 -1.36 0.72 -0.88 -0.55 0.58 2.09 3.42 
CGCRC305 -1.33 -2.25 -0.46 -0.41 1.68 -0.23 -0.05 -0.26 0.29 0.72 0.07 2.57 -1.17 1.05 0.07 -2.31 0.82 2.00 1.30 
CGCRC306 -0.79 -0.35 -0.72 0.48 30.50 -0.84 -2.11 0.36 -0.98 -1.64 -2.72 -0.22 -0.01 0.10 0.12 1.08 -0.76 -0.56 -1.31 
CGCRC307 -0.20 -0.56 -0.85 -1.21 1.54 -1.27 0.42 -0.25 0.26 -1.03 -0.67 0.71 0.04 0.45 -0.44 -0.50 -0.26 2.58 0.97 
CGCRC308 -1.59 -1.78 -2.03 0.24 1.85 0.47 -1.38 1.20 0.29 1.03 -1.83 2.52 0.66 0.12 0.51 0.73 1.37 1.60 1.64 
CGCRC311 0.58 -0.37 -1.45 0.09 1.10 -0.58 0.78 0.24 -0.43 0.13 -1.69 1.69 1.18 -0.56 -1.10 -0.47 0.14 0.88 -0.37 
CGCRC315 -3.12 -2.53 -2.07 -3.06 2.15 -2.17 -0.24 1.86 0.90 2.44 -0.04 -0.65 -2.11 2.36 1.31 -0.53 -0.52 2.60 3.05 
CGCRC316 3.98 -20.57 -7.80 -38.60 90.29 -26.34 -26.34 2.72 -6.28 -24.89 9.90 -31.14 -18.45 0.92 -3.39 78.90 64.81 -17.78 -10.66 
CGCRC317 -2.01 -2.76 -1.99 -3.15 2.28 -3.53 -1.69 1.11 0.25 -0.62 -1.10 -0.18 -1.46 1.15 0.11 -0.88 1.38 0.65 1.86 
CGCRC318 -2.37 -4.12 -2.78 -6.00 2.55 -1.46 -0.70 1.84 1.30 2.10 0.28 0.10 -0.90 2.55 1.30 -1.08 -0.30 4.53 2.89 
CGCRC319 -2.94 -1.76 -1.77 -4.23 0.80 -1.98 -0.92 1.38 -0.39 0.11 -0.40 2.62 -1.74 2.18 1.71 -1.24 -0.68 1.88 0.97 
CGCRC320 -2.86 -1.85 -0.94 -3.21 1.64 -1.30 -0.33 0.98 1.42 -0.03 -0.44 3.16 0.16 0.53 -0.59 -0.25 0.54 3.89 2.49 
CGCRC321 0.04 -0.85 -1.04 -0.24 2.01 1.10 -1.31 1.25 -0.48 -0.07 -1.96 0.28 0.13 0.57 0.27 0.03 -0.46 1.76 -1.98 
CGCRC333 -86.46 77.65 23.72 46.14 187.13 37.84 -27.25 -26.75 -22.51 -51.87 -21.92 57.32 -47.36 -9.88 -0.41 35.28 96.06 14.98 -7.71 
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CGCRC336 -102.44 -133.85 -24.76 55.25 168.68 -23.94 -12.40 25.10 50.03 -78.34 -3.93 -123.32 -122.02 0.15 -1.76 -67.95 184.24 -5.40 -69.43 
CGCRC338 -23.70 -26.13 22.40 54.88 107.91 -35.45 -20.88 -9.83 -22.24 20.83 15.73 -28.75 -27.68 -3.07 -4.73 76.65 67.28 -29.82 -16.91 
CGCRC341 -1.13 -1.84 -1.75 -1.33 2.25 -1.98 -2.30 1.09 -0.50 0.89 -1.15 1.52 -1.00 2.47 1.53 -0.14 -0.04 1.50 0.67 
CGCRC342 105.68 -13.58 -23.25 -57.44 180.22 -40.52 -78.09 10.27 -18.11 -82.89 -57.47 -131.18 -128.50 9.25 10.52 21.92 155.64 -27.56 -56.40 
CGPLBR100 1.43 -1.61 0.85 0.09 2.41 0.76 -1.09 -0.20 -1.08 -1.08 -1.85 1.67 0.73 -0.03 0.31 -2.16 -2.29 0.09 -2.89 
CGPLBR101 0.09 -0.54 -1.53 0.10 1.33 -0.11 -1.27 1.01 0.35 0.06 -2.13 1.48 1.17 0.38 0.86 -0.25 -1.31 -0.06 0.22 
CGPLBR102 0.05 0.34 -0.60 2.02 0.00 -0.56 0.17 0.64 1.10 -1.33 -1.87 -0.28 3.30 -0.71 -0.41 1.33 0.11 -0.13 -0.79 
CGPLBR103 -0.07 0.97 -0.85 -1.12 0.61 -0.33 -0.29 0.91 1.10 0.37 -2.19 1.22 2.13 -0.45 0.53 0.90 0.28 -1.24 1.30 
CGPLBR104 0.77 1.17 -2.35 1.32 3.05 -0.05 -2.55 0.04 0.29 -2.49 -3.54 2.57 1.47 -0.80 -0.76 0.58 -1.38 0.20 -2.27 
CGPLBR12 0.33 -2.53 1.69 -1.63 -0.45 -1.24 -1.04 0.08 0.79 -1.45 3.86 -2.18 -2.04 -0.55 -0.23 -0.74 1.48 2.57 -0.28 
CGPLBR18 -1.87 -0.72 0.86 0.53 -0.25 -0.01 0.75 0.27 -1.56 0.92 4.10 -1.17 -2.67 0.69 0.32 -2.23 -0.27 0.82 1.31 
CGPLBR23 1.46 0.47 -0.23 -1.02 -0.25 1.00 1.11 0.18 0.09 1.74 -0.25 0.25 -0.35 -0.94 -0.34 1.99 1.26 0.82 0.49 
CGPLBR24 -1.07 -1.17 -0.85 -1.66 0.85 0.01 -0.43 0.27 -0.28 0.52 -0.18 2.18 -0.23 0.83 0.47 1.15 0.60 1.40 0.92 
CGPLBR28 1.57 -1.62 -0.47 1.35 2.37 0.93 -1.61 0.19 -0.48 -0.90 -2.45 -0.03 0.04 0.40 0.89 -1.49 -1.64 -0.13 -3.10 
CGPLBR30 76.19 -23.73 18.94 34.07 -57.23 -15.33 -42.43 -6.60 4.97 8.93 59.41 -14.70 -13.90 -1.16 -11.97 8.41 1.50 -20.14 -32.55 
CGPLBR31 -0.68 0.03 -0.34 -0.17 0.69 0.64 -0.18 -0.18 -1.30 0.12 0.04 -1.35 -1.80 0.30 0.55 -0.23 0.20 -1.59 0.89 
CGPLBR32 -0.21 0.87 0.68 2.11 1.37 0.87 -0.84 -1.02 -1.94 -2.02 -2.92 0.49 0.30 -1.26 -1.07 -1.57 -1.75 -1.16 -2.33 
CGPLBR33 -0.07 0.94 -0.86 0.75 1.26 -0.58 -0.85 0.02 -0.18 0.51 -1.20 0.97 0.87 0.19 0.85 -0.32 -0.80 -0.66 -1.44 
CGPLBR34 0.42 -0.88 0.11 0.08 0.31 -0.49 -0.37 0.22 -1.11 -0.01 0.02 0.68 -1.03 0.41 -0.16 -1.71 -0.53 0.06 -0.73 
CGPLBR35 0.20 -0.28 -0.67 1.10 1.57 0.48 -0.83 0.00 0.45 -0.46 -1.98 2.99 1.09 -0.35 0.47 -1.14 -1.38 -1.18 -0.98 
CGPLBR36 -1.20 -3.09 0.41 0.21 -1.30 0.29 0.11 1.97 1.53 2.74 1.30 2.16 0.77 0.93 2.09 0.51 -0.25 0.90 0.41 
CGPLBR37 0.11 -0.36 -0.45 0.55 1.52 -0.15 -0.71 -0.24 0.09 0.70 -0.32 0.36 -0.24 0.29 0.67 -0.35 -0.68 0.24 -0.39 
CGPLBR38 0.91 -0.05 0.42 -0.77 1.49 0.21 0.90 -1.43 -0.72 -1.29 1.75 -0.74 -2.54 -0.51 -0.53 -1.59 0.11 0.14 0.00 
CGPLBR40 0.30 -0.14 -1.62 -0.89 0.49 -0.28 -1.28 1.10 1.69 -0.05 -3.80 1.65 1.95 -0.61 -0.26 0.62 -0.69 -1.23 0.36 
CGPLBR41 -0.02 -0.70 -0.71 0.48 -0.10 0.77 -0.61 1.18 0.61 -0.12 -1.64 -1.12 -0.03 0.73 0.65 -0.89 0.29 -0.13 -0.46 
CGPLBR45 -0.55 0.38 0.50 -0.77 0.99 0.14 2.01 -0.68 -1.52 0.60 1.73 -1.79 -2.21 -0.33 0.06 -0.30 0.22 -0.69 0.47 
CGPLBR46 -0.66 -0.65 0.69 1.78 0.84 -0.51 -1.08 -0.05 -1.43 -1.40 -1.39 2.59 -0.58 -0.83 -0.26 0.93 -0.99 -0.29 -3.04 
CGPLBR47 0.95 0.91 1.24 -0.02 0.09 1.63 0.16 -1.33 -1.21 -0.32 0.27 1.09 -1.05 -0.96 -0.96 -0.85 0.50 0.04 0.12 
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CGPLBR48 -1.74 0.81 6.00 5.88 0.77 0.06 0.07 -3.80 -4.76 -2.83 -0.48 1.89 0.87 -3.11 -4.50 -4.55 -4.46 -1.72 -1.08 
CGPLBR49 -5.23 -1.20 5.12 6.33 -0.01 -1.00 -0.35 -3.97 -6.48 -2.07 0.05 4.56 -0.84 -0.42 -2.66 -3.89 -5.77 -0.49 -0.62 
CGPLBR50 -0.52 0.76 -1.51 -1.51 0.81 -0.30 -1.08 0.79 0.52 -1.30 -3.43 1.99 2.56 -0.31 -0.43 2.79 0.33 0.15 0.18 
CGPLBR51 0.79 2.38 0.96 1.05 -1.25 -0.60 0.27 -0.39 -0.58 -1.44 -0.57 0.35 -1.26 -1.13 -0.53 2.97 0.43 -0.92 0.09 
CGPLBR52 0.13 0.20 -1.98 0.18 -0.74 -0.87 -0.14 1.81 0.83 1.79 -0.64 3.54 0.65 1.12 1.99 1.07 -0.24 -0.42 1.47 
CGPLBR55 2.03 0.57 -0.66 1.85 -0.60 0.50 -0.90 0.70 -1.47 -0.29 -2.75 -1.89 -0.20 -0.35 -0.06 -0.34 -0.90 -0.13 -1.79 
CGPLBR56 -0.20 0.35 -0.22 -0.42 1.55 -0.99 -0.04 -0.06 -0.58 -0.36 -0.31 0.17 -0.69 0.31 0.19 1.79 0.61 1.37 0.68 
CGPLBR57 -0.20 -0.08 0.29 1.35 0.30 0.71 -0.05 -0.03 -0.93 0.81 -0.65 2.63 -0.28 -0.08 0.14 -0.31 -0.51 -0.32 -1.12 
CGPLBR59 2.32 0.03 -0.39 -0.91 1.24 -0.94 0.77 0.50 0.59 -0.54 -2.00 -0.28 -0.42 -0.32 0.43 0.91 1.37 0.49 -0.43 
CGPLBR60 0.91 0.45 -0.65 2.77 1.30 1.30 -0.71 0.22 0.99 -1.64 -2.13 -0.76 0.89 -0.93 0.18 -0.64 0.61 -2.25 -0.15 
CGPLBR61 0.54 1.32 -1.38 -0.33 0.30 0.06 -0.25 0.30 0.30 0.09 -0.42 0.16 -0.07 -0.22 0.11 -0.41 -0.04 -0.23 0.72 
CGPLBR63 0.87 0.43 1.75 2.44 1.33 1.16 0.07 -0.93 -0.42 -1.85 -2.35 0.75 1.86 -1.29 -1.55 -0.47 -1.64 -0.70 -1.47 
CGPLBR65 -0.65 -0.98 1.27 3.48 0.24 0.24 -0.50 -1.06 -0.98 -1.64 -2.04 4.79 1.20 -1.30 -0.70 -0.64 -2.07 -1.20 -1.54 
CGPLBR68 0.37 1.63 1.61 -2.19 -0.07 -0.61 1.91 -1.66 -1.44 -0.80 1.45 -1.34 -0.44 -1.41 -2.16 1.79 2.26 1.85 2.02 
CGPLBR69 0.89 0.31 -1.50 -0.27 1.52 0.65 0.68 -0.32 -0.53 -0.95 -0.91 0.84 0.38 -0.81 -0.34 0.99 -0.04 1.15 0.05 
CGPLBR70 0.78 0.00 -1.12 -0.59 1.14 -0.52 -0.48 0.51 0.72 -0.65 -2.12 1.86 1.42 0.04 0.26 0.29 -0.53 -0.97 -1.02 
CGPLBR71 1.69 -0.08 -0.89 1.19 1.47 -1.32 -0.87 0.63 -0.43 -0.56 -1.74 -0.60 0.56 0.21 0.67 -1.38 -1.74 -0.63 -1.80 
CGPLBR72 -0.32 -1.09 -1.30 -1.31 0.93 -0.31 -0.65 1.00 0.09 0.79 -0.46 1.26 -0.01 1.55 1.37 -1.03 -0.70 0.30 1.06 
CGPLBR73 -0.53 0.10 -1.32 -1.14 0.02 -0.53 0.23 0.47 0.76 0.58 -1.49 1.01 0.54 0.00 0.56 1.28 0.29 0.47 1.08 
CGPLBR76 -0.23 0.66 -0.75 -0.31 1.69 -0.71 -0.70 0.12 1.41 -1.50 -3.13 1.18 2.27 -0.79 -0.21 -0.75 -1.02 -0.64 -0.19 
CGPLBR81 -0.99 0.00 3.50 5.95 2.11 0.53 -0.43 -3.17 -3.40 -3.68 -3.13 4.89 0.51 -2.97 -3.01 -2.74 -4.12 -2.19 -2.39 
CGPLBR82 -0.45 -0.32 0.72 -0.62 2.10 -0.67 0.01 -1.56 -2.13 -0.87 -0.16 1.02 0.88 -0.54 -1.39 -0.70 -0.11 1.89 1.10 
CGPLBR83 0.91 0.33 3.71 2.97 -0.70 0.60 1.01 -2.19 -1.83 -2.52 -1.27 2.70 1.64 -2.13 -2.25 0.38 -1.27 0.41 -0.68 
CGPLBR84 0.06 0.83 3.64 5.94 -0.06 0.71 -1.38 -1.84 -2.48 -3.96 -3.95 2.06 0.86 -2.05 -2.49 -1.48 -4.77 -2.21 -2.28 
CGPLBR87 -2.18 -0.60 4.23 6.41 -0.60 -0.01 -0.79 -2.58 -4.58 -3.73 -2.21 6.75 0.98 -2.21 -3.23 -3.69 -3.94 -1.11 -1.76 
CGPLBR88 -3.66 -1.76 3.31 2.05 -1.13 0.28 -1.43 -2.15 -2.59 -3.61 -4.63 9.21 2.68 -1.85 -3.01 -1.99 -3.32 -0.77 -0.83 
CGPLBR90 -0.20 -1.25 3.37 4.93 2.25 0.80 -0.43 -2.30 -4.43 -3.11 -2.34 3.06 1.52 -2.14 -2.41 -2.80 -3.91 -2.51 -3.12 
CGPLBR91 0.59 0.50 -1.11 -0.04 -0.09 -0.63 -0.96 0.10 0.06 0.30 -2.20 -0.38 0.92 -0.49 -0.11 0.65 0.44 -0.87 -0.03 
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CGPLBR92 -2.89 -2.35 -1.98 -4.06 0.30 -2.48 -0.11 1.22 0.50 2.11 1.70 2.69 -0.99 2.12 0.73 0.27 2.26 2.20 2.94 
CGPLBR93 0.66 -0.53 -0.71 0.34 -0.07 -0.94 -0.70 0.03 0.64 0.57 -0.48 1.59 -1.11 -0.15 -0.31 -0.78 0.59 -0.36 0.14 
CGPLH189 -0.01 -0.95 -0.20 -0.33 0.27 1.39 0.97 -1.85 0.35 -0.18 0.07 1.68 1.01 -1.20 -1.22 1.28 -0.18 0.90 0.44 
CGPLH190 -0.33 1.59 -2.55 -1.10 1.29 -1.55 -0.83 0.25 0.86 0.14 -2.39 -0.39 0.01 -0.50 0.10 2.13 0.20 -0.05 -0.56 
CGPLH192 -0.69 0.46 -0.45 -0.84 -0.84 -0.90 -0.22 0.55 -0.39 0.95 0.13 -0.38 -1.18 0.21 0.44 -0.11 0.86 -1.46 -0.11 
CGPLH193 1.15 0.38 -0.22 1.10 -0.12 -1.01 -0.78 0.35 0.53 0.50 -0.74 -1.30 -0.39 0.63 0.52 -0.27 -0.88 -1.08 -0.38 
CGPLH194 0.66 1.17 1.53 -1.51 -0.01 -0.35 1.08 -2.16 -0.64 -0.35 1.14 1.34 -0.95 -2.05 -2.68 1.39 1.63 0.36 1.00 
CGPLH196 0.23 0.64 -0.54 -0.60 0.63 -0.75 0.19 0.18 -0.51 1.04 0.67 -0.13 -0.83 -0.25 -0.13 1.64 0.00 -0.07 -0.07 
CGPLH197 0.14 -0.33 -1.14 0.79 1.73 0.06 -1.31 -0.21 -1.24 0.40 -1.16 0.12 -0.92 0.02 0.46 -1.94 -1.98 -2.61 -1.36 
CGPLH198 -0.23 0.47 0.30 0.34 -1.93 -1.47 -0.01 0.56 0.48 0.87 0.71 -0.61 -0.36 0.00 0.15 0.17 0.85 -2.42 -0.76 
CGPLH199 2.60 1.01 -1.72 2.68 -0.70 0.33 0.17 1.62 2.18 -1.54 0.00 1.37 -1.13 -0.45 0.64 0.47 -0.69 -0.57 0.32 
CGPLH200 0.17 -0.61 -1.31 0.62 -0.74 -1.55 -1.33 1.07 1.25 1.45 -0.33 -0.29 -1.05 1.42 1.54 -0.81 -0.42 -0.96 -1.15 
CGPLH201 0.43 0.33 -0.49 0.96 -0.78 0.04 -0.94 0.34 0.09 0.36 -0.74 0.16 0.47 0.75 0.54 -1.35 -0.25 -0.52 -0.77 
CGPLH202 -0.66 -0.40 -0.36 0.59 -0.53 -0.22 0.50 0.57 -0.54 0.12 0.00 -1.10 -0.39 0.03 -0.29 -0.51 0.72 -1.33 0.90 
CGPLH203 0.52 0.42 1.02 -1.19 0.43 0.01 1.21 -0.12 -0.96 -1.13 0.59 -0.43 -0.90 -0.84 -0.85 0.87 0.22 0.24 1.00 
CGPLH205 0.00 0.57 1.67 1.25 -1.85 -0.69 1.07 -1.32 -1.35 -0.02 2.25 0.74 -0.42 -1.18 -1.57 -0.94 -0.11 -0.18 0.29 
CGPLH208 0.43 1.07 -1.22 -0.11 -0.34 -1.01 -1.83 0.69 0.23 -0.34 -0.85 -2.31 -0.34 0.43 0.49 0.66 0.06 -0.51 -0.80 
CGPLH209 0.72 0.76 -1.52 -0.39 0.24 0.23 -1.01 0.33 0.67 -0.63 -2.22 -0.30 0.69 -0.06 0.27 1.50 0.44 -0.37 0.43 
CGPLH210 0.38 0.48 -1.13 -1.34 -0.47 -0.63 -0.26 -0.55 1.31 -1.06 -1.32 0.90 1.80 -1.47 -0.60 1.02 0.69 -0.22 0.17 
CGPLH211 0.10 0.01 4.32 0.15 -0.32 -0.41 -0.23 -1.63 -0.85 -0.92 -0.42 0.82 0.52 -1.01 -1.04 0.57 0.23 -0.38 0.73 
CGPLH300 0.15 0.36 -1.26 1.03 0.74 -0.35 0.45 -0.49 -1.58 0.39 -0.91 2.19 -0.02 -0.71 0.07 0.10 0.31 -1.95 0.06 
CGPLH307 0.20 -1.01 -0.02 1.93 0.23 1.15 -0.13 -0.57 -1.91 -0.70 -1.11 1.60 -0.29 -0.43 -0.75 -1.13 -0.37 -0.13 -1.35 
CGPLH308 0.87 0.66 0.21 0.94 1.07 0.35 0.66 0.48 -0.13 -1.32 -0.65 0.03 -0.27 -1.21 -0.89 -0.33 1.12 -0.15 -0.02 
CGPLH309 0.66 -0.52 1.14 0.15 -0.52 0.65 0.87 -0.09 -0.64 -0.41 2.34 0.91 -0.30 -1.25 -1.09 -0.26 -0.49 -0.10 -0.16 
CGPLH310 1.73 0.47 -2.72 0.36 1.37 -0.98 -0.64 0.19 0.26 0.19 -1.95 0.76 0.91 -0.35 -0.32 -0.30 -0.11 1.45 -0.76 
CGPLH311 0.33 -1.61 -0.62 0.38 0.48 0.58 -0.41 0.78 0.09 0.83 -0.48 0.59 -0.93 0.42 0.83 -1.33 -0.26 -0.41 -0.78 
CGPLH314 0.34 0.56 -0.68 0.35 -0.45 0.19 0.95 0.28 0.42 0.41 0.70 -0.02 -0.34 -0.80 -1.06 1.76 1.85 0.67 0.82 
CGPLH315 0.13 -0.09 -0.82 0.42 0.49 -0.34 -0.36 0.86 -0.42 0.95 -0.27 1.34 -0.78 1.36 0.90 0.76 0.36 0.49 0.27 
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CGPLH316 1.38 0.79 -1.55 -0.56 0.43 -1.15 0.01 0.48 1.12 -0.30 -0.61 1.68 -0.59 -0.44 -0.02 2.65 0.79 1.05 0.30 
CGPLH317 0.40 1.35 -0.86 -0.63 0.32 -0.98 0.19 0.68 0.97 -1.73 -1.87 0.95 -0.07 -1.15 -0.90 0.69 0.83 -1.50 1.13 
CGPLH319 0.49 -0.80 -1.20 0.76 1.50 -0.20 -1.00 0.45 0.42 -0.31 -2.32 0.09 0.27 -0.41 0.10 -1.11 -1.31 0.13 -0.76 
CGPLH320 0.62 -0.72 -0.41 2.05 0.28 -0.37 0.16 0.41 0.23 -0.38 0.21 -0.04 -0.34 0.19 -0.04 0.28 -0.61 0.24 -0.34 
CGPLH322 0.34 0.12 -0.01 -0.53 1.16 -0.61 0.61 -0.10 -0.57 -0.08 0.95 -0.44 -0.49 -0.57 -0.47 1.04 1.84 0.34 1.54 
CGPLH324 0.12 0.44 -1.11 1.13 0.14 0.46 -0.02 -0.19 -0.15 0.21 -0.07 -0.12 0.23 -0.49 0.13 -0.19 -0.23 0.48 0.35 
CGPLH325 -0.27 -0.74 -0.84 0.85 0.34 -0.61 -0.20 0.36 -1.01 0.31 -1.11 -1.31 -0.98 0.67 0.53 -1.32 -0.73 -1.17 -0.37 
CGPLH326 0.09 1.37 -0.64 0.35 0.48 -0.54 0.31 1.15 -1.23 -0.24 0.28 0.68 0.34 -0.49 -0.97 0.10 0.24 0.43 -0.03 
CGPLH327 -0.04 -0.22 -0.66 0.72 1.10 0.40 -1.11 2.54 -0.12 0.11 -0.75 -0.79 -0.89 0.38 0.65 -0.72 -0.40 -0.59 -0.63 
CGPLH328 -0.89 -1.53 -1.41 1.61 0.60 -1.61 -2.13 1.16 -0.33 1.28 -0.71 -1.41 -0.33 2.08 1.88 -0.74 -1.07 -0.06 -1.54 
CGPLH329 0.00 0.85 -0.16 0.99 -0.38 0.05 0.29 0.60 -7.35 0.37 -0.02 -0.41 -0.78 -0.26 -0.49 0.97 -0.04 1.29 0.25 
CGPLH330 -0.20 -1.11 -0.74 0.63 0.91 -0.63 -1.10 1.34 -0.39 0.73 0.33 -0.85 -0.89 1.26 0.43 -1.74 -1.30 -0.03 0.39 
CGPLH331 -0.68 -1.45 -0.37 1.42 -0.63 0.83 0.17 1.06 -1.42 1.85 1.10 0.55 -1.90 0.94 1.08 -0.81 -0.37 0.01 -0.27 
CGPLH333 0.71 0.38 -0.90 0.70 -0.63 0.69 0.31 0.50 0.49 0.86 -1.03 0.73 1.10 -1.10 -0.25 0.18 0.42 -1.15 0.86 
CGPLH335 -0.71 -0.44 -0.34 1.62 0.21 0.08 -0.31 0.88 -0.52 0.07 -1.02 -1.39 0.42 -0.01 0.12 -0.22 0.17 0.36 -0.11 
CGPLH336 -0.13 0.97 -0.92 0.14 1.35 0.65 -0.26 -0.01 -1.53 -0.48 -0.25 1.30 1.17 -0.54 0.14 -0.48 -0.86 -1.09 2.62 
CGPLH337 0.87 1.16 0.54 0.19 1.45 0.90 0.54 -1.20 -0.04 -0.90 0.05 0.21 0.06 -0.74 -0.50 -0.71 0.20 -0.50 0.15 
CGPLH338 0.95 1.14 -1.26 0.37 2.56 -1.76 -1.18 -0.04 -1.04 -0.70 -1.72 -0.61 0.87 0.38 0.04 -0.19 -0.22 0.34 -0.72 
CGPLH339 0.92 0.06 -0.74 -0.78 0.33 0.04 0.67 0.29 -0.33 0.48 -1.40 2.54 0.09 -0.60 0.07 0.10 -2.01 -0.79 0.50 
CGPLH340 1.23 -0.16 -0.27 1.23 0.36 0.60 -0.23 -0.10 -0.11 0.53 -0.71 -0.36 -0.80 -0.13 0.52 0.57 -0.23 0.72 -1.15 
CGPLH341 0.02 0.59 -1.84 2.46 2.37 0.35 -1.07 1.60 0.46 -1.32 -2.54 0.53 0.67 -0.22 0.98 -0.19 -2.03 -2.63 -2.37 
CGPLH342 -0.11 0.70 -1.61 0.14 1.38 0.24 -1.24 -0.30 0.66 0.32 -1.27 0.72 -0.18 0.21 0.69 0.72 -0.05 0.17 -0.11 
CGPLH343 -1.36 0.11 -1.08 0.29 0.08 0.45 0.49 0.36 0.94 2.15 0.42 -0.06 0.18 0.36 1.38 -0.70 0.93 -1.04 0.42 
CGPLH344 0.84 0.25 -0.90 -0.36 0.08 0.56 0.63 -0.67 -0.81 -0.17 -1.64 2.65 0.96 -1.56 -0.52 1.08 0.92 -0.67 -0.44 
CGPLH345 0.28 0.63 1.82 0.65 -0.24 0.03 0.52 0.02 0.72 1.09 -0.35 0.96 0.78 -0.92 0.28 -0.60 0.74 -1.17 0.64 
CGPLH346 0.88 0.42 -0.28 0.94 -0.41 0.63 -0.15 0.37 -0.99 -0.04 -0.85 0.37 -0.35 0.11 0.36 -0.54 -1.87 -1.77 -0.01 
CGPLH350 -0.55 -0.61 0.21 -0.20 -2.19 1.66 1.19 0.56 0.85 0.62 -0.38 2.99 0.60 -1.04 -1.21 -1.29 1.75 0.51 2.94 
CGPLH351 -2.51 -1.75 -0.85 -0.36 -0.04 -1.18 -0.57 1.48 -0.38 1.75 0.03 2.84 -0.44 1.80 1.75 -1.69 -0.25 -0.25 0.51 
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CGPLH352 0.81 1.02 -0.34 0.70 -1.18 1.51 0.17 -0.11 -0.26 1.20 0.62 -0.59 -1.29 -0.01 0.32 0.40 0.62 0.09 0.15 
CGPLH353 -0.33 0.32 0.40 1.24 0.82 0.57 0.88 -1.69 -0.46 -0.93 0.52 1.32 0.24 -1.08 -0.33 -0.32 -0.11 -0.17 0.49 
CGPLH354 0.60 0.84 -1.45 1.67 -0.73 0.16 0.50 0.40 0.22 1.27 -0.19 -0.57 -0.86 0.11 0.48 -0.03 0.72 -1.15 -0.32 
CGPLH355 0.17 -1.01 1.83 2.87 0.38 2.56 0.00 -0.90 -2.34 -0.53 1.46 1.44 -2.02 -0.41 -0.74 -1.07 -0.58 -0.30 -0.68 
CGPLH356 1.22 1.25 2.71 -1.11 3.04 0.46 3.36 -3.98 -3.19 -1.99 2.37 0.35 -1.44 -2.12 -2.62 0.76 -0.37 0.68 1.75 
CGPLH357 0.11 -0.91 -1.50 -0.06 -0.08 -1.42 -1.36 0.82 -0.27 1.23 0.56 0.14 -0.84 1.93 1.82 -1.05 -0.04 -0.09 0.36 
CGPLH358 0.20 -1.44 -0.42 -2.46 2.55 0.05 0.05 -0.64 -1.32 0.30 -0.94 0.42 1.20 0.17 -1.04 -0.71 -0.29 1.17 -0.01 
CGPLH360 0.50 0.52 0.03 0.70 -0.28 -0.16 0.04 -0.48 -0.65 0.27 -0.77 0.73 -0.33 -0.25 0.01 -0.74 -0.66 -1.62 1.66 
CGPLH361 0.55 -0.11 -0.53 -1.37 0.99 -0.66 0.68 -0.73 0.46 0.07 0.25 -0.24 0.17 -0.02 -0.27 0.76 1.39 -0.11 2.47 
CGPLH362 0.83 -1.15 -1.64 0.48 0.72 -0.38 -0.44 0.24 -0.18 -0.16 0.12 0.85 -0.03 0.91 0.83 -0.77 -2.00 0.22 -0.05 
CGPLH363 0.42 1.12 -2.08 -0.53 0.96 -0.71 -0.97 0.10 0.38 -0.08 -1.54 0.54 0.15 -0.25 0.17 0.36 1.11 -1.06 0.02 
CGPLH364 -1.10 -1.55 -2.88 -2.03 0.18 -0.17 -0.91 1.29 0.68 0.27 -0.84 3.76 -0.22 1.19 0.83 -1.63 -0.49 1.19 0.63 
CGPLH365 0.12 -1.12 0.56 1.66 1.67 1.20 -0.24 -1.84 -3.26 -1.70 0.43 0.93 -0.78 -0.76 -1.13 -2.39 -2.47 0.28 -0.43 
CGPLH366 -0.25 1.24 -0.03 0.15 2.33 0.81 0.41 -1.45 -1.40 -0.63 0.45 -0.41 -0.26 -1.27 -1.02 -0.31 -0.37 0.50 0.62 
CGPLH367 0.21 0.38 -1.23 0.49 -0.03 -1.44 -0.15 0.64 1.12 -0.02 -0.76 1.37 0.10 0.39 0.57 1.10 0.36 -0.55 0.69 
CGPLH368 0.50 1.34 -0.64 -0.38 -0.21 1.00 -0.47 0.22 0.17 -1.46 -1.39 -0.12 0.76 -0.30 -0.04 0.32 -0.20 0.54 -0.79 
CGPLH369 0.55 -0.78 -1.79 -0.75 0.80 -0.80 -0.93 0.55 0.77 0.97 -0.54 1.14 -0.95 1.08 0.90 -0.86 -0.11 2.10 -0.34 
CGPLH370 0.54 1.01 -1.75 -2.85 1.17 -1.01 -0.31 -0.14 0.26 0.19 -0.72 -1.01 0.82 -0.76 -0.27 3.15 1.88 1.67 1.36 
CGPLH371 0.02 1.31 -0.29 -1.08 0.30 -1.06 -0.08 0.36 -0.19 -0.55 -2.62 0.18 1.03 -0.87 -0.42 2.12 0.25 0.05 0.64 
CGPLH380 -1.98 -1.65 -0.92 -0.33 -0.51 0.43 0.98 0.88 -0.66 2.65 1.61 0.36 -2.00 1.35 0.95 -2.13 -0.15 -0.40 1.75 
CGPLH381 -1.70 -0.46 -1.57 -0.26 0.20 -1.12 -0.17 0.53 0.49 1.91 -0.80 1.66 -0.88 0.99 1.40 -0.48 0.08 -0.69 1.44 
CGPLH382 -0.77 -1.44 -1.52 0.09 1.35 -0.04 -1.20 0.53 -0.62 1.34 0.52 0.33 -1.37 1.33 0.94 -1.38 -0.34 0.03 0.51 
CGPLH383 -1.77 -0.92 0.41 -0.39 -1.06 0.25 2.01 0.41 -0.26 3.27 2.56 1.99 -1.98 0.45 0.29 -1.28 1.77 -0.11 2.74 
CGPLH384 0.69 1.15 -0.34 1.66 0.60 1.49 0.97 -1.15 -1.11 -0.65 0.58 0.10 -0.71 -0.97 -0.58 -0.40 -0.33 -1.77 1.55 
CGPLH385 -0.40 -0.36 -0.99 -0.90 0.35 -1.51 0.63 1.30 0.18 0.89 -0.46 1.08 -0.91 0.55 0.68 0.09 0.92 -1.25 1.24 
CGPLH386 1.56 0.83 0.02 0.54 0.98 -0.24 -0.13 -0.16 -1.17 -0.29 -1.65 0.44 0.03 -0.58 -0.35 -1.19 -0.31 -0.73 -0.76 
CGPLH387 1.33 0.24 -0.49 1.47 0.79 1.21 0.12 -0.14 0.12 -0.30 -0.17 0.00 1.82 -0.78 -0.77 -0.03 0.06 0.33 0.87 
CGPLH388 0.22 -0.28 0.73 -0.26 0.87 -0.20 1.04 -1.18 -1.00 -0.04 0.84 1.34 -1.79 -0.05 -0.28 -0.41 -0.23 0.43 1.90 
292 
 
CGPLH389 0.36 -0.89 -1.70 1.86 1.41 -0.02 -1.74 0.84 -0.63 -0.37 -2.21 1.02 0.55 0.30 0.52 0.05 -0.67 0.03 -1.28 
CGPLH390 0.38 0.94 -0.55 0.48 -0.77 -0.94 1.84 0.29 -0.93 1.72 2.11 -0.50 -0.54 -0.33 -0.50 2.41 1.86 0.41 2.44 
CGPLH391 1.11 -0.08 -1.73 0.38 0.74 -0.57 -2.08 0.50 -0.57 -0.06 -1.26 -0.49 -0.55 1.08 1.60 -0.72 -1.41 -1.60 -0.71 
CGPLH392 -0.44 -0.44 1.78 1.12 1.74 1.03 -0.99 0.43 -1.91 -0.74 -1.21 0.95 -0.46 0.40 0.36 -2.56 -2.29 -1.45 -1.87 
CGPLH393 -0.08 0.52 -0.09 1.04 -0.36 0.25 1.43 -1.22 0.28 0.58 -0.23 2.01 -0.64 -0.74 -0.42 -0.97 -0.36 -0.86 1.47 
CGPLH394 0.29 -0.05 0.58 2.25 -0.28 0.61 0.12 -0.32 -2.52 0.05 0.77 -2.02 -1.15 0.43 -0.28 -2.16 0.02 -0.86 0.50 
CGPLH395 0.57 -0.42 -0.72 -0.58 -0.31 0.46 -0.85 1.28 -0.81 0.56 0.11 -1.78 -1.73 1.51 1.53 -1.02 -0.06 -0.20 -0.19 
CGPLH396 0.74 -0.18 -0.12 -0.47 1.71 -0.26 -0.13 -0.73 0.01 -0.35 -2.27 2.14 1.58 -0.87 0.06 -0.38 0.03 -0.51 -0.15 
CGPLH398 0.94 0.77 -2.30 -0.49 1.04 -0.86 -0.79 0.89 0.95 0.68 -2.17 1.68 0.68 -0.13 0.20 0.60 0.47 -0.30 -0.28 
CGPLH399 -0.49 -0.94 0.25 2.04 1.75 0.92 -1.06 -0.21 -1.73 0.45 -0.95 0.92 -0.91 0.74 0.43 -2.18 -8.14 -0.69 0.33 
CGPLH400 0.06 0.44 2.61 -0.54 0.77 0.84 2.25 -2.69 -2.35 -0.33 2.63 0.85 -0.98 -1.50 -2.37 -2.89 0.72 -0.27 2.60 
CGPLH401 0.93 1.44 -1.39 -2.09 -1.27 -0.65 0.32 0.38 -0.22 2.28 -0.31 2.41 -0.34 -0.10 -0.10 1.63 1.44 0.07 0.23 
CGPLH402 0.11 1.42 -0.47 1.63 0.01 0.14 -0.36 0.68 -1.72 2.55 0.33 -2.23 -2.07 1.37 1.67 -2.45 0.52 -2.66 0.17 
CGPLH403 -0.53 -0.95 -0.07 -1.04 -0.53 -1.04 -0.44 0.56 -2.08 2.61 0.25 -1.05 -2.01 1.19 1.90 -2.01 -0.18 -1.26 1.33 
CGPLH404 -1.23 0.22 -0.46 1.35 0.32 -0.11 -1.42 1.03 -1.38 1.95 -1.78 -1.39 -1.36 1.23 2.06 -1.69 -1.84 -2.28 -0.24 
CGPLH405 0.45 1.52 0.31 1.93 -0.41 0.76 -1.28 -0.60 -2.76 1.16 0.38 -1.83 -1.80 0.70 0.86 -1.67 -0.36 -0.83 -0.78 
CGPLH406 0.03 0.17 1.43 1.24 0.47 0.08 -0.85 -0.27 -1.89 1.50 -0.69 -0.68 -1.91 1.18 2.20 -0.38 -1.97 -2.22 0.31 
CGPLH407 0.11 1.14 0.16 1.12 0.13 -0.92 -0.87 0.46 -0.44 0.63 -0.46 -1.27 -2.17 0.42 0.44 -3.04 0.15 -2.11 1.59 
CGPLH408 0.18 0.16 -0.70 0.90 -0.03 -0.04 0.00 0.90 0.06 0.91 -0.29 0.11 0.41 1.18 1.64 0.65 -0.85 0.14 0.09 
CGPLH409 0.11 0.50 -0.36 -0.68 -0.49 0.09 1.02 -0.49 -0.77 1.74 -0.24 0.68 -1.45 0.08 1.09 -0.59 -0.51 -0.78 0.90 
CGPLH410 -0.05 0.52 0.58 0.93 -0.16 -0.56 -0.23 0.38 -1.19 1.55 -0.52 1.31 -1.23 0.21 1.05 -0.53 -1.03 -1.46 -0.17 
CGPLH411 0.98 0.62 -0.04 -0.02 0.02 -1.23 -0.08 0.05 -0.64 0.45 -1.91 1.70 0.60 0.14 1.04 -0.61 -0.03 -1.31 1.09 
CGPLH412 -0.41 0.49 -0.28 0.63 -0.58 -0.55 -0.28 0.78 -1.14 0.69 -0.04 0.38 -1.08 0.86 1.70 -1.14 -0.01 -1.81 0.04 
CGPLH413 -0.92 -0.03 -1.32 0.37 -1.05 -1.46 -0.19 1.82 0.20 1.50 -0.76 0.15 -0.74 1.38 2.15 -1.78 0.77 -1.50 0.74 
CGPLH414 -0.91 0.27 -0.10 -0.87 0.24 0.31 -0.23 0.09 -0.83 1.07 -1.75 -0.69 -1.03 0.47 1.21 -0.31 -0.90 -2.31 0.57 
CGPLH415 -0.65 0.39 -1.33 0.06 -0.96 -0.29 -0.65 1.47 -1.11 1.15 -1.13 1.64 -0.75 0.63 1.63 -1.60 1.08 -2.83 0.87 
CGPLH416 -0.73 1.85 2.23 -0.11 -0.32 -1.32 1.33 -2.40 -2.43 1.08 1.50 2.85 -1.79 -1.26 -1.58 -0.02 3.05 0.25 1.88 
CGPLH417 0.03 2.22 2.48 1.08 -0.03 -0.16 0.69 -1.81 -3.69 1.20 1.76 0.49 -2.43 -0.27 -0.56 -0.85 -0.91 -0.51 1.21 
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CGPLH418 -1.79 0.94 -0.11 -1.68 -0.57 0.16 0.01 -0.21 0.07 0.37 -1.06 3.00 -0.61 -0.50 0.42 -1.94 0.76 -1.68 1.97 
CGPLH419 0.15 0.28 1.34 2.05 0.93 0.03 0.19 -0.49 -0.90 -0.41 0.33 1.14 0.14 -0.42 -0.42 -1.50 -0.69 0.76 0.19 
CGPLH420 0.46 0.36 -0.92 1.45 -0.20 0.66 0.05 0.40 1.44 0.61 -0.60 -1.12 -0.46 -0.43 0.45 -0.64 0.06 -0.69 -0.23 
CGPLH422 -0.53 0.24 0.48 1.27 0.24 0.07 1.13 -0.52 -1.96 0.55 1.66 -0.19 -1.78 -0.26 -0.19 -1.00 0.01 -0.22 1.67 
CGPLH423 -1.05 -0.56 0.54 0.82 -1.55 0.84 0.53 -0.09 -0.99 1.56 1.74 0.96 -1.20 0.32 0.30 -0.83 -0.06 -1.01 0.85 
CGPLH424 -0.67 -1.30 -0.13 1.12 0.06 -0.91 -0.98 0.89 -0.55 1.90 0.22 -0.16 -1.72 1.44 1.66 0.02 -0.55 -0.62 -0.34 
CGPLH425 0.14 -0.23 0.15 1.15 1.07 0.21 -0.28 -0.80 -1.51 -0.29 -0.01 1.49 -1.08 -0.15 -0.06 0.69 -0.16 0.89 0.46 
CGPLH426 -1.09 -0.77 0.68 2.27 -0.62 0.46 0.51 0.05 -1.65 1.45 0.03 -0.36 -0.97 -0.17 0.32 -2.18 -0.09 -1.48 0.50 
CGPLH427 -0.41 0.09 -0.38 1.19 -0.05 0.24 -0.21 0.11 -0.90 0.40 -0.03 -1.25 -1.58 0.57 1.26 -0.64 -1.04 -1.50 -0.14 
CGPLH428 -0.75 0.87 -0.19 1.28 -1.44 -0.27 0.24 0.38 -0.01 -0.47 0.44 0.10 -0.49 0.08 1.18 -0.78 -0.03 -1.53 0.08 
CGPLH429 1.36 0.31 1.75 1.63 1.29 0.79 0.89 -1.79 -1.53 -1.93 -0.89 2.28 -0.04 -2.31 -1.92 -1.38 0.15 0.20 0.38 
CGPLH430 0.72 -0.10 -0.64 1.69 0.95 -0.59 -0.74 0.49 -0.32 0.42 -0.66 0.72 -0.21 0.43 0.37 -1.07 -0.44 0.56 -1.22 
CGPLH431 0.18 1.33 -0.04 0.88 0.27 -0.17 0.94 0.44 -0.98 1.64 1.22 -0.65 -2.32 0.48 0.78 -1.02 0.52 -0.80 0.76 
CGPLH432 -0.16 0.13 -0.22 1.61 0.53 -0.25 -0.36 -0.52 -0.17 0.10 -0.32 0.75 -0.98 0.60 0.94 -1.02 -1.28 -2.79 -0.56 
CGPLH434 0.26 0.78 -0.15 0.91 0.41 0.73 0.38 -0.40 -0.28 0.75 0.63 -0.92 -0.94 0.31 0.18 0.18 0.01 -0.80 0.45 
CGPLH435 0.61 0.05 -0.80 -1.36 0.17 -0.91 -0.19 0.14 0.20 0.89 -0.68 2.58 -0.44 0.27 0.24 -0.39 1.33 0.35 0.91 
CGPLH436 0.35 -0.22 0.14 2.37 1.09 1.39 -1.20 0.47 -0.89 -1.42 -0.83 0.64 -0.49 0.34 0.58 -0.43 -1.77 -0.83 -0.82 
CGPLH437 -1.26 0.57 -0.67 1.46 -1.06 0.17 -0.43 1.88 0.52 1.86 -0.69 -1.58 -1.04 0.42 1.05 0.76 0.23 -2.13 0.39 
CGPLH438 -0.06 0.00 -0.16 2.63 0.17 0.35 -0.25 0.46 0.18 0.50 -1.16 -0.80 0.60 0.08 0.78 -1.31 -1.16 -1.25 -1.13 
CGPLH439 -0.40 -1.09 -0.74 1.67 0.37 1.12 -0.46 0.80 0.72 -0.28 -0.86 0.12 0.26 -0.14 0.78 -0.86 -0.96 -0.61 0.07 
CGPLH440 -0.15 -1.22 -0.72 1.21 -0.13 -0.03 -0.08 -0.26 0.26 1.12 -0.65 1.14 -0.98 0.05 0.43 -0.75 -0.20 -1.14 0.92 
CGPLH441 -0.56 0.90 -0.62 0.07 -0.33 -0.18 -0.87 1.01 0.16 0.35 -0.89 -0.67 -0.54 0.33 0.74 0.00 0.16 -1.33 0.94 
CGPLH442 -0.24 0.11 -0.38 1.49 0.58 0.28 0.12 -0.40 -1.16 0.14 0.30 -2.10 -2.07 0.62 0.56 -0.82 1.25 0.74 1.01 
CGPLH443 0.90 0.37 -0.22 -0.70 0.88 1.91 -0.17 -0.93 -0.80 -1.12 -0.28 3.17 1.37 -1.16 -1.23 -2.85 -0.73 -1.02 -0.24 
CGPLH444 -0.14 -0.01 0.88 0.35 0.38 1.47 1.37 -1.10 -0.63 0.78 1.77 2.35 -0.57 -0.57 -0.78 -2.10 0.77 0.04 1.49 
CGPLH445 -0.08 -0.58 1.42 1.71 0.43 0.90 0.57 0.29 -0.67 -0.67 -0.34 2.37 0.27 -0.57 -0.18 -0.82 -1.72 -1.15 -0.22 
CGPLH446 -0.59 1.21 0.29 0.67 1.15 0.81 1.12 -0.65 -1.03 -0.17 0.87 -0.64 -0.90 -0.58 -0.42 -1.80 -0.29 -0.99 0.01 
CGPLH447 -0.50 -0.99 0.03 -0.76 1.12 1.24 0.20 -0.29 -1.02 0.31 -0.38 0.97 -0.06 -0.29 0.24 -2.14 0.09 -0.69 1.24 
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CGPLH448 -0.16 -0.36 0.04 0.06 1.64 1.05 -0.37 -0.30 -0.29 0.38 -0.77 -0.26 -1.35 0.41 1.35 -0.94 -0.40 -0.62 -1.60 
CGPLH449 0.01 0.52 0.83 -0.31 -0.77 1.19 1.54 -1.42 -0.83 0.55 2.17 2.35 -1.06 -0.91 -0.62 -1.33 1.45 1.13 1.98 
CGPLH450 -0.48 -1.07 0.22 0.08 0.20 1.53 0.25 -0.03 -0.06 2.00 0.25 0.17 -1.76 0.97 1.31 -0.44 0.16 -0.89 0.78 
CGPLH451 0.21 0.78 0.07 -0.39 -0.05 1.17 1.39 -0.51 -0.53 0.72 0.26 2.53 0.06 -1.03 -0.28 -1.12 0.44 -0.48 0.83 
CGPLH452 1.34 -1.70 0.95 2.07 2.35 0.85 -0.29 -0.43 -1.66 0.02 -0.78 2.98 -0.09 0.00 -0.48 -3.32 -2.05 0.28 -1.89 
CGPLH453 0.14 0.45 -1.03 -0.41 -1.46 -0.34 1.31 0.82 -0.08 1.11 2.27 -0.34 -1.56 0.30 -0.03 -0.52 1.24 -1.17 1.87 
CGPLH455 -0.67 0.51 1.28 1.06 1.48 0.82 -0.81 -0.61 -1.88 -0.88 0.39 -0.84 -1.89 0.48 0.11 -1.98 0.05 -0.74 -0.52 
CGPLH456 -0.82 -1.19 0.80 1.66 0.61 1.47 0.19 0.38 0.20 0.88 -0.27 -0.01 -1.10 0.74 1.09 -2.45 -2.16 -1.77 -0.22 
CGPLH457 -1.25 -0.99 -0.38 1.22 1.31 -0.78 -0.77 0.73 0.61 0.66 -0.77 2.40 -1.02 0.24 0.63 -0.86 -0.64 -1.33 -1.09 
CGPLH458 0.03 0.26 1.30 1.81 1.15 1.42 0.14 -1.60 -2.44 0.00 1.36 0.42 -1.43 -0.43 -0.61 -2.48 -1.09 -1.00 -0.19 
CGPLH459 -0.02 -0.61 -0.16 1.05 0.26 0.01 -0.04 -0.26 -1.09 0.74 1.91 2.34 -0.85 -0.42 -0.12 -1.11 -1.25 -0.75 -0.22 
CGPLH460 -1.12 -1.60 -0.59 -0.14 -0.36 0.15 0.70 0.95 -0.13 3.00 0.73 0.27 -2.19 1.61 1.82 -1.20 -0.36 -0.71 1.02 
CGPLH463 0.42 0.31 -0.39 0.55 0.68 -0.01 -0.03 1.32 -0.29 0.17 -0.11 -0.35 -0.63 0.71 0.79 -0.10 0.57 -0.63 -0.15 
CGPLH464 0.38 -0.52 0.00 0.31 0.32 -0.13 0.99 0.63 -0.94 0.49 -0.89 2.19 -0.39 -0.22 0.14 -2.56 -1.97 -2.10 -0.26 
CGPLH465 0.10 -0.19 0.57 0.41 1.24 0.64 0.65 -0.12 -0.31 0.32 0.05 0.56 0.99 -0.60 -0.15 0.17 -0.06 -1.59 0.21 
CGPLH466 -0.90 -1.53 0.44 0.65 -0.66 1.16 1.11 0.77 -1.53 1.69 0.97 -1.09 -1.45 0.64 0.95 -0.73 0.79 0.35 0.27 
CGPLH467 0.88 -0.12 0.61 1.55 0.35 1.53 0.11 -0.06 -1.20 -0.52 -1.30 0.15 0.15 -0.79 -0.13 -1.09 -1.19 -0.70 -1.33 
CGPLH468 -0.23 -1.33 -0.03 1.46 -0.10 0.37 -0.79 0.24 0.21 0.21 -1.32 1.53 0.17 0.26 0.65 -1.55 -1.21 0.25 -0.89 
CGPLH469 0.29 -0.63 1.35 3.32 2.00 2.72 0.56 -0.59 -1.64 -0.42 -1.25 -0.81 0.25 -0.65 -0.60 -2.07 -1.42 -1.67 -2.10 
CGPLH470 0.39 0.49 -0.37 -0.75 0.75 -0.67 -0.51 0.89 -0.68 0.16 -1.06 1.32 0.65 -0.10 0.37 0.63 0.65 -0.62 0.53 
CGPLH471 1.07 -0.03 -0.54 1.00 0.32 0.06 -0.08 0.69 -0.63 0.99 0.40 0.04 -1.14 0.86 -0.21 -0.43 0.37 0.72 0.28 
CGPLH472 -0.76 0.16 -1.30 0.47 1.38 -0.34 -1.98 1.69 -0.55 0.10 -2.37 -1.02 -0.86 1.04 1.58 0.19 -1.62 -0.47 -2.15 
CGPLH473 -0.40 -1.14 -0.90 1.80 0.65 1.06 -1.04 0.76 -0.86 0.58 -0.71 0.57 -0.63 1.18 1.16 -2.23 -2.59 -0.23 -1.50 
CGPLH474 -0.72 -0.49 -0.63 2.02 0.32 0.87 -1.24 0.61 -0.45 1.08 -1.08 1.89 0.62 0.40 0.20 -0.38 -0.34 1.67 -0.59 
CGPLH475 -0.83 -0.07 -0.45 1.80 0.90 -0.61 -1.17 0.90 0.38 -0.53 -1.04 1.94 0.08 0.40 0.79 -1.08 -1.04 -1.21 -0.31 
CGPLH476 -0.96 -1.43 -1.01 0.50 0.98 0.02 -0.88 0.77 0.33 0.22 -2.24 0.79 -0.01 0.25 0.90 -0.40 -0.60 -0.59 -0.57 
CGPLH477 -0.10 0.85 0.46 2.55 0.18 0.31 0.78 -0.92 -1.54 -0.14 1.34 1.33 -0.83 -0.71 -0.95 -1.13 0.91 0.29 1.38 
CGPLH478 0.72 -0.51 -0.21 -1.74 1.44 0.53 0.20 -0.68 -0.20 0.09 -1.20 1.79 0.29 -1.18 -0.85 0.15 1.64 0.05 0.82 
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CGPLH479 1.00 -0.08 0.41 1.16 0.84 1.54 1.36 -1.21 -1.51 -0.01 1.21 0.05 -1.99 -0.85 -1.37 -0.76 1.11 0.61 1.67 
CGPLH480 0.54 0.19 -1.60 1.04 1.72 0.70 -1.29 -0.40 -1.39 -0.54 -1.72 1.17 1.66 -0.80 -0.56 -0.43 -0.72 -0.61 -1.64 
CGPLH481 -0.26 -0.71 0.43 0.60 0.86 1.95 0.17 -0.11 -0.67 1.36 0.27 1.74 -0.02 0.19 0.06 -1.65 -0.85 0.13 -1.22 
CGPLH482 -0.02 -0.07 -1.48 0.36 0.38 0.72 -0.16 -0.20 0.75 2.05 -0.54 -1.10 -1.57 0.51 0.74 0.69 0.73 -1.18 1.03 
CGPLH483 -1.00 0.10 -0.85 1.71 1.08 0.36 -0.96 1.50 -0.31 -0.32 -0.08 -0.24 -1.97 1.20 1.54 -1.87 -0.53 -1.01 -0.68 
CGPLH484 -1.40 -0.74 -1.31 -0.10 -0.84 -0.94 0.11 1.15 -0.45 2.06 -0.09 1.05 -0.96 0.87 1.00 -1.04 0.42 -0.03 0.49 
CGPLH485 -1.19 -1.61 -0.75 1.40 1.29 0.48 -0.95 0.39 -0.33 0.76 -0.56 1.08 -0.23 1.03 1.12 -1.11 -1.42 -1.04 -0.80 
CGPLH486 -0.79 0.02 1.72 0.59 0.30 1.46 1.34 -0.17 -0.90 -0.58 -0.54 1.30 -0.07 -1.12 -1.21 -0.25 -0.92 -1.44 -0.94 
CGPLH487 1.33 -0.80 0.75 1.17 1.50 0.57 0.64 -2.48 -1.59 -0.72 -0.18 1.71 0.19 -1.27 -1.49 -0.61 -0.68 1.97 -0.10 
CGPLH488 1.17 1.16 0.40 -1.30 0.59 0.48 1.71 -1.57 -1.29 0.75 1.58 -0.17 -0.33 -1.32 -1.21 -0.28 1.11 0.29 1.28 
CGPLH490 0.44 1.23 3.26 -0.66 1.10 2.02 2.02 -2.72 -2.55 -1.74 1.65 0.71 0.67 -2.35 -2.48 -1.17 0.16 -0.26 1.63 
CGPLH491 1.66 0.92 -0.09 0.55 1.71 0.15 0.21 -0.14 -0.84 -0.60 -0.83 1.28 0.90 -0.90 -0.58 -0.17 0.45 -0.22 -0.20 
CGPLH492 -0.29 -1.02 -0.81 0.00 0.17 1.24 -0.16 0.55 0.27 1.25 -1.55 1.93 1.12 -0.54 -0.27 -0.89 -0.75 -0.81 -0.13 
CGPLH493 0.36 -1.26 -0.87 0.93 -0.14 -0.73 -0.17 1.86 0.83 0.35 -0.70 0.54 -0.28 0.41 0.61 -0.10 0.25 -0.37 -0.01 
CGPLH494 0.33 -0.51 -0.53 0.23 0.92 0.55 0.13 1.98 -0.25 0.50 -1.09 1.37 -0.04 0.38 0.28 1.80 -0.07 -0.27 -0.50 
CGPLH495 -0.16 0.75 -0.35 -0.72 1.23 0.87 0.62 -2.02 -0.62 -0.43 -0.01 2.70 0.46 -0.77 -0.66 0.17 0.48 1.01 0.88 
CGPLH496 0.93 0.10 -0.35 -0.11 1.51 0.05 -0.47 -0.79 -0.70 -0.21 -0.36 0.48 0.33 -0.14 -0.57 -1.65 -0.89 -0.03 -1.12 
CGPLH497 -0.44 0.32 -0.26 0.26 0.52 -0.20 0.36 -0.33 -0.76 -0.13 0.14 -0.87 -0.88 -0.10 0.45 -0.81 -0.39 -0.12 1.00 
CGPLH498 -0.36 -0.43 -0.02 -0.92 0.05 1.38 1.19 0.06 1.44 0.66 0.38 2.05 1.28 -1.00 0.08 0.30 0.02 -0.02 1.40 
CGPLH499 0.01 -0.37 0.03 0.71 2.04 0.07 -0.25 -0.20 -0.89 0.28 -0.01 0.49 -0.01 -0.10 0.67 -0.97 -0.87 0.06 -0.25 
CGPLH500 -0.91 -2.46 -1.23 0.37 1.58 -0.10 -0.51 0.27 0.34 1.23 -0.57 0.73 -0.82 0.95 1.35 -0.89 -0.37 -1.21 0.35 
CGPLH501 0.49 1.25 -0.77 -0.22 1.42 0.43 0.86 -0.88 0.51 -0.59 -0.48 0.37 1.34 -1.91 -1.18 1.03 1.17 -0.86 1.26 
CGPLH502 -0.88 -0.54 -1.48 -1.96 0.99 -0.95 0.11 1.21 -0.21 1.57 -0.35 -0.45 -0.61 1.24 1.49 -1.22 -0.12 -1.61 1.01 
CGPLH503 0.42 0.58 -0.91 -2.01 1.34 -0.93 0.49 -0.37 0.09 -0.38 -1.52 0.81 1.57 -1.53 -0.76 1.77 0.09 0.87 0.85 
CGPLH504 -0.71 -0.26 -0.96 -0.14 2.21 -0.47 -0.62 0.22 0.11 0.55 -1.18 1.23 -0.55 0.68 1.17 -0.76 -1.35 -1.57 -0.78 
CGPLH505 0.44 0.24 -0.50 1.43 0.98 1.22 0.79 -1.62 0.12 -0.71 0.68 -1.08 -0.81 -0.57 -0.08 0.43 -0.15 0.63 0.06 
CGPLH506 0.48 0.18 -0.87 0.14 0.24 0.26 -0.76 0.69 0.37 -0.65 -0.66 6.21 0.05 -0.35 0.14 0.07 -0.47 0.65 -0.83 
CGPLH507 0.88 0.97 -0.25 -2.51 0.81 -0.56 1.36 -2.63 -1.38 -1.36 0.36 1.28 -0.75 -1.76 -1.66 -0.06 1.41 0.83 1.76 
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CGPLH508 0.16 1.09 0.28 -1.65 0.00 -0.57 2.09 -1.39 -0.62 0.34 2.72 -0.80 -0.43 -1.57 -2.06 0.99 2.09 1.12 1.81 
CGPLH509 -0.65 1.68 0.34 0.30 1.48 0.00 1.08 -1.05 -0.51 -0.45 1.29 -1.20 -0.41 -1.02 -0.63 1.26 1.17 1.54 1.67 
CGPLH510 0.19 2.35 0.35 -1.19 -0.58 -0.52 1.46 -0.91 -1.94 0.45 0.84 0.92 -0.47 -0.33 -0.99 -0.10 0.44 0.65 1.56 
CGPLH511 1.41 0.96 -0.78 2.13 0.26 1.40 -0.30 -0.60 0.21 -1.02 -1.72 0.33 0.65 -1.75 -1.28 -0.09 1.46 0.37 0.31 
CGPLH512 0.79 0.38 -0.21 0.27 0.66 0.77 0.94 -0.57 -0.73 -0.36 0.50 -0.02 0.36 -0.95 -0.72 0.10 0.05 0.59 0.42 
CGPLH513 -0.06 -0.88 -1.53 -0.30 1.43 -0.90 -0.53 0.20 0.75 -0.38 -1.74 1.34 0.60 -0.12 0.11 1.31 0.80 -0.09 0.70 
CGPLH514 1.25 0.72 -0.32 0.24 0.43 -0.21 0.35 0.38 -0.73 1.18 0.69 -0.14 -0.32 -0.38 -0.06 0.55 -0.52 -0.83 -0.76 
CGPLH515 1.28 1.21 -1.51 0.55 1.76 0.34 -0.05 -1.18 -0.40 -1.14 -1.35 2.78 -0.10 -1.18 -0.66 1.18 0.23 -0.09 0.24 
CGPLH516 1.51 -0.45 -0.52 0.56 0.38 1.52 0.93 -0.18 -0.10 0.45 -0.45 -0.05 0.18 -0.47 -0.29 0.24 -0.22 -0.32 -0.56 
CGPLH517 0.12 -0.14 -1.20 -0.06 -0.51 0.09 0.64 0.56 1.11 1.11 0.85 0.99 -1.32 -0.03 0.75 -0.99 0.55 -1.13 0.54 
CGPLH518 -0.47 -0.02 -1.31 -0.94 0.33 -0.03 0.29 0.12 0.79 0.02 -0.30 1.55 0.52 -0.21 0.27 0.66 0.25 -1.87 0.88 
CGPLH519 -0.39 -0.24 -1.85 -0.90 0.01 -0.33 -0.03 -0.53 -0.09 0.30 -1.08 1.21 -0.78 0.09 1.17 0.34 -0.82 -1.22 0.86 
CGPLH520 0.47 0.28 -1.18 -0.76 2.37 0.40 0.53 -0.57 -0.63 1.37 -0.15 2.21 -0.06 -0.50 0.25 1.01 0.54 0.71 0.30 
CGPLH625 -0.30 -0.39 0.37 -0.22 1.01 1.01 0.64 -1.03 -1.12 -0.26 -0.92 -0.22 0.79 0.11 -0.16 -0.66 -1.82 -0.03 -1.00 
CGPLH626 -0.45 -0.69 -0.66 -1.06 -0.11 0.08 0.65 0.97 1.45 0.59 -1.71 1.67 2.70 -0.81 0.38 1.07 0.18 0.61 1.34 
CGPLH639 1.32 1.21 -0.37 -0.43 2.29 -0.18 0.02 -0.63 -1.13 -0.58 -0.56 -2.80 -0.14 0.11 -0.33 -0.45 -0.64 0.00 0.33 
CGPLH640 0.89 1.31 -1.57 -1.23 -0.19 -0.53 -0.10 0.81 0.07 1.46 -1.89 0.67 0.08 -0.07 1.32 1.41 -1.29 -2.72 -0.18 
CGPLH642 0.32 0.85 -0.69 0.23 1.62 0.68 -0.09 -0.60 -0.78 -1.33 -0.34 -1.89 -0.45 -1.01 -0.68 0.03 1.37 0.50 0.08 
CGPLH643 0.61 -0.48 -0.26 1.71 0.66 0.19 0.01 0.48 0.21 -0.79 -1.67 0.82 0.55 -0.53 -0.56 0.05 -0.93 -0.21 -0.54 
CGPLH644 0.62 1.70 -0.89 0.05 1.27 0.88 -0.45 -0.84 0.38 -1.82 -1.80 -0.23 0.16 -1.83 -0.56 0.84 -0.90 -1.26 -0.46 
CGPLH646 0.94 -0.07 -0.04 -0.08 -2.08 0.36 0.87 0.50 1.27 1.39 -0.05 -0.70 1.01 -0.94 0.08 1.43 0.68 -0.45 0.16 
CGPLLU144 11.14 -0.91 -1.16 -1.77 0.00 -4.65 -6.46 2.72 -4.24 -4.27 -3.77 7.92 -0.42 -0.07 1.15 2.20 -2.17 -1.28 -2.50 
CGPLLU161 -0.90 -0.23 0.14 -0.95 1.18 -1.65 -0.48 -0.32 -1.01 -0.66 -1.69 2.28 0.59 -0.29 -1.16 0.58 0.55 1.55 0.51 
CGPLLU162 -0.42 -0.58 -0.37 0.40 -0.29 -1.48 -1.95 0.20 -1.79 -1.37 -2.14 2.61 -0.15 0.03 0.09 0.48 -1.08 0.73 -1.33 
CGPLLU163 -4.81 -3.34 -1.11 68.97 8.82 1.59 -23.01 6.25 -6.11 -6.47 -9.87 -0.21 -5.50 -1.09 -1.83 10.36 14.85 -7.16 -10.44 
CGPLLU168 -0.54 -0.47 -0.40 1.30 1.28 0.24 -1.25 1.53 -0.49 -0.76 -1.35 -0.66 -1.52 0.98 1.78 -1.31 -1.01 -0.80 -1.03 
CGPLLU169 0.45 0.03 -0.37 -0.08 0.37 0.04 -0.54 1.29 -0.66 0.23 -1.29 0.84 0.12 0.46 1.34 -0.44 -1.82 -0.87 -2.26 
CGPLLU176 0.17 -0.69 0.17 3.45 0.33 1.79 -0.83 -0.47 -0.15 -0.09 -2.13 1.69 -0.17 -0.31 0.37 -1.10 -1.11 0.01 -1.43 
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CGPLLU177 -1.12 3.20 2.02 4.61 -1.91 5.12 -2.75 -1.81 -3.71 0.09 -1.46 1.46 -0.50 -2.75 -0.96 0.86 0.10 2.43 -4.22 
CGPLLU203 0.84 0.63 0.32 1.11 0.93 -0.91 -2.36 1.16 -0.25 1.72 -1.46 1.63 -0.99 0.50 0.92 -1.61 -1.84 -0.38 -1.90 
CGPLLU205 1.34 1.65 -0.56 2.29 1.27 -0.91 -0.76 0.15 -0.73 -0.70 -1.28 -1.24 0.69 0.38 0.91 -0.26 -1.68 0.48 -1.29 
CGPLLU207 0.56 -0.77 -1.22 -0.70 1.43 0.52 -1.62 0.57 -0.04 -0.66 -1.66 0.77 0.49 0.52 0.53 -2.35 -1.06 1.04 -1.33 
CGPLLU208 1.49 3.21 -1.13 1.89 -1.25 3.44 -3.39 1.29 0.02 -2.59 -1.49 0.56 -1.32 -0.18 0.71 -0.56 1.39 -2.68 -2.85 
CGPLOV11 2.85 1.71 -0.11 -3.55 0.67 -4.81 -3.03 -0.27 -5.05 -4.96 -1.00 -2.91 0.25 -0.15 -1.79 2.56 1.63 2.12 1.73 
CGPLOV12 -0.69 0.82 -0.95 0.55 1.68 -0.55 -2.16 0.13 3.82 -1.05 -2.26 -0.20 -1.08 0.25 0.40 -1.70 -1.32 -0.34 -1.70 
CGPLOV13 0.60 0.00 -0.73 -0.02 0.65 -0.50 -0.78 0.66 -0.19 -0.24 -1.18 -0.61 0.06 0.44 0.59 0.34 1.04 1.67 0.35 
CGPLOV15 -3.85 0.36 14.20 -10.50 -2.62 -5.24 -2.96 -2.13 -4.32 -5.59 -5.05 2.11 -4.13 -1.17 -0.44 8.76 6.80 -6.83 -6.84 
CGPLOV16 -2.54 -0.20 -1.04 -4.76 2.58 -0.35 -2.36 -0.25 -2.32 -1.97 -0.55 1.42 1.10 0.34 0.08 4.14 -0.83 1.79 1.49 
CGPLOV19 -14.01 -19.40 -50.86 -104.56 61.93 -95.47 -10.00 20.99 39.79 -100.59 -12.67 -80.06 -73.16 -0.96 0.04 6.95 170.74 -11.61 -10.54 
CGPLOV20 0.97 -0.96 -1.72 2.02 1.75 -0.81 -2.57 1.15 -0.44 -1.85 -3.87 -0.94 2.16 0.81 0.66 -1.04 -3.07 0.28 -2.96 
CGPLOV21 -4.03 2.33 -5.93 -2.63 0.19 -2.59 -4.16 1.68 -6.53 -2.21 -2.25 0.68 -0.12 1.88 3.80 9.16 0.84 -5.14 0.22 
CGPLOV22 0.40 0.77 -0.17 0.42 2.71 -0.41 -1.07 -0.26 -0.75 -1.15 -0.43 -0.56 -0.97 0.42 0.30 1.48 2.51 0.86 -0.13 
CGPLOV23 -1.61 -2.29 -2.31 2.28 -0.03 -0.12 -2.37 1.27 0.34 -0.53 -4.25 -2.02 0.96 0.78 1.57 1.20 2.41 -1.80 -1.63 
CGPLOV24 2.54 1.13 0.16 0.78 1.28 0.94 -0.80 0.17 -0.09 -0.80 -1.45 -1.91 1.48 -1.01 -0.45 0.86 -1.18 1.75 -1.79 
CGPLOV25 1.63 1.14 -0.30 0.18 2.72 1.41 -0.86 -0.07 -0.60 -1.11 -1.89 5.15 0.61 -1.32 -0.47 0.29 -1.33 0.78 -1.43 
CGPLOV26 1.66 -0.19 -0.83 2.72 1.73 0.30 -2.06 0.67 0.02 -1.67 -2.73 -0.71 1.13 0.57 1.00 -0.86 -2.25 -1.56 -2.97 
CGPLOV28 -0.11 -0.50 -0.89 0.79 0.88 -0.38 -1.12 0.85 -0.92 1.32 -0.62 1.03 -1.03 0.78 0.61 -1.45 -1.41 -0.48 0.04 
CGPLOV31 -0.61 -1.11 -0.31 0.33 0.81 -0.95 -0.73 0.56 -0.19 0.47 -0.82 0.28 -0.75 0.77 0.85 -0.43 0.31 -0.33 0.03 
CGPLOV32 -0.04 -0.14 -0.37 0.88 0.99 0.25 -0.63 0.38 -0.22 -0.70 -1.34 -0.22 0.52 0.13 -0.40 -0.25 -1.13 0.53 -0.09 
CGPLOV37 -0.90 -1.85 -1.55 -0.51 1.75 -1.56 -1.59 0.95 -0.22 -0.53 -3.97 3.75 1.70 -0.48 -0.16 0.24 -0.41 0.26 0.19 
CGPLOV38 2.02 15.28 2.36 -11.82 -3.16 0.64 -1.65 -6.19 -13.51 -10.47 -8.04 -15.59 -14.83 -0.99 0.99 22.29 2.10 5.07 -1.39 
CGPLOV40 -1.83 -2.18 -5.31 -4.54 2.68 -1.84 -3.89 1.69 -0.48 -0.67 -5.12 5.03 2.37 0.94 1.07 -0.61 0.02 -0.70 -1.37 
CGPLOV41 -1.08 -0.98 -0.19 -0.22 -0.09 1.41 -1.05 -1.13 -2.68 -1.54 -0.80 3.69 0.93 0.59 0.60 -0.01 1.34 1.84 -0.47 
CGPLOV42 -2.06 4.27 3.01 -0.94 1.71 0.56 -0.86 0.09 -1.21 -1.30 -1.49 -0.99 -0.84 1.20 1.12 -1.41 -1.68 -1.43 -0.45 
CGPLOV43 -0.10 0.05 1.11 0.64 1.24 0.07 0.24 -0.84 -0.86 -0.84 -1.55 0.49 1.66 -0.90 -0.65 -1.62 -1.94 0.32 -1.50 
CGPLOV44 -0.01 -0.82 -0.82 1.34 2.69 0.28 -3.55 1.11 -0.92 -1.44 -3.50 0.74 0.03 0.60 1.52 0.11 -2.24 -1.77 -3.05 
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CGPLOV46 0.87 -1.42 -0.92 2.09 1.20 0.47 -1.51 -0.26 -0.02 -0.15 -2.35 0.55 -0.05 1.27 1.22 0.60 -1.59 -1.05 -0.86 
CGPLOV47 1.03 2.12 -1.02 -1.80 -0.01 0.91 0.33 -0.02 -0.43 -0.22 -0.86 0.12 0.84 -0.68 0.17 1.21 0.19 0.07 0.75 
CGPLOV48 0.37 0.75 0.89 -0.72 1.24 -0.34 0.82 -1.39 -0.44 -1.85 1.03 0.13 -0.30 -1.09 -1.00 -1.34 -0.39 -1.45 1.91 
CGPLOV49 -4.21 -1.92 4.86 0.43 4.30 -5.03 -2.80 -1.45 -5.60 -3.27 -6.36 -4.30 -1.42 -0.36 1.76 5.20 3.07 -5.15 -5.78 
CGPLOV50 0.55 0.30 -1.18 0.66 1.44 0.02 -2.65 0.33 1.02 -0.94 -3.60 0.16 1.01 0.33 0.81 -0.66 -1.86 -1.06 -0.77 
CGPLPA112 0.89 0.22 -1.02 -0.96 0.32 -0.10 0.56 -0.55 0.15 0.05 0.09 -1.12 -0.20 -0.58 -0.41 0.60 0.73 0.34 0.21 
CGPLPA113 1.50 1.06 -2.41 0.01 1.72 1.62 -2.90 -0.90 -0.94 -1.98 -3.82 2.23 4.04 -2.37 -0.90 1.27 -1.18 -0.69 -4.36 
CGPLPA114 0.38 0.14 -1.29 -0.33 0.68 -0.32 -0.86 0.65 0.08 -0.03 -1.36 1.16 0.21 0.41 1.02 1.14 0.08 -0.72 -0.74 
CGPLPA115 -9.24 -14.11 0.57 0.79 -22.22 -6.31 -8.67 -1.81 -3.64 -8.58 -7.45 14.51 3.87 -1.46 6.27 -5.04 -2.80 -4.79 -1.47 
CGPLPA117 -0.81 -3.22 -0.37 1.90 1.20 1.33 -0.91 0.82 -1.29 -1.48 -1.28 2.34 -1.44 0.71 1.12 3.65 -2.13 0.21 -2.93 
CGPLPA118 1.12 1.76 -1.33 1.30 1.64 0.39 -0.89 -0.29 -0.50 -0.90 -2.61 -0.44 0.88 -1.39 -0.68 1.40 0.14 0.51 -2.57 
CGPLPA122 2.11 0.95 -3.11 -13.76 3.35 -1.55 -3.74 1.17 1.47 -2.43 -5.07 2.98 -1.57 -0.33 1.36 -0.70 -0.73 -0.75 -4.10 
CGPLPA124 -0.72 -0.13 -0.90 0.63 2.50 0.68 -0.97 -0.04 0.12 -0.95 -2.40 2.56 0.05 -0.10 0.53 -0.13 -0.17 -0.58 -1.04 
CGPLPA125 0.84 1.30 -0.45 3.30 1.51 1.47 -0.20 0.13 -0.37 -0.15 -0.34 -0.04 -0.26 -0.95 -0.73 -1.17 -1.29 -2.51 -0.67 
CGPLPA126 -0.69 -0.48 -2.73 -1.81 4.12 -0.09 -1.76 0.55 1.82 -1.85 -3.79 3.38 2.26 -0.45 0.24 0.49 -0.99 1.04 -0.23 
CGPLPA127 2.18 1.94 -1.29 1.14 1.62 -0.18 -1.95 -0.60 -0.67 -2.30 -2.93 -0.42 0.14 -1.06 -0.22 -0.32 -0.74 -0.93 -4.02 
CGPLPA128 0.55 -0.57 -0.05 0.50 2.45 0.78 0.50 -0.60 0.24 -1.32 -1.40 2.05 0.76 -0.98 -0.99 -1.57 -0.74 1.29 -0.80 
CGPLPA129 0.45 -0.97 -3.39 0.59 3.46 -0.35 -2.67 0.38 0.93 -1.43 -4.19 4.71 1.90 -0.46 0.20 -0.19 -0.44 0.56 -1.61 
CGPLPA130 -0.60 0.42 -1.56 -0.18 2.15 -1.12 -0.54 -0.52 0.04 -0.73 -1.36 1.80 1.99 -1.00 -0.85 -1.35 -1.73 -0.51 -1.55 
CGPLPA131 -1.62 -2.37 0.72 -0.23 0.35 2.31 0.17 0.33 1.01 1.80 -0.36 4.34 0.17 -0.24 0.41 1.23 2.11 1.51 2.45 
CGPLPA134 0.71 -0.30 -1.85 -3.83 1.81 -1.34 -0.65 -1.15 0.68 -0.37 -1.31 1.74 2.06 -0.86 -0.77 2.45 1.07 3.61 0.73 
CGPLPA135 1.86 3.15 -1.24 1.49 0.99 -1.10 -0.89 -0.80 -0.39 -0.98 -1.00 -0.35 -0.67 -1.31 -0.75 0.34 0.67 -0.64 -0.21 
CGPLPA136 0.29 -0.24 -0.42 -1.40 2.44 0.51 0.75 -0.91 0.48 -1.17 -0.46 -0.27 0.29 -1.99 -2.18 0.41 0.51 2.01 1.25 
CGPLPA137 2.27 1.27 0.69 0.36 1.96 1.36 0.84 -1.50 -1.17 -1.15 -1.47 1.66 -0.78 -1.72 -1.11 2.08 -0.38 0.05 -1.17 
CGPLPA139 1.30 2.53 -1.29 -1.90 -0.41 0.13 0.20 -0.31 -0.30 0.31 -1.10 -1.44 -0.69 -1.24 -0.43 2.68 3.53 -0.13 1.70 
CGPLPA14 1.51 0.86 -1.29 1.01 0.04 -0.87 -1.75 1.55 2.60 -1.93 -3.45 -3.06 2.81 -0.62 -0.48 1.92 -0.60 0.08 -3.79 
CGPLPA140 -0.83 -1.64 -2.84 -2.57 1.87 -1.75 -1.80 1.22 0.67 0.43 -1.85 3.82 0.05 1.56 0.88 -0.23 -0.16 2.34 1.50 
CGPLPA141 -0.47 -1.32 -2.02 -0.93 0.11 -3.05 -1.94 1.43 1.30 -1.00 -2.61 0.41 2.18 0.72 0.32 3.29 0.27 1.91 -1.72 
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CGPLPA15 1.20 2.10 0.06 0.89 0.34 0.30 -0.20 -0.40 1.37 -2.20 -2.04 0.11 2.03 -1.97 -1.08 1.25 -0.52 0.03 -2.09 
CGPLPA155 1.94 1.49 -1.15 -0.12 -0.08 0.43 0.24 -1.12 0.60 -1.83 -2.75 -0.83 1.23 -2.67 -1.43 3.86 1.77 -0.01 -0.19 
CGPLPA156 -0.03 -0.13 -1.07 0.15 1.39 0.57 -0.10 -0.28 -0.51 -0.01 -0.71 2.07 0.20 -0.24 0.63 0.04 -0.25 -0.55 0.42 
CGPLPA165 1.02 0.59 -1.01 -0.06 -0.26 0.59 0.14 -0.81 0.98 -0.12 -1.74 0.07 0.12 -0.91 0.03 2.21 1.27 0.78 -0.02 
CGPLPA168 0.07 1.03 -5.35 -2.96 3.92 -3.23 -4.47 1.40 2.00 -2.67 -6.38 2.52 2.99 -0.54 0.78 1.83 -1.37 -0.66 -4.34 
CGPLPA17 -9.09 -8.49 -8.04 -8.15 4.93 -9.32 -3.95 7.02 4.28 1.36 -9.38 5.93 5.44 2.19 2.60 10.73 5.14 4.33 -3.52 
CGPLPA184 1.64 2.02 -2.10 -1.19 0.87 -0.25 -0.72 0.31 1.41 -0.90 -2.48 -0.01 1.74 -0.79 -0.51 2.35 2.37 1.42 -0.52 
CGPLPA187 1.98 0.89 -0.65 -0.72 1.60 0.10 0.42 -0.63 -0.51 -2.18 -3.07 0.39 0.23 -1.93 -1.67 3.13 1.14 1.01 -0.99 
CGPLPA23 0.19 0.99 -4.32 1.94 1.70 -2.89 -5.50 3.18 0.49 -2.53 -6.27 -2.96 1.43 1.98 2.86 2.90 -1.14 -0.80 -6.50 
CGPLPA25 1.20 0.42 -1.16 2.56 -0.39 -0.01 -1.39 1.04 0.50 -0.02 -2.40 -0.35 0.73 0.23 0.92 0.35 0.37 -2.14 -2.19 
CGPLPA26 0.93 0.96 0.25 1.09 0.25 -0.34 -0.50 -0.41 -0.78 0.17 -0.36 0.08 0.09 -1.00 -0.40 1.27 0.89 1.05 0.95 
CGPLPA28 0.35 -0.15 -0.47 0.96 1.10 -0.05 -1.98 1.05 1.55 -1.09 -3.30 0.32 1.78 -0.04 0.75 0.93 -1.30 -0.93 -2.06 
CGPLPA33 2.01 0.69 -2.21 4.30 -0.10 -1.83 -3.31 1.98 0.38 -3.61 -4.49 -3.22 2.44 0.06 -0.07 3.17 0.77 -1.21 -5.32 
CGPLPA34 0.30 0.63 -0.32 1.22 0.11 -0.47 -0.70 1.15 0.89 -1.10 -2.04 1.06 1.61 -0.14 0.95 0.67 -1.03 -0.29 -1.37 
CGPLPA37 0.68 1.45 -2.40 -2.06 0.52 -2.48 -1.74 1.05 1.25 -2.74 -3.95 -1.60 4.06 -0.63 -0.23 4.67 1.17 0.19 -1.30 
CGPLPA38 1.40 0.43 -0.37 1.89 -1.05 -1.70 -1.16 1.56 0.84 -1.65 -1.09 -2.72 0.97 -0.08 -0.20 1.93 0.51 -0.78 -2.74 
CGPLPA39 0.45 0.22 -3.01 1.02 -0.32 -1.73 -2.80 1.67 0.14 -1.44 -3.70 -0.76 -0.19 1.01 2.29 2.69 0.33 -1.90 -5.03 
CGPLPA40 0.65 1.08 -2.79 -0.67 -0.40 -2.67 -2.12 1.80 1.62 -1.70 -4.60 -3.03 2.55 -0.50 0.38 4.21 2.27 0.67 -2.81 
CGPLPA42 1.73 1.55 0.60 0.47 0.87 -0.75 0.82 -1.63 -0.21 -0.30 0.65 -4.60 0.55 -1.74 -1.56 0.50 -0.21 0.07 0.52 
CGPLPA46 -7.16 -7.43 -6.38 -1.76 3.11 -8.09 -3.60 5.66 2.35 -1.48 -6.35 2.68 5.03 1.65 1.33 8.16 3.91 2.30 -4.79 
CGPLPA47 -0.74 -1.90 -4.09 -0.71 1.54 -5.38 -3.68 4.83 2.61 -0.48 -5.62 -3.31 3.66 1.31 1.40 5.68 2.07 1.15 -3.55 
CGPLPA48 0.05 0.61 -0.42 0.71 -0.05 -1.27 -0.60 -0.17 0.66 -0.56 -1.44 -0.94 -0.12 -0.17 0.98 1.42 -0.07 -1.85 -0.38 
CGPLPA52 0.47 -0.09 -0.46 1.91 0.90 0.09 -0.34 0.04 -0.60 0.72 -1.60 1.98 -0.44 0.18 0.75 -0.32 -0.38 -1.19 -0.38 
CGPLPA53 1.38 3.25 -1.65 -0.96 -0.53 -1.69 -1.47 -0.10 0.18 -0.41 -2.05 -1.02 0.07 -0.30 0.75 1.88 1.44 -0.57 -2.46 
CGPLPA58 0.64 0.11 -1.17 0.88 -1.18 -0.16 -0.53 1.24 0.56 1.57 -0.65 -1.09 -1.14 1.03 1.27 -0.86 0.14 -3.51 -1.40 
CGPLPA59 1.40 -0.28 -2.01 2.23 1.48 0.62 -2.68 2.05 -0.92 -0.19 -3.08 0.69 -0.27 1.36 1.84 0.66 -0.96 -0.37 -3.21 
CGPLPA67 1.99 1.96 0.39 1.00 1.62 0.58 0.10 -0.85 -0.37 -0.17 -1.24 -0.31 0.43 -1.45 -0.85 0.64 -0.82 0.32 -0.31 
CGPLPA69 -0.35 -0.91 1.30 1.65 1.72 0.18 0.84 -1.33 -2.20 0.78 0.52 0.92 -0.29 -0.35 -0.86 -1.79 -1.08 0.59 0.05 
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CGPLPA71 -0.53 -0.52 0.86 1.05 0.18 2.03 1.09 -1.25 -1.42 -0.39 0.23 1.97 -0.94 -0.78 -0.23 -2.56 -2.26 -1.89 -0.22 
CGPLPA74 0.32 0.94 0.41 -1.33 0.77 -0.15 0.93 -0.68 -1.03 1.71 1.82 -0.24 -2.63 0.03 0.09 -0.75 0.56 -0.49 1.70 
CGPLPA76 1.66 1.41 -1.14 -0.34 1.43 -0.72 -0.13 -0.24 3.86 0.64 -0.55 -1.69 0.05 0.06 0.51 1.97 1.05 0.11 -0.77 
CGPLPA85 -1.41 -0.30 0.32 0.70 1.07 -0.23 -0.26 0.20 -0.32 0.85 -1.53 1.46 -0.66 0.67 0.48 -1.67 -0.92 0.69 0.35 
CGPLPA86 0.33 0.95 -1.41 2.38 2.77 -0.20 -2.88 0.33 -1.49 -1.62 -4.17 1.42 0.47 -0.50 1.16 1.00 -1.58 -1.08 -5.50 
CGPLPA92 -0.79 -1.30 0.13 1.48 -0.69 1.09 0.08 0.44 -0.59 0.83 1.15 -0.51 -1.29 0.82 1.45 -2.15 -0.59 -1.43 -0.71 
CGPLPA93 0.64 -1.44 -2.16 -0.97 3.56 -1.02 -3.45 1.34 1.10 -1.93 -5.16 3.48 0.91 0.62 1.00 0.40 -5.50 -0.26 -4.45 
CGPLPA94 1.87 1.46 0.09 -0.98 1.26 0.29 0.13 -0.72 -2.10 -2.41 -1.66 0.55 0.80 -2.30 -1.81 1.50 0.37 -0.59 -0.62 
CGPLPA95 1.17 2.79 -3.30 -1.96 -0.64 -2.17 -2.28 1.26 -0.21 -2.36 -4.83 -1.45 0.17 0.09 1.35 3.93 0.84 -0.91 -4.27 
CGST102 -0.90 0.29 0.50 1.13 2.39 1.56 1.60 -1.56 -2.04 -1.43 0.61 2.51 -1.77 -1.45 -1.09 -2.65 -0.48 -2.89 -0.17 
CGST11 0.25 -0.17 1.48 0.21 0.14 -0.13 0.82 -1.31 -0.98 0.27 1.41 0.65 -1.05 -0.64 -1.05 -1.38 -0.73 -0.32 1.08 
CGST110 0.14 -1.32 0.86 2.37 0.09 1.91 -0.10 0.25 -1.61 0.77 1.22 -0.63 -3.18 0.72 0.14 -2.38 0.13 -2.11 -1.07 
CGST114 1.84 1.65 -0.03 -0.54 0.85 0.22 0.76 -1.43 -1.48 -0.35 -0.59 2.54 0.05 -1.50 -0.62 0.30 1.40 -0.71 0.35 
CGST13 0.11 -2.36 -0.61 0.26 1.89 1.69 -1.23 0.38 -0.08 -0.27 -1.48 2.07 1.26 -0.27 -0.27 -0.35 -1.44 1.95 -1.10 
CGST131 0.95 1.14 3.13 2.70 -0.64 1.39 1.14 -2.33 -2.39 -1.17 -0.64 3.93 -0.93 -2.58 -2.24 -2.13 -1.24 -2.92 0.81 
CGST141 0.64 -0.28 -0.55 0.05 -0.43 1.19 0.07 0.56 -0.15 1.40 -0.72 0.06 -0.35 -0.68 0.26 0.33 0.22 0.32 1.43 
CGST16 0.32 -1.46 -3.47 -0.62 3.85 -1.33 -2.90 0.79 0.35 -2.21 -3.52 1.76 -2.16 1.48 1.58 -0.52 -0.84 0.52 -2.41 
CGST18 0.90 -0.75 0.74 -0.46 -0.09 0.05 1.54 -0.81 0.45 -1.49 -0.07 2.33 1.18 -1.74 -2.16 0.34 0.03 1.25 0.39 
CGST21 -5.36 -8.70 -1.83 -0.92 11.09 -4.96 -1.49 -3.12 -6.49 1.14 -3.98 5.59 1.01 2.56 2.11 -8.91 -4.25 5.57 -3.64 
CGST26 0.99 -1.34 1.48 2.79 1.22 1.34 0.96 -0.77 -2.27 -0.87 0.49 0.84 -0.86 -0.63 -0.73 -2.78 -3.02 -0.09 -0.87 
CGST28 0.42 -0.42 0.36 0.33 0.01 -0.82 -0.44 -2.30 -3.65 -2.26 -0.62 -0.82 -2.39 -1.62 -1.40 5.73 4.11 -1.40 -2.29 
CGST30 0.53 -1.87 1.92 5.82 -0.70 1.53 -0.04 -1.13 -2.34 -1.43 1.29 -1.47 -2.42 -0.57 -1.09 -2.11 -2.04 -1.94 -0.80 
CGST32 -2.01 -0.17 2.31 8.22 -4.82 4.02 0.23 1.27 -3.39 -2.35 8.07 -6.06 -6.60 -1.25 -0.87 5.92 4.43 -3.01 -0.21 
CGST33 -1.95 -1.20 2.32 2.42 0.61 0.10 0.35 -3.42 -4.79 0.03 3.08 3.38 -1.52 -0.90 -1.26 -0.87 1.72 -1.20 0.16 
CGST38 -1.56 -3.15 1.96 2.74 4.50 1.77 1.30 -2.11 -1.98 -1.11 0.36 7.44 1.03 -2.22 -2.52 -2.71 -2.09 2.34 -1.40 
CGST39 -1.51 -3.57 -1.69 -0.41 2.93 0.17 0.04 0.32 0.66 0.33 -1.09 3.15 0.95 0.32 0.39 -2.64 -2.09 2.09 -0.54 
CGST41 -1.39 -2.94 -0.03 1.44 0.54 1.53 -0.91 0.48 -2.80 1.79 3.33 3.87 -1.39 -0.54 -0.14 -4.26 -1.92 -0.39 1.08 
CGST45 -1.82 -3.29 -0.22 0.75 3.39 -0.28 -0.94 -0.63 -1.12 -0.22 -0.09 4.09 0.21 -0.06 -0.87 -2.76 -0.93 3.01 -0.17 
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CGST47 -1.61 -2.77 -0.59 -0.24 3.29 -0.51 0.42 -0.53 1.56 -0.83 0.48 4.02 1.54 -1.06 -1.41 -0.95 0.87 2.99 0.68 
CGST48 5.19 -1.06 7.29 10.95 1.85 -6.77 -5.15 0.99 -6.29 -5.41 1.57 17.71 0.53 -2.09 -0.55 -2.32 2.44 -5.12 -4.20 
CGST53 -3.70 -6.15 1.47 0.52 10.62 -1.00 -2.57 -2.35 -3.74 -2.12 -3.51 8.07 4.16 -1.11 -2.74 -7.39 -5.96 0.05 -2.83 
CGST58 -3.50 -3.48 -0.17 0.83 0.93 -1.33 -1.12 1.08 -0.65 2.19 0.85 2.91 0.08 0.84 0.08 -2.94 -1.01 0.22 1.06 
CGST67 -3.80 -3.95 2.49 2.42 0.89 -0.24 -0.05 -0.85 -2.36 0.71 -0.77 6.03 -0.98 0.32 -0.58 -3.98 -1.85 0.80 -0.03 
CGST77 -2.96 -1.59 1.07 0.25 1.58 -1.87 -2.29 -0.05 -0.80 -2.00 -4.32 6.75 1.58 -0.08 -1.64 -2.17 -3.23 -0.13 -1.20 
CGST80 -2.42 -4.30 0.79 1.77 3.38 0.75 1.45 -0.68 -0.64 0.02 1.22 3.50 -1.36 -0.63 -1.05 -0.05 1.88 0.17 1.34 




Table 4.9. DELFI performance for cancer detection. 
    Individuals analyzed 





       
Healthy 215 10 - 4 - 
       
Cancer 208 166 80% 152 73% 




Breast 54 38 70% 31 57% 
Bile duct 26 23 88% 21 81% 
Colorectal 27 22 81% 19 70% 
Gastric 27 22 81% 22 81% 
Lung 12 12 100% 12 100% 
Ovarian 28 25 89% 25 89% 
Pancreatic 34 24 71% 22 65% 




I 41 30 73% 28 68% 
II 109 85 78% 78 72% 
III 33 30 91% 26 79% 
IV 22 18 82% 17 77% 









 Top Prediction  Top Two Predictions  Random Assignment 
 Patients Accuracy (95% CI)  Patients Accuracy (95% CI)  Patients Accuracy 
Breast 42  32 76% (61%-88%)  38 91% (77%-97%)  9 22% 
Bile Duct 23  10 44% (23%-66%)  15 65% (43%-84%)  3 12% 
Colorectal 24  17 71% (49%-87%)  19 79% (58%-93%)  3 12% 
Gastric 24  16 67% (45%-84%)  19 79% (58%-93%)  3 12% 
Lung 30  16 53% (34%-72%)  23 77% (58%-90%)  2 6% 
Ovarian 27  13 48% (29%-68%)  16 59% (38%-78%)  4 14% 
Pancreatic 24   12 50% (29%-71%)   16 67% (45%-84%)   3 12% 








The three studies herein presented indicate the feasibility of novel liquid biopsy approaches in the 
cancer care continuum of patients with early- and late-stage cancers, adding value to the body of 
evidence that shows ctDNA analyses as a useful biomarker for early detection, minimal residual 
disease, and treatment response assessment.  
Despite the success of targeted therapies for many cancers, durable responses eventually lead to 
progressive disease through the evolution of resistant clones.  The standard approach for assessing 
treatment efficacy has been based on imaging measurement of tumor dimensions (70) which may 
not capture changes in clonal subpopulations and may be confounded by the tumor 
microenvironment.  More recently, ctDNA methods have been used for disease monitoring, but 
these have largely been based on technologies that evaluate a limited number of genes or specific 
mutations and do not allow for evaluation of the dynamics of multiple tumor clones (20-22, 25-28).   
In our first study, we have developed an approach for evaluating tumor burden through a cell-free 
tumor load measurement that incorporates both sequence changes across many driver genes as well 
as whole genome structural changes, allowing detection of tumor-related alterations in all patients 
analyzed.  This effort addresses the value of comprehensive measurements of ctDNA within hours 
to days after targeted therapy initiation. 
Through this approach we demonstrate that dynamic changes in plasma ctDNA after drug exposure 
may provide insights into clinical efficacy of targeted therapy.  We observed a reduction of cell-
free tumor load in patients with radiographic response and limited changes in ctDNA in non-
responders after initiation of therapy.  We also showed that patients with radiographic non-
measurable disease and those with stable disease at first imaging evaluation can be more accurately 
classified using ctDNA analyses after TKI initiation.  These examples reflect the utility of ctDNA 
for addressing current unmet clinical needs for real-time biomarkers of response and evolution of 
tumor burden.  Although individual mutation analyses may miss specific subclones or may be 
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absent in individual patients, the integrated analysis of sequence and structural changes permitted 
evaluation of the majority of cases for cfTL changes.  The tiered complementary approach has the 
benefit of incorporating sequence mutations in cfDNA that have both qualitative and quantitative 
characteristics in the type and level of detected alterations, while chromosomal changes add 
quantitative assessment of genome-wide alterations that are typically present in every cancer.    
Despite the clinical utility of this approach, these analyses have a number of limitations.  First, our 
genome-wide analyses were based on whole genome data at low coverage (<1x) and these could 
be improved in the future through deeper complementary sequencing.  Additionally, the cohort 
analyzed in this study was small and may not reflect the full repertoire of the disease complexity 
of advanced NSCLC patients.  Larger studies will be needed to validate these observations for 
patients with lung cancer treated with these and other targeted therapies, as well as for patients with 
other cancer types.  Prospective trials with blood samples collected at regular intervals would allow 
for standardization of liquid biopsy analyses and for evaluation of responses to treatment compared 
to CT imaging. 
Despite the value of multimodal curative treatment approaches, a significant fraction of patients 
will eventually perish as a consequence of locoregional relapse, peritoneal recurrence, or distant 
metastasis (40, 41).  Current methods to estimate the risk of disease recurrence after surgery mostly 
rely on the assessment of pathological staging and microscopic residual disease score systems (44-
46).  However, there are several limitations with these approaches, especially with tumor regression 
grading scales, that make their implementation difficult in daily clinical practice, including 
interobserver variability and lack of standardization.  Furthermore, the poor sensitivity of currently 
available imaging methods and blood protein biomarkers to detect remaining disease after curative 
surgery has provided an opportunity for ctDNA analyses for minimal residual disease assessment 
in gastric cancer.   
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In our second study, we have developed a tissue-independent sequencing approach using 
ultrasensitive sequencing of matched cfDNA and white blood cells to detect tumor-specific 
mutations in cfDNA after completion of preoperative chemotherapy as well as after surgery in 
patients with resectable gastric cancer. 
To our knowledge, this is the first study to investigate the value of parallel deep sequencing of 
cfDNA and WBCs to detect cfDNA alterations associated with clonal hematopoiesis in the 
circulation and to use this approach to longitudinally identify bona fide tumor-specific alterations.  
This approach allows direct identification of ctDNA without requiring tumor tissue, which is often 
available to a limited extent and where sequencing analyses may be hampered by intra-tumoral 
heterogeneity.  We observed that plasma samples from patients with Lauren’s intestinal subtype 
were associated with higher mutant allele fractions when compared with patients with diffuse 
subtype tumors.  Further work will be needed to determine if intracellular mucin, stromal reaction, 
vascular density, or other pathological features in diffuse carcinomas play a role in determining 
lower levels of ctDNA alterations in the blood.  
A major challenge for the development of MRD assays using noninvasive liquid biopsies is 
distinguishing tumor-specific mutations from background changes associated with biological 
variation.  The vast majority of cfDNA in healthy individuals arises from hematopoietic cells (95).  
Normal ageing is associated with the accumulation of somatic mutations in bone marrow-derived 
hematopoietic cells in the form of CHIP in asymptomatic individuals (35).  WBC-derived 
alterations that arise as a consequence of CHIP may confound liquid biopsy analyses that are based 
on characterization of cfDNA as these may occur in common cancer driver genes, as observed with 
hotspot alterations in TP53 and KRAS (96).  As we have shown in our cohort of 50 patients, cfDNA 
analyses without WBC filters would have been unable to appropriately identify patients that benefit 
from perioperative treatment in terms of event-free and overall survival. 
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Finally, in our third study, we have determined that genome-wide cfDNA fragmentation profiles 
are different between cancer patients and healthy individuals.  The variability in fragment lengths 
and coverage in a position dependent manner throughout the genome may explain the apparently 
contradictory observations of previous analyses of cfDNA at specific loci or of overall fragment 
sizes.  In patients with cancer, heterogeneous fragmentation patterns in cfDNA appear to be a result 
of mixtures of nucleosomal DNA from both blood and neoplastic cells.  Despite these encouraging 
results, our approach can be improved in the future, including through recovery of smaller cfDNA 
fragments (<100 bp) (64, 97), evaluation of single-stranded libraries (65, 98, 99), or use of 
alternative sequencing technologies.  Additionally, generation of libraries without the use of PCR 
could reduce GC bias and potential sequence and structural artifacts. 
Although analyses of a larger numbers of individuals will be needed to validate this approach for 
clinical use, these observations already have important implications for future research and 
applications of non-invasive approaches for detection of human cancer.  First, these studies provide 
a method for simultaneous analysis of tens to potentially hundreds of tumor-specific abnormalities 
from minute amounts of cfDNA, overcoming a limitation that has precluded the possibility of more 
sensitive analyses of cfDNA.  DELFI analyses detected a higher fraction of cancer patients than 
previous cfDNA analysis methods that have focused on sequence or overall fragmentation sizes.  
As we have shown, combining DELFI with analyses of other cfDNA alterations may further 
increase the sensitivity of detection.  Second, as fragmentation profiles appear related to 
nucleosomal DNA patterns, DELFI may be useful for determining the primary source of tumor-
derived cfDNA.  Our identification of the source of circulating tumor DNA in over half of patients 
analyzed may be further improved by including clinical characteristics, other biomarkers, including 





In summary, these studies provide a new paradigm for the use of liquid biopsy approaches in the 
management of patients with cancer.  In late-stage disease, longitudinal ctDNA assessment in 
patients receiving systemic treatment may be helpful for the development of new molecular 
response criteria and to provide insight into survival outcomes.  In patients with localized cancer 
treated with perioperative chemotherapy, tissue-independent approaches designed to detect tumor-
specific cfDNA alterations can be applied to early risk stratification.  Finally, cfDNA fragmentation 
analyses may be used to detect early-stage cancers and identify their tissue of origin.  Overall, the 
results of these analyses highlight the clinical value of ctDNA as a biomarker in the cancer care 
continuum, providing evidence for treatment response assessment, detection of minimal residual 
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